



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 110656

TO: James Schultz
Location: CM1/12E18/11E12
Art Unit: 1635
Thursday, December 18, 2003

Case Serial Number: 09/960143

From: David Schreiber
Location: Biotech-Chem Library
CM1-6A03
Phone: 308-4292

david.schreiber@uspto.gov

Search Notes

SEARCH REQUEST FORM

Requestor's Name: _____ Serial Number: _____
Date: _____ Phone: _____ Art Unit: _____

Search Topic:

Please write a detailed statement of search topic. Describe specifically as possible the subject matter to be searched. Define any terms that may have a special meaning. Give examples or relevant citations, authors, keywords, etc., if known. For sequences, please attach a copy of the sequence. You may include a copy of the broadest and/or most relevant claim(s).

STAFF USE ONLY

Date completed: 12/18
Searcher: D. Schreiber 308-4292
Terminal time: 90
Elapsed time: 13
CPU time: _____
Total time: _____
Number of Searches: _____
Number of Databases: _____

Search Site
____ STIC
☒ CM-1 CA 03
____ Pre-S
Type of Search
15 N.A. Sequence
____ A.A. Sequence
____ Structure
____ Bibliographic

Vendors
____ IG
____ STN
____ Dialog
____ APS
____ Geninfo
____ SDC
____ DARC/Questel
☒ Other CompuLink

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: December 18, 2003, 07:17:07 ; Search time 14 Seconds
(without alignments)
2.891 Million cell updates/sec

Title: us-09-960-143-3

Perfect score: 1249

Sequence: 1 aaaaattcattctgtggt.....atataattgtctcaagt 1249

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 0.5

Searched: 947 seqs, 16203 residues

Total number of hits satisfying chosen parameters: 1894

Minimum DB seq length: 8

Maximum DB seq length: 50

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 984 summaries

Database : rge.seq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
C 1	30	2.4	30	1	ACCESSION:AX419968
C 2	30	2.4	30	1	BD182174
C 3	30	2.4	30	1	BD182175
C 4	26	2.1	26	1	AX280042
C 5	25	2.0	26	1	AX280041
C 6	24	1.9	24	1	AX207732
C 7	24	1.9	24	1	AX265058
C 8	21	1.7	21	1	AX040833
C 9	21	1.7	21	1	AX133222
10	21	1.7	21	1	AX133224
11	21	1.7	21	1	AX419973
12	21	1.7	21	1	AX419975
C 13	20	1.6	20	1	AX130442
C 14	20	1.6	20	1	AX419972
C 15	18.2	1.5	24	1	AX084499
C 16	17.4	1.4	21	1	AX236360
C 17	17	1.4	17	1	AX419971
C 18	16.6	1.3	26	1	AX280042
C 19	16.2	1.3	22	1	AX051334
C 20	16.2	1.3	23	1	AX059999
C 21	16.2	1.3	23	1	BD081029
C 22	15.8	1.3	20	1	AX295620
C 23	15.8	1.3	20	1	BD090846
C 24	15.8	1.3	21	1	AX092810
C 25	15.6	1.2	22	1	AX164318
C 26	15.6	1.2	22	1	AX164319
C 27	15.6	1.2	22	1	AX131810
C 28	15.6	1.2	22	1	I31811
C 29	15.6	1.2	22	1	I69407
C 30	15.6	1.2	22	1	I59408
C 31	15.6	1.2	26	1	AX280041
C 32	15.4	1.2	17	1	AX500365
C 33	15.4	1.2	17	1	I24434

34	15.4	1.2	18	1	AR076329
C 35	15.4	1.2	20	1	AR168620
C 36	15.4	1.2	21	1	ACCESSION:AX555826
C 37	15.2	1.2	20	1	AR031041
C 38	15.2	1.2	20	1	AR232302
C 39	15.2	1.2	20	1	AX429785
C 40	15.2	1.2	20	1	BD144143
C 41	15.2	1.2	21	1	ACCESSION:AX26944
C 42	15.2	1.2	21	1	AR050156
C 43	15.2	1.2	21	1	AR130275
C 44	15.2	1.2	21	1	AX008949
C 45	15.2	1.2	21	1	I23731
C 46	15.2	1.2	21	1	ACCESSION:AX528526
C 47	15	1.2	15	1	AX419974
C 48	14.8	1.2	18	1	AX67086
C 49	14.8	1.2	19	1	AX129263
C 50	14.8	1.2	20	1	AR181777
C 51	14.8	1.2	20	1	AR181778
C 52	14.8	1.2	20	1	AX269437
C 53	14.8	1.2	20	1	AX270968
C 54	14.8	1.2	20	1	AX599078
C 55	14.8	1.2	20	1	BD138313
C 56	14.8	1.2	20	1	E15986
C 57	14.8	1.2	21	1	AR069029
C 58	14.8	1.2	21	1	AR299016
C 59	14.8	1.2	21	1	I26583
C 60	14.4	1.2	17	1	AX500364
C 61	14.4	1.2	17	1	AX500366
C 62	14.4	1.2	17	1	AX722454
C 63	14.4	1.2	17	1	AX731903
C 64	14.4	1.2	17	1	BD017427
C 65	14.4	1.2	18	1	AX599320
C 66	14.4	1.2	20	1	AX119636
C 67	14.4	1.2	20	1	AX149130
C 68	14.4	1.2	20	1	ATH521162
C 69	14.2	1.1	19	1	AR178736
C 70	14.2	1.1	19	1	AR205441
C 71	14.2	1.1	19	1	AR220133
C 72	14.2	1.1	19	1	AR221522
C 73	14.2	1.1	19	1	AR254224
C 74	14.2	1.1	19	1	AR282430
C 75	14.2	1.1	19	1	AX129503
C 76	14.2	1.1	19	1	AX599113
C 77	14.2	1.1	20	1	AR030970
C 78	14.2	1.1	20	1	AR108815
C 79	14.2	1.1	20	1	AR145988
C 80	14.2	1.1	20	1	AR145989
C 81	14.2	1.1	20	1	AR159243
C 82	14.2	1.1	20	1	AR159247
C 83	14.2	1.1	20	1	AR159248
C 84	14.2	1.1	20	1	AR180879
C 85	14.2	1.1	20	1	AR180880
C 86	14.2	1.1	20	1	AR205764
C 87	14.2	1.1	20	1	AR224476
C 88	14.2	1.1	20	1	AR272014
C 89	14.2	1.1	20	1	AR315173
C 90	14.2	1.1	20	1	AR315174
C 91	14.2	1.1	20	1	BD161924
C 92	14.2	1.1	20	1	YSCMT021
C 93	14.2	1.1	15	1	AR041399
C 94	14	1.1	15	1	AR041407
C 95	14	1.1	15	1	AR041916
C 96	14	1.1	15	1	AR041917
C 97	14	1.1	15	1	AR041918
C 98	14	1.1	15	1	AX636857
C 99	14	1.1	15	1	AX636872
100	14	1.1	15	1	AX637381
101	14	1.1	15	1	AX637383
102	14	1.1	15	1	AX637385
103	14	1.1	15	1	AX637387
C 104	14	1.1	17	1	AX738727
C 105	14	1.1	17	1	BD067874
C 106	14	1.1	18	1	AX069089

107	C	107	1.1	20	1	AR067181	ACCESSION:AR067181	180	13.4	1.1	15	1	AR041921	ACCESSION:AR041921
108		14	1.1	20	1	AR315239	ACCESSION:AR315239	181	13.4	1.1	15	1	AR041922	ACCESSION:AR041922
109		14	1.1	20	1	ATH552863	ACCESSION:ATH552863	182	13.4	1.1	15	1	AR041923	ACCESSION:AR041923
110		13.8	1.1	17	1	AR046179	ACCESSION:AR046179	183	13.4	1.1	15	1	AR041924	ACCESSION:AR041924
111	C	111	1.1	17	1	AR047260	ACCESSION:AR047260	184	13.4	1.1	15	1	AR041925	ACCESSION:AR041925
112		13.8	1.1	17	1	AR020789	ACCESSION:AR020789	185	13.4	1.1	15	1	AR041926	ACCESSION:AR041926
113	C	113	1.1	17	1	AX500623	ACCESSION:AX500623	186	13.4	1.1	15	1	AR041931	ACCESSION:AR041931
114		13.8	1.1	17	1	AX580024	ACCESSION:AX580024	187	13.4	1.1	15	1	AR074423	ACCESSION:AR074423
115	C	115	1.1	17	1	AX673523	ACCESSION:AX673523	188	13.4	1.1	15	1	AR174801	ACCESSION:AR174801
116	C	116	1.1	17	1	AX734639	ACCESSION:AX734639	189	13.4	1.1	15	1	AX577646	ACCESSION:AX577646
117	C	117	1.1	17	1	I53231	ACCESSION:I53231	190	13.4	1.1	15	1	AX636860	ACCESSION:AX636860
118		13.8	1.1	17	1	I54312	ACCESSION:I54312	191	13.4	1.1	15	1	AX636862	ACCESSION:AX636862
119		13.8	1.1	18	1	AR297659	ACCESSION:AR297659	192	13.4	1.1	15	1	AX636874	ACCESSION:AX636874
120		13.8	1.1	18	1	AR297664	ACCESSION:AR297664	193	13.4	1.1	15	1	AX636876	ACCESSION:AX636876
121	C	121	1.1	18	1	AX132978	ACCESSION:AX132978	194	13.4	1.1	15	1	AX636878	ACCESSION:AX636878
122		13.8	1.1	18	1	AX599395	ACCESSION:AX599395	195	13.4	1.1	15	1	AX636880	ACCESSION:AX636880
123	C	123	1.1	18	1	E12707	ACCESSION:E12707	196	13.4	1.1	15	1	AX636882	ACCESSION:AX636882
124		13.8	1.1	19	1	A88564	ACCESSION:A88564	197	13.4	1.1	15	1	AX637387	ACCESSION:AX637387
125		13.8	1.1	19	1	A90531	ACCESSION:A90531	198	13.4	1.1	15	1	AX637389	ACCESSION:AX637389
126		13.8	1.1	19	1	AR030969	ACCESSION:AR030969	199	13.4	1.1	15	1	AX637391	ACCESSION:AX637391
127		13.8	1.1	19	1	AR030972	ACCESSION:AR030972	200	13.4	1.1	15	1	AX637393	ACCESSION:AX637393
128		13.8	1.1	19	1	AR030974	ACCESSION:AR030974	201	13.4	1.1	15	1	AX637395	ACCESSION:AX637395
129		13.8	1.1	19	1	AR030975	ACCESSION:AR030975	202	13.4	1.1	15	1	AX637397	ACCESSION:AX637397
130		13.8	1.1	19	1	AR030976	ACCESSION:AR030976	203	13.4	1.1	15	1	AX637399	ACCESSION:AX637399
131		13.8	1.1	19	1	AR030977	ACCESSION:AR030977	204	13.4	1.1	15	1	AX637401	ACCESSION:AX637401
132		13.8	1.1	19	1	AR030978	ACCESSION:AR030978	205	13.4	1.1	15	1	AX637411	ACCESSION:AX637411
133		13.8	1.1	19	1	AR030981	ACCESSION:AR030981	206	13.4	1.1	15	1	E11393	ACCESSION:E11393
134		13.8	1.1	19	1	AR030982	ACCESSION:AR030982	207	13.4	1.1	15	1	I30514	ACCESSION:I30514
135		13.8	1.1	19	1	AR030983	ACCESSION:AR030983	208	13.4	1.1	15	1	I30530	ACCESSION:I30530
136		13.8	1.1	19	1	AR030984	ACCESSION:AR030984	209	13.4	1.1	15	1	I34061	ACCESSION:I34061
137		13.8	1.1	19	1	AR108814	ACCESSION:AR108814	210	13.4	1.1	16	1	I30516	ACCESSION:I30516
138		13.8	1.1	19	1	AR108817	ACCESSION:AR108817	211	13.4	1.1	16	1	I30521	ACCESSION:I30521
139		13.8	1.1	19	1	AR108819	ACCESSION:AR108819	212	13.4	1.1	16	1	ATH552647	ACCESSION:ATH552647
140		13.8	1.1	19	1	AR108820	ACCESSION:AR108820	213	13.4	1.1	17	1	A08233	ACCESSION:A08233
141		13.8	1.1	19	1	AR108821	ACCESSION:AR108821	214	13.4	1.1	17	1	A08234	ACCESSION:A08234
142		13.8	1.1	19	1	AR108822	ACCESSION:AR108822	215	13.4	1.1	17	1	A13281	ACCESSION:A13281
143		13.8	1.1	19	1	AR108823	ACCESSION:AR108823	216	13.4	1.1	17	1	A13282	ACCESSION:A13282
144		13.8	1.1	19	1	AR108826	ACCESSION:AR108826	217	13.4	1.1	17	1	AR046177	ACCESSION:AR046177
145		13.8	1.1	19	1	AR108827	ACCESSION:AR108827	218	13.4	1.1	17	1	AR047258	ACCESSION:AR047258
146		13.8	1.1	19	1	AR108828	ACCESSION:AR108828	219	13.4	1.1	17	1	AR053084	ACCESSION:AR053084
147		13.8	1.1	19	1	AR108829	ACCESSION:AR108829	220	13.4	1.1	17	1	AR065045	ACCESSION:AR065045
148		13.8	1.1	19	1	AR205763	ACCESSION:AR205763	221	13.4	1.1	17	1	AR186811	ACCESSION:AR186811
149		13.8	1.1	19	1	AR205766	ACCESSION:AR205766	222	13.4	1.1	17	1	AR187297	ACCESSION:AR187297
150		13.8	1.1	19	1	AR205768	ACCESSION:AR205768	223	13.4	1.1	17	1	AR192330	ACCESSION:AR192330
151		13.8	1.1	19	1	AR205769	ACCESSION:AR205769	224	13.4	1.1	17	1	AX421942	ACCESSION:AX421942
152		13.8	1.1	19	1	AR205770	ACCESSION:AR205770	225	13.4	1.1	17	1	AX421943	ACCESSION:AX421943
153		13.8	1.1	19	1	AR205771	ACCESSION:AR205771	226	13.4	1.1	17	1	AX500363	ACCESSION:AX500363
154		13.8	1.1	19	1	AR205772	ACCESSION:AR205772	227	13.4	1.1	17	1	AX500367	ACCESSION:AX500367
155		13.8	1.1	19	1	AR205776	ACCESSION:AR205776	228	13.4	1.1	17	1	AX672147	ACCESSION:AX672147
156		13.8	1.1	19	1	AR205777	ACCESSION:AR205777	229	13.4	1.1	17	1	AX722330	ACCESSION:AX722330
157		13.8	1.1	19	1	AR205778	ACCESSION:AR205778	230	13.4	1.1	17	1	AX724050	ACCESSION:AX724050
158		13.8	1.1	19	1	AR205778	ACCESSION:AR205778	231	13.4	1.1	17	1	AX724812	ACCESSION:AX724812
159		13.8	1.1	19	1	AR297082	ACCESSION:AR297082	232	13.4	1.1	17	1	AX725086	ACCESSION:AX725086
160		13.8	1.1	19	1	AX130049	ACCESSION:AX130049	233	13.4	1.1	17	1	AX725462	ACCESSION:AX725462
161		13.8	1.1	19	1	BD066077	ACCESSION:BD066077	234	13.4	1.1	17	1	AX728738	ACCESSION:AX728738
162		13.8	1.1	19	1	I62823	ACCESSION:I62823	235	13.4	1.1	17	1	AX729041	ACCESSION:AX729041
163		13.6	1.1	20	1	BD161924	ACCESSION:BD161924	236	13.4	1.1	17	1	AX733613	ACCESSION:AX733613
164		13.6	1.1	22	1	AR164318	ACCESSION:AR164318	237	13.4	1.1	17	1	AX736985	ACCESSION:AX736985
165		13.6	1.1	22	1	AR164319	ACCESSION:AR164319	238	13.4	1.1	17	1	AX738225	ACCESSION:AX738225
166		13.6	1.1	22	1	I31810	ACCESSION:I31810	239	13.4	1.1	17	1	I04892	ACCESSION:I04892
167		13.6	1.1	22	1	I31811	ACCESSION:I31811	240	13.4	1.1	17	1	I32590	ACCESSION:I32590
168		13.6	1.1	22	1	I69407	ACCESSION:I69407	241	13.4	1.1	17	1	I53229	ACCESSION:I53229
169		13.6	1.1	22	1	I69408	ACCESSION:I69408	242	13.4	1.1	17	1	I54310	ACCESSION:I54310
170		13.6	1.1	30	1	BD182175	ACCESSION:BD182175	243	13.4	1.1	18	1	AR087081	ACCESSION:AR087081
171		13.4	1.1	15	1	AR041400	ACCESSION:AR041400	244	13.4	1.1	18	1	AR165969	ACCESSION:AR165969
172		13.4	1.1	15	1	AR041401	ACCESSION:AR041401	245	13.4	1.1	18	1	AR285276	ACCESSION:AR285276
173		13.4	1.1	15	1	AR041402	ACCESSION:AR041402	246	13.4	1.1	18	1	AX032800	ACCESSION:AX032800
174		13.4	1.1	15	1	AR041408	ACCESSION:AR041408	247	13.4	1.1	18	1	AX092726	ACCESSION:AX092726
175		13.4	1.1	15	1	AR041409	ACCESSION:AR041409	248	13.4	1.1	18	1	AX643248	ACCESSION:AX643248
176		13.4	1.1	15	1	AR041410	ACCESSION:AR041410	249	13.4	1.1	18	1	AX643251	ACCESSION:AX643251
177		13.4	1.1	15	1	AR041411	ACCESSION:AR041411	250	13.4	1.1	18	1	E60081	ACCESSION:E60081
178		13.4	1.1	15	1	AR041919	ACCESSION:AR041919	251	13.4	1.1	19	1	AR293234	ACCESSION:AR293234
179		13.4	1.1	15	1	AR041920	ACCESSION:AR041920	252	13.4	1.1	19	1	AX079136	ACCESSION:AX079136

C 253	13.4	1.1	19	1	AX130601	ACCESSION:AX130601	C 326	12.8	1.0	17	1	AR186678	ACCESSION:AR186678
C 254	13.4	1.1	19	1	AX149204	ACCESSION:AX149204	C 327	12.8	1.0	17	1	AR187068	ACCESSION:AR187068
C 255	13.4	1.1	19	1	AX183607	ACCESSION:AX183607	C 328	12.8	1.0	17	1	AR187069	ACCESSION:AR187069
C 256	13.4	1.1	19	1	I31433	ACCESSION:I31433	C 329	12.8	1.0	17	1	AR187340	ACCESSION:AR187340
C 257	13.2	1.1	18	1	A67082	ACCESSION:A67082	C 330	12.8	1.0	17	1	AR188362	ACCESSION:AR188362
C 258	13.2	1.1	18	1	A67087	ACCESSION:A67087	C 331	12.8	1.0	17	1	AR188737	ACCESSION:AR188737
C 259	13.2	1.1	18	1	A67088	ACCESSION:A67088	C 332	12.8	1.0	17	1	AR188738	ACCESSION:AR188738
C 260	13.2	1.1	18	1	A67090	ACCESSION:A67090	C 333	12.8	1.0	17	1	AR308284	ACCESSION:AR308284
C 261	13.2	1.1	18	1	A81026	ACCESSION:A81026	C 334	12.8	1.0	17	1	AR308286	ACCESSION:AR308286
C 262	13.2	1.1	18	1	A95480	ACCESSION:A95480	C 335	12.8	1.0	17	1	AX029041	ACCESSION:AX029041
C 263	13.2	1.1	18	1	AX130089	ACCESSION:AX130089	C 336	12.8	1.0	17	1	AX029043	ACCESSION:AX029043
C 264	13.2	1.1	18	1	AR208426	ACCESSION:AR208426	C 337	12.8	1.0	17	1	AX076472	ACCESSION:AX076472
C 265	13.2	1.1	18	1	AR222905	ACCESSION:AR222905	C 338	12.8	1.0	17	1	AX132943	ACCESSION:AX132943
C 266	13.2	1.1	18	1	AR222919	ACCESSION:AR222919	C 339	12.8	1.0	17	1	AX214988	ACCESSION:AX214988
C 267	13.2	1.1	18	1	AR241972	ACCESSION:AR241972	C 340	12.8	1.0	17	1	AX215015	ACCESSION:AX215015
C 268	13.2	1.1	18	1	AR293701	ACCESSION:AR293701	C 341	12.8	1.0	17	1	AX215874	ACCESSION:AX215874
C 269	13.2	1.1	18	1	AX085252	ACCESSION:AX085252	C 342	12.8	1.0	17	1	AX216170	ACCESSION:AX216170
C 270	13.2	1.1	18	1	AX571969	ACCESSION:AX571969	C 343	12.8	1.0	17	1	AX216751	ACCESSION:AX216751
C 271	13.2	1.1	18	1	AX599270	ACCESSION:AX599270	C 344	12.8	1.0	17	1	AX263368	ACCESSION:AX263368
C 272	13.2	1.1	18	1	BD104062	ACCESSION:BD104062	C 345	12.8	1.0	17	1	AX263369	ACCESSION:AX263369
C 273	13.2	1.1	18	1	I25305	ACCESSION:I25305	C 346	12.8	1.0	17	1	AX264068	ACCESSION:AX264068
C 274	13.2	1.1	18	1	ATH529366	ACCESSION:ATH529366	C 347	12.8	1.0	17	1	AX264069	ACCESSION:AX264069
C 275	13.2	1.1	18	1	A63576	ACCESSION:A63576	C 348	12.8	1.0	17	1	AX422979	ACCESSION:AX422979
C 276	13.2	1.1	20	1	YSWTP021	ACCESSION:J01510	C 349	12.8	1.0	17	1	AX423008	ACCESSION:AX423008
C 277	13	1.0	15	1	AR041398	ACCESSION:AR041398	C 350	12.8	1.0	17	1	AX500622	ACCESSION:AX500622
C 278	13	1.0	15	1	AR041406	ACCESSION:AR041406	C 351	12.8	1.0	17	1	AX500624	ACCESSION:AX500624
C 279	13	1.0	15	1	AR041915	ACCESSION:AR041915	C 352	12.8	1.0	17	1	AX503015	ACCESSION:AX503015
C 280	13	1.0	15	1	AR041930	ACCESSION:AR041930	C 353	12.8	1.0	17	1	AX503016	ACCESSION:AX503016
C 281	13	1.0	15	1	AX636855	ACCESSION:AX636855	C 354	12.8	1.0	17	1	AX531353	ACCESSION:AX531353
C 282	13	1.0	15	1	AX636870	ACCESSION:AX636870	C 355	12.8	1.0	17	1	AX531354	ACCESSION:AX531354
C 283	13	1.0	15	1	AX637379	ACCESSION:AX637379	C 356	12.8	1.0	17	1	AX578728	ACCESSION:AX578728
C 284	13	1.0	15	1	AX637409	ACCESSION:AX637409	C 357	12.8	1.0	17	1	AX579226	ACCESSION:AX579226
C 285	13	1.0	15	1	AX638326	ACCESSION:AX638326	C 358	12.8	1.0	17	1	AX579385	ACCESSION:AX579385
C 286	13	1.0	15	1	I77803	ACCESSION:I77803	C 359	12.8	1.0	17	1	AX579496	ACCESSION:AX579496
C 287	13	1.0	17	1	AR072365	ACCESSION:AR072365	C 360	12.8	1.0	17	1	AX579591	ACCESSION:AX579591
C 288	13	1.0	17	1	AR078137	ACCESSION:AR078137	C 361	12.8	1.0	17	1	AX634813	ACCESSION:AX634813
C 289	13	1.0	17	1	AX264383	ACCESSION:AX264383	C 362	12.8	1.0	17	1	AX671653	ACCESSION:AX671653
C 290	13	1.0	17	1	AX264384	ACCESSION:AX264384	C 363	12.8	1.0	17	1	AX671834	ACCESSION:AX671834
C 291	13	1.0	17	1	AX264387	ACCESSION:AX264387	C 364	12.8	1.0	17	1	AX672853	ACCESSION:AX672853
C 292	13	1.0	17	1	AX264388	ACCESSION:AX264388	C 365	12.8	1.0	17	1	AX673783	ACCESSION:AX673783
C 293	13	1.0	17	1	AX421944	ACCESSION:AX421944	C 366	12.8	1.0	17	1	AX673947	ACCESSION:AX673947
C 294	13	1.0	17	1	AX578689	ACCESSION:AX578689	C 367	12.8	1.0	17	1	AX673993	ACCESSION:AX673993
C 295	13	1.0	17	1	AX580015	ACCESSION:AX580015	C 368	12.8	1.0	17	1	AX674214	ACCESSION:AX674214
C 296	13	1.0	17	1	AX572466	ACCESSION:AX572466	C 369	12.8	1.0	17	1	AX722385	ACCESSION:AX722385
C 297	13	1.0	17	1	AX728692	ACCESSION:AX728692	C 370	12.8	1.0	17	1	AX722386	ACCESSION:AX722386
C 298	13	1.0	17	1	BD067674	ACCESSION:BD067674	C 371	12.8	1.0	17	1	AX723547	ACCESSION:AX723547
C 299	13	1.0	17	1	BD067675	ACCESSION:BD067675	C 372	12.8	1.0	17	1	AX726127	ACCESSION:AX726127
C 300	13	1.0	17	1	BD067676	ACCESSION:BD067676	C 373	12.8	1.0	17	1	AX726135	ACCESSION:AX726135
C 301	13	1.0	17	1	BD067677	ACCESSION:BD067677	C 374	12.8	1.0	17	1	AX726286	ACCESSION:AX726286
C 302	13	1.0	17	1	I09655	ACCESSION:I09655	C 375	12.8	1.0	17	1	AX726492	ACCESSION:AX726492
C 303	13	1.0	17	1	I26476	ACCESSION:I26476	C 376	12.8	1.0	17	1	AX727740	ACCESSION:AX727740
C 304	13	1.0	18	1	AX004292	ACCESSION:AX004292	C 377	12.8	1.0	17	1	AX727854	ACCESSION:AX727854
C 305	13	1.0	18	1	AX383945	ACCESSION:AX383945	C 378	12.8	1.0	17	1	AX728103	ACCESSION:AX728103
C 306	13	1.0	18	1	AX417565	ACCESSION:AX417565	C 379	12.8	1.0	17	1	AX728686	ACCESSION:AX728686
C 307	13	1.0	18	1	AX599862	ACCESSION:AX599862	C 380	12.8	1.0	17	1	AX728701	ACCESSION:AX728701
C 308	13	1.0	18	1	BD094132	ACCESSION:BD094132	C 381	12.8	1.0	17	1	AX729056	ACCESSION:AX729056
C 309	13	1.0	18	1	BD094138	ACCESSION:BD094138	C 382	12.8	1.0	17	1	AX729980	ACCESSION:AX729980
C 310	13	1.0	30	1	AX419968	ACCESSION:AX419968	C 383	12.8	1.0	17	1	AX730354	ACCESSION:AX730354
C 311	12.8	1.0	16	1	A89384	ACCESSION:A89384	C 384	12.8	1.0	17	1	AX730419	ACCESSION:AX730419
C 312	12.8	1.0	16	1	AR083145	ACCESSION:AR083145	C 385	12.8	1.0	17	1	AX731759	ACCESSION:AX731759
C 313	12.8	1.0	16	1	AX015629	ACCESSION:AX015629	C 386	12.8	1.0	17	1	AX732065	ACCESSION:AX732065
C 314	12.8	1.0	16	1	BD066897	ACCESSION:BD066897	C 387	12.8	1.0	17	1	AX732416	ACCESSION:AX732416
C 315	12.8	1.0	17	1	AR046181	ACCESSION:AR046181	C 388	12.8	1.0	17	1	AX733161	ACCESSION:AX733161
C 316	12.8	1.0	17	1	AR047244	ACCESSION:AR047244	C 389	12.8	1.0	17	1	AX733379	ACCESSION:AX733379
C 317	12.8	1.0	17	1	AR047262	ACCESSION:AR047262	C 390	12.8	1.0	17	1	AX733381	ACCESSION:AX733381
C 318	12.8	1.0	17	1	AR047360	ACCESSION:AR047360	C 391	12.8	1.0	17	1	AX733982	ACCESSION:AX733982
C 319	12.8	1.0	17	1	AR047362	ACCESSION:AR047362	C 392	12.8	1.0	17	1	AX734084	ACCESSION:AX734084
C 320	12.8	1.0	17	1	AR054096	ACCESSION:AR054096	C 393	12.8	1.0	17	1	AX734468	ACCESSION:AX734468
C 321	12.8	1.0	17	1	AR057779	ACCESSION:AR057779	C 394	12.8	1.0	17	1	AX735132	ACCESSION:AX735132
C 322	12.8	1.0	17	1	AR083146	ACCESSION:AR083146	C 395	12.8	1.0	17	1	AX735198	ACCESSION:AX735198
C 323	12.8	1.0	17	1	AR101662	ACCESSION:AR101662	C 396	12.8	1.0	17	1	AX735395	ACCESSION:AX735395
C 324	12.8	1.0	17	1	AR101663	ACCESSION:AR101663	C 397	12.8	1.0	17	1	AX736068	ACCESSION:AX736068
C 325	12.8	1.0	17	1	AR115537	ACCESSION:AR115537	C 398	12.8	1.0	17	1	AX736295	ACCESSION:AX736295

C 399	12.8	1.0	17	1	AX736998	ACCESSION:AX736998	472	12.4	1.0	15	1	AR193000	ACCESSION:AR193000
C 400	12.8	1.0	17	1	AX737306	ACCESSION:AX737306	473	12.4	1.0	15	1	AR241892	ACCESSION:AR241892
C 401	12.8	1.0	17	1	AX737543	ACCESSION:AX737543	474	12.4	1.0	15	1	AX374587	ACCESSION:AX374587
C 402	12.8	1.0	17	1	AX738128	ACCESSION:AX738128	475	12.4	1.0	15	1	AX419993	ACCESSION:AX419993
C 403	12.8	1.0	17	1	AX738442	ACCESSION:AX738442	476	12.4	1.0	15	1	AX554013	ACCESSION:AX554013
C 404	12.8	1.0	17	1	AX739113	ACCESSION:AX739113	477	12.4	1.0	15	1	AX587124	ACCESSION:AX587124
C 405	12.8	1.0	17	1	BD009326	ACCESSION:BD009326	478	12.4	1.0	15	1	AX633104	ACCESSION:AX633104
C 406	12.8	1.0	17	1	BD009328	ACCESSION:BD009328	479	12.4	1.0	15	1	AX633459	ACCESSION:AX633459
C 407	12.8	1.0	17	1	IS3233	ACCESSION:IS3233	480	12.4	1.0	15	1	AX633577	ACCESSION:AX633577
C 408	12.8	1.0	17	1	IS4296	ACCESSION:IS4296	481	12.4	1.0	15	1	AX635377	ACCESSION:AX635377
C 409	12.8	1.0	17	1	IS4314	ACCESSION:IS4314	482	12.4	1.0	15	1	AX635379	ACCESSION:AX635379
C 410	12.8	1.0	17	1	IS4412	ACCESSION:IS4412	483	12.4	1.0	15	1	AX636864	ACCESSION:AX636864
C 411	12.8	1.0	17	1	IS4414	ACCESSION:IS4414	484	12.4	1.0	15	1	AX636882	ACCESSION:AX636882
C 412	12.8	1.0	18	1	A58293	ACCESSION:A58293	485	12.4	1.0	15	1	AX637403	ACCESSION:AX637403
C 413	12.8	1.0	18	1	A85663	ACCESSION:A85663	486	12.4	1.0	15	1	AX637884	ACCESSION:AX637884
C 414	12.8	1.0	18	1	A90530	ACCESSION:A90530	487	12.4	1.0	15	1	E29991	ACCESSION:E29991
C 415	12.8	1.0	18	1	A91289	ACCESSION:A91289	488	12.4	1.0	15	1	E31788	ACCESSION:E31788
C 416	12.8	1.0	18	1	A96945	ACCESSION:A96945	489	12.4	1.0	15	1	E31789	ACCESSION:E31789
C 417	12.8	1.0	18	1	A97456	ACCESSION:A97456	490	12.4	1.0	15	1	E31790	ACCESSION:E31790
C 418	12.8	1.0	18	1	A99272	ACCESSION:A99272	491	12.4	1.0	15	1	E31791	ACCESSION:E31791
C 419	12.8	1.0	18	1	AR083978	ACCESSION:AR083978	492	12.4	1.0	15	1	E31792	ACCESSION:E31792
C 420	12.8	1.0	18	1	AR087025	ACCESSION:AR087025	493	12.4	1.0	15	1	E31793	ACCESSION:E31793
C 421	12.8	1.0	18	1	AR144082	ACCESSION:AR144082	494	12.4	1.0	15	1	E36075	ACCESSION:E36075
C 422	12.8	1.0	18	1	AR173914	ACCESSION:AR173914	495	12.4	1.0	15	1	E39122	ACCESSION:E39122
C 423	12.8	1.0	18	1	AR215601	ACCESSION:AR215601	496	12.4	1.0	15	1	E39123	ACCESSION:E39123
C 424	12.8	1.0	18	1	AR223848	ACCESSION:AR223848	497	12.4	1.0	15	1	E49631	ACCESSION:E49631
C 425	12.8	1.0	18	1	AR223849	ACCESSION:AR223849	498	12.4	1.0	15	1	E77618	ACCESSION:E77618
C 426	12.8	1.0	18	1	AR242371	ACCESSION:AR242371	499	12.4	1.0	15	1	E81253	ACCESSION:E81253
C 427	12.8	1.0	18	1	AR275401	ACCESSION:AR275401	500	12.4	1.0	15	1	E89848	ACCESSION:E89848
C 428	12.8	1.0	18	1	AR275453	ACCESSION:AR275453	501	12.4	1.0	16	1	AO8781	ACCESSION:AO8781
C 429	12.8	1.0	18	1	AR293315	ACCESSION:AR293315	502	12.4	1.0	16	1	A88098	ACCESSION:A88098
C 430	12.8	1.0	18	1	AR294351	ACCESSION:AR294351	503	12.4	1.0	16	1	A88522	ACCESSION:A88522
C 431	12.8	1.0	18	1	AX132977	ACCESSION:AX132977	504	12.4	1.0	16	1	A88613	ACCESSION:A88613
C 432	12.8	1.0	18	1	AX132979	ACCESSION:AX132979	505	12.4	1.0	16	1	A90065	ACCESSION:A90065
C 433	12.8	1.0	18	1	AX133131	ACCESSION:AX133131	506	12.4	1.0	16	1	A90489	ACCESSION:A90489
C 434	12.8	1.0	18	1	AX235061	ACCESSION:AX235061	507	12.4	1.0	16	1	A90580	ACCESSION:A90580
C 435	12.8	1.0	18	1	AX252918	ACCESSION:AX252918	508	12.4	1.0	16	1	AX088232	ACCESSION:AX088232
C 436	12.8	1.0	18	1	AX348483	ACCESSION:AX348483	509	12.4	1.0	16	1	AX235073	ACCESSION:AX235073
C 437	12.8	1.0	18	1	AX349206	ACCESSION:AX349206	510	12.4	1.0	16	1	AX235096	ACCESSION:AX235096
C 438	12.8	1.0	18	1	AX468612	ACCESSION:AX468612	511	12.4	1.0	16	1	BD065611	ACCESSION:BD065611
C 439	12.8	1.0	18	1	AX599210	ACCESSION:AX599210	512	12.4	1.0	16	1	BD066035	ACCESSION:BD066035
C 440	12.8	1.0	18	1	AX599319	ACCESSION:AX599319	513	12.4	1.0	16	1	BD066126	ACCESSION:BD066126
C 441	12.8	1.0	18	1	AX599396	ACCESSION:AX599396	514	12.4	1.0	16	1	BD091246	ACCESSION:BD091246
C 442	12.8	1.0	18	1	AX599722	ACCESSION:AX599722	515	12.4	1.0	17	1	A89165	ACCESSION:A89165
C 443	12.8	1.0	18	1	AX657871	ACCESSION:AX657871	516	12.4	1.0	17	1	AR046644	ACCESSION:AR046644
C 444	12.8	1.0	18	1	AX705830	ACCESSION:AX705830	517	12.4	1.0	17	1	AR186350	ACCESSION:AR186350
C 445	12.8	1.0	18	1	BD066076	ACCESSION:BD066076	518	12.4	1.0	17	1	AR186590	ACCESSION:AR186590
C 446	12.8	1.0	18	1	BD080876	ACCESSION:BD080876	519	12.4	1.0	17	1	AR186885	ACCESSION:AR186885
C 447	12.8	1.0	19	1	AX129503	ACCESSION:AX129503	520	12.4	1.0	17	1	AR186886	ACCESSION:AR186886
C 448	12.6	1.0	17	1	AR207847	ACCESSION:AR207847	521	12.4	1.0	17	1	AR188361	ACCESSION:AR188361
C 449	12.6	1.0	18	1	AX417571	ACCESSION:AX417571	522	12.4	1.0	17	1	AR188739	ACCESSION:AR188739
C 450	12.6	1.0	24	1	AX084499	ACCESSION:AX084499	523	12.4	1.0	17	1	AR190158	ACCESSION:AR190158
C 451	12.4	1.0	14	1	AR131430	ACCESSION:AR131430	524	12.4	1.0	17	1	AR192044	ACCESSION:AR192044
C 452	12.4	1.0	14	1	AR154236	ACCESSION:AR154236	525	12.4	1.0	17	1	AR192329	ACCESSION:AR192329
C 453	12.4	1.0	14	1	AR176706	ACCESSION:AR176706	526	12.4	1.0	17	1	AR192331	ACCESSION:AR192331
C 454	12.4	1.0	14	1	AR221843	ACCESSION:AR221843	527	12.4	1.0	17	1	AX215016	ACCESSION:AX215016
C 455	12.4	1.0	14	1	I07800	ACCESSION:I07800	528	12.4	1.0	17	1	AX215685	ACCESSION:AX215685
C 456	12.4	1.0	15	1	AR029016	ACCESSION:AR029016	529	12.4	1.0	17	1	AX216740	ACCESSION:AX216740
C 457	12.4	1.0	15	1	AR029017	ACCESSION:AR029017	530	12.4	1.0	17	1	AX217082	ACCESSION:AX217082
C 458	12.4	1.0	15	1	AR041403	ACCESSION:AR041403	531	12.4	1.0	17	1	AX217114	ACCESSION:AX217114
C 459	12.4	1.0	15	1	AR041412	ACCESSION:AR041412	532	12.4	1.0	17	1	AX226925	ACCESSION:AX226925
C 460	12.4	1.0	15	1	AR041927	ACCESSION:AR041927	533	12.4	1.0	17	1	AX226926	ACCESSION:AX226926
C 461	12.4	1.0	15	1	AR056013	ACCESSION:AR056013	534	12.4	1.0	17	1	AX226927	ACCESSION:AX226927
C 462	12.4	1.0	15	1	AR056307	ACCESSION:AR056307	535	12.4	1.0	17	1	AX263192	ACCESSION:AX263192
C 463	12.4	1.0	15	1	AR056547	ACCESSION:AR056547	536	12.4	1.0	17	1	AX263193	ACCESSION:AX263193
C 464	12.4	1.0	15	1	AR087176	ACCESSION:AR087176	537	12.4	1.0	17	1	AX265663	ACCESSION:AX265663
C 465	12.4	1.0	15	1	AR113771	ACCESSION:AR113771	538	12.4	1.0	17	1	AX265664	ACCESSION:AX265664
C 466	12.4	1.0	15	1	AR114065	ACCESSION:AR114065	539	12.4	1.0	17	1	AX272720	ACCESSION:AX272720
C 467	12.4	1.0	15	1	AR114305	ACCESSION:AR114305	540	12.4	1.0	17	1	AX272721	ACCESSION:AX272721
C 468	12.4	1.0	15	1	AR132468	ACCESSION:AR132468	541	12.4	1.0	17	1	AX383942	ACCESSION:AX383942
C 469	12.4	1.0	15	1	AR133635	ACCESSION:AR133635	542	12.4	1.0	17	1	AX421941	ACCESSION:AX421941
C 470	12.4	1.0	15	1	AR170387	ACCESSION:AR170387	543	12.4	1.0	17	1	AX423390	ACCESSION:AX423390
C 471	12.4	1.0	15	1	AR170388	ACCESSION:AR170388	544	12.4	1.0	17	1	AX500362	ACCESSION:AX500362

C 545	12.4	1.0	17	1	AX500368	ACBSSION:AX500368	618	12.2	1.0	17	1	AR047358	ACBSSION:AR047358
C 546	12.4	1.0	17	1	AX500620	ACBSSION:AX500620	619	12.2	1.0	17	1	AR047364	ACBSSION:AR047364
C 547	12.4	1.0	17	1	AX500621	ACBSSION:AX500621	620	12.2	1.0	17	1	AR047604	ACBSSION:AR047604
C 548	12.4	1.0	17	1	AX578723	ACBSSION:AX578723	621	12.2	1.0	17	1	AR051620	ACBSSION:AR051620
C 549	12.4	1.0	17	1	AX579367	ACBSSION:AX579367	622	12.2	1.0	17	1	AR051641	ACBSSION:AR051641
C 550	12.4	1.0	17	1	AX671564	ACBSSION:AX671564	623	12.2	1.0	17	1	AR057785	ACBSSION:AR057785
C 551	12.4	1.0	17	1	AX671663	ACBSSION:AX671663	624	12.2	1.0	17	1	AR057803	ACBSSION:AR057803
C 552	12.4	1.0	17	1	AX672450	ACBSSION:AX672450	625	12.2	1.0	17	1	AR057805	ACBSSION:AR057805
C 553	12.4	1.0	17	1	AX672835	ACBSSION:AX672835	626	12.2	1.0	17	1	AR065109	ACBSSION:AR065109
C 554	12.4	1.0	17	1	AX673316	ACBSSION:AX673316	627	12.2	1.0	17	1	AR080426	ACBSSION:AR080426
C 555	12.4	1.0	17	1	AX673453	ACBSSION:AX673453	628	12.2	1.0	17	1	AR093550	ACBSSION:AR093550
C 556	12.4	1.0	17	1	AX674582	ACBSSION:AX674582	629	12.2	1.0	17	1	AR093550	ACBSSION:AR093550
C 557	12.4	1.0	17	1	AX674587	ACBSSION:AX674587	630	12.2	1.0	17	1	AR115378	ACBSSION:AR115378
C 558	12.4	1.0	17	1	AX722336	ACBSSION:AX722336	631	12.2	1.0	17	1	AR115399	ACBSSION:AR115399
C 559	12.4	1.0	17	1	AX722545	ACBSSION:AX722545	632	12.2	1.0	17	1	AR115543	ACBSSION:AR115543
C 560	12.4	1.0	17	1	AX723257	ACBSSION:AX723257	633	12.2	1.0	17	1	AR115561	ACBSSION:AR115561
C 561	12.4	1.0	17	1	AX724038	ACBSSION:AX724038	634	12.2	1.0	17	1	AR115563	ACBSSION:AR115563
C 562	12.4	1.0	17	1	AX724983	ACBSSION:AX724983	635	12.2	1.0	17	1	AR157370	ACBSSION:AR157370
C 563	12.4	1.0	17	1	AX725250	ACBSSION:AX725250	636	12.2	1.0	17	1	AR186327	ACBSSION:AR186327
C 564	12.4	1.0	17	1	AX726061	ACBSSION:AX726061	637	12.2	1.0	17	1	AR186562	ACBSSION:AR186562
C 565	12.4	1.0	17	1	AX726396	ACBSSION:AX726396	638	12.2	1.0	17	1	AR186699	ACBSSION:AR186699
C 566	12.4	1.0	17	1	AX727438	ACBSSION:AX727438	639	12.2	1.0	17	1	AR186816	ACBSSION:AR186816
C 567	12.4	1.0	17	1	AX729724	ACBSSION:AX729724	640	12.2	1.0	17	1	AR186817	ACBSSION:AR186817
C 568	12.4	1.0	17	1	AX730214	ACBSSION:AX730214	641	12.2	1.0	17	1	AR186851	ACBSSION:AR186851
C 569	12.4	1.0	17	1	AX730221	ACBSSION:AX730221	642	12.2	1.0	17	1	AR186887	ACBSSION:AR186887
C 570	12.4	1.0	17	1	AX730379	ACBSSION:AX730379	643	12.2	1.0	17	1	AR187067	ACBSSION:AR187067
C 571	12.4	1.0	17	1	AX731157	ACBSSION:AX731157	644	12.2	1.0	17	1	AR187212	ACBSSION:AR187212
C 572	12.4	1.0	17	1	AX731513	ACBSSION:AX731513	645	12.2	1.0	17	1	AR187213	ACBSSION:AR187213
C 573	12.4	1.0	17	1	AX731889	ACBSSION:AX731889	646	12.2	1.0	17	1	AR187227	ACBSSION:AR187227
C 574	12.4	1.0	17	1	AX732329	ACBSSION:AX732329	647	12.2	1.0	17	1	AR187306	ACBSSION:AR187306
C 575	12.4	1.0	17	1	AX733592	ACBSSION:AX733592	648	12.2	1.0	17	1	AR187339	ACBSSION:AR187339
C 576	12.4	1.0	17	1	AX735084	ACBSSION:AX735084	649	12.2	1.0	17	1	AR187369	ACBSSION:AR187369
C 577	12.4	1.0	17	1	AX735477	ACBSSION:AX735477	650	12.2	1.0	17	1	AR188360	ACBSSION:AR188360
C 578	12.4	1.0	17	1	AX736558	ACBSSION:AX736558	651	12.2	1.0	17	1	AR188498	ACBSSION:AR188498
C 579	12.4	1.0	17	1	AX736937	ACBSSION:AX736937	652	12.2	1.0	17	1	AR188771	ACBSSION:AR188771
C 580	12.4	1.0	17	1	AX737227	ACBSSION:AX737227	653	12.2	1.0	17	1	AR192457	ACBSSION:AR192457
C 581	12.4	1.0	17	1	AX738005	ACBSSION:AX738005	654	12.2	1.0	17	1	AR192474	ACBSSION:AR192474
C 582	12.4	1.0	17	1	AX738018	ACBSSION:AX738018	655	12.2	1.0	17	1	AR192646	ACBSSION:AR192646
C 583	12.4	1.0	17	1	AX738565	ACBSSION:AX738565	656	12.2	1.0	17	1	AR196327	ACBSSION:AR196327
C 584	12.4	1.0	17	1	AX739077	ACBSSION:AX739077	657	12.2	1.0	17	1	AR207848	ACBSSION:AR207848
C 585	12.4	1.0	17	1	AX739138	ACBSSION:AX739138	658	12.2	1.0	17	1	AR207851	ACBSSION:AR207851
C 586	12.4	1.0	17	1	AX739438	ACBSSION:AX739438	659	12.2	1.0	17	1	AR207853	ACBSSION:AR207853
C 587	12.4	1.0	17	1	AX739515	ACBSSION:AX739515	660	12.2	1.0	17	1	AR207853	ACBSSION:AR207853
C 588	12.4	1.0	17	1	AX739551	ACBSSION:AX739551	661	12.2	1.0	17	1	AR221781	ACBSSION:AR221781
C 589	12.4	1.0	17	1	AX739830	ACBSSION:AX739830	662	12.2	1.0	17	1	AR254826	ACBSSION:AR254826
C 590	12.4	1.0	17	1	BD066678	ACBSSION:BD066678	663	12.2	1.0	17	1	AR258348	ACBSSION:AR258348
C 591	12.4	1.0	17	1	BD067358	ACBSSION:BD067358	664	12.2	1.0	17	1	AR262898	ACBSSION:AR262898
C 592	12.4	1.0	17	1	BD092096	ACBSSION:BD092096	665	12.2	1.0	17	1	AR266625	ACBSSION:AR266625
C 593	12.4	1.0	17	1	I37415	ACBSSION:I37415	666	12.2	1.0	17	1	AR286163	ACBSSION:AR286163
C 594	12.4	1.0	17	1	I53696	ACBSSION:I53696	667	12.2	1.0	17	1	AX029315	ACBSSION:AX029315
C 595	12.4	1.0	17	1	I94265	ACBSSION:I94265	668	12.2	1.0	17	1	AX206986	ACBSSION:AX206986
C 596	12.4	1.0	17	1	BD182174	ACBSSION:BD182174	669	12.2	1.0	17	1	AX214665	ACBSSION:AX214665
C 597	12.4	1.0	17	1	A04026	ACBSSION:A04026	670	12.2	1.0	17	1	AX215017	ACBSSION:AX215017
C 598	12.2	1.0	17	1	A04027	ACBSSION:A04027	671	12.2	1.0	17	1	AX215079	ACBSSION:AX215079
C 599	12.2	1.0	17	1	A09201	ACBSSION:A09201	672	12.2	1.0	17	1	AX215156	ACBSSION:AX215156
C 600	12.2	1.0	17	1	A64296	ACBSSION:A64296	673	12.2	1.0	17	1	AX215198	ACBSSION:AX215198
C 601	12.2	1.0	17	1	A88483	ACBSSION:A88483	674	12.2	1.0	17	1	AX215220	ACBSSION:AX215220
C 602	12.2	1.0	17	1	A90450	ACBSSION:A90450	675	12.2	1.0	17	1	AX215570	ACBSSION:AX215570
C 603	12.2	1.0	17	1	A97833	ACBSSION:A97833	676	12.2	1.0	17	1	AX216249	ACBSSION:AX216249
C 604	12.2	1.0	17	1	AR045949	ACBSSION:AR045949	677	12.2	1.0	17	1	AX216420	ACBSSION:AX216420
C 605	12.2	1.0	17	1	AR045999	ACBSSION:AR045999	678	12.2	1.0	17	1	AX216599	ACBSSION:AX216599
C 606	12.2	1.0	17	1	AR045999	ACBSSION:AR045999	679	12.2	1.0	17	1	AX216808	ACBSSION:AX216808
C 607	12.2	1.0	17	1	AR046167	ACBSSION:AR046167	680	12.2	1.0	17	1	AX217250	ACBSSION:AX217250
C 608	12.2	1.0	17	1	AR046169	ACBSSION:AR046169	681	12.2	1.0	17	1	AX217422	ACBSSION:AX217422
C 609	12.2	1.0	17	1	AR046255	ACBSSION:AR046255	682	12.2	1.0	17	1	AX218022	ACBSSION:AX218022
C 610	12.2	1.0	17	1	AR046255	ACBSSION:AR046255	683	12.2	1.0	17	1	AX218103	ACBSSION:AX218103
C 611	12.2	1.0	17	1	AR046285	ACBSSION:AR046285	684	12.2	1.0	17	1	AX218166	ACBSSION:AX218166
C 612	12.2	1.0	17	1	AR047078	ACBSSION:AR047078	685	12.2	1.0	17	1	AX2227049	ACBSSION:AX2227049
C 613	12.2	1.0	17	1	AR047092	ACBSSION:AR047092	686	12.2	1.0	17	1	AX227468	ACBSSION:AX227468
C 614	12.2	1.0	17	1	AR047108	ACBSSION:AR047108	687	12.2	1.0	17	1	AX263172	ACBSSION:AX263172
C 615	12.2	1.0	17	1	AR047190	ACBSSION:AR047190	688	12.2	1.0	17	1	AX263173	ACBSSION:AX263173
C 616	12.2	1.0	17	1	AR047354	ACBSSION:AR047354	689	12.2	1.0	17	1	AX263380	ACBSSION:AX263380
C 617	12.2	1.0	17	1	AR047356	ACBSSION:AR047356	690	12.2	1.0	17	1	AX263381	ACBSSION:AX263381

691	12.2	1.0	17	1	AX264332	ACCESSION:AX264332
692	12.2	1.0	17	1	AX264333	ACCESSION:AX264333
693	12.2	1.0	17	1	AX264767	ACCESSION:AX264767
694	12.2	1.0	17	1	AX264768	ACCESSION:AX264768
695	12.2	1.0	17	1	AX265047	ACCESSION:AX265047
696	12.2	1.0	17	1	AX265048	ACCESSION:AX265048
697	12.2	1.0	17	1	AX265051	ACCESSION:AX265051
698	12.2	1.0	17	1	AX265052	ACCESSION:AX265052
699	12.2	1.0	17	1	AX265147	ACCESSION:AX265147
700	12.2	1.0	17	1	AX265148	ACCESSION:AX265148
701	12.2	1.0	17	1	AX265151	ACCESSION:AX265151
702	12.2	1.0	17	1	AX265152	ACCESSION:AX265152
703	12.2	1.0	17	1	AX266795	ACCESSION:AX266795
704	12.2	1.0	17	1	AX266796	ACCESSION:AX266796
705	12.2	1.0	17	1	AX272674	ACCESSION:AX272674
706	12.2	1.0	17	1	AX272675	ACCESSION:AX272675
707	12.2	1.0	17	1	AX272689	ACCESSION:AX272689
708	12.2	1.0	17	1	AX273017	ACCESSION:AX273017
709	12.2	1.0	17	1	AX274693	ACCESSION:AX274693
710	12.2	1.0	17	1	AX324694	ACCESSION:AX324694
711	12.2	1.0	17	1	AX325141	ACCESSION:AX325141
712	12.2	1.0	17	1	AX325142	ACCESSION:AX325142
713	12.2	1.0	17	1	AX326013	ACCESSION:AX326013
714	12.2	1.0	17	1	AX326014	ACCESSION:AX326014
715	12.2	1.0	17	1	AX326473	ACCESSION:AX326473
716	12.2	1.0	17	1	AX326474	ACCESSION:AX326474
717	12.2	1.0	17	1	AX393409	ACCESSION:AX393409
718	12.2	1.0	17	1	AX421792	ACCESSION:AX421792
719	12.2	1.0	17	1	AX421950	ACCESSION:AX421950
720	12.2	1.0	17	1	AX422015	ACCESSION:AX422015
721	12.2	1.0	17	1	AX422082	ACCESSION:AX422082
722	12.2	1.0	17	1	AX422103	ACCESSION:AX422103
723	12.2	1.0	17	1	AX422116	ACCESSION:AX422116
724	12.2	1.0	17	1	AX422708	ACCESSION:AX422708
725	12.2	1.0	17	1	AX423057	ACCESSION:AX423057
726	12.2	1.0	17	1	AX423166	ACCESSION:AX423166
727	12.2	1.0	17	1	AX423167	ACCESSION:AX423167
728	12.2	1.0	17	1	AX423293	ACCESSION:AX423293
729	12.2	1.0	17	1	AX423345	ACCESSION:AX423345
730	12.2	1.0	17	1	AX423389	ACCESSION:AX423389
731	12.2	1.0	17	1	AX423598	ACCESSION:AX423598
732	12.2	1.0	17	1	AX428711	ACCESSION:AX428711
733	12.2	1.0	17	1	AX499533	ACCESSION:AX499533
734	12.2	1.0	17	1	AX499867	ACCESSION:AX499867
735	12.2	1.0	17	1	AX499868	ACCESSION:AX499868
736	12.2	1.0	17	1	AX499997	ACCESSION:AX499997
737	12.2	1.0	17	1	AX502719	ACCESSION:AX502719
738	12.2	1.0	17	1	AX502968	ACCESSION:AX502968
739	12.2	1.0	17	1	AX503052	ACCESSION:AX503052
740	12.2	1.0	17	1	AX503053	ACCESSION:AX503053
741	12.2	1.0	17	1	AX527175	ACCESSION:AX527175
742	12.2	1.0	17	1	AX531355	ACCESSION:AX531355
743	12.2	1.0	17	1	AX531356	ACCESSION:AX531356
744	12.2	1.0	17	1	AX531483	ACCESSION:AX531483
745	12.2	1.0	17	1	AX532080	ACCESSION:AX532080
746	12.2	1.0	17	1	AX572026	ACCESSION:AX572026
747	12.2	1.0	17	1	AX572825	ACCESSION:AX572825
748	12.2	1.0	17	1	AX578220	ACCESSION:AX578220
749	12.2	1.0	17	1	AX578273	ACCESSION:AX578273
750	12.2	1.0	17	1	AX578687	ACCESSION:AX578687
751	12.2	1.0	17	1	AX578733	ACCESSION:AX578733
752	12.2	1.0	17	1	AX578825	ACCESSION:AX578825
753	12.2	1.0	17	1	AX579184	ACCESSION:AX579184
754	12.2	1.0	17	1	AX579358	ACCESSION:AX579358
755	12.2	1.0	17	1	AX579392	ACCESSION:AX579392
756	12.2	1.0	17	1	AX579804	ACCESSION:AX579804
757	12.2	1.0	17	1	AX579811	ACCESSION:AX579811
758	12.2	1.0	17	1	AX634690	ACCESSION:AX634690
759	12.2	1.0	17	1	AX634732	ACCESSION:AX634732
760	12.2	1.0	17	1	AX634825	ACCESSION:AX634825
761	12.2	1.0	17	1	AX634861	ACCESSION:AX634861
762	12.2	1.0	17	1	AX634864	ACCESSION:AX634864
763	12.2	1.0	17	1	AX648466	ACCESSION:AX648466
1	12.2	1.0	17	1	AX648467	ACCESSION:AX648467
1	12.2	1.0	17	1	AX648579	ACCESSION:AX648579
1	12.2	1.0	17	1	AX648581	ACCESSION:AX648581
1	12.2	1.0	17	1	AX648667	ACCESSION:AX648667
1	12.2	1.0	17	1	AX671571	ACCESSION:AX671571
1	12.2	1.0	17	1	AX671571	ACCESSION:AX671571
1	12.2	1.0	17	1	AX671600	ACCESSION:AX671600
1	12.2	1.0	17	1	AX671657	ACCESSION:AX671657
1	12.2	1.0	17	1	AX672578	ACCESSION:AX672578
1	12.2	1.0	17	1	AX672799	ACCESSION:AX672799
1	12.2	1.0	17	1	AX672898	ACCESSION:AX672898
1	12.2	1.0	17	1	AX673031	ACCESSION:AX673031
1	12.2	1.0	17	1	AX673430	ACCESSION:AX673430
1	12.2	1.0	17	1	AX674727	ACCESSION:AX674727
1	12.2	1.0	17	1	AX674800	ACCESSION:AX674800
1	12.2	1.0	17	1	AX687406	ACCESSION:AX687406
1	12.2	1.0	17	1	AX687451	ACCESSION:AX687451
1	12.2	1.0	17	1	AX691337	ACCESSION:AX691337
1	12.2	1.0	17	1	AX692522	ACCESSION:AX692522
1	12.2	1.0	17	1	AX692526	ACCESSION:AX692526
1	12.2	1.0	17	1	AX722376	ACCESSION:AX722376
1	12.2	1.0	17	1	AX722391	ACCESSION:AX722391
1	12.2	1.0	17	1	AX723177	ACCESSION:AX723177
1	12.2	1.0	17	1	AX723495	ACCESSION:AX723495
1	12.2	1.0	17	1	AX723876	ACCESSION:AX723876
1	12.2	1.0	17	1	AX724563	ACCESSION:AX724563
1	12.2	1.0	17	1	AX726475	ACCESSION:AX726475
1	12.2	1.0	17	1	AX726611	ACCESSION:AX726611
1	12.2	1.0	17	1	AX726698	ACCESSION:AX726698
1	12.2	1.0	17	1	AX727922	ACCESSION:AX727922
1	12.2	1.0	17	1	AX728060	ACCESSION:AX728060
1	12.2	1.0	17	1	AX728122	ACCESSION:AX728122
1	12.2	1.0	17	1	AX728315	ACCESSION:AX728315
1	12.2	1.0	17	1	AX728823	ACCESSION:AX728823
1	12.2	1.0	17	1	AX728846	ACCESSION:AX728846
1	12.2	1.0	17	1	AX728945	ACCESSION:AX728945
1	12.2	1.0	17	1	AX730965	ACCESSION:AX730965
1	12.2	1.0	17	1	AX731415	ACCESSION:AX731415
1	12.2	1.0	17	1	AX732425	ACCESSION:AX732425
1	12.2	1.0	17	1	AX733105	ACCESSION:AX733105
1	12.2	1.0	17	1	AX733543	ACCESSION:AX733543
1	12.2	1.0	17	1	AX735047	ACCESSION:AX735047
1	12.2	1.0	17	1	AX735909	ACCESSION:AX735909
1	12.2	1.0	17	1	AX735978	ACCESSION:AX735978
1	12.2	1.0	17	1	AX736175	ACCESSION:AX736175
1	12.2	1.0	17	1	AX736626	ACCESSION:AX736626
1	12.2	1.0	17	1	AX737074	ACCESSION:AX737074
1	12.2	1.0	17	1	AX738139	ACCESSION:AX738139
1	12.2	1.0	17	1	AX738829	ACCESSION:AX738829
1	12.2	1.0	17	1	AX738984	ACCESSION:AX738984
1	12.2	1.0	17	1	AX744141	ACCESSION:AX744141
1	12.2	1.0	17	1	AX745054	ACCESSION:AX745054
1	12.2	1.0	17	1	AX745056	ACCESSION:AX745056
1	12.2	1.0	17	1	BD065996	ACCESSION:BD065996
1	12.2	1.0	17	1	BD067425	ACCESSION:BD067425
1	12.2	1.0	17	1	BD067935	ACCESSION:BD067935
1	12.2	1.0	17	1	BD073195	ACCESSION:BD073195
1	12.2	1.0	17	1	BD087253	ACCESSION:BD087253
1	12.2	1.0	17	1	I32318	ACCESSION:I32318
1	12.2	1.0	17	1	I32319	ACCESSION:I32319
1	12.2	1.0	17	1	I53001	ACCESSION:I53001
1	12.2	1.0	17	1	I53051	ACCESSION:I53051
1	12.2	1.0	17	1	I53051	ACCESSION:I53051
1	12.2	1.0	17	1	I53219	ACCESSION:I53219
1	12.2	1.0	17	1	I53221	ACCESSION:I53221
1	12.2	1.0	17	1	I53307	ACCESSION:I53307
1	12.2	1.0	17	1	I53307	ACCESSION:I53307
1	12.2	1.0	17	1	I53317	ACCESSION:I53317
1	12.2	1.0	17	1	I54130	ACCESSION:I54130
1	12.2	1.0	17	1	I54144	ACCESSION:I54144
1	12.2	1.0	17	1	I54160	ACCESSION:I54160
1	12.2	1.0	17	1	I54242	ACCESSION:I54242
1	12.2	1.0	17	1	I54406	ACCESSION:I54406
1	12.2	1.0	17	1	I54408	ACCESSION:I54408

837	12.2	1.0	17	1	154410	ACCESSION:154410	C 910	12	1.0	15	1	177804	ACCESSION:177804
838	12.2	1.0	17	1	154416	ACCESSION:154416	C 911	12	1.0	15	1	177891	ACCESSION:177891
839	12.2	1.0	17	1	154556	ACCESSION:154556	C 912	12	1.0	16	1	A88497	ACCESSION:A88497
840	12.2	1.0	17	1	ATH529445	ACCESSION:ATH529445	C 913	12	1.0	16	1	A88647	ACCESSION:A88647
841	12.2	1.0	18	1	AR165969	ACCESSION:AR165969	C 914	12	1.0	16	1	A90464	ACCESSION:A90464
842	12.2	1.0	18	1	AR285276	ACCESSION:AR285276	C 915	12	1.0	16	1	A90614	ACCESSION:A90614
843	12.2	1.0	18	1	AX643248	ACCESSION:AX643248	C 916	12	1.0	16	1	AR165130	ACCESSION:AR165130
844	12.2	1.0	18	1	AX643251	ACCESSION:AX643251	C 917	12	1.0	16	1	BD066010	ACCESSION:BD066010
845	12.2	1.0	18	1	E60081	ACCESSION:E60081	C 918	12	1.0	16	1	BD066160	ACCESSION:BD066160
846	12.2	1.0	18	1	AX599396	ACCESSION:AX599396	C 919	12	1.0	17	1	AX736998	ACCESSION:AX736998
847	12.2	1.0	20	1	AX419972	ACCESSION:AX419972	C 920	12	1.0	17	1	A88498	ACCESSION:A88498
848	12.2	1.0	20	1	BD138313	ACCESSION:BD138313	C 921	12	1.0	17	1	A90465	ACCESSION:A90465
849	12.2	1.0	20	1	ATH552863	ACCESSION:ATH552863	C 922	12	1.0	17	1	AR047246	ACCESSION:AR047246
850	12.2	1.0	21	1	BD236360	ACCESSION:BD236360	C 923	12	1.0	17	1	AR186564	ACCESSION:AR186564
851	12	1.0	12	1	A61502	ACCESSION:A61502	C 924	12	1.0	17	1	AR187325	ACCESSION:AR187325
852	12	1.0	12	1	AR199094	ACCESSION:AR199094	C 925	12	1.0	17	1	AR187326	ACCESSION:AR187326
853	12	1.0	12	1	AR241715	ACCESSION:AR241715	C 926	12	1.0	17	1	AR190442	ACCESSION:AR190442
854	12	1.0	14	1	A88495	ACCESSION:A88495	C 927	12	1.0	17	1	AR190443	ACCESSION:AR190443
855	12	1.0	14	1	A88649	ACCESSION:A88649	C 928	12	1.0	17	1	AR190444	ACCESSION:AR190444
856	12	1.0	14	1	A90462	ACCESSION:A90462	C 929	12	1.0	17	1	AX214676	ACCESSION:AX214676
857	12	1.0	14	1	A90616	ACCESSION:A90616	C 930	12	1.0	17	1	AX214677	ACCESSION:AX214677
858	12	1.0	14	1	BD066008	ACCESSION:BD066008	C 931	12	1.0	17	1	AX214678	ACCESSION:AX214678
859	12	1.0	14	1	BD066162	ACCESSION:BD066162	C 932	12	1.0	17	1	AX214795	ACCESSION:AX214795
860	12	1.0	15	1	A15311	ACCESSION:A15311	C 933	12	1.0	17	1	AX214989	ACCESSION:AX214989
861	12	1.0	15	1	AL6511	ACCESSION:AL6511	C 934	12	1.0	17	1	AX214990	ACCESSION:AX214990
862	12	1.0	15	1	A88496	ACCESSION:A88496	C 935	12	1.0	17	1	AX214991	ACCESSION:AX214991
863	12	1.0	15	1	A88646	ACCESSION:A88646	C 936	12	1.0	17	1	AX215858	ACCESSION:AX215858
864	12	1.0	15	1	A90463	ACCESSION:A90463	C 937	12	1.0	17	1	AX216684	ACCESSION:AX216684
865	12	1.0	15	1	A90613	ACCESSION:A90613	C 938	12	1.0	17	1	AX216730	ACCESSION:AX216730
866	12	1.0	15	1	AR041397	ACCESSION:AR041397	C 939	12	1.0	17	1	AX217071	ACCESSION:AX217071
867	12	1.0	15	1	AR041405	ACCESSION:AR041405	C 940	12	1.0	17	1	AX263360	ACCESSION:AX263360
868	12	1.0	15	1	AR041418	ACCESSION:AR041418	C 941	12	1.0	17	1	AX263361	ACCESSION:AX263361
869	12	1.0	15	1	AR041419	ACCESSION:AR041419	C 942	12	1.0	17	1	AX264543	ACCESSION:AX264543
870	12	1.0	15	1	AR041420	ACCESSION:AR041420	C 943	12	1.0	17	1	AX264544	ACCESSION:AX264544
871	12	1.0	15	1	AR041913	ACCESSION:AR041913	C 944	12	1.0	17	1	AX272719	ACCESSION:AX272719
872	12	1.0	15	1	AR041914	ACCESSION:AR041914	C 945	12	1.0	17	1	AX273119	ACCESSION:AX273119
873	12	1.0	15	1	AR041929	ACCESSION:AR041929	C 946	12	1.0	17	1	AX500360	ACCESSION:AX500360
874	12	1.0	15	1	AR041939	ACCESSION:AR041939	C 947	12	1.0	17	1	AX500361	ACCESSION:AX500361
875	12	1.0	15	1	AR041940	ACCESSION:AR041940	C 948	12	1.0	17	1	AX500436	ACCESSION:AX500436
876	12	1.0	15	1	AR041941	ACCESSION:AR041941	C 949	12	1.0	17	1	AX500437	ACCESSION:AX500437
877	12	1.0	15	1	AR056012	ACCESSION:AR056012	C 950	12	1.0	17	1	AX500438	ACCESSION:AX500438
878	12	1.0	15	1	AR056294	ACCESSION:AR056294	C 951	12	1.0	17	1	AX500439	ACCESSION:AX500439
879	12	1.0	15	1	AR056374	ACCESSION:AR056374	C 952	12	1.0	17	1	AX500440	ACCESSION:AX500440
880	12	1.0	15	1	AR113770	ACCESSION:AR113770	C 953	12	1.0	17	1	AX500441	ACCESSION:AX500441
881	12	1.0	15	1	AR114052	ACCESSION:AR114052	C 954	12	1.0	17	1	AX578690	ACCESSION:AX578690
882	12	1.0	15	1	AR114132	ACCESSION:AR114132	C 955	12	1.0	17	1	AX671598	ACCESSION:AX671598
883	12	1.0	15	1	AX633102	ACCESSION:AX633102	C 956	12	1.0	17	1	AX672197	ACCESSION:AX672197
884	12	1.0	15	1	AX633446	ACCESSION:AX633446	C 957	12	1.0	17	1	AX672415	ACCESSION:AX672415
885	12	1.0	15	1	AX633616	ACCESSION:AX633616	C 958	12	1.0	17	1	AX672536	ACCESSION:AX672536
886	12	1.0	15	1	AX635389	ACCESSION:AX635389	C 959	12	1.0	17	1	AX673577	ACCESSION:AX673577
887	12	1.0	15	1	AX635391	ACCESSION:AX635391	C 960	12	1.0	17	1	AX723158	ACCESSION:AX723158
888	12	1.0	15	1	AX635393	ACCESSION:AX635393	C 961	12	1.0	17	1	AX723252	ACCESSION:AX723252
889	12	1.0	15	1	AX635413	ACCESSION:AX635413	C 962	12	1.0	17	1	AX723252	ACCESSION:AX723252
890	12	1.0	15	1	AX636853	ACCESSION:AX636853	C 963	12	1.0	17	1	AX725994	ACCESSION:AX725994
891	12	1.0	15	1	AX636868	ACCESSION:AX636868	C 964	12	1.0	17	1	AX726152	ACCESSION:AX726152
892	12	1.0	15	1	AX636894	ACCESSION:AX636894	C 965	12	1.0	17	1	AX727032	ACCESSION:AX727032
893	12	1.0	15	1	AX636896	ACCESSION:AX636896	C 966	12	1.0	17	1	AX727182	ACCESSION:AX727182
894	12	1.0	15	1	AX636898	ACCESSION:AX636898	C 967	12	1.0	17	1	AX727214	ACCESSION:AX727214
895	12	1.0	15	1	AX637375	ACCESSION:AX637375	C 968	12	1.0	17	1	AX728795	ACCESSION:AX728795
896	12	1.0	15	1	AX637377	ACCESSION:AX637377	C 969	12	1.0	17	1	AX730870	ACCESSION:AX730870
897	12	1.0	15	1	AX637407	ACCESSION:AX637407	C 970	12	1.0	17	1	AX731363	ACCESSION:AX731363
898	12	1.0	15	1	AX637423	ACCESSION:AX637423	C 971	12	1.0	17	1	AX732412	ACCESSION:AX732412
899	12	1.0	15	1	AX637424	ACCESSION:AX637424	C 972	12	1.0	17	1	AX732979	ACCESSION:AX732979
900	12	1.0	15	1	AX637425	ACCESSION:AX637425	C 973	12	1.0	17	1	AX733611	ACCESSION:AX733611
901	12	1.0	15	1	AX638328	ACCESSION:AX638328	C 974	12	1.0	17	1	AX734657	ACCESSION:AX734657
902	12	1.0	15	1	AX638404	ACCESSION:AX638404	C 975	12	1.0	17	1	BD066011	ACCESSION:BD066011
903	12	1.0	15	1	BD066009	ACCESSION:BD066009	C 976	12	1.0	17	1	BD067356	ACCESSION:BD067356
904	12	1.0	15	1	BD066159	ACCESSION:BD066159	C 977	12	1.0	17	1	BD067357	ACCESSION:BD067357
905	12	1.0	15	1	I35095	ACCESSION:I35095	C 978	12	1.0	17	1	BD067673	ACCESSION:BD067673
906	12	1.0	15	1	I39128	ACCESSION:I39128	C 979	12	1.0	17	1	BD067873	ACCESSION:BD067873
907	12	1.0	15	1	I39129	ACCESSION:I39129	C 980	12	1.0	17	1	I54298	ACCESSION:I54298
908	12	1.0	15	1	I39130	ACCESSION:I39130	C 981	11.8	0.9	15	1	AR041398	ACCESSION:AR041398
909	12	1.0	15	1	I39140	ACCESSION:I39140	C 982	11.8	0.9	15	1	AR041915	ACCESSION:AR041915

C 983	11.8	15 1	AX636855	ACCESSION:AX636855
C 984	11.8	15 1	AX637379	ACCESSION:AX637379

ALIGNMENTS

RESULT 1	AX419968/c	AX419968	Sequence 305 from Patent WO0198537.	30 bp	DNA	linear	PAT 18-JUN-2002
LOCUS	AX419968	AX419968	Sequence 305 from Patent WO0198537.				
DEFINITION	AX419968	AX419968	Sequence 305 from Patent WO0198537.				
ACCESSION	AX419968	AX419968	Sequence 305 from Patent WO0198537.				
VERSION	AX419968.1	AX419968.1	GI:21524335				
KEYWORDS			synthetic construct				
SOURCE			synthetic construct				
ORGANISM			artificial sequences.				
REFERENCE			1				
AUTHORS			Lyamichev, V., Allawi, H., Dong, P., Neri, B. P. and Vener, I. T.				
TITLE			Nucleic acid accessible hybridization sites				
JOURNAL			Patent: WO 0198537-A 305 27-DEC-2001;				
FEATURES			THIRD WAVE TECHNOLOGIES, INC. (US)				
source			Location/Qualifiers				
			1..30				
			/organism="synthetic construct"				
			/mol_type="genomic DNA"				
			/db_xref="taxon:32630"				
			13 a	2 5	11 t		
BASE COUNT							
			Query Match	2.4%	Score 30;	DB 1;	Length 30;
			Best Local Similarity	100.0%;	Pred. No. 0.056;		
			Matches 30;	Conservative	0;	Mismatches	0;
						Indels	0;
						Gaps	0;

QY 1165 ATGATGTTTATTAGATAAAATTCATCAG 1194
|||||

D6 30 ATGATGTTTATTAGATAAAATTCATCAG 1

RESULT 2	
BD182174	
LOCUS	30 bp DNA
DEFINITION	Method for synthesizing of nucleic acid.
ACCESSION	BD182174
VERSION	BD182174.1 GI:30793032
KEYWORDS	WO 02090538-A/6.
SOURCE	synthetic construct
ORGANISM	artificial sequences.
REFERENCE	1 (bases 1 to 30)
AUTHORS	Nagamine,K.
TITLE	Method for synthesizing of nucleic acid
JOURNAL	Patent: WO 02090538-A 5 14-NOV-2002;
	BIKEN CHEMICAL CO LTD,KENTARO NAGAMINE
COMMENT	OS Artificial Sequence

```

PC      C12N15/09.C12Q1/68
CC      Description of Artificial Sequence:an artificially synthesized

CC      CC
CC      primer
CC      sequence
FH      key          Location/Qualifiers
FT      source       1..30
                    /organism='Artificial Sequence'.

FEATURES
    source
        1..30
            /organism='synthetic construct'
            /mol_type='Genomic DNA'
            /db_xref='taxon:32630'
    13 a_3 c 5 g 9 t
BASE COUNT

```

```

Query Match      2.4%  Score 30;  DB 1;  Length 30;
Best Local Similarity 100.0%;  Pred. No. 0.056;
Matches 30;  Conservative 0;  Mismatches 0;  Indels
QY 1065  CATCAATAATTTGTGCAAGAAATTTGCAAAA 1094
Db 1 CATCAATAATTTGTGCAAGAAATTTGCAAAA 30

```

RESULT 3	
BD182175/c	
LOCUS	BD182175 30 bp DNA linear
DEFINITION	Method for synthesizing of nucleic acid.
ACCESSION	BD182175
VERSION	BD182175.1 GI:30793093
KEYWORDS	WO 02090538-A/7.
SOURCE	synthetic construct
ORGANISM	synthetic construct artificial sequences. 1 (bases 1 to 30) Nagamine,K.
REFERENCE	Method for synthesizing of nucleic acid
AUTHORS	Title Patent: WO 02090538-A 7 14-NOV-2002;
TITLE	EIKEN CHEMICAL CO LTD,KENTARO NAGAMINE
JOURNAL	OS Artificial Sequence
COMMENT	

PD	14-NOV-2002	WO	2002JP004479		
PR	08-MAY-2002	JP	01P	137060,18-JUN-2001	JP 01P 184131 PT
PC	08-MAY-2001	JP	01P	137060,18-JUN-2001	JP 01P 184131 PT
CC	KENTARO NAGAMINE				
CC	C12N15/09,C12Q1/68				
CC	Description of Artificial Sequence:an artificially synthesized				

```

CC      sequence      primer
CC      key           Location/Qualifiers
FH      1..30        /organism='Artificial Sequence',
FT      source        Location/Qualifiers
                    1..30
                    /organism='synthetic construct'
                    /mol_type='genomic DNA'
                    /db_xref='taxon:32630'
15 a      2 g      11 t
BASE COUNT

```

Query Match	2.4%;	Score 30;	DB 1;	Length 30;
Best Local Similarity	100.0%;	Pred. No. 0.056;		
Matches 30;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;
QY	1045	TATTTATGTATTTTATTTTAAAGCATCAATAT	1074	
Ph	30	TATTTATGTATTTTATTTTAAAGCATCAATAT	1	

[illegible]

SOURCE	synthetic construct
ORGANISM	synthetic construct
	artificial sequences.
REFERENCE	1
AUTHORS	Hull, J. and Kwiatkowski, D. P.
TITLE	Genetic factor affecting cytokine expression
JOURNAL	Patent: WO 9177382-A 17 18-OCT-2001;
	ISIS INNOVATION LIMITED (GB)
FEATURES	Location/Qualifiers
source	1. .26 /organism="synthetic construct"

```

/mol_type="genomic DNA"
/db_xref="taxon:32630"
/notes="Oligonucleotide"
BASE COUNT      9 a      5 c      2 g      10 t

Query Match
Best Local Similarity 2.1%; Score 26; DB 1; Length 26;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1228 CCCAGTTAAATTTTCATTTCAGATA 1253
Db 1 CCCAGTTAAATTTTCATTTCAGATA 26

RESULT 5
AX280041
LOCUS      AX280041      26 bp      DNA      linear      PAT 02-NOV-2001
DEFINITION Sequence 16 from Patent WO0177382.
ACCESSION  AX280041
VERSION     AX280041.1 GI:16607492
KEYWORDS   .
SOURCE      synthetic construct
ORGANISM    synthetic construct
            artificial sequences.
REFERENCE   1
AUTHORS     Hull, J. and Kwiatkowski, D. P.
TITLE       Genetic factor affecting cytokine expression
JOURNAL     Patent: WO 0177382-A 16 18-OCT-2001;
            ISIS INNOVATION LIMITED (GB)
FEATURES   Location/Qualifiers
            source
            1..26
            /organism="synthetic construct"
            /mol_type="genomic DNA"
            /db_xref="taxon:32630"
            /notes="Oligonucleotide"
BASE COUNT      8 a      5 c      2 g      11 t

Query Match
Best Local Similarity 2.0%; Score 25; DB 1; Length 26;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1228 CCCAGTTAAATTTTCATTTCAGATA 1252
Db 1 CCCAGTTAAATTTTCATTTCAGATA 25

RESULT 6
AR207732/c
LOCUS      AR207732      24 bp      DNA      linear      PAT 20-JUN-2002
DEFINITION Sequence 72 from patent US 6379897.
ACCESSION  AR207732
VERSION     AR207732.1 GI:21507563
KEYWORDS   .
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE   1 (bases 1 to 24)
AUTHORS     Weidenhammer, E.M., Wang, L., Xu, X., Heller, M.J. and Kahl, B.F.
TITLE       Methods for gene expression monitoring on electronic microarrays
JOURNAL     Patent: US 6379897-A 72 30-APR-2002;
            Location/Qualifiers
            source
            1..24
            /organism="unknown"
BASE COUNT      9 a      11 c      3 g      1 t

Query Match
Best Local Similarity 1.9%; Score 24; DB 1; Length 24;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 475 GTGTGGTCTGTGTAGGTTGCC 498
Db 24 GTGTGGTCTGTGTAGGTTGCC 1

/mol_type="genomic DNA"
/db_xref="taxon:32630"
/notes="Oligonucleotide"
BASE COUNT      9 a      5 c      2 g      10 t

Query Match
Best Local Similarity 2.1%; Score 26; DB 1; Length 26;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1228 CCCAGTTAAATTTTCATTTCAGATA 1253
Db 1 CCCAGTTAAATTTTCATTTCAGATA 26

RESULT 5
AX280041
LOCUS      AX280041      26 bp      DNA      linear      PAT 02-NOV-2001
DEFINITION Sequence 16 from Patent WO0177382.
ACCESSION  AX280041
VERSION     AX280041.1 GI:16607492
KEYWORDS   .
SOURCE      synthetic construct
ORGANISM    synthetic construct
            artificial sequences.
REFERENCE   1
AUTHORS     Hull, J. and Kwiatkowski, D. P.
TITLE       Genetic factor affecting cytokine expression
JOURNAL     Patent: WO 0177382-A 16 18-OCT-2001;
            ISIS INNOVATION LIMITED (GB)
FEATURES   Location/Qualifiers
            source
            1..26
            /organism="synthetic construct"
            /mol_type="genomic DNA"
            /db_xref="taxon:32630"
            /notes="Oligonucleotide"
BASE COUNT      8 a      5 c      2 g      11 t

Query Match
Best Local Similarity 2.0%; Score 25; DB 1; Length 26;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1228 CCCAGTTAAATTTTCATTTCAGATA 1252
Db 1 CCCAGTTAAATTTTCATTTCAGATA 25

RESULT 6
AR207732/c
LOCUS      AR207732      24 bp      DNA      linear      PAT 20-JUN-2002
DEFINITION Sequence 72 from patent US 6379897.
ACCESSION  AR207732
VERSION     AR207732.1 GI:21507563
KEYWORDS   .
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE   1 (bases 1 to 24)
AUTHORS     Weidenhammer, E.M., Wang, L., Xu, X., Heller, M.J. and Kahl, B.F.
TITLE       Methods for gene expression monitoring on electronic microarrays
JOURNAL     Patent: US 6379897-A 72 30-APR-2002;
            Location/Qualifiers
            source
            1..24
            /organism="unknown"
BASE COUNT      9 a      11 c      3 g      1 t

Query Match
Best Local Similarity 1.9%; Score 24; DB 1; Length 24;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 475 GTGTGGTCTGTGTAGGTTGCC 498
Db 24 GTGTGGTCTGTGTAGGTTGCC 1

```

```

RESULT 7
AR265058/c
LOCUS      AR265058      24 bp      DNA      linear      PAT 10-APR-2003
DEFINITION Sequence 72 from patent US 6492122.
ACCESSION  AR265058
VERSION     AR265058.1 GI:29693445
KEYWORDS   .
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE   1 (bases 1 to 24)
AUTHORS     Weidenhammer, E.M., Wang, L., Xu, X., Heller, M.J. and Kahl, B.F.
TITLE       Quantitative analysis methods on active electronic microarrays
JOURNAL     Patent: US 6492122-A 72 10-DEC-2002;
            Location/Qualifiers
            source
            1..24
            /organism="unknown"
BASE COUNT      9 a      11 c      3 g      1 t

Query Match
Best Local Similarity 1.9%; Score 24; DB 1; Length 24;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 475 GTGTGGTCTGTGTAGGTTGCC 498
Db 24 GTGTGGTCTGTGTAGGTTGCC 1

RESULT 8
AR040833/c
LOCUS      AR040833      21 bp      DNA      linear      PAT 29-SEP-1999
DEFINITION Sequence 16 from patent US 5811233.
ACCESSION  AR040833
VERSION     AR040833.1 GI:5961329
KEYWORDS   .
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE   1 (bases 1 to 21)
AUTHORS     Bowcock, A., Tomfohrde, J., Menter, A. and Gaynor, R.
TITLE       Compositions and uses thereof in the diagnosis of psoriasis
JOURNAL     Patent: US 5811233-A 16 22-SEP-1998;
            Location/Qualifiers
            source
            1..21
            /organism="unknown"
BASE COUNT      6 a      5 c      4 g      6 t

Query Match
Best Local Similarity 1.7%; Score 21; DB 1; Length 21;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 403 TCTGTGGTATCCAGATCAG 423
Db 21 TCTGTGGTATCCAGATCAG 1

RESULT 9
AX133222
LOCUS      AX133222      21 bp      DNA      linear      PAT 15-MAY-2001
DEFINITION Sequence 4440 from Patent WO0130362.
ACCESSION  AX133222
VERSION     AX133222.1 GI:14139532
KEYWORDS   .
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Robbins, J.M. and Tritz, R.
TITLE       Ribozyme therapy for the treatment of proliferative skin and eye
            diseases
JOURNAL     Patent: WO 0130362-A 4440 03-MAY-2001;

```

```

FEATURES
  source
    IMMUSOL, INC. (US)
    1. .21
    /organism="Homo sapiens"
    /mol_type="genomic DNA"
    /db_xref="taxon:9606"
    /note="IL8 ribozyme recognition site"
  BASE COUNT
    1 a 1 c 10 g 9 t

Query Match
  1.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.7;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 473 TTGTGTGGTCTGTGTAGGG 493
  |||||
Db 1 TTGTGTGGTCTGTGTAGGG 21

RESULT 10
AX133224
LOCUS
  AX133224
  Sequence 4442 from Patent WO0130362.
  ACCESSION
  AX133224
  VERSION
  AX133224.1 GI:14139534
  KEYWORDS
  Homo sapiens (human)
  ORGANISM
  Homo sapiens
  Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
  REFERENCE
  1 Robbins, J.M. and Tritz, R.
  Ribozyme therapy for the treatment of proliferative skin and eye
  diseases
  JOURNAL
  IMMUSOL, INC. (US)
  Patent: WO 0130362-A 4442 03-MAY-2001;
  FEATURES
    source
      1. .21
      /organism="Homo sapiens"
      /mol_type="genomic DNA"
      /db_xref="taxon:9606"
      /note="IL8 ribozyme recognition site"
    BASE COUNT
      5 a 8 c 4 g 4 t

Query Match
  1.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.7;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 853 CAACCTAGTCTGTAGCCAG 873
  |||||
Db 1 CAACCTAGTCTGTAGCCAG 21

RESULT 11
AX119973
LOCUS
  AX119973
  Sequence 310 from Patent WO0198537.
  ACCESSION
  AX119973
  VERSION
  AX119973.1 GI:21524340
  KEYWORDS
  synthetic construct
  SOURCE
  synthetic construct
  artificial sequences.
  REFERENCE
  1 Lyamichev, V., Allawi, H., Dong, F., Neri, B.P. and Vener, I.T.
  Nucleic acid accessible hybridization sites
  JOURNAL
  Patent: WO 0198537-A 310 27-DEC-2001;
  THIRD WAVE TECHNOLOGIES, INC. (US)
  FEATURES
    source
      1. .21
      /organism="synthetic construct"
      /mol_type="genomic DNA"
      /db_xref="taxon:32630"
    BASE COUNT
      7 a 2 c 4 g 8 t

Query Match
  1.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.7;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1017 TTCAAGTGTAACCTATTAAAC 1037
  |||||
Db 1 TTCAAGTGTAACCTATTAAAC 21

RESULT 13
ARI130442/c
LOCUS
  ARI130442
  Sequence 11 from patent US 6190857.
  ACCESSION
  ARI130442
  VERSION
  ARI130442.1 GI:14118767
  KEYWORDS
  Unknown.
  SOURCE
  Unknown.
  ORGANISM
  Unclassified.
  REFERENCE
  1 (bases 1 to 20)
  AUTHORS
  Ralph, D., An, G., O'Hara, S., Mark, and Veltri, R.
  TITLE
  Diagnosis of disease state using mRNA profiles in peripheral
  leukocytes
  JOURNAL
  Patent: US 6190857-A 11 20-FEB-2001;
  FEATURES
    source
      1. .20
      /organism="unknown"
    BASE COUNT
      7 a 8 c 3 g 2 t

Query Match
  1.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 9.3;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 480 GGTCTGTGTAGGTTGCCA 499
  |||||
Db 20 GGTCTGTGTAGGTTGCCA 1

RESULT 14
AX119972
LOCUS
  AX119972
  Sequence 20 bp DNA
  PAT 18-JUN-2002

```



```

DEFINITION      Sequence 309 from Patent WO0198537.
ACCESSION       AX419972
VERSION         AX419972.1 GI:21524339
KEYWORDS        synthetic construct
SOURCE          synthetic construct
ORGANISM        artificial sequences.
REFERENCE       1
AUTHORS         Lyamichev,V., Allawi,H., Dong,P., Neri,B.P. and Vener,I.T.
TITLE           Nucleic acid accessible hybridization sites
JOURNAL         Patent: WO 0198537-A 309 27-DEC-2001;
                THIRD WAVE TECHNOLOGIES, INC. (US)
FEATURES        Location/Qualifiers
                source
                1..20
                /organism="synthetic construct"
                /mol_type="genomic DNA"
                /db_xref="taxon:32630"
                7 a 5 c 2 g 6 t
BASE COUNT      7 a 5 c 2 g 6 t
Query Match     1.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred.No.9.3;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 557 CATTGTACCATGAATATCC 576
Db 1 CATTGTACCATGAATATCC 20

RESULT 15
AX084499
LOCUS           AX084499
DEFINITION      Sequence 41 from Patent WO0112213.
ACCESSION       AX084499
VERSION         AX084499.1 GI:13185910
KEYWORDS        Mus musculus
SOURCE          Mus musculus (house mouse)
ORGANISM        Mus musculus
REFERENCE       1
AUTHORS         Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
                Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
TITLE           Blackshear,P.J., Lai,W.S. and Carballo-Jane,P.
JOURNAL         Ttp-related zinc finger domains and methods of use
                Patent: WO 0112213-A 41 22-FEB-2001;
                THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US)
FEATURES        Location/Qualifiers
                source
                1..24
                /organism="Mus musculus"
                /mol_type="mRNA"
                /db_xref="taxon:10090"
                6 a 0 c 0 g 18 t
BASE COUNT      6 a 0 c 0 g 18 t
Query Match     1.5%; Score 18.2; DB 1; Length 24;
Best Local Similarity 87.0%; Pred.No.39;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1038 TATTATTATTATGATTATT 1060
Db 2 TATTATTATTATGATTATT 24

RESULT 16
AR236360
LOCUS           AR236360
DEFINITION      Sequence 8 from patent US 6465176.
ACCESSION       AR236360
VERSION         AR236360.1 GI:27280288
KEYWORDS        Unknown.
SOURCE          Unknown.
ORGANISM        Unclassified.
REFERENCE       1 (bases 1 to 21)
AUTHORS         Giordano,T., Beach,D.L. and Temeles,G.L.
TITLE           Method for identifying compounds RNA/RNA binding protein

```

```

interactions
Patent: US 6465176-A 8 15-OCT-2002;
Location/Qualifiers
source
1..21
/organism="unknown"
6 a 0 c 0 g 15 t
BASE COUNT      6 a 0 c 0 g 15 t
Query Match     1.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred.No.48;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1044 TTATTATGTTATTATTTA 1062
Db 3 TTATTATGTTATTATTTA 21

RESULT 17
AX419971
LOCUS           AX419971
DEFINITION      Sequence 308 from Patent WO0198537.
ACCESSION       AX419971
VERSION         AX419971.1 GI:21524338
KEYWORDS        synthetic construct
SOURCE          synthetic construct
ORGANISM        artificial sequences.
REFERENCE       1
AUTHORS         Lyamichev,V., Allawi,H., Dong,P., Neri,B.P. and Vener,I.T.
TITLE           Nucleic acid accessible hybridization sites
JOURNAL         Patent: WO 0198537-A 308 27-DEC-2001;
                THIRD WAVE TECHNOLOGIES, INC. (US)
FEATURES        Location/Qualifiers
                source
                1..17
                /organism="synthetic construct"
                /mol_type="genomic DNA"
                /db_xref="taxon:32630"
                6 a 3 c 5 g 3 t
BASE COUNT      6 a 3 c 5 g 3 t
Query Match     1.4%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred.No.39;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 417 GAATCAGTGAAGATGCC 433
Db 1 GAATCAGTGAAGATGCC 17

RESULT 18
AX280042/c
LOCUS           AX280042/c
DEFINITION      Sequence 17 from Patent WO0177382.
ACCESSION       AX280042
VERSION         AX280042.1 GI:16607493
KEYWORDS        synthetic construct
SOURCE          synthetic construct
ORGANISM        artificial sequences.
REFERENCE       1
AUTHORS         Hull,J. and Kwiatkowski,D.P.
TITLE           Genetic factor affecting cytokine expression
JOURNAL         Patent: WO 0177382-A 17 18-OCT-2001;
                ISIS INNOVATION LIMITED (GB)
FEATURES        Location/Qualifiers
                source
                1..26
                /organism="synthetic construct"
                /mol_type="genomic DNA"
                /db_xref="taxon:32630"
                /note="Oligonucleotide"
                9 a 5 c 2 g 10 t
BASE COUNT      9 a 5 c 2 g 10 t
Query Match     1.3%; Score 16.6; DB 1; Length 26;
Best Local Similarity 82.6%; Pred.No.1.1e+02;
Matches 19; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

```

```

QY      1290 TTATCTGAATTTTAAATGAACT 1312
Db      ||||| ||||| ||||| |||||
        26 TTATCTGAATGAAATTTAACT 4

RESULT 19
AR051334/c
LOCUS   AR051334 22 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 58 from patent US 5830662.
ACCESSION AR051334
VERSION   AR051334.1 GI:5974698
KEYWORDS   .
SOURCE     Unknown.
ORGANISM   Unknown.
REFERENCE 1 (bases 1 to 22)
AUTHORS   Soares,M.B. and Sefstradiadis,A.
TITLE     Method for construction of normalized cDNA libraries
JOURNAL   Patent: US 5830662-A 58 03-NOV-1998;
FEATURES   Location/Qualifiers
            source          1..22
            /organism="unknown"
BASE COUNT      7 a      2 c      5 g      8 t

Query Match      1.3%; Score 16.2; DB 1; Length 22;
Best Local Similarity 85.7%; Pred. No. 1.e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1068 CAAATATTGTGCGAGAAATTT 1088
Db      ||||| ||||| ||||| |||||
        21 CAAAATTTGTCCAGAAATTT 1

RESULT 20
AX059999/c
LOCUS   AX059999 23 bp DNA linear PAT 22-JAN-2001
DEFINITION Sequence 117 from Patent WO0078970.
ACCESSION AX059999
VERSION   AX059999.1 GI:12405657
KEYWORDS   .
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
REFERENCE 1
AUTHORS   Denefle,P., Robier-Montus,M.F., Arnould-Reguigne,I., Prades,C.,
            Naudin,L., Lemoine,C., Duverger,N., Assmann,G., Rust,S., Funke,H.
            and Brewer,H.B.
TITLE     Nucleic and proteinic acids corresponding to human gene abcl1
JOURNAL   Patent: WO 0078970-A 117 28-DEC-2000;
            Aventis Pharma S.A. (FR)
FEATURES   Location/Qualifiers
            source          1..23
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"
BASE COUNT      8 a      5 c      3 g      7 t

Query Match      1.3%; Score 16.2; DB 1; Length 23;
Best Local Similarity 85.7%; Pred. No. 1.1e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      514 TTCTGTGTTAAATTTGAATTT 534
Db      ||||| ||||| ||||| |||||
        23 TACTGTGAGAAATTTGAATTT 3

RESULT 21
BD081029/c
LOCUS   BD081029 23 bp DNA linear PAT 27-AUG-2002
DEFINITION Coding sequence haplotypes of the human BRCA2 gene.
ACCESSION BD081029

```

```

VERSION BD081029.1 GI:22626632
KEYWORDS JP 2001514887-A/37.
SOURCE   unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 23)
AUTHORS   Murphy,P.D., White,M.B., Rabin,M.B., Olson,S.J., Yoshikawa,M.,
            Jackson,G.M., Eskandari,T., Schryer,B. and Park,M.
TITLE     Coding sequence haplotypes of the human BRCA2 gene
JOURNAL   Patent: JP 2001514887-A 37 18-SEP-2001;
CONCORD INC
COMMENT   OS Unidentified
            PN JP 2001514887-A/37
            PD 18-SEP-2001
            PP 14-AUG-1998 JP 2000509828
            PR 15-AUG-1997 US 60/055784, 07-NOV-1997 US 60/064926 PR
            12-NOV-1997 US 60/065367, 01-MAY-1998 US 09/071715 PR
            22-MAY-1998 US 09/084471
            PI PATRICIA D MURPHY,MARGA B WHITE,MARK B RABIN,SHERI J OLSON, PI
            MATTHEW YOSHIKAWA,GEOFFREY M JACKSON,TARA ESKANDARI,BRENDA PI
            SCHRYER,
            PI MICHAEL PARK
            PC C12N15/09,A61K38/00,A61K39/395,A61K48/00,A61P35/00,C07K14/47,
            PC C07K16/18,
            PC C12N1/15,C12N1/19,C12N1/21,C12N5/10,C12Q1/68//C12P21/02,C12P21/
            08,
            PC C12N15/00,A61K37/02,C12N5/00
            CC 11DR primer Location/Qualifiers
            FH Key 1..23
            FT source
            FT Location/Qualifiers
            /organism="Unidentified".
            /db_xref="taxon:32644"
BASE COUNT      4 a      4 c      3 g      12 t

Query Match      1.3%; Score 16.2; DB 1; Length 23;
Best Local Similarity 85.7%; Pred. No. 1.1e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      763 TGAAGCATCATATAAATGA 783
Db      ||||| ||||| ||||| |||||
        22 TAAAGCAGATATAAATGA 2

RESULT 22
AR295620
LOCUS   AR295620 20 bp DNA linear PAT 12-JUN-2003
DEFINITION Sequence 7355 from patent US 6537751.
ACCESSION AR295620
VERSION   AR295620.1 GI:31682904
KEYWORDS   .
SOURCE     Unknown.
ORGANISM   Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS   Cohen,D., Chumakov,I. and Blumenfeld,M.
TITLE     Biallelic markers for use in constructing a high density
            disequilibrium map of the human genome
JOURNAL   Patent: US 6537751-A 7355 25-MAR-2003;
FEATURES   Location/Qualifiers
            source          1..20
            /organism="unknown"
BASE COUNT      1 a      3 c      5 g      11 t

Query Match      1.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      901 CTTGGTTTCTCCTTTATT 919

```

Db 1 CTGGGTTCTGCTTTATTT 19

BD090846
LOCUS Mammalian osteo regulin.
DEFINITION BD090846
ACCESSION BD090846.1 GI:22636456
VERSION JP 2001321187-A/30.
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 20)
Brown, I.A., Wet, U.R.D., Gowen, L.C. and Hames, L.M.
Mammalian osteo regulin
Patent: JP 2001321187-A 30 20-NOV-2001;
PFIZER PRODUCTS INC
OS Homo sapiens (human)
PN JP 2001321187-A/30
PD 20-NOV-2001
PF 28-FEB-2001 JP 2001055757
PR 29-FEB-2000 US 60/185617, 22-SEP-2000 US 60/234500 PI
THOMAS AQUINAS BROWN, JEFFREY ROUX DE WET, LORI CHRISTINE GOWEN, PI
LYNN MARIE HAMES
PC C12N15/09, A01K67/027, A61K38/00, A61K45/00, A61P3/04, A61P9/10, PC
A61P9/10, A61P19/00, A61P19/10, A61P43/00, C07K14/47, C07K16/18, C12N1/15, PC
C12N1/19,
PC C12N1/21, C12N5/10, C12N5/10, C12P21/02, C12Q1/02, C12Q1/68 PC
PC G01N33/15, G01N33/50,
PC G01N33/566, G01N33/68//C12P21/08, (C12P21/02, C12R1:91), C12N15/00, PC
A61K37/02,
PC C12N5/00, C12N5/00
CC Mammalian osteo regulin
FH Key Location/Qualifiers
FT source 1..20
FT /organism='Homo sapiens (human)'.
Location/Qualifiers
1..20
/organism='Homo sapiens'
/mol_type='genomic DNA'
/db_xref='taxon:9606'
/db_xref='taxon:9606'
9 a 4 c 1 g 6 t

BASE COUNT 9 a 4 c 1 g 6 t

Query Match 1.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 716 CGAAGTTTAAATTCAGGAA 734
Db 1 CAAAGTTTAAATTCAGGAA 19

RESULT 24
AX092810/c
LOCUS
DEFINITION Sequence 222 from Patent WO0115676.
ACCESSION AX092810
VERSION AX092810.1 GI:13444867
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1
AUTHORS Hayden, M.R., Brooks-Wilson, A.R., Pimstone, S.N. and Clee, S.M.
TITLE Compositions and methods for modulating hdl cholesterol and
triglyceride levels
JOURNAL Patent: WO 0115676-A 222 08-MAR-2001;
University of British Columbia (CA); Xenon Genetics Inc. (CA)

FEATURES source

Location/Qualifiers
1..21
/organism='synthetic construct'
/mol_type='genomic DNA'
/db_xref='taxon:32630'
/note='Synthetic primer'
7 a 5 c 3 g 6 t

BASE COUNT 7 a 5 c 3 g 6 t

Query Match 1.3%; Score 15.9; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 516 CCTGGTTAAATTTGAATTT 534
Db 21 CCTGGAGAAATTTGAATTT 3

RESULT 25
ARI64318/c
LOCUS
DEFINITION Sequence 1 from patent US 6271369.
ACCESSION ARI64318
VERSION ARI64318.1 GI:16235432
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 22)
AUTHORS Torrence, P.F., Silverman, R.H., Maitra, R.K. and Lesiak, K.
TITLE Chimeric molecules targeted to viral RNAs
JOURNAL Patent: US 6271369-A 1 07-AUG-2001;
Location/Qualifiers
source 1..22
/organism='unknown'
4 a 0 c 0 g 18 t

BASE COUNT 4 a 0 c 0 g 18 t

Query Match 1.2%; Score 15.6; DB 1; Length 22;
Best Local Similarity 81.8%; Pred. No. 1.5e+02;
Matches 18; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 616 ACAAAAACCAATTAATTTT 637
Db 22 AAAAAAATAAAAAAATTTT 1

RESULT 26
ARI64319/c
LOCUS
DEFINITION Sequence 2 from patent US 6271369.
ACCESSION ARI64319
VERSION ARI64319.1 GI:16235434
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 22)
AUTHORS Torrence, P.F., Silverman, R.H., Maitra, R.K. and Lesiak, K.
TITLE Chimeric molecules targeted to viral RNAs
JOURNAL Patent: US 6271369-A 2 07-AUG-2001;
Location/Qualifiers
source 1..22
/organism='unknown'
4 a 0 c 0 g 18 t

BASE COUNT 4 a 0 c 0 g 18 t

Query Match 1.2%; Score 15.6; DB 1; Length 22;
Best Local Similarity 81.8%; Pred. No. 1.5e+02;
Matches 18; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 616 ACAAAAACCAATTAATTTT 637
Db 22 AAAAAAATAAAAAAATTTT 1

```
RESULT 27
LOCUS      I31810/c
DEFINITION Sequence 1 from patent US 5583032.
ACCESSION  I31810
VERSION     I31810.1 GI:1822601
KEYWORDS   .
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE   1 (bases 1 to 22)
AUTHORS     Torrence,P., Silverman,R., Maitra,R. and Lesiak,K.
TITLE       Method of cleaving specific strands of RNA
JOURNAL     Patent: US 5583032-A 1 10-DEC-1996;
FEATURES    Location/Qualifiers
             source
             1..22
BASE COUNT  4 a 0 c 0 g 18 t
Query Match 1.2%; Score 15.6; DB 1; Length 22;
Best Local Similarity 81.8%; Pred. No. 1.5e+02;
Matches 18; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 616 ACAAAAACACAAATAATTTT 637
Db 22 AAAAAAAAAAAAAAAAAAATTTT 1

RESULT 28
LOCUS      I31811/c
DEFINITION Sequence 2 from patent US 5583032.
ACCESSION  I31811
VERSION     I31811.1 GI:1822602
KEYWORDS   .
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE   1 (bases 1 to 22)
AUTHORS     Torrence,P., Silverman,R., Maitra,R. and Lesiak,K.
TITLE       Method of cleaving specific strands of RNA
JOURNAL     Patent: US 5583032-A 2 10-DEC-1996;
FEATURES    Location/Qualifiers
             source
             1..22
BASE COUNT  4 a 0 c 0 g 18 t
Query Match 1.2%; Score 15.6; DB 1; Length 22;
Best Local Similarity 81.8%; Pred. No. 1.5e+02;
Matches 18; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 616 ACAAAAACACAAATAATTTT 637
Db 22 AAAAAAAAAAAAAAAAAAATTTT 1

RESULT 29
LOCUS      I69407/c
DEFINITION Sequence 1 from patent US 5677289.
ACCESSION  I69407
VERSION     I69407.1 GI:12831529
KEYWORDS   .
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE   1 (bases 1 to 22)
AUTHORS     Torrence,P., Silverman,R., Maitra,R. and Lesiak,K.
TITLE       Method of cleaving specific strands of RNA and medical treatments
JOURNAL     Patent: US 5677289-A 1 14-OCT-1997;
FEATURES    Location/Qualifiers
             source
             1..22
```

```
BASE COUNT  4 a 0 c 0 g 18 t
Query Match 1.2%; Score 15.6; DB 1; Length 22;
Best Local Similarity 81.8%; Pred. No. 1.5e+02;
Matches 18; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 616 ACAAAAACACAAATAATTTT 637
Db 22 AAAAAAAAAAAAAAAAAAATTTT 1

RESULT 30
LOCUS      I69408/c
DEFINITION Sequence 2 from patent US 5677289.
ACCESSION  I69408
VERSION     I69408.1 GI:2831530
KEYWORDS   .
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE   1 (bases 1 to 22)
AUTHORS     Torrence,P., Silverman,R., Maitra,R. and Lesiak,K.
TITLE       Method of cleaving specific strands of RNA and medical treatments
JOURNAL     Patent: US 5677289-A 2 14-OCT-1997;
FEATURES    Location/Qualifiers
             source
             1..22
BASE COUNT  4 a 0 c 0 g 18 t
Query Match 1.2%; Score 15.6; DB 1; Length 22;
Best Local Similarity 81.8%; Pred. No. 1.5e+02;
Matches 18; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 616 ACAAAAACACAAATAATTTT 637
Db 22 AAAAAAAAAAAAAAAAAAATTTT 1

RESULT 31
LOCUS      AX280041/c
DEFINITION Sequence 16 from Patent WO0177382.
ACCESSION  AX280041
VERSION     AX280041.1 GI:16607492
KEYWORDS   .
SOURCE      synthetic construct
ORGANISM    synthetic construct
REFERENCE   1
AUTHORS     Hull,J. and Kwiatkowski,D.P.
TITLE       Genetic factor affecting cytokine expression
JOURNAL     Patent: WO 0177382-A 16 18-OCT-2001;
FEATURES    Location/Qualifiers
             source
             1..26
             /organism="synthetic construct"
             /mol_type="genomic DNA"
             /db_xref="taxon:32630"
             /note="Oligonucleotide"
BASE COUNT  8 a 5 c 2 g 11 t
Query Match 1.2%; Score 15.6; DB 1; Length 26;
Best Local Similarity 81.8%; Pred. No. 2e+02;
Matches 19; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 1291 TATCTGAATTTTAATTTGAAT 1312
Db 25 TATCTGAATGAATAATTTAACT 4
```

RESULT 32
AX500365/c
LOCUS 17 bp DNA linear PAT 27-SEP-2002
DEFINITION Sequence 1672 from Patent EP1229046.
ACCESSION AX500365
VERSION AX500365.1 GI:23382658
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
AUTHORS Zhan, J.
TITLE Human testis expressed patched like protein
JOURNAL Patent: EP 1229046-A 1672 07-AUG-2002;
Aeonica, Inc. (US)
FEATURES
source
I. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 4 a 1 c 1 g 11 t
Query Match 1.2%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 675 TATACAAATAGCAAAAT 691
|||||
Db 17 TATATAAATAGCAAAAT 1
Unknown.
LOCUS 124434 17 bp DNA linear PAT 07-OCT-1996
DEFINITION Sequence 9 from patent US 5543499.
ACCESSION 124434
VERSION 124434.1 GI:1604304
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Brewer, G.
TITLE DNA sequence encoding a polypeptide with anti-tumor properties
JOURNAL Patent: US 5543499-A 9 06-AUG-1996;
FEATURES
source
I. .17
/organism="unknown"
BASE COUNT 5 a 0 c 0 g 12 t
Query Match 1.2%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1046 ATTATGTTATTATTATTA 1062
|||||
Db 1 ATTATTTATTATTATTA 17
Unknown.
LOCUS 124434 18 bp DNA linear PAT 30-AUG-2000
DEFINITION Sequence 43 from patent US 5958771.
ACCESSION AR076329
VERSION AR076329.1 GI:10003075
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Bennett, C. Frank., Ackermann, E. J. and Cowse, J. M.
TITLE Antisense modulation of cellular inhibitor of Apoptosis-2

expression
JOURNAL Patent: US 5958771-A 43 28-SEP-1999;
FEATURES
source
I. .18
/organism="unknown"
BASE COUNT 6 a 1 c 3 g 8 t
Query Match 1.2%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1294 CTGAAATTTTAAATGAA 1310
|||||
Db 1 CTGAAATTTTGAATGAA 17
Unknown.
LOCUS 1294 20 bp DNA linear PAT 17-DEC-2001
DEFINITION Sequence 83 from patent US 6287860.
ACCESSION AR168620
VERSION AR168620.1 GI:17904633
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia, B. P., Gaarde, W., Ward, D. T., Freier, S. M. and Wyatt, J.
TITLE Antisense inhibition of MRK2 expression
JOURNAL Patent: US 6287860-A 83 11-SEP-2001;
FEATURES
source
I. .20
/organism="unknown"
BASE COUNT 11 a 3 c 2 g 4 t
Query Match 1.2%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 512 GATTCCTGTTAAATTT 528
|||||
Db 17 GATTCCTGTTAAATTT 1
Unknown.
LOCUS 512 21 bp DNA linear PAT 27-NOV-2002
DEFINITION Sequence 422 from Patent WO02070755.
ACCESSION AX555826
VERSION AX555826.1 GI:25899299
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Lyamichev, V. I., Kaiser, M. W. and Lyamicheva, N.
TITLE Fen endonucleases
JOURNAL Patent: WO 02070755-A 422 12-SEP-2002;
Third Wave Technologies, Inc. (US)
FEATURES
source
I. .21
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
BASE COUNT 12 a 1 c 6 g 2 t
Query Match 1.2%; Score 15.4; DB 1; Length 21;
Best Local Similarity 94.1%; Pred. No. 1.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 900 CCTGTGTTTCCTTTA 916
|||||
Db 21 CCTGTGTTTCCTTTA 5

RESULT 37
AR031041/c
LOCUS
DEFINITION Sequence 29 from patent US 5861504.
ACCESSION AR031041
VERSION AR031041.1 GI:5944255
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Polymeropoulos,M.H. and Merrill,C.R.
TITLE Eleven highly informative microsatellite repeat polymorphic DNA markers
JOURNAL Patent: US 5861504-A 29 19-JAN-1999;
FEATURES Location/Qualifiers
1..20
/organism="unknown"
BASE COUNT 4 a 3 c 7 g 6 t
Query Match 1.2%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 427 ACATGCCAGTGAACCTTCAA 446
DB 20 ACATGCCAGTGAACCTTCAA 1
RESULT 38
AR232302/c
LOCUS
DEFINITION Sequence 92 from patent US 6455307.
ACCESSION AR232302
VERSION AR232302.1 GI:27274294
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS McKay,R., Freier,S.M. and Wyatt,J.
TITLE Antisense modulation of casein kinase 2-alpha prime expression
JOURNAL Patent: US 6455307-A 92 24-SEP-2002;
FEATURES Location/Qualifiers
1..20
/organism="unknown"
BASE COUNT 9 a 3 c 0 g 8 t
Query Match 1.2%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 633 ATTTTGAATATAAGGATTT 652
DB 20 ATTTTGAATATAAGGATTT 1
RESULT 39
AX429785
LOCUS
DEFINITION Sequence 13 from Patent EP1203826.
ACCESSION AX429785
VERSION AX429785.1 GI:21540961
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Ishizuka,T., Ishiguro,T. and Saitoh,J.
TITLE Oligonucleotide for detection of hiv-1 and detection method
JOURNAL Patent: EP 1203826-A 13 08-MAY-2002;
Tosoh Corporation (JP)
Location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/note="Oligonucleotide hybridizable with a specific site of HIV-1 RNA"
BASE COUNT 6 a 2 c 0 g 12 t
Query Match 1.2%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1476 ATCTTATAATATTATTAA 1495
DB 1 ATCTTATAATATTATTAA 20
RESULT 40
BD144143
LOCUS
DEFINITION Oligonucleotide for detecting HIV-1 and detection method.
ACCESSION BD144143
VERSION BD144143.1 GI:27849901
KEYWORDS JP 2002125687-A/13.
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1 (bases 1 to 20)
AUTHORS Ishizuka,T., Ishiguro,T. and Saitoh,J.
TITLE Oligonucleotide for detecting HIV-1 and detection method
JOURNAL Patent: JP 2002125687-A 13 08-MAY-2002;
COMMENT TOSOH CORP
OS Artificial Sequence
PN JP 2002125687-A/13
PD 08-MAY-2002
PF 30-OCT-2000 JP 2000334937
PI TETSUYA ISHIZUKA,TAKAHIKO ISHIGURO, JUICHI SAITO PC
C12N15/09,C12Q1/68,G01N33/58,C12N15/00
CC Oligonucleotide capable of binding specifically to a specified site of
CC HIV-1 RNA
FH Key Location/Qualifiers
FT source 1..20
/organism='Artificial Sequence'.
FEATURES Location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
BASE COUNT 6 a 2 c 0 g 12 t
Query Match 1.2%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1476 ATCTTATAATATTATTAA 1495
DB 1 ATCTTATAATATTATTAA 20
RESULT 41
A26944/c
LOCUS
DEFINITION Oligonucleotide QWB28.
ACCESSION A26944
VERSION A26944.1 GI:1248367
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Ishizuka,T., Ishiguro,T. and Saitoh,J.
TITLE Oligonucleotide for detection of hiv-1 and detection method
JOURNAL Patent: EP 1203826-A 13 08-MAY-2002;

REFERENCE 1 (bases 1 to 21)
AUTHORS Broekaert, W.F., Cammue, B.P.A., Terras, F.R.G., Vanderleyden, J., Osborn, R.W., and Rees, S.B.
TITLE BIOCIDAL PROTEINS
JOURNAL Patent: WO 9305153-A 2 18-MAR-1993;
ICI PLC (GB)
FEATURES
source 1..21
Location/Qualifiers
BASE COUNT 3 a 7 c 4 g 7 t
Query Match 1.2%; Score 15.2; DB 1; Length 21;
Best Local Similarity 85.0%; Pred. No. 1.7e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 688 AAATTGGCCCAAGGCCCAAG 707
DB 20 AAGTTGTGCGCAAGGCCCAAG 1

RESULT 42
LOCUS AR050156/c
DEFINITION Sequence 53 from patent US 5824869.
ACCESSION AR050156
VERSION AR050156.1 GI:5972148
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 21)
AUTHORS Broekaert, W.F., Cammue, B.P.A., Osborn, R.W., Rees, S.B., Terras, F.R.G., and Vanderleyden, J.
TITLE BIOCIDAL PROTEINS
JOURNAL Patent: US 5824869-A 53 20-OCT-1998;
FEATURES
source 1..21
Location/Qualifiers
BASE COUNT 3 a 7 c 4 g 7 t
Query Match 1.2%; Score 15.2; DB 1; Length 21;
Best Local Similarity 85.0%; Pred. No. 1.7e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 688 AAATTGGCCCAAGGCCCAAG 707
DB 20 AAGTTGTGCGCAAGGCCCAAG 1

RESULT 43
LOCUS AR130275/c
DEFINITION Sequence 53 from patent US 6187904.
ACCESSION AR130275
VERSION AR130275.1 GI:14118172
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 21)
AUTHORS Broekaert, W.F., Cammue, B.P.A., Osborn, R.W., Rees, S.B., Terras, F.R.G., and Vanderleyden, J.
TITLE BIOCIDAL PROTEINS
JOURNAL Patent: US 6187904-A 53 13-FEB-2001;
FEATURES
source 1..21
Location/Qualifiers
BASE COUNT 3 a 7 c 4 g 7 t
Query Match 1.2%; Score 15.2; DB 1; Length 21;
Best Local Similarity 85.0%; Pred. No. 1.7e+02;

REFERENCE 1 (bases 1 to 21)
AUTHORS Broekaert, W.F., Cammue, B.P.A., Terras, F.R.G., Vanderleyden, J., Osborn, R.W., and Rees, S.B.
TITLE BIOCIDAL PROTEINS
JOURNAL Patent: WO 9305153-A 2 18-MAR-1993;
ICI PLC (GB)
FEATURES
source 1..21
Location/Qualifiers
BASE COUNT 3 a 7 c 4 g 7 t
Query Match 1.2%; Score 15.2; DB 1; Length 21;
Best Local Similarity 85.0%; Pred. No. 1.7e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 688 AAATTGGCCCAAGGCCCAAG 707
DB 20 AAGTTGTGCGCAAGGCCCAAG 1

RESULT 44
LOCUS AX008949/c
DEFINITION Sequence 9 from Patent WO9964448.
ACCESSION AX008949
VERSION AX008949.1 GI:9996338
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1
AUTHORS Ruelle, J.L., Vinals-Bassols, C. and Tommassen, J.P.
TITLE Novel compounds
JOURNAL Patent: WO 9964448-A 9 16-DEC-1999;
RUELLE JEAN LOUIS (BE); SMITHKLINE BEECHAM BIOLOG (BE); VINALS
BASSOLS CARLOTA (BE); TOMMASSEN JOHANNES PETRUS MARI (NL)
FEATURES
source 1..21
Location/Qualifiers
BASE COUNT 8 a 5 c 2 g 6 t
Query Match 1.2%; Score 15.2; DB 1; Length 21;
Best Local Similarity 85.0%; Pred. No. 1.7e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1420 ACAGTCAATATTAGTAATTT 1439
DB 20 ACTGTCATATGCGTAATTT 1

RESULT 45
LOCUS I23731/c
DEFINITION Sequence 53 from patent US 5538525.
ACCESSION I23731
VERSION I23731.1 GI:1603601
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 21)
AUTHORS Broekaert, W.F., Cammue, B.P.A., Osborn, R.W., Rees, S.B., Terras, F.R.G., and Vanderleyden, J.
TITLE BIOCIDAL PROTEINS
JOURNAL Patent: US 5538525-A 53 23-JUL-1996;
FEATURES
source 1..21
Location/Qualifiers
BASE COUNT 3 a 7 c 4 g 7 t
Query Match 1.2%; Score 15.2; DB 1; Length 21;
Best Local Similarity 85.0%; Pred. No. 1.7e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 688 AAATTGGCCCAAGGCCCAAG 707
DB 20 AAGTTGTGCGCAAGGCCCAAG 1

RESULT 46
LOCUS ATH528526/c
DEFINITION Arabidopsis thaliana T-DNA flanking sequence, left border, clone

```

166G10.
AJ528526
VERSION AJ528526.1 GI:26796786
SOURCE left border; T-DNA flanking sequence.
ORGANISM Arabidopsis thaliana (thale cress)
Arabidopsis thaliana
Eukaryota; Viridiplantae; Streptophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
rosids; eurosids II; Brassicaceae; Arabidopsi.
1
REFERENCE
AUTHORS Brunaud,V., Balzerque,S., Dubreucq,B., Aubourg,S., Samson,F.,
Chauvin,S., Bechtold,N., Cruaud,C., DeRose,R., Pelletier,G.,
Lepiniec,L., Caboche,M. and Lecharny,A.
TITLE T-DNA integration into the Arabidopsis genome depends on sequences
of pre-insertion sites
JOURNAL EMBO Rep. 3 (12), 1152-1157 (2002)
MEDLINE 22363535
PUBMED 12446565
REFERENCE
AUTHORS Balzerque,S.
TITLE Direct Submision
JOURNAL Submitted (21-NOV-2002) Balzerque S., UMRGV, INRA/CNRS, 2 rue
Gaston Cremieux, 91057 Evry cedex, FRANCE
COMMENT PCR was performed on DNA from transformants of Arabidopsis thaliana
plants from INRA (Versailles). The DNA fragment(s) resulting from
the PCR were directly sequenced from the left or the right border
to determine the genomic sequence flanking the insertion. T-DNA
derived sequences were removed. Information to order the
corresponding mutant line and a link to a database providing a
graphical display of the insertion site are available at
http://dbgap.versailles.inra.fr/publiclines/. This sequence has
been generated in the framework of the French plant genomics
program 'Genoplante' (http://www.genoplante.com and
http://genoplante-info.infobiogen.fr/).
FEATURES
source
1..21
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"
/db_xref="taxon:3702"
/clone="166G10"
misc_feature 1..21
/notes="T-DNA flanking sequence
left border"
BASE COUNT 7 a 4 c 2 g 8 t
Query Match 1.2%; Score 15.2; DB 1; Length 21;
Best Local Similarity 85.0%; Pred. No. 1.7e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 539 AAACATGATGATGTTTCA 558
DB 21 AAAGATGTTATGTTTCA 2
RESULT 47
AX1419974
LOCUS AX1419974 15 bp DNA linear PAT 18-JUN-2002
DEFINITION Sequence 311 from Patent WO0198537.
ACCESSION AX1419974
VERSION AX1419974.1 GI:21524341
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.
1
REFERENCE
AUTHORS Lyamichiev,V., Allawi,H., Dong,F., Neri,B.P. and Vener,I.T.
TITLE Nucleic acid accessible hybridization sites
JOURNAL Patent: WO 0198537-A 311 27-DEC-2001;
THIRD WAVE TECHNOLOGIES, INC. (US)
FEATURES
source
1..15
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
4 t
BASE COUNT 2 a 6 c 3 g
Query Match 1.2%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 99;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 856 CCTAGTCTGCTAGC 870
DB 1 CCTAGTCTGCTAGC 15
RESULT 48
A67086
LOCUS A67086 18 bp DNA linear PAT 29-MAR-1999
DEFINITION Sequence 253 from Patent WO9740193.
ACCESSION A67086
VERSION A67086.1 GI:4538457
KEYWORDS unidentified
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Stuyver,L., Rossau,R. and Maertens,G.
TITLE METHOD FOR TYPING AND DETECTING HBV
JOURNAL Patent: WO 9740193-A 253 30-OCT-1997;
INNOGENETICS NV (BE)
FEATURES
source
1..18
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
7 t
BASE COUNT 8 a 0 c 3 g
Query Match 1.2%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1123 TATAAAGATGTTATAGTA 1140
DB 1 TATATAGATGATATAGTA 18
RESULT 49
AX129263/c
LOCUS AX129263 19 bp DNA linear PAT 15-MAY-2001
DEFINITION Sequence 481 from Patent WO0130362.
ACCESSION AX129263
VERSION AX129263.1 GI:14135568
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Robbins,J.M. and Tritz,R.
TITLE Ribozyme therapy for the treatment of proliferative skin and eye
diseases
JOURNAL Patent: WO 0130362-A 481 03-MAY-2001;
IMMUSOL, INC. (US)
FEATURES
source
1..19
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/notes="cdk4 ribozyme binding site"
7 c
BASE COUNT 2 a 2 c 8 g
Query Match 1.2%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.7e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```



```

QY 1404 AAACAGCCAAACTCCAC 1421
Db 18 ATACAGCCAACTCCAC 1

RESULT 50
AR181777
LOCUS 20 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 239 from patent US 6335194.
ACCESSION AR181777
VERSION AR181777.1 GI:20223991
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank., Ackermann,E.J., Swayze,E.E. and Cowsert,I.M.
TITLE Antisense modulation of survivin expression
JOURNAL Patent: US 6335194-A 239 01-JAN-2002;
FEATURES
    Location/Qualifiers
        1..20
            /organism="unknown"
        5 a 0 c 3 g 12 t
        Query Match 1..2%; Score 14.8; DB 1; Length 20;
        Best Local Similarity 88.9%; Pred. No. 1.9e+02;
        Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1039 ATTATTATTATTGTTATT 1056
Db 2 AGTTATTATTGTTATT 19

RESULT 51
AR181778
LOCUS 20 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 240 from patent US 6335194.
ACCESSION AR181778
VERSION AR181778.1 GI:20223992
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank., Ackermann,E.J., Swayze,E.E. and Cowsert,I.M.
TITLE Antisense modulation of survivin expression
JOURNAL Patent: US 6335194-A 240 01-JAN-2002;
FEATURES
    Location/Qualifiers
        1..20
            /organism="unknown"
        6 a 0 c 2 g 12 t
        Query Match 1..2%; Score 14.8; DB 1; Length 20;
        Best Local Similarity 88.9%; Pred. No. 1.9e+02;
        Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1039 ATTATTATTATTGTTATT 1056
Db 3 AGTTATTATTGTTATT 20

RESULT 52
AX269437/c
LOCUS 20 bp DNA linear PAT 30-NOV-2001
DEFINITION Sequence 68 from Patent WO0164876.
ACCESSION AX269437
VERSION AX269437.1 GI:16542213
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
REFERENCE 1 (bases 1 to 20)
AUTHORS Berlin,K., Braun,A., Distler,J., Guetig,D., Howe,A., Mueller,J.,
Olek,A., Piepenbrock,C., Adorjan,P., Grabs,G., Lesche,R., Leh,R.,
Lewin,A., Lipscher,E., Maier,S., Model,F., Mueller,V., Otto,T.,
Pelet,C. and Ziebarth,H.
TITLE Methods and nucleic acids for the analysis of hematopoietic cell
proliferative disorders
JOURNAL Patent: WO 02077272-A 418 03-OCT-2002;
FEATURES
    Location/Qualifiers
        1..20
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"
        9 a 6 c 4 g 1 t
        Query Match 1..2%; Score 14.8; DB 1; Length 20;
        Best Local Similarity 88.9%; Pred. No. 1.9e+02;
        Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1352 GCTGTGTTGTTAGTCTG 1369
Db 20 GCTGTGTTGTTAGTCTG 3

RESULT 53
AX270968/c
LOCUS 20 bp DNA linear PAT 30-NOV-2001
DEFINITION Sequence 68 from Patent WO0164877.
ACCESSION AX270968
VERSION AX270968.1 GI:16543705
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
REFERENCE 1 (bases 1 to 20)
AUTHORS Stefanoson,H., Steinthorsdottir,V. and Gulcher,J.R.
TITLE Human schizophrania gene
JOURNAL Patent: WO 0164877-A 68 07-SEP-2001;
FEATURES
    Location/Qualifiers
        1..20
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"
        9 a 6 c 4 g 1 t
        Query Match 1..2%; Score 14.8; DB 1; Length 20;
        Best Local Similarity 88.9%; Pred. No. 1.9e+02;
        Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1352 GCTGTGTTGTTAGTCTG 1369
Db 20 GCTGTGTTGTTAGTCTG 3

RESULT 54
AX599078
LOCUS 20 bp DNA linear PAT 14-FEB-2003
DEFINITION Sequence 418 from Patent WO02077272.
ACCESSION AX599078
VERSION AX599078.1 GI:28399218
KEYWORDS
SOURCE synthetic construct
ORGANISM
REFERENCE 1 (bases 1 to 20)
AUTHORS Berlin,K., Braun,A., Distler,J., Guetig,D., Howe,A., Mueller,J.,
Olek,A., Piepenbrock,C., Adorjan,P., Grabs,G., Lesche,R., Leh,R.,
Lewin,A., Lipscher,E., Maier,S., Model,F., Mueller,V., Otto,T.,
Pelet,C. and Ziebarth,H.
TITLE Methods and nucleic acids for the analysis of hematopoietic cell
proliferative disorders
JOURNAL Patent: WO 02077272-A 418 03-OCT-2002;
FEATURES
    Location/Qualifiers
        1..20
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"
        9 a 6 c 4 g 1 t
        Query Match 1..2%; Score 14.8; DB 1; Length 20;
        Best Local Similarity 88.9%; Pred. No. 1.9e+02;
        Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1352 GCTGTGTTGTTAGTCTG 1369
Db 20 GCTGTGTTGTTAGTCTG 3

```

source
1. .20
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/note="Detection primer for ABL1"
8 a 8 c 0 g 4 t

BASE COUNT
Query Match 1.2%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.9e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 439 AACTTCACGCAATCTAC 456
|||||
Db 3 AACTTCACGCAATCTCC 20
|||||

RESULT 55
BD138313/c
LOCUS
DEFINITION Antisense modulation of human MDM2 expression.
ACCESSION BD138313
VERSION BD138313.1 GI:23233258
KEYWORDS JP 2002508944-A/239.
SOURCE unidentified
ORGANISM unidentified

REFERENCE 1 (bases 1 to 20)
AUTHORS Miraglia, L.J., Nero, P., Graham, M.J., Monia, B.P. and Cowsert, L.M.
TITLE Antisense modulation of human MDM2 expression
JOURNAL Patent: JP 2002508944-A 239 26-MAR-2002;
ISIS PHARMACEUTICALS INC

COMMENT OS Unidentified
PN JP 2002508944-A/239
PD 26-MAR-2002
PF 26-MAR-1999 JP 2000538025
PR 26-MAR-1998 US 09/048810
PI LOREN J MIRAGLIA, PAMELA NERO, MARK J GRAHAM, BRETT P MONIA, LEX M

PI COMSERT
PC C12N15/09, A61K48/00, A61P9/10, A61P17/06, A61P35/00, C07H21/04//
PC C12Q1/68.
PC C12N15/00
CC Strandedness: Single;
CC Topology: Linear;
CC Antisense modulation of human MDM2 expression FH Key
CC Location/Qualifiers
FT source 1. .20
FT Location/Qualifiers
/organism="Unidentified".
1. .20
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

BASE COUNT 9 a 1 c 2 g 8 t

Query Match 1.2%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.9e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1017 TTCAGTGTAACTTATTA 1034
|||||
Db 18 TTTAAATGTAACCTATTA 1
|||||

RESULT 56
E15986
LOCUS
DEFINITION Oligonucleotide.
ACCESSION E15986
VERSION E15986.1 GI:5710669
KEYWORDS JP 1998127286-A/11.
SOURCE unidentified
ORGANISM unidentified

unclassified.
1 (bases 1 to 20)
AUTHORS Ishikawa, T., Shigematsu, T. and Yamamoto, A.
TITLE OLIGONUCLEOTIDE FOR SUPPRESSING PRODUCTION OF HGF
JOURNAL Patent: JP 1998127286-A 11 19-MAY-1998;
TERUMO CORP

COMMENT OS None
OC Artificial sequences.
PN JP 1998127286-A/11
PD 19-MAY-1998
PF 01-NOV-1996 JP 1996291499
PI ISHIKAWA TETSUYA, SHIGEMATSU TAKASHI, YAMAMOTO AKIHIRO PC
C12N15/09, A61K31/70, A61K31/70, C07H21/04;
CC strandedness: Single;
CC topology: Linear;
CC hypothetical: No;
FH Key
FT source 1. .20
FT Location/Qualifiers
/organism="Artificial sequences".
1. .20
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

BASE COUNT 0 a 0 c 11 g 9 t

Query Match 1.2%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.9e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 477 GTGGGCTGTGTAGGGT 494
|||||
Db 1 GTGGGCTGTGTGTAGGGT 18
|||||

RESULT 57
AR069029/c
LOCUS
DEFINITION Sequence 7 from patent US 5854395.
ACCESSION AR069029
VERSION AR069029.1 GI:6001236
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

REFERENCE 1 (bases 1 to 21)
AUTHORS Champion, C.I., Lovett, M.A., Haake, D.A., Miller, J.N. and Blanco, D.R.
TITLE Cloned borrelia burgdorferi virulence protein
JOURNAL Patent: US 5854395-A 7 29-DEC-1998;
FEATURES Location/Qualifiers
source 1. .21
/organism="unknown"

BASE COUNT 10 a 0 c 4 g 7 t

Query Match 1.2%; Score 14.8; DB 1; Length 21;
Best Local Similarity 88.9%; Pred. No. 2.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 542 CAATGAATAGTTTTCAT 559
|||||
Db 18 CAATAAATATTTTTCAT 1
|||||

RESULT 58
AR299016/c
LOCUS
DEFINITION Sequence 10751 from patent US 6537751.
ACCESSION AR299016
VERSION AR299016.1 GI:31686300
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

Unclassified.
 REFERENCE 1 (bases 1 to 21)
 AUTHORS Cohen, D., Chumakov, I. and Blumenfeld, M.
 TITLE Biallelic markers for use in constructing a high density disequilibrium map of the human genome
 JOURNAL Patent: US 6537751-A 10751 25-MAR-2003;
 FEATURES Location/Qualifiers
 source 1. .21
 BASE COUNT 3 a 7 c 0 g 11 t
 Query Match 1.2%; Score 14.8; DB 1; Length 21;
 Best Local Similarity 88.9%; Pred. No. 2.1e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1593 TATAAAGTAATGAA 1610
 |||||
 Db 20 TATAAAGTAATGAA 3
 |||||
 RESULT 59
 LOCUS 126583/c
 DEFINITION Sequence 7 from patent US 5558993.
 ACCESSION 126583
 VERSION 126583.1 GI:1606453
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 21)
 AUTHORS Champion, C.I., Lovett, M.A., Haake, D.A., Miller, J.N. and Blanco, D.R.
 TITLE Cloned Borrelia burgdorferi virulence protein
 JOURNAL Patent: US 5558993-A 7 24-SEP-1996;
 FEATURES Location/Qualifiers
 source 1. .21
 BASE COUNT 10 a 0 c 4 g 7 t
 Query Match 1.2%; Score 14.8; DB 2; Length 21;
 Best Local Similarity 88.9%; Pred. No. 2.1e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 542 CAATGATAGTTTTCAT 559
 |||||
 Db 18 CAATGATAGTTTTCAT 1
 |||||
 RESULT 60
 LOCUS AX500364/c
 DEFINITION Sequence 1671 from Patent EPI229046.
 ACCESSION AX500364
 VERSION AX500364.1 GI:23382657
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1
 AUTHORS Zhan, J.
 TITLE Human testis expressed patched like protein
 JOURNAL Patent: EP 1229046-A 1671 07-AUG-2002;
 FEATURES Location/Qualifiers
 source 1. .17
 BASE COUNT 3 a 1 c 1 g 12 t
 Query Match 1.2%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 1.8e+02;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 576 ATACAAATAGCAAAAT 691
 |||||
 Db 17 ATAAATAGCAAAAT 2
 |||||
 RESULT 61
 LOCUS AX500366/c
 DEFINITION Sequence 1673 from Patent EPI229046.
 ACCESSION AX500366
 VERSION AX500366.1 GI:23382659
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1
 AUTHORS Zhan, J.
 TITLE Human testis expressed patched like protein
 JOURNAL Patent: EP 1229046-A 1673 07-AUG-2002;
 FEATURES Location/Qualifiers
 source 1. .17
 BASE COUNT 4 a 1 c 1 g 11 t
 Query Match 1.2%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 1.8e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 675 TATCAAAATAGCAAAA 690
 |||||
 Db 16 TATAAAATAGCAAAA 1
 |||||
 RESULT 62
 LOCUS AX722454/c
 DEFINITION Sequence 141 from Patent WO03025176.
 ACCESSION AX722454
 VERSION AX722454.1 GI:30422955
 KEYWORDS
 SOURCE Mus musculus (house mouse)
 ORGANISM Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 REFERENCE 1
 AUTHORS Tellerman, A., Anson, R. and Tuijinder, M.
 TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
 JOURNAL Patent: WO 03025176-A 141 27-MAR-2003;
 FEATURES Location/Qualifiers
 source 1. .17
 BASE COUNT 10 a 1 c 1 g 5 t
 Query Match 1.2%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 1.8e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1144 TTATTTTATTATAGAT 1159
 |||||
 Db 17 TTATTTTATTATAGAT 2
 |||||

```

RESULT 63
LOCUS AX731903/c 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 3537 from Patent WO03025175.
ACCESSION AX731903
VERSION AX731903.1 GI:30511246
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Telerman,A., Anson,R. and Tuijinder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025175-A 3537 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 7 a 1 c 1 g 8 t
Query Match 1.2%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1616 TAAATATTAATTGTT 1631
DB 17 TAAATATTAATTGAT 2

RESULT 64
LOCUS BD017427/c 17 bp DNA linear PAT 27-AUG-2002
DEFINITION Nucleic acid for assaying genus Shigella or genus Salmonella and
detection method.
ACCESSION BD017427
VERSION BD017427.1 GI:22558603
KEYWORDS JP 2001245677-A/38.
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1 (bases 1 to 17)
AUTHORS Fukushima,M., Kakinuma,K. and Kawaguchi,R.
TITLE Nucleic acid for assaying genus Shigella or genus Salmonella and
detection method
JOURNAL Patent: JP 2001245677-A 38 11-SEP-2001;
SRL INC,MARINE BIOTECHNOLOGY INSTITUTE CO LTD,NIPPON GENE CO LTD
COMMENT OS Artificial Sequence
PN JP 2001245677-A/38
PD 11-SEP-2001
PF 27-DEC-2000 JP 2000398087
PI MASAO FUKUSHIMA,KENICHI KAKINUMA,RYUJI KAWAGUCHI PC
C12N15/09,C12N15/09,C12M1/00,C12Q1/68,G01N33/53,G01N33/566, PC
G01N33/569//
PC (C12Q1/68,C12R1:42), (C12Q1/68,C12R1:01),C12N15/00,C12N15/00 CC
DNA probe for detecting Salmonella typhi, Salmonella CC
typhimurium and
CC Salmonella aerogenes
FH Key Location/Qualifiers
FT Source 1..17
/organism="Artificial Sequence".
FEATURES
source
1..17
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
BASE COUNT 3 a 6 c 0 g 8 t
Query Match 1.2%; Score 14.4; DB 1; Length 17;

```

```

Best Local Similarity 93.8%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1088 TGGAAAATAGACAT 1103
DB 16 TGGAGAATAGACAT 1

RESULT 65
LOCUS AX599320/c 18 bp DNA linear PAT 14-FEB-2003
DEFINITION Sequence 660 from Patent WO02077272.
ACCESSION AX599320
VERSION AX599320.1 GI:28399462
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1
AUTHORS Berlin,K., Braun,A., Distler,J., Guetig,D., Howe,A., Mueller,J.,
Olek,A., Pispembrock,C., Adorjan,P., Grabs,G., Lesche,R., Leu,E.,
Lewin,A., Lipscher,E., Maier,S., Model,F., Mueller,V., Otto,T.,
Pelet,C. and Ziebarth,H.
TITLE Methods and nucleic acids for the analysis of hematopoietic cell
proliferative disorders
JOURNAL Patent: WO 02077272-A 660 03-OCT-2002;
Epigenomics AG (DE)
FEATURES
source
1..18
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/notes="Detection oligonucleotide for ARH1"
BASE COUNT 4 a 0 c 4 g 10 t
Query Match 1.2%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 620 AAAACAACAATAATT 635
DB 17 AAAACTACAATAATT 2

RESULT 66
LOCUS AX119636 20 bp DNA linear PAT 11-MAY-2001
DEFINITION Sequence 29 from Patent WO0129213.
ACCESSION AX119636
VERSION AX119636.1 GI:14036534
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1
AUTHORS Todd,J.A., Twella,R.C., Hess,J.W., Hey,P., Caskey,C.T.,
Hammond,H. and Metzker,M.L.
TITLE Human si4 associated proteins like (sap1) proteins and encoding
Genes; uses thereof
JOURNAL Patent: WO 0129213-A 29 26-APR-2001;
The Wellcome Trust Limited as Trustee to the Wellcome Trust (GB) ;
Merck & Co., Inc. (US)
FEATURES
source
1..20
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/notes="Primer"
BASE COUNT 6 a 3 c 7 g 4 t
Query Match 1.2%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 2.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

QY 1097 AGAGATGAATCATTTG 1112
 DB 4 AGAGATGAATCATTTG 19

RESULT 67
 AX149130
 LOCUS AX149130 20 bp DNA linear PAT 08-JUN-2001
 DEFINITION Sequence 332 from Patent WO0136625.
 ACCESSION AX149130
 VERSION AX149130.1 GI:14347654
 KEYWORDS synthetic construct
 SOURCE synthetic construct
 ORGANISM artificial sequences.

REFERENCE 1
 Wright, J.A., Young, A.H. and Dugourd, D.
 Antisense oligonucleotide sequences derived from groel and groes as
 inhibitors of microorganisms
 Patent: WO 0136625-A 332 25-MAY-2001;
 GenSense Technologies Inc. (CA)
 Location/Qualifiers
 1..20
 /organism="synthetic construct"
 /mol_type="genomic DNA"
 /db_xref="taxon:32630"
 /note="Antisense oligonucleotide"

BASE COUNT 15 a 4 c 1 g 0 t
 Query Match 1.2%; Score 14.4; DB 1; Length 20;
 Best Local Similarity 93.8%; Pred. No. 2.4e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 618 AAAAAACACCAATTA 633
 DB 4 AAAAAACACCAAGAA 19

RESULT 68
 ATH521162
 LOCUS ATH521162 20 bp DNA linear PLN 29-MAR-2003
 DEFINITION Arabidopsis thaliana T-DNA flanking sequence, left border, clone
 053805.
 ACCESSION AJ521162
 VERSION AJ521162.1 GI:26789398
 KEYWORDS left border; T-DNA flanking sequence.
 SOURCE Arabidopsis thaliana (thale cress)
 ORGANISM Arabidopsis thaliana
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
 rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.

REFERENCE 1
 Brunaud, V., Balzerque, S., Dubreucq, B., Aubourg, S., Samson, F.,
 Chauvin, S., Bechtold, N., Cruaud, C., DeRose, R., Pelletier, G.,
 Lepiniec, L., Caboche, M. and Lecharny, A.
 T-DNA integration into the Arabidopsis genome depends on sequences
 of pre-insertion sites
 EMBO Rep. 3 (12), 1152-1157 (2002)

JOURNAL
 MEDLINE 22363535
 PUBMED 1246565

REFERENCE 2 (bases 1 to 20)
 Balzerque, S.
 Direct Submission
 Submitted (21-NOV-2002) Balzerque S., UMRGV, INRA/CNRS, 2 rue
 Gaston Cremieux, 91057 Evry cedex, FRANCE
 PCR was performed on DNA from transformants of Arabidopsis thaliana
 plants from INRA (Versailles). The DNA fragment(s) resulting from
 the PCR were directly sequenced from the left or the right border
 to determine the genomic sequence flanking the insertion. T-DNA
 derived sequences were removed. Information to order the
 corresponding mutant line and a link to a database providing a
 graphical display of the insertion site are available at

http://dbgap.versailles.inra.fr/publiclines/. This sequence has
 been generated in the framework of the French plant genomics
 program 'Genoplatte' (http://www.genoplatte.com and
 http://genoplatte-info.infobiogen.fr).

FEATURES
 source
 1..20
 /organism="Arabidopsis thaliana"
 /mol_type="genomic DNA"
 /cultivar="Wassiliewskaja"
 /db_xref="taxon:3702"
 /clone="053B05"
 /clone_lib="Arabidopsis thaliana T-DNA insertion lines"
 misc_feature
 1..20
 /note="T-DNA flanking sequence
 left border"

BASE COUNT 6 a 3 c 2 g 9 t
 Query Match 1.2%; Score 14.4; DB 1; Length 20;
 Best Local Similarity 93.8%; Pred. No. 2.4e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1135 ATAGTAAATTTATTTT 1150
 DB 5 ATAGTAACTTTATTTT 20

RESULT 69
 ARL178736
 LOCUS ARL178736 19 bp DNA linear PAT 20-APR-2002
 DEFINITION Sequence 23 from patent US 6319714.
 ACCESSION ARL178736
 VERSION ARL178736.1 GI:20219874
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 19)
 Cramer, A., Stemmer, W.P.C., Minshull, J., Bass, S.H., Welch, M.,
 Ness, J.S., Gustafson, C. and Patten, P.A.
 Oligonucleotide mediated nucleic acid recombination
 Patent: US 6319714-A 23 20-NOV-2001;
 Location/Qualifiers
 1..19
 /organism="unknown"

BASE COUNT 9 a 0 c 3 g 7 t
 Query Match 1.1%; Score 14.2; DB 1; Length 19;
 Best Local Similarity 84.2%; Pred. No. 2.4e+02;
 Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1102 ATGAATCATTTGATTA 1120
 DB 1 ATGAATTAATTTGATTA 19

RESULT 70
 AR205441
 LOCUS AR205441 19 bp DNA linear PAT 20-JUN-2002
 DEFINITION Sequence 23 from patent US 6368861.
 ACCESSION AR205441
 VERSION AR205441.1 GI:21503024
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 19)
 Cramer, A., Stemmer, W.P.C., Minshull, J., Bass, S.H., Welch, M.,
 Ness, J.S., Gustafson, C. and Patten, P.A.
 Oligonucleotide mediated nucleic acid recombination
 Patent: US 6368861-A 23 09-APR-2002;
 Location/Qualifiers
 1..19
 /organism="unknown"

```

BASE COUNT      9 a      0 c      3 g      7 t
Query Match
Best Local Similarity 1.1%; Score 14.2; DB 1; Length 19;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1102 ATGAATCATTGATTGAATA 1120
Db 1 ATGAATAATGATTGAATA 19

RESULT 71
LOCUS AR220133 19 bp DNA PAT 26-SEP-2002
DEFINITION Sequence 23 from patent US 6423542.
ACCESSION AR220133
VERSION AR220133.1 GI:23324575
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 19)
AUTHORS Crameri,A., Stemmer,W.P.C., Minshull,J., Bass,S.H., Welch,M.,
Ness,J.E., Gustafsson,C. and Patten,P.A.
TITLE Oligonucleotide mediated nucleic acid recombination
JOURNAL Patent: US 6423542-A 23 23-JUL-2002;
FEATURES Location/Qualifiers
source 1. .19
/organism="unknown"

BASE COUNT      9 a      0 c      3 g      7 t
Query Match
Best Local Similarity 1.1%; Score 14.2; DB 1; Length 19;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1102 ATGAATCATTGATTGAATA 1120
Db 1 ATGAATAATGATTGAATA 19

RESULT 72
LOCUS AR221522 19 bp DNA PAT 26-SEP-2002
DEFINITION Sequence 23 from patent US 6426224.
ACCESSION AR221522
VERSION AR221522.1 GI:23328572
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 19)
AUTHORS Crameri,A., Stemmer,W.P.C., Minshull,J., Bass,S.H., Welch,M.,
Ness,J.E., Gustafsson,C. and Patten,P.A.
TITLE Oligonucleotide mediated nucleic acid recombination
JOURNAL Patent: US 6426224-A 23 30-JUL-2002;
FEATURES Location/Qualifiers
source 1. .19
/organism="unknown"

BASE COUNT      9 a      0 c      3 g      7 t
Query Match
Best Local Similarity 1.1%; Score 14.2; DB 1; Length 19;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1102 ATGAATCATTGATTGAATA 1120
Db 1 ATGAATAATGATTGAATA 19

RESULT 73
LOCUS AR254224 19 bp DNA PAT 20-DEC-2002
DEFINITION Sequence 23 from patent US 6479652.

```

```

ACCESSION AR254224
VERSION AR254224.1 GI:27302961
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 19)
AUTHORS Crameri,A., Stemmer,W.P.C., Minshull,J., Bass,S.H., Welch,M.,
Ness,J.E., Gustafsson,C. and Patten,P.A.
TITLE Oligonucleotide mediated nucleic acid recombination
JOURNAL Patent: US 6479652-A 23 12-NOV-2002;
FEATURES Location/Qualifiers
source 1. .19
/organism="unknown"

BASE COUNT      9 a      0 c      3 g      7 t
Query Match
Best Local Similarity 1.1%; Score 14.2; DB 1; Length 19;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1102 ATGAATCATTGATTGAATA 1120
Db 1 ATGAATAATGATTGAATA 19

RESULT 74
LOCUS AR282430 19 bp DNA PAT 10-APR-2003
DEFINITION Sequence 23 from patent US 6521453.
ACCESSION AR282430
VERSION AR282430.1 GI:29718586
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 19)
AUTHORS Crameri,A., Stemmer,W.P.C., Minshull,J., Bass,S.H., Welch,M.,
Ness,J.E., Gustafsson,C. and Patten,P.A.
TITLE Oligonucleotide mediated nucleic acid recombination
JOURNAL Patent: US 6521453-A 23 18-FEB-2003;
FEATURES Location/Qualifiers
source 1. .19
/organism="unknown"

BASE COUNT      9 a      0 c      3 g      7 t
Query Match
Best Local Similarity 1.1%; Score 14.2; DB 1; Length 19;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1102 ATGAATCATTGATTGAATA 1120
Db 1 ATGAATAATGATTGAATA 19

RESULT 75
LOCUS AX129503 19 bp DNA PAT 15-MAY-2001
DEFINITION Sequence 721 from Patent WO0130362.
ACCESSION AX129503
VERSION AX129503.1 GI:14135808
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Robbins,J.M. and Tritz,R.
TITLE Ribozyme therapy for the treatment of proliferative skin and eye
JOURNAL Patent: WO 0130362-A 721 03-MAY-2001;
FEATURES Location/Qualifiers
source 1. .19
/organism="unknown"

```


REFERENCE 1 (bases 1 to 20)
 AUTHORS Umori,T., Sato,Y., Fujita,T., Miyake,K., Mukai,H., Asada,K. and Kato,I.
 TITLE DNA polymerase-related factors
 JOURNAL Patent: US 6218150-A 54 17-APR-2001;
 FEATURES Location/Qualifiers
 source 1..20
 BASE COUNT 9 a 4 c 2 g 5 t
 Query Match 1.1%; Score 14.2; DB 1; Length 20;
 Best Local Similarity 84.2%; Pred. No. 2.7e+02;
 Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 Db 583 TACTTATATGTAAGTATT 601
 20 TTCTGCTATGTAAGTATT 2

RESULT 81
 ARI59242/c
 LOCUS ARI59242 20 bp DNA linear PAT 17-OCT-2001
 DEFINITION Sequence 864 from patent US 6251588.
 ACCESSION ARI59242
 VERSION ARI59242.1 GI:16221866
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unclassified.
 REFERENCE 1 (bases 1 to 20)
 AUTHORS Shannon,K.W., Wolber,P.K., Delenstarr,G.C., Webb,P.G. and Kincaid,R.H.
 TITLE Method for evaluating oligonucleotide probe sequences
 JOURNAL Patent: US 6251588-A 864 26-JUN-2001;
 FEATURES Location/Qualifiers
 source 1..20
 BASE COUNT 9 a 1 c 5 g 5 t
 Query Match 1.1%; Score 14.2; DB 1; Length 20;
 Best Local Similarity 84.2%; Pred. No. 2.7e+02;
 Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 Db 982 GCACCTTAAGTTTTCAT 1000
 20 GCACCTTAAGTTTTCAT 2

RESULT 82
 ARI59243/c
 LOCUS ARI59243 20 bp DNA linear PAT 17-OCT-2001
 DEFINITION Sequence 865 from patent US 6251588.
 ACCESSION ARI59243
 VERSION ARI59243.1 GI:16221867
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unclassified.
 REFERENCE 1 (bases 1 to 20)
 AUTHORS Shannon,K.W., Wolber,P.K., Delenstarr,G.C., Webb,P.G. and Kincaid,R.H.
 TITLE Method for evaluating oligonucleotide probe sequences
 JOURNAL Patent: US 6251588-A 865 26-JUN-2001;
 FEATURES Location/Qualifiers
 source 1..20
 BASE COUNT 9 a 1 c 5 g 5 t
 Query Match 1.1%; Score 14.2; DB 1; Length 20;
 Best Local Similarity 84.2%; Pred. No. 2.7e+02;
 Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 Db 982 GCACCTTAAGTTTTCAT 1000

Db 19 GCACCTTAAGTTTTCAT 1

RESULT 83
 ARI59247/c
 LOCUS ARI59247 20 bp DNA linear PAT 17-OCT-2001
 DEFINITION Sequence 869 from patent US 6251588.
 ACCESSION ARI59247
 VERSION ARI59247.1 GI:16221872
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unclassified.
 REFERENCE 1 (bases 1 to 20)
 AUTHORS Shannon,K.W., Wolber,P.K., Delenstarr,G.C., Webb,P.G. and Kincaid,R.H.
 TITLE Method for evaluating oligonucleotide probe sequences
 JOURNAL Patent: US 6251588-A 869 26-JUN-2001;
 FEATURES Location/Qualifiers
 source 1..20
 BASE COUNT 10 a 3 c 3 g 4 t
 Query Match 1.1%; Score 14.2; DB 1; Length 20;
 Best Local Similarity 84.2%; Pred. No. 2.7e+02;
 Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 977 TGGAGGACACTTTAAGTTT 995
 Db 20 TGGTTGCACCTTAAGTTT 2

RESULT 84
 ARI59248/c
 LOCUS ARI59248 20 bp DNA linear PAT 17-OCT-2001
 DEFINITION Sequence 870 from patent US 6251588.
 ACCESSION ARI59248
 VERSION ARI59248.1 GI:16221873
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unclassified.
 REFERENCE 1 (bases 1 to 20)
 AUTHORS Shannon,K.W., Wolber,P.K., Delenstarr,G.C., Webb,P.G. and Kincaid,R.H.
 TITLE Method for evaluating oligonucleotide probe sequences
 JOURNAL Patent: US 6251588-A 870 26-JUN-2001;
 FEATURES Location/Qualifiers
 source 1..20
 BASE COUNT 11 a 3 c 2 g 4 t
 Query Match 1.1%; Score 14.2; DB 1; Length 20;
 Best Local Similarity 84.2%; Pred. No. 2.7e+02;
 Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 977 TGGAGGACACTTTAAGTTT 995
 Db 19 TGGTTGCACCTTAAGTTT 1

RESULT 85
 ARI80879
 LOCUS ARI80879 20 bp DNA linear PAT 20-APR-2002
 DEFINITION Sequence 53 from patent US 6333158.
 ACCESSION ARI80879
 VERSION ARI80879.1 GI:20222912
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unclassified.
 REFERENCE 1 (bases 1 to 20)

AUTHORS Umori,T., Sato,Y., Fujita,T., Miyake,K., Mukai,H., Asada,K. and Kato,I.
 TITLE DNA polymerase-related factors
 JOURNAL Patent: US 6333158-A 53 25-DEC-2001;
 FEATURES Location/Qualifiers
 source 1..20
 BASE COUNT 5 a 2 c 4 g 9 t
 Query Match 1.1%; Score 14.2; DB 1; Length 20;
 Best Local Similarity 84.2%; Pred. No. 2.7e+02;
 Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 583 TACTTATATGTAAGTATT 601
 Db 1 TTCTGCTATGTAAGTATT 19

RESULT 86
 AR180880/c
 LOCUS AR180880 20 bp DNA linear PAT 20-APR-2002
 DEFINITION Sequence 54 from patent US 6333158.
 ACCESSION AR180880
 VERSION AR180880.1 GI:20222913
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 20)
 AUTHORS Umori,T., Sato,Y., Fujita,T., Miyake,K., Mukai,H., Asada,K. and Kato,I.
 TITLE DNA polymerase-related factors
 JOURNAL Patent: US 6333158-A 54 25-DEC-2001;
 FEATURES Location/Qualifiers
 source 1..20
 BASE COUNT 9 a 4 c 2 g 5 t
 Query Match 1.1%; Score 14.2; DB 1; Length 20;
 Best Local Similarity 84.2%; Pred. No. 2.7e+02;
 Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 583 TACTTATATGTAAGTATT 601
 Db 20 TTCTGCTATGTAAGTATT 2

RESULT 87
 AR205764
 LOCUS AR205764 20 bp DNA linear PAT 20-JUN-2002
 DEFINITION Sequence 2 from patent US 6369208.
 ACCESSION AR205764
 VERSION AR205764.1 GI:21503429
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 20)
 AUTHORS Cole,J.L., Kuo,L.C., Olsen,D.B. and Benseler,F.
 TITLE Capped synthetic RNA, analogs, and aptamers
 JOURNAL Patent: US 6369208-A 2 09-APR-2002;
 FEATURES Location/Qualifiers
 source 1..20
 BASE COUNT 3 a 1 c 2 g 14 t
 Query Match 1.1%; Score 14.2; DB 1; Length 20;
 Best Local Similarity 84.2%; Pred. No. 2.7e+02;
 Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 1519 GCCTTATATTTTAACTTT 1537
 Db 1 GGTATTATTTTAAATTT 19

RESULT 88
 AR224476
 LOCUS AR224476 20 bp DNA linear PAT 26-SEP-2002
 DEFINITION Sequence 21 from patent US 6440737.
 ACCESSION AR224476
 VERSION AR224476.1 GI:23333316
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 20)
 AUTHORS Freier,S.M.
 TITLE Antisense modulation of cellular apoptosis susceptibility gene expression
 JOURNAL Patent: US 6440737-A 21 27-AUG-2002;
 FEATURES Location/Qualifiers
 source 1..20
 BASE COUNT 8 a 3 c 3 g 6 t
 Query Match 1.1%; Score 14.2; DB 1; Length 20;
 Best Local Similarity 84.2%; Pred. No. 2.7e+02;
 Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 1307 TGAATAACATCCTAGTT 1325
 Db 1 TGAATAACATCCTAGTT 19

RESULT 89
 AR272014/c
 LOCUS AR272014 20 bp DNA linear PAT 10-APR-2003
 DEFINITION Sequence 84 from patent US 6503756.
 ACCESSION AR272014
 VERSION AR272014.1 GI:29703582
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 20)
 AUTHORS Freier,S.M. and Wyatt,J.
 TITLE Antisense modulation of syntaxin 4 interacting protein expression
 JOURNAL Patent: US 6503756-A 84 07-JAN-2003;
 FEATURES Location/Qualifiers
 source 1..20
 BASE COUNT 10 a 1 c 2 g 7 t
 Query Match 1.1%; Score 14.2; DB 1; Length 20;
 Best Local Similarity 84.2%; Pred. No. 2.7e+02;
 Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 1045 TATTATATCTATTATTAA 1063
 Db 19 TATTCTGTATACATTAA 1

RESULT 90
 AR315173/c
 LOCUS AR315173 20 bp DNA linear PAT 12-JUN-2003
 DEFINITION Sequence 5710 from patent US 6559294.
 ACCESSION AR315173
 VERSION AR315173.1 GI:31708599
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 20)
 AUTHORS Griffiths,R., Hoigeth,S.K., Zagursky,R.J., Metcalf,B.J., Peek,J.A., Santaran,B. and Fletcher,L.D.
 TITLE Chlamydia pneumoniae polynucleotides and uses thereof

JOURNAL Patent: US 6559294-A 5710 06-MAY-2003;
FEATURES
source Location/Qualifiers
1. .20
/organism="unknown"
BASE COUNT 5 a 6 c 4 g 5 t
Query Match 1.1%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 968 GAGGACATCTGGAAGCACT 986
|||||
Db 19 GAGGATATTGGAAGCCT 1
|||||
RESULT 91
AXI49154 20 bp DNA linear PAT 08-JUN-2001
LOCUS
DEFINITION Sequence 356 from Patent WO0136625.
ACCESSION AXI49154
VERSION AXI49154.1 GI:14347678
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1
AUTHORS Wright J.A., Young A.H. and Dugourd D.
TITLE Antisense oligonucleotide sequences derived from groel and groes as
inhibitors of microorganisms
JOURNAL Patent: WO 0136625-A 356 25-MAY-2001;
GenSense Technologies Inc. (CA)
FEATURES
source Location/Qualifiers
1. .20
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/notes="Antisense oligonucleotide"
BASE COUNT 3 a 5 c 2 g 10 t
Query Match 1.1%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1566 TTTTACTGTTCTGATTG 1584
|||||
Db 2 TTTTACCGCTTCTCATTT 20
|||||
RESULT 92
BD161924/c 20 bp DNA linear PAT 17-JAN-2003
LOCUS
DEFINITION Method for carrying out thermal cycle of PCR using DNA-immobilized
substrate.
ACCESSION BD161924
VERSION BD161924.1 GI:27867682
KEYWORDS JP 2002191369-A/1
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1
AUTHORS Tanga M., Okamura H. and Takahashi K.
TITLE Method for carrying out thermal cycle of PCR using DNA-immobilized
substrate
JOURNAL Patent: JP 2002191369-A 1 09-JUL-2002;
TOYO KOKAN CO LTD, KOJIRO TAKAHASHI
OS Artificial Sequence
PN JP 2002191369-A/1
PD 09-JUL-2002
PF 27-DEC-2000 JP 2000399573
PI MICHIFUMI TANGA, HIROSHI OKAMURA, KOJIRO TAKAHASHI PC
C12N15/09, C12N15/00, C12N15/00 CC Method for
carrying out thermal cycle of PCR using DNA- CC
immobilized

CC substrate Location/Qualifiers
PH Key 1. .20
FT source /organism="Artificial Sequence".
FEATURES
source Location/Qualifiers
1. .20
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
BASE COUNT 3 a 0 c 0 g 17 t
Query Match 1.1%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 618 AAAAAACACAAATAATTT 636
|||||
Db 19 AAAAAAATAATAATTT 1
|||||
RESULT 93
YSCWTP021 20 bp DNA linear PLN 04-AUG-1993
LOCUS
DEFINITION Yeast (S.cerevisiae) mitochondrial petite mutant excision seq 2,
left end.
ACCESSION J01510
VERSION J01510.1 GI:343846
KEYWORDS AT-rich region; GC rich region.
SEGMENT 1 of 2
SOURCE mitochondrion Saccharomyces cerevisiae (baker's yeast)
ORGANISM Saccharomyces cerevisiae
Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;
Saccharomycetales; Saccharomycetaceae; Saccharomycetes.
REFERENCE 1 (bases 1 to 20)
AUTHORS de Zamaroczy M., Faugeron-Fonty G. and Bernardi G.
TITLE Excision sequences in the mitochondrial genome of yeast
JOURNAL Gene 21 (3), 193-202 (1983)
MEDLINE 83210931
PubMed 6343188
COMMENT Original source text: Yeast (Saccharomyces cerevisiae)
mitochondrial DNA.
Additional sequences reported in [1], but sequenced in earlier
papers, appear in separate entries.
FEATURES
source Location/Qualifiers
1. .20
/organism="Saccharomyces cerevisiae"
/organelle="mitochondrion"
/mol_type="genomic DNA"
/db_xref="taxon:4932"
BASE COUNT 7 a 0 c 0 g 13 t
Query Match 1.1%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1143 TTTATTTTATTTAGATAT 1161
|||||
Db 2 TATATTATTTTATATAT 20
|||||
RESULT 94
AR041399 15 bp DNA linear PAT 29-SEP-1999
LOCUS
DEFINITION Sequence 189 from patent US 5811300.
ACCESSION AR041399
VERSION AR041399.1 GI:5961895
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Sullivan S., Draper K., Kisich K., Stinchcomb D.T. and McSwiggen J.
TITLE TNF-alpha ribozymes

JOURNAL Patent: US 5811300-A 189 22-SEP-1998;
 FEATURES
 source
 BASE COUNT 4 a 0 c 0 g 11 t

Query Match 1.1%; Score 14; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 1.8e+02;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1038 TATTATTATTAT 1051
 Db 1 TATTATTATTAT 14

RESULT 95
 AR041407
 LOCUS 15 bp DNA linear PAT 29-SEP-1999
 DEFINITION Sequence 197 from patent US 5811300.
 ACCESSION AR041407
 VERSION AR041407.1 GI:5961903
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 15)
 AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
 TITLE TNP-.alpha. ribozymes
 JOURNAL Patent: US 5811300-A 197 22-SEP-1998;
 FEATURES Location/Qualifiers
 source 1..15
 BASE COUNT 4 a 0 c 0 g 11 t

Query Match 1.1%; Score 14; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 1.8e+02;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1038 TATTATTATTAT 1051
 Db 1 TATTATTATTAT 14

RESULT 96
 AR041916
 LOCUS 15 bp DNA linear PAT 29-SEP-1999
 DEFINITION Sequence 706 from patent US 5811300.
 ACCESSION AR041916
 VERSION AR041916.1 GI:5962412
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 15)
 AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
 TITLE TNP-.alpha. ribozymes
 JOURNAL Patent: US 5811300-A 706 22-SEP-1998;
 FEATURES Location/Qualifiers
 source 1..15
 BASE COUNT 4 a 0 c 0 g 11 t

Query Match 1.1%; Score 14; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 1.8e+02;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1038 TATTATTATTAT 1051
 Db 1 TATTATTATTAT 14

RESULT 97
 AR041917
 LOCUS 15 bp DNA linear PAT 29-SEP-1999
 DEFINITION Sequence 707 from patent US 5811300.
 ACCESSION AR041917
 VERSION AR041917.1 GI:5962413
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 15)
 AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
 TITLE TNP-.alpha. ribozymes
 JOURNAL Patent: US 5811300-A 707 22-SEP-1998;
 FEATURES Location/Qualifiers
 source 1..15
 BASE COUNT 4 a 0 c 0 g 11 t

Query Match 1.1%; Score 14; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 1.8e+02;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1038 TATTATTATTAT 1051
 Db 1 TATTATTATTAT 14

RESULT 98
 AR041918
 LOCUS 15 bp DNA linear PAT 29-SEP-1999
 DEFINITION Sequence 708 from patent US 5811300.
 ACCESSION AR041918
 VERSION AR041918.1 GI:5962414
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 15)
 AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
 TITLE TNP-.alpha. ribozymes
 JOURNAL Patent: US 5811300-A 708 22-SEP-1998;
 FEATURES Location/Qualifiers
 source 1..15
 BASE COUNT 4 a 0 c 0 g 11 t

Query Match 1.1%; Score 14; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 1.8e+02;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1038 TATTATTATTAT 1051
 Db 1 TATTATTATTAT 14

RESULT 99
 AX636857
 LOCUS 15 bp mRNA linear PAT 21-FEB-2003
 DEFINITION Sequence 3996 from Patent EP1260586.
 ACCESSION AX636857
 VERSION AX636857.1 GI:28472471
 KEYWORDS
 SOURCE unidentified
 ORGANISM unidentified
 REFERENCE 1
 AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A., Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J., McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M., Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and Woolf,T.
 TITLE Method and reagent for inhibiting the expression of disease related genes
 JOURNAL Patent: EP 1260586-A 3996 27-NOV-2002;

LOCUS AR041917 15 bp DNA linear PAT 29-SEP-1999
 DEFINITION Sequence 707 from patent US 5811300.
 ACCESSION AR041917
 VERSION AR041917.1 GI:5962413
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 15)
 AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
 TITLE TNP-.alpha. ribozymes
 JOURNAL Patent: US 5811300-A 707 22-SEP-1998;
 FEATURES Location/Qualifiers
 source 1..15
 BASE COUNT 4 a 0 c 0 g 11 t

Query Match 1.1%; Score 14; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 1.8e+02;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1038 TATTATTATTAT 1051
 Db 1 TATTATTATTAT 14

RESULT 98
 AR041918
 LOCUS 15 bp DNA linear PAT 29-SEP-1999
 DEFINITION Sequence 708 from patent US 5811300.
 ACCESSION AR041918
 VERSION AR041918.1 GI:5962414
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 15)
 AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
 TITLE TNP-.alpha. ribozymes
 JOURNAL Patent: US 5811300-A 708 22-SEP-1998;
 FEATURES Location/Qualifiers
 source 1..15
 BASE COUNT 4 a 0 c 0 g 11 t

Query Match 1.1%; Score 14; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 1.8e+02;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1038 TATTATTATTAT 1051
 Db 1 TATTATTATTAT 14

RESULT 99
 AX636857
 LOCUS 15 bp mRNA linear PAT 21-FEB-2003
 DEFINITION Sequence 3996 from Patent EP1260586.
 ACCESSION AX636857
 VERSION AX636857.1 GI:28472471
 KEYWORDS
 SOURCE unidentified
 ORGANISM unidentified
 REFERENCE 1
 AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A., Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J., McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M., Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and Woolf,T.
 TITLE Method and reagent for inhibiting the expression of disease related genes
 JOURNAL Patent: EP 1260586-A 3996 27-NOV-2002;

FEATURES	source	Location/Qualifiers
BASE COUNT	4 a	1.15 /organism="unidentified" /mol_type="mRNA" /db_xref="taxon:32644" 11 t
Query Match	1.1%;	Score 14; DB 1; Length 15;
Best Local Similarity	100.0%;	Pred. No. 1.8e+02;
Matches	14;	Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY	1038	TATTTATTATTAT 1051
Db	1	TATTTATTATTAT 14
RESULT 102		
AX637383		
LOCUS	AX637383	15 bp mRNA linear PAT 21-FEB-2003
DEFINITION	Sequence 4522 from Patent EP1260586.	
ACCESSION	AX637383	
VERSION	AX637383.1	GI:28472997
KEYWORDS		
SOURCE	unidentified	
ORGANISM	unidentified	
REFERENCE	1	unclassified.
AUTHORS	Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A., Karpeisky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J., McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M., Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and Woolf,T.	
TITLE	Method and reagent for inhibiting the expression of disease related genes	
JOURNAL	Patent: EP 1260586-A 4522 27-NOV-2002;	
FEATURES		
source	1.15	Location/Qualifiers
BASE COUNT	4 a	1.15 /organism="unidentified" /mol_type="mRNA" /db_xref="taxon:32644" 11 t
Query Match	1.1%;	Score 14; DB 1; Length 15;
Best Local Similarity	100.0%;	Pred. No. 1.8e+02;
Matches	14;	Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY	1038	TATTTATTATTAT 1051
Db	1	TATTTATTATTAT 14
RESULT 103		
AX637385		
LOCUS	AX637385	15 bp mRNA linear PAT 21-FEB-2003
DEFINITION	Sequence 4524 from Patent EP1260586.	
ACCESSION	AX637385	
VERSION	AX637385.1	GI:28472999
KEYWORDS		
SOURCE	unidentified	
ORGANISM	unidentified	
REFERENCE	1	unclassified.
AUTHORS	Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A., Karpeisky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J., McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M., Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and Woolf,T.	
TITLE	Method and reagent for inhibiting the expression of disease related genes	
JOURNAL	Patent: EP 1260586-A 4524 27-NOV-2002;	
FEATURES		
source	1.15	Location/Qualifiers
BASE COUNT	4 a	1.15 /organism="unidentified" /mol_type="mRNA" /db_xref="taxon:32644" 11 t
Query Match	1.1%;	Score 14; DB 1; Length 15;
Best Local Similarity	100.0%;	Pred. No. 1.8e+02;
Matches	14;	Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY	1038	TATTTATTATTAT 1051
Db	1	TATTTATTATTAT 14
RESULT 101		
AX637381		
LOCUS	AX637381	15 bp mRNA linear PAT 21-FEB-2003
DEFINITION	Sequence 4520 from Patent EP1260586.	
ACCESSION	AX637381	
VERSION	AX637381.1	GI:28472995
KEYWORDS		
SOURCE	unidentified	
ORGANISM	unidentified	
REFERENCE	1	unclassified.
AUTHORS	Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A., Karpeisky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J., McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M., Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and Woolf,T.	
TITLE	Method and reagent for inhibiting the expression of disease related genes	
JOURNAL	Patent: EP 1260586-A 4520 27-NOV-2002;	
FEATURES		
source	1.15	Location/Qualifiers
BASE COUNT	4 a	1.15 /organism="unidentified" /mol_type="mRNA" /db_xref="taxon:32644" 11 t
Query Match	1.1%;	Score 14; DB 1; Length 15;
Best Local Similarity	100.0%;	Pred. No. 1.8e+02;
Matches	14;	Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY	1038	TATTTATTATTAT 1051
Db	1	TATTTATTATTAT 14

```

source 1. 15
/organism="unidentified"
/mol_type="mRNA"
/db_xref="taxon:32644"
BASE COUNT 4 a 0 c 0 g 11 t

Query Match 1.1%; Score 14; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1038 TATTATTATTAT 1051
|||||
Db 1 TATTATTATTAT 14

RESULT 104
AX738727/c
LOCUS AX738727 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 4317 from Patent WO03025177.
ACCESSION AX738727
VERSION AX738727.1 GI:30518017
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
REFERENCE
AUTHORS
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL Patent: WO 03025177-A 4317 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source 1. 17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 6 a 4 c 2 g 5 t

Query Match 1.1%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1076 TGTGCAAGATTG 1089
|||||
Db 17 TGTGCAAGATTG 4

RESULT 105
BD067874
LOCUS BD067874 17 bp RNA linear PAT 27-AUG-2002
DEFINITION Enzymatic nucleic acid treatment of diseases or conditions related
to levels of epidermal growth factor receptors.
ACCESSION BD067874
VERSION BD067874.1 GI:22613477
KEYWORDS JP 2001511003-A/714.
SOURCE unidentified
ORGANISM
REFERENCE 1 (bases 1 to 17)
AUTHORS Akhtar, S., Fell, P. and McSwiggen, J.A.
TITLE Enzymatic nucleic acid treatment of diseases or conditions related
to levels of epidermal growth factor receptors
JOURNAL Patent: JP 2001511003-A 714 07-AUG-2001;
RIBOZYME PHARMACEUTICALS INC, ASTON UNIV
COMMENT OS Unidentified
PN JP 2001511003-A/714
PD 07-AUG-2001
PP 14-JAN-1998 JP 1998532913
PR 31-JAN-1997 US 60/036475, 04-DEC-1997 US 08/985162 PI
SAGHIR AKHTAR, PATRICIA FELL, JAMES A MCSWIGGEN PC
CL2N9/00, C07K14/71

```

```

CC Strandedness: Single;
CC Topology: Linear;
CC Enzymatic nucleic acid treatment of diseases or conditions related to
CC levels of epidermal growth factor receptors
FH Key 1..17 Location/Qualifiers
FT source 1..17 /organism="Unidentified".
FEATURES
source 1. 17
/organism="unidentified"
/mol_type="genomic RNA"
/db_xref="taxon:32644"
BASE COUNT 9 a 1 c 2 g 5 t

Query Match 1.1%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1599 AGTAATATGAAC 1612
|||||
Db 2 AGTAATATGAAC 15

RESULT 106
AX069089/c
LOCUS AX069089 18 bp DNA linear PAT 25-JAN-2001
DEFINITION Sequence 7 from Patent WO0102604.
ACCESSION AX069089
VERSION AX069089.1 GI:12578971
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Tournier-Lasserre, E., Laberge-Le, S. and Labauge, P.
TITLE Use of the krt11 gene in angiogenesis
JOURNAL Patent: WO 0102604-A 7 11-JAN-2001;
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM).
(FR)
FEATURES
source 1. 18
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/feature="Amorce sens"
BASE COUNT 0 a 0 c 5 g 13 t

Query Match 1.1%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 616 ACAAAAACACAA 629
|||||
Db 15 ACAAAAACACAA 2

RESULT 107
AR067181/c
LOCUS AR067181 20 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 529 from patent US 5851760.
ACCESSION AR067181
VERSION AR067181.1 GI:5998403
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Evans, G.A. and Smith, M.W.
TITLE Method for generation of sequence sampled maps of complex genomes
JOURNAL Patent: US 5851760-A 529 22-DEC-1998;
FEATURES
source 1. 20
Location/Qualifiers

```

BASE COUNT 6 a 5 c 6 g 3 t
Query Match 1.1%; Score 14; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3e+02; Indels 0; Gaps 0;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 889 GTTCCACTGTGCT 902
Db 17 GTTCCACTGTGCT 4

RESULT 108
AR315239 20 bp DNA linear PAT 12-JUN-2003
LOCUS Sequence 5776 from patent US 6559294.
DEFINITION AR315239
ACCESSION AR315239
VERSION AR315239.1 GI:31708665
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Griffais, R., Hoieth, S.K., Zagursky, R.J., Metcalf, B.J., Peek, J.A., Sankaran, B. and Fletcher, L.D.
TITLE Chlamydia pneumoniae polynucleotides and uses thereof
JOURNAL Patent: US 6559294-A 5776 06-MAY-2003;
FEATURES Location/Qualifiers
source 1. .20
/organism="unknown"

BASE COUNT 4 a 7 c 3 g 6 t
Query Match 1.1%; Score 14; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3e+02; Indels 0; Gaps 0;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 644 TAAGGATTTTCTTA 657
Db 7 TAAGGATTTTCTTA 20

RESULT 109
ATH552863 20 bp DNA linear PLN 29-MAR-2003
LOCUS Arabidopsis thaliana T-DNA flanking sequence, left border, clone 345309.
DEFINITION AJ552863.1 GI:29369014
ACCESSION AJ552863
VERSION AJ552863.1
KEYWORDS left border; T-DNA flanking sequence.
SOURCE Arabidopsis thaliana (thale cress)
ORGANISM Arabidopsis thaliana
REFERENCE Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.

1
Brunaud, V., Balzerque, S., Dubreucq, B., Aubourg, S., Samson, F., Chauvin, S., Bechtold, N., Cruaud, C., DeRose, R., Pelletier, G., Lepiniec, L., Caboche, M. and Lecharny, A.
T-DNA integration into the Arabidopsis genome depends on sequences of pre-insertion sites
EMBO Rep. 3 (12), 1152-1157 (2002)
JOURNAL 22363535
MEDLINE 12446565
PUBMED
REFERENCE 2 (bases 1 to 20)
AUTHORS Balzerque, S.
TITLE Direct Submission
JOURNAL Submitted (21-NOV-2002) Balzerque S., UMRGV, INRA/CNRS, 2 rue Gaston Cremieux, 91057 Evry cedex, FRANCE
COMMENT PCR was performed on DNA from transformants of Arabidopsis thaliana plants from INRA (Versailles). The DNA fragment(s) resulting from the PCR were directly sequenced from the left or the right border to determine the genomic sequence flanking the insertion. T-DNA derived sequences were removed. Information to order the

corresponding mutant line and a link to a database providing a graphical display of the insertion site are available at <http://dbsegap.versailles.inra.fr/publiclines/>. This sequence has been generated in the framework of the French plant genomics program 'Genoplante' (<http://www.genoplante.com> and <http://genoplante-info.infobiogen.fr>).

FEATURES Location/Qualifiers
source 1. .20
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"
/cultivar="Wassillewskija"
/db_xref="taxon:3702"
/clone="345E09"
/clone_lib="Arabidopsis thaliana T-DNA insertion lines"
misc_feature 1. .20
/note="T-DNA flanking sequence left border"
BASE COUNT 13 a 4 c 0 g 3 t
Query Match 1.1%; Score 14; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3e+02; Indels 0; Gaps 0;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1207 AACCAACAAACAA 1220
Db 1 AACCAACAAACAA 14

RESULT 110
AR046179/c 17 bp DNA linear PAT 29-SEP-1999
LOCUS AR046179
DEFINITION Sequence 972 from patent US 5817796.
ACCESSION AR046179
VERSION AR046179.1 GI:5967644
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb, D.T., Draper, K., McSwiggen, J. and Jarvis, T.
TITLE C-myb ribozymes having 2'-5'-linked adenylate residues
JOURNAL Patent: US 5817796-A 972 06-OCT-1998;
FEATURES Location/Qualifiers
source 1. .17
/organism="unknown"
BASE COUNT 9 a 0 c 0 g 8 t
Query Match 1.1%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.5e+02; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1615 TTAATAATATAATTGTT 1631
Db 17 TAAATAATATAATTTTT 1

RESULT 111
AR047260/c 17 bp DNA linear PAT 29-SEP-1999
LOCUS AR047260
DEFINITION Sequence 2053 from patent US 5817796.
ACCESSION AR047260
VERSION AR047260.1 GI:5968725
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb, D.T., Draper, K., McSwiggen, J. and Jarvis, T.
TITLE C-myb ribozymes having 2'-5'-linked adenylate residues
JOURNAL Patent: US 5817796-A 2053 06-OCT-1998;
FEATURES Location/Qualifiers
source 1. .17
/organism="unknown"

[illegible]

<hr/>					
RESULT 114					
AX580024					
LOCUS					
Sequence 1862 from Patent WO0211674.					
ACCESSION AX580024					
VERSION AX580024.1 GI:27649226					
KEYWORDS					
Homo sapiens (human)					
SOURCE					
ORGANISM					
REFERENCE					
AUTHORS					
Thompson,J., Mcswiggen,J., Mckenzie,T., Ayers,D., Szymkowski,D.E.					
TITLE					
Method and reagent for the inhibition of calcium activated chloride channel-1 (Cica-1)					
JOURNAL					
Patent: WO 0211674-A 1862 14-FEB-2002;					
RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;					
Thompson, James (US)					
FEATURES					
Location/Qualifiers					
1..17					
/organism="Homo sapiens"					
/mol_type="mRNA"					
/db_xref="taxon:9606"					
BASE COUNT					
6 a 1 c 1 g 9 t					
Query Match					
Best Local Similarity 1.1%; Score 13.8; DB 1; Length 17;					
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;					
QY					
1134 TATAGTAAATTATTT 1150					
Db					
1 TATACTAAATGTATTT 17					
RESULT 115					
AX673523/c					
LOCUS					
Sequence 1968 from Patent WO03004526.					
ACCESSION AX673523					
VERSION AX673523.1 GI:29331871					
KEYWORDS					
Homo sapiens (human)					
SOURCE					
ORGANISM					
REFERENCE					
AUTHORS					
Telerman,A., Amson,R. and Tuljinder,M.					
TITLE					
Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and their use as medicines					
JOURNAL					
Patent: WO 03004526-A 1968 16-JAN-2003;					
Molecular Engines Laboratories (FR)					
FEATURES					
Location/Qualifiers					
1..17					
/organism="Homo sapiens"					
/mol_type="Genomic DNA"					
/db_xref="taxon:9606"					
BASE COUNT					
7 a 5 c 1 g 4 t					
Query Match					
Best Local Similarity 1.1%; Score 13.8; DB 1; Length 17;					
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;					
QY					
755 CTGATATTGAAGCATC 771					
Db					
17 CTGATTTTGAAGGCATC 1					
RESULT 116					
AX734639/c					
LOCUS					
Sequence 229 from Patent WO03025177.					
ACCESSION AX734639					
VERSION AX734639.1 GI:29331871					
KEYWORDS					
Homo sapiens (human)					
SOURCE					
ORGANISM					
REFERENCE					
AUTHORS					
Zhan,J.					
TITLE					
Human testis expressed patched like protein					
JOURNAL					
Patent: EP 1229046-A 1930 07-AUG-2002;					
Aeomica, Inc. (US)					
FEATURES					
Location/Qualifiers					
1..17					
/organism="Homo sapiens"					
/mol_type="Genomic DNA"					
/db_xref="taxon:9606"					
BASE COUNT					
6 a 3 c 2 g 6 t					
Query Match					
Best Local Similarity 1.1%; Score 13.8; DB 1; Length 17;					
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;					
QY					
1456 TGCTTATGATGACAAA 1472					
Db					
17 TGCTTATGATGACAAA 1					
RESULT 117					
AX500623/c					
LOCUS					
Sequence 1930 from Patent EP1229046.					
ACCESSION AX500623					
VERSION AX500623.1 GI:23382916					
KEYWORDS					
Homo sapiens (human)					
SOURCE					
ORGANISM					
REFERENCE					
AUTHORS					
Zhan,J.					
TITLE					
Human testis expressed patched like protein					
JOURNAL					
Patent: EP 1229046-A 1930 07-AUG-2002;					
Aeomica, Inc. (US)					
FEATURES					
Location/Qualifiers					
1..17					
/organism="Homo sapiens"					
/mol_type="Genomic DNA"					
/db_xref="taxon:9606"					
BASE COUNT					
6 a 3 c 2 g 6 t					
Query Match					
Best Local Similarity 1.1%; Score 13.8; DB 1; Length 17;					
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;					
QY					
1456 TGCTTATGATGACAAA 1472					
Db					
17 TGCTTATGATGACAAA 1					
RESULT 118					
AX500623/c					
LOCUS					
Sequence 1930 from Patent EP1229046.					
ACCESSION AX500623					
VERSION AX500623.1 GI:23382916					
KEYWORDS					
Homo sapiens (human)					
SOURCE					
ORGANISM					
REFERENCE					
AUTHORS					
Zhan,J.					
TITLE					
Human testis expressed patched like protein					
JOURNAL					
Patent: EP 1229046-A 1930 07-AUG-2002;					
Aeomica, Inc. (US)					
FEATURES					
Location/Qualifiers					
1..17					
/organism="Homo sapiens"					
/mol_type="Genomic DNA"					
/db_xref="taxon:9606"					
BASE COUNT					
6 a 3 c 2 g 6 t					
Query Match					
Best Local Similarity 1.1%; Score 13.8; DB 1; Length 17;					
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;					
QY					
1456 TGCTTATGATGACAAA 1472					
Db					
17 TGCTTATGATGACAAA 1					
RESULT 119					
AX500623/c					
LOCUS					
Sequence 1930 from Patent EP1229046.					
ACCESSION AX500623					
VERSION AX500623.1 GI:23382916					
KEYWORDS					
Homo sapiens (human)					
SOURCE					
ORGANISM					
REFERENCE					
AUTHORS					
Zhan,J.					
TITLE					
Human testis expressed patched like protein					
JOURNAL					
Patent: EP 1229046-A 1930 07-AUG-2002;					
Aeomica, Inc. (US)					
FEATURES					
Location/Qualifiers					

[illegible]

ACCESSION AX734639
 VERSION AX734639.1 GI:30513916
 KEYWORDS Homo sapiens (human)
 SOURCE Homo sapiens
 ORGANISM Homo sapiens
 REFERENCE Telerman, A., Anson, R. and Tuijinder, M.
 AUTHORS Sequences involved in phenomena of tumour suppression, tumour
 TITLE reversion, apoptosis and/or resistance to viruses and the use
 thereof as medicaments
 JOURNAL Patent: WO 03025177-A 229 27-MAR-2003;
 FEATURES Molecular Engines Laboratories (FR)
 source Location/Qualifiers
 1. .17
 /organism="Homo sapiens"
 /mol type="genomic DNA"
 /db_xref="taxon:9606"
 BASE COUNT 3 a 3 c 1 g 10 t
 Query Match 1.1%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.5e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1092 AAAATAGAGATGATC 1108
 Db 17 AAAATAGAGATGATC 1
 RESULT 117
 I53231/c 153231 17 bp DNA linear PAT 07-OCT-1997
 LOCUS Sequence 972 from patent US 5646042.
 DEFINITION 153231
 ACCESSION 153231 GI:2474434
 VERSION 153231.1
 KEYWORDS Unknown.
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 17)
 AUTHORS Stinchcomb, D.T., Draper, K., McSwiggen, J. and Jarvis, T.
 TITLE C-myb targeted ribozymes
 JOURNAL Patent: US 5646042-A 972 08-JUL-1997;
 FEATURES Location/Qualifiers
 1. .17
 /organism="unknown"
 BASE COUNT 9 a 0 c 0 g 8 t
 Query Match 1.1%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.5e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1615 TTAATAATATAATTGTT 1631
 Db 17 TTAATAATATAATTGTT 1
 RESULT 118
 I54312/c 154312 17 bp DNA linear PAT 07-OCT-1997
 LOCUS Sequence 2053 from patent US 5646042.
 DEFINITION 154312
 ACCESSION 154312 GI:2475515
 VERSION 154312.1
 KEYWORDS Unknown.
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 17)
 AUTHORS Stinchcomb, D.T., Draper, K., McSwiggen, J. and Jarvis, T.
 TITLE C-myb targeted ribozymes
 JOURNAL Patent: US 5646042-A 2053 08-JUL-1997;
 FEATURES Location/Qualifiers
 1. .17
 /organism="unknown"
 BASE COUNT 9 a 0 c 0 g 8 t
 Query Match 1.1%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.5e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1615 TTAATAATATAATTGTT 1631
 Db 17 TTAATAATATAATTGTT 1
 RESULT 119
 AR297659 18 bp DNA linear PAT 12-JUN-2003
 LOCUS Sequence 9394 from patent US 6537751.
 DEFINITION AR297659
 ACCESSION AR297659
 VERSION AR297659.1 GI:31684943
 KEYWORDS Unknown.
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 18)
 AUTHORS Cohen, D., Chumakov, I. and Blumenfeld, M.
 TITLE Biallelic markers for use in constructing a high density
 disequilibrium map of the human genome
 JOURNAL Patent: US 6537751-A 9394 25-MAR-2003;
 FEATURES Location/Qualifiers
 1. .18
 /organism="unknown"
 BASE COUNT 0 a 6 c 3 g 9 t
 Query Match 1.1%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 2.8e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 895 CTGTGCTTGTCTTC 911
 Db 2 CTGTGCTTGTCTTC 18
 RESULT 120
 AR297664 18 bp DNA linear PAT 12-JUN-2003
 LOCUS Sequence 9399 from patent US 6537751.
 DEFINITION AR297664
 ACCESSION AR297664
 VERSION AR297664.1 GI:31684948
 KEYWORDS Unknown.
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 18)
 AUTHORS Cohen, D., Chumakov, I. and Blumenfeld, M.
 TITLE Biallelic markers for use in constructing a high density
 disequilibrium map of the human genome
 JOURNAL Patent: US 6537751-A 9399 25-MAR-2003;
 FEATURES Location/Qualifiers
 1. .18
 /organism="unknown"
 BASE COUNT 0 a 6 c 3 g 9 t
 Query Match 1.1%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 2.8e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 895 CTGTGCTTGTCTTC 911
 Db 2 CTGTGCTTGTCTTC 18
 RESULT 121
 AX132978/c

LOCUS AX132978 18 bp DNA linear PAT 15-MAY-2001
 DEFINITION Sequence 4196 from Patent WO0130362.
 ACCESSION AX132978
 VERSION AX132978.1 GI:14139288
 KEYWORDS Homo sapiens (human)
 SOURCE
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1
 AUTHORS Robbins, J.M. and Tritz, R.
 TITLE Ribosome therapy for the treatment of proliferative skin and eye diseases
 JOURNAL
 PATENT: WO 0130362-A 4196 03-MAY-2001;
 IMMUSOL, INC. (US)
 FEATURES
 source
 1..18
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"
 /note="Hammerhead ribozyme recognition site for cdc 2 kinase"
 BASE COUNT 7 a 2 c 2 g 7 t
 Query Match 1.1%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 2.8e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1172 TTTATTAGATAAATTC 1188
 |||||
 DB 18 TTTAATAGAGAAATTC 2
 RESULT 122
 AX599395
 LOCUS AX599395 18 bp DNA linear PAT 14-FEB-2003
 DEFINITION Sequence 735 from Patent WO0207272.
 ACCESSION AX599395
 VERSION AX599395.1 GI:28399539
 KEYWORDS
 SOURCE synthetic construct
 ORGANISM synthetic construct
 artificial sequences.
 REFERENCE 1
 AUTHORS Berlin, K., Braun, A., Distler, J., Guetig, D., Howe, A., Mueller, J.,
 Olek, A., Piepenbrock, C., Adorjan, P., Grabs, G., Lesche, R., Leu, E.,
 Lewin, A., Lipscher, E., Maier, S., Model, P., Mueller, V., Otto, T.,
 Pelet, C., and Ziebarth, H.
 TITLE Methods and nucleic acids for the analysis of hematopoietic cell
 proliferative disorders
 JOURNAL
 PATENT: WO 0207272-A 735 03-OCT-2002;
 Epigenomics AG (DE)
 FEATURES
 source
 1..18
 /organism="synthetic construct"
 /mol_type="genomic DNA"
 /db_xref="taxon:32630"
 /note="Detection oligonucleotide for DAPK1"
 BASE COUNT 3 a 1 c 4 g 10 t
 Query Match 1.1%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 2.8e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1286 TTGTTTATCTGGAATTT 1302
 |||||
 DB 1 TTGTTTTCGGAATTT 17
 RESULT 123
 E12707/c
 LOCUS E12707 18 bp DNA linear PAT 27-APR-1998
 DEFINITION Primer.

ACCESSION E12707
 VERSION E12707.1 GI:3251539
 KEYWORDS JP 1997056382-A/3.
 SOURCE unidentified
 ORGANISM unidentified
 unclassified.
 REFERENCE 1 (bases 1 to 18)
 AUTHORS Mitsukawa, N. and Robaato, E.U.
 TITLE GENE CODING FOR PROTEIN CONTROLLING MORPHOGENESIS OF PLANT
 JOURNAL Patent: JP 1997056382-A 3 04-MAR-1997;
 CHIKYU KANKYO SANGYO GIJUTSU KENKYU KIKO, MITSUI GYOSAI SHOKUBUTSU
 BIO KENKYUSHO.KK
 COMMENT OS None
 OC Artificial sequences.
 FN JP 1997056382-A/3
 PD 04-MAR-1997
 PF 24-AUG-1995 JP 1995216187
 PI MITSUKAWA NORIHIRO, ROBAATO EFU UITSUTSUA
 PC C12N15/09, A01H5/00, C12N5/10;
 CC strandedness: Single;
 CC topology: Linear;
 CC key Location/Qualifiers
 FH Key
 FT source 1..18
 /organism="Artificial sequences".
 FT Location/Qualifiers
 1..18
 /organism="unidentified"
 /mol_type="genomic DNA"
 /db_xref="taxon:32644"
 BASE COUNT 7 a 4 c 3 g 4 t
 Query Match 1.1%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 2.8e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1498 GACTGCATTTTAAATA 1514
 |||||
 DB 17 GACTGCGTTTATAGATA 1
 RESULT 124
 A88564
 LOCUS A88564 19 bp DNA linear PAT 22-JAN-2000
 DEFINITION Sequence 712 from Patent WO9833904.
 ACCESSION A88564
 VERSION A88564.1 GI:6737134
 KEYWORDS
 SOURCE unidentified
 ORGANISM unidentified
 unclassified.
 REFERENCE 1 (bases 1 to 19)
 AUTHORS Brysch, W. and Schlingensiepen, K.
 TITLE AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
 JOURNAL Patent: WO 9833904-A 712 06-AUG-1998;
 BIOGNOSTIK GES (DE); BRYSCH WOLFGANG (DE)
 FEATURES
 source
 1..19
 /organism="unidentified"
 /mol_type="genomic DNA"
 /db_xref="taxon:32644"
 BASE COUNT 6 a 1 c 1 g 11 t
 Query Match 1.1%; Score 13.8; DB 1; Length 19;
 Best Local Similarity 88.2%; Pred. No. 3e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1172 TTTATTAGATAAATTC 1188
 |||||
 DB 1 TTTTAAAGATAAATTC 17
 RESULT 125

```
A90531
LOCUS       A90531               19 bp      DNA
DEFINITION  Sequence 712 from Patent EP0856579.
ACCESSION   A90531
VERSION     A90531.1  GI:6739045
KEYWORDS    unidentified
            unidentified
            unclassified.
REFERENCE   1 (bases 1 to 19)
AUTHORS     Brysch,W.D. and Schlingensiepen,K.D.
TITLE       An antisense oligonucleotide preparation method
JOURNAL     Patent: EP 0856579-A 712 05-AUG-1998;
            BIOGOSTIK GES (DB)
FEATURES
  source
  BASE COUNT  6 a 1 c 1 g 11 t
    Query Match      1.1%; Score 13.8; DB 1; Length 19;
    Best Local Similarity 88.2%; Pred. No. 3e+02; 2; Indels 0; Gaps 0;
    Matches 15; Conservative 0; Mismatches 0;

QY 1172 TTTATTAGATAAATTC 1188
Db 1 TTTTAAAGATAAATTC 17

RESULT 126
LOCUS       AR030969             19 bp      DNA
DEFINITION  Sequence 1 from patent US 5861501.
ACCESSION   AR030969
VERSION     AR030969.1  GI:5944183
KEYWORDS    Unknown.
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 19)
AUTHORS     Benseler,F., Cole,J.L., Olsen,D.B. and Kuo,L.C.
TITLE       Capped synthetic RNA, analogs, and aptamers
JOURNAL     Patent: US 5861501-A 1 19-JAN-1999;
            Location/Qualifiers
FEATURES
  source
  BASE COUNT  3 a 1 c 1 g 14 t
    Query Match      1.1%; Score 13.8; DB 1; Length 19;
    Best Local Similarity 88.2%; Pred. No. 3e+02; 2; Indels 0; Gaps 0;
    Matches 15; Conservative 0; Mismatches 0;

QY 1521 TTTATATTTTAACTTT 1537
Db 2 TTTTATTTTAAATTT 18

RESULT 127
LOCUS       AR030972             19 bp      DNA
DEFINITION  Sequence 4 from patent US 5861501.
ACCESSION   AR030972
VERSION     AR030972.1  GI:5944186
KEYWORDS    Unknown.
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 19)
AUTHORS     Benseler,F., Cole,J.L., Olsen,D.B. and Kuo,L.C.
TITLE       Capped synthetic RNA, analogs, and aptamers
JOURNAL     Patent: US 5861501-A 4 19-JAN-1999;
            Location/Qualifiers
FEATURES
  source
  BASE COUNT  3 a 1 c 1 g 14 t
    Query Match      1.1%; Score 13.8; DB 1; Length 19;
    Best Local Similarity 88.2%; Pred. No. 3e+02; 2; Indels 0; Gaps 0;
    Matches 15; Conservative 0; Mismatches 0;

QY 1521 TTTATATTTTAACTTT 1537
Db 2 TTTTATTTTAAATTT 18

RESULT 128
LOCUS       AR030974             19 bp      DNA
DEFINITION  Sequence 6 from patent US 5861501.
ACCESSION   AR030974
VERSION     AR030974.1  GI:5944188
KEYWORDS    Unknown.
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 19)
AUTHORS     Benseler,F., Cole,J.L., Olsen,D.B. and Kuo,L.C.
TITLE       Capped synthetic RNA, analogs, and aptamers
JOURNAL     Patent: US 5861501-A 6 19-JAN-1999;
            Location/Qualifiers
FEATURES
  source
  BASE COUNT  3 a 1 c 1 g 14 t
    Query Match      1.1%; Score 13.8; DB 1; Length 19;
    Best Local Similarity 88.2%; Pred. No. 3e+02; 2; Indels 0; Gaps 0;
    Matches 15; Conservative 0; Mismatches 0;

QY 1521 TTTATATTTTAACTTT 1537
Db 2 TTTTATTTTAAATTT 18

RESULT 129
LOCUS       AR030975             19 bp      DNA
DEFINITION  Sequence 7 from patent US 5861501.
ACCESSION   AR030975
VERSION     AR030975.1  GI:5944189
KEYWORDS    Unknown.
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 19)
AUTHORS     Benseler,F., Cole,J.L., Olsen,D.B. and Kuo,L.C.
TITLE       Capped synthetic RNA, analogs, and aptamers
JOURNAL     Patent: US 5861501-A 7 19-JAN-1999;
            Location/Qualifiers
FEATURES
  source
  BASE COUNT  3 a 1 c 1 g 14 t
    Query Match      1.1%; Score 13.8; DB 1; Length 19;
    Best Local Similarity 88.2%; Pred. No. 3e+02; 2; Indels 0; Gaps 0;
    Matches 15; Conservative 0; Mismatches 0;

QY 1521 TTTATATTTTAACTTT 1537
Db 2 TTTTATTTTAAATTT 18

RESULT 130
LOCUS       AR030976             19 bp      DNA
DEFINITION  Sequence 8 from patent US 5861501.
ACCESSION   AR030976
VERSION     AR030976
KEYWORDS    Unknown.
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 19)
AUTHORS     Benseler,F., Cole,J.L., Olsen,D.B. and Kuo,L.C.
TITLE       Capped synthetic RNA, analogs, and aptamers
JOURNAL     Patent: US 5861501-A 8 19-JAN-1999;
            Location/Qualifiers
FEATURES
  source
  BASE COUNT  3 a 1 c 1 g 14 t
    Query Match      1.1%; Score 13.8; DB 1; Length 19;
    Best Local Similarity 88.2%; Pred. No. 3e+02; 2; Indels 0; Gaps 0;
    Matches 15; Conservative 0; Mismatches 0;

QY 1521 TTTATATTTTAACTTT 1537
Db 2 TTTTATTTTAAATTT 18
```

```
ACCESSION AR030976 GI:5944190
VERSION AR030976.1
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 19)
AUTHORS Benseler,F., Cole,J.L., Olsen,D.B. and Kuo,L.C.
TITLE Capped synthetic RNA, analogs, and aptamers
JOURNAL Patent: US 5861501-A 8 19-JAN-1999;
FEATURES Location/Qualifiers
source 1..19
/organism="unknown"
BASE COUNT 3 a 1 c 1 g 14 t
Query Match 1.1%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1521 TTTATATTTTAACTTT 1537
|||||
Db 2 TTTTATTTTAAATTT 18

RESULT 133
AR030976
LOCUS
DEFINITION Sequence 9 from patent US 5861501.
ACCESSION AR030977
VERSION AR030977.1 GI:5944191
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 19)
AUTHORS Benseler,F., Cole,J.L., Olsen,D.B. and Kuo,L.C.
TITLE Capped synthetic RNA, analogs, and aptamers
JOURNAL Patent: US 5861501-A 9 19-JAN-1999;
FEATURES Location/Qualifiers
source 1..19
/organism="unknown"
BASE COUNT 3 a 1 c 1 g 14 t
Query Match 1.1%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1521 TTTATATTTTAACTTT 1537
|||||
Db 2 TTTTATTTTAAATTT 18

RESULT 132
AR030978
LOCUS
DEFINITION Sequence 10 from patent US 5861501.
ACCESSION AR030978
VERSION AR030978.1 GI:5944192
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 19)
AUTHORS Benseler,F., Cole,J.L., Olsen,D.B. and Kuo,L.C.
TITLE Capped synthetic RNA, analogs, and aptamers
JOURNAL Patent: US 5861501-A 10 19-JAN-1999;
FEATURES Location/Qualifiers
source 1..19
/organism="unknown"
BASE COUNT 3 a 1 c 1 g 14 t
Query Match 1.1%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1521 TTTATATTTTAACTTT 1537
|||||
Db 2 TTTTATTTTAAATTT 18

RESULT 131
AR030977
LOCUS
DEFINITION Sequence 9 from patent US 5861501.
ACCESSION AR030977
VERSION AR030977.1 GI:5944191
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 19)
AUTHORS Benseler,F., Cole,J.L., Olsen,D.B. and Kuo,L.C.
TITLE Capped synthetic RNA, analogs, and aptamers
JOURNAL Patent: US 5861501-A 9 19-JAN-1999;
FEATURES Location/Qualifiers
source 1..19
/organism="unknown"
BASE COUNT 3 a 1 c 1 g 14 t
Query Match 1.1%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1521 TTTATATTTTAACTTT 1537
|||||
Db 2 TTTTATTTTAAATTT 18

RESULT 132
AR030978
LOCUS
DEFINITION Sequence 10 from patent US 5861501.
ACCESSION AR030978
VERSION AR030978.1 GI:5944192
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 19)
AUTHORS Benseler,F., Cole,J.L., Olsen,D.B. and Kuo,L.C.
TITLE Capped synthetic RNA, analogs, and aptamers
JOURNAL Patent: US 5861501-A 10 19-JAN-1999;
FEATURES Location/Qualifiers
source 1..19
/organism="unknown"
BASE COUNT 3 a 1 c 1 g 14 t
Query Match 1.1%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1521 TTTATATTTTAACTTT 1537
|||||
Db 2 TTTTATTTTAAATTT 18

RESULT 133
AR030981
LOCUS
DEFINITION Sequence 13 from patent US 5861501.
ACCESSION AR030981
VERSION AR030981.1 GI:5944195
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 19)
AUTHORS Benseler,F., Cole,J.L., Olsen,D.B. and Kuo,L.C.
TITLE Capped synthetic RNA, analogs, and aptamers
JOURNAL Patent: US 5861501-A 13 19-JAN-1999;
FEATURES Location/Qualifiers
source 1..19
/organism="unknown"
BASE COUNT 3 a 1 c 1 g 14 t
Query Match 1.1%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1521 TTTATATTTTAACTTT 1537
|||||
Db 2 TTTTATTTTAAATTT 18

RESULT 134
AR030982
LOCUS
DEFINITION Sequence 14 from patent US 5861501.
ACCESSION AR030982
VERSION AR030982.1 GI:5944196
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 19)
AUTHORS Benseler,F., Cole,J.L., Olsen,D.B. and Kuo,L.C.
TITLE Capped synthetic RNA, analogs, and aptamers
JOURNAL Patent: US 5861501-A 14 19-JAN-1999;
FEATURES Location/Qualifiers
source 1..19
/organism="unknown"
BASE COUNT 3 a 1 c 1 g 14 t
Query Match 1.1%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1521 TTTATATTTTAACTTT 1537
|||||
Db 2 TTTTATTTTAAATTT 18

RESULT 135
AR030983
LOCUS
DEFINITION Sequence 15 from patent US 5861501.
ACCESSION AR030983
VERSION AR030983.1 GI:5944197
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 19)
AUTHORS Benseler,F., Cole,J.L., Olsen,D.B. and Kuo,L.C.
TITLE Capped synthetic RNA, analogs, and aptamers
JOURNAL Patent: US 5861501-A 15 19-JAN-1999;
FEATURES Location/Qualifiers
source 1..19
/organism="unknown"
BASE COUNT 3 a 1 c 1 g 14 t
Query Match 1.1%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1521 TTTATATTTTAACTTT 1537
|||||
Db 2 TTTTATTTTAAATTT 18

RESULT 136
AR030984
LOCUS
DEFINITION Sequence 16 from patent US 5861501.
ACCESSION AR030984
VERSION AR030984.1 GI:5944198
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 19)
AUTHORS Benseler,F., Cole,J.L., Olsen,D.B. and Kuo,L.C.
TITLE Capped synthetic RNA, analogs, and aptamers
JOURNAL Patent: US 5861501-A 16 19-JAN-1999;
FEATURES Location/Qualifiers
source 1..19
/organism="unknown"
BASE COUNT 3 a 1 c 1 g 14 t
Query Match 1.1%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1521 TTTATATTTTAACTTT 1537
|||||
Db 2 TTTTATTTTAAATTT 18
```

RESULT 138	AR108817	19 bp	DNA	linear	PAT 14-FEB-2001
LOCUS	Sequence 4 from patent US 6111095.				
DEFINITION	AR108817				
ACCESSION	AR108817.1	GI:12824304			
VERSION	1				
KEYWORDS	Unknown.				
SOURCE	Unknown.				
ORGANISM	Unclassified.				
REFERENCE	1 (bases 1 to 19)				
AUTHORS	Bensele, F., Cole, J.L., Olsen, D.B. and Kuo, L.C.				
TITLE	Capped synthetic RNA, analogs, and aptamers				
JOURNAL	Patent: US 6111095-A 4 29-AUG-2000;				
FEATURES	Location/Qualifiers				
source	1..19				
BASE COUNT	3 a 1 c 1 g 14 t				
Query Match	1.1%; Score 13.8; DB 1; Length 19;				
Best Local Similarity	88.2%; Pred. NO. 3e+02;				
Matches	15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;				
Qy	1521 TTTATATTTTAACTTT 1537				
Db	2 TTTTATTTTAACTTT 18				
RESULT 139	AR108819	19 bp	DNA	linear	PAT 14-FEB-2001
LOCUS	Sequence 6 from patent US 6111095.				
DEFINITION	AR108819				
ACCESSION	AR108819.1	GI:12824306			
VERSION	1				
KEYWORDS	Unknown.				
SOURCE	Unknown.				
ORGANISM	Unclassified.				
REFERENCE	1 (bases 1 to 19)				
AUTHORS	Bensele, F., Cole, J.L., Olsen, D.B. and Kuo, L.C.				
TITLE	Capped synthetic RNA, analogs, and aptamers				
JOURNAL	Patent: US 6111095-A 6 29-AUG-2000;				
FEATURES	Location/Qualifiers				
source	1..19				
BASE COUNT	3 a 1 c 1 g 14 t				
Query Match	1.1%; Score 13.8; DB 1; Length 19;				
Best Local Similarity	88.2%; Pred. NO. 3e+02;				
Matches	15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;				
Qy	1521 TTTATATTTTAACTTT 1537				
Db	2 TTTTATTTTAACTTT 18				
RESULT 140	AR108820	19 bp	DNA	linear	PAT 14-FEB-2001
LOCUS	Sequence 7 from patent US 6111095.				
DEFINITION	AR108820				
ACCESSION	AR108820.1	GI:12824307			
VERSION	1				
KEYWORDS	Unknown.				
SOURCE	Unknown.				
ORGANISM	Unclassified.				
REFERENCE	1 (bases 1 to 19)				
AUTHORS	Bensele, F., Cole, J.L., Olsen, D.B. and Kuo, L.C.				
TITLE	Capped synthetic RNA, analogs, and aptamers				
JOURNAL	Patent: US 6111095-A 7 29-AUG-2000;				
FEATURES	Location/Qualifiers				
source	1..19				

[illegible]

BASE COUNT		3 a 1 c 1 g 14 t		/organism="unknown"	
Query Match	1.1%;	Score 13.8;	DB 1;	Length 19;	
Best Local Similarity	88.2%;	Pred. No. 3e+02;			
Matches	15;	Conservative	0;	Mismatches	2; Indels 0; Gaps 0;
<p>QY 1521 TTTATATTTTAACTTT 1537</p> <p> </p> <p>2 TTTTATTTTAAATTT 18</p>					
Db					
<p>RESULT 141</p> <p>ARI08821</p> <p>LOCUS</p> <p>DEFINITION</p> <p>Sequence 8 from patent US 6111095.</p> <p>ARI08821</p> <p>ACCESSION</p> <p>ARI08821.1 GI:12824308</p> <p>KEYWORDS</p> <p>SOURCE</p> <p>ORGANISM</p> <p>Unknown.</p> <p>Unclassified.</p> <p>1 (bases 1 to 19)</p> <p>AUTHORS</p> <p>Bensele, F., Cole, J.L., Olsen, D.B. and Kuo, L.C.</p> <p>TITLE</p> <p>Capped synthetic RNA, analogs, and aptamers</p> <p>JOURNAL</p> <p>Patent: US 6111095-A 8 29-AUG-2000;</p> <p>FEATURES</p> <p>Location/Qualifiers</p> <p>1..19</p> <p>source</p> <p>/organism="unknown"</p>					
BASE COUNT		3 a 1 c 1 g 14 t			
Query Match	1.1%;	Score 13.8;	DB 1;	Length 19;	
Best Local Similarity	88.2%;	Pred. No. 3e+02;			
Matches	15;	Conservative	0;	Mismatches	2; Indels 0; Gaps 0;
<p>QY 1521 TTTATATTTTAACTTT 1537</p> <p> </p> <p>2 TTTTATTTTAAATTT 18</p>					
Db					
<p>RESULT 142</p> <p>ARI08822</p> <p>LOCUS</p> <p>DEFINITION</p> <p>Sequence 9 from patent US 6111095.</p> <p>ARI08822</p> <p>ACCESSION</p> <p>ARI08822.1 GI:12824309</p> <p>KEYWORDS</p> <p>SOURCE</p> <p>Unknown.</p> <p>Unclassified.</p> <p>1 (bases 1 to 19)</p> <p>AUTHORS</p> <p>Bensele, F., Cole, J.L., Olsen, D.B. and Kuo, L.C.</p> <p>TITLE</p> <p>Capped synthetic RNA, analogs, and aptamers</p> <p>JOURNAL</p> <p>Patent: US 6111095-A 9 29-AUG-2000;</p> <p>FEATURES</p> <p>Location/Qualifiers</p> <p>1..19</p> <p>source</p> <p>/organism="unknown"</p>					
BASE COUNT		3 a 1 c 1 g 14 t			
Query Match	1.1%;	Score 13.8;	DB 1;	Length 19;	
Best Local Similarity	88.2%;	Pred. No. 3e+02;			
Matches	15;	Conservative	0;	Mismatches	2; Indels 0; Gaps 0;
<p>QY 1521 TTTATATTTTAACTTT 1537</p> <p> </p> <p>2 TTTTATTTTAAATTT 18</p>					
Db					
<p>RESULT 143</p> <p>ARI08823</p> <p>LOCUS</p> <p>DEFINITION</p> <p>Sequence 10 from patent US 6111095.</p> <p>ARI08823</p> <p>ACCESSION</p>					

```

QY 1521 TTTATATTTTAACTTT 1537
Db 2 TTTTATTTTAAATTT 18

RESULT 146
LOCUS AR108828 19 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 15 from patent US 6111095.
ACCESSION AR108828
VERSION AR108828.1 GI:12824315
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 19)
AUTHORS Benseleer, F., Cole, J.L., Olsen, D.B. and Kuo, L.C.
TITLE Capped synthetic RNA, analogs, and aptamers
JOURNAL Patent: US 6111095-A 15 29-AUG-2000;
FEATURES Location/Qualifiers
source 1..19
/organism="unknown"
BASE COUNT 3 a 1 c 1 g 14 t

Query Match 1.1%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1521 TTTATATTTTAACTTT 1537
Db 2 TTTTATTTTAAATTT 18

RESULT 147
LOCUS AR108829 19 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 16 from patent US 6111095.
ACCESSION AR108829
VERSION AR108829.1 GI:12824316
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 19)
AUTHORS Benseleer, F., Cole, J.L., Olsen, D.B. and Kuo, L.C.
TITLE Capped synthetic RNA, analogs, and aptamers
JOURNAL Patent: US 6111095-A 16 29-AUG-2000;
FEATURES Location/Qualifiers
source 1..19
/organism="unknown"
BASE COUNT 3 a 1 c 1 g 14 t

Query Match 1.1%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1521 TTTATATTTTAACTTT 1537
Db 2 TTTTATTTTAAATTT 18

RESULT 148
LOCUS AR205763 19 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 1 from patent US 6369208.
ACCESSION AR205763
VERSION AR205763.1 GI:21503428
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 19)

AUTHORS Cole, J.L., Kuo, L.C., Olsen, D.B. and Benseleer, F.
TITLE Capped synthetic RNA, analogs, and aptamers
JOURNAL Patent: US 6369208-A 1 09-APR-2002;
FEATURES Location/Qualifiers
source 1..19
/organism="unknown"
BASE COUNT 3 a 1 c 1 g 14 t

Query Match 1.1%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1521 TTTATATTTTAACTTT 1537
Db 2 TTTTATTTTAAATTT 18

RESULT 149
LOCUS AR205766 19 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 4 from patent US 6369208.
ACCESSION AR205766
VERSION AR205766.1 GI:21503432
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 19)
AUTHORS Cole, J.L., Kuo, L.C., Olsen, D.B. and Benseleer, F.
TITLE Capped synthetic RNA, analogs, and aptamers
JOURNAL Patent: US 6369208-A 4 09-APR-2002;
FEATURES Location/Qualifiers
source 1..19
/organism="unknown"
BASE COUNT 3 a 1 c 1 g 14 t

Query Match 1.1%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1521 TTTATATTTTAACTTT 1537
Db 2 TTTTATTTTAAATTT 18

RESULT 150
LOCUS AR205768 19 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 6 from patent US 6369208.
ACCESSION AR205768
VERSION AR205768.1 GI:21503434
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 19)
AUTHORS Cole, J.L., Kuo, L.C., Olsen, D.B. and Benseleer, F.
TITLE Capped synthetic RNA, analogs, and aptamers
JOURNAL Patent: US 6369208-A 6 09-APR-2002;
FEATURES Location/Qualifiers
source 1..19
/organism="unknown"
BASE COUNT 3 a 1 c 1 g 14 t

Query Match 1.1%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1521 TTTATATTTTAACTTT 1537
Db 2 TTTTATTTTAAATTT 18

RESULT 151
LOCUS AR205768 19 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 6 from patent US 6369208.
ACCESSION AR205768
VERSION AR205768.1 GI:21503434
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 19)
AUTHORS Cole, J.L., Kuo, L.C., Olsen, D.B. and Benseleer, F.
TITLE Capped synthetic RNA, analogs, and aptamers
JOURNAL Patent: US 6369208-A 6 09-APR-2002;
FEATURES Location/Qualifiers
source 1..19
/organism="unknown"
BASE COUNT 3 a 1 c 1 g 14 t

Query Match 1.1%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1521 TTTATATTTTAACTTT 1537
Db 2 TTTTATTTTAAATTT 18
```

RESULT	LOCUS	SEQUENCE	FROM	BP	DNA	LINEAR	PAT
151	AR205769	Sequence 7	from patent US 6369208.	19	bp	linear	PAT 20-JUN-2002
LOCUS	AR205769	Accession	AR205769				
DEFINITION	AR205769	Version	GI:21503435				
KEYWORDS	AR205769	Keywords	Unknown.				
SOURCE	AR205769	Source	Unknown.				
ORGANISM	AR205769	Organism	Unknown.				
REFERENCE	AR205769	Reference	1 (bases 1 to 19)				
AUTHORS	AR205769	Authors	Cole, J.L., Kuo, L.C., Olsen, D.B. and Benseler, F.				
TITLE	AR205769	Title	Capped synthetic RNA, analogs, and aptamers				
JOURNAL	AR205769	Journal	Patent: US 6369208-A 7 09-APR-2002;				
FEATURES	AR205769	Features	Location/Qualifiers				
source	AR205769	Source	1..19				
BASE COUNT	AR205769	Base Count	3 a 1 c 1 g 14 t				
Query Match	AR205769	Query Match	1..1%; Score 13.8; DB 1; Length 19;				
Best Local Similarity	AR205769	Best Local Similarity	88.2%; Pred. No. 3e+02; 2; Indels 0; Gaps 0;				
Matches	AR205769	Matches	15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;				
QY	1521	TTTTATATTTTAACTTT	1537				
Db	2	TTTTATATTTTAACTTT	18				
RESULT 152	AR205770	Sequence 8	from patent US 6369208.	19	bp	linear	PAT 20-JUN-2002
LOCUS	AR205770	Accession	AR205770				
DEFINITION	AR205770	Version	GI:21503437				
KEYWORDS	AR205770	Keywords	Unknown.				
SOURCE	AR205770	Source	Unknown.				
ORGANISM	AR205770	Organism	Unknown.				
REFERENCE	AR205770	Reference	1 (bases 1 to 19)				
AUTHORS	AR205770	Authors	Cole, J.L., Kuo, L.C., Olsen, D.B. and Benseler, F.				
TITLE	AR205770	Title	Capped synthetic RNA, analogs, and aptamers				
JOURNAL	AR205770	Journal	Patent: US 6369208-A 8 09-APR-2002;				
FEATURES	AR205770	Features	Location/Qualifiers				
source	AR205770	Source	1..19				
BASE COUNT	AR205770	Base Count	3 a 1 c 1 g 14 t				
Query Match	AR205770	Query Match	1..1%; Score 13.8; DB 1; Length 19;				
Best Local Similarity	AR205770	Best Local Similarity	88.2%; Pred. No. 3e+02; 2; Indels 0; Gaps 0;				
Matches	AR205770	Matches	15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;				
QY	1521	TTTTATATTTTAACTTT	1537				
Db	2	TTTTATATTTTAACTTT	18				
RESULT 153	AR205771	Sequence 9	from patent US 6369208.	19	bp	linear	PAT 20-JUN-2002
LOCUS	AR205771	Accession	AR205771				
DEFINITION	AR205771	Version	GI:21503438				
KEYWORDS	AR205771	Keywords	Unknown.				
SOURCE	AR205771	Source	Unknown.				
ORGANISM	AR205771	Organism	Unknown.				
REFERENCE	AR205771	Reference	1 (bases 1 to 19)				
AUTHORS	AR205771	Authors	Cole, J.L., Kuo, L.C., Olsen, D.B. and Benseler, F.				
TITLE	AR205771	Title	Capped synthetic RNA, analogs, and aptamers				
JOURNAL	AR205771	Journal	Patent: US 6369208-A 9 09-APR-2002;				
FEATURES	AR205771	Features	Location/Qualifiers				
source	AR205771	Source	1..19				
BASE COUNT	AR205771	Base Count	3 a 1 c 1 g 14 t				
Query Match	AR205771	Query Match	1..1%; Score 13.8; DB 1; Length 19;				
Best Local Similarity	AR205771	Best Local Similarity	88.2%; Pred. No. 3e+02; 2; Indels 0; Gaps 0;				
Matches	AR205771	Matches	15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;				
QY	1521	TTTTATATTTTAACTTT	1537				
Db	2	TTTTATATTTTAACTTT	18				

```
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE   1 (bases 1 to 19)
AUTHORS    Cole,J.L., Kuo,L.C., Olsen,D.B. and Benseler,F.
TITLE      Capped synthetic RNA, analogs, and aptamers
JOURNAL    Patent: US 6369208-A 14 09-APR-2002;
FEATURES   Location/Qualifiers
            source
            1..19
            /organism="unknown"
BASE COUNT  3 a 1 c 1 g 14 t
Query Match 1.1%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1521 TTTATATTTTAACTTT 1537
Db 2 TTTTATTTTAAATTT 18
RESULT 157
AR205777 19 bp DNA linear PAT 20-JUN-2002
LOCUS
DEFINITION Sequence 15 from patent US 6369208.
ACCESSION AR205777
VERSION AR205777.1 GI:21503445
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE   1 (bases 1 to 19)
AUTHORS    Cole,J.L., Kuo,L.C., Olsen,D.B. and Benseler,F.
TITLE      Capped synthetic RNA, analogs, and aptamers
JOURNAL    Patent: US 6369208-A 15 09-APR-2002;
FEATURES   Location/Qualifiers
            source
            1..19
            /organism="unknown"
BASE COUNT  3 a 1 c 1 g 14 t
Query Match 1.1%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1521 TTTATATTTTAACTTT 1537
Db 2 TTTTATTTTAAATTT 18
RESULT 158
AR205778 19 bp DNA linear PAT 20-JUN-2002
LOCUS
DEFINITION Sequence 16 from patent US 6369208.
ACCESSION AR205778
VERSION AR205778.1 GI:21503447
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE   1 (bases 1 to 19)
AUTHORS    Cole,J.L., Kuo,L.C., Olsen,D.B. and Benseler,F.
TITLE      Capped synthetic RNA, analogs, and aptamers
JOURNAL    Patent: US 6369208-A 16 09-APR-2002;
FEATURES   Location/Qualifiers
            source
            1..19
            /organism="unknown"
BASE COUNT  3 a 1 c 1 g 14 t
Query Match 1.1%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1521 TTTATATTTTAACTTT 1537
Db 2 TTTTATTTTAAATTT 18
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE   1 (bases 1 to 19)
AUTHORS    Cole,J.L., Kuo,L.C., Olsen,D.B. and Benseler,F.
TITLE      Capped synthetic RNA, analogs, and aptamers
JOURNAL    Patent: US 6369208-A 14 09-APR-2002;
FEATURES   Location/Qualifiers
            source
            1..19
            /organism="unknown"
BASE COUNT  3 a 1 c 1 g 14 t
Query Match 1.1%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1521 TTTATATTTTAACTTT 1537
Db 2 TTTTATTTTAAATTT 18
RESULT 159
AR297082 19 bp DNA linear PAT 12-JUN-2003
LOCUS
DEFINITION Sequence 8817 from patent US 6537751.
ACCESSION AR297082
VERSION AR297082.1 GI:31684366
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE   1 (bases 1 to 19)
AUTHORS    Cohen,D., Chumakov,I. and Blumenfeld,W.
TITLE      Biallelic markers for use in constructing a high density
            disequilibrium map of the human genome
JOURNAL    Patent: US 6537751-A 8817 25-MAR-2003;
FEATURES   Location/Qualifiers
            source
            1..19
            /organism="unknown"
BASE COUNT  11 a 6 c 1 g 1 t
Query Match 1.1%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1208 AACAAACAACAATGG 1224
Db 1 AACAACAACAACACTAG 17
RESULT 160
AX130049 19 bp DNA linear PAT 15-MAY-2001
LOCUS
DEFINITION Sequence 1267 from Patent WO0130362.
ACCESSION AX130049
VERSION AX130049.1 GI:14136354
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS    Robbins,J.M. and Tritz,R.
TITLE      Ribozyme therapy for the treatment of proliferative skin and eye
            diseases
JOURNAL    Patent: WO 0130362-A 1267 03-MAY-2001;
FEATURES   Location/Qualifiers
            source
            1..19
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"
            /note="Cdk-we-hu ribozyme binding site"
BASE COUNT  7 a 4 c 3 g 5 t
Query Match 1.1%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1378 TACCGAATCATGAGTTA 1394
Db 2 TACAGAATCATGAGTTA 18
RESULT 161
BD066077 19 bp DNA linear PAT 27-AUG-2002
LOCUS
DEFINITION An antisense oligonucleotide preparation method.
ACCESSION BD066077
```



```

VERSION      BD066077.1  GI:22611680
KEYWORDS
SOURCE       JP 2001511000-A/712.
ORGANISM
REFERENCE    1 (bases 1 to 19)
AUTHORS      Schlingensiefen, K.H. and Brysch, W.
TITLE        An antisense oligonucleotide preparation method
JOURNAL      Patent: JP 2001511000-A 712 07-AUG-2001;
COMMENT      BIOLOGISTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK MBH
OS           Unknown
PN           JP 2001511000-A/712
PD           07-AUG-2001
PF           30-JAN-1998  JP 1998532633
PR           31-JAN-1997  EP 97101331.8
PI           KARL HERMANN SCHLINGENSIEPEN, WOLFGANG BRYSCH
PC           C12N15/11, C07H21/04, A61K31/70
CC           An antisense oligonucleotide preparation method
FT           Location/Qualifiers
FT           source 1..19
FT           Location/Qualifiers
FT           /organism="Unknown".
FEATURES
source
1..19
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
BASE COUNT  6 a 1 c 1 g 11 t
Query Match 1.1%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1172 TTTATTAGATAAATTC 1188
Db 1 TTTTAAAGATAAATTC 17
RESULT 162
LOCUS      162823
DEFINITION Sequence 1 from patent US 5660989.
ACCESSION 162823
VERSION    162823.1  GI:2480531
KEYWORDS
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 19)
AUTHORS    Cole, J.L., Kuo, L.C. and Olsen, D.B.
TITLE      DNA polymerase extension assay for influenza virus endonuclease
JOURNAL    Patent: US 5660989-A 1 26-AUG-1997;
FEATURES
source
1..19
/organism="unknown"
BASE COUNT  3 a 1 c 1 g 14 t
Query Match 1.1%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1521 TTTATATTTTAACTTT 1537
Db 2 TTTTATTTTAAATTT 18
RESULT 163
LOCUS      BD161924
DEFINITION Method for carrying out thermal cycle of PCR using DNA-immobilized
ACCESSION  BD161924
VERSION     BD161924.1  GI:27867682
KEYWORDS    JP 2002191369-A/1.

```

```

SOURCE       synthetic construct
ORGANISM      synthetic construct
REFERENCE     1 (bases 1 to 20)
AUTHORS      Tanga, M., Okamura, H. and Takahashi, K.
TITLE        Method for carrying out thermal cycle of PCR using DNA-immobilized
JOURNAL      Patent: JP 2002191369-A 1 09-JUL-2002;
COMMENT      TOYO KOKAN CO LTD, KOJIRO TAKAHASHI
OS           Artificial Sequence
PN           JP 2002191369-A/1
PD           09-JUL-2002
PF           27-DEC-2000  JP 2000399573
PR           MIUCHIFUMI TANGA, HIROSHI OKAMURA, KOJIRO TAKAHASHI
PC           C12N15/09, C12N15/01, C12N15/00, C12N15/00 CC Method for
CC           carrying out thermal cycle of PCR using DNA-CC
FT           immobilized
FT           substrate
FT           FH Key
FT           FT source 1..20
FT           Location/Qualifiers
FT           /organism="Artificial Sequence".
FEATURES
source
1..20
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
BASE COUNT  3 a 0 c 0 g 17 t
Query Match 1.1%; Score 13.6; DB 1; Length 20;
Best Local Similarity 80.0%; Pred. No. 3.7e+02;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
QY 1560 AAATTTTCTACTCTCTCT 1579
Db 1 AAATTTTCTACTCTCTCT 20
RESULT 164
LOCUS      AR164318
DEFINITION Sequence 1 from patent US 6271369.
ACCESSION  AR164318
VERSION     AR164318.1  GI:16235432
KEYWORDS
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 22)
AUTHORS    Torrence, P.F., Silverman, R.H., Maitra, R.K. and Lesiak, K.
TITLE      Chimeric molecules targeted to viral RNAs
JOURNAL    Patent: US 6271369-A 1 07-AUG-2001;
FEATURES
source
1..22
/organism="unknown"
BASE COUNT  4 a 0 c 0 g 18 t
Query Match 1.1%; Score 13.6; DB 1; Length 22;
Best Local Similarity 80.0%; Pred. No. 4.3e+02;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
QY 1560 AAATTTTCTACTCTCTCT 1579
Db 2 AAATTTTCTACTCTCTCT 21
RESULT 165
LOCUS      AR164319
DEFINITION Sequence 2 from patent US 6271369.
ACCESSION  AR164319
VERSION     AR164319.1  GI:16235434
KEYWORDS
SOURCE     Unknown.

```

```
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 22)
AUTHORS Torrence,P., Silverman,R.H., Maitra,R.K. and Lesiak,K.
TITLE Chimeric molecules targeted to viral RNAs
JOURNAL Patent: US 6271369-A 2 07-AUG-2001;
FEATURES
  source
    location/Qualifiers
  1..22
  /organism="unknown"
BASE COUNT 4 a 0 c 0 g 18 t
  Query Match 1.1%; Score 13.6; DB 1; Length 22;
  Best Local Similarity 80.0%; Pred. No. 4.3e+02;
  Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
QY 1560 AAATTTTTTTTACTGTTTCT 1579
Db 2 AAATTTTTTTTCTTTTCT 21

RESULT 166
LOCUS I31810 22 bp DNA linear PAT 06-FEB-1997
DEFINITION Sequence 1 from patent US 5583032.
ACCESSION I31810
VERSION I31810.1 GI:1822601
KEYWORDS
  source
    location/Qualifiers
  1..22
  /organism="unknown"
BASE COUNT 4 a 0 c 0 g 18 t
  Query Match 1.1%; Score 13.6; DB 1; Length 22;
  Best Local Similarity 80.0%; Pred. No. 4.3e+02;
  Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
QY 1560 AAATTTTTTTTACTGTTTCT 1579
Db 2 AAATTTTTTTTCTTTTCT 21

RESULT 167
LOCUS I31811 22 bp DNA linear PAT 06-FEB-1997
DEFINITION Sequence 2 from patent US 5583032.
ACCESSION I31811
VERSION I31811.1 GI:1822602
KEYWORDS
  source
    location/Qualifiers
  1..22
  /organism="unknown"
BASE COUNT 4 a 0 c 0 g 18 t
  Query Match 1.1%; Score 13.6; DB 1; Length 22;
  Best Local Similarity 80.0%; Pred. No. 4.3e+02;
  Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
QY 1560 AAATTTTTTTTACTGTTTCT 1579
Db 2 AAATTTTTTTTCTTTTCT 21

RESULT 168
LOCUS I69407 22 bp DNA linear PAT 04-FEB-1998
DEFINITION Sequence 1 from patent US 5677289.
ACCESSION I69407
VERSION I69407.1 GI:2831529
KEYWORDS
  source
    location/Qualifiers
  1..22
  /organism="unknown"
BASE COUNT 4 a 0 c 0 g 18 t
  Query Match 1.1%; Score 13.6; DB 1; Length 22;
  Best Local Similarity 80.0%; Pred. No. 4.3e+02;
  Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
QY 1560 AAATTTTTTTTACTGTTTCT 1579
Db 2 AAATTTTTTTTCTTTTCT 21

RESULT 169
LOCUS I69408 22 bp DNA linear PAT 04-FEB-1998
DEFINITION Sequence 2 from patent US 5677289.
ACCESSION I69408
VERSION I69408.1 GI:2831530
KEYWORDS
  source
    location/Qualifiers
  1..22
  /organism="unknown"
BASE COUNT 4 a 0 c 0 g 18 t
  Query Match 1.1%; Score 13.6; DB 1; Length 22;
  Best Local Similarity 80.0%; Pred. No. 4.3e+02;
  Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
QY 1560 AAATTTTTTTTACTGTTTCT 1579
Db 2 AAATTTTTTTTCTTTTCT 21

RESULT 170
LOCUS BD182175 30 bp DNA linear PAT 15-MAY-2003
DEFINITION Method for synthesizing of nucleic acid.
ACCESSION BD182175
VERSION BD182175.1 GI:30793093
KEYWORDS WO 02090538-A/7.
  source
    location/Qualifiers
  1..22
  /organism="unknown"
BASE COUNT 4 a 0 c 0 g 18 t
  Query Match 1.1%; Score 13.6; DB 1; Length 22;
  Best Local Similarity 80.0%; Pred. No. 4.3e+02;
  Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
QY 1560 AAATTTTTTTTACTGTTTCT 1579
Db 2 AAATTTTTTTTCTTTTCT 21

ORGANISM Unknown.
REFERENCE 1 (bases 1 to 22)
AUTHORS Torrence,P., Silverman,R., Maitra,R. and Lesiak,K.
TITLE Method of cleaving specific strands of RNA
JOURNAL Patent: US 5583032-A 1 10-DEC-1996;
FEATURES
  source
    location/Qualifiers
  1..22
  /organism="unknown"
BASE COUNT 4 a 0 c 0 g 18 t
  Query Match 1.1%; Score 13.6; DB 1; Length 22;
  Best Local Similarity 80.0%; Pred. No. 4.3e+02;
  Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
QY 1560 AAATTTTTTTTACTGTTTCT 1579
Db 2 AAATTTTTTTTCTTTTCT 21

RESULT 167
LOCUS I31811 22 bp DNA linear PAT 06-FEB-1997
DEFINITION Sequence 2 from patent US 5583032.
ACCESSION I31811
VERSION I31811.1 GI:1822602
KEYWORDS
  source
    location/Qualifiers
  1..22
  /organism="unknown"
BASE COUNT 4 a 0 c 0 g 18 t
  Query Match 1.1%; Score 13.6; DB 1; Length 22;
  Best Local Similarity 80.0%; Pred. No. 4.3e+02;
  Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
QY 1560 AAATTTTTTTTACTGTTTCT 1579
Db 2 AAATTTTTTTTCTTTTCT 21

RESULT 168
LOCUS I69407 22 bp DNA linear PAT 04-FEB-1998
DEFINITION Sequence 1 from patent US 5677289.
ACCESSION I69407
VERSION I69407.1 GI:2831529
KEYWORDS
  source
    location/Qualifiers
  1..22
  /organism="unknown"
BASE COUNT 4 a 0 c 0 g 18 t
  Query Match 1.1%; Score 13.6; DB 1; Length 22;
  Best Local Similarity 80.0%; Pred. No. 4.3e+02;
  Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
QY 1560 AAATTTTTTTTACTGTTTCT 1579
Db 2 AAATTTTTTTTCTTTTCT 21

RESULT 169
LOCUS I69408 22 bp DNA linear PAT 04-FEB-1998
DEFINITION Sequence 2 from patent US 5677289.
ACCESSION I69408
VERSION I69408.1 GI:2831530
KEYWORDS
  source
    location/Qualifiers
  1..22
  /organism="unknown"
BASE COUNT 4 a 0 c 0 g 18 t
  Query Match 1.1%; Score 13.6; DB 1; Length 22;
  Best Local Similarity 80.0%; Pred. No. 4.3e+02;
  Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
QY 1560 AAATTTTTTTTACTGTTTCT 1579
Db 2 AAATTTTTTTTCTTTTCT 21

RESULT 170
LOCUS BD182175 30 bp DNA linear PAT 15-MAY-2003
DEFINITION Method for synthesizing of nucleic acid.
ACCESSION BD182175
VERSION BD182175.1 GI:30793093
KEYWORDS WO 02090538-A/7.
  source
    location/Qualifiers
  1..22
  /organism="unknown"
BASE COUNT 4 a 0 c 0 g 18 t
  Query Match 1.1%; Score 13.6; DB 1; Length 22;
  Best Local Similarity 80.0%; Pred. No. 4.3e+02;
  Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
QY 1560 AAATTTTTTTTACTGTTTCT 1579
Db 2 AAATTTTTTTTCTTTTCT 21
```

```

TITLE      Method for synthesizing of nucleic acid
JOURNAL    Patent: WO 02090538-A 7 14-NOV-2002;
           BIKEN CHEMICAL CO LTD,KENTARO NAGAMINE
COMMENT    OS Artificial Sequence
           PN WO 02090538-A/7
           PD 14-NOV-2002
           PF 08-MAY-2002 WO 2002JP004479
           PR 08-MAY-2001 JP 01P 137060,18-JUN-2001 JP 01P 184131 PI
           PC C12N15/09,C12Q1/68
           CC Description of Artificial Sequence:an artificially synthesized

CC sequence primer
CC key Location/Qualifiers
FH key 1..30
FT source /organism='Artificial Sequence'.

FEATURES   source
           1..30 Location/Qualifiers
           /organism='synthetic construct'
           /mol_type='genomic DNA'
           /db_xref='taxon:32630'
BASE COUNT 15 a 2 c 2 g 11 t

Query Match 1..1%; Score 13.6; DB 1; Length 30;
Best Local Similarity 67.9%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 753 ATTGATATTGAGCATCATCAATAAA 780
   |||||
Db 3 ATTGATGCTTAATAATAACATAATA 30

RESULT 171
AR041400
LOCUS AR041400 15 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 190 from patent US 5811300.
ACCESSION AR041400
VERSION AR041400.1 GI:5961896
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE TNF- $\alpha$ . ribozymes
JOURNAL Patent: US 5811300-A 190 22-SEP-1998;
FEATURES source
           1..15 Location/Qualifiers
           /organism='unknown'
BASE COUNT 4 a 0 c 0 g 11 t

Query Match 1..1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1039 ATTATTATTATGT 1053
   |||||
Db 1 ATTATTATTATT 15

RESULT 172
AR041401
LOCUS AR041401 15 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 191 from patent US 5811300.
ACCESSION AR041401
VERSION AR041401.1 GI:5961897
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.

```

```

TITLE      TNF- $\alpha$ . ribozymes
JOURNAL    Patent: US 5811300-A 191 22-SEP-1998;
FEATURES   source
           1..15 Location/Qualifiers
           /organism='unknown'
BASE COUNT 4 a 0 c 0 g 11 t

Query Match 1..1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1041 TTATTATTATGT 1055
   |||||
Db 1 TTATTATTATTAT 15

RESULT 173
AR041402
LOCUS AR041402 15 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 192 from patent US 5811300.
ACCESSION AR041402
VERSION AR041402.1 GI:5961898
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE TNF- $\alpha$ . ribozymes
JOURNAL Patent: US 5811300-A 192 22-SEP-1998;
FEATURES source
           1..15 Location/Qualifiers
           /organism='unknown'
BASE COUNT 4 a 0 c 0 g 11 t

Query Match 1..1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1042 TATTATTATGT 1056
   |||||
Db 1 TATTATTATTAT 15

RESULT 174
AR041408
LOCUS AR041408 15 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 198 from patent US 5811300.
ACCESSION AR041408
VERSION AR041408.1 GI:5961904
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE TNF- $\alpha$ . ribozymes
JOURNAL Patent: US 5811300-A 198 22-SEP-1998;
FEATURES source
           1..15 Location/Qualifiers
           /organism='unknown'
BASE COUNT 4 a 0 c 0 g 11 t

Query Match 1..1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1039 ATTATTATTATGT 1053
   |||||
Db 1 ATTATTATTATT 15

RESULT 175

```

AR041409
LOCUS AR041409 15 bp DNA PAT 29-SEP-1999
DEFINITION Sequence 199 from patent US 5811300.
ACCESSION AR041409
VERSION AR041409.1 GI:5961905
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE TNF-.alpha. ribozymes
JOURNAL Patent: US 5811300-A 199 22-SEP-1998;
FEATURES Location/Qualifiers
source 1..15
/organism="unknown"
BASE COUNT 4 a 0 c 0 g 11 t

Query Match 1.1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1041 TTATTATTATGAT 1055
|||||
Db 1 TTATTATTATTTAT 15

RESULT 176
AR041410 15 bp DNA PAT 29-SEP-1999
LOCUS AR041410
DEFINITION Sequence 200 from patent US 5811300.
ACCESSION AR041410
VERSION AR041410.1 GI:5961906
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE TNF-.alpha. ribozymes
JOURNAL Patent: US 5811300-A 200 22-SEP-1998;
FEATURES Location/Qualifiers
source 1..15
/organism="unknown"
BASE COUNT 4 a 0 c 0 g 11 t

Query Match 1.1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1042 TATTATTATGAT 1056
|||||
Db 1 TATTATTATTTAT 15

RESULT 177
AR041411 15 bp DNA PAT 29-SEP-1999
LOCUS AR041411
DEFINITION Sequence 201 from patent US 5811300.
ACCESSION AR041411
VERSION AR041411.1 GI:5961907
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE TNF-.alpha. ribozymes
JOURNAL Patent: US 5811300-A 201 22-SEP-1998;
FEATURES Location/Qualifiers
source 1..15
/organism="unknown"
BASE COUNT 4 a 0 c 0 g 11 t

Query Match 1.1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1043 TATTATTATGAT 1057
|||||
Db 1 ATTATTATTATTT 15

RESULT 178
AR041919 15 bp DNA PAT 29-SEP-1999
LOCUS AR041919
DEFINITION Sequence 709 from patent US 5811300.
ACCESSION AR041919
VERSION AR041919.1 GI:5962415
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE TNF-.alpha. ribozymes
JOURNAL Patent: US 5811300-A 709 22-SEP-1998;
FEATURES Location/Qualifiers
source 1..15
/organism="unknown"
BASE COUNT 4 a 0 c 0 g 11 t

Query Match 1.1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1039 ATTATTATTATGAT 1053
|||||
Db 1 ATTATTATTATTT 15

RESULT 179
AR041920 15 bp DNA PAT 29-SEP-1999
LOCUS AR041920
DEFINITION Sequence 710 from patent US 5811300.
ACCESSION AR041920
VERSION AR041920.1 GI:5962416
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE TNF-.alpha. ribozymes
JOURNAL Patent: US 5811300-A 710 22-SEP-1998;
FEATURES Location/Qualifiers
source 1..15
/organism="unknown"
BASE COUNT 4 a 0 c 0 g 11 t

Query Match 1.1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1039 ATTATTATTATGAT 1053
|||||
Db 1 ATTATTATTATTT 15

RESULT 180
AR041921 15 bp DNA PAT 29-SEP-1999
LOCUS AR041921
DEFINITION Sequence 711 from patent US 5811300.
ACCESSION AR041921
VERSION AR041921.1 GI:5962417
KEYWORDS

SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE TNF-.alpha. ribozymes
JOURNAL Patent: US 5811300-A 711 22-SEP-1998;
FEATURES Location/Qualifiers
source 1..15
BASE COUNT 4 a 0 c 0 g 11 t
Query Match 1.1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1039 ATTATTATTATGAT 1053
Db 1 ATTATTATTATTT 15

RESULT 181
AR041922
LOCUS AR041922 15 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 712 from patent US 5811300.
ACCESSION AR041922
VERSION AR041922.1 GI:5962418
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE TNF-.alpha. ribozymes
JOURNAL Patent: US 5811300-A 712 22-SEP-1998;
FEATURES Location/Qualifiers
source 1..15
BASE COUNT 4 a 0 c 0 g 11 t
Query Match 1.1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1041 TTATTATTATGAT 1055
Db 1 TTATTATTATTTAT 15

RESULT 182
AR041923
LOCUS AR041923 15 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 713 from patent US 5811300.
ACCESSION AR041923
VERSION AR041923.1 GI:5962419
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE TNF-.alpha. ribozymes
JOURNAL Patent: US 5811300-A 713 22-SEP-1998;
FEATURES Location/Qualifiers
source 1..15
BASE COUNT 4 a 0 c 0 g 11 t
Query Match 1.1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1041 TTATTATTATGAT 1055
Db 1 TTATTATTATTTAT 15

RESULT 183
AR041924
LOCUS AR041924 15 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 714 from patent US 5811300.
ACCESSION AR041924
VERSION AR041924.1 GI:5962420
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE TNF-.alpha. ribozymes
JOURNAL Patent: US 5811300-A 714 22-SEP-1998;
FEATURES Location/Qualifiers
source 1..15
BASE COUNT 4 a 0 c 0 g 11 t
Query Match 1.1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1041 TTATTATTATGAT 1055
Db 1 TTATTATTATTTAT 15

RESULT 184
AR041925
LOCUS AR041925 15 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 715 from patent US 5811300.
ACCESSION AR041925
VERSION AR041925.1 GI:5962421
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE TNF-.alpha. ribozymes
JOURNAL Patent: US 5811300-A 715 22-SEP-1998;
FEATURES Location/Qualifiers
source 1..15
BASE COUNT 4 a 0 c 0 g 11 t
Query Match 1.1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1042 TATTATTATGAT 1056
Db 1 TATTATTATTTAT 15

RESULT 185
AR041926
LOCUS AR041926 15 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 716 from patent US 5811300.
ACCESSION AR041926
VERSION AR041926.1 GI:5962422
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE TNF-.alpha. ribozymes

Db 1 TTATTATTATTTAT 15

RESULT 183
AR041924
LOCUS AR041924 15 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 714 from patent US 5811300.
ACCESSION AR041924
VERSION AR041924.1 GI:5962420
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE TNF-.alpha. ribozymes
JOURNAL Patent: US 5811300-A 714 22-SEP-1998;
FEATURES Location/Qualifiers
source 1..15
BASE COUNT 4 a 0 c 0 g 11 t
Query Match 1.1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1041 TTATTATTATGAT 1055
Db 1 TTATTATTATTTAT 15

RESULT 184
AR041925
LOCUS AR041925 15 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 715 from patent US 5811300.
ACCESSION AR041925
VERSION AR041925.1 GI:5962421
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE TNF-.alpha. ribozymes
JOURNAL Patent: US 5811300-A 715 22-SEP-1998;
FEATURES Location/Qualifiers
source 1..15
BASE COUNT 4 a 0 c 0 g 11 t
Query Match 1.1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1042 TATTATTATGAT 1056
Db 1 TATTATTATTTAT 15

RESULT 185
AR041926
LOCUS AR041926 15 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 716 from patent US 5811300.
ACCESSION AR041926
VERSION AR041926.1 GI:5962422
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE TNF-.alpha. ribozymes

```

JOURNAL Patent: US 5811300-A 716 22-SEP-1998;
FEATURES Location/Qualifiers
SOURCE 1..15
BASE COUNT 4 a 0 c 0 g 11 t
Query Match 1.1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1042 TTATTATTATGTTT 1056
Db 1 TTATTATTATTT 15

RESULT 186
LOCUS AR041931 15 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 721 from patent US 5811300.
ACCESSION AR041931
VERSION AR041931.1 GI:5962427
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE TNF-alpha ribozymes
JOURNAL Patent: US 5811300-A 721 22-SEP-1998;
FEATURES Location/Qualifiers
SOURCE 1..15
/organism="unknown"
BASE COUNT 4 a 0 c 0 g 11 t
Query Match 1.1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1043 ATTATTATGTTT 1057
Db 1 ATTATTATTT 15

RESULT 187
LOCUS AR074423/c 15 bp DNA linear PAT 28-AUG-2000
DEFINITION Sequence 13 from patent US 5955072.
ACCESSION AR074423
VERSION AR074423.1 GI:10001173
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Takahashi,T., Serizawa,N., Koishi,R. and Kawashima,I.
TITLE Expression systems utilizing autolyzing fusion proteins and a
reducing polypeptide
JOURNAL Patent: US 5955072-A 13 21-SEP-1999;
FEATURES Location/Qualifiers
SOURCE 1..15
/organism="unknown"
BASE COUNT 11 a 0 c 0 g 4 t
Query Match 1.1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1044 TTATTATGTTT 1058
Db 15 TTATTATTATTT 1

RESULT 188
LOCUS AR041931 15 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 721 from patent US 5811300.
ACCESSION AR041931
VERSION AR041931.1 GI:5962427
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE TNF-alpha ribozymes
JOURNAL Patent: US 5811300-A 721 22-SEP-1998;
FEATURES Location/Qualifiers
SOURCE 1..15
/organism="unknown"
BASE COUNT 4 a 0 c 0 g 11 t
Query Match 1.1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1043 ATTATTATGTTT 1057
Db 1 ATTATTATTT 15

RESULT 187
LOCUS AR074423/c 15 bp DNA linear PAT 28-AUG-2000
DEFINITION Sequence 13 from patent US 5955072.
ACCESSION AR074423
VERSION AR074423.1 GI:10001173
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Takahashi,T., Serizawa,N., Koishi,R. and Kawashima,I.
TITLE Expression systems utilizing autolyzing fusion proteins and a
reducing polypeptide
JOURNAL Patent: US 5955072-A 13 21-SEP-1999;
FEATURES Location/Qualifiers
SOURCE 1..15
/organism="unknown"
BASE COUNT 11 a 0 c 0 g 4 t
Query Match 1.1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1044 TTATTATGTTT 1058
Db 15 TTATTATTATTT 1

RESULT 188
LOCUS AR041931 15 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 721 from patent US 5811300.
ACCESSION AR041931
VERSION AR041931.1 GI:5962427
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE TNF-alpha ribozymes
JOURNAL Patent: US 5811300-A 721 22-SEP-1998;
FEATURES Location/Qualifiers
SOURCE 1..15
/organism="unknown"
BASE COUNT 4 a 0 c 0 g 11 t
Query Match 1.1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1043 ATTATTATGTTT 1057
Db 1 ATTATTATTT 15

RESULT 187
LOCUS AR074423/c 15 bp DNA linear PAT 28-AUG-2000
DEFINITION Sequence 13 from patent US 5955072.
ACCESSION AR074423
VERSION AR074423.1 GI:10001173
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Takahashi,T., Serizawa,N., Koishi,R. and Kawashima,I.
TITLE Expression systems utilizing autolyzing fusion proteins and a
reducing polypeptide
JOURNAL Patent: US 5955072-A 13 21-SEP-1999;
FEATURES Location/Qualifiers
SOURCE 1..15
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/note="PCR Primer"
BASE COUNT 11 a 0 c 0 g 4 t
Query Match 1.1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1044 TTATTATGTTT 1058
Db 15 TTATTATTATTT 1

RESULT 190
LOCUS AX636858 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 3997 from Patent EP1260586.
ACCESSION AX636858
VERSION AX636858.1 GI:28472472
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,

```

```

ARI174801/c
LOCUS ARI174801 15 bp DNA linear PAT 17-DEC-2001
DEFINITION Sequence 13 from patent US 6307038.
ACCESSION ARI174801
VERSION ARI174801.1 GI:17915121
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Takahashi,T., Serizawa,N., Koishi,R. and Kawashima,I.
TITLE Expression systems utilizing autolyzing fusion proteins and a novel
reducing polypeptide
JOURNAL Patent: US 6307038-A 13 23-OCT-2001;
FEATURES Location/Qualifiers
SOURCE 1..15
/organism="unknown"
BASE COUNT 11 a 0 c 0 g 4 t
Query Match 1.1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1044 TTATTATGTTT 1058
Db 15 TTATTATTATTT 1

RESULT 189
LOCUS AX577646/c 15 bp DNA linear PAT 08-JAN-2003
DEFINITION Sequence 13 from Patent EP1251176.
ACCESSION AX577646
VERSION AX577646.1 GI:27646929
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Takahashi,T., Koishi,R., Kawashima,I. and Serizawa,N.
TITLE Expression systems utilizing autolyzing fusion proteins and a
reducing polypeptide
JOURNAL Patent: EP 1251176-A 13 23-OCT-2002;
FEATURES Location/Qualifiers
SOURCE 1..15
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/note="PCR Primer"
BASE COUNT 11 a 0 c 0 g 4 t
Query Match 1.1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1044 TTATTATGTTT 1058
Db 15 TTATTATTATTT 1

RESULT 190
LOCUS AX636858 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 3997 from Patent EP1260586.
ACCESSION AX636858
VERSION AX636858.1 GI:28472472
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,

```

Karpeisky, A., Draper, K.G., Kisich, K., Matulic-Adamic, J., McSwiggen, J.A., Modak, A., Pavco, P., Beigelman, L., Sullivan, S.M., Sweedler, D., Thompson, J.D., Tracz, D., Usman, N., Wincott, P.E. and Woolf, T.
Method and reagent for inhibiting the expression of disease related genes
Patent: EP 1260586-A 3997 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
Location/Qualifiers
1. 15
/organism="unidentified"
/mol_type="mRNA"
/db_xref="taxon:32644"
4 a 0 c 0 g 11 t

Query Match 1.1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1039 ATTATTATTATGAT 1053
|||||
1 ATTATTATTATTT 15

RESULT 191
AX636860
LOCUS AX636860 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 3999 from Patent EP1260586.
ACCESSION AX636860
VERSION AX636860.1 GI:28472474
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Stinchcomb, D.T., Dudycz, L.W., Chowrira, B., Grimm, S., Drenzo, A., Karpeisky, A., Draper, K.G., Kisich, K., Matulic-Adamic, J., McSwiggen, J.A., Modak, A., Pavco, P., Beigelman, L., Sullivan, S.M., Sweedler, D., Thompson, J.D., Tracz, D., Usman, N., Wincott, P.E. and Woolf, T.
Method and reagent for inhibiting the expression of disease related genes
Patent: EP 1260586-A 3997 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
Location/Qualifiers
1. 15
/organism="unidentified"
/mol_type="mRNA"
/db_xref="taxon:32644"
4 a 0 c 0 g 11 t

Query Match 1.1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1041 TTATTATTATGAT 1055
|||||
1 TTATTATTATTTAT 15

RESULT 192
AX636862
LOCUS AX636862 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 4001 from Patent EP1260586.
ACCESSION AX636862
VERSION AX636862.1 GI:28472476
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Stinchcomb, D.T., Dudycz, L.W., Chowrira, B., Grimm, S., Drenzo, A., Karpeisky, A., Draper, K.G., Kisich, K., Matulic-Adamic, J., McSwiggen, J.A., Modak, A., Pavco, P., Beigelman, L., Sullivan, S.M., Sweedler, D., Thompson, J.D., Tracz, D., Usman, N., Wincott, P.E. and Woolf, T.
Method and reagent for inhibiting the expression of disease related genes
Patent: EP 1260586-A 3997 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
Location/Qualifiers
1. 15
/organism="unidentified"
/mol_type="mRNA"
/db_xref="taxon:32644"
4 a 0 c 0 g 11 t

Query Match 1.1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1041 TTATTATTATGAT 1055
|||||
1 TTATTATTATTTAT 15

RESULT 193
AX636874
LOCUS AX636874 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 4013 from Patent EP1260586.
ACCESSION AX636874
VERSION AX636874.1 GI:28472488
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Stinchcomb, D.T., Dudycz, L.W., Chowrira, B., Grimm, S., Drenzo, A., Karpeisky, A., Draper, K.G., Kisich, K., Matulic-Adamic, J., McSwiggen, J.A., Modak, A., Pavco, P., Beigelman, L., Sullivan, S.M., Sweedler, D., Thompson, J.D., Tracz, D., Usman, N., Wincott, P.E. and Woolf, T.
Method and reagent for inhibiting the expression of disease related genes
Patent: EP 1260586-A 4013 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
Location/Qualifiers
1. 15
/organism="unidentified"
/mol_type="mRNA"
/db_xref="taxon:32644"
4 a 0 c 0 g 11 t

Query Match 1.1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1039 ATTATTATTATGAT 1053
|||||
1 ATTATTATTATTT 15

RESULT 194
AX636876
LOCUS AX636876 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 4015 from Patent EP1260586.
ACCESSION AX636876
VERSION AX636876.1 GI:28472490
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Stinchcomb, D.T., Dudycz, L.W., Chowrira, B., Grimm, S., Drenzo, A., Karpeisky, A., Draper, K.G., Kisich, K., Matulic-Adamic, J., McSwiggen, J.A., Modak, A., Pavco, P., Beigelman, L., Sullivan, S.M., Sweedler, D., Thompson, J.D., Tracz, D., Usman, N., Wincott, P.E. and Woolf, T.
Method and reagent for inhibiting the expression of disease related genes
Patent: EP 1260586-A 4013 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
Location/Qualifiers
1. 15
/organism="unidentified"
/mol_type="mRNA"
/db_xref="taxon:32644"
4 a 0 c 0 g 11 t

Query Match 1.1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1039 ATTATTATTATGAT 1053
|||||
1 ATTATTATTATTT 15

McSwiggen, J.A., Modak, A., Pavco, P., Beigelman, L., Sullivan, S.M., Sweedler, D., Thompson, J.D., Tracz, D., Usman, N., Wincott, P.E. and Woolf, T.
Method and reagent for inhibiting the expression of disease related genes
Patent: EP 1260586-A 4001 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
Location/Qualifiers
1. 15
/organism="unidentified"
/mol_type="mRNA"
/db_xref="taxon:32644"
4 a 0 c 0 g 11 t

Query Match 1.1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1042 TATTATTATGAT 1056
|||||
1 TATTATTATTTAT 15

RESULT 193
AX636874
LOCUS AX636874 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 4013 from Patent EP1260586.
ACCESSION AX636874
VERSION AX636874.1 GI:28472488
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Stinchcomb, D.T., Dudycz, L.W., Chowrira, B., Grimm, S., Drenzo, A., Karpeisky, A., Draper, K.G., Kisich, K., Matulic-Adamic, J., McSwiggen, J.A., Modak, A., Pavco, P., Beigelman, L., Sullivan, S.M., Sweedler, D., Thompson, J.D., Tracz, D., Usman, N., Wincott, P.E. and Woolf, T.
Method and reagent for inhibiting the expression of disease related genes
Patent: EP 1260586-A 4013 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
Location/Qualifiers
1. 15
/organism="unidentified"
/mol_type="mRNA"
/db_xref="taxon:32644"
4 a 0 c 0 g 11 t

Query Match 1.1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1039 ATTATTATTATGAT 1053
|||||
1 ATTATTATTATTT 15

RESULT 194
AX636876
LOCUS AX636876 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 4015 from Patent EP1260586.
ACCESSION AX636876
VERSION AX636876.1 GI:28472490
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Stinchcomb, D.T., Dudycz, L.W., Chowrira, B., Grimm, S., Drenzo, A., Karpeisky, A., Draper, K.G., Kisich, K., Matulic-Adamic, J., McSwiggen, J.A., Modak, A., Pavco, P., Beigelman, L., Sullivan, S.M., Sweedler, D., Thompson, J.D., Tracz, D., Usman, N., Wincott, P.E. and Woolf, T.
Method and reagent for inhibiting the expression of disease related genes
Patent: EP 1260586-A 4013 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
Location/Qualifiers
1. 15
/organism="unidentified"
/mol_type="mRNA"
/db_xref="taxon:32644"
4 a 0 c 0 g 11 t

Query Match 1.1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1039 ATTATTATTATGAT 1053
|||||
1 ATTATTATTATTT 15

Sweedler, D., Thompson, J.D., Tracz, D., Usman, N., Wincott, F.E. and Woolf, T.
Method and reagent for inhibiting the expression of disease related genes

Patent: EP 1260586-A 4015 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)

Location/Qualifiers
1. 15
/organism="unidentified"
/mol_type="mRNA"
/db_xref="taxon:32644"

BASE COUNT 4 a 0 c 0 g 11 t

Query Match 1.1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1041 TTATTATTATGTTAT 1055
|||||

Db 1 TTATTATTATTTAT 15

RESULT 195
AX636878 15 bp mRNA linear PAT 21-FEB-2003
LOCUS
DEFINITION Sequence 4015 from Patent EP1260586.
ACCESSION AX636878
VERSION AX636878.1 GI:28472492
KEYWORDS
SOURCE unidentified
ORGANISM unclassified.

REFERENCE 1
AUTHORS Stinchcomb, D.T., Dudycz, L.W., Chowrira, B., Grimm, S., Drenzo, A., Karpelisky, A., Draper, K.G., Kisch, K., Matulic-Adamic, J., McSwiggen, J.A., Modak, A., Pavco, P., Beigelman, L., Sullivan, S.M., Sweedler, D., Thompson, J.D., Tracz, D., Usman, N., Wincott, F.E. and Woolf, T.

TITLE Method and reagent for inhibiting the expression of disease related genes

JOURNAL Patent: EP 1260586-A 4017 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)

Location/Qualifiers
1. 15
/organism="unidentified"
/mol_type="mRNA"
/db_xref="taxon:32644"

BASE COUNT 4 a 0 c 0 g 11 t

Query Match 1.1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1042 TATTATTATGTTAT 1056
|||||

Db 1 TATTATTATTTAT 15

RESULT 196
AX636880 15 bp mRNA linear PAT 21-FEB-2003
LOCUS
DEFINITION Sequence 4019 from Patent EP1260586.
ACCESSION AX636880
VERSION AX636880.1 GI:28472494
KEYWORDS
SOURCE unidentified
ORGANISM unclassified.

REFERENCE 1
AUTHORS Stinchcomb, D.T., Dudycz, L.W., Chowrira, B., Grimm, S., Drenzo, A., Karpelisky, A., Draper, K.G., Kisch, K., Matulic-Adamic, J., McSwiggen, J.A., Modak, A., Pavco, P., Beigelman, L., Sullivan, S.M., Sweedler, D., Thompson, J.D., Tracz, D., Usman, N., Wincott, F.E. and Woolf, T.

Woolf, T.
Method and reagent for inhibiting the expression of disease related genes

Patent: EP 1260586-A 4019 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)

Location/Qualifiers
1. 15
/organism="unidentified"
/mol_type="mRNA"
/db_xref="taxon:32644"

BASE COUNT 4 a 0 c 0 g 11 t

Query Match 1.1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1043 ATTATTATGTTATTT 1057
|||||

Db 1 ATTATTATTTATTT 15

RESULT 197
AX637387 15 bp mRNA linear PAT 21-FEB-2003
LOCUS
DEFINITION Sequence 4526 from Patent EP1260586.
ACCESSION AX637387
VERSION AX637387.1 GI:28473001
KEYWORDS
SOURCE unidentified
ORGANISM unclassified.

REFERENCE 1
AUTHORS Stinchcomb, D.T., Dudycz, L.W., Chowrira, B., Grimm, S., Drenzo, A., Karpelisky, A., Draper, K.G., Kisch, K., Matulic-Adamic, J., McSwiggen, J.A., Modak, A., Pavco, P., Beigelman, L., Sullivan, S.M., Sweedler, D., Thompson, J.D., Tracz, D., Usman, N., Wincott, F.E. and Woolf, T.

TITLE Method and reagent for inhibiting the expression of disease related genes

JOURNAL Patent: EP 1260586-A 4526 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)

Location/Qualifiers
1. 15
/organism="unidentified"
/mol_type="mRNA"
/db_xref="taxon:32644"

BASE COUNT 4 a 0 c 0 g 11 t

Query Match 1.1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1039 ATTATTATGTTATTT 1053
|||||

Db 1 ATTATTATTTATTT 15

RESULT 198
AX637389 15 bp mRNA linear PAT 21-FEB-2003
LOCUS
DEFINITION Sequence 4528 from Patent EP1260586.
ACCESSION AX637389
VERSION AX637389.1 GI:28473003
KEYWORDS
SOURCE unidentified
ORGANISM unclassified.

REFERENCE 1
AUTHORS Stinchcomb, D.T., Dudycz, L.W., Chowrira, B., Grimm, S., Drenzo, A., Karpelisky, A., Draper, K.G., Kisch, K., Matulic-Adamic, J., McSwiggen, J.A., Modak, A., Pavco, P., Beigelman, L., Sullivan, S.M., Sweedler, D., Thompson, J.D., Tracz, D., Usman, N., Wincott, F.E. and Woolf, T.


```

TITLE      Method and reagent for inhibiting the expression of disease related
Genes
JOURNAL    Patent: EP 1260586-A 4528 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES   Location/Qualifiers
source     1..15
            /organism="unidentified"
            /mol_type="mRNA"
            /db_xref="taxon:32644"
BASE COUNT 4 a 0 c 0 g 11 t
Query Match      1.1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1039 ATTATTATTATCT 1053
      |||||
Db 1 ATTATTATTATT 15

RESULT 199
AX637391 15 bp mRNA linear PAT 21-FEB-2003
LOCUS
DEFINITION Sequence 4530 from Patent EP1260586.
ACCESSION AX637391
VERSION AX637391.1 GI:28473005
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,P.E. and
Woolf,T.
TITLE      Method and reagent for inhibiting the expression of disease related
Genes
JOURNAL    Patent: EP 1260586-A 4530 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES   Location/Qualifiers
source     1..15
            /organism="unidentified"
            /mol_type="mRNA"
            /db_xref="taxon:32644"
BASE COUNT 4 a 0 c 0 g 11 t
Query Match      1.1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1039 ATTATTATTATCT 1053
      |||||
Db 1 ATTATTATTATT 15

RESULT 200
AX637393 15 bp mRNA linear PAT 21-FEB-2003
LOCUS
DEFINITION Sequence 4532 from Patent EP1260586.
ACCESSION AX637393
VERSION AX637393.1 GI:28473007
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,P.E. and
Woolf,T.
TITLE      Method and reagent for inhibiting the expression of disease related

```

```

Genes
JOURNAL    Patent: EP 1260586-A 4532 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES   Location/Qualifiers
source     1..15
            /organism="unidentified"
            /mol_type="mRNA"
            /db_xref="taxon:32644"
BASE COUNT 4 a 0 c 0 g 11 t
Query Match      1.1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1041 TTATTATTATCTAT 1055
      |||||
Db 1 TTATTATTATTAT 15

RESULT 201
AX637395 15 bp mRNA linear PAT 21-FEB-2003
LOCUS
DEFINITION Sequence 4534 from Patent EP1260586.
ACCESSION AX637395
VERSION AX637395.1 GI:28473009
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,P.E. and
Woolf,T.
TITLE      Method and reagent for inhibiting the expression of disease related
Genes
JOURNAL    Patent: EP 1260586-A 4534 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES   Location/Qualifiers
source     1..15
            /organism="unidentified"
            /mol_type="mRNA"
            /db_xref="taxon:32644"
BASE COUNT 4 a 0 c 0 g 11 t
Query Match      1.1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1041 TTATTATTATCTAT 1055
      |||||
Db 1 TTATTATTATTAT 15

RESULT 202
AX637397 15 bp mRNA linear PAT 21-FEB-2003
LOCUS
DEFINITION Sequence 4536 from Patent EP1260586.
ACCESSION AX637397
VERSION AX637397.1 GI:28473011
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,P.E. and
Woolf,T.
TITLE      Method and reagent for inhibiting the expression of disease related

```

```

JOURNAL Patent: EP 1260586-A 4536 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
  source
    Location/Qualifiers
      1..15
      /organism="unidentified"
      /mol_type="mRNA"
      /db_xref="taxon:32644"
BASE COUNT      4 a      0 c      0 g      11 t

Query Match      1.1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1041 TTATTATTATGTTAT 1055
DB 1 TTATTATTATTTAT 15

RESULT 203
AX637399
LOCUS AX637399 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 4538 from Patent EP1260586.
ACCESSION AX637399
VERSION AX637399.1 GI:28473013
KEYWORDS
SOURCE
  unidentified
  unidentified
  unclassified.
REFERENCE
  1 Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
    Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
    Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
    Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
    Woolf,T.
  Method and reagent for inhibiting the expression of disease related
  genes
JOURNAL Patent: EP 1260586-A 4538 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
  source
    Location/Qualifiers
      1..15
      /organism="unidentified"
      /mol_type="mRNA"
      /db_xref="taxon:32644"
BASE COUNT      4 a      0 c      0 g      11 t

Query Match      1.1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1042 TATTATTATGTTAT 1056
DB 1 TATTATTATTTAT 15

RESULT 204
AX637401
LOCUS AX637401 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 4540 from Patent EP1260586.
ACCESSION AX637401
VERSION AX637401.1 GI:28473015
KEYWORDS
SOURCE
  unidentified
  unidentified
  unclassified.
REFERENCE
  1 Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
    Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
    Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
    Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
    Woolf,T.
  Method and reagent for inhibiting the expression of disease related
  genes
JOURNAL Patent: EP 1260586-A 4540 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
  source
    Location/Qualifiers
      1..15
      /organism="unidentified"
      /mol_type="mRNA"
      /db_xref="taxon:32644"
BASE COUNT      4 a      0 c      0 g      11 t

Query Match      1.1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1043 ATTATTATGTTAT 1057
DB 1 ATTATTATTTAT 15

RESULT 205
AX637411
LOCUS AX637411 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 4550 from Patent EP1260586.
ACCESSION AX637411
VERSION AX637411.1 GI:28473025
KEYWORDS
SOURCE
  unidentified
  unidentified
  unclassified.
REFERENCE
  1 Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
    Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
    Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
    Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
    Woolf,T.
  Method and reagent for inhibiting the expression of disease related
  genes
JOURNAL Patent: EP 1260586-A 4550 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
  source
    Location/Qualifiers
      1..15
      /organism="unidentified"
      /mol_type="mRNA"
      /db_xref="taxon:32644"
BASE COUNT      4 a      0 c      0 g      11 t

Query Match      1.1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1043 ATTATTATGTTAT 1057
DB 1 ATTATTATTTAT 15

RESULT 206
E11393/c
LOCUS E11393 15 bp DNA linear PAT 29-SEP-1997
DEFINITION DNA probe for detecting human novel enzyme.
ACCESSION E11393
VERSION E11393.1 GI:22025027
KEYWORDS
SOURCE
  unidentified
  unidentified
  unclassified.
REFERENCE
  1 (bases 1 to 15)
    Koishi,R., Kawashima,I. and Serizawa,N.
  REDUCTIVE PROTEIN, AND DNA CODING THE SAME
  Patent: JP 1996131178-A 2 28-MAY-1996;
  SANKYO CO LTD
  OS None
  OC Artificial sequences.
  PN JP 1996131178-A/2
  PD 28-MAY-1996
  PF 12-SEP-1995 JP 1995233833

```

PR 13-SEP-1994 JP 94P 218392
PI KOISHI RYUTA, KAWASHIMA ICHIRO, SERIZAWA NOBUKI PC
C12N15/09, C07H21/04, C07K14/47, C07K16/44, C12N1/21, C12N5/10, PC
C12N15/02,
PC C12P21/02, C12P21/08//A61K38/00, A61K38/00, A61K38/00, A61K38/00,
PC A61K38/00,
PC A61K38/00, A61K38/00, A61K38/00, A61K38/00, A61K38/00, A61K38/00,
PC A61K38/00,
PC A61K38/00, A61K38/00, A61K38/00, A61K38/00, A61K38/00, A61K38/44,
PC A61K39/395,
PC
G01N33/53, G01N33/573, G01N33/577, (C12N1/21, C12R1:19), (C12P21/02, PC
C12R1:19),
PC (C12P21/02, C12R1:91), (C12P21/08, C12R1:91);
CC strandness: Single;
CC topology: linear;
CC hypothetical: No;
CC anti-sense: No; Location/Qualifiers
FH Key
FT source 1.15
FT Location/Qualifiers
FT /organism='Artificial sequences'.
FEATURES
source 1.15
Location/Qualifiers
BASE COUNT 11 a 0 c 0 g 4 t
Query Match 1.1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1044 TTATTATGATTTA 1058
Db TTTATTATTATT 1
RESULT 207
I30514/c
LOCUS 15 bp DNA linear PAT 06-FEB-1997
DEFINITION Sequence 5 from patent US 5580967.
ACCESSION I30514
VERSION I30514.1 GI:1821305
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Joyce, G.F.
TITLE Optimized catalytic DNA-cleaving ribozymes
JOURNAL Patent: US 5580967-A 5 03-DEC-1996;
FEATURES
source 1.15
Location/Qualifiers
BASE COUNT 12 a 0 c 0 g 3 t
Query Match 1.1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1047 TTATGATTTATT 1061
Db TTTATTATTATT 1
RESULT 208
I30530
LOCUS 15 bp DNA linear PAT 06-FEB-1997
DEFINITION Sequence 21 from patent US 5580967.
ACCESSION I30530
VERSION I30530.1 GI:1821321
KEYWORDS

SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Joyce, G.F.
TITLE Optimized catalytic DNA-cleaving ribozymes
JOURNAL Patent: US 5580967-A 21 03-DEC-1996;
FEATURES
source 1.15
Location/Qualifiers
BASE COUNT 3 a 0 c 0 g 12 t
Query Match 1.1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1047 TTTATGATTTATT 1061
Db TTTATTATTATT 15
RESULT 209
I34061
LOCUS 15 bp DNA linear PAT 06-FEB-1997
DEFINITION Sequence 6 from patent US 5595873.
ACCESSION I34061
VERSION I34061.1 GI:1824852
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Joyce, G.F.
TITLE T. thermophila group I introns that cleave amide bonds
JOURNAL Patent: US 5595873-A 6 21-JAN-1997;
FEATURES
source 1.15
Location/Qualifiers
BASE COUNT 3 a 0 c 0 g 12 t
Query Match 1.1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1047 TTTATGATTTATT 1061
Db TTTATTATTATT 15
RESULT 210
I30516
LOCUS 16 bp DNA linear PAT 06-FEB-1997
DEFINITION Sequence 7 from patent US 5580967.
ACCESSION I30516
VERSION I30516.1 GI:1821307
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 16)
AUTHORS Joyce, G.F.
TITLE Optimized catalytic DNA-cleaving ribozymes
JOURNAL Patent: US 5580967-A 7 03-DEC-1996;
FEATURES
source 1.16
Location/Qualifiers
BASE COUNT 3 a 1 c 0 g 12 t
Query Match 1.1%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1047 TTTATGATTTATT 1061

QY 1046 ATTATGATTTATT 1060
Db 17 ATTATGATTTATT 3
|||||
RESULT 215
A13281
LOCUS 17 bp DNA linear PAT 03-JAN-1994
DEFINITION oligonucleotide.
ACCESSION A13281
VERSION A13281.1 GI:491595
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1 (bases 1 to 17)
AUTHORS Hollis.M., Pioli.D. and Valenzuela.D.
TITLE Regulation of gene expression
JOURNAL Patent: EP 0338690-A 12 25-OCT-1989;
IMPERIAL CHEMICAL INDUSTRIES PLC; PRESIDENT AND FELLOWS OF HARVARD
COLLEGE; IMPERIAL CHEMICAL INDUSTRIES PLC; THE PRESIDENT AND
FELLOWS OF HARVARD COLLEGE
FEATURES Location/Qualifiers
source 1..17
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
BASE COUNT 5 a 2 g 10 t
Query Match 1..1%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1046 ATTATGATTTATT 1060
Db 1 ATTATGATTTATT 15
|||||
RESULT 215
A13282/c
LOCUS 17 bp DNA linear PAT 03-JAN-1994
DEFINITION oligonucleotide.
ACCESSION A13282
VERSION A13282.1 GI:491596
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1 (bases 1 to 17)
AUTHORS Hollis.M., Pioli.D. and Valenzuela.D.
TITLE Regulation of gene expression
JOURNAL Patent: EP 0338690-A 13 25-OCT-1989;
IMPERIAL CHEMICAL INDUSTRIES PLC; PRESIDENT AND FELLOWS OF HARVARD
COLLEGE; IMPERIAL CHEMICAL INDUSTRIES PLC; THE PRESIDENT AND
FELLOWS OF HARVARD COLLEGE
FEATURES Location/Qualifiers
source 1..17
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
BASE COUNT 10 a 2 c 0 g 5 t
Query Match 1..1%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1046 ATTATGATTTATT 1060
Db 17 ATTATGATTTATT 3
|||||
RESULT 217
AR046177/c

LOCUS AR046177 17 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 970 from patent US 5817796.
ACCESSION AR046177
VERSION AR046177.1 GI:5967642
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myb ribozymes having 2'-5'-linked adenylylate residues
JOURNAL Patent: US 5817796-A 970 06-OCT-1998;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
BASE COUNT 8 a 0 c 0 g 9 t
Query Match 1..1%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1617 AAAATATATTTTGT 1631
Db 16 AAAATATATTTT 2
|||||
RESULT 218
AR047258/c
LOCUS 17 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 2051 from patent US 5817796.
ACCESSION AR047258
VERSION AR047258.1 GI:5968723
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myb ribozymes having 2'-5'-linked adenylylate residues
JOURNAL Patent: US 5817796-A 2051 06-OCT-1998;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
BASE COUNT 8 a 0 c 1 g 8 t
Query Match 1..1%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1617 AAAATATATTTTGT 1631
Db 16 AAAATATATTTT 2
|||||
RESULT 219
AR053084/c
LOCUS 17 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 54 from patent US 5834181.
ACCESSION AR053084
VERSION AR053084.1 GI:5977946
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Shuber,A.P.
TITLE High throughput screening method for sequences or genetic
alterations in nucleic acids
JOURNAL Patent: US 5834181-A 54 10-NOV-1998;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
BASE COUNT 1 a 1 c 3 g 12 t

VERSION	AR187297.1	GI:20233262
Query Match	1.1%; Score 13.4; DB 1; Length 17;	
Best Local Similarity	93.3%; Pred. No. 3.1e+02;	
Matches	14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
QY	1207 AACAAACAAACAT 1221	
DB	16 AACAAACAAACAT 2	
RESULT 220		
LOCUS	AR065045	17 bp DNA linear PAT 29-SEP-1999
DEFINITION	Sequence 54 from patent US 5849483.	
ACCESSION	AR065045	
VERSION	AR065045.1	GI:5995261
KEYWORDS	Unknown.	
SOURCE	Unknown.	
ORGANISM	Unknown.	
REFERENCE	1 (bases 1 to 17)	
AUTHORS	Shuber,A.P.	
TITLE	High throughput screening method for sequences or genetic alterations in nucleic acids	
JOURNAL	Patent: US 5849483-A 54 15-DEC-1998;	
FEATURES	Location/Qualifiers	
source	1..17	
BASE COUNT	1 a 1 c 3 g 12 t	
Query Match	1.1%; Score 13.4; DB 1; Length 17;	
Best Local Similarity	93.3%; Pred. No. 3.1e+02;	
Matches	14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
QY	1207 AACAAACAAACAT 1221	
DB	16 AACAAACAAACAT 2	
RESULT 221		
LOCUS	AR186811/c	17 bp DNA linear PAT 20-APR-2002
DEFINITION	Sequence 2299 from patent US 6346398.	
ACCESSION	AR186811	
VERSION	AR186811.1	GI:20232776
KEYWORDS	Unknown.	
SOURCE	Unknown.	
ORGANISM	Unknown.	
REFERENCE	1 (bases 1 to 17)	
AUTHORS	Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.	
TITLE	Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor	
JOURNAL	Patent: US 6346398-A 2299 12-FEB-2002;	
FEATURES	Location/Qualifiers	
source	1..17	
BASE COUNT	7 a 3 c 2 g 5 t	
Query Match	1.1%; Score 13.4; DB 1; Length 17;	
Best Local Similarity	93.3%; Pred. No. 3.1e+02;	
Matches	14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
QY	749 TAGAATGTGATATT 763	
DB	17 TAGAATGTGATATT 3	
RESULT 222		
LOCUS	AR187297	17 bp DNA linear PAT 20-APR-2002
DEFINITION	Sequence 2785 from patent US 6346398.	
ACCESSION	AR187297	
VERSION	AR187297	
KEYWORDS	Unknown.	
SOURCE	Unknown.	
ORGANISM	Unknown.	
REFERENCE	1 (bases 1 to 17)	
AUTHORS	Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.	
TITLE	Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor	
JOURNAL	Patent: US 6346398-A 2785 12-FEB-2002;	
FEATURES	Location/Qualifiers	
source	1..17	
BASE COUNT	7 a 3 c 2 g 5 t	
Query Match	1.1%; Score 13.4; DB 1; Length 17;	
Best Local Similarity	93.3%; Pred. No. 3.1e+02;	
Matches	14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
QY	1207 AACAAACAAACAT 1221	
DB	16 AACAAACAAACAT 2	
RESULT 223		
LOCUS	AR192330/c	17 bp DNA linear PAT 20-APR-2002
DEFINITION	Sequence 7818 from patent US 6346398.	
ACCESSION	AR192330	
VERSION	AR192330.1	GI:20238295
KEYWORDS	Unknown.	
SOURCE	Unknown.	
ORGANISM	Unknown.	
REFERENCE	1 (bases 1 to 17)	
AUTHORS	Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.	
TITLE	Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor	
JOURNAL	Patent: US 6346398-A 7818 12-FEB-2002;	
FEATURES	Location/Qualifiers	
source	1..17	
BASE COUNT	0 a 0 c 2 g 15 t	
Query Match	1.1%; Score 13.4; DB 1; Length 17;	
Best Local Similarity	93.3%; Pred. No. 3.1e+02;	
Matches	14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
QY	616 ACAAAAACACAAA 630	
DB	15 ACAAAAACACAAA 1	
RESULT 224		
LOCUS	AX421942/c	17 bp mRNA linear PAT 18-JUN-2002
DEFINITION	Sequence 278 from Patent WO0188124.	
ACCESSION	AX421942	
VERSION	AX421942.1	GI:21525324
KEYWORDS	Homo sapiens (human)	
SOURCE	Homo sapiens	
ORGANISM	Homo sapiens	
REFERENCE	1	
AUTHORS	Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., McLaughlin,F.G. and Randi,A.M.	
TITLE	Method and reagent for the inhibition of erg	
JOURNAL	Patent: WO 0188124-A 278 22-NOV-2001;	
FEATURES	Location/Qualifiers	
source	1..17	
BASE COUNT	0 a 0 c 2 g 15 t	
Query Match	1.1%; Score 13.4; DB 1; Length 17;	
Best Local Similarity	93.3%; Pred. No. 3.1e+02;	
Matches	14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
QY	616 ACAAAAACACAAA 630	
DB	15 ACAAAAACACAAA 1	
RESULT 225		

```

QY 1504 ATTTTAAATACAGG 1518
Db 16 ATTTTAAATACAGG 2

/mol_type="mRNA"
/db_xref="taxon:9606"
BASE COUNT      8 a      2 c      1 g      6 t

Query Match      1.1%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

RESULT 225
AX500363/c
LOCUS      AX421943      17 bp      mRNA      linear      PAT 18-JUN-2002
DEFINITION Sequence 279 from Patent WO0188124.
ACCESSION  AX421943
VERSION     AX421943.1 GI:21525325
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Jarvis, T., von Carlowitz, I., Mcswiggen, J.A., McLaughlin, P.G. and
            Randi, A.M.
TITLE       Method and reagent for the inhibition of erg
JOURNAL     RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES    source
            1..17
            /organism="Homo sapiens"
            /mol_type="mRNA"
            /db_xref="taxon:9606"
BASE COUNT      7 a      2 c      2 g      6 t

Query Match      1.1%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1504 ATTTTAAATACAGG 1518
Db 15 ATTTTAAATACAGG 1

/mol_type="mRNA"
/db_xref="taxon:9606"
BASE COUNT      7 a      2 c      2 g      6 t

Query Match      1.1%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

RESULT 226
AX500363/c
LOCUS      AX500363      17 bp      DNA      linear      PAT 27-SEP-2002
DEFINITION Sequence 1670 from Patent EP1229046.
ACCESSION  AX500363
VERSION     AX500363.1 GI:23382656
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Zhan, J.
TITLE       Human testis expressed patched like protein
JOURNAL     Patent: EP 1229046-A 1670 07-AUG-2002;
            Acomica, Inc. (US)
FEATURES    source
            1..17
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"
BASE COUNT      3 a      1 c      1 g      12 t

Query Match      1.1%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

QY 677 TACAAATAGCAAAAT 691
Db 17 TAAATATAGCAAAAT 3

/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT      4 a      2 c      1 g      10 t

Query Match      1.1%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 675 TATCAATAGCAAA 689
Db 15 TATCAATAGCAAA 1

/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT      4 a      2 c      1 g      10 t

Query Match      1.1%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

RESULT 228
AX672147
LOCUS      AX672147      17 bp      DNA      linear      PAT 27-MAR-2003
DEFINITION Sequence 592 from Patent WO03004536.
ACCESSION  AX672147
VERSION     AX672147.1 GI:29330495
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Telerman, A., Anson, R. and Tuijnder, M.
TITLE       Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and their use as
            medicines
JOURNAL     Patent: WO 03004526-A 592 16-JAN-2003;
            Molecular Engines Laboratories (FR)
FEATURES    source
            1..17
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"
BASE COUNT      8 a      3 c      3 g      3 t

Query Match      1.1%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 534 TCAGTAAACAAATGAA 548
Db 3 TCAGTAAACAAATGAA 17

/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT      534 TCAGTAAACAAATGAA 548
            3 TCAGTAAACAAATGAA 17

RESULT 229
AX722330

```

```
LOCUS       AX722330                      17 bp    DNA          linear    PAT 08-MAY-2003
DEFINITION   Sequence 17 from Patent WO03025176.
ACCESSION    AX722330
VERSION      AX722330.1  GI:30422831
KEYWORDS     Mus musculus (house mouse)
SOURCE       Mus musculus
ORGANISM     Mus musculus
REFERENCE    1
AUTHORS      Telerman,A., Anson,R. and Tuijnder,M.
TITLE        Sequences involved in phenomena of tumour suppression, tumour
              reversion, apoptosis and/or virus resistance and their use as
              medicines
JOURNAL      Patent: WO 03025176-A 17 27-MAR-2003;
              Molecular Engines Laboratories (FR)
FEATURES     source
              1..17
              Location/Qualifiers
BASE COUNT   12 a 2 c 1 g 2 t
              Query Match          1.1%; Score 13.4; DB 1; Length 17;
              Best Local Similarity 93.3%; Pred. No. 3.1e+02;
              Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 612 ATCTACAAAAACAA 626
Db 2 ATCTACAAAAAAA 16

RESULT 230
LOCUS       AX724050/c                    17 bp    DNA          linear    PAT 08-MAY-2003
DEFINITION   Sequence 1737 from Patent WO03025176.
ACCESSION    AX724050
VERSION      AX724050.1  GI:30503393
KEYWORDS     Mus musculus (house mouse)
SOURCE       Mus musculus
ORGANISM     Mus musculus
REFERENCE    1
AUTHORS      Telerman,A., Anson,R. and Tuijnder,M.
TITLE        Sequences involved in phenomena of tumour suppression, tumour
              reversion, apoptosis and/or virus resistance and their use as
              medicines
JOURNAL      Patent: WO 03025176-A 1737 27-MAR-2003;
              Molecular Engines Laboratories (FR)
FEATURES     source
              1..17
              Location/Qualifiers
BASE COUNT   4 a 6 c 3 g 4 t
              Query Match          1.1%; Score 13.4; DB 1; Length 17;
              Best Local Similarity 93.3%; Pred. No. 3.1e+02;
              Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 424 TGAAGATGCCAGTGA 438
Db 17 TGAAGATGCCGTGA 3

RESULT 231
LOCUS       AX724812                      17 bp    DNA          linear    PAT 08-MAY-2003
DEFINITION   Sequence 2499 from Patent WO03025176.
ACCESSION    AX724812
VERSION      AX724812.1  GI:30504155
KEYWORDS     Mus musculus (house mouse)
SOURCE       Mus musculus
ORGANISM     Mus musculus
REFERENCE    1
AUTHORS      Telerman,A., Anson,R. and Tuijnder,M.
TITLE        Sequences involved in phenomena of tumour suppression, tumour
              reversion, apoptosis and/or virus resistance and their use as
              medicines
JOURNAL      Patent: WO 03025176-A 2499 27-MAR-2003;
              Molecular Engines Laboratories (FR)
FEATURES     source
              1..17
              Location/Qualifiers
BASE COUNT   12 a 2 c 1 g 2 t
              Query Match          1.1%; Score 13.4; DB 1; Length 17;
              Best Local Similarity 93.3%; Pred. No. 3.1e+02;
              Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 825 ATCTCGGATTTT 839
Db 2 ATCTCGGATTTT 16

RESULT 232
LOCUS       AX725086                      17 bp    DNA          linear    PAT 08-MAY-2003
DEFINITION   Sequence 2773 from Patent WO03025176.
ACCESSION    AX725086
VERSION      AX725086.1  GI:30504429
KEYWORDS     Mus musculus (house mouse)
SOURCE       Mus musculus
ORGANISM     Mus musculus
REFERENCE    1
AUTHORS      Telerman,A., Anson,R. and Tuijnder,M.
TITLE        Sequences involved in phenomena of tumour suppression, tumour
              reversion, apoptosis and/or virus resistance and their use as
              medicines
JOURNAL      Patent: WO 03025176-A 2773 27-MAR-2003;
              Molecular Engines Laboratories (FR)
FEATURES     source
              1..17
              Location/Qualifiers
BASE COUNT   8 a 1 c 3 g 5 t
              Query Match          1.1%; Score 13.4; DB 1; Length 17;
              Best Local Similarity 93.3%; Pred. No. 3.1e+02;
              Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1237 ATTTTCATTCAGAT 1251
Db 16 ATTTTCATTCAGAT 2

RESULT 233
LOCUS       AX725462                      17 bp    DNA          linear    PAT 08-MAY-2003
DEFINITION   Sequence 3149 from Patent WO03025176.
ACCESSION    AX725462
VERSION      AX725462.1  GI:30504805
KEYWORDS     Mus musculus (house mouse)
SOURCE       Mus musculus
ORGANISM     Mus musculus
REFERENCE    1
AUTHORS      Telerman,A., Anson,R. and Tuijnder,M.
TITLE        Sequences involved in phenomena of tumour suppression, tumour
              reversion, apoptosis and/or virus resistance and their use as
              medicines
JOURNAL      Patent: WO 03025176-A 3149 27-MAR-2003;
              Molecular Engines Laboratories (FR)
FEATURES     source
              1..17
              Location/Qualifiers
BASE COUNT   12 a 2 c 1 g 2 t
              Query Match          1.1%; Score 13.4; DB 1; Length 17;
              Best Local Similarity 93.3%; Pred. No. 3.1e+02;
              Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 424 TGAAGATGCCAGTGA 438
Db 17 TGAAGATGCCGTGA 3
```


AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
 TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
 JOURNAL Patent: WO 03025176-A 3149 27-MAR-2003;
 Molecular Engines Laboratories (FR)
 FEATURES Location/Qualifiers
 source 1..17
 /organism="Mus musculus"
 /mol_type="genomic DNA"
 /db_xref="taxon:10090"
 6 a 4 c 1 g 6 t
 BASE COUNT 6 a 4 c 1 g 6 t
 Query Match 1.1%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 3.1e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 458 TCAACACTTCATGTA 472
 Db 3 TCAACACTTCATGTA 17
 RESULT 234
 AX728738
 LOCUS 17 bp DNA linear PAT 08-MAY-2003
 DEFINITION Sequence 372 from Patent WO03025175.
 ACCESSION AX728738
 VERSION AX728738.1 GI:30508081
 KEYWORDS Homo sapiens (human)
 SOURCE Homo sapiens
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1
 AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
 TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
 JOURNAL Patent: WO 03025175-A 372 27-MAR-2003;
 Molecular Engines Laboratories (FR)
 FEATURES Location/Qualifiers
 source 1..17
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"
 8 a 3 c 3 t
 BASE COUNT 8 a 3 c 3 t
 Query Match 1.1%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 3.1e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 534 TCAGTAACCAATGAA 548
 Db 3 TCAGTAACCAATGAA 17
 RESULT 235
 AX729041/c
 LOCUS 17 bp DNA linear PAT 08-MAY-2003
 DEFINITION Sequence 675 from Patent WO03025175.
 ACCESSION AX729041
 VERSION AX729041.1 GI:30508384
 KEYWORDS Homo sapiens (human)
 SOURCE Homo sapiens
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1
 AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
 TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
 JOURNAL Patent: WO 03025175-A 675 27-MAR-2003;

FEATURES Molecular Engines Laboratories (FR)
 source 1..17
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"
 9 a 1 c 3 g 4 t
 BASE COUNT 9 a 1 c 3 g 4 t
 Query Match 1.1%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 3.1e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1237 ATTTCATTTCAGAT 1251
 Db 16 ATTTCATTTCAGAT 2
 RESULT 236
 AX733613
 LOCUS 17 bp DNA linear PAT 08-MAY-2003
 DEFINITION Sequence 5247 from Patent WO03025175.
 ACCESSION AX733613
 VERSION AX733613.1 GI:30512956
 KEYWORDS Homo sapiens (human)
 SOURCE Homo sapiens
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1
 AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
 TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
 JOURNAL Patent: WO 03025175-A 5247 27-MAR-2003;
 Molecular Engines Laboratories (FR)
 FEATURES Location/Qualifiers
 source 1..17
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"
 6 a 1 c 2 g 8 t
 BASE COUNT 6 a 1 c 2 g 8 t
 Query Match 1.1%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 3.1e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1149 TTATTTTAGATATTA 1163
 Db 3 TCATTTTAGATATTA 17
 RESULT 237
 AX736985
 LOCUS 17 bp DNA linear PAT 08-MAY-2003
 DEFINITION Sequence 2575 from Patent WO03025177.
 ACCESSION AX736985
 VERSION AX736985.1 GI:30516273
 KEYWORDS Homo sapiens (human)
 SOURCE Homo sapiens
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1
 AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
 TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments
 JOURNAL Patent: WO 03025177-A 2575 27-MAR-2003;
 Molecular Engines Laboratories (FR)
 FEATURES Location/Qualifiers
 source 1..17
 /organism="Homo sapiens"
 /mol_type="genomic DNA"

```

BASE COUNT      8 a      2 c      3 g      4 t
Query Match      1.1%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 534 TCAGTAAACAAATGAA 548
Db 3 TCAGTATACAAATGAA 17

RESULT 238
AX738625
LOCUS AX738625
DEFINITION Sequence 4215 from Patent WO03025177.
ACCESSION AX738625
VERSION AX738625.1 GI:30517915
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Telerman,A., Anson,R. and Tuijinder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL Patent: WO 03025177-A 4215 27-MAR-2003;
FEATURES Molecular Engines Laboratories (PR)
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT      8 a      3 c      3 g      3 t
Query Match      1.1%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 534 TCAGTAAACAAATGAA 548
Db 3 TCAGTATACAAATGAA 17

RESULT 239
I04892/c
LOCUS I04892
DEFINITION Sequence 16 from Patent EP 0215594.
ACCESSION I04892
VERSION I04892.1 GI:591423
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE
AUTHORS Berka,R.M., Cullen,D., Gray,G.L., Hayenga,K.J. and Lawlis,V.B.
TITLE Heterologous polypeptide expressed in filamentous fungi, processes
for their preparation, and vectors for their preparation
JOURNAL Patent: EP 0215594-A2 16 25-MAR-1987;
FEATURES Location/Qualifiers
1..17
/organism="unknown"
BASE COUNT     11 a      2 c      0 g      4 t
Query Match      1.1%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1047 TTTATGTATTATTAT 1061
Db 17 TTTATGTATTATTAT 3

/ db_xref="taxon:9606"
4 t
Query Match      1.1%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 534 TCAGTAAACAAATGAA 548
Db 3 TCAGTATACAAATGAA 17

RESULT 240
I04892/c
LOCUS I04892
DEFINITION Sequence 54 from patent US 5589330.
ACCESSION I04892
VERSION I04892.1 GI:1823381
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE
AUTHORS Shuber,A.P.
TITLE High-throughput screening method for sequence or genetic
alterations in nucleic acids using elution and sequencing of
complementary oligonucleotides
JOURNAL Patent: US 5589330-A 54 31-DEC-1996;
FEATURES Location/Qualifiers
1..17
source /organism="unknown"
BASE COUNT      1 a      1 c      3 g      12 t
Query Match      1.1%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1207 AACAAACAAACAAAT 1221
Db 16 AACAAACAAACAAAT 2

RESULT 241
I53229/c
LOCUS I53229
DEFINITION Sequence 970 from patent US 5646042.
ACCESSION I53229
VERSION I53229.1 GI:2474432
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myb targeted ribozymes
JOURNAL Patent: US 5646042-A 970 08-JUL-1997;
FEATURES Location/Qualifiers
1..17
source /organism="unknown"
BASE COUNT      8 a      0 c      0 g      9 t
Query Match      1.1%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1617 AAAATATATTTTGT 1631
Db 16 AAAATATATTTT 2

RESULT 242
I54310/c
LOCUS I54310
DEFINITION Sequence 2051 from patent US 5646042.
ACCESSION I54310
VERSION I54310.1 GI:2475513
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myb targeted ribozymes
```

```
JOURNAL Patent: US 5646042-A 2051 08-JUL-1997;
FEATURES
  source
    1.17
  /organism="unknown"
BASE COUNT      8 a      0 c      1 g      8 t
Query Match
  Best Local Similarity 1.1%; Score 13.4; DB 1; Length 17;
  Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1617 AAAATATAATTTGTT 1631
Db 16 AAAATATAATTTT 2
RESULT 243
AR087081
LOCUS AR087081 18 bp DNA linear PAT 07-SEP-2000
DEFINITION Sequence 31 from patent US 5985664.
ACCESSION AR087081
VERSION AR087081.1 GI:10013847
KEYWORDS
SOURCE
ORGANISM
REFERENCE
  1 (bases 1 to 18)
AUTHORS Baker,B.F. and Cowser,L.M.
TITLE Antisense modulation of Sentrin expression
JOURNAL Patent: US 5985664-A 31 16-NOV-1999;
FEATURES
  source
    1.18
  /organism="unknown"
BASE COUNT      8 a      4 c      1 g      5 t
Query Match
  Best Local Similarity 1.1%; Score 13.4; DB 1; Length 18;
  Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1179 GATAAATTCATCA 1193
Db 1 GATAAATTCATCA 15
RESULT 244
AR165969
LOCUS AR165969 18 bp DNA linear PAT 17-OCT-2001
DEFINITION Sequence 22 from patent US 6280942.
ACCESSION AR165969
VERSION AR165969.1 GI:16241085
KEYWORDS
SOURCE
ORGANISM
REFERENCE
  1 (bases 1 to 18)
AUTHORS Morishima,N., Mizumura,H. and Shibata,T.
TITLE Endonuclease
JOURNAL Patent: US 6280942-A 22 28-AUG-2001;
FEATURES
  source
    1.18
  /organism="unknown"
BASE COUNT      4 a      1 c      4 g      9 t
Query Match
  Best Local Similarity 1.1%; Score 13.4; DB 1; Length 18;
  Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1282 ATTATGTTTATCTG 1296
Db 3 ATTATGTTTATCTG 17
RESULT 245
AR285276
LOCUS AR285276 18 bp DNA linear PAT 10-APR-2003
DEFINITION Sequence 22 from patent US 6528296.
ACCESSION AR285276
VERSION AR285276.1 GI:29722376
KEYWORDS
SOURCE
ORGANISM
REFERENCE
  1 (bases 1 to 18)
AUTHORS Morishima,N., Mizumura,H. and Shibata,T.
TITLE Endonuclease
JOURNAL Patent: US 6528296-A 22 04-MAR-2003;
FEATURES
  source
    1.18
  /organism="unknown"
BASE COUNT      4 a      1 c      4 g      9 t
Query Match
  Best Local Similarity 1.1%; Score 13.4; DB 1; Length 18;
  Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1282 ATTATGTTTATCTG 1296
Db 3 ATTATGTTTATCTG 17
RESULT 246
AX032800
LOCUS AX032800 18 bp DNA linear PAT 21-SEP-2000
DEFINITION Sequence 40 from patent WO046358.
ACCESSION AX032800
VERSION AX032800.1 GI:10279776
KEYWORDS
SOURCE
ORGANISM
REFERENCE
  1
AUTHORS Dean,C., West,J. and Johanson,U.
TITLE Plant Gene
JOURNAL Patent: WO 0046358-A 40 10-AUG-2000;
DEAN CAROLINE (GB) ; WEST JOANNE (GB) ; PLANT BIOSCIENCE LTD (GB) ;
JOHANSON URBAN (SE)
FEATURES
  source
    1.18
  /organism="synthetic construct"
  /mol_type="genomic DNA"
  /db_xref="taxon:32630"
  /notes="Primer"
BASE COUNT      3 a      4 c      3 g      8 t
Query Match
  Best Local Similarity 1.1%; Score 13.4; DB 1; Length 18;
  Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1545 TTTTATGTCCTCTCC 1559
Db 4 TTTGATGTCCTCTCC 18
RESULT 247
AX092726
LOCUS AX092726 18 bp DNA linear PAT 21-MAR-2001
DEFINITION Sequence 138 from Patent WO0115676.
ACCESSION AX092726
VERSION AX092726.1 GI:13444783
KEYWORDS
SOURCE
ORGANISM
REFERENCE
  1
AUTHORS Hayden,M.R., Brooks-Wilson,A.R., Pimstone,S.N. and Clee,S.M.
TITLE Compositions and methods for modulating hdl cholesterol and
```

triglyceride levels
Patent: WO 0115676-A 138 08-MAR-2001; Xenon Genetics Inc. (CA)
University of British Columbia (CA); Xenon Genetics Inc. (CA)
JOURNAL
FEATURES
source
1. .18
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
10 a 1 c 5 g 2 t

Query Match 1.1%; Score 13.4; DB 1; Length 18;
Best Local Similarity 93.3%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

BASE COUNT 10 a 1 c 5 g 2 t

QY 705 AAGAGAAATATCGAA 719
Db 2 AAGAGAAATATCGAA 16

RESULT 248
AX643248/c
LOCUS
DEFINITION
Sequence 114 from Patent WO2099099.
ACCESSION
AX643248
VERSION
AX643248.1 GI:28550445
KEYWORDS
synthetic construct
artificial sequences.
ORGANISM
Penger, A., Sprenger, R. and Brinkmann, U.
AUTHORS
Polymorphisms in the human gene for cytochrome p450 polypeptide 2c8
and their use in diagnostic and therapeutic applications
TITLE
Patent: WO 02099099-A 114 12-DEC-2002;
JOURNAL
Epidaurus Biotechnologie AG (DE)
FEATURES
source
1. .18
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
4 a 0 c 3 g 11 t

BASE COUNT 4 a 0 c 3 g 11 t

Query Match 1.1%; Score 13.4; DB 1; Length 18;
Best Local Similarity 93.3%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 998 CATCAATACATAAAT 1012
Db 17 CATATAACATAAAT 3

RESULT 249
AX643251
LOCUS
DEFINITION
Sequence 117 from Patent WO2099099.
ACCESSION
AX643251
VERSION
AX643251.1 GI:28550449
KEYWORDS
synthetic construct
artificial sequences.
ORGANISM
Penger, A., Sprenger, R. and Brinkmann, U.
AUTHORS
Polymorphisms in the human gene for cytochrome p450 polypeptide 2c8
and their use in diagnostic and therapeutic applications
TITLE
Patent: WO 02099099-A 117 12-DEC-2002;
JOURNAL
Epidaurus Biotechnologie AG (DE)
FEATURES
source
1. .18
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
11 a 3 c 0 g 4 t

BASE COUNT 11 a 3 c 0 g 4 t

Query Match 1.1%; Score 13.4; DB 1; Length 18;
Best Local Similarity 93.3%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 998 CATCAATACATAAAT 1012
Db 2 CATATAACATAAAT 16

RESULT 250
E60081
LOCUS
DEFINITION
Endonuclease.
ACCESSION
E60081
VERSION
E60081.1 GI:13023331
KEYWORDS
JP 2000041686-A/21
SOURCE
synthetic construct
artificial sequences.
ORGANISM
Nobuhiro, M., Hikaru, M. and Takehiko, S.
REFERENCE
1 (bases 1 to 18)
AUTHORS
Nobuhiro, M., Hikaru, M. and Takehiko, S.
TITLE
Patent: JP 2000041686-A 21 15-FEB-2000;
JOURNAL
RIXAGAKU KENKYUSHO
COMMENT
OS Artificial Sequence
PN JP 2000041686-A/21
PD 15-FEB-2000
PF 24-MAY-1999 JP 1999144005
PR
PI NOBUHIRO MORISHIMA, HIKARU WIZUMURA, TAKEHIKO SHIBATA PC
C12N15/09, C12N1/15, C12N1/19, C12N1/21, C12N5/10, C12N9/16// PC
C12N15/16, C12R1/19, C12N15/00, C12N5/00
CC
FH Key Location/Qualifiers
FT source 1. .18
/organism="Artificial Sequence".

FEATURES
source
1. .18
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
4 a 1 c 4 g 9 t

BASE COUNT 4 a 1 c 4 g 9 t

Query Match 1.1%; Score 13.4; DB 1; Length 18;
Best Local Similarity 93.3%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1282 ATTATTGTTATCTG 1296
Db 3 ATTATTGTTATCTG 17

RESULT 251
AR293234
LOCUS
DEFINITION
Sequence 4969 from patent US 6537751.
ACCESSION
AR293234
VERSION
AR293234.1 GI:31680518
KEYWORDS
Unknown.
SOURCE
Unknown.
ORGANISM
Unclassified.
REFERENCE
1 (bases 1 to 19)
AUTHORS
Cohen, D., Chumakov, I. and Blumenfeld, M.
TITLE
Biallelic markers for use in constructing a high density
disequilibrium map of the human genome
JOURNAL
Patent: US 6537751-A 4969 25-MAR-2003;
FEATURES
source
1. .19
/organism="unknown"
2 a 5 c 2 g 10 t

BASE COUNT 2 a 5 c 2 g 10 t

Query Match 1.1%; Score 13.4; DB 1; Length 19;
 Best Local Similarity 93.3%; Pred. No. 3.7e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1567 TTTTACTGTTCTCA 1581
 |||||
 Db 1 TTTTACTGTTCTCA 15

RESULT 252
 AX079136/c
 LOCUS 19 bp DNA linear PAT 22-FEB-2001
 DEFINITION Sequence 16 from Patent WO0106004.
 ACCESSION AX079136
 VERSION AX079136.1 GI:13158709
 KEYWORDS synthetic construct
 ORGANISM synthetic construct
 SOURCE artificial sequences.
 REFERENCE 1
 AUTHORS Richardson,P. and Cox,P.
 TITLE A method for amplifying low abundance nucleic acid sequences and means for performing said method
 JOURNAL Patent: WO 0106004-A 16 25-JAN-2001;
 CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LIMITED (GB)
 FEATURES Location/Qualifiers
 1..19
 /organism="synthetic construct"
 /mol_type="genomic DNA"
 /db_xref="taxon:32630"
 /note="oligonucleotide"
 BASE COUNT 6 a 6 c 4 g 3 t

Query Match 1.1%; Score 13.4; DB 1; Length 19;
 Best Local Similarity 93.3%; Pred. No. 3.7e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1348 GCCAGCTGTTCTGT 1362
 |||||
 Db 19 GCCAGCTTCTGT 5

RESULT 253
 AX130601/c
 LOCUS 19 bp DNA linear PAT 15-MAY-2001
 DEFINITION Sequence 1819 from Patent WO0130362.
 ACCESSION AX130601
 VERSION AX130601.1 GI:14136906
 KEYWORDS Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1
 AUTHORS Robbins,J.M. and Tritz,R.
 TITLE Ribozyme therapy for the treatment of proliferative skin and eye diseases
 JOURNAL Patent: WO 0130362-A 1819 03-MAY-2001;
 IMMUSOL, INC. (US)
 FEATURES Location/Qualifiers
 1..19
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"
 /note="Cyclin C ribozyme binding site"
 BASE COUNT 8 a 3 c 4 g 4 t

Query Match 1.1%; Score 13.4; DB 1; Length 19;
 Best Local Similarity 93.3%; Pred. No. 3.7e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 913 TTTTATTCTAAGTGG 927
 |||||

Db 19 TTTATTCCAACTGG 5

RESULT 254
 AX149204/c
 LOCUS 19 bp DNA linear PAT 08-JUN-2001
 DEFINITION Sequence 406 from Patent WO0136625.
 ACCESSION AX149204
 VERSION AX149204.1 GI:14347728
 KEYWORDS synthetic construct
 ORGANISM synthetic construct
 SOURCE artificial sequences.
 REFERENCE 1
 AUTHORS Wright,J.A., Young,A.H. and Dugourd,D.
 TITLE Antisense oligonucleotide sequences derived from groel and groes as inhibitors of microorganisms
 JOURNAL Patent: WO 0136625-A 406 25-MAY-2001;
 GeneSense Technologies Inc. (CA)
 FEATURES Location/Qualifiers
 1..19
 /organism="synthetic construct"
 /mol_type="genomic DNA"
 /db_xref="taxon:32630"
 /note="Antisense oligonucleotide"
 BASE COUNT 6 a 1 c 0 g 12 t

Query Match 1.1%; Score 13.4; DB 1; Length 19;
 Best Local Similarity 93.3%; Pred. No. 3.7e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1591 AATATAAAAGTAAAT 1605
 |||||
 Db 15 AATATAAAATTAAT 1

RESULT 255
 AX183607
 LOCUS 19 bp DNA linear PAT 06-AUG-2001
 DEFINITION Sequence 1360 from Patent WO0142511.
 ACCESSION AX183607
 VERSION AX183607.1 GI:15134927
 KEYWORDS Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1
 AUTHORS Daly,M., Hudson,T.J., Lander,E.S., Rioux,J. and Siminovitch,K.
 TITLE Ibd-related polymorphisms
 JOURNAL Patent: WO 0142511-A 1360 14-JUN-2001;
 WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) ; Ellipsis
 Biotherapeutics Corporation (CA)
 FEATURES Location/Qualifiers
 1..19
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"
 BASE COUNT 5 a 1 g 12 t 1 others

Query Match 1.1%; Score 13.4; DB 1; Length 19;
 Best Local Similarity 87.5%; Pred. No. 3.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1140 AAATTATTATTATT 1155
 |||||
 Db 4 AAATTATTATTATT 19

RESULT 256
 I31433/c
 LOCUS 19 bp DNA linear PAT 06-FEB-1997
 DEFINITION Sequence 345 from patent US 5562979.

Accession	Version	Keywords	Source	Organism	Reference	Authors	Title	Journal	Features	Base Count	Query Match	Best Local Similarity	Mismatches	Indels	Gaps	Length
131433	1	GI:1822224	Unknown	Unknown	Unclassified	1 (bases 1 to 19)	Length polymorphisms in (dC-da).sub.n.(dG-dT).sub.n sequences and method of using the same	Patent: US 5582979-A 345 10-DEC-1996;	Location/Qualifiers	1..19	Score 13.4; DB 1; Length 19;	93.3%; Pred. No. 3.7e+02;	0; Mismatches 1;	Indels 0;	Gaps 0;	
ACCESSION	131433.1	GI:1822224	Unknown	Unknown	Unclassified	1 (bases 1 to 19)	Length polymorphisms in (dC-da).sub.n.(dG-dT).sub.n sequences and method of using the same	Patent: US 5582979-A 345 10-DEC-1996;	Location/Qualifiers	1..19	Score 13.4; DB 1; Length 19;	93.3%; Pred. No. 3.7e+02;	0; Mismatches 1;	Indels 0;	Gaps 0;	
VERSION	131433.1	GI:1822224	Unknown	Unknown	Unclassified	1 (bases 1 to 19)	Length polymorphisms in (dC-da).sub.n.(dG-dT).sub.n sequences and method of using the same	Patent: US 5582979-A 345 10-DEC-1996;	Location/Qualifiers	1..19	Score 13.4; DB 1; Length 19;	93.3%; Pred. No. 3.7e+02;	0; Mismatches 1;	Indels 0;	Gaps 0;	
KEYWORDS	131433.1	GI:1822224	Unknown	Unknown	Unclassified	1 (bases 1 to 19)	Length polymorphisms in (dC-da).sub.n.(dG-dT).sub.n sequences and method of using the same	Patent: US 5582979-A 345 10-DEC-1996;	Location/Qualifiers	1..19	Score 13.4; DB 1; Length 19;	93.3%; Pred. No. 3.7e+02;	0; Mismatches 1;	Indels 0;	Gaps 0;	
SOURCE	131433.1	GI:1822224	Unknown	Unknown	Unclassified	1 (bases 1 to 19)	Length polymorphisms in (dC-da).sub.n.(dG-dT).sub.n sequences and method of using the same	Patent: US 5582979-A 345 10-DEC-1996;	Location/Qualifiers	1..19	Score 13.4; DB 1; Length 19;	93.3%; Pred. No. 3.7e+02;	0; Mismatches 1;	Indels 0;	Gaps 0;	
ORGANISM	131433.1	GI:1822224	Unknown	Unknown	Unclassified	1 (bases 1 to 19)	Length polymorphisms in (dC-da).sub.n.(dG-dT).sub.n sequences and method of using the same	Patent: US 5582979-A 345 10-DEC-1996;	Location/Qualifiers	1..19	Score 13.4; DB 1; Length 19;	93.3%; Pred. No. 3.7e+02;	0; Mismatches 1;	Indels 0;	Gaps 0;	
REFERENCE	131433.1	GI:1822224	Unknown	Unknown	Unclassified	1 (bases 1 to 19)	Length polymorphisms in (dC-da).sub.n.(dG-dT).sub.n sequences and method of using the same	Patent: US 5582979-A 345 10-DEC-1996;	Location/Qualifiers	1..19	Score 13.4; DB 1; Length 19;	93.3%; Pred. No. 3.7e+02;	0; Mismatches 1;	Indels 0;	Gaps 0;	
AUTHORS	131433.1	GI:1822224	Unknown	Unknown	Unclassified	1 (bases 1 to 19)	Length polymorphisms in (dC-da).sub.n.(dG-dT).sub.n sequences and method of using the same	Patent: US 5582979-A 345 10-DEC-1996;	Location/Qualifiers	1..19	Score 13.4; DB 1; Length 19;	93.3%; Pred. No. 3.7e+02;	0; Mismatches 1;	Indels 0;	Gaps 0;	
TITLE	131433.1	GI:1822224	Unknown	Unknown	Unclassified	1 (bases 1 to 19)	Length polymorphisms in (dC-da).sub.n.(dG-dT).sub.n sequences and method of using the same	Patent: US 5582979-A 345 10-DEC-1996;	Location/Qualifiers	1..19	Score 13.4; DB 1; Length 19;	93.3%; Pred. No. 3.7e+02;	0; Mismatches 1;	Indels 0;	Gaps 0;	
JOURNAL	131433.1	GI:1822224	Unknown	Unknown	Unclassified	1 (bases 1 to 19)	Length polymorphisms in (dC-da).sub.n.(dG-dT).sub.n sequences and method of using the same	Patent: US 5582979-A 345 10-DEC-1996;	Location/Qualifiers	1..19	Score 13.4; DB 1; Length 19;	93.3%; Pred. No. 3.7e+02;	0; Mismatches 1;	Indels 0;	Gaps 0;	
FEATURES	131433.1	GI:1822224	Unknown	Unknown	Unclassified	1 (bases 1 to 19)	Length polymorphisms in (dC-da).sub.n.(dG-dT).sub.n sequences and method of using the same	Patent: US 5582979-A 345 10-DEC-1996;	Location/Qualifiers	1..19	Score 13.4; DB 1; Length 19;	93.3%; Pred. No. 3.7e+02;	0; Mismatches 1;	Indels 0;	Gaps 0;	
BASE COUNT	131433.1	GI:1822224	Unknown	Unknown	Unclassified	1 (bases 1 to 19)	Length polymorphisms in (dC-da).sub.n.(dG-dT).sub.n sequences and method of using the same	Patent: US 5582979-A 345 10-DEC-1996;	Location/Qualifiers	1..19	Score 13.4; DB 1; Length 19;	93.3%; Pred. No. 3.7e+02;	0; Mismatches 1;	Indels 0;	Gaps 0;	
Query Match	131433.1	GI:1822224	Unknown	Unknown	Unclassified	1 (bases 1 to 19)	Length polymorphisms in (dC-da).sub.n.(dG-dT).sub.n sequences and method of using the same	Patent: US 5582979-A 345 10-DEC-1996;	Location/Qualifiers	1..19	Score 13.4; DB 1; Length 19;	93.3%; Pred. No. 3.7e+02;	0; Mismatches 1;	Indels 0;	Gaps 0;	
Best Local Similarity	131433.1	GI:1822224	Unknown	Unknown	Unclassified	1 (bases 1 to 19)	Length polymorphisms in (dC-da).sub.n.(dG-dT).sub.n sequences and method of using the same	Patent: US 5582979-A 345 10-DEC-1996;	Location/Qualifiers	1..19	Score 13.4; DB 1; Length 19;	93.3%; Pred. No. 3.7e+02;	0; Mismatches 1;	Indels 0;	Gaps 0;	
Mismatches	131433.1	GI:1822224	Unknown	Unknown	Unclassified	1 (bases 1 to 19)	Length polymorphisms in (dC-da).sub.n.(dG-dT).sub.n sequences and method of using the same	Patent: US 5582979-A 345 10-DEC-1996;	Location/Qualifiers	1..19	Score 13.4; DB 1; Length 19;	93.3%; Pred. No. 3.7e+02;	0; Mismatches 1;	Indels 0;	Gaps 0;	
Indels	131433.1	GI:1822224	Unknown	Unknown	Unclassified	1 (bases 1 to 19)	Length polymorphisms in (dC-da).sub.n.(dG-dT).sub.n sequences and method of using the same	Patent: US 5582979-A 345 10-DEC-1996;	Location/Qualifiers	1..19	Score 13.4; DB 1; Length 19;	93.3%; Pred. No. 3.7e+02;	0; Mismatches			

Db 1 TATGTAGATGATATAGTA 18

RESULT 261
A81026
LOCUS 18 bp DNA linear PAT 21-JAN-2000
DEFINITION Sequence 5 from Patent EP0916726.
ACCESSION A81026
VERSION A81026.1 GI:6731598
KEYWORDS
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS
TITLE Attaching substances to micro-organisms
JOURNAL Patent: EP 0916726-A 5 19-MAY-1999;
UNIV GRONINGEN (NL)
FEATURES
source 1. .18
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644" 7 t

BASE COUNT 7 a 2 c 2 g 7 t

Query Match 1.1%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 3.8e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1313 AACAACTCCTAGTTTGATA 1330
Db 1 AGCAACTACTAGTTTATA 18

RESULT 262
A95480
LOCUS 18 bp DNA linear PAT 26-JAN-2000
DEFINITION Sequence 5 from Patent WO9925836.
ACCESSION A95480
VERSION A95480.1 GI:6779514
KEYWORDS
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Leenhouts, C.J. and Buist, G.
TITLE ATTACHING SUBSTANCES TO MICRO-ORGANISMS
JOURNAL Patent: WO 9925836-A 5 27-MAY-1999;
LEENHOUTS CORNELIS JOHANNES (NL); BUIST GIRBE (NL)
FEATURES
source 1. .18
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644" 7 t

BASE COUNT 7 a 2 c 2 g 7 t

Query Match 1.1%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 3.8e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1313 AACAACTCCTAGTTTGATA 1330
Db 1 AGCAACTACTAGTTTATA 18

RESULT 263
AR130089/c
LOCUS 18 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 81 from patent US 6187586.
ACCESSION AR130089
VERSION AR130089.1 GI:14117986
KEYWORDS
SOURCE Unknown.

ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Monia, B.P., Cowsett, L.M. and Roth, R.A.
TITLE Antisense modulation of AKT-3 expression
JOURNAL Patent: US 6187586-A 81 13-FEB-2001;
FEATURES
source 1. .18
/organism="unknown"
BASE COUNT 3 a 3 c 1 g 11 t

Query Match 1.1%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 3.8e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1596 AAAAGTAAATATGAACA 1613
Db 18 AAAGAAATTATGACACA 1

RESULT 264
AR208426/c
LOCUS 18 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 6 from patent US 6383754.
ACCESSION AR208426
VERSION AR208426.1 GI:21509577
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Kaufman, J.C., Roth, M.B., Lizardi, P.M., Peng, L. and Latimer, D.R.
TITLE Binary encoded sequence tags
JOURNAL Patent: US 6383754-A 6 07-MAY-2002;
FEATURES
source 1. .18
/organism="unknown"
BASE COUNT 0 a 0 c 1 g 17 t

Query Match 1.1%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 3.8e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 616 ACACAAAACACACAAATAA 633
Db 18 ACACAAAACACACAAATAA 1

RESULT 265
AR222905
LOCUS 18 bp DNA linear PAT 26-SEP-2002
DEFINITION Sequence 15 from patent US 6432639.
ACCESSION AR222905
VERSION AR222905.1 GI:23330742
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Lichter, J.B. and Guida, M.
TITLE Isolated CYP3A4 nucleic acid molecules and detection methods
JOURNAL Patent: US 6432639-A 15 13-AUG-2002;
FEATURES
source 1. .18
/organism="unknown"
BASE COUNT 10 a 2 c 6 g 0 t

Query Match 1.1%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 3.8e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 414 CAGATCAGTGAATG 431

Db 1 CAAGAAACAGAGAGAGG 18

RESULT 266
LOCUS AR222919 18 bp DNA linear PAT 26-SEP-2002
DEFINITION Sequence 29 from patent US 6432639.
ACCESSION AR222919
VERSION AR222919.1 GI:23330756
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Lichter,J.B. and Guida,M.
TITLE Isolated CYP3A4 nucleic acid molecules and detection methods
JOURNAL Patent: US 6432639-A 29 13-AUG-2002;
FEATURES Location/Qualifiers
1..18
/organism="unknown"
BASE COUNT 10 a 2 c 6 g 0 t

Query Match 1.1%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 3.8e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 414 CAAGATCTGTCAGATG 431
|||||
Db 1 CAAGAAACAGAGAGAGG 18

RESULT 267
LOCUS AR241972 18 bp DNA linear PAT 20-DEC-2002
DEFINITION Sequence 260 from patent US 6472154.
ACCESSION AR241972
VERSION AR241972.1 GI:27287784
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Garner,H.R., Wren,J.D., Minna,J.D. and Fondon,J.W. III.
TITLE Polymorphic repeats in human genes
JOURNAL Patent: US 6472154-A 260 29-OCT-2002;
FEATURES Location/Qualifiers
1..18
/organism="unknown"
BASE COUNT 5 a 2 c 5 g 6 t

Query Match 1.1%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 3.8e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 819 CTGGAATCTGGATTTT 836
|||||
Db 1 CTGGAACATCGGATTTT 18

RESULT 268
LOCUS AR293701/c 18 bp DNA linear PAT 12-JUN-2003
DEFINITION Sequence 5436 from patent US 6537751.
ACCESSION AR293701
VERSION AR293701.1 GI:31680985
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Cohen,D., Chumakov,I. and Blumenfeld,M.
TITLE Biallelic markers for use in constructing a high density disequilibrium map of the human genome

JOURNAL Patent: US 6537751-A 5436 25-MAR-2003;
FEATURES Location/Qualifiers
1..18
/organism="unknown"
BASE COUNT 5 a 6 c 2 g 5 t

Query Match 1.1%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 3.8e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 421 CAGTCAGATGCCAGTGA 438
|||||
Db 18 CAGTGAAGGTGTCTAGTTA 1

RESULT 269
LOCUS AX085252 18 bp DNA linear PAT 09-MAR-2001
DEFINITION Sequence 6 from Patent WO0112855.
ACCESSION AX085252
VERSION AX085252.1 GI:13275310
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Kaufman,J.C., Roth,M.E., Lizardi,P.M., Peng,L. and Latimer,D.R.
TITLE Binary encoded sequence tags
JOURNAL Patent: WO 0112855-A 6 22-FEB-2001;
YALE UNIVERSITY (US)
FEATURES Location/Qualifiers
1..18
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/note="Primer"
BASE COUNT 0 a 0 c 1 g 17 t

Query Match 1.1%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 3.8e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 616 ACAAAAACACACAAATAA 633
|||||
Db 18 ACAAAAACACACAAATAA 1

RESULT 270
LOCUS AX571969 18 bp DNA linear PAT 29-NOV-2002
DEFINITION Sequence 9 from Patent WO02055741.
ACCESSION AX571969
VERSION AX571969.1 GI:26004059
KEYWORDS
SOURCE Human immunodeficiency virus
ORGANISM Human immunodeficiency virus
REFERENCE 1
AUTHORS de Smet,K. and Stuyver,L.
TITLE Method for detection of drug-induced mutations in the hiv reverse transcriptase gene
JOURNAL Patent: WO 02055741-A 9 18-JUL-2002;
INNOGENETICS N.V. (BE)
FEATURES Location/Qualifiers
1..18
/organism="Human immunodeficiency virus"
/mol_type="genomic DNA"
/db_xref="taxon:12721"
BASE COUNT 11 a 2 c 2 g 3 t

Query Match 1.1%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 3.8e+02;


```

Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1570 TACTGTTCTGATGAT 1587
    |||||
Db 18 TACTGTTCTGATTTT 1

RESULT 271
AX599270
LOCUS AX599270 18 bp DNA linear PAT 14-FEB-2003
DEFINITION Sequence 610 from Patent WO02077272.
ACCESSION AX599270
VERSION AX599270.1 GI:28399412
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1
AUTHORS Berlin,K., Braun,A., Distler,J., Guetig,D., Howe,A., Mueller,J.,
Olek,A., Piepenbrock,C., Adorjan,P., Grabe,G., Lesche,R., Ieu,R.,
Lewin,A., Lipscher,R., Maier,S., Model,F., Mueller,V., Otto,T.,
Pelet,C. and Ziebarth,H.
TITLE Methods and nucleic acids for the analysis of hematopoietic cell
proliferative disorders
JOURNAL Patent: WO 02077272-A 610 03-OCT-2002;
Epigenomics AG (DE)
FEATURES
source
1. .18
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/notes="Detection oligonucleotide for MYOD1"
BASE COUNT 7 a 0 c 4 g 7 t

Query Match 1.1%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 3.8e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1457 GTTATTATGACAAATA 1474
    |||||
Db 1 GGTATTATGACAAATA 18

RESULT 272
BD104062
LOCUS BD104062 18 bp DNA linear PAT 27-AUG-2002
DEFINITION Kit and method for determining HLA type.
ACCESSION BD104062
VERSION BD104062.1 GI:22649636
KEYWORDS WO 0192572-A/166.
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1 (bases 1 to 18)
AUTHORS Inoko,H., Kagiya,T., Ichihara,T., Matsumura,Y., Moriya,S. and
Nishida,M.
TITLE Kit and method for determining HLA type
JOURNAL Patent: WO 0192572-A 166 06-DEC-2001;
NISHINOBO INDUSTRIES INC.SYSTEM RESEARCH INC.HIDETOSHI INOKO, TAEKO
KAGIYA, TATSUO ICHIHARA, YOSHIYUKI MATSUMURA, SHOGO MORIYA, MICHIO
NISHIDA
COMMENT OS Artificial Sequence
PN WO 0192572-A/166
PD 06-DEC-2001
PF 01-JUN-2001 WO 2001JP004662
PR 01-JUN-2000 JP OOP 164798
PI HIDETOSHI INOKO, TAEKO KAGIYA, TATSUO ICHIHARA, YOSHIYUKI PI
MATSUMURA,
PI SHOGO MORIYA, MICHIO NISHIDA
PC C12Q1/68, C12M1/00, C12N15/09, G01N33/53
CC Description of Artificial Sequence:capture
FH Key Location/Qualifiers
FT source 1. .18

```

```

FEATURES
source
Location/Qualifiers
1. .18
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
BASE COUNT 5 a 2 c 4 g 7 t

Query Match 1.1%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 3.8e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 519 GCTTAAATTCGATTTCA 536
    |||||
Db 1 GCTTAAATTCGATTTCA 18

RESULT 273
I25305/c
LOCUS I25305 18 bp DNA linear PAT 07-OCT-1996
DEFINITION Sequence 92 from patent US 5550020.
ACCESSION I25305
VERSION I25305.1 GI:1605175
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Gallie,B.L., Dunn,J.M. and Stevens,J.K.
TITLE Method, reagents and kit for diagnosis and targeted screening for
retinoblastoma
JOURNAL Patent: US 5550020-A 92 27-AUG-1996;
FEATURES
source
Location/Qualifiers
1. .18
/organism="unknown"
BASE COUNT 10 a 3 c 1 g 4 t

Query Match 1.1%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 3.8e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1566 TTTTACTGTTCTGATT 1583
    |||||
Db 18 TTTATAGTGTTCAGATT 1

RESULT 274
ATH529366
LOCUS ATH529366 18 bp DNA linear PLN 29-MAR-2003
DEFINITION Arabidopsis thaliana T-DNA flanking sequence, left border, clone
185F08.
ACCESSION AJ529366
VERSION AJ529366.1 GI:26797626
KEYWORDS left border; T-DNA flanking sequence.
SOURCE Arabidopsis thaliana (thale cress)
ORGANISM Arabidopsis thaliana
REFERENCE 1
AUTHORS Brunaud,V., Balzerque,S., Dubreucq,B., Aubourg,S., Samson,F.,
Chauvin,S., Bechtold,N., Cruaud,C., DeRose,R., Pelletier,G.,
Lepoint,L., Caboche,M. and Leclercq,A.
TITLE T-DNA integration into the Arabidopsis genome depends on sequences
of pre-insertion sites
JOURNAL EMBO Rep. 3 (12), 1152-1157 (2002)
MEDLINE 22363535
PUBMED 12446565
REFERENCE 2 (bases 1 to 18)
AUTHORS Balzerque,S.
TITLE Direct Submission
JOURNAL Submitted (21-NOV-2002) Balzerque S., UMRGV, INRA/CNRS, 2 rue
Gaston Cremieux, 91057 Evry cedex, FRANCE

```

COMMENT PCR was performed on DNA from transformants of *Arabidopsis thaliana* plants from INRA (Versailles). The DNA fragment(s) resulting from the PCR were directly sequenced from the left or the right border to determine the genomic sequence flanking the insertion. T-DNA derived sequences were removed. Information to order the corresponding mutant line and a link to a database providing a graphical display of the insertion site are available at <http://dbgap.versailles.inra.fr/publicines/>. This sequence has been generated in the framework of the French plant genomics program 'Genoplante' (<http://www.genoplante.com> and <http://genoplante-info.infobiogen.fr>).

FEATURES
 source
 1..18
 /organism="Arabidopsis thaliana"
 /mol_type="genomic DNA"
 /cultivar="Massiliewskijsa"
 /db_xref="taxon:3702"
 /clone="185F08"
 /clone_lib="Arabidopsis thaliana T-DNA insertion lines"
 misc_feature
 1..18
 /note="T-DNA flanking sequence
 left border"
 BASE COUNT 5 a 2 c 0 g 11 t
 Query Match 1.1%; Score 13.2; DB 1; Length 18;
 Best Local Similarity 83.3%; Pred. No. 3.8e+02;
 Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 1040 TTTATTATTATGTTT 1057
 |||||
 Db 1 TTTATTATTATCCATT 18
 |||||

RESULT 275
 YSCWTP021/c YSCWTP021 20 bp DNA linear PLN 04-AUG-1993
 LOCUS
 DEFINITION Yeast (*S.cerevisiae*) mitochondrial petite mutant excision seq 2,
 left end.
 ACCESSION J01510
 VERSION J01510.1 GI:343846
 KEYWORDS AT-rich region; GC rich region.
 SEGMENT 1 of 2
 SOURCE mitochondrion *Saccharomyces cerevisiae* (baker's yeast)
 ORGANISM
Saccharomyces cerevisiae
 Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;
 Saccharomycetales; Saccharomycetaceae; Saccharomycetes.
 REFERENCE 1 (bases 1 to 20)
 AUTHORS de Zamaroczy, M., Faugeron-Fonty, G. and Bernardi, G.
 TITLE Excision sequences in the mitochondrial genome of yeast
 JOURNAL Gene 21 (3), 193-202 (1983)
 MEDLINE 83210931
 PUBMED 6343188
 COMMENT Original source text: Yeast (*Saccharomyces cerevisiae*)
 mitochondrial DNA.
 Additional sequences reported in [1], but sequenced in earlier
 papers, appear in separate entries.
 FEATURES
 source
 1..20
 /organism="Saccharomyces cerevisiae"
 /organelle="mitochondrion"
 /mol_type="genomic DNA"
 /db_xref="taxon:4932"
 BASE COUNT 7 a 2 c 0 g 13 t
 Query Match 1.1%; Score 13.2; DB 1; Length 20;
 Best Local Similarity 83.3%; Pred. No. 4.5e+02;
 Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 1611 ACATTATAAATAATTT 1628
 |||||
 Db 20 ATATATAAATAATATAT 3
 |||||

RESULT 276
 A63576/c A63576 15 bp DNA linear PAT 12-MAR-1998
 LOCUS
 DEFINITION Sequence 17 from Patent WO9720924.
 ACCESSION A63576
 A63576.1 GI:3717231
 KEYWORDS unidentified
 SOURCE unidentified
 ORGANISM unidentified
 REFERENCE 1
 AUTHORS Scagliante, B. and Quadrioglio, F.
 TITLE A CLASS OF OLIGONUCLEOTIDES, THERAPEUTICALLY USEFUL AS ANTITUMORAL
 AGENTS
 JOURNAL Patent: WO 9720924-A 17 12-JUN-1997;
 SAICOM S R L (IT)
 COMMENT Other publication IT MI952539 19970604
 Other publication AU 1175497 19970627.
 FEATURES
 source
 1..15
 /organism="unidentified"
 /mol_type="genomic DNA"
 /db_xref="taxon:32644"
 BASE COUNT 0 a 0 c 4 g 11 t
 Query Match 1.0%; Score 13; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 3.1e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1207 AACCAACCAACA 1219
 |||||
 Db 13 AACCAACCAACA 1
 |||||

RESULT 277
 AR041398 AR041398 15 bp DNA linear PAT 29-SEP-1999
 LOCUS
 DEFINITION Sequence 188 from patent US 5811300.
 ACCESSION AR041398
 VERSION AR041398.1 GI:5961894
 KEYWORDS Unknown.
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 15)
 AUTHORS Sullivan, S., Draper, K., Kisich, K., Stinchcomb, D.T. and McSwiggen, J.
 TITLE TNP- α ribozymes
 JOURNAL Patent: US 5811300-A 188 22-SEP-1998;
 FEATURES
 source
 1..15
 /organism="unknown"
 BASE COUNT 5 a 0 c 0 g 10 t
 Query Match 1.0%; Score 13; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 3.1e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1038 TATTATTATTATTA 1050
 |||||
 Db 3 TATTATTATTATTA 15
 |||||

RESULT 278
 AR041406 AR041406 15 bp DNA linear PAT 29-SEP-1999
 LOCUS
 DEFINITION Sequence 196 from patent US 5811300.
 ACCESSION AR041406
 VERSION AR041406.1 GI:5961902
 KEYWORDS Unknown.
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 15)

AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE TNP- alpha. ribozymes
JOURNAL Patent: US 5811300-A 196 22-SEP-1998;
FEATURES Location/Qualifiers
source 1. .15
BASE COUNT 4 a 0 c 0 g 11 t
Query Match 1.0%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1038 TATTATTATTATTA 1050
Db 3 TATTATTATTATTA 15
RESULT 279
AR041915
LOCUS AR041915 15 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 705 from patent US 5811300.
ACCESSION AR041915
VERSION AR041915.1 GI:5962411
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE TNP- alpha. ribozymes
JOURNAL Patent: US 5811300-A 705 22-SEP-1998;
FEATURES Location/Qualifiers
source 1. .15
BASE COUNT 5 a 0 c 0 g 10 t
Query Match 1.0%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1038 TATTATTATTATTA 1050
Db 3 TATTATTATTATTA 15
RESULT 280
AR041930
LOCUS AR041930 15 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 720 from patent US 5811300.
ACCESSION AR041930
VERSION AR041930.1 GI:5962426
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE TNP- alpha. ribozymes
JOURNAL Patent: US 5811300-A 720 22-SEP-1998;
FEATURES Location/Qualifiers
source 1. .15
BASE COUNT 4 a 0 c 0 g 11 t
Query Match 1.0%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1038 TATTATTATTATTA 1050
Db 3 TATTATTATTATTA 15

RESULT 281
AX636855
LOCUS AX636855 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 3994 from Patent EP1260586.
ACCESSION AX636855
VERSION AX636855.1 GI:28472469
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A., Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J., McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M., Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related genes
JOURNAL Patent: EP 1260586-A 3994 27-NOV-2002;
FEATURES Location/Qualifiers
source 1. .15
BASE COUNT 5 a 0 c 0 g 10 t
Query Match 1.0%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1038 TATTATTATTATTA 1050
Db 3 TATTATTATTATTA 15
RESULT 282
AX636870
LOCUS AX636870 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 4009 from Patent EP1260586.
ACCESSION AX636870
VERSION AX636870.1 GI:28472484
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A., Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J., McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M., Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related genes
JOURNAL Patent: EP 1260586-A 4009 27-NOV-2002;
FEATURES Location/Qualifiers
source 1. .15
BASE COUNT 4 a 0 c 0 g 11 t
Query Match 1.0%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1038 TATTATTATTATTA 1050
Db 3 TATTATTATTATTA 15
RESULT 283

AX637379
LOCUS AX637379 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 4518 from Patent EP1260586.
ACCESSION AX637379
VERSION AX637379.1 GI:28472993
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related
Genes
JOURNAL Patent: EP 1260586-A 4518 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
source
1..15
/organism="unidentified"
/mol_type="mRNA"
/db_xref="taxon:32644"
BASE COUNT 5 a 0 c 0 g 10 t
Query Match 1.0%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1038 TATTATTATTATTA 1050
|||||
Db 3 TATTATTATTATTA 15
RESULT 284
AX637409
LOCUS AX637409 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 4548 from Patent EP1260586.
ACCESSION AX637409
VERSION AX637409.1 GI:28473023
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related
Genes
JOURNAL Patent: EP 1260586-A 4548 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
source
1..15
/organism="unidentified"
/mol_type="mRNA"
/db_xref="taxon:32644"
BASE COUNT 4 a 0 c 0 g 11 t
Query Match 1.0%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1038 TATTATTATTATTA 1050
|||||
Db 3 TATTATTATTATTA 15
RESULT 285
AX638326/c

AX638326
LOCUS AX638326 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 5465 from Patent EP1260586.
ACCESSION AX638326
VERSION AX638326.1 GI:28473940
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related
Genes
JOURNAL Patent: EP 1260586-A 5465 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
source
1..15
/organism="unidentified"
/mol_type="mRNA"
/db_xref="taxon:32644"
BASE COUNT 7 a 1 g 4 t
Query Match 1.0%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 525 ATTGAATTCAG 537
|||||
Db 13 ATTGAATTCAG 1
RESULT 286
I77803/c
LOCUS I77803 15 bp DNA linear PAT 03-APR-1998
DEFINITION Sequence 510 from patent US 5693532.
ACCESSION I77803
VERSION I77803.1 GI:3013957
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
AUTHORS McSwiggen,J., Draper,K., Pavco,P. and Woolf,T.
TITLE Respiratory syncytial virus ribozymes
JOURNAL Patent: US 5693532-A 510 02-DEC-1997;
FEATURES
source
1..15
/organism="unknown"
BASE COUNT 7 a 3 c 1 g 4 t
Query Match 1.0%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 525 ATTGAATTCAG 537
|||||
Db 13 ATTGAATTCAG 1
RESULT 287
AR072365/c
LOCUS AR072365 17 bp DNA linear PAT 28-AUG-2000
DEFINITION Sequence 168 from patent US 5948611.
ACCESSION AR072365
VERSION AR072365.1 GI:9999129
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
1 {bases 1 to 17}

AUTHORS Prockop,D.J., Ala-Kokko,L., Williams,C.J., Ritvaniemi,P.,
Baldwin,C., Hopkinson,I. and Ahmad,N.Nina.
TITLE Primers and methods for detecting mutations in the procollagen II
gene (COL2A1) that indicate a genetic predisposition for a
COL2A1-associated disease
JOURNAL Patent: US 5948611-A 169 07-SEP-1999;
FEATURES Location/Qualifiers
source 1..17
BASE COUNT 6 a 3 c 3 g 5 t
Query Match 1.0%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.8e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 744 TTTCCTAGATGT 756
Db 15 TTTCCTAGATGT 3
RESULT 288
LOCUS AR078137 17 bp DNA linear PAT 31-AUG-2000
DEFINITION Sequence 17 from patent US 5962289.
ACCESSION AR078137
VERSION AR078137.1 GI:10004883
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Kilburn,D.G., Miller,R.C., Warren,R.A.J. and Gilkes,N.R.
TITLE Polyaccharide binding fusion proteins and conjugates
JOURNAL Patent: US 5962289-A 17 05-OCT-1999;
FEATURES Location/Qualifiers
source 1..17
BASE COUNT 8 a 0 c 3 g 6 t
Query Match 1.0%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.8e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1084 AATTGGAAAAAT 1096
Db 1 AATTGGAAAAAT 13
RESULT 289
LOCUS AX264383 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 1774 from Patent WO0173002.
ACCESSION AX264383
VERSION AX264383.1 GI:16513182
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Kniec,E.B., Gamper,H.B. and Rice,M.C.
TITLE Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 1774 04-OCT-2001;
FEATURES Location/Qualifiers
source 1..17
BASE COUNT 8 a 3 c 3 g 3 t
Query Match 1.0%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.8e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Best Local Similarity 100.0%; Pred. No. 3.8e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 510 AAGATTCCTGGTT 522
Db 17 AAGATTCCTGGTT 5
RESULT 290
LOCUS AX264384 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 1775 from Patent WO0173002.
ACCESSION AX264384
VERSION AX264384.1 GI:16513183
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Kniec,E.B., Gamper,H.B. and Rice,M.C.
TITLE Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 1775 04-OCT-2001;
FEATURES Location/Qualifiers
source 1..17
BASE COUNT 3 a 3 c 3 g 8 t
Query Match 1.0%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.8e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 510 AAGATTCCTGGTT 522
Db 1 AAGATTCCTGGTT 13
RESULT 291
LOCUS AX264387 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 1778 from Patent WO0173002.
ACCESSION AX264387
VERSION AX264387.1 GI:16513186
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Kniec,E.B., Gamper,H.B. and Rice,M.C.
TITLE Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 1778 04-OCT-2001;
FEATURES Location/Qualifiers
source 1..17
BASE COUNT 8 a 3 c 3 g 3 t
Query Match 1.0%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.8e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 510 AAGATTCCTGGTT 522
Db 16 AAGATTCCTGGTT 4

```

RESULT 292
AX264388
LOCUS      17 bp      DNA      linear      PAT 26-OCT-2001
DEFINITION Sequence 1779 from Patent WO0173002.
ACCESSION AX264388
VERSION   AX264388.1 GI:16513187
KEYWORDS
SOURCE    Homo sapiens (human)
ORGANISM  Homo sapiens
REFERENCE 1
AUTHORS   Kmiec, E.B., Gamper, H.B. and Rice, M.C.
TITLE     Targeted chromosomal genomic alterations with modified single
          stranded oligonucleotides
JOURNAL   Patent: WO 0173002-A 1779 04-OCT-2001;
          UNIVERSITY OF DELAWARE (US)
FEATURES  Location/Qualifiers
          source
            1..17
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"
BASE COUNT 3 a 3 c 3 g 8 t
          Query Match      1.0%; Score 13; DB 1; Length 17;
          Best Local Similarity 100.0%; Pred. No. 3.8e+02;
          Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 510 AAGATTCCTGGTT 522
Db 2 AAGATTCCTGGTT 14

RESULT 293
AX421944/c
LOCUS      17 bp      mRNA      linear      PAT 18-JUN-2002
DEFINITION Sequence 280 from Patent WO0188124.
ACCESSION AX421944
VERSION   AX421944.1 GI:21525326
KEYWORDS
SOURCE    Homo sapiens (human)
ORGANISM  Homo sapiens
REFERENCE 1
AUTHORS   Jarvis, T., von Carlwiltz, I., Mcswiggen, J.A., McLaughlin, F.G. and
          Randi, A.M.
TITLE     Method and reagent for the inhibition of erg
JOURNAL   Patent: WO 0188124-A 280 22-NOV-2001;
          RIBOZYME PHARMACEUTICALS, INC. (US); GLAXO GROUP LIMITED (GB)
FEATURES  Location/Qualifiers
          source
            1..17
            /organism="Homo sapiens"
            /mol_type="mRNA"
            /db_xref="taxon:9606"
BASE COUNT 7 a 1 c 2 g 7 t
          Query Match      1.0%; Score 13; DB 1; Length 17;
          Best Local Similarity 100.0%; Pred. No. 3.8e+02;
          Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1504 ATTTTAAATACA 1516
Db 14 ATTTTAAATACA 2

RESULT 294
AX578689/c
LOCUS      17 bp      mRNA      linear      PAT 10-JAN-2003
DEFINITION Sequence 527 from Patent WO0211674.
ACCESSION AX578689
VERSION   AX578689.1 GI:27647891
KEYWORDS
SOURCE    Homo sapiens (human)
ORGANISM  Homo sapiens

```

```

KEYWORDS
SOURCE    Homo sapiens (human)
ORGANISM  Homo sapiens
REFERENCE 1
AUTHORS   Thompson, J., Mcswiggen, J., Mckenzie, T., Ayers, D., Szymkowski, D.E.
          and Grupe, A.
TITLE     Method and reagent for the inhibition of calcium activated chloride
          channel-1 (clca-1)
JOURNAL   Patent: WO 0211674-A 527 14-FEB-2002;
          RIBOZYME PHARMACEUTICALS, INC. (US); Syntex (U.S.A.) LLC (US);
          Thompson, James (US)
FEATURES  Location/Qualifiers
          source
            1..17
            /organism="Homo sapiens"
            /mol_type="mRNA"
            /db_xref="taxon:9606"
BASE COUNT 12 a 1 g 4 t
          Query Match      1.0%; Score 13; DB 1; Length 17;
          Best Local Similarity 100.0%; Pred. No. 3.8e+02;
          Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1142 ATTTATTTTATT 1154
Db 17 ATTTATTTTATT 5

RESULT 295
AX580015/c
LOCUS      17 bp      mRNA      linear      PAT 10-JAN-2003
DEFINITION Sequence 1853 from Patent WO0211674.
ACCESSION AX580015
VERSION   AX580015.1 GI:27649217
KEYWORDS
SOURCE    Homo sapiens (human)
ORGANISM  Homo sapiens
REFERENCE 1
AUTHORS   Thompson, J., Mcswiggen, J., Mckenzie, T., Ayers, D., Szymkowski, D.E.
          and Grupe, A.
TITLE     Method and reagent for the inhibition of calcium activated chloride
          channel-1 (clca-1)
JOURNAL   Patent: WO 0211674-A 1853 14-FEB-2002;
          RIBOZYME PHARMACEUTICALS, INC. (US); Syntex (U.S.A.) LLC (US);
          Thompson, James (US)
FEATURES  Location/Qualifiers
          source
            1..17
            /organism="Homo sapiens"
            /mol_type="mRNA"
            /db_xref="taxon:9606"
BASE COUNT 11 a 1 c 0 g 5 t
          Query Match      1.0%; Score 13; DB 1; Length 17;
          Best Local Similarity 100.0%; Pred. No. 3.8e+02;
          Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1142 ATTTATTTTATT 1154
Db 14 ATTTATTTTATT 2

RESULT 296
AX672466
LOCUS      17 bp      DNA      linear      PAT 27-MAR-2003
DEFINITION Sequence 911 from Patent WO03004526.
ACCESSION AX672466
VERSION   AX672466.1 GI:293330814
KEYWORDS
SOURCE    Homo sapiens (human)
ORGANISM  Homo sapiens

```

```

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines
JOURNAL Patent: WO 03004526-A 911 16-JAN-2003;
Molecular Engines Laboratories (FR)
FEATURES
source Location/Qualifiers
1. .17
BASE COUNT 6 a 2 c 4 g 5 t
Query Match 1.0%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.8e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1073 ATTGTGCAAGAA 1085
Db |||||||||||
5 ATTGTGCAAGAA 17

RESULT 297
AX728692 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 326 from Patent WO03025175.
ACCESSION AX728692
VERSION AX728692.1 GI:30508035
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025175-A 326 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source Location/Qualifiers
1. .17
BASE COUNT 7 a 1 c 5 g 4 t
Query Match 1.0%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.8e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 419 ATCAGTGAAGATG 431
Db |||||||||||
2 ATCAGTGAAGATG 14

RESULT 298
BD067674 17 bp RNA linear PAT 27-AUG-2002
LOCUS Enzymatic nucleic acid treatment of diseases or conditions related
DEFINITION to levels of epidermal growth factor receptors.
ACCESSION BD067674
VERSION BD067674.1 GI:22613277
KEYWORDS JP 2001511003-A/514.
SOURCE unidentified
ORGANISM unclassified.
1 (bases 1 to 17)
REFERENCE Akhtar,S., Fell,P. and Mcswiggen,J.A.
AUTHORS Enzymatic nucleic acid treatment of diseases or conditions related
TITLE to levels of epidermal growth factor receptors.
JOURNAL Patent: JP 2001511003-A 515 07-AUG-2001;
RIBOZYME PHARMACEUTICALS INC,ASTON UNIV
COMMENT OS Unidentified
PN JP 2001511003-A/515
PD 07-AUG-2001
PF 14-JAN-1998 JP 1998532913
PR 31-JAN-1997 US 60/036476,04-DEC-1997 US 08/985162 PI
SAGHIR AKHTAR,PATRICIA FELL,JAMES A MCSWIGGEN PC
C12N9/00,C07K14/71
CC Strandedness: Single;
CC Topology: Linear;
CC Enzymatic nucleic acid treatment of diseases or conditions CC
related to
CC levels of epidermal growth factor receptors
PH Key Location/Qualifiers
FT source 1. .17
FEATURES Location/Qualifiers
1. .17
/organism="unidentified"
/mol_type="genomic RNA"
/db_xref="taxon:32644"
BASE COUNT 2 a 1 c 4 g 9 t

```

```

to levels of epidermal growth factor receptors
Patent: JP 2001511003-A 514 07-AUG-2001;
RIBOZYME PHARMACEUTICALS INC,ASTON UNIV
COMMENT OS Unidentified
PN JP 2001511003-A/514
PD 07-AUG-2001
PF 14-JAN-1998 JP 1998532913
PR 31-JAN-1997 US 60/036476,04-DEC-1997 US 08/985162 PI
SAGHIR AKHTAR,PATRICIA FELL,JAMES A MCSWIGGEN PC
C12N9/00,C07K14/71
CC Strandedness: Single;
CC Topology: Linear;
CC Enzymatic nucleic acid treatment of diseases or conditions CC
related to
CC levels of epidermal growth factor receptors
PH Key Location/Qualifiers
FT source 1. .17
FEATURES Location/Qualifiers
1. .17
/organism="unidentified"
/mol_type="genomic RNA"
/db_xref="taxon:32644"
BASE COUNT 2 a 1 c 4 g 10 t
Query Match 1.0%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.8e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 550 ACTTTTTCATTGT 562
Db |||||||||||
5 ACTTTTTCATTGT 17

RESULT 299
BD067675 17 bp RNA linear PAT 27-AUG-2002
LOCUS Enzymatic nucleic acid treatment of diseases or conditions related
DEFINITION to levels of epidermal growth factor receptors.
ACCESSION BD067675
VERSION BD067675.1 GI:22613278
KEYWORDS JP 2001511003-A/515.
SOURCE unidentified
ORGANISM unclassified.
1 (bases 1 to 17)
REFERENCE Akhtar,S., Fell,P. and Mcswiggen,J.A.
AUTHORS Enzymatic nucleic acid treatment of diseases or conditions related
TITLE to levels of epidermal growth factor receptors
JOURNAL Patent: JP 2001511003-A 515 07-AUG-2001;
RIBOZYME PHARMACEUTICALS INC,ASTON UNIV
COMMENT OS Unidentified
PN JP 2001511003-A/515
PD 07-AUG-2001
PF 14-JAN-1998 JP 1998532913
PR 31-JAN-1997 US 60/036476,04-DEC-1997 US 08/985162 PI
SAGHIR AKHTAR,PATRICIA FELL,JAMES A MCSWIGGEN PC
C12N9/00,C07K14/71
CC Strandedness: Single;
CC Topology: Linear;
CC Enzymatic nucleic acid treatment of diseases or conditions CC
related to
CC levels of epidermal growth factor receptors
PH Key Location/Qualifiers
FT source 1. .17
FEATURES Location/Qualifiers
1. .17
/organism="unidentified"
/mol_type="genomic RNA"
/db_xref="taxon:32644"
BASE COUNT 2 a 2 c 4 g 9 t

```

```

Query Match      1.0%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.8e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 550 AGTTTTCATTGT 562
DB 4 AGTTTTCATTGT 16

RESULT 300
LOCUS BD067676
DEFINITION Enzymatic nucleic acid treatment of diseases or conditions related
ACCESSION BD067676
VERSION BD067676.1 GI:22613279
KEYWORDS JP 2001511003-A/516.
SOURCE Unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Akhtar,S., Fell,P. and McSwiggen,J.A.
TITLE Enzymatic nucleic acid treatment of diseases or conditions related
JOURNAL to levels of epidermal growth factor receptors
Patent: JP 2001511003-A 516 07-AUG-2001;
RIBOZYME PHARMACEUTICALS INC,ASTON UNIV
COMMENT OS Unidentified
PN JP 2001511003-A/516
PD 07-AUG-2001
PF 14-JAN-1998 JP 1998532913
PR 31-JAN-1997 US 60/036476,04-DEC-1997 US 08/985162 PI
SAGHIR AKHTAR,PATRICIA FELL,JAMES A MCSWIGGEN PC
C12N9/00,C07K14/71
CC Strandedness: Single;
CC Topology: Linear;
CC Enzymatic nucleic acid treatment of diseases or conditions CC
CC levels of epidermal growth factor receptors
FH Key 17 bp RNA linear PAT 27-AUG-2002
FT source Location/Qualifiers
FEATURES
source
1..17
/organism="Unidentified"
/mol_type="genomic RNA"
/db_xref="taxon:32644"
BASE COUNT 2 a 2 c 5 g 8 t
Query Match 1.0%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.8e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 550 AGTTTTCATTGT 562
DB 3 AGTTTTCATTGT 15

RESULT 301
LOCUS BD067677
DEFINITION Enzymatic nucleic acid treatment of diseases or conditions related
ACCESSION BD067677
VERSION BD067677.1 GI:22613280
KEYWORDS JP 2001511003-A/517.
SOURCE Unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Akhtar,S., Fell,P. and McSwiggen,J.A.
TITLE Enzymatic nucleic acid treatment of diseases or conditions related
JOURNAL to levels of epidermal growth factor receptors
Patent: JP 2001511003-A 517 07-AUG-2001;
RIBOZYME PHARMACEUTICALS INC,ASTON UNIV
COMMENT OS Unidentified
PN JP 2001511003-A/516
PD 07-AUG-2001
PF 14-JAN-1998 JP 1998532913
PR 31-JAN-1997 US 60/036476,04-DEC-1997 US 08/985162 PI
SAGHIR AKHTAR,PATRICIA FELL,JAMES A MCSWIGGEN PC
C12N9/00,C07K14/71
CC Strandedness: Single;
CC Topology: Linear;
CC Enzymatic nucleic acid treatment of diseases or conditions CC
CC levels of epidermal growth factor receptors
FH Key 17 bp RNA linear PAT 27-AUG-2002
FT source Location/Qualifiers
FEATURES
source
1..17
/organism="Unidentified"
/mol_type="genomic RNA"
/db_xref="taxon:32644"
BASE COUNT 2 a 2 c 5 g 8 t
Query Match 1.0%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.8e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 550 AGTTTTCATTGT 562
DB 3 AGTTTTCATTGT 15

RESULT 302
LOCUS I09655
DEFINITION Sequence 1 from Patent WO 9000609.
ACCESSION I09655
VERSION I09655.1 GI:587631
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Kilburn,D.G., Miller,R.C., Warren,R.A.J. and Gilkes,N.R.
TITLE CELLULOSE BINDING FISSION PROTEINS
JOURNAL Patent: WO 9000609-A 1 25-JAN-1990;
FEATURES
source
1..17
/organism="unknown"
/mol_type="genomic RNA"
/db_xref="taxon:32644"
BASE COUNT 8 a 0 c 3 g 6 t
Query Match 1.0%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.8e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1084 AATTGGGAAAAT 1096
DB 1 AATTGGGAAAAT 13

RESULT 303
LOCUS I26476/c
DEFINITION Sequence 168 from patent US 5558988.
ACCESSION I26476
VERSION I26476.1 GI:1606346
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Prockop,D.J., Ala-Kokko,L. and Ritvanemi,P.
TITLE Primers and methods for detecting mutations in the procollagen II

```


gene that indicate a genetic predisposition for osteoarthritis
Patent: US 5559888-A 168 24-SEP-1996;
Location/Qualifiers

source
1. .17
/organism="unknown"

BASE COUNT 6 a 3 c 3 g 5 t

Query Match 1.0%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.8e+02; Indels 0; Gaps 0;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 744 TTGCTAGAAATGT 756

Db 15 TTGCTAGAAATGT 3

RESULT 304

AX004292/c

LOCUS AX004292 18 bp DNA linear PAT 24-AUG-2000

DEFINITION Sequence 44 from Patent WO9919492.

ACCESSION AX004292

VERSION AX004292.1 GI:9927774

KEYWORDS synthetic construct

SOURCE synthetic construct

ORGANISM artificial sequences.

REFERENCE 1

AUTHORS Betzner A.S. and Doutriaux M.P.

TITLE Methods for obtaining plant varieties

JOURNAL Patent: WO 9919492-A 44 22-APR-1999;

BTZNER ANDREAS STEFAN (AU); DOUTRIAUX MARIE PASCALE (FR)

FEATURES Location/Qualifiers

source 1. .18

/organism="synthetic construct"

/mol_type="genomic DNA"

/db_xref="taxon:32630"

/note="Forward primer for PCR amplification of NGA63 SSLP

marker in Arabidopsis thaliana subspecies"

BASE COUNT 8 a 5 c 5 g 0 t

Query Match 1.0%; Score 13; DB 1; Length 18;

Best Local Similarity 100.0%; Pred. No. 4.2e+02; Indels 0; Gaps 0;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 895 CTGTGCTTGGTT 907

Db 13 CTGTGCTTGGTT 1

RESULT 305

AX383945/c

LOCUS AX383945 18 bp DNA linear PAT 19-MAR-2002

DEFINITION Sequence 48 from Patent WO0214546.

ACCESSION AX383945

VERSION AX383945.1 GI:19577516

KEYWORDS Salmonella typhimurium

SOURCE Salmonella typhimurium

ORGANISM Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;

Enterobacteriaceae; Salmonella.

REFERENCE 1

AUTHORS Fritzsche M.

TITLE Use of microbial dna sequences for the identification of human

diseases

JOURNAL Patent: WO 0214546-A 48 21-FEB-2002;

Fritzsche, Markus (CH)

FEATURES Location/Qualifiers

source 1. .18

/organism="Salmonella typhimurium"

/mol_type="genomic DNA"

/db_xref="taxon:602"

BASE COUNT 8 a 2 c 1 g 7 t

Query Match 1.0%; Score 13; DB 1; Length 18;

Best Local Similarity 100.0%; Pred. No. 4.2e+02; Indels 0; Gaps 0;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1050 ATGTATTATTTA 1062

Db 15 ATGTATTATTTA 3

RESULT 306

AX417565/c

LOCUS AX417565 18 bp DNA linear PAT 19-JUN-2002

DEFINITION Sequence 13 from Patent WO0231157.

ACCESSION AX417565

VERSION AX417565.1 GI:21522804

KEYWORDS synthetic construct

SOURCE synthetic construct

ORGANISM artificial sequences.

REFERENCE 1

AUTHORS Gardner R., Nilsen I. and Oeverboe K.

TITLE Shrimp alkaline phosphatase

JOURNAL Patent: WO 0231157-A 13 18-APR-2002;

NORWEGIAN INST OF FISHERIES & (NO)

FEATURES Location/Qualifiers

source 1. .18

/organism="synthetic construct"

/mol_type="genomic DNA"

/db_xref="taxon:32630"

/note="Primer"

modified_base 6

/mod_base=1

BASE COUNT 7 a 4 g 2 t 4 others

Query Match 1.0%; Score 13; DB 1; Length 18;

Best Local Similarity 72.2%; Pred. No. 4.2e+02; Indels 0; Gaps 0;

Matches 13; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 886 CTGTTCACCTGTGCCTT 903

Db 18 YTTTTCCTTANGCCTT 1

RESULT 307

AX599862/c

LOCUS AX599862 18 bp DNA linear PAT 14-FEB-2003

DEFINITION Sequence 1202 from Patent WO02077272.

ACCESSION AX599862

VERSION AX599862.1 GI:28400012

KEYWORDS synthetic construct

SOURCE synthetic construct

ORGANISM artificial sequences.

REFERENCE 1

AUTHORS Berlin K., Braun A., Distler J., Guetig D., Howe A., Mueller J.,

Olek A., Piepenbrock C., Adorjan P., Grabs G., Lesche R., Leu E.,

Lewin A., Lipscher E., Maier S., Model F., Mueller V., Otto T.,

Pellet C. and Ziebarth H.

TITLE Methods and nucleic acids for the analysis of hematopoietic cell

proliferative disorders

JOURNAL Patent: WO 02077272-A 1202 03-OCT-2002;

EpiGenomics AG (DE)

FEATURES Location/Qualifiers

source 1. .18

/organism="synthetic construct"

/mol_type="genomic DNA"

/db_xref="taxon:32630"

/note="Detection oligonucleotide for CMYCex3"

BASE COUNT 4 a 0 c 3 g 11 t

Query Match 1.0%; Score 13; DB 1; Length 18;

Best Local Similarity 100.0%; Pred. No. 4.2e+02; Indels 0; Gaps 0;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1205 TTAACACAAACAA 1217
 Db 15 TTAACACAAACAA 3

RESULT 308
 BD094192
 LOCUS BD094192
 DEFINITION Genes for heat resistant enzymes of amino acid biosynthetic pathway derived from thermophilic coryneform bacteria.
 ACCESSION BD094192.1 GI:22639780
 VERSION WO 0125447-A/50.
 KEYWORDS synthetic construct
 SOURCE synthetic construct
 ORGANISM artificial sequences.
 REFERENCE 1 (bases 1 to 18)
 AUTHORS Hirano,S., Nonaka,G., Matsuzaki,Y., Akiyoshi,N., Nakamura,K., Kimura,E., Osumi,T., Matsui,K., Kawahara,Y., Kurahashi,O., Nakamatsu,T. and Sugimoto,S.
 TITLE Genes for heat resistant enzymes of amino acid biosynthetic pathway derived from thermophilic coryneform bacteria
 JOURNAL PATENT: WO 0125447-A 50 12-APR-2001;
 AJINOMOTO CO INC,SEIKO HIRANO,GEN NONAKA,YUMI MATSUZAKI, NAOKI AKIYOSHI, KANAE NAKAMURA,EIICHIRO KIMURA,TSUYOSHI OSUMI,KAZUHIKO MATSUI, YOSHIO KAWAHARA,OSAMU KURAHASHI,TSUYOSHI NAKAMATSU, SHINICHI SUGIMOTO
 COMMENT OS Artificial Sequence
 PN WO 0125447-A/50
 PD 12-APR-2001
 PF 04-OCT-2000 WO 2000JP006913
 PR 04-OCT-1999 JP 99P 282716,01-NOV-1999 JP 99P 311147 PR 21-APR-2000 JP 00P 120687
 PI SEIKO HIRANO,GEN NONAKA,YUMI MATSUZAKI,NAOKI AKIYOSHI,KANAE NAKAMURA,PI NAKAMURA,PI EIICHIRO KIMURA,TSUYOSHI OSUMI,KAZUHIKO MATSUI,YOSHIO KAWAHARA,PI OSAMU KURAHASHI,TSUYOSHI NAKAMATSU,SHINICHI SUGIMOTO PC C12N15/60,C12N15/54,C12N15/53,C12N15/31,C12N15/56,C12N9/88, PC C12N9/12,
 PC C12N9/04,C07K14/34,C12N9/26,C12N13/04
 CC Description of Artificial Sequence: primer for LA cloning of
 CC icd Location/Qualifiers.
 FH Key Location/Qualifiers
 source
 1..18
 /organism="synthetic construct"
 /mol_type="genomic DNA"
 /db_xref="taxon:32630"

BASE COUNT 7 a 3 c 6 g 2 t

Query Match 1.0%; Score 13; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 4.2e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 883 GTCCTGTGTCAC 895
 Db 15 GTCCTGTGTCAC 3

RESULT 310
 BD0941968
 LOCUS AX419968 30 bp DNA linear PAT 18-JUN-2002
 DEFINITION Sequence 305 from Patent WO0198537.
 ACCESSION AX419968
 VERSION AX419968.1 GI:21524335
 KEYWORDS synthetic construct
 SOURCE synthetic construct
 ORGANISM artificial sequences.
 REFERENCE 1
 AUTHORS Lyamichev,V., Allawi,H., Dong,F., Neri,B.P. and Vener,I.T.
 TITLE Nucleic acid accessible hybridization sites
 JOURNAL Patent: WO 0198537-A 305 27-DEC-2001;
 THIRD WAVE TECHNOLOGIES, INC. (US)
 COMMENT OS Artificial Sequence
 PN WO 0125447-A/56
 PD 12-APR-2001
 PF 04-OCT-2000 WO 2000JP006913
 PR 04-OCT-1999 JP 99P 282716,01-NOV-1999 JP 99P 311147 PR 21-APR-2000 JP 00P 120687
 PI SEIKO HIRANO,GEN NONAKA,YUMI MATSUZAKI,NAOKI AKIYOSHI,KANAE NAKAMURA,PI NAKAMURA,PI EIICHIRO KIMURA,TSUYOSHI OSUMI,KAZUHIKO MATSUI,YOSHIO KAWAHARA,PI OSAMU KURAHASHI,TSUYOSHI NAKAMATSU,SHINICHI SUGIMOTO PC C12N15/60,C12N15/54,C12N15/53,C12N15/31,C12N15/56,C12N9/88, PC C12N9/12,
 PC C12N9/04,C07K14/34,C12N9/26,C12N13/04
 CC Description of Artificial Sequence: primer for LA cloning of
 CC icd Location/Qualifiers.
 FH Key Location/Qualifiers
 source
 1..18
 /organism="synthetic construct"
 /mol_type="genomic DNA"
 /db_xref="taxon:32630"

BASE COUNT 2 a 7 c 2 g 7 t

Query Match 1.0%; Score 13; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 4.2e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 883 GTCCTGTGTCAC 895
 Db 3 GTCCTGTGTCAC 15

RESULT 309
 BD094198/c
 LOCUS BD094198 18 bp DNA linear PAT 27-AUG-2002
 DEFINITION Genes for heat resistant enzymes of amino acid biosynthetic pathway derived from thermophilic coryneform bacteria.
 ACCESSION BD094198.1 GI:22639786
 VERSION WO 0125447-A/50.
 KEYWORDS synthetic construct
 SOURCE synthetic construct
 ORGANISM artificial sequences.
 REFERENCE 1 (bases 1 to 18)

QY 1444 CTGGTTGAACCTGTTATTA 1464
 Db 1 CTGGTTGAACCTGTTATTA 21

Query Match 1.0%; Score 13; DB 1; Length 30;
 Best Local Similarity 76.2%; Pred. No. 7.7e+02;
 Matches 16; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 1444 CTGGTTGAACCTGTTATTA 1464
 Db 1 CTGGTTGAACCTGTTATTA 21

RESULT 311
A89384
LOCUS A89384 16 bp DNA linear PAT 22-JAN-2000
DEFINITION Sequence 1532 from Patent WO9833904.
ACCESSION A89384
VERSION A89384.1 GI:6737954
KEYWORDS
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Brysch,W. and Schlingensiepen,K.
TITLE AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
JOURNAL Patent: WO 9833904-A 1532 06-AUG-1998;
BIOGOSTIK GES (DE); BRYSCH WOLFGANG (DE)
FEATURES
source
1. .16
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
BASE COUNT 5 a 3 c 5 g 3 t
Query Match 1.0%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 586 CAAATTTGGCCAGG 701
|||||
Db 1 CAAATTTGGCCAGG 16
RESULT 312
AR083145/c
LOCUS AR083145 16 bp DNA linear PAT 01-SEP-2000
DEFINITION Sequence 28 from patent US 5976805.
ACCESSION AR083145
VERSION AR083145.1 GI:10009935
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS You,Q.
TITLE Neisseria gonorrhoeae specific DNA fragment--GC3
JOURNAL Patent: US 5976805-A 28 02-NOV-1999;
FEATURES
source
1. .16
/organism="unknown"
BASE COUNT 5 a 3 c 4 g 4 t
Query Match 1.0%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 756 TGATATTGGAGCATC 771
|||||
Db 16 TGATATTGGAGCATC 1
RESULT 313
AX015629/c
LOCUS AX015629 16 bp DNA linear PAT 07-SEP-2000
DEFINITION Sequence 4 from Patent WO9950451.
ACCESSION AX015629
VERSION AX015629.1 GI:10041458
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1
AUTHORS Bhattacharyya,S., Leaves,N., Cookson,W.O. and Moffatt,M.F.
TITLE Polymorphism i: linkage of asthma to a locus on chromosome 2

JOURNAL Patent: WO 9950451-A 4 07-OCT-1999;
BHATTACHARYYA SUMIT (GB); ISIS INNOVATION (GB); LEAVES NICHOLAS
(GB); COOKSON WILLIAM OSMOND CHARLES (GB); MOFFATT MIRIAM FLEUR
(GB)
FEATURES
source
1. .16
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/note="Synthetic DNA"
BASE COUNT 1 a 5 c 3 g 7 t
Query Match 1.0%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 685 GCAAAATTTGGCCAGG 700
|||||
Db 16 GCAAAATTTGGCCAGG 1
RESULT 314
BD066897
LOCUS BD066897 16 bp DNA linear PAT 27-AUG-2002
DEFINITION An antisense oligonucleotide preparation method.
ACCESSION BD066897
VERSION BD066897.1 GI:22612500
KEYWORDS JP 2001511000-A/1532.
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Schlingensiepen,K.H. and Brysch,W.
TITLE An antisense oligonucleotide preparation method
JOURNAL Patent: JP 2001511000-A 1532 07-AUG-2001;
BIOGOSTIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH
COMMENT OS Unknown
FN JP 2001511000-A/1532
PD 30-JAN-1998 JP 1998532533
PF 31-JAN-1997 BP 97101531.8
PI KARL HERMANN SCHLINGENSIEPEN,WOLFGANG BRYSCH
PC C12N15/11,C07H21/04,A61K31/70
CC An antisense oligonucleotide preparation method FH Key
FT source
1. .16
/organism="Unknown".
FEATURES
source
1. .16
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
BASE COUNT 5 a 3 c 5 g 3 t
Query Match 1.0%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 686 CAAATTTGGCCAGG 701
|||||
Db 1 CAAATTTGGCCAGG 16
RESULT 315
AR046181/c
LOCUS AR046181 17 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 974 from patent US 5817796.
ACCESSION AR046181
VERSION AR046181.1 GI:5967646
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.

```
REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myb ribozymes having 2'-5'-linked adenylylate residues
JOURNAL Patent: US 5817796-A 974 06-OCT-1998;
FEATURES Location/Qualifiers
source
BASE COUNT 7 a 0 c 0 g 10 t
Query Match 1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1613 ATTAAATATATATTT 1628
Db 17 AATAAATATATATTT 2

RESULT 316
AR047244 17 bp DNA linear PAT 29-SEP-1999
LOCUS Sequence 2037 from patent US 5817796.
DEFINITION AR047244
ACCESSION AR047244
VERSION AR047244.1 GI:5968709
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myb ribozymes having 2'-5'-linked adenylylate residues
JOURNAL Patent: US 5817796-A 2037 06-OCT-1998;
FEATURES Location/Qualifiers
source
BASE COUNT 6 a 0 c 3 g 8 t
Query Match 1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1460 TATTATGTACAAATAG 1475
Db 1 TATTATGTATGAATAG 16

RESULT 317
AR047262/c 17 bp DNA linear PAT 29-SEP-1999
LOCUS Sequence 2055 from patent US 5817796.
DEFINITION AR047262
ACCESSION AR047262
VERSION AR047262.1 GI:5968727
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myb ribozymes having 2'-5'-linked adenylylate residues
JOURNAL Patent: US 5817796-A 2055 06-OCT-1998;
FEATURES Location/Qualifiers
source
BASE COUNT 7 a 0 c 0 g 10 t
Query Match 1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1613 ATTAAATATATATTT 1628
Db 17 AATAAATATATATTT 2

RESULT 318
AR047360 17 bp DNA linear PAT 29-SEP-1999
LOCUS Sequence 2153 from patent US 5817796.
DEFINITION AR047360
ACCESSION AR047360
VERSION AR047360.1 GI:5968825
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myb ribozymes having 2'-5'-linked adenylylate residues
JOURNAL Patent: US 5817796-A 2153 06-OCT-1998;
FEATURES Location/Qualifiers
source
BASE COUNT 4 a 0 c 0 g 13 t
Query Match 1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1040 TTTATTTATTTATGTAT 1055
Db 2 TTTATTTTATATATAT 17

RESULT 319
AR047362 17 bp DNA linear PAT 29-SEP-1999
LOCUS Sequence 2155 from patent US 5817796.
DEFINITION AR047362
ACCESSION AR047362
VERSION AR047362.1 GI:5968827
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myb ribozymes having 2'-5'-linked adenylylate residues
JOURNAL Patent: US 5817796-A 2155 06-OCT-1998;
FEATURES Location/Qualifiers
source
BASE COUNT 5 a 0 c 0 g 12 t
Query Match 1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1040 TTTATTTATTTATGTAT 1055
Db 1 TTTATTTTATATATAT 16

RESULT 320
AR054096/c 17 bp DNA linear PAT 29-SEP-1999
LOCUS Sequence 23 from patent US 5834440.
DEFINITION AR054096
ACCESSION AR054096
VERSION AR054096.1 GI:5978958
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Goldenberg,T. and Tritz,R.
TITLE Ribozyme therapy for the inhibition of restenosis
JOURNAL Patent: US 5834440-A 23 10-NOV-1998;
FEATURES Location/Qualifiers
source
```

```

BASE COUNT      7 a      2 c      1 g      7 t
Query Match      1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1172 TTATAGATAAATTT 1187
|||||
Db 16 TTATAGATAAATTT 1

RESULT 321
LOCUS AR057779 17 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 1983 from patent US 5837542.
ACCESSION AR057779
VERSION AR057779.1 GI:5983356
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and Draper,K.G.
TITLE Intercellular adhesion molecule-1 (ICAM-1) ribozymes
JOURNAL Patent: US 5837542-A 1983 17-NOV-1998;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
BASE COUNT 5 a 0 c 3 g 9 t
Query Match 1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1047 TTTATGATTTATTTA 1062
|||||
Db 2 TTTATGATTTATTTAA 17

RESULT 322
LOCUS AR083146/c 17 bp DNA linear PAT 01-SEP-2000
DEFINITION Sequence 29 from patent US 5976805.
ACCESSION AR083146
VERSION AR083146.1 GI:10009936
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS You,Q.
TITLE Neisseria gonorrhoeae specific DNA fragment--GC3
JOURNAL Patent: US 5976805-A 29 02-NOV-1999;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
BASE COUNT 5 a 3 c 5 g 4 t
Query Match 1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 756 TGATATTGAAGATC 771
|||||
Db 17 TGATATTGAAGATC 2

RESULT 323
LOCUS AR101662/c 17 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 17 from patent US 6083698.

```

```

ACCESSION AR101662
VERSION AR101662.1 GI:12812460
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Olson,S.Jon., Angelly,T.Staton., Lawrence,T., Lescallott,J.Lee., Murphy,P.Davis., Allen,A.Preisinger., Thurber,D.Bernadette., White,M.Belle., Zeng,B. and Sadzewicz,L.K.
TITLE Cancer susceptibility mutations of BRCA1
JOURNAL Patent: US 6083698-A 17 04-JUL-2000;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
BASE COUNT 6 a 2 c 3 g 5 t
Query Match 1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 524 AATTTGAATTCAGTA 539
|||||
Db 17 AATTTGAATTCAGTA 2

RESULT 324
LOCUS AR101663/c 17 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 18 from patent US 6083698.
ACCESSION AR101663
VERSION AR101663.1 GI:12812461
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Olson,S.Jon., Angelly,T.Staton., Lawrence,T., Lescallott,J.Lee., Murphy,P.Davis., Allen,A.Preisinger., Thurber,D.Bernadette., White,M.Belle., Zeng,B. and Sadzewicz,L.K.
TITLE Cancer susceptibility mutations of BRCA1
JOURNAL Patent: US 6083698-A 18 04-JUL-2000;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
BASE COUNT 6 a 3 c 3 g 5 t
Query Match 1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 524 AATTTGAATTCAGTA 539
|||||
Db 17 AATTTGAATTCAGTA 2

RESULT 325
LOCUS AR115537 17 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 1983 from patent US 6132967.
ACCESSION AR115537
VERSION AR115537.1 GI:14095859
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and Draper,K.G.
TITLE Ribozyme treatment of diseases or conditions related to levels of intercellular adhesion molecule-1 (ICAM-1)
JOURNAL Patent: US 6132967-A 1983 17-OCT-2000;
FEATURES Location/Qualifiers

```

```

source      1. .17
/organism="unknown"
BASE COUNT      5 a      0 c      3 g      9 t

Query Match      1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1047 TTTATGATTTATTATTA 1062
Db      2 TTGATGATTTATTATTA 17

RESULT 326
AR186678/c
LOCUS      AR186678      17 bp      DNA      linear      PAT 20-APR-2002
DEFINITION      Sequence 2166 from patent US 6346398.
ACCESSION      AR186678
VERSION      AR186678.1 GI:20232643
KEYWORDS
SOURCE      Unknown.
ORGANISM      Unknown.
REFERENCE      1 (bases 1 to 17)
AUTHORS      Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE      Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL      Patent: US 6346398-A 2166 12-FEB-2002;
FEATURES
source      Location/Qualifiers
1. .17
/organism="unknown"
BASE COUNT      3 a      5 c      1 g      8 t

Query Match      1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1586 ATGGAATATATAAAGT 1601
Db      16 ATGGAAGATAAAGT 1

RESULT 327
AR187068/c
LOCUS      AR187068      17 bp      DNA      linear      PAT 20-APR-2002
DEFINITION      Sequence 2556 from patent US 6346398.
ACCESSION      AR187068
VERSION      AR187068.1 GI:20233033
KEYWORDS
SOURCE      Unknown.
ORGANISM      Unknown.
REFERENCE      1 (bases 1 to 17)
AUTHORS      Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE      Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL      Patent: US 6346398-A 2556 12-FEB-2002;
FEATURES
source      Location/Qualifiers
1. .17
/organism="unknown"
BASE COUNT      3 a      2 c      0 g      12 t

Query Match      1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1085 ATTTGGAAAAATAGAA 1100
Db      17 ATTTGGAAAAAAGAAA 2

RESULT 328
AR187069/c

```

```

LOCUS      AR187069      17 bp      DNA      linear      PAT 20-APR-2002
DEFINITION      Sequence 2557 from patent US 6346398.
ACCESSION      AR187069
VERSION      AR187069.1 GI:20233034
KEYWORDS
SOURCE      Unknown.
ORGANISM      Unknown.
REFERENCE      1 (bases 1 to 17)
AUTHORS      Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE      Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL      Patent: US 6346398-A 2557 12-FEB-2002;
FEATURES
source      Location/Qualifiers
1. .17
/organism="unknown"
BASE COUNT      3 a      3 c      0 g      11 t

Query Match      1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1085 ATTTGGAAAAATAGAA 1100
Db      16 ATTTGGAAAAAAGAAA 1

RESULT 329
AR187340/c
LOCUS      AR187340      17 bp      DNA      linear      PAT 20-APR-2002
DEFINITION      Sequence 2828 from patent US 6346398.
ACCESSION      AR187340
VERSION      AR187340.1 GI:20233305
KEYWORDS
SOURCE      Unknown.
ORGANISM      Unknown.
REFERENCE      1 (bases 1 to 17)
AUTHORS      Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE      Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL      Patent: US 6346398-A 2828 12-FEB-2002;
FEATURES
source      Location/Qualifiers
1. .17
/organism="unknown"
BASE COUNT      2 a      2 c      2 g      11 t

Query Match      1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1201 TAGATTAACAACAACAA 1216
Db      16 TAGGTAACAACAACAA 1

RESULT 330
AR188362/c
LOCUS      AR188362      17 bp      DNA      linear      PAT 20-APR-2002
DEFINITION      Sequence 3850 from patent US 6346398.
ACCESSION      AR188362
VERSION      AR188362.1 GI:20234327
KEYWORDS
SOURCE      Unknown.
ORGANISM      Unknown.
REFERENCE      1 (bases 1 to 17)
AUTHORS      Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE      Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL      Patent: US 6346398-A 3850 12-FEB-2002;
FEATURES
source      Location/Qualifiers
1. .17

```

BASE COUNT 6 a 2 c 2 g 7 t
Query Match 1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1457 GTTATTATCTACAAA 1472
Db 2 GCTATTATGTCACATA 17
RESULT 331
AR188737
LOCUS AR188737 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 4225 from patent US 6346398.
ACCESSION AR188737
VERSION AR188737.1 GI:20234702
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 4225 12-FEB-2002;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
BASE COUNT 7 a 0 c 4 g 6 t
Query Match 1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1116 GAATAGTTATAAGAT 1131
Db 2 GGATATTATAAGAT 17
RESULT 332
AR188738
LOCUS AR188738 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 4226 from patent US 6346398.
ACCESSION AR188738
VERSION AR188738.1 GI:20234703
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 4226 12-FEB-2002;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
BASE COUNT 7 a 1 c 3 g 6 t
Query Match 1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1116 GAATAGTTATAAGAT 1131
Db 1 GGATATTATAAGAT 16
RESULT 333
AR308284
LOCUS AR308284 17 bp DNA linear PAT 12-JUN-2003

DEFINITION Sequence 2 from patent US 6555311.
ACCESSION AR308284
VERSION AR308284.1 GI:31699677
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Locarnini,S.A., Bartholomeusz,A.I., Aye,T.T. and de Man,R.A.
TITLE Viral variants and methods for detecting same
JOURNAL Patent: US 6555311-A 2 29-APR-2003;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
BASE COUNT 5 a 4 c 1 g 7 t
Query Match 1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1556 CTCCAAATTTTATA 1571
Db 2 CTCCAAATTTTATA 17
RESULT 334
AR308286
LOCUS AR308286 17 bp DNA linear PAT 12-JUN-2003
DEFINITION Sequence 4 from patent US 6555311.
ACCESSION AR308286
VERSION AR308286.1 GI:31699679
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Locarnini,S.A., Bartholomeusz,A.I., Aye,T.T. and de Man,R.A.
TITLE Viral variants and methods for detecting same
JOURNAL Patent: US 6555311-A 4 29-APR-2003;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
BASE COUNT 5 a 4 c 1 g 7 t
Query Match 1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1556 CTCCAAATTTTATA 1571
Db 2 CTCCAAATTTTATA 17
RESULT 335
AX029041
LOCUS AX029041 17 bp DNA linear PAT 16-SEP-2000
DEFINITION Sequence 2 from Patent WO9821317.
ACCESSION AX029041
VERSION AX029041.1 GI:10190029
KEYWORDS
SOURCE Hepatitis B virus
ORGANISM Hepatitis B virus
REFERENCE 1
AUTHORS Bartholomeusz,A.I., Locarnini,S.A., Aye,T.T. and de Man,R.A.
TITLE Viral variants and methods for detecting same
JOURNAL Patent: WO 9821317-A 2 22-MAY-1998;
BARTHOLOMEUSZ ANGELINE INGRID (AU) ; LOCARNINI STEPHEN ALISTER (AU) ; WESTERN HEALTH CARE NETWORK (AU) ; AYE THEIN THEIN (AU) ; MAN ROBERT A DE (AU)
FEATURES Location/Qualifiers
source 1..17
/organism="Hepatitis B virus"

QY 1046 ATTATGTATTATT 1061
Db 17 AGTTAAGTATTATT 2

RESULT 338
LOCUS AX132943
DEFINITION Sequence 4161 from Patent WO0130362.
ACCESSION AX132943
VERSION AX132943.1 GI:14139253
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 Robbins, J.M. and Tritz, R.
TITLE Ribozyme therapy for the treatment of proliferative skin and eye diseases
JOURNAL Patent: WO 0130362-A 4161 03-MAY-2001;
IMMUSOL, INC. (US)
FEATURES
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/note="Hammerhead ribozyme recognition site for cdc 2 kinase"

BASE COUNT 7 a 2 c 1 g 7 t
Query Match 1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1172 TTTATTAGATAAATTT 1187
Db 16 TTAAATAGAGAAATTT 1

RESULT 339
LOCUS AX214988
DEFINITION Sequence 430 from Patent WO0159103.
ACCESSION AX214988
VERSION AX214988.1 GI:15525031
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
JOURNAL Patent: WO 0159103-A 430 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US); McSwiggen, James (US); Chowrira, Bharat M. (US)
FEATURES
Location/Qualifiers
1..17
/organism="synthetic construct"
/mol_type="mRNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

BASE COUNT 5 a 2 c 1 g 9 t
Query Match 1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 909 CTCCTTTATTCTAAG 924
Db 2 CTTATTATTCTAAG 17

BASE COUNT 5 a 4 c 1 g 7 t
Query Match 1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1556 CTCGAAATTTTATA 1571
Db 2 CTCGAAATTTTATA 17

RESULT 336
LOCUS AX029043
DEFINITION Sequence 4 from Patent WO9821317.
ACCESSION AX029043
VERSION AX029043.1 GI:10190031
KEYWORDS
SOURCE Hepatitis B virus
ORGANISM Hepatitis B virus
Viruses; Retroid viruses; Hepadnaviridae; Orthohepadnavirus.
REFERENCE 1
AUTHORS Bartholomusz, A.I., Locarnini, S.A., Aye, T.T. and de Man, R.
TITLE Viral variants and methods for detecting same
JOURNAL Patent: WO 9821317-A 4 22-MAY-1998;
BARTHOLOMEUSZ ANGELINE INGRID (AU); LOCARNINI STEPHEN ALISTER (AU); WESTERN HEALTH CARE NETWORK (AU); AYE THEIN THEIN (AU); MAN ROBERT A DE (AU)
FEATURES
Location/Qualifiers
1..17
/organism="Hepatitis B virus"
/mol_type="genomic DNA"
/db_xref="taxon:10407"

BASE COUNT 5 a 4 c 1 g 7 t
Query Match 1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1556 CTCGAAATTTTATA 1571
Db 2 CTCGAAATTTTATA 17

RESULT 337
LOCUS AX076472/c
DEFINITION Sequence 17 from Patent WO0103686.
ACCESSION AX076472
VERSION AX076472.1 GI:12711025
KEYWORDS
SOURCE Staphylococcus aureus
ORGANISM Staphylococcus aureus
Bacteria; Firmicutes; Bacillales; Staphylococcus.
REFERENCE 1
AUTHORS Hurlburt, B.K., Smeltzer, M.S. and Reicht, T.M.
TITLE Inhibitors of staphylococcus sara protein and their use in treating staphylococcal infections
JOURNAL Patent: WO 0103686-A 17 18-JAN-2001;
THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US)
FEATURES
Location/Qualifiers
1..17
/organism="Staphylococcus aureus"
/mol_type="genomic DNA"
/db_xref="taxon:1280"

BASE COUNT 9 a 2 c 1 g 5 t
Query Match 1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

RESULT 340
AX215015/c
LOCUS AX215015 17 bp mRNA linear PAT 07-SEP-2001
DEFINITION Sequence 457 from Patent WO0159103.
ACCESSION AX215015
VERSION AX215015.1 GI:15525058
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
JOURNAL Patent: WO 0159103-A 457 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
source
1. .17
/organism="synthetic construct"
/mol_type="mRNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"
BASE COUNT 5 a 3 c 1 g 8 t
Query Match 1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1096 TAGAAGATGAATCATT 1111
Db 17 TAGAAGATGAATCAGT 2
RESULT 341
AX215874/c
LOCUS AX215874 17 bp mRNA linear PAT 07-SEP-2001
DEFINITION Sequence 1316 from Patent WO0159103.
ACCESSION AX215874
VERSION AX215874.1 GI:15525917
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
JOURNAL Patent: WO 0159103-A 1316 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
source
1. .17
/organism="synthetic construct"
/mol_type="mRNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"
BASE COUNT 5 a 3 c 1 g 8 t
Query Match 1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1096 TAGAAGATGAATCATT 1111
Db 16 TAGAAGATGAATCAGT 1
RESULT 342
AX216170
LOCUS AX216170 17 bp mRNA linear PAT 07-SEP-2001
DEFINITION Sequence 1612 from Patent WO0159103.

ACCESSION AX216170
VERSION AX216170.1 GI:15526213
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
JOURNAL Patent: WO 0159103-A 1612 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
source
1. .17
/organism="synthetic construct"
/mol_type="mRNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"
BASE COUNT 4 a 3 c 4 g 6 t
Query Match 1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 429 ATCCAGTCGAACTTC 444
Db 1 ATGTAGTCGAACTTC 16
RESULT 343
AX216751/c
LOCUS AX216751 17 bp mRNA linear PAT 07-SEP-2001
DEFINITION Sequence 2193 from Patent WO0159103.
ACCESSION AX216751
VERSION AX216751.1 GI:15526812
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
JOURNAL Patent: WO 0159103-A 2193 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
source
1. .17
/organism="synthetic construct"
/mol_type="mRNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"
BASE COUNT 9 a 2 c 3 g 3 t
Query Match 1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1276 AGTACATTATTGTTT 1291
Db 16 AGTCCATTATTGTTT 1
RESULT 344
AX263368/c
LOCUS AX263368 17 bp DNA linear PAT 25-OCT-2001
DEFINITION Sequence 759 from Patent WO0173002.
ACCESSION AX263368
VERSION AX263368.1 GI:16512167
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens

REFERENCE
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
AUTHORS
 1 Kmiec, E.B., Gamper, H.B. and Rice, M.C.
TITLE
 Targeted chromosomal genomic alterations with modified single
 stranded oligonucleotides
JOURNAL
 Patent: WO 0173002-A 759 04-OCT-2001;
 UNIVERSITY OF DELAWARE (US)
FEATURES
 source
 1..17
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"
 6 a 2 c 3 g 6 t
BASE COUNT
 Query Match 1.0%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 4.3e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 524 AATTGCAATTCAGTA 539
 16 AATTGCAATTCAGTA 1
Db
RESULT 345
 AX263369 17 bp DNA linear PAT 26-OCT-2001
 LOCUS
 DEFINITION Sequence 760 from Patent WO0173002.
 ACCESSION AX263369
 VERSION AX263369.1 GI:16512168
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
 1 Kmiec, E.B., Gamper, H.B. and Rice, M.C.
AUTHORS
 Targeted chromosomal genomic alterations with modified single
 stranded oligonucleotides
TITLE
 Patent: WO 0173002-A 760 04-OCT-2001;
 UNIVERSITY OF DELAWARE (US)
JOURNAL
FEATURES
 source
 1..17
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"
 6 a 3 c 2 g 6 t
BASE COUNT
 Query Match 1.0%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 4.3e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 524 AATTGCAATTCAGTA 539
 2 AATTGCAATTCAGTA 17
Db
RESULT 346
 AX264068 17 bp DNA linear PAT 26-OCT-2001
 LOCUS
 DEFINITION Sequence 1459 from Patent WO0173002.
 ACCESSION AX264068
 VERSION AX264068.1 GI:16512867
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
 1 Kmiec, E.B., Gamper, H.B. and Rice, M.C.
AUTHORS
 Targeted chromosomal genomic alterations with modified single
 stranded oligonucleotides
TITLE
 Patent: WO 0173002-A 1459 04-OCT-2001;
JOURNAL

REFERENCE
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
AUTHORS
 1 Kmiec, E.B., Gamper, H.B. and Rice, M.C.
TITLE
 Targeted chromosomal genomic alterations with modified single
 stranded oligonucleotides
JOURNAL
 Patent: WO 0173002-A 759 04-OCT-2001;
 UNIVERSITY OF DELAWARE (US)
FEATURES
 source
 1..17
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"
 6 a 4 c 1 g 6 t
BASE COUNT
 Query Match 1.0%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 4.3e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1577 TCTGATTCGTATGAAA 1592
 16 TCTGTTTGTAGGAAA 1
Db
RESULT 347
 AX264069 17 bp DNA linear PAT 26-OCT-2001
 LOCUS
 DEFINITION Sequence 1460 from Patent WO0173002.
 ACCESSION AX264069
 VERSION AX264069.1 GI:16512868
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
 1 Kmiec, E.B., Gamper, H.B. and Rice, M.C.
AUTHORS
 Targeted chromosomal genomic alterations with modified single
 stranded oligonucleotides
TITLE
 Patent: WO 0173002-A 1460 04-OCT-2001;
 UNIVERSITY OF DELAWARE (US)
JOURNAL
FEATURES
 source
 1..17
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"
 6 a 1 c 4 g 6 t
BASE COUNT
 Query Match 1.0%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 4.3e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1577 TCTGATTCGTATGAAA 1592
 2 TCTGTTTGTAGGAAA 17
Db
RESULT 348
 AX422979 17 bp mRNA linear PAT 18-JUN-2002
 LOCUS
 DEFINITION Sequence 1315 from Patent WO0188124.
 ACCESSION AX422979
 VERSION AX422979.1 GI:21526361
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
 1 Jarvis, T., von Carlowitz, I., Mcswiggen, J.A., McLaughlin, P.G. and
 Randi, A.M.
AUTHORS
 Method and reagent for the inhibition of erg
TITLE
 Patent: WO 0188124-A 1315 22-NOV-2001;
 RIBOZYME PHARMACEUTICALS, INC. (US); GLAXO GROUP LIMITED (GB)
JOURNAL
FEATURES
 source
 1..17
 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 7 a 1 c 2 g 7 t
BASE COUNT

```

Query Match      1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1235 AAATTTTCATTTGACA 1250
DB 16 AAATTTTCATTTGACA 1

RESULT 349
AX423008/c
LOCUS AX423008 17 bp mRNA linear PAT 18-JUN-2002
DEFINITION Sequence 1344 from Patent WO0188124.
ACCESSION AX423008
VERSION AX423008.1 GI:21526390
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Jarvis,T., von Carlowitz,I., McSwiggen,J.A., McLaughlin,P.G. and
Randi,A.M.
TITLE Method and reagent for the inhibition of erg
JOURNAL Patent: WO 0188124-A 1344 22-NOV-2001.
RIBOZYME PHARMACEUTICALS, INC. (US); GLAXO GROUP LIMITED (GB)
FEATURES
Location/Qualifiers
1..17
source
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
BASE COUNT 9 a 0 c 3 g 5 t

Query Match      1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1171 TTTTATTAGTAATTT 1186
DB 17 TTTTATTAGTAATTT 2

RESULT 350
AX500622/c
LOCUS AX500622 17 bp DNA linear PAT 27-SEP-2002
DEFINITION Sequence 1929 from Patent EP1229046.
ACCESSION AX500622
VERSION AX500622.1 GI:23382915
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Zhan,J.
TITLE Human testis expressed patched like protein
JOURNAL Patent: EP 1229046-A 1929 07-AUG-2002;
Aeomica, Inc. (US)
FEATURES
Location/Qualifiers
1..17
source
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 5 a 2 g 7 t

Query Match      1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1457 GTTTATTATGTACAAA 1472
DB 17 GCTTATGATGTACAAA 2

```

```

RESULT 351
AX500624/c
LOCUS AX500624 17 bp DNA linear PAT 27-SEP-2002
DEFINITION Sequence 1931 from Patent EP1229046.
ACCESSION AX500624
VERSION AX500624.1 GI:23382917
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Zhan,J.
TITLE Human testis expressed patched like protein
JOURNAL Patent: EP 1229046-A 1931 07-AUG-2002;
Aeomica, Inc. (US)
FEATURES
Location/Qualifiers
1..17
source
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 6 a 3 c 3 g 5 t

Query Match      1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1456 TGTATTATGTACAAA 1471
DB 16 TGTATTATGTACAAA 1

RESULT 352
AX503015/c
LOCUS AX503015 17 bp DNA linear PAT 27-SEP-2002
DEFINITION Sequence 4322 from Patent EP1229046.
ACCESSION AX503015
VERSION AX503015.1 GI:23385308
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Zhan,J.
TITLE Human testis expressed patched like protein
JOURNAL Patent: EP 1229046-A 4322 07-AUG-2002;
Aeomica, Inc. (US)
FEATURES
Location/Qualifiers
1..17
source
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 5 a 2 c 2 g 8 t

Query Match      1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 603 TTTATTGATCTACA 618
DB 2 TTTATTGATCTACA 17

RESULT 353
AX503016/c
LOCUS AX503016 17 bp DNA linear PAT 27-SEP-2002
DEFINITION Sequence 4323 from Patent EP1229046.
ACCESSION AX503016
VERSION AX503016.1 GI:23385309
KEYWORDS

```

SOURCE	Homo sapiens (human)		
ORGANISM	Homo sapiens		
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.		
REFERENCE	1		
AUTHORS	Zhan, J.		
TITLE	Human testis expressed patched like protein		
JOURNAL	Patent: EP 1229046-A 4323 07-AUG-2002;		
FEATURES	Aeomica, Inc. (US)		
source	1. 17		
BASE COUNT	5 a 3 c 1 g 8 t		
	Query Match 1.0%; Score 12.8; DB 1; Length 17;		
	Best Local Similarity 87.5%; Pred. No. 4.3e+02;		
	Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;		
QY	603 TTTATTTCGAATCTACA 618		
Db			
	1 TTTATTTCGAATCTACA 16		
RESULT 354			
AX531353/c			
LOCUS	AX531353 17 bp DNA linear PAT 22-NOV-2002		
DEFINITION	Sequence 862 from Patent EP1239051.		
ACCESSION	AX531353		
VERSION	AX531353.1 GI:25254489		
KEYWORDS			
SOURCE	Homo sapiens (human)		
ORGANISM	Homo sapiens		
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.		
REFERENCE	1		
AUTHORS	Shannon, M.		
TITLE	Human posh-like protein 1		
JOURNAL	Patent: EP 1239051-A 862 11-SEP-2002;		
	Aeomica, Inc. (US)		
FEATURES	Location/Qualifiers		
source	1. 17		
BASE COUNT	7 a 2 c 7 g 1 t		
	Query Match 1.0%; Score 12.8; DB 1; Length 17;		
	Best Local Similarity 87.5%; Pred. No. 4.3e+02;		
	Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;		
QY	1335 CAGTCCTTGTCATGCC 1350		
Db			
	17 CACTCTGTGCTTGCC 2		
RESULT 355			
AX531354/c			
LOCUS	AX531354 17 bp DNA linear PAT 22-NOV-2002		
DEFINITION	Sequence 863 from Patent EP1239051.		
ACCESSION	AX531354		
VERSION	AX531354.1 GI:25254491		
KEYWORDS			
SOURCE	Homo sapiens (human)		
ORGANISM	Homo sapiens		
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.		
REFERENCE	1		
AUTHORS	Shannon, M.		
TITLE	Human posh-like protein 1		
JOURNAL	Patent: EP 1239051-A 863 11-SEP-2002;		
	Aeomica, Inc. (US)		

FEATURES	source	Location/Qualifiers
BASE COUNT	7 a 2 c 7 g 1 t	
Query Match	1.0%; Score 12.8; DB 1; Length 17;	
Best Local Similarity	87.5%; Pred. No. 4.3e+02;	
Matches	14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
QY	1335 CAGCTCTGTCATGGCC 1350	
DB	16 CACTCTGTCCTGGC 1	
RESULT 356		
AX578728	17 bp mRNA linear PAT 10-JAN-2003	
LOCUS	Sequence 566 from Patent WO0211674.	
DEFINITION	AX578728	
ACCESSION	AX578728.1 GI:27647930	
VERSION		
KEYWORDS		
SOURCE	Homo sapiens (human)	
ORGANISM	Homo sapiens	
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;	
AUTHORS	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.	
TITLE	1 Thompson,J., Meswigen,J., Mckenzie,T., Ayers,D., Szymkowski,D.E.	
JOURNAL	Method and reagent for the inhibition of calcium activated chloride channel-1 (clca-1)	
Patent: WO 0211674-A 566 14-FEB-2002;		
RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;		
Thompson, James (US)		
FEATURES	Location/Qualifiers	
source	1. 17	
	/organism="Homo sapiens"	
	/mol_type="mRNA"	
	/db_xref="taxon:9606"	
BASE COUNT	6 a 1 c 1 g 9 t	
Query Match	1.0%; Score 12.8; DB 1; Length 17;	
Best Local Similarity	87.5%; Pred. No. 4.3e+02;	
Matches	14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
QY	1133 TTATAGTAAATTTATT 1148	
DB	2 TTATAGTAAATTTATT 17	
RESULT 357		
AX579226/c	17 bp mRNA linear PAT 10-JAN-2003	
LOCUS	Sequence 1064 from Patent WO0211674.	
DEFINITION	AX579226	
ACCESSION	AX579226.1 GI:27648428	
VERSION		
KEYWORDS		
SOURCE	Homo sapiens (human)	
ORGANISM	Homo sapiens	
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;	
AUTHORS	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.	
TITLE	1 Thompson,J., Meswigen,J., Mckenzie,T., Ayers,D., Szymkowski,D.E.	
JOURNAL	Method and reagent for the inhibition of calcium activated chloride channel-1 (clca-1)	
Patent: WO 0211674-A 1064 14-FEB-2002;		
RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;		
Thompson, James (US)		
FEATURES	Location/Qualifiers	
source	1. 17	
	/organism="Homo sapiens"	

```
/mol_type="mRNA"
/db_xref="taxon:9606"
BASE COUNT      8 a      4 c      3 t

Query Match      1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 722 TTAATTTCAGGAATTG 737
    |||||
Db 17 TTAATTTCAGGTCCTG 2

RESULT 358
AX579385
LOCUS      17 bp mRNA linear PAT 10-JAN-2003
DEFINITION Sequence 1223 from Patent WO0211674.
ACCESSION AX579385
VERSION   AX579385.1 GI:27648587
KEYWORDS
SOURCE    Homo sapiens (human)
ORGANISM  Homo sapiens
REFERENCE
AUTHORS   Thompson,J., McSwiggen,J., McKenzie,T., Ayers,D., Szymkowski,D.E.
          and Grupe,A.
TITLE     Method and reagent for the inhibition of calcium activated chloride
          channel-1 (clca-1)
JOURNAL   Patent: WO 0211674-A 1223 14-FEB-2002;
          RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
          Thompson, James (US)
FEATURES
source    1..17
          /organism="Homo sapiens"
          /mol_type="mRNA"
          /db_xref="taxon:9606"
BASE COUNT      8 a      4 c      3 t

Query Match      1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1245 TTCAGATAAACACAA 1260
    |||||
Db 2 TTCAGCTGAACACAA 17

RESULT 359
AX579496/c
LOCUS      17 bp mRNA linear PAT 10-JAN-2003
DEFINITION Sequence 1334 from Patent WO0211674.
ACCESSION AX579496
VERSION   AX579496.1 GI:27648698
KEYWORDS
SOURCE    Homo sapiens (human)
ORGANISM  Homo sapiens
REFERENCE
AUTHORS   Thompson,J., McSwiggen,J., McKenzie,T., Ayers,D., Szymkowski,D.E.
          and Grupe,A.
TITLE     Method and reagent for the inhibition of calcium activated chloride
          channel-1 (clca-1)
JOURNAL   Patent: WO 0211674-A 1334 14-FEB-2002;
          RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
          Thompson, James (US)
FEATURES
source    1..17
          /organism="Homo sapiens"
          /mol_type="mRNA"
          /db_xref="taxon:9606"
BASE COUNT      8 a      3 c      4 t
```

```
Query Match      1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 722 TTAATTTCAGGAATTG 737
    |||||
Db 16 TTAATTTCAGGTCCTG 1

RESULT 360
AX579591
LOCUS      17 bp mRNA linear PAT 10-JAN-2003
DEFINITION Sequence 1429 from Patent WO0211674.
ACCESSION AX579591
VERSION   AX579591.1 GI:27648793
KEYWORDS
SOURCE    Homo sapiens (human)
ORGANISM  Homo sapiens
REFERENCE
AUTHORS   Thompson,J., McSwiggen,J., McKenzie,T., Ayers,D., Szymkowski,D.E.
          and Grupe,A.
TITLE     Method and reagent for the inhibition of calcium activated chloride
          channel-1 (clca-1)
JOURNAL   Patent: WO 0211674-A 1429 14-FEB-2002;
          RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
          Thompson, James (US)
FEATURES
source    1..17
          /organism="Homo sapiens"
          /mol_type="mRNA"
          /db_xref="taxon:9606"
BASE COUNT      6 a      1 c      2 g      8 t

Query Match      1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1136 TACTAAATTTATTTTA 1151
    |||||
Db 1 TACTAAATGTATTTTA 16

RESULT 361
AX634813
LOCUS      17 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 1952 from Patent EP1260586.
ACCESSION AX634813
VERSION   AX634813.1 GI:28470427
KEYWORDS
SOURCE    unidentified
          unclassified.
ORGANISM
REFERENCE
AUTHORS   Stinchcomb,D.T., Dudycz,L.W., Chowira,B., Grimm,S., Drenzo,A.,
          Karpeisky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J.,
          McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
          Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
          Woolf,T.
TITLE     Method and reagent for inhibiting the expression of disease related
          genes
JOURNAL   Patent: EP 1260586-A 1952 27-NOV-2002;
          RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
source    1..17
          /organism="unidentified"
          /mol_type="mRNA"
          /db_xref="taxon:32644"
BASE COUNT      5 a      0 c      3 g      9 t

Query Match      1.0%; Score 12.8; DB 1; Length 17;
```

Best Local Similarity 87.5%; Pred. No. 4.3e+02; Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;		2 ATCACATAAAACAGAT 17		2 ATCACATAAAACAGAT 17	
QY	1047	TTTATGATATTATTAA 1062		AX672853	17 bp DNA linear PAT 27-MAR-2003
Db	2	TTGATGATATTATTAA 17		Sequence 1298 from Patent WO03004526.	
RESULT 364		AX672853		AX672853.1 GI:293331201	
LOCUS		AX672853		Homo sapiens (human)	
DEFINITION		AX672853		Homo sapiens	
ACCESSION		AX672853		Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;	
VERSION		AX671653.1 GI:293330001		Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.	
KEYWORDS		Homo sapiens (human)		Telerman, A., Anson, R. and Tuijinder, M.	
SOURCE		Homo sapiens		Sequences involved in phenomena of tumour suppression, tumour	
ORGANISM		Homo sapiens		reversion, apoptosis and/or resistance to viruses and their use as	
REFERENCE		Homo sapiens		medicines	
AUTHORS		Telerman, A., Anson, R. and Tuijinder, M.		Patent: WO 03004526-A 1298 16-JAN-2003;	
TITLE		Sequences involved in phenomena of tumour suppression, tumour		Molecular Engines Laboratories (FR)	
JOURNAL		Patent: WO 03004526-A 98 16-JAN-2003;		Location/Qualifiers	
FEATURES		Molecular Engines Laboratories (FR)		1. 17	
source		Location/Qualifiers		/organism="Homo sapiens"	
BASE COUNT		7 a 1 c 4 g 5 t		/mol_type="genomic DNA"	
Query Match		1.0%; Score 12.8; DB 1; Length 17;		/db_xref="taxon:9606"	
Best Local Similarity 87.5%; Pred. No. 4.3e+02;		7 a 1 c 4 g 5 t		2 a 5 c 4 g 6 t	
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;		1.0%; Score 12.8; DB 1; Length 17;		Query Match	
QY	454	TACTTCAACACTTCAT 469		395 ATTCATTCTCTGTGT 410	
Db	17	TACTTCAACACTTCAT 2		2 ATCCATTCCCTGTGT 17	
RESULT 365		AX673783/c		AX673783	
LOCUS		AX673783/c		Sequence 2228 from Patent WO03004526.	
DEFINITION		AX673783		AX673783	
ACCESSION		AX673783		AX673783.1 GI:29332131	
VERSION		AX671834.1 GI:293330182		Homo sapiens (human)	
KEYWORDS		Homo sapiens (human)		Homo sapiens	
SOURCE		Homo sapiens		Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;	
ORGANISM		Homo sapiens		Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.	
REFERENCE		Homo sapiens		Telerman, A., Anson, R. and Tuijinder, M.	
AUTHORS		Sequences involved in phenomena of tumour suppression, tumour		reversion, apoptosis and/or resistance to viruses and their use as	
TITLE		medicines		medicines	
JOURNAL		Patent: WO 03004526-A 279 16-JAN-2003;		Patent: WO 03004526-A 2228 16-JAN-2003;	
FEATURES		Molecular Engines Laboratories (FR)		Molecular Engines Laboratories (FR)	
source		Location/Qualifiers		Location/Qualifiers	
BASE COUNT		9 a 3 c 2 g 3 t		1. 17	
Query Match		1.0%; Score 12.8; DB 1; Length 17;		/organism="Homo sapiens"	
Best Local Similarity 87.5%; Pred. No. 4.3e+02;		9 a 3 c 2 g 3 t		/mol_type="genomic DNA"	
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;		1.0%; Score 12.8; DB 1; Length 17;		/db_xref="taxon:9606"	
QY	769	ATCACATAAAATCAT 784		13 a 1 c 1 g 2 t	
Db	17	TTTATTATTATTAGAT 2		BASE COUNT	
RESULT 366		AX673947/c		Query Match	
LOCUS		AX673947/c		Best Local Similarity 87.5%; Pred. No. 4.3e+02;	
DEFINITION		AX673947/c		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
ACCESSION		AX673947/c		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
VERSION		AX673947.1 GI:293330182		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
KEYWORDS		Homo sapiens (human)		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
SOURCE		Homo sapiens		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
ORGANISM		Homo sapiens		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
REFERENCE		Homo sapiens		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
AUTHORS		Telerman, A., Anson, R. and Tuijinder, M.		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
TITLE		Sequences involved in phenomena of tumour suppression, tumour		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
JOURNAL		Patent: WO 03004526-A 279 16-JAN-2003;		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
FEATURES		Molecular Engines Laboratories (FR)		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
source		Location/Qualifiers		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
BASE COUNT		9 a 3 c 2 g 3 t		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
Query Match		1.0%; Score 12.8; DB 1; Length 17;		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
Best Local Similarity 87.5%; Pred. No. 4.3e+02;		9 a 3 c 2 g 3 t		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;		1.0%; Score 12.8; DB 1; Length 17;		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
QY	769	ATCACATAAAATCAT 784		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
Db	17	TTTATTATTATTAGAT 2		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
RESULT 366		AX673947/c		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
LOCUS		AX673947/c		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
DEFINITION		AX673947/c		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
ACCESSION		AX673947/c		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
VERSION		AX673947.1 GI:293330182		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
KEYWORDS		Homo sapiens (human)		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
SOURCE		Homo sapiens		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
ORGANISM		Homo sapiens		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
REFERENCE		Homo sapiens		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
AUTHORS		Telerman, A., Anson, R. and Tuijinder, M.		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
TITLE		Sequences involved in phenomena of tumour suppression, tumour		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
JOURNAL		Patent: WO 03004526-A 279 16-JAN-2003;		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
FEATURES		Molecular Engines Laboratories (FR)		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
source		Location/Qualifiers		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
BASE COUNT		9 a 3 c 2 g 3 t		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
Query Match		1.0%; Score 12.8; DB 1; Length 17;		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
Best Local Similarity 87.5%; Pred. No. 4.3e+02;		9 a 3 c 2 g 3 t		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;		1.0%; Score 12.8; DB 1; Length 17;		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
QY	769	ATCACATAAAATCAT 784		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
Db	17	TTTATTATTATTAGAT 2		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
RESULT 366		AX673947/c		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
LOCUS		AX673947/c		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
DEFINITION		AX673947/c		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
ACCESSION		AX673947/c		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
VERSION		AX673947.1 GI:293330182		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
KEYWORDS		Homo sapiens (human)		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
SOURCE		Homo sapiens		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
ORGANISM		Homo sapiens		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
REFERENCE		Homo sapiens		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
AUTHORS		Telerman, A., Anson, R. and Tuijinder, M.		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
TITLE		Sequences involved in phenomena of tumour suppression, tumour		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
JOURNAL		Patent: WO 03004526-A 279 16-JAN-2003;		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
FEATURES		Molecular Engines Laboratories (FR)		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
source		Location/Qualifiers		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
BASE COUNT		9 a 3 c 2 g 3 t		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
Query Match		1.0%; Score 12.8; DB 1; Length 17;		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
Best Local Similarity 87.5%; Pred. No. 4.3e+02;		9 a 3 c 2 g 3 t		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;		1.0%; Score 12.8; DB 1; Length 17;		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
QY	769	ATCACATAAAATCAT 784		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
Db	17	TTTATTATTATTAGAT 2		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
RESULT 366		AX673947/c		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
LOCUS		AX673947/c		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
DEFINITION		AX673947/c		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
ACCESSION		AX673947/c		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
VERSION		AX673947.1 GI:293330182		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
KEYWORDS		Homo sapiens (human)		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
SOURCE		Homo sapiens		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
ORGANISM		Homo sapiens		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
REFERENCE		Homo sapiens		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
AUTHORS		Telerman, A., Anson, R. and Tuijinder, M.		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
TITLE		Sequences involved in phenomena of tumour suppression, tumour		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
JOURNAL		Patent: WO 03004526-A 279 16-JAN-2003;		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
FEATURES		Molecular Engines Laboratories (FR)		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
source		Location/Qualifiers		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
BASE COUNT		9 a 3 c 2 g 3 t		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
Query Match		1.0%; Score 12.8; DB 1; Length 17;		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
Best Local Similarity 87.5%; Pred. No. 4.3e+02;		9 a 3 c 2 g 3 t		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;		1.0%; Score 12.8; DB 1; Length 17;		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
QY	769	ATCACATAAAATCAT 784		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
Db	17	TTTATTATTATTAGAT 2		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
RESULT 366		AX673947/c		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
LOCUS		AX673947/c		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
DEFINITION		AX673947/c		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
ACCESSION		AX673947/c		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
VERSION		AX673947.1 GI:293330182		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
KEYWORDS		Homo sapiens (human)		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
SOURCE		Homo sapiens		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
ORGANISM		Homo sapiens		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
REFERENCE		Homo sapiens		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
AUTHORS		Telerman, A., Anson, R. and Tuijinder, M.		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
TITLE		Sequences involved in phenomena of tumour suppression, tumour		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
JOURNAL		Patent: WO 03004526-A 279 16-JAN-2003;		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
FEATURES		Molecular Engines Laboratories (FR)		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
source		Location/Qualifiers		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
BASE COUNT		9 a 3 c 2 g 3 t		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
Query Match		1.0%; Score 12.8; DB 1; Length 17;		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
Best Local Similarity 87.5%; Pred. No. 4.3e+02;		9 a 3 c 2 g 3 t		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;		1.0%; Score 12.8; DB 1; Length 17;		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
QY	769	ATCACATAAAATCAT 784		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
Db	17	TTTATTATTATTAGAT 2		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
RESULT 366		AX673947/c		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
LOCUS		AX673947/c		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
DEFINITION		AX673947/c		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
ACCESSION		AX673947/c		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
VERSION		AX673947.1 GI:293330182		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
KEYWORDS		Homo sapiens (human)		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
SOURCE		Homo sapiens		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
ORGANISM		Homo sapiens		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
REFERENCE		Homo sapiens		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
AUTHORS		Telerman, A., Anson, R. and Tuijinder, M.		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
TITLE		Sequences involved in phenomena of tumour suppression, tumour		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
JOURNAL		Patent: WO 03004526-A 279 16-JAN-2003;		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
FEATURES		Molecular Engines Laboratories (FR)		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
source		Location/Qualifiers		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
BASE COUNT		9 a 3 c 2 g 3 t		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
Query Match		1.0%; Score 12.8; DB 1; Length 17;		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
Best Local Similarity 87.5%; Pred. No. 4.3e+02;		9 a 3 c 2 g 3 t		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;		1.0%; Score 12.8; DB 1; Length 17;		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
QY	769	ATCACATAAAATCAT 784		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
Db	17	TTTATTATTATTAGAT 2		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
RESULT 366		AX673947/c		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
LOCUS		AX673947/c		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
DEFINITION		AX673947/c		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
ACCESSION		AX673947/c		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
VERSION		AX673947.1 GI:293330182		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
KEYWORDS		Homo sapiens (human)		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
SOURCE		Homo sapiens		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
ORGANISM		Homo sapiens		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
REFERENCE		Homo sapiens		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
AUTHORS		Telerman, A., Anson, R. and Tuijinder, M.		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
TITLE		Sequences involved in phenomena of tumour suppression, tumour		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
JOURNAL		Patent: WO 03004526-A 279 16-JAN-2003;		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
FEATURES		Molecular Engines Laboratories (FR)		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
source		Location/Qualifiers		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
BASE COUNT		9 a 3 c 2 g 3 t		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
Query Match		1.0%; Score 12.8; DB 1; Length 17;		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
Best Local Similarity 87.5%; Pred. No. 4.3e+02;		9 a 3 c 2 g 3 t		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;		1.0%; Score 12.8; DB 1; Length 17;		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
QY	769	ATCACATAAAATCAT 784		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
Db	17	TTTATTATTATTAGAT 2		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
RESULT 366		AX673947/c		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
LOCUS		AX673947/c		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
DEFINITION		AX673947/c		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
ACCESSION		AX673947/c		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
VERSION		AX673947.1 GI:293330182		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
KEYWORDS		Homo sapiens (human)		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
SOURCE		Homo sapiens		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
ORGANISM		Homo sapiens		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
REFERENCE		Homo sapiens		Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;</	

LOCUS AX673947 17 bp DNA linear PAT 27-MAR-2003
 DEFINITION Sequence 2392 from Patent WO03004526.
 ACCESSION AX673947
 VERSION AX673947.1 GI:293322295
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1
 AUTHORS Telerman, A., Anson, R. and Tuijinder, M.
 TITLE Sequences involved in phenomena of tumour suppression, tumour
 reversion, apoptosis and/or resistance to viruses and their use as
 medicines
 JOURNAL Patent: WO 03004526-A 2392 16-JAN-2003;
 Molecular Engines Laboratories (FR)
 FEATURES
 source
 1..17
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"
 BASE COUNT 7 a 3 c 1 g 6 t
 Query Match 1.0%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 4.3e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1462 TTATGTACAAATAGAT 1477
 |||||
 Db 17 TTATGTATAGATAGAT 2
 RESULT 367
 AX673993/c
 LOCUS AX673993 17 bp DNA linear PAT 27-MAR-2003
 DEFINITION Sequence 2438 from Patent WO03004526.
 ACCESSION AX673993
 VERSION AX673993.1 GI:29332341
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1
 AUTHORS Telerman, A., Anson, R. and Tuijinder, M.
 TITLE Sequences involved in phenomena of tumour suppression, tumour
 reversion, apoptosis and/or resistance to viruses and their use as
 medicines
 JOURNAL Patent: WO 03004526-A 2438 16-JAN-2003;
 Molecular Engines Laboratories (FR)
 FEATURES
 source
 1..17
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"
 BASE COUNT 5 a 1 c 3 g 8 t
 Query Match 1.0%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 4.3e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1462 TTATGTACAAATAGAT 1477
 |||||
 Db 17 TTATGTACAAATAGAT 2
 RESULT 368
 AX674214
 LOCUS AX674214 17 bp DNA linear PAT 27-MAR-2003
 DEFINITION Sequence 2659 from Patent WO03004526.
 ACCESSION AX674214
 VERSION AX674214.1 GI:29332562
 KEYWORDS

SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1
 AUTHORS Telerman, A., Anson, R. and Tuijinder, M.
 TITLE Sequences involved in phenomena of tumour suppression, tumour
 reversion, apoptosis and/or resistance to viruses and their use as
 medicines
 JOURNAL Patent: WO 03004526-A 2659 16-JAN-2003;
 Molecular Engines Laboratories (FR)
 FEATURES
 source
 1..17
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"
 BASE COUNT 6 a 1 c 3 g 7 t
 Query Match 1.0%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 4.3e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 525 ATTGAATTCAGTAA 540
 |||||
 Db 2 ATCTGAATTTAGTAA 17
 RESULT 369
 AX722385
 LOCUS AX722385 17 bp DNA linear PAT 08-MAY-2003
 DEFINITION Sequence 72 from Patent WO03025176.
 ACCESSION AX722385
 VERSION AX722385.1 GI:30422886
 KEYWORDS
 SOURCE Mus musculus (house mouse)
 ORGANISM Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 REFERENCE 1
 AUTHORS Telerman, A., Anson, R. and Tuijinder, M.
 TITLE Sequences involved in phenomena of tumour suppression, tumour
 reversion, apoptosis and/or virus resistance and their use as
 medicines
 JOURNAL Patent: WO 03025176-A 72 27-MAR-2003;
 Molecular Engines Laboratories (FR)
 FEATURES
 source
 1..17
 /organism="Mus musculus"
 /mol_type="genomic DNA"
 /db_xref="taxon:10090"
 BASE COUNT 3 a 4 c 3 g 7 t
 Query Match 1.0%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 4.3e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 825 ATCTGGACTTTATTC 840
 |||||
 Db 2 ATCTGGACTTTATTC 17
 RESULT 370
 AX722936/c
 LOCUS AX722936 17 bp DNA linear PAT 08-MAY-2003
 DEFINITION Sequence 623 from Patent WO03025176.
 ACCESSION AX722936
 VERSION AX722936.1 GI:30423437
 KEYWORDS
 SOURCE Mus musculus (house mouse)
 ORGANISM Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 REFERENCE 1

[illegible]


```

BASE COUNT      5 a      5 c      3 g      4 t
Query Match      1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 874 GATCCACAGTCTTGG 889
Db 1 GATCCACAGTCTTAG 16

RESULT 375
AX726492/c
LOCUS AX726492 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 4179 from Patent WO03025176.
ACCESSION AX726492
VERSION AX726492.1 GI:30505835
KEYWORDS Mus musculus (house mouse)
SOURCE Mus musculus
ORGANISM Mus musculus
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025176-A 4179 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
Location/Qualifiers
1..17
/organism="Mus musculus"
/mol_type="genomic DNA"
/db_xref="taxon:10090"
BASE COUNT      3 a      2 c      2 g      10 t
Query Match      1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 499 AGATGCAATACAGAT 514
Db 17 AGATAAATACAGAT 2

RESULT 376
AX727740
LOCUS AX727740 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 5427 from Patent WO03025176.
ACCESSION AX727740
VERSION AX727740.1 GI:30507083
KEYWORDS Mus musculus (house mouse)
SOURCE Mus musculus
ORGANISM Mus musculus
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025176-A 5427 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
Location/Qualifiers
1..17
/organism="Mus musculus"
/mol_type="genomic DNA"
/db_xref="taxon:10090"
BASE COUNT      9 a      3 c      2 g      3 t
Query Match      1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1604 ATATGGAACATTATA 1619
Db 2 ATCTGAACATTATA 17

```

```

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 769 ATCATAAAATGAT 784
Db 2 ATCATAAAACAGAT 17

RESULT 377
AX727854
LOCUS AX727854 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 5541 from Patent WO03025176.
ACCESSION AX727854
VERSION AX727854.1 GI:30507197
KEYWORDS Mus musculus (house mouse)
SOURCE Mus musculus
ORGANISM Mus musculus
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025176-A 5541 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
Location/Qualifiers
1..17
/organism="Mus musculus"
/mol_type="genomic DNA"
/db_xref="taxon:10090"
BASE COUNT      8 a      2 c      2 g      5 t
Query Match      1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 999 ATCATAAACAATTATA 1014
Db 2 ATCATAAACAATTATA 17

RESULT 378
AX728103
LOCUS AX728103 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 5790 from Patent WO03025176.
ACCESSION AX728103
VERSION AX728103.1 GI:30507446
KEYWORDS Mus musculus (house mouse)
SOURCE Mus musculus
ORGANISM Mus musculus
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025176-A 5790 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
Location/Qualifiers
1..17
/organism="Mus musculus"
/mol_type="genomic DNA"
/db_xref="taxon:10090"
BASE COUNT      7 a      2 c      2 g      6 t
Query Match      1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1604 ATATGGAACATTATA 1619
Db 2 ATCTGAACATTATA 17

```

```

RESULT 379
LOCUS AX728686/c 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 320 from Patent WO03025175.
ACCESSION AX728686
VERSION AX728686.1 GI:30508029
KEYWORDS Homo sapiens (human)
SOURCE
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Telerman,A., Anson,R. and Tuijinder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025175-A 320 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 2 a 5 g 8 t
Query Match 1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 438 AAACCTTCAGCAATC 453
DB 16 AAATCCAGCAGATC 1

RESULT 380
LOCUS AX728701/c 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 335 from Patent WO03025175.
ACCESSION AX728701
VERSION AX728701.1 GI:30508044
KEYWORDS Homo sapiens (human)
SOURCE
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Telerman,A., Anson,R. and Tuijinder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025175-A 335 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 5 a 1 c 3 g 8 t
Query Match 1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1462 TTATGTACAAATAGAT 1477
DB 17 TTAATACAAATAGAT 2

RESULT 381
LOCUS AX729056/c 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 690 from Patent WO03025175.
ACCESSION AX729056
VERSION AX729056.1 GI:30508399
KEYWORDS Homo sapiens (human)
SOURCE
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Telerman,A., Anson,R. and Tuijinder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025175-A 690 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 5 a 3 c 3 g 6 t
Query Match 1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 566 ATGAATATCCAGAAC 581
DB 16 ATGAATATCCAGATC 1

RESULT 382
LOCUS AX729980 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 1614 from Patent WO03025175.
ACCESSION AX729980
VERSION AX729980.1 GI:30509323
KEYWORDS Homo sapiens (human)
SOURCE
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Telerman,A., Anson,R. and Tuijinder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025175-A 1614 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 9 a 2 c 1 g 5 t
Query Match 1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 999 ATCATACATAAATTA 1014
DB 2 ATCATACATAAATTA 17

RESULT 383
LOCUS AX730354/c 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 1988 from Patent WO03025175.
ACCESSION AX730354
VERSION AX730354.1 GI:30509697
KEYWORDS Homo sapiens (human)
SOURCE

```

ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines

JOURNAL Patent: WO 03025175-A 1988 27-MAR-2003;
Molecular Engines Laboratories (FR)

FEATURES source
1. .17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

BASE COUNT 5 a 2 c 4 g 6 t

Query Match 1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1462 TTATGTCACAAATGAT 1477
Db 17 TTATGTCACACAGAT 2

RESULT 384
AX730419/c
LOCUS AX730419 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 2053 from Patent WO03025175.
ACCESSION AX730419
VERSION AX730419.1 GI:30509762
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines

JOURNAL Patent: WO 03025175-A 2053 27-MAR-2003;
Molecular Engines Laboratories (FR)

FEATURES source
1. .17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

BASE COUNT 6 a 3 c 3 g 5 t

Query Match 1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 744 TTGCTAGAAATGAT 759
Db 17 TATGTCACAAATGAT 2

RESULT 385
AX731759
LOCUS AX731759 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 3393 from Patent WO03025175.
ACCESSION AX731759
VERSION AX731759.1 GI:30511102
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.

TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines

JOURNAL Patent: WO 03025175-A 3393 27-MAR-2003;
Molecular Engines Laboratories (FR)

FEATURES source
1. .17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

BASE COUNT 9 a 3 c 2 g 3 t

Query Match 1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 769 ATCACATAAAATGAT 784
Db 2 ATCACATAAAACAGAT 17

RESULT 386
AX732065
LOCUS AX732065 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 3699 from Patent WO03025175.
ACCESSION AX732065
VERSION AX732065.1 GI:30511408
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines

JOURNAL Patent: WO 03025175-A 3699 27-MAR-2003;
Molecular Engines Laboratories (FR)

FEATURES source
1. .17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

BASE COUNT 8 a 3 c 3 g 3 t

Query Match 1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 573 ATCCAGACATACCTTA 588
Db 2 ATCCAGAGATACCTAA 17

RESULT 387
AX732416/c
LOCUS AX732416 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 4050 from Patent WO03025175.
ACCESSION AX732416
VERSION AX732416.1 GI:30511759
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines

JOURNAL Patent: WO 03025175-A 4050 27-MAR-2003;
Molecular Engines Laboratories (FR)

```

FEATURES
  source
    Location/Qualifiers
      1..17
        /organism="Homo sapiens"
        /mol_type="genomic DNA"
        /db_xref="taxon:9606"
BASE COUNT      3 a      3 c      2 g      9 t
Query Match      1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1099 AAGATGAATCATTTGAT 1114
      |||||
Db 17 AAGATGAACATAGAT 2

RESULT 388
AX733161/c
LOCUS
DEFINITION
ACCESSION AX733161
VERSION
KEYWORDS
SOURCE
ORGANISM
Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS
Telerman, A., Anson, R. and Tuijinder, M.
TITLE
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL
Patent: WO 03025175-A 4795 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
  source
    1..17
      /organism="Homo sapiens"
      /mol_type="genomic DNA"
      /db_xref="taxon:9606"
BASE COUNT      4 a      3 c      2 g      8 t
Query Match      1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1608 GAAACATTTAAATAT 1623
      |||||
Db 17 GGAACATTTAAAGAT 2

RESULT 389
AX733379
LOCUS
DEFINITION
ACCESSION AX733379
VERSION
KEYWORDS
SOURCE
ORGANISM
Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS
Telerman, A., Anson, R. and Tuijinder, M.
TITLE
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL
Patent: WO 03025175-A 5013 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
  source
    1..17
      /organism="Homo sapiens"
      /mol_type="genomic DNA"
      /db_xref="taxon:9606"
BASE COUNT      3 a      3 c      2 g      9 t
Query Match      1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1243 ATTCAGATAAACAC 1258
      |||||
Db 2 ATTCATAATAACAC 17

RESULT 390
AX733381
LOCUS
DEFINITION
ACCESSION AX733381
VERSION
KEYWORDS
SOURCE
ORGANISM
Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS
Telerman, A., Anson, R. and Tuijinder, M.
TITLE
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL
Patent: WO 03025175-A 5015 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
  source
    1..17
      /organism="Homo sapiens"
      /mol_type="genomic DNA"
      /db_xref="taxon:9606"
BASE COUNT      5 a      2 c      2 g      8 t
Query Match      1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1292 ATCTGAAATTTTAATT 1307
      |||||
Db 2 ATCTCAGATTTTAATT 17

RESULT 391
AX733982/c
LOCUS
DEFINITION
ACCESSION AX733982
VERSION
KEYWORDS
SOURCE
ORGANISM
Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS
Telerman, A., Anson, R. and Tuijinder, M.
TITLE
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL
Patent: WO 03025175-A 5616 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
  source
    1..17
      /organism="Homo sapiens"
      /mol_type="genomic DNA"
      /db_xref="taxon:9606"
BASE COUNT      6 a      3 c      2 g      6 t
Query Match      1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

QY 1462 TTATGTACAAATAGAT 1477
 Db 17 TTCTGTAGAAATAGAT 2

RESULT 392
 AX734084
 LOCUS 17 bp DNA linear PAT 08-MAY-2003
 DEFINITION Sequence 5718 from Patent WO03025175.
 ACCESSION AX734084
 VERSION AX734084.1 GI:30513427
 KEYWORDS Homo sapiens (human)
 SOURCE Homo sapiens
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
 Telerman, A., Anson, R. and Tuijnder, M.
 Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
 Patent: WO 03025175-A 5718 27-MAR-2003;
 Molecular Engines Laboratories (FR)
 Location/Qualifiers
 1..17
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"

BASE COUNT 6 a 3 c 2 g 6 t

Query Match 1.0%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 4.3e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1066 ATCAAAATATTGTGCA 1081
 Db 2 ATCAAAATCTTTGACA 17

RESULT 393
 AX734468/c
 LOCUS 17 bp DNA linear PAT 08-MAY-2003
 DEFINITION Sequence 58 from Patent WO03025177.
 ACCESSION AX734468
 VERSION AX734468.1 GI:30513745
 KEYWORDS Homo sapiens (human)
 SOURCE Homo sapiens
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
 Telerman, A., Anson, R. and Tuijnder, M.
 Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments
 Patent: WO 03025177-A 58 27-MAR-2003;
 Molecular Engines Laboratories (FR)
 Location/Qualifiers
 1..17
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"

BASE COUNT 10 a 2 c 1 g 4 t

Query Match 1.0%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 4.3e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1535 TTAAAGATGTTTTTAT 1550
 Db 17 TTATATATGTTTGAT 2

RESULT 394
 AX735132
 LOCUS 17 bp DNA linear PAT 08-MAY-2003
 DEFINITION Sequence 722 from Patent WO03025177.
 ACCESSION AX735132
 VERSION AX735132.1 GI:30514409
 KEYWORDS Homo sapiens (human)
 SOURCE Homo sapiens
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
 Telerman, A., Anson, R. and Tuijnder, M.
 Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments
 Patent: WO 03025177-A 722 27-MAR-2003;
 Molecular Engines Laboratories (FR)
 Location/Qualifiers
 1..17
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"

BASE COUNT 6 a 3 c 2 g 6 t

Query Match 1.0%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 4.3e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 573 ATCCGAGACATCTTA 588
 Db 2 ATCCGTGAACATATTTA 17

RESULT 395
 AX735198/c
 LOCUS 17 bp DNA linear PAT 08-MAY-2003
 DEFINITION Sequence 788 from Patent WO03025177.
 ACCESSION AX735198
 VERSION AX735198.1 GI:30514475
 KEYWORDS Homo sapiens (human)
 SOURCE Homo sapiens
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
 Telerman, A., Anson, R. and Tuijnder, M.
 Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments
 Patent: WO 03025177-A 788 27-MAR-2003;
 Molecular Engines Laboratories (FR)
 Location/Qualifiers
 1..17
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"

BASE COUNT 9 a 3 c 2 g 3 t

Query Match 1.0%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 4.3e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1567 TTTTACTGTTTCTGAT 1582
 Db 17 TTTTACTGTTTGAGAT 2

RESULT 396
 AX735395/c
 LOCUS 17 bp DNA linear PAT 08-MAY-2003
 DEFINITION Sequence 985 from Patent WO03025177.


```

source
1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606" 2 t
BASE COUNT 13 a 1 c 1 g 2 t
Query Match 1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1144 TTATTTATTTAGAT 1159
17 TTTTATTTTATTTAGAT 2
RESULT 403
AX738442/c 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 4032 from Patent WO03025177.
ACCESSION AX738442
VERSION AX738442.1 GI:30517730
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL Patent: WO 03025177-A 4032 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source 1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606" 10 t
BASE COUNT 2 a 2 c 3 g 10 t
Query Match 1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 619 AAAAAACACAAATAT 634
17 AAAAAACACAAAGTAT 2
RESULT 404
AX739113/c 17 bp DNA linear PAT 08-MAY-2003
LOCUS AX739113
DEFINITION Sequence 4703 from Patent WO03025177.
ACCESSION AX739113
VERSION AX739113.1 GI:30518410
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL Patent: WO 03025177-A 4703 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source 1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606" 9 t
BASE COUNT 4 a 1 c 3 g 9 t

```

```

Query Match      1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1250 ATAAACAACAATAAT 1265
DB 17 ATTAACAACAATGAT 2

RESULT 405
BD009326
LOCUS      17 bp      DNA      linear      PAT 31-JAN-2002
DEFINITION Viral variants and methods for detecting same.
ACCESSION  BD009326
VERSION     BD009326.1 GI:18637699
KEYWORDS   JP 2001503277-A/2.
SOURCE     unidentified
ORGANISM   unclassified.
REFERENCE  1 (bases 1 to 17)
AUTHORS   Locarnini,S.A., Bartholomeusz,A.I., Aye,T.T. and Man,R.A.D.
TITLE     Viral variants and methods for detecting same
JOURNAL   Patent: JP 2001503277-A 2 13-MAR-2001;
          NORTH WESTERN HEALTH CARE NETWORK
COMMENT   OS Hepatitis virus (hepatitis B virus)
          PN JP 2001503277-A/2
          PD 13-MAR-2001
          PP 15-AUG-1997 JP 1998521944
          PR 08-NOV-1996 AU PO 3519
          PI STEPHEN ALISTER LOCARNINI,ANGELINE INGRID BARTHOLOMEUSZ, PI
          THEIN THEIN AYE,
          FC C12N7/01,C12N7/00,C12N15/36,C12N15/54,C07K14/02 CC
          FH Key Location/Qualifiers
          FT Source 1..17
          /organism='Hepatitis virus (hepatitis B virus)'

FEATURES
source      Location/Qualifiers
1..17
/organism='unidentified'
/mol_type='genomic DNA'
/db_xref='taxon:32644'

BASE COUNT  5 a      4 c      1 g      7 t

Query Match      1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1556 CTCCAAAATTTTATA 1571
DB 2 CTCCAAAATCTTTATA 17

RESULT 406
BD009328
LOCUS      17 bp      DNA      linear      PAT 31-JAN-2002
DEFINITION Viral variants and methods for detecting same.
ACCESSION  BD009328
VERSION     BD009328.1 GI:18637701
KEYWORDS   JP 2001503277-A/4.
SOURCE     unidentified
ORGANISM   unclassified.
REFERENCE  1 (bases 1 to 17)
AUTHORS   Locarnini,S.A., Bartholomeusz,A.I., Aye,T.T. and Man,R.A.D.
TITLE     Viral variants and methods for detecting same
JOURNAL   Patent: JP 2001503277-A 4 13-MAR-2001;
          NORTH WESTERN HEALTH CARE NETWORK
COMMENT   OS Hepatitis virus (hepatitis B virus)
          PN JP 2001503277-A/4
          PD 13-MAR-2001
          PP 15-AUG-1997 JP 1998521944

```

```

PR 08-NOV-1996 AU PO 3519
PI STEPHEN ALISTER LOCARNINI,ANGELINE INGRID BARTHOLOMEUSZ, PI
THEIN THEIN AYE,
PI ROBERT A DE MAN
PC C12N7/01,C12N7/00,C12N15/36,C12N15/54,C07K14/02 CC
FH Key Location/Qualifiers
FT Source 1..17
/organism='Hepatitis virus (hepatitis B virus)'

FEATURES
source      Location/Qualifiers
1..17
/organism='unidentified'
/mol_type='genomic DNA'
/db_xref='taxon:32644'

BASE COUNT  5 a      4 c      1 g      7 t

Query Match      1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1556 CTCCAAAATTTTATA 1571
DB 2 CTCCAAAATCTTTATA 17

RESULT 407
BD009328
LOCUS      17 bp      DNA      linear      PAT 07-OCT-1997
DEFINITION Sequence 974 from patent US 5646042.
ACCESSION  I53233
VERSION     I53233.1 GI:2474436
KEYWORDS   Unknown.
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 17)
AUTHORS   Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE     C-myb targeted ribozymes
JOURNAL   Patent: US 5646042-A 974 08-JUL-1997;
FEATURES   Location/Qualifiers
source      1..17
/organism='unknown'

BASE COUNT  7 a      0 c      0 g      10 t

Query Match      1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1613 ATTTAAAATATAATT 1628
DB 17 AATAAAAATATAATT 2

RESULT 408
BD009328
LOCUS      17 bp      DNA      linear      PAT 07-OCT-1997
DEFINITION Sequence 2037 from patent US 5646042.
ACCESSION  I54296
VERSION     I54296.1 GI:2475499
KEYWORDS   Unknown.
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 17)
AUTHORS   Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE     C-myb targeted ribozymes
JOURNAL   Patent: US 5646042-A 2037 08-JUL-1997;
FEATURES   Location/Qualifiers
source      1..17
/organism='unknown'

BASE COUNT  6 a      0 c      3 g      8 t

Query Match      1.0%; Score 12.8; DB 1; Length 17;

```



```

Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1460 TATTATGTAACATAG 1475
Db 1 TATTATGTAACATAG 16

RESULT 409
LOCUS 154314/c
DEFINITION Sequence 2055 from patent US 5646042.
ACCESSION 154314
VERSION 154314.1 GI:2475517
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myb targeted ribozymes
JOURNAL Patent: US 5646042-A 2055 08-JUL-1997;
FEATURES Location/Qualifiers
source 1..17
BASE COUNT 7 a 0 c 0 g 10 t

Query Match 1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1613 ATTAAATATATATTT 1628
Db 17 AATAAATATATATTT 2

RESULT 410
LOCUS 154412
DEFINITION Sequence 2153 from patent US 5646042.
ACCESSION 154412
VERSION 154412.1 GI:2475615
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myb targeted ribozymes
JOURNAL Patent: US 5646042-A 2153 08-JUL-1997;
FEATURES Location/Qualifiers
source 1..17
BASE COUNT 4 a 0 c 0 g 13 t

Query Match 1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1040 TTTATTTATTTATGAT 1055
Db 2 TTTATTTATTTATAT 17

RESULT 411
LOCUS 154414
DEFINITION Sequence 2155 from patent US 5646042.
ACCESSION 154414
VERSION 154414.1 GI:2475617
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

```

```

Unclassified.
1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myb targeted ribozymes
JOURNAL Patent: US 5646042-A 2155 08-JUL-1997;
FEATURES Location/Qualifiers
source 1..17
BASE COUNT 5 a 0 c 0 g 12 t

Query Match 1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1040 TTTATTTATTTATGAT 1055
Db 1 TTTATTTATTTATAT 16

RESULT 412
LOCUS A58293
DEFINITION Sequence 5 from Patent WO9634980.
ACCESSION A58293
VERSION A58293.1 GI:3713957
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Laurent,C., Mallet,J. and Meloni,R.
TITLE METHOD FOR DIAGNOSING SCHIZOPHRENIA
JOURNAL Patent: WO 9634980-A 5 07-NOV-1996;
COMMENT RHONE POULENC RORER SA (FR)
Other publication AU 5767896 961121
Other publication FR 2732766 961108.
FEATURES Location/Qualifiers
source 1..18
BASE COUNT 1 a 8 c 1 g 8 t

Query Match 1.0%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 4.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 905 GTTCTCCCTTTATTC 920
Db 1 GTTCTCCCTTTATTC 16

RESULT 413
LOCUS A88563
DEFINITION Sequence 711 from Patent WO9833904.
ACCESSION A88563
VERSION A88563.1 GI:6737133
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 18)
AUTHORS Brysch,W. and Schlingensiepen,K.
TITLE AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
JOURNAL Patent: WO 9833904-A 711 06-AUG-1998;
FEATURES Location/Qualifiers
source 1..18
BASE COUNT 6 a 1 c 1 g 10 t

```

```

Query Match      1.0%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 4.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1173 TTATTAGATAAATTC 1188
Db 1 TTTTAAGATAAATTC 16

RESULT 414
A90530
LOCUS      A90530
DEFINITION Sequence 711 from Patent EP0856579.
ACCESSION  A90530
VERSION     A90530.1 GI:6739044
KEYWORDS   .
SOURCE      unidentified
ORGANISM    unclassified.
REFERENCE   1 (bases 1 to 18)
AUTHORS     Brysch,W.D. and Schlingsensiepen,K.D.
TITLE       An antisense oligonucleotide preparation method
JOURNAL     Patent: EP 0856579-A 711 05-AUG-1998;
            BIOGNOSTIK GES (DE)
FEATURES    Location/Qualifiers
            source
            1..18
            /organism="unidentified"
            /mol_type="genomic DNA"
            /db_xref="taxon:32644"
BASE COUNT  6 a 1 c 1 g 10 t

Query Match      1.0%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 4.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1173 TTATTAGATAAATTC 1188
Db 1 TTTTAAGATAAATTC 16

RESULT 415
A91289
LOCUS      A91289
DEFINITION Sequence 35 from Patent WO9826075.
ACCESSION  A91289
VERSION     A91289.1 GI:6740302
KEYWORDS   .
SOURCE      unidentified
ORGANISM    unclassified.
REFERENCE   1 (bases 1 to 18)
AUTHORS     Lousset-Ajaka,I. and Mauciere,P.
TITLE       NON-M NON-O HIV STRAINS, FRAGMENTS AND APPLICATIONS
JOURNAL     Patent: WO 9826075-A 35 18-JUN-1998;
            ASSIST PUBL HOPITAUX DE PARIS (FR); INST NAT SANTE RECH MED (FR)
FEATURES    Location/Qualifiers
            source
            1..18
            /organism="unidentified"
            /mol_type="genomic DNA"
            /db_xref="taxon:32644"
BASE COUNT  6 a 4 c 4 g 4 t

Query Match      1.0%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 4.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 410 TATCCAGGATCAGTG 425
Db 3 TATCCAGGATCAGAG 18

RESULT 416
A96945/c
LOCUS      A96945
DEFINITION Sequence 23 from Patent WO9922023.
ACCESSION  A96945
VERSION     A96945.1 GI:6780386
KEYWORDS   .
SOURCE      unidentified
ORGANISM    unclassified.
REFERENCE   1 (bases 1 to 18)
AUTHORS     Epping,B. and Leiser,M.
TITLE       METHOD FOR IDENTIFYING MICRO-ORGANISMS
JOURNAL     Patent: WO 9922023-A 23 06-MAY-1999;
            MIRA DIAGNOSTICA GMBH (DE); EPPING BERND (DE)
FEATURES    Location/Qualifiers
            source
            1..18
            /organism="unidentified"
            /mol_type="genomic DNA"
            /db_xref="taxon:32644"
BASE COUNT  5 a 5 c 5 t

Query Match      1.0%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 4.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 726 TTTCCAGGAATGATG 741
Db 17 TTTCCAGGATGCGATG 2

RESULT 417
A97456/c
LOCUS      A97456
DEFINITION Sequence 12 from Patent WO9916780.
ACCESSION  A97456
VERSION     A97456.1 GI:6780802
KEYWORDS   .
SOURCE      unidentified
ORGANISM    unclassified.
REFERENCE   1 (bases 1 to 18)
AUTHORS     Gala,J. and Vannuffel,P.
TITLE       GENETIC SEQUENCES, DIAGNOSTIC AND/OR QUANTIFICATION METHODS AND
            DEVICES FOR THE IDENTIFICATION OF STAPHYLOCOCCI STRAINS
JOURNAL     Patent: WO 9916780-A 12 08-APR-1999;
            GALA JEAN LUC (BE); UNIV LOUVAIN (BE)
FEATURES    Location/Qualifiers
            source
            1..18
            /organism="unidentified"
            /mol_type="genomic DNA"
            /db_xref="taxon:32644"
BASE COUNT  12 a 1 c 3 g 2 t

Query Match      1.0%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 4.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1562 ATTTTCTTACTGTTT 1577
Db 16 ATTTTCTTACTGTTT 1

RESULT 418
A99272
LOCUS      A99272
DEFINITION Sequence 48 from Patent WO9907839.
ACCESSION  A99272
VERSION     A99272.1 GI:6782201
KEYWORDS   .
SOURCE      unidentified
ORGANISM    unclassified.
REFERENCE   1 (bases 1 to 18)

```

AUTHORS Min.J.W. and Piers,W.
TITLE NEW IMMUNOPROTECTIVE INFLUENZA ANTIGEN AND ITS USE IN VACCINATION
JOURNAL Patent: WO 9907839-A 48 18-FEB-1999;
VLAAMS INTERUNIV INST BIOTECH (BE); MIN JOU WILLY (BE)
FEATURES
source
1. .18
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
BASE COUNT 7 a 0 c 6 g 5 t
Query Match 1.0%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 4.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1155 TAGATATTAATGATG 1170
|||||
Db 3 TAGATATTGAAGATG 18
RESULT 419
AR083978/c
LOCUS AR083978 18 bp DNA linear PAT 01-SEP-2000
DEFINITION Sequence 37 from patent US 5977337.
ACCESSION AR083978
VERSION AR083978.1 GI:10010749
KEYWORDS
SOURCE Unknown.
ORGANISM
Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Loomore,S.M., Du,R.-P., Wang,Q., Yang,Y.-P. and Klein,M.H.
TITLE Lactoferrin receptor genes of Moraxella
JOURNAL Patent: US 5977337-A 37 02-NOV-1999;
FEATURES
source
1. .18
/organism="unknown"
BASE COUNT 7 a 1 c 3 g 7 t
Query Match 1.0%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 4.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1233 TTAATTTTCATTTC 1248
|||||
Db 18 TTAATACTTCATTCA 3
RESULT 420
AR087025/c
LOCUS AR087025 18 bp DNA linear PAT 07-SEP-2000
DEFINITION Sequence 22 from patent US 5985663.
ACCESSION AR087025
VERSION AR087025.1 GI:10013791
KEYWORDS
SOURCE Unknown.
ORGANISM
Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Bennett,C.Frank. and Cowser,L.M.
TITLE Antisense inhibition of interleukin-15 expression
JOURNAL Patent: US 5985663-A 22 16-NOV-1999;
FEATURES
source
1. .18
/organism="unknown"
BASE COUNT 4 a 3 c 8 g 3 t
Query Match 1.0%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 4.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1339 CTGTGATTCAGCT 1354
|||||

Db 16 CTGTCATAGCCAGCT 1
RESULT 421
AR144082
LOCUS AR144082 18 bp DNA linear PAT 08-AUG-2001
DEFINITION Sequence 5 from patent US 6210879.
ACCESSION AR144082
VERSION AR144082.1 GI:15105949
KEYWORDS
SOURCE Unknown.
ORGANISM
Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Meloni,R., Laurent,C. and Mallet,J.
TITLE Method for diagnosing schizophrenia
JOURNAL Patent: US 6210879-A 5 03-APR-2001;
FEATURES
source
1. .18
/organism="unknown"
BASE COUNT 1 a 8 c 1 g 8 t
Query Match 1.0%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 4.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 905 GTTCTCCTTATTC 920
|||||
Db 1 GTTCTCCTTATTC 16
RESULT 422
AR173914
LOCUS AR173914 18 bp DNA linear PAT 17-DEC-2001
DEFINITION Sequence 112 from patent US 6306606.
ACCESSION AR173914
VERSION AR173914.1 GI:17914234
KEYWORDS
SOURCE Unknown.
ORGANISM
Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Weber,M.J., Wyatt,J. and Cowser,L.M.
TITLE Antisense modulation of MP-1 expression
JOURNAL Patent: US 6306606-A 112 23-OCT-2001;
FEATURES
source
1. .18
/organism="unknown"
BASE COUNT 1 a 5 c 5 g 7 t
Query Match 1.0%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 4.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1353 CTGTGTTGCTAGTCT 1368
|||||
Db 3 CTGTGTTGCTAGTCT 18
RESULT 423
AR215601/c
LOCUS AR215601 18 bp DNA linear PAT 25-SEP-2002
DEFINITION Sequence 149 from patent US 6410323.
ACCESSION AR215601
VERSION AR215601.1 GI:23313857
KEYWORDS
SOURCE Unknown.
ORGANISM
Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Roberts,M.L. and Cowser,L.M.
TITLE Antisense modulation of human Rho family gene expression
JOURNAL Patent: US 6410323-A 149 25-JUN-2002;

```
FEATURES          Location/Qualifiers
source            1..18
                /organism="unknown"
BASE COUNT      7 a 5 c 4 g 2 t
Query Match      1.0%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 4.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 827 CCTGGATTTTCTG 842
Db 18 CCTGGATTTTCTG 3
RESULT 424
AR223848
LOCUS            18 bp mRNA linear PAT 26-SEP-2002
DEFINITION      Sequence 15 from patent US 6440660.
ACCESSION       AR223848
VERSION         AR223848.1 GI:23332430
KEYWORDS
SOURCE          Unknown.
ORGANISM        Unclassified.
REFERENCE       1 (bases 1 to 18)
AUTHORS        Barker,R.H. Jr., Rapaport,E. and Zamecnik,P.C.
TITLE          Oligonucleotide mediated reversal of drug resistance
JOURNAL        Patent: US 6440660-A 15 27-AUG-2002;
FEATURES
source          1..18
                /organism="unknown"
BASE COUNT      7 a 2 c 2 g 7 t
Query Match      1.0%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 4.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1259 AAATAATTTTCTAGTA 1274
Db 2 AAATAATTTTCTCGTA 17
RESULT 425
AR223849/c
LOCUS            18 bp mRNA linear PAT 26-SEP-2002
DEFINITION      Sequence 16 from patent US 6440660.
ACCESSION       AR223849
VERSION         AR223849.1 GI:23332431
KEYWORDS
SOURCE          Unknown.
ORGANISM        Unclassified.
REFERENCE       1 (bases 1 to 18)
AUTHORS        Barker,R.H. Jr., Rapaport,E. and Zamecnik,P.C.
TITLE          Oligonucleotide mediated reversal of drug resistance
JOURNAL        Patent: US 6440660-A 15 27-AUG-2002;
FEATURES
source          1..18
                /organism="unknown"
BASE COUNT      7 a 2 c 2 g 7 t
Query Match      1.0%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 4.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1259 AAATAATTTTCTAGTA 1274
Db 17 AAATAATTTTCTCGTA 2
RESULT 426
AR242371/c
LOCUS            18 bp DNA linear PAT 20-DEC-2002
FEATURES          Location/Qualifiers
source            1..18
                /organism="unknown"
BASE COUNT      7 a 5 c 4 g 2 t
Query Match      1.0%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 4.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 827 CCTGGATTTTCTG 842
Db 18 CCTGGATTTTCTG 3
RESULT 427
AR275401
LOCUS            18 bp DNA linear PAT 10-APR-2003
DEFINITION      Sequence 35 from patent US 6509018.
ACCESSION       AR275401
VERSION         AR275401.1 GI:29708514
KEYWORDS
SOURCE          Unknown.
ORGANISM        Unclassified.
REFERENCE       1 (bases 1 to 18)
AUTHORS        Mauciere,P., Lousert-Ajaka,I., Simon,P., Saragosti,S. and
                Barre-Sinoussi,F.
TITLE          Non-M non-O HIV strains, fragments and uses
JOURNAL        Patent: US 6509018-A 35 21-JAN-2003;
FEATURES
source          1..18
                /organism="unknown"
BASE COUNT      6 a 4 c 4 g 4 t
Query Match      1.0%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 4.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 410 TATCCAGATCATCGTG 425
Db 3 TATCCAGATCATCGAG 18
RESULT 428
AR275453
LOCUS            18 bp DNA linear PAT 10-APR-2003
DEFINITION      Sequence 91 from patent US 6509018.
ACCESSION       AR275453
VERSION         AR275453.1 GI:29708566
KEYWORDS
SOURCE          Unknown.
ORGANISM        Unclassified.
REFERENCE       1 (bases 1 to 18)
AUTHORS        Mauciere,P., Lousert-Ajaka,I., Simon,P., Saragosti,S. and
                Barre-Sinoussi,F.
TITLE          Non-M non-O HIV strains, fragments and uses
JOURNAL        Patent: US 6509018-A 91 21-JAN-2003;
FEATURES
source          1..18
                /organism="unknown"
```

BASE COUNT 6 a 4 c 4 g 4 t

Query Match 1.0%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 4.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 410 TATCCAGATCAGTG 425
 Db 3 TATCCAGATCAGG 18

RESULT 429
 AR293515/c
 LOCUS 18 bp DNA linear PAT 12-JUN-2003
 DEFINITION Sequence 5250 from patent US 6537751.
 ACCESSION AR293515
 VERSION AR293515.1 GI:31680799
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.

REFERENCE 1 (bases 1 to 18)
 AUTHORS Cohen, D., Chumakov, I. and Blumenfeld, M.
 TITLE Biallelic markers for use in constructing a high density disequilibrium map of the human genome
 JOURNAL Patent: US 6537751-A 5250 25-MAR-2003;
 FEATURES Location/Qualifiers
 source 1..18 /organism="unknown"

BASE COUNT 6 a 6 c 3 g 3 t

Query Match 1.0%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 4.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 820 TGGAAATCCTGGATT 835
 Db 17 TGGAAAGCCTGGTTT 2

RESULT 430
 AR294351
 LOCUS 18 bp DNA linear PAT 12-JUN-2003
 DEFINITION Sequence 6086 from patent US 6537751.
 ACCESSION AR294351
 VERSION AR294351.1 GI:31681635
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.

REFERENCE 1 (bases 1 to 18)
 AUTHORS Cohen, D., Chumakov, I. and Blumenfeld, M.
 TITLE Biallelic markers for use in constructing a high density disequilibrium map of the human genome
 JOURNAL Patent: US 6537751-A 6086 25-MAR-2003;
 FEATURES Location/Qualifiers
 source 1..18 /organism="unknown"

BASE COUNT 2 a 2 c 6 g 8 t

Query Match 1.0%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 4.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1566 TTTTACTGTTCTGA 1581
 Db 1 TGTTACTGTTCTGA 16

RESULT 431
 AX132977/c
 LOCUS 18 bp DNA linear PAT 15-MAY-2001
 DEFINITION Sequence 4195 from Patent WO0130362.

ACCESSION AX132977
 VERSION AX132977.1 GI:14139287
 KEYWORDS Homo sapiens (human)
 SOURCE Homo sapiens
 ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
 AUTHORS Robbins, J.M. and Tritz, R.
 TITLE Ribozyme therapy for the treatment of proliferative skin and eye diseases
 JOURNAL Patent: WO 0130362-A 4195 03-MAY-2001;
 JOURNAL IMMUSOL, INC. (US)
 FEATURES Location/Qualifiers
 source 1..18 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"
 /note="Hammerhead ribozyme recognition site for cdc 2 kinase"

BASE COUNT 6 a 2 c 3 g 7 t

Query Match 1.0%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 4.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1173 TTATTAGATAAATTC 1188
 Db 18 TTATTAGAGAAATTC 3

RESULT 432
 AX132979/c
 LOCUS 18 bp DNA linear PAT 15-MAY-2001
 DEFINITION Sequence 4197 from Patent WO0130362.
 ACCESSION AX132979
 VERSION AX132979.1 GI:14139289
 KEYWORDS Homo sapiens (human)
 SOURCE Homo sapiens
 ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
 AUTHORS Robbins, J.M. and Tritz, R.
 TITLE Ribozyme therapy for the treatment of proliferative skin and eye diseases
 JOURNAL Patent: WO 0130362-A 4197 03-MAY-2001;
 JOURNAL IMMUSOL, INC. (US)
 FEATURES Location/Qualifiers
 source 1..18 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"
 /note="Hammerhead ribozyme recognition site for cdc 2 kinase"

BASE COUNT 7 a 2 c 2 g 7 t

Query Match 1.0%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 4.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1172 TTATTAGATAAATTC 1187
 Db 16 TTATTAGAGAAATTC 1

RESULT 433
 AX133131/c
 LOCUS 18 bp DNA linear PAT 15-MAY-2001
 DEFINITION Sequence 4349 from Patent WO0130362.
 ACCESSION AX133131
 VERSION AX133131.1 GI:14139441
 KEYWORDS

SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1
 AUTHORS Robbins,J.M. and Tritz,R.
 TITLE Ribozyme therapy for the treatment of proliferative skin and eye diseases
 JOURNAL Patent: WO 0130362-A 4349 03-MAY-2001;
 IMXUSOL, INC. (US)
 FEATURES source
 1..18
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"
 /note="Hammerhead ribozyme recognition site for cdc 2 kinase"
 BASE COUNT 7 a 3 c 3 g 5 t
 Query Match 1.0%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 4.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 795 ATTTTCCATAAAGTC 810
 Db 18 ATTTTCCAGAAATTC 3
 RESULT 434
 AX235061/c
 LOCUS AX235061 18 bp DNA linear PAT 11-SEP-2001
 DEFINITION Sequence 18 from Patent WO0163540.
 ACCESSION AX235061
 VERSION AX235061.1 GI:15593709
 KEYWORDS synthetic construct
 SOURCE synthetic construct
 ORGANISM artificial sequences.
 REFERENCE 1
 AUTHORS Bureau,T.
 TITLE Method for identifying transposons from a nucleic acid database
 JOURNAL Patent: WO 0163540-A 18 30-AUG-2001;
 MCGILL UNIVERSITY (CA)
 FEATURES source
 1..18
 /organism="synthetic construct"
 /mol_type="genomic DNA"
 /db_xref="taxon:32630"
 /note="sequence from gi 2264308"
 BASE COUNT 7 a 1 c 2 g 8 t
 Query Match 1.0%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 4.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1593 TATAAAGTAAATATG 1608
 Db 18 TATAAATCTAAATATG 3
 RESULT 435
 AX252918
 LOCUS AX252918 18 bp DNA linear PAT 05-OCT-2001
 DEFINITION Sequence 388 from Patent WO0168910.
 ACCESSION AX252918
 VERSION AX252918.1 GI:15986189
 KEYWORDS synthetic construct
 SOURCE synthetic construct
 ORGANISM artificial sequences.
 REFERENCE 1
 AUTHORS Berlin,K.
 TITLE Oligonucleotides or pna oligomers and a method for detecting the

methylation state of genomic dna in a parallel manner
 Patent: WO 0168910-A 388 20-SEP-2001;
 JOURNAL Epigenomics AG (DE)
 FEATURES source
 1..18
 /organism="synthetic construct"
 /mol_type="genomic DNA"
 /db_xref="taxon:32630"
 /note="Beschreibung der kunstlichen Sequenz:Oligonukleotid"
 BASE COUNT 4 a 0 c 3 g 11 t
 Query Match 1.0%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 4.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1143 TTATTATTTATTAGA 1158
 Db 3 TTATGTTGATTTAGA 18
 RESULT 436
 AX348483/c
 LOCUS AX348483 18 bp DNA linear PAT 06-FEB-2002
 DEFINITION Sequence 178 from Patent WO0202806.
 ACCESSION AX348483
 VERSION AX348483.1 GI:18614519
 KEYWORDS synthetic construct
 SOURCE synthetic construct
 ORGANISM artificial sequences.
 REFERENCE 1
 AUTHORS Olek,A., Piepenbrock,C. and Berlin,K.
 TITLE Method and nucleic acids for pharmacogenomic methylation analysis
 JOURNAL Patent: WO 0202806-A 178 10-JAN-2002;
 Epigenomics AG (DE)
 FEATURES source
 1..18
 /organism="synthetic construct"
 /mol_type="genomic DNA"
 /db_xref="taxon:32630"
 /note="SOD1 detection oligomer"
 BASE COUNT 2 a 0 c 5 g 11 t
 Query Match 1.0%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 4.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1400 ATTAAACAGCCAAA 1415
 Db 17 ATTAAACACCCAAA 2
 RESULT 437
 AX349206
 LOCUS AX349206 18 bp DNA linear PAT 06-FEB-2002
 DEFINITION Sequence 132 from Patent WO0202808.
 ACCESSION AX349206
 VERSION AX349206.1 GI:18615241
 KEYWORDS synthetic construct
 SOURCE synthetic construct
 ORGANISM artificial sequences.
 REFERENCE 1
 AUTHORS Olek,A., Piepenbrock,C. and Berlin,K.
 TITLE Method and nucleic acids for the analysis of astrocytomas
 JOURNAL Patent: WO 0202808-A 132 10-JAN-2002;
 Epigenomics AG (DE)
 FEATURES source
 1..18
 /organism="synthetic construct"
 /mol_type="genomic DNA"
 /db_xref="taxon:32630"

Best Local Similarity 87.5%; Pred. No. 4.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

BASE COUNT 11 a 4 c 0 g 3 t

Query Match 1.0%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 4.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1400 ATTAACACAGCCAAA 1415
Db 2 ATTAACACACCTAAA 17

RESULT 438

AX468612
LOCUS AX468612 18 bp DNA linear PAT 16-JUL-2002
DEFINITION Sequence 7 from Patent WO240710.

ACCESSION AX468612

VERSION AX468612.1 GI:21901410

KEYWORDS synthetic construct

SOURCE synthetic construct

ORGANISM synthetic construct

REFERENCE 1

AUTHORS Olek.A., Piepenbrock,C. and Berlin.K.

TITLE Method for detecting methylation states for a toxicological

JOURNAL diagnostic

Patent: WO 0240710-A 7 23-MAY-2002;

Epigenomics AG (DE)

FEATURES Location/Qualifiers

source 1..18

/organism="synthetic construct"

/mol_type="genomic DNA"

/db_xref="taxon:32630"

/note="Chemically treated genomic DNA (Homo sapiens)"

BASE COUNT 2 a 0 c 4 g 12 t

Query Match 1.0%; Score 12.8; DB 1; Length 18;

Best Local Similarity 87.5%; Pred. No. 4.7e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1143 TTTATTTATTTAGG 1158
Db 2 TTTTATTTGTTTAGA 17

RESULT 439

AX599210
LOCUS AX599210 18 bp DNA linear PAT 14-FEB-2003
DEFINITION Sequence 550 from Patent WO02077272.

ACCESSION AX599210

VERSION AX599210.1 GI:28399352

KEYWORDS synthetic construct

SOURCE synthetic construct

ORGANISM synthetic construct

REFERENCE 1

AUTHORS Berlin,K., Braun,A., Distler,J., Guetig,D., Howe,A., Mueller,J.,

Olek.A., Piepenbrock,C., Adorjan,P., Grabs,G., Lesche,R., Leu,E.,

Lewin,A., Lipscher,E., Maier,S., Model,F., Mueller,V., Otto,T.,

Pelet,C. and Ziebarth,H.

TITLE Methods and nucleic acids for the analysis of hematopoietic cell

proliferative disorders

JOURNAL Patent: WO 02077272-A 550 03-OCT-2002;

Epigenomics AG (DE)

FEATURES Location/Qualifiers

source 1..18

/organism="synthetic construct"

/mol_type="genomic DNA"

/db_xref="taxon:32630"

/note="Detection oligonucleotide for EGR4"

BASE COUNT 8 a 0 c 2 g 8 t

Query Match 1.0%; Score 12.8; DB 1; Length 18;

Best Local Similarity 87.5%; Pred. No. 4.7e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1124 ATAAAGATCTTAGT 1139
Db 2 ATAAATATGTTTAGT 17

RESULT 440

AX599319/c
LOCUS AX599319/c 18 bp DNA linear PAT 14-FEB-2003
DEFINITION Sequence 659 from Patent WO02077272.

ACCESSION AX599319

VERSION AX599319.1 GI:28399461

KEYWORDS synthetic construct

SOURCE synthetic construct

ORGANISM synthetic construct

REFERENCE 1

AUTHORS Berlin,K., Braun,A., Distler,J., Guetig,D., Howe,A., Mueller,J.,

Olek.A., Piepenbrock,C., Adorjan,P., Grabs,G., Lesche,R., Leu,E.,

Lewin,A., Lipscher,E., Maier,S., Model,F., Mueller,V., Otto,T.,

Pelet,C. and Ziebarth,H.

TITLE Methods and nucleic acids for the analysis of hematopoietic cell

proliferative disorders

JOURNAL Patent: WO 02077272-A 659 03-OCT-2002;

Epigenomics AG (DE)

FEATURES Location/Qualifiers

source 1..18

/organism="synthetic construct"

/mol_type="genomic DNA"

/db_xref="taxon:32630"

/note="Detection oligonucleotide for ARHI"

BASE COUNT 4 a 1 c 4 g 9 t

Query Match 1.0%; Score 12.8; DB 1; Length 18;

Best Local Similarity 87.5%; Pred. No. 4.7e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 620 AAAACACAAATTAAT 635
Db 17 AAAACTACGAATAAT 2

RESULT 441

AX599396/c
LOCUS AX599396/c 18 bp DNA linear PAT 14-FEB-2003
DEFINITION Sequence 736 from Patent WO02077272.

ACCESSION AX599396

VERSION AX599396.1 GI:28399540

KEYWORDS synthetic construct

SOURCE synthetic construct

ORGANISM synthetic construct

REFERENCE 1

AUTHORS Berlin,K., Braun,A., Distler,J., Guetig,D., Howe,A., Mueller,J.,

Olek.A., Piepenbrock,C., Adorjan,P., Grabs,G., Lesche,R., Leu,E.,

Lewin,A., Lipscher,E., Maier,S., Model,F., Mueller,V., Otto,T.,

Pelet,C. and Ziebarth,H.

TITLE Methods and nucleic acids for the analysis of hematopoietic cell

proliferative disorders

JOURNAL Patent: WO 02077272-A 736 03-OCT-2002;

Epigenomics AG (DE)

FEATURES Location/Qualifiers

source 1..18

/organism="synthetic construct"

/mol_type="genomic DNA"

/db_xref="taxon:32630"

/note="Detection oligonucleotide for DAPK1"

BASE COUNT 3 a 0 c 4 g 11 t

Query Match 1.0%; Score 12.8; DB 1; Length 18;

Best Local Similarity 87.5%; Pred. No. 4.7e+02;

```

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 611 AATCTACAAAACAA 626
Db 16 AATTTCCAAAACAA 1

RESULT 442
AX599722
LOCUS AX599722
DEFINITION Sequence 1062 from Patent WO02077272.
ACCESSION AX599722
VERSION AX599722.1 GI:28399870
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Berlin, K., Braun, A., Distler, J., Guetig, D., Howe, A., Mueller, J.,
Olek, A., Piepenbrock, C., Adorian, P., Grabs, G., Lesche, R., Leu, E.,
Lewin, A., Lipscher, E., Maier, S., Model, F., Mueller, V., Otto, T.,
Pellet, C., and Ziebarth, H.
TITLE Methods and nucleic acids for the analysis of hematopoietic cell
proliferative disorders
JOURNAL Patent: WO 02077272-A 1062 03-OCT-2002;
Epigenomics AG (DE)
FEATURES
source
Location/Qualifiers
1..18
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/note="Detection oligonucleotide for ELK1"
BASE COUNT 4 a 1 c 1 g 12 t

Query Match 1.0%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 4.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 833 TTTTTCGTTAAAT 848
Db 1 TTTTTCGTTAAAT 15

RESULT 443
AX657871
LOCUS AX657871
DEFINITION Sequence 116 from Patent WO02103042.
ACCESSION AX657871
VERSION AX657871.1 GI:29160567
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Distler, J., Model, F., and Adorian, P.
TITLE Method and nucleic acids for the differentiation of prostate tumors
JOURNAL Patent: WO 02103042-A 116 27-DEC-2002;
Epigenomics AG (DE)
FEATURES
source
Location/Qualifiers
1..18
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/note="TGFA detection oligomer"
BASE COUNT 2 a 0 c 4 g 12 t

Query Match 1.0%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 4.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1143 TTTATTATTATTAGA 1158
Db 2 TTTTTCGTTAAAT 17

```

```

RESULT 444
AX705830
LOCUS AX705830
DEFINITION Sequence 499 from Patent WO03014388.
ACCESSION AX705830
VERSION AX705830.1 GI:29562495
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Distler, J., Model, F., and Taubert, H.
TITLE Method and nucleic acids for the analysis of colon cancer
JOURNAL Patent: WO 03014388-A 499 20-FEB-2003;
Epigenomics AG (DE)
FEATURES
source
Location/Qualifiers
1..18
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/note="Detection oligonucleotide for CEA"
BASE COUNT 4 a 0 c 4 g 10 t

Query Match 1.0%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 4.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1535 TTTAAGATGTTTAT 1550
Db 2 TTTAAGATGTTTAT 17

RESULT 445
BD066076
LOCUS BD066076
DEFINITION An antisense oligonucleotide preparation method.
ACCESSION BD066076
VERSION BD066076.1 GI:22611679
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Schlingensiepen, K.H. and Brysch, W.
TITLE An antisense oligonucleotide preparation method
JOURNAL Patent: JP 2001511000-A 711 07-AUG-2001;
BIOGNOSTIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH
COMMENT
OS Unknown
PN JP 2001511000-A/711
PD 07-AUG-2001
PF 30-JAN-1998 JP 1998532533
PR 31-JAN-1997 EP 97101531.8
PI KARL HERMANN SCHLINGENSIEPEN, WOLFGANG BRYSCH
PC C12N15/11.C07H21/04.A61K31/70
CC An antisense oligonucleotide preparation method FH Key
FT source
Location/Qualifiers
1..18
/organism="Unknown"
FEATURES
source
Location/Qualifiers
1..18
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
BASE COUNT 6 a 1 c 1 g 10 t

Query Match 1.0%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 4.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1173 TTTATGATTAATTC 1188
Db 2 TTTTTCGTTAAAT 17

```


Db	1	TTTTAGATAAATTC	16	
RESULT 446				
BD080876/c				
LOCUS		18 bp	DNA	linear
DEFINITION		Gene sequence for identification of Staphylococci strains, diagnosis and/or quantitation method, and apparatus.		
ACCESSION	BD080876			
VERSION	BD080876.1	GI:22626479		
KEYWORDS	JP 2001518283-A/12.			
SOURCE	unidentified			
ORGANISM	unclassified.			
REFERENCE	1	(bases 1 to 18)		
AUTHORS	Vannuffel, P. and Gala, J.L.			
TITLE	Gene sequence for identification of Staphylococci strains, diagnosis and/or quantitation method, and apparatus			
JOURNAL	Patent: JP 2001518283-A 12 16-OCT-2001;			
COMMENT	UNIVERSITE CATHOLIQUE DE LOUVAIN, MINISTRE DE LA DEFENSE NATIONALE			
OS	Fsq2S			
PN	JP 2001518283-A/12			
PD	16-OCT-2001			
PF	28-SEP-1998	JP 2000513862		
PR	26-SEP-1997	EP 97870146.4		
PI	PASCAL VANNUFFEL, JEAN LUC GALA			
PC	Cl2Q1/68, Cl2NI15/09, Cl2NI15/00			
CC	Strandedness: Single;			
CC	Topology: Linear;			
CC	Gene sequence for identification of Staphylococci strains, CC diagnosis			
CC	and/or quantitation method, and apparatus			
FT	Key	Location/Qualifiers		
FT	source	1..18		
FEATURES	source	Location/Qualifiers		
		1..18		
		/organism="unidentified"		
		/mol_type="genomic DNA"		
		/db_xref="taxon:32644"		
BASE COUNT	12 a	1 c	3 g	2 t
Query Match		1.0%;	Score 12.6;	DB 1; Length 18;
Best Local Similarity		87.5%;	Pred. No. 4.7e+02;	
Matches	14;	Conservative	0; Mismatches	2; Indels 0; Gaps 0;
Qy	1562	ATTTTCTTACTGTTT	1577	
Db	16	ATTTTCTTACTGTTT	1	
RESULT 447				
AX129503/c				
LOCUS		19 bp	DNA	linear
DEFINITION		Sequence 721 from Patent WO0130362.		
ACCESSION	AX129503			
VERSION	AX129503.1	GI:14135808		
KEYWORDS	Homo sapiens (human)			
SOURCE	Homo sapiens			
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.			
REFERENCE	1			
AUTHORS	Robbins, J.M. and Tritz, R.			
TITLE	Ribozyme therapy for the treatment of proliferative skin and eye diseases			
JOURNAL	Patent: WO 0130362-A 721 03-MAY-2001;			
FEATURES	IMMUSOL, INC. (US)			
source	Location/Qualifiers			
	1..19			
	/organism="Homo sapiens"			
	/mol_type="genomic DNA"			
	/db_xref="taxon:9606"			
BASE COUNT	12 a	1 c	3 g	2 t
Query Match		1.0%;	Score 12.6;	DB 1; Length 18;
Best Local Similarity		87.5%;	Pred. No. 4.7e+02;	
Matches	14;	Conservative	0; Mismatches	2; Indels 0; Gaps 0;
Qy	1562	ATTTTCTTACTGTTT	1577	
Db	16	ATTTTCTTACTGTTT	1	
RESULT 448				
AX129503/c				
LOCUS		19 bp	DNA	linear
DEFINITION		Sequence 721 from Patent WO0130362.		
ACCESSION	AX129503			
VERSION	AX129503.1	GI:14135808		
KEYWORDS	Homo sapiens (human)			
SOURCE	Homo sapiens			
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.			
REFERENCE	1			
AUTHORS	Robbins, J.M. and Tritz, R.			
TITLE	Ribozyme therapy for the treatment of proliferative skin and eye diseases			
JOURNAL	Patent: WO 0130362-A 721 03-MAY-2001;			
FEATURES	IMMUSOL, INC. (US)			
source	Location/Qualifiers			
	1..19			
	/organism="Homo sapiens"			
	/mol_type="genomic DNA"			
	/db_xref="taxon:9606"			
BASE COUNT	12 a	1 c	3 g	2 t
Query Match		1.0%;	Score 12.6;	DB 1; Length 18;
Best Local Similarity		87.5%;	Pred. No. 4.7e+02;	
Matches	14;	Conservative	0; Mismatches	2; Indels 0; Gaps 0;
Qy	1562	ATTTTCTTACTGTTT	1577	
Db	16	ATTTTCTTACTGTTT	1	
RESULT 449				
AX129503/c				
LOCUS		18 bp	DNA	linear
DEFINITION		Sequence 19 from Patent WO0231157.		
ACCESSION	AX417571			
VERSION	AX417571.1	GI:21522808		
KEYWORDS	synthetic construct			
SOURCE	synthetic construct			
ORGANISM	artificial sequences.			
REFERENCE	1			
AUTHORS	Gardner, R., Nilsen, I. and Overboe, K.			
TITLE	Shrimp alkaline phosphatase			
JOURNAL	Patent: WO 0231157-A 19 18-APR-2002;			
FEATURES	NORWEGIAN INST OF FISHERIES & (NO)			
source	Location/Qualifiers			
	1..18			
	/organism="synthetic construct"			
	/mol_type="genomic DNA"			
	/db_xref="taxon:32630"			
BASE COUNT	7 a	1 c	3 g	2 t
Query Match		1.0%;	Score 12.6;	DB 1; Length 18;
Best Local Similarity		66.7%;	Pred. No. 5.2e+02;	
Matches	12;	Conservative	3; Mismatches	3; Indels 0; Gaps 0;
Qy	886	CTGTGTCACCTGCTT	903	
Db	18	YTTTTCCTGCTGCTT	1	
BASE COUNT	5 a	1 c	4 g	9 t
Query Match		1.0%;	Score 12.8;	DB 1; Length 19;
Best Local Similarity		87.5%;	Pred. No. 5.1e+02;	
Matches	14;	Conservative	0; Mismatches	2; Indels 0; Gaps 0;
Qy	798	TTGCCATAAAGTCAAA	813	
Db	19	TTTCCATAAATCAAA	4	
RESULT 448				
AR207847				
LOCUS		17 bp	DNA	linear
DEFINITION		Sequence 20 from patent US 6379928.		
ACCESSION	AR207847			
VERSION	AR207847.1	GI:21507707		
KEYWORDS	Unknown.			
SOURCE	Unknown.			
ORGANISM	Unclassified.			
REFERENCE	1	(bases 1 to 17)		
AUTHORS	Berka, R. Michael., Cullen, D., Gray, G. Lawrence., Hayenga, K. James. and Lawlis, V. Bryan.			
TITLE	Heterologous polypeptides expressed in filamentous fungi, processes for making same, and vectors for making same			
JOURNAL	Patent: US 6379928-A 20 30-APR-2002;			
FEATURES	Location/Qualifiers			
source	1..17			
	/organism="unknown"			
BASE COUNT	8 a	1 c	0 g	3 t
Query Match		1.0%;	Score 12.6;	DB 1; Length 17;
Best Local Similarity		66.7%;	Pred. No. 4.7e+02;	
Matches	10;	Conservative	5; Mismatches	0; Indels 0; Gaps 0;
Qy	1271	AGTATAGTACATTA	1285	
Db	2	ARTAYAAATAYATTA	16	
RESULT 449				
AX417571/c				
LOCUS		18 bp	DNA	linear
DEFINITION		Sequence 19 from Patent WO0231157.		
ACCESSION	AX417571			
VERSION	AX417571.1	GI:21522808		
KEYWORDS	synthetic construct			
SOURCE	synthetic construct			
ORGANISM	artificial sequences.			
REFERENCE	1			
AUTHORS	Gardner, R., Nilsen, I. and Overboe, K.			
TITLE	Shrimp alkaline phosphatase			
JOURNAL	Patent: WO 0231157-A 19 18-APR-2002;			
FEATURES	NORWEGIAN INST OF FISHERIES & (NO)			
source	Location/Qualifiers			
	1..18			
	/organism="synthetic construct"			
	/mol_type="genomic DNA"			
	/db_xref="taxon:32630"			
BASE COUNT	7 a	1 c	3 g	2 t
Query Match		1.0%;	Score 12.6;	DB 1; Length 18;
Best Local Similarity		66.7%;	Pred. No. 5.2e+02;	
Matches	12;	Conservative	3; Mismatches	3; Indels 0; Gaps 0;
Qy	886	CTGTGTCACCTGCTT	903	
Db	18	YTTTTCCTGCTGCTT	1	

JOURNAL	PATENT	US	6238871-A	14	29-MAY-2001
FEATURES	source	1.14	Location/Qualifiers		
BASE COUNT	4 a	4 c	2 g	4 t	
Query Match	1.0%;	Score 12.4;	DB 1;	Length 14;	
Best Local Similarity	92.9%;	Pred. No. 3.8e+02;			
Matches	13;	Conservative	0;	Mismatches 1;	Indels 0;
Gaps	0;				
QY	458	TCACACTTCATGT	471		
Db	1	TCACACTTCATGT	14		
RESULT 453					
LOCUS	ARI176706				
DEFINITION	Sequence 37 from patent US 6312894.				
ACCESSION	ARI176706				
VERSION	ARI176706.1				
KEYWORDS	GI:17919061				
SOURCE	Unknown.				
ORGANISM	Unkown.				
REFERENCE	1 (bases 1 to 14)				
AUTHORS	Hedgpeh, J., Afonina, I.A., Kutyavin, I.V., Lukhtanov, E.A., Selousov, E.S., and Meyer, R.B. Jr.				
TITLE	Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders				
JOURNAL	Patent: US 6312894-A 37 06-NOV-2001;				
FEATURES	Location/Qualifiers				
source	1.14				
BASE COUNT	1 a	1 c	2 g	10 t	
Query Match	1.0%;	Score 12.4;	DB 1;	Length 14;	
Best Local Similarity	92.9%;	Pred. No. 3.8e+02;			
Matches	13;	Conservative	0;	Mismatches 1;	Indels 0;
Gaps	0;				
QY	1564	TTTTTTTACTGTTT	1577		
Db	1	TTTTTTTACTGTTT	14		
RESULT 454					
LOCUS	AR221843				
DEFINITION	Sequence 24 from patent US 6428955.				
ACCESSION	AR221843				
VERSION	AR221843.1				
KEYWORDS	GI:23328958				
SOURCE	Unknown.				
ORGANISM	Unkown.				
REFERENCE	1 (bases 1 to 14)				
AUTHORS	Koster, H., Tang, K., Fu, D.-J., Siebert, C.W., Little, D.P., Braun, A., Darnhofer-Demari, B., Jurinke, C. and Van den Boom, D.				
TITLE	DNA diagnostics based on mass spectrometry				
JOURNAL	Patent: US 6428955-A 24 06-AUG-2002;				
FEATURES	Location/Qualifiers				
source	1.14				
BASE COUNT	4 a	4 c	2 g	4 t	
Query Match	1.0%;	Score 12.4;	DB 1;	Length 14;	
Best Local Similarity	92.9%;	Pred. No. 3.8e+02;			
Matches	13;	Conservative	0;	Mismatches 1;	Indels 0;
Gaps	0;				
QY	458	TCACACTTCATGT	471		
Db	1	TCACACTTCATGT	14		

RESULT 455
107800
LOCUS 107800 14 bp DNA linear PAT 02-DEC-1994
DEFINITION Sequence 2 from Patent EP 0337799.
ACCESSION 107800
VERSION 107800.1 GI:589936
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 14)
AUTHORS Nedwin,G.E., Bringham,T.S. and Couraud,P.-O.
TITLE 14-Beta-gal mammalian lectins
JOURNAL Patent: EP 0337799-A2 2 18-OCT-1989;
FEATURES Location/Qualifiers
source 1..14
BASE COUNT 6 a 1 c 0 g 7 t
Query Match 1.0%; Score 12.4; DB 1; Length 14;
Best Local Similarity 92.9%; Pred. No. 3.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1294 CTGAATTTTAATT 1307
Db 1 CTGAATTTTAATT 14
RESULT 456
AR029016 15 bp DNA linear PAT 29-SEP-1999
LOCUS AR029016
DEFINITION Sequence 3 from patent US 5858988.
ACCESSION AR029016
VERSION AR029016.1 GI:5940989
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Wang,J.H.
TITLE Poly-substituted-phenyl-oligoribo nucleotides having enhanced
JOURNAL stability and membrane permeability and methods of use
PATENT: US 5858988-A 3 12-JAN-1999;
FEATURES Location/Qualifiers
source 1..15
BASE COUNT 6 a 3 c 4 g 2 t
Query Match 1.0%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 4.3e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 781 TGATGGGACAAATAA 794
Db 2 TGATGGGACAAATAA 15
RESULT 457
AR029017/c 15 bp DNA linear PAT 29-SEP-1999
LOCUS AR029017
DEFINITION Sequence 4 from patent US 5858988.
ACCESSION AR029017
VERSION AR029017.1 GI:5940990
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Wang,J.H.
TITLE Poly-substituted-phenyl-oligoribo nucleotides having enhanced
JOURNAL stability and membrane permeability and methods of use
PATENT: US 5858988-A 4 12-JAN-1999;

FEATURES Location/Qualifiers
source 1..15
BASE COUNT 2 a 4 c 3 g 6 t
Query Match 1.0%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 4.3e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 781 TGATGGGACAAATAA 794
Db 14 TGATGGGACAAATAA 1
RESULT 458
AR041403 15 bp DNA linear PAT 29-SEP-1999
LOCUS AR041403
DEFINITION Sequence 193 from patent US 5811300.
ACCESSION AR041403
VERSION AR041403.1 GI:5961899
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Sullivan,S., Draper,K., Kieich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE TNF-.alpha. ribozymes
JOURNAL Patent: US 5811300-A 193 22-SEP-1998;
FEATURES Location/Qualifiers
source 1..15
BASE COUNT 5 a 0 c 0 g 10 t
Query Match 1.0%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 4.3e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1043 ATTATTATGATT 1056
Db 1 ATTATTATGATT 14
RESULT 459
AR041412 15 bp DNA linear PAT 29-SEP-1999
LOCUS AR041412
DEFINITION Sequence 202 from patent US 5811300.
ACCESSION AR041412
VERSION AR041412.1 GI:5961908
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Sullivan,S., Draper,K., Kieich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE TNF-.alpha. ribozymes
JOURNAL Patent: US 5811300-A 202 22-SEP-1998;
FEATURES Location/Qualifiers
source 1..15
BASE COUNT 4 a 1 c 0 g 10 t
Query Match 1.0%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 4.3e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1045 TATTATGATTATTA 1058
Db 1 TATTATGATTATTA 14
RESULT 460
AR041927 15 bp DNA linear PAT 29-SEP-1999
LOCUS AR041927

Query Match	1.0%;	Score 12.4;	DB 1;	Length 15;
Best Local Similarity	92.9%;	Pred. No. 4.3e+02;		
Matches 13;	Conservative 0;	Mismatches 1;	Indels 0;	Gaps 0;
QY	1047	TTTATGTAATTTATT	1060	
DB	1	TTTGATGTAATTTATT	14	
RESULT 463				
LOCUS	AR056547		15 bp	DNA
DEFINITION	Sequence 751 from patent US 5837542.			linear
ACCESSION	AR056547			
VERSION	AR056547.1	GI:5982124		
KEYWORDS	Unknown.			
SOURCE	Unknown.			
ORGANISM	Unknown.			
REFERENCE	1 (bases 1 to 15)			
AUTHORS	Grimm, S., Stinchcomb, D.T., McSwiggen, J., Sullivan, S. and			
TITLE	Draper, K.G. Interleukin adhesion molecule-1 (ICAM-1) ribozymes			
JOURNAL	Patent: US 5837542-A 751 17-NOV-1998;			
FEATURES	Location/Qualifiers			
source	1. .15			
	/organism="unknown"			
BASE COUNT	4 a	0 c	2 g	9 t
Query Match	1.0%;	Score 12.4;	DB 1;	Length 15;
Best Local Similarity	92.9%;	Pred. No. 4.3e+02;		
Matches 13;	Conservative 0;	Mismatches 1;	Indels 0;	Gaps 0;
QY	1047	TTTATGTAATTTATT	1060	
DB	1	TTTGATGTAATTTATT	14	
RESULT 464				
LOCUS	AR087176/c		15 bp	DNA
DEFINITION	Sequence 52 from patent US 5986053.			linear
ACCESSION	AR087176			
VERSION	AR087176.1	GI:10013939		
KEYWORDS	Unknown.			
SOURCE	Unknown.			
ORGANISM	Unknown.			
REFERENCE	1 (bases 1 to 15)			
AUTHORS	Ecker, D.J., Buchardt, O., Egholm, M., Nielsen, P.E., Berg, R.H. and			
TITLE	Mollegaard, N.E. Peptide nucleic acids complexes of two peptide nucleic acid strands			
JOURNAL	and one nucleic acid strand			
FEATURES	Patent: US 5986053-A 52 16-NOV-1999;			
source	Location/Qualifiers			
	1. .15			
	/organism="unknown"			
BASE COUNT	4 a	2 c	4 g	5 t
Query Match	1.0%;	Score 12.4;	DB 1;	Length 15;
Best Local Similarity	92.9%;	Pred. No. 4.3e+02;		
Matches 13;	Conservative 0;	Mismatches 1;	Indels 0;	Gaps 0;
QY	458	TCAACACTTCATGT	471	
DB	14	TCAACACTGCATGT	1	
RESULT 465				
LOCUS	AR113771		15 bp	DNA
DEFINITION	Sequence 217 from patent US 6132967.			linear
LOCUS	AR113771			

```

ACCESSION AR113771
VERSION AR113771.1 GI:14094093
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and Draper,K.C.
TITLE Ribozyme treatment of diseases or conditions related to levels of intercellular adhesion molecule-1 (ICAM-1)
JOURNAL Patent: US 6132967-A 217 17-OCT-2000;
FEATURES
source 1..15
location/Qualifiers
BASE COUNT 4 a 1 c 1 g 9 t
Query Match 1.0%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 4.3e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1049 TATGATATTATTATTA 1062
Db 1 TATGATATTATTATTA 14
RESULT 466
AR114065
LOCUS AR114065 15 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 511 from patent US 6132967.
ACCESSION AR114065
VERSION AR114065.1 GI:14094387
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and Draper,K.C.
TITLE Ribozyme treatment of diseases or conditions related to levels of intercellular adhesion molecule-1 (ICAM-1)
JOURNAL Patent: US 6132967-A 511 17-OCT-2000;
FEATURES
source 1..15
location/Qualifiers
BASE COUNT 4 a 0 c 2 g 9 t
Query Match 1.0%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 4.3e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1047 TTTATGATATTATTAT 1060
Db 1 TTGATGATATTATTAT 14
RESULT 467
AR114305
LOCUS AR114305 15 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 751 from patent US 6132967.
ACCESSION AR114305
VERSION AR114305.1 GI:14094627
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and Draper,K.C.
TITLE Ribozyme treatment of diseases or conditions related to levels of intercellular adhesion molecule-1 (ICAM-1)
JOURNAL Patent: US 6132967-A 751 17-OCT-2000;
FEATURES
source 1..15
location/Qualifiers
BASE COUNT 4 a 0 c 2 g 9 t
Query Match 1.0%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 4.3e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1047 TTTATGATATTATTAT 1060
Db 1 TTGATGATATTATTAT 14
RESULT 468
AR132468/c
LOCUS AR132468 15 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 893 from patent US 6194150.
ACCESSION AR132468
VERSION AR132468.1 GI:14121373
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.
TITLE Nucleic acid based inhibition of CD40
JOURNAL Patent: US 6194150-A 893 27-FEB-2001;
FEATURES
source 1..15
location/Qualifiers
BASE COUNT 9 a 0 c 0 g 6 t
Query Match 1.0%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 4.3e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1038 TATTTATTTATTAT 1051
Db 15 TATTTATTTATTAT 2
RESULT 469
AR133635/c
LOCUS AR133635 15 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 2060 from patent US 6194150.
ACCESSION AR133635
VERSION AR133635.1 GI:14122540
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.
TITLE Nucleic acid based inhibition of CD40
JOURNAL Patent: US 6194150-A 2060 27-FEB-2001;
FEATURES
source 1..15
location/Qualifiers
BASE COUNT 8 a 3 c 1 g 3 t
Query Match 1.0%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 4.3e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1456 TGTTTATTATGTAC 1469
Db 15 TGTTTATTATGTAC 2
RESULT 470
AR170387
LOCUS AR170387 15 bp DNA linear PAT 17-DEC-2001
DEFINITION Sequence 13 from patent US 6291438.

```



```

DEFINITION Sequence 330 from Patent WO0198537.
ACCESSION AX419993
VERSION AX419993.1 GI:21524360
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1
AUTHORS Lyamichev,V., Allawi,H., Dong,F., Neri,B.P. and Vener,I.T.
TITLE Nucleic acid accessible hybridization sites
JOURNAL Patent: WO 0198537-A 330 27-DEC-2001;
THIRD WAVE TECHNOLOGIES, INC. (US)
FEATURES
source
1. .15
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
BASE COUNT 5 a 2 c 3 g 5 t
Query Match 1.0%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 4.3e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1511 AATCAAGGCTTTA 1524
Db 2 ATTACAGGCTTTA 15
RESULT 476
AX554013
LOCUS AX554013 15 bp DNA linear PAT 27-NOV-2002
DEFINITION Sequence 36 from Patent WO02074799.
ACCESSION AX554013
VERSION AX554013.1 GI:25897950
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1
AUTHORS Freysinet,G., Rang,C. and Prutos,R.
TITLE Pepsin-sensitive modified bacillus thuringiensis insecticidal toxin
JOURNAL Patent: WO 02074799-A 36 26-SEP-2002;
AVENTIS CROPS SCIENCE S.A. (FR)
FEATURES
source
1. .15
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/notes="mutant 24"
BASE COUNT 7 a 0 c 1 g 7 t
Query Match 1.0%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 4.3e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1392 TTGAACCTATTAAA 1405
Db 1 TTGAATATTATAAA 14
RESULT 477
AX587124/c
LOCUS AX587124 15 bp DNA linear PAT 10-JAN-2003
DEFINITION Sequence 146 from Patent WO02072883.
ACCESSION AX587124
VERSION AX587124.1 GI:27655999
KEYWORDS unidentified
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1
AUTHORS Roetger,A.
TITLE Nucleotide carrier for diagnosing and treating oral diseases

```

```

JOURNAL Patent: WO 02072883-A 146 19-SEP-2002;
ROETGER, Antje (DE)
FEATURES
source
1. .15
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
/notes="Bacteria"
BASE COUNT 2 a 1 c 7 g 5 t
Query Match 1.0%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 4.3e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 938 AGCCACCATCTTAC 951
Db 14 AGCCACCATCTTAC 1
RESULT 478
AX633104
LOCUS AX633104 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 243 from Patent EP1260586.
ACCESSION AX633104
VERSION AX633104.1 GI:28468718
KEYWORDS unidentified
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related
genes
JOURNAL Patent: EP 1260586-A 243 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
source
1. .15
/organism="unidentified"
/mol_type="mRNA"
/db_xref="taxon:32644"
BASE COUNT 4 a 1 c 1 g 9 t
Query Match 1.0%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 4.3e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1049 TATGTATTATTATTA 1062
Db 1 TATGTATTATTATTA 14
RESULT 479
AX633459
LOCUS AX633459 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 598 from Patent EP1260586.
ACCESSION AX633459
VERSION AX633459.1 GI:28469073
KEYWORDS unidentified
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related
genes

```

```

JOURNAL Patent: EP 1260586-A 598 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
  source
    1. .15
    /organism="unidentified"
    /mol_type="mRNA"
    /db_xref="taxon:32644"
BASE COUNT      4 a      0 c      2 g      9 t
Query Match      1.0%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. NO. 4.3e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1047 TTATGCTATTATT 1060
  ||| ||||| |||||
Db 1 TTGATGCTATTATT 14

RESULT 480
AX635377
LOCUS AX635377 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 716 from Patent EP1260586.
ACCESSION AX635377
VERSION AX635377.1 GI:28469191
KEYWORDS
SOURCE
ORGANISM
  unidentified
  unclassified.
REFERENCE
  1
AUTHORS
  Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
  Karpetsky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
  McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
  Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
  Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related
  genes
JOURNAL Patent: EP 1260586-A 716 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
  source
    1. .15
    /organism="unidentified"
    /mol_type="mRNA"
    /db_xref="taxon:32644"
BASE COUNT      4 a      0 c      2 g      9 t
Query Match      1.0%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. NO. 4.3e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1047 TTATGCTATTATT 1060
  ||| ||||| |||||
Db 1 TTGATGCTATTATT 14

RESULT 481
AX635377
LOCUS AX635377 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 2516 from Patent EP1260586.
ACCESSION AX635377
VERSION AX635377.1 GI:28470991
KEYWORDS
SOURCE
ORGANISM
  unidentified
  unclassified.
REFERENCE
  1
AUTHORS
  Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
  Karpetsky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
  McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
  Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
  Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related
  genes
JOURNAL Patent: EP 1260586-A 2516 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)

JOURNAL Patent: EP 1260586-A 598 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
  source
    1. .15
    /organism="unidentified"
    /mol_type="mRNA"
    /db_xref="taxon:32644"
BASE COUNT      7 a      0 c      3 g      5 t
Query Match      1.0%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. NO. 4.3e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1081 AAGAAATTTGGAAA 1094
  ||||| ||||| |||||
Db 2 AAGAAATTTGGTAAA 15

RESULT 482
AX635379
LOCUS AX635379 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 2518 from Patent EP1260586.
ACCESSION AX635379
VERSION AX635379.1 GI:28470993
KEYWORDS
SOURCE
ORGANISM
  unidentified
  unclassified.
REFERENCE
  1
AUTHORS
  Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
  Karpetsky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
  McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
  Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
  Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related
  genes
JOURNAL Patent: EP 1260586-A 2518 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
  source
    1. .15
    /organism="unidentified"
    /mol_type="mRNA"
    /db_xref="taxon:32644"
BASE COUNT      7 a      0 c      3 g      5 t
Query Match      1.0%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. NO. 4.3e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1081 AAGAAATTTGGAAA 1094
  ||||| ||||| |||||
Db 1 AAGAAATTTGGTAAA 14

RESULT 483
AX636864
LOCUS AX636864 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 4003 from Patent EP1260586.
ACCESSION AX636864
VERSION AX636864.1 GI:28472478
KEYWORDS
SOURCE
ORGANISM
  unidentified
  unclassified.
REFERENCE
  1
AUTHORS
  Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
  Karpetsky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
  McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
  Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
  Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related
  genes
JOURNAL Patent: EP 1260586-A 4003 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)

```


FEATURES source Location/Qualifiers
1.15
/organism="unidentified"
/mol_type="mRNA"
/db_xref="taxon:32644"
BASE COUNT 5 a 0 c 0 g 10 t
Query Match 1.0%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 4.3e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1043 ATTATTATGTTATT 1056
|||||
1 ATTATTATGTTATT 14
Db 1 ATTATTATGTTATT 14
RESULT 484
AX637403
LOCUS AX637403 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 4542 from Patent EPI260586.
ACCESSION AX637403
VERSION AX637403.1 GI:28473017
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweeder,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related
genes
JOURNAL Patent: EP 1260586-A 4021 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES source Location/Qualifiers
1.15
/organism="unidentified"
/mol_type="mRNA"
/db_xref="taxon:32644"
BASE COUNT 4 a 1 c 0 g 10 t
Query Match 1.0%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 4.3e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1045 TATTATGTTATTTA 1058
|||||
1 TATTATGTTATTTA 14
Db 1 TATTATGTTATTTA 14
RESULT 485
AX637403
LOCUS AX637403 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 4542 from Patent EPI260586.
ACCESSION AX637403
VERSION AX637403.1 GI:28473017
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweeder,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related
genes
JOURNAL Patent: EP 1260586-A 4542 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES source Location/Qualifiers

1.15
/organism="unidentified"
/mol_type="mRNA"
/db_xref="taxon:32644"
BASE COUNT 5 a 0 c 0 g 10 t
Query Match 1.0%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 4.3e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1043 ATTATTATGTTATT 1056
|||||
1 ATTATTATGTTATT 14
Db 1 ATTATTATGTTATT 14
RESULT 486
AX637884/C
LOCUS AX637884 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 5023 from Patent EPI260586.
ACCESSION AX637884
VERSION AX637884.1 GI:28473498
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweeder,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related
genes
JOURNAL Patent: EP 1260586-A 5023 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES source Location/Qualifiers
1.15
/organism="unidentified"
/mol_type="mRNA"
/db_xref="taxon:32644"
BASE COUNT 7 a 3 c 1 g 4 t
Query Match 1.0%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 4.3e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1453 ACTTGTTATTTATG 1466
|||||
15 ACTTGTTATTTATG 2
Db 15 ACTTGTTATTTATG 2
RESULT 487
E29991/C
LOCUS E29991 15 bp DNA linear PAT 18-JUN-2001
DEFINITION Method for detecting higher-order structure of RNA.
ACCESSION E29991
VERSION E29991.1 GI:13021377
KEYWORDS JP 1999285386-A/17.
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 15)
AUTHORS Hiroyuki, K., Satoshi, K., Kaname, I. and Akihiko, T.
TITLE Method for detecting higher-order structure of RNA
JOURNAL Patent: JP 1999285386-A 17 19-OCT-1999;
COMMENT EUNSHI BIO HOTOHOKUSU KENKYUSHO
OS Unidentified
PN JP 1999285386-A/17
PF 19-OCT-1999
PR 03-APR-1998 JP 1998091580
PI HIROYUKI KOSHIMOTO, SATOSHI KONDO, KANAME ISHIBASHI, PI
AKIHIKO TSUJI

```
PC C12N15/09,C12Q1/68,G01N21/78,G01N33/58//G01N21/64,C12N15/00 CC
Strandedness: Double;
CC Topology: Linear;
FH Key Location/Qualifiers
FT source 1..15 /organism='Unidentified'.
FT Location/Qualifiers
1..15
/organism='unidentified'
/mol_type='genomic DNA'
/db_xref='taxon:32644'
BASE COUNT 9 a 0 g 5 t 1 others
Query Match 1.0%; Score 12.4; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 4.3e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1148 TTTATTTAGATATT 1162
DB 15 TTTATTTAGATATT 1

RESULT 488
E31788/c
LOCUS E31788 15 bp RNA linear PAT 18-JUN-2001
DEFINITION Pyrene-modified RNA and method for analyzing RNA.
ACCESSION E31788
VERSION E31788.1 GI:13018622
KEYWORDS JP 2000032999-A/1.
SOURCE synthetic construct
ORGANISM artificial construct.
REFERENCE 1 (bases 1 to 15)
AUTHORS Kazunari,Y., Hirofumi,Z., Hidehiko,N., Reiko,I. and Akira,M.
TITLE Pyrene-modified RNA and method for analyzing RNA
JOURNAL Patent: JP 2000032999-A 1 02-FEB-2000;
TOGOSSEI CHEM IND CO LTD
OS Artificial Sequence
PN JP 2000032999-A/1
PD 02-FEB-2000
PF 17-JUL-1998 JP 1998202589
PR KAZUNARI YAMANA,HIROFUMI ZAKKO,HIDEHIKO NAKANO,REIKO IWASE, PI
PI AKIRA MURAKAMI
PC C12Q1/68,C12Q1/69,G01N15/09,G01N33/53,G01N33/566,C12N15/00 CC

FH Key Location/Qualifiers
FT modified base (4).
1..15
/organism='synthetic construct'
/mol_type='genomic RNA'
/db_xref='taxon:32630'
BASE COUNT 4 a 2 c 4 g 5 t

QY 458 TCAACACTTCATGT 471
DB 14 TCAACACTGCATGT 1

RESULT 489
E31789/c
LOCUS E31789 15 bp RNA linear PAT 18-JUN-2001
DEFINITION Pyrene-modified RNA and method for analyzing RNA.
ACCESSION E31789
VERSION E31789.1 GI:13018623
KEYWORDS JP 2000032999-A/2.
SOURCE synthetic construct
ORGANISM synthetic construct.
```

```
artificial sequences.
1 (bases 1 to 15)
Kazunari,Y., Hirofumi,Z., Hidehiko,N., Reiko,I. and Akira,M.
Pyrene-modified RNA and method for analyzing RNA
Patent: JP 2000032999-A 2 02-FEB-2000;
TOGOSSEI CHEM IND CO LTD
OS Artificial Sequence
PN JP 2000032999-A/2
PD 02-FEB-2000
PF 17-JUL-1998 JP 1998202589
PR KAZUNARI YAMANA,HIROFUMI ZAKKO,HIDEHIKO NAKANO,REIKO IWASE, PI
PI AKIRA MURAKAMI
PC C12Q1/68,C12Q1/69,G01N15/09,G01N33/53,G01N33/566,C12N15/00 CC

FH Key Location/Qualifiers
FT modified base (9).
1..15
/organism='synthetic construct'
/mol_type='genomic RNA'
/db_xref='taxon:32630'
BASE COUNT 4 a 2 c 4 g 5 t

QY 458 TCAACACTTCATGT 471
DB 14 TCAACACTGCATGT 1

RESULT 490
E31790/c
LOCUS E31790 15 bp RNA linear PAT 18-JUN-2001
DEFINITION Pyrene-modified RNA and method for analyzing RNA.
ACCESSION E31790
VERSION E31790.1 GI:13018624
KEYWORDS JP 2000032999-A/3.
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1 (bases 1 to 15)
AUTHORS Kazunari,Y., Hirofumi,Z., Hidehiko,N., Reiko,I. and Akira,M.
TITLE Pyrene-modified RNA and method for analyzing RNA
JOURNAL Patent: JP 2000032999-A 3 02-FEB-2000;
TOGOSSEI CHEM IND CO LTD
OS Artificial Sequence
PN JP 2000032999-A/3
PD 02-FEB-2000
PF 17-JUL-1998 JP 1998202589
PR KAZUNARI YAMANA,HIROFUMI ZAKKO,HIDEHIKO NAKANO,REIKO IWASE, PI
PI AKIRA MURAKAMI
PC C12Q1/68,C12Q1/69,G01N15/09,G01N33/53,G01N33/566,C12N15/00 CC

FH Key Location/Qualifiers
FT modified base (11).
1..15
/organism='synthetic construct'
/mol_type='genomic RNA'
/db_xref='taxon:32630'
BASE COUNT 4 a 2 c 4 g 5 t

QY 458 TCAACACTTCATGT 471
DB 14 TCAACACTGCATGT 1
```

RESULT 491		E31791/c		E31791		Pyrene-modified RNA and method for analyzing RNA.		E31791		PAT 18-JUN-2001	
LOCUS		E31791		Pyrene-modified RNA and method for analyzing RNA.		E31791		PAT 18-JUN-2001			
DEFINITION		E31791		Pyrene-modified RNA and method for analyzing RNA.		E31791		PAT 18-JUN-2001			
ACCESSION		E31791		Pyrene-modified RNA and method for analyzing RNA.		E31791		PAT 18-JUN-2001			
VERSION		E31791.1		GI:13018625		JP 2000032999-A/4		JP 2000032999-A/4			
KEYWORDS		JP 2000032999-A/4		synthetic construct		synthetic construct		synthetic construct			
SOURCE		JP 2000032999-A/4		artificial sequences.		artificial sequences.		artificial sequences.			
ORGANISM		JP 2000032999-A/4		1 (bases 1 to 15)		1 (bases 1 to 15)		1 (bases 1 to 15)			
REFERENCE		JP 2000032999-A/4		Kazunari, Y., Hirofumi, Z., Hidehiko, N., Reiko, I. and Akira, M.		Kazunari, Y., Hirofumi, Z., Hidehiko, N., Reiko, I. and Akira, M.		Kazunari, Y., Hirofumi, Z., Hidehiko, N., Reiko, I. and Akira, M.			
AUTHORS		JP 2000032999-A/4		Pyrene-modified RNA and method for analyzing RNA.		Pyrene-modified RNA and method for analyzing RNA.		Pyrene-modified RNA and method for analyzing RNA.			
TITLE		JP 2000032999-A/4		Pyrene-modified RNA and method for analyzing RNA.		Pyrene-modified RNA and method for analyzing RNA.		Pyrene-modified RNA and method for analyzing RNA.			
JOURNAL		JP 2000032999-A/4		TOAGOSEI CHEM IND CO LTD		TOAGOSEI CHEM IND CO LTD		TOAGOSEI CHEM IND CO LTD			
COMMENT		JP 2000032999-A/4		OS Artificial Sequence		OS Artificial Sequence		OS Artificial Sequence			
		JP 2000032999-A/4		PN JP 2000032999-A/4		PN JP 2000032999-A/4		PN JP 2000032999-A/4			
		JP 2000032999-A/4		PD 02-FEB-2000		PD 02-FEB-2000		PD 02-FEB-2000			
		JP 2000032999-A/4		PP 17-JUL-1998		PP 1998202589		PP 17-JUL-1998			
		JP 2000032999-A/4		PR KAZUNARI YAMANA, HIROFUMI ZAKKO, HIDEHIKO NAKANO, REIKO IWASE, PI		PR KAZUNARI YAMANA, HIROFUMI ZAKKO, HIDEHIKO NAKANO, REIKO IWASE, PI		PR KAZUNARI YAMANA, HIROFUMI ZAKKO, HIDEHIKO NAKANO, REIKO IWASE, PI			
		JP 2000032999-A/4		PI AKIRA MURAKAMI		PI AKIRA MURAKAMI		PI AKIRA MURAKAMI			
		JP 2000032999-A/4		PC C12Q1/68, C12Q1/68, C12N15/09, G01N33/53, G01N33/566, C12N15/00 CC		PC C12Q1/68, C12Q1/68, C12N15/09, G01N33/53, G01N33/566, C12N15/00 CC		PC C12Q1/68, C12Q1/68, C12N15/09, G01N33/53, G01N33/566, C12N15/00 CC			
		JP 2000032999-A/4		PH Key		PH Key		PH Key			
		JP 2000032999-A/4		FT modified base (4).		FT modified base (4).		FT modified base (4).			
		JP 2000032999-A/4		Location/Qualifiers		Location/Qualifiers		Location/Qualifiers			
		JP 2000032999-A/4		1..15		1..15		1..15			
		JP 2000032999-A/4		/organism="synthetic construct"		/organism="synthetic construct"		/organism="synthetic construct"			
		JP 2000032999-A/4		/mol_type="genomic DNA"		/mol_type="genomic DNA"		/mol_type="genomic DNA"			
		JP 2000032999-A/4		/db_xref="taxon:32630"		/db_xref="taxon:32630"		/db_xref="taxon:32630"			
		JP 2000032999-A/4		4 a		4 a		4 a			
		JP 2000032999-A/4		2 c		2 c		2 c			
		JP 2000032999-A/4		4 g		4 g		4 g			
		JP 2000032999-A/4		5 t		5 t		5 t			
		JP 2000032999-A/4		Query Match		Query Match		Query Match			
		JP 2000032999-A/4		Best Local Similarity		Best Local Similarity		Best Local Similarity			
		JP 2000032999-A/4		1.0%		1.0%		1.0%			
		JP 2000032999-A/4		Score 12.4;		Score 12.4;		Score 12.4;			
		JP 2000032999-A/4		DB 1;		DB 1;		DB 1;			
		JP 2000032999-A/4		Length 15;		Length 15;		Length 15;			
		JP 2000032999-A/4		Pred. No. 4.3e+02;		Pred. No. 4.3e+02;		Pred. No. 4.3e+02;			
		JP 2000032999-A/4		Matches 13;		Matches 13;		Matches 13;			
		JP 2000032999-A/4		Conservative 0;		Conservative 0;		Conservative 0;			
		JP 2000032999-A/4		Mismatches 1;		Mismatches 1;		Mismatches 1;			
		JP 2000032999-A/4		Indels 0;		Indels 0;		Indels 0;			
		JP 2000032999-A/4		Gaps 0;		Gaps 0;		Gaps 0;			
		JP 2000032999-A/4		QY		QY		QY			
		JP 2000032999-A/4		458 TCAACACTTCATGT 471		458 TCAACACTTCATGT 471		458 TCAACACTTCATGT 471			
		JP 2000032999-A/4									
		JP 2000032999-A/4		14 TCAACACTGCATGT 1		14 TCAACACTGCATGT 1		14 TCAACACTGCATGT 1			
		JP 2000032999-A/4		FEATURES		FEATURES		FEATURES			
		JP 2000032999-A/4		source		source		source			
		JP 2000032999-A/4		1..15		1..15		1..15			
		JP 2000032999-A/4		/organism="synthetic construct"		/organism="synthetic construct"		/organism="synthetic construct"			
		JP 2000032999-A/4		/mol_type="genomic DNA"		/mol_type="genomic DNA"		/mol_type="genomic DNA"			
		JP 2000032999-A/4		/db_xref="taxon:32630"		/db_xref="taxon:32630"		/db_xref="taxon:32630"			
		JP 2000032999-A/4		4 a		4 a		4 a			
		JP 2000032999-A/4		2 c		2 c		2 c			
		JP 2000032999-A/4		4 g		4 g		4 g			
		JP 2000032999-A/4		5 t		5 t		5 t			
		JP 2000032999-A/4		Query Match		Query Match		Query Match			
		JP 2000032999-A/4		Best Local Similarity		Best Local Similarity		Best Local Similarity			
		JP 2000032999-A/4		1.0%		1.0%		1.0%			
		JP 2000032999-A/4		Score 12.4;		Score 12.4;		Score 12.4;			
		JP 2000032999-A/4		DB 1;		DB 1;		DB 1;			
		JP 2000032999-A/4		Length 15;		Length 15;		Length 15;			
		JP 2000032999-A/4		Pred. No. 4.3e+02;		Pred. No. 4.3e+02;		Pred. No. 4.3e+02;			
		JP 2000032999-A/4		Matches 13;		Matches 13;		Matches 13;			
		JP 2000032999-A/4		Conservative 0;		Conservative 0;		Conservative 0;			
		JP 2000032999-A/4		Mismatches 1;		Mismatches 1;		Mismatches 1;			
		JP 2000032999-A/4		Indels 0;		Indels 0;		Indels 0;			
		JP 2000032999-A/4		Gaps 0;		Gaps 0;		Gaps 0;			
		JP 2000032999-A/4		QY		QY		QY			
		JP 2000032999-A/4		458 TCAACACTTCATGT 471		458 TCAACACTTCATGT 471		458 TCAACACTTCATGT 471			
		JP 2000032999-A/4									
		JP 2000032999-A/4		14 TCAACACTGCATGT 1		14 TCAACACTGCATGT 1		14 TCAACACTGCATGT 1			
		JP 2000032999-A/4		FEATURES		FEATURES		FEATURES			
		JP 2000032999-A/4		source		source		source			
		JP 2000032999-A/4		1..15		1..15		1..15			
		JP 2000032999-A/4		/organism="synthetic construct"		/organism="synthetic construct"		/organism="synthetic construct"			
		JP 2000032999-A/4		/mol_type="genomic DNA"		/mol_type="genomic DNA"		/mol_type="genomic DNA"			
		JP 2000032999-A/4		/db_xref="taxon:32630"		/db_xref="taxon:32630"		/db_xref="taxon:32630"			
		JP 2000032999-A/4		4 a		4 a		4 a			
		JP 2000032999-A/4		2 c		2 c		2 c			
		JP 2000032999-A/4		4 g		4 g		4 g			
		JP 2000032999-A/4		5 t		5 t		5 t			
		JP 2000032999-A/4		Query Match		Query Match		Query Match			
		JP 2000032999-A/4		Best Local Similarity		Best Local Similarity		Best Local Similarity			
		JP 2000032999-A/4		1.0%		1.0%		1.0%			
		JP 2000032999-A/4		Score 12.4;		Score 12.4;		Score 12.4;			
		JP 2000032999-A/4		DB 1;		DB 1;		DB 1;			
		JP 2000032999-A/4		Length 15;		Length 15;		Length 15;			
		JP 2000032999-A/4		Pred. No. 4.3e+02;		Pred. No. 4.3e+02;		Pred. No. 4.3e+02;			
		JP 2000032999-A/4		Matches 13;		Matches 13;		Matches 13;			
		JP 2000032999-A/4		Conservative 0;		Conservative 0;		Conservative 0;			
		JP 2000032999-A/4		Mismatches 1;		Mismatches 1;		Mismatches 1;			
		JP 2000032999-A/4		Indels 0;		Indels 0;		Indels 0;			
		JP 2000032999-A/4		Gaps 0;		Gaps 0;		Gaps 0;			
		JP 2000032999-A/4		QY		QY		QY			
		JP 2000032999-A/4		458 TCAACACTTCATGT 471		458 TCAACACTTCATGT 471		458 TCAACACTTCATGT 471			
		JP 2000032999-A/4									
		JP 2000032999-A/4		14 TCAACACTGCATGT 1		14 TCAACACTGCATGT 1		14 TCAACACTGCATGT 1			
		JP 2000032999-A/4		FEATURES		FEATURES		FEATURES			
		JP 2000032999-A/4		source		source		source			
		JP 2000032999-A/4		1..15		1..15		1..15			
		JP 2000032999-A/4		/organism="synthetic construct"		/organism="synthetic construct"		/organism="synthetic construct"			
		JP 2000032999-A/4		/mol_type="genomic DNA"		/mol_type="genomic DNA"		/mol_type="genomic DNA"			
		JP 2000032999-A/4		/db_xref="taxon:32630"		/db_xref="taxon:32630"		/db_xref="taxon:32630"			
		JP 2000032999-A/4		4 a		4 a		4 a			
		JP 2000032999-A/4		2 c		2 c		2 c			
		JP 2000032999-A/4		4 g		4 g		4 g			
		JP 2000032999-A/4		5 t		5 t		5 t			
		JP 2000032999-A/4		Query Match		Query Match		Query Match			
		JP 2000032999-A/4		Best Local Similarity		Best Local Similarity		Best Local Similarity			
		JP 2000032999-A/4		1.0%		1.0%		1.0%			
		JP 2000032999-A/4		Score 12.4;		Score 12.4;		Score 12.4;			
		JP 2000032999-A/4		DB 1;		DB 1;		DB 1;			
		JP 2000032999-A/4		Length 15;		Length 15;		Length 15;			
		JP 2000032999-A/4		Pred. No. 4.3e+02;		Pred. No. 4.3e+02;		Pred. No. 4.3e+02;			
		JP 2000032999-A/4		Matches 13;		Matches 13;		Matches 13;			
		JP 2000032999-A/4		Conservative 0;		Conservative 0;		Conservative 0;			
		JP 2000032999-A/4		Mismatches 1;		Mismatches 1;		Mismatches 1;			
		JP 2000032999-A/4		Indels 0;		Indels 0;		Indels 0;			
		JP 2000032999-A/4		Gaps 0;		Gaps 0;		Gaps 0;			
		JP 2000032999-A/4		QY		QY		QY			
		JP 2000032999-A/4		458 TCAACACTTCATGT 471		458 TCAACACTTCATGT 471		458 TCAACACTTCATGT 471			
		JP 2000032999-A/4									
		JP 2000032999-A/4		14 TCAACACTGCATGT 1		14 TCAACACTGCATGT 1		14 TCAACACTGCATGT 1			
		JP 2000032999-A/4		FEATURES		FEATURES		FEATURES			
		JP 2000032999-A/4		source		source		source			
		JP 2000032999-A/4		1..15		1..15		1..15			
		JP 2000032999-A/4		/organism="synthetic construct"		/organism="synthetic construct"		/organism="synthetic construct"			
		JP 2000032999-A/4		/mol_type="genomic DNA"		/mol_type="genomic DNA"		/mol_type="genomic DNA"			
		JP 2000032999-A/4		/db_xref="taxon:32630"		/db_xref="taxon:32630"		/db_xref="taxon:32630"			
		JP 2000032999-A/4		4 a		4 a		4 a			
		JP 2000032999-A/4		2 c		2 c		2 c			
		JP 2000032999-A/4		4 g		4 g		4 g			
		JP 2000032999-A/4		5 t		5 t		5 t			
		JP 2000032999-A/4		Query Match		Query Match		Query Match			
		JP 2000032999-A/4		Best Local Similarity		Best Local Similarity		Best Local Similarity			
		JP 2000032999-A/4		1.0%		1.0%		1.0%			
		JP 2000032999-A/4		Score 12.4;		Score 12.4;		Score 12.4;			
		JP 2000032999-A/4		DB 1;		DB 1;		DB 1;			
		JP 2000032999-A/4		Length 15;		Length 15;		Length 15;			
		JP 2000032999-A/4		Pred. No. 4.3e+02;		Pred. No. 4.3e+02;		Pred. No. 4.3e+02;			
		JP 2000032999-A/4		Matches 13;		Matches 13;		Matches 13;			
		JP 2000032999-A/4		Conservative 0;		Conservative 0;		Conservative 0;			
		JP 2000032999-A/4		Mismatches 1;		Mismatches 1;		Mismatches 1;			
		JP 2000032999-A/4		Indels 0;		Indels 0;		Indels 0;			
		JP 2000032999-A/4		Gaps 0;		Gaps 0;		Gaps 0;			
		JP 2000032999-A/4		QY		QY		QY			
		JP 2000032999-A/4		458 TCAACACTTCATGT 471		458 TCAACACTTCATGT 471		458 TCAACACTTCATGT 471			
		JP 2000032999-A/4									
		JP 2000									

```
PN JP 1999236396-A/20
PD 31-AUG-1999
PR 14-OCT-1998 JP 1998291590
PR 02-JUL-1993 US 088638
PI BUSHATO ORE, EGUHORUMU MICHAEL, NIELSEN PATER A, BERG RORUFU HO,
PI EKKA DAVID JAY, MORUGADO NILUS A
PC C07H21/04, A61K31/00, A61K31/00, A61K31/00, A61K48/00,
PC C07H21/02, A61K31/00, A61K31/00, A61K31/00, A61K48/00,
PC C12N15/09, C12Q1/68, C12N15/00
CC Strandedness: Single;
CC Topology: Linear;
FH Key Location/Qualifiers
FT source 1.15
    Location/Qualifiers
    1.15
    /organism="unidentified"
    /mol_type="genomic DNA"
    /db_xref="taxon:32644"
    4 a 2 c 4 g 5 t
BASE COUNT
Query Match 1.0%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 4.3e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 458 TCACACTTCATGT 471
Db 14 TCACACTGCATGT 1

RESULT 495
LOCUS 15 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 160 from patent US 5616488.
ACCESSION I39122
VERSION I39122.1 GI:2083602
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Sullivan, S., Draper, K.G., McSwiggen, J. and Stinchcomb, D.T.
TITLE IL-5 targeted ribozymes
JOURNAL Patent: US 5616488-A 160 01-APR-1997;
FEATURES
    source
    1.15
    /organism="unknown"
    7 a 0 c 3 g 5 t
BASE COUNT
Query Match 1.0%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 4.3e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1081 AAGATTTCGAAA 1094
Db 2 AAGATTTCGAAA 15

RESULT 496
LOCUS 15 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 161 from patent US 5616488.
ACCESSION I39123
VERSION I39123.1 GI:2083603
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Sullivan, S., Draper, K.G., McSwiggen, J. and Stinchcomb, D.T.
TITLE IL-5 targeted ribozymes
JOURNAL Patent: US 5616488-A 161 01-APR-1997;
FEATURES
    Location/Qualifiers

PN JP 1999236396-A/20
PD 31-AUG-1999
PR 14-OCT-1998 JP 1998291590
PR 02-JUL-1993 US 088638
PI BUSHATO ORE, EGUHORUMU MICHAEL, NIELSEN PATER A, BERG RORUFU HO,
PI EKKA DAVID JAY, MORUGADO NILUS A
PC C07H21/04, A61K31/00, A61K31/00, A61K31/00, A61K48/00,
PC C07H21/02, A61K31/00, A61K31/00, A61K31/00, A61K48/00,
PC C12N15/09, C12Q1/68, C12N15/00
CC Strandedness: Single;
CC Topology: Linear;
FH Key Location/Qualifiers
FT source 1.15
    Location/Qualifiers
    1.15
    /organism="unidentified"
    /mol_type="genomic DNA"
    /db_xref="taxon:32644"
    4 a 2 c 4 g 5 t
BASE COUNT
Query Match 1.0%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 4.3e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 458 TCACACTTCATGT 471
Db 14 TCACACTGCATGT 1

RESULT 495
LOCUS 15 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 160 from patent US 5616488.
ACCESSION I39122
VERSION I39122.1 GI:2083602
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Sullivan, S., Draper, K.G., McSwiggen, J. and Stinchcomb, D.T.
TITLE IL-5 targeted ribozymes
JOURNAL Patent: US 5616488-A 160 01-APR-1997;
FEATURES
    source
    1.15
    /organism="unknown"
    7 a 0 c 3 g 5 t
BASE COUNT
Query Match 1.0%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 4.3e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1081 AAGATTTCGAAA 1094
Db 2 AAGATTTCGAAA 15

RESULT 496
LOCUS 15 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 161 from patent US 5616488.
ACCESSION I39123
VERSION I39123.1 GI:2083603
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Sullivan, S., Draper, K.G., McSwiggen, J. and Stinchcomb, D.T.
TITLE IL-5 targeted ribozymes
JOURNAL Patent: US 5616488-A 161 01-APR-1997;
FEATURES
    Location/Qualifiers
```

DEFINITION Sequence 4 from patent US 5710028.
ACCESSION I81253
VERSION I81253.1 GI:3209543
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Eyal,N. and Navot,N.
TITLE Method of quick screening and identification of specific DNA
sequences by single nucleotide primer extension and kits therefor
JOURNAL Patent: US 5710028-A 4 20-JAN-1998,
FEATURES Location/Qualifiers
source
1. .15
BASE COUNT 2 a 3 c 3 g 7 t
Query Match 1.0%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 4.3e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1438 TTCTGCTGCTGA 1451
Db 2 TTCTGCTGCTGA 15
RESULT 500
S89848/c
LOCUS XPAC-XP group A complementing [exon 3] [human, mRNA Partial Mutant,
DEFINITION 15 nt].
ACCESSION S89848
VERSION S89848.1 GI:247717
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1 (bases 1 to 15)
AUTHORS Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
TITLE Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.
JOURNAL Satokata,I., Tanaka,K. and Okada,Y.
MEDLINE Molecular basis of group A xeroderma pigmentosum: a missense
92201821 mutation and two deletions located in a zinc finger consensus
PUBMED sequence of the XPAC gene
REMARK Hum. Genet. 88 (6), 603-607 (1992)
GenBank staff at the National Library of Medicine created this
entry [NCBI Gibbsq 89848] from the original journal article.
COMMENT This sequence comes from Figure 6.
G to T transversion at nucleotide 323, alters the Cys-108 codon to
a Phe codon.
FEATURES
source
1. .15
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
gene 1. .15
/gene="XPAC"
/note="XP group A complementing"
BASE COUNT 6 a 1 c 1 g 7 t
Query Match 1.0%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 4.3e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1000 TCATACATAAAT 1013
Db 14 TCATACATAAAT 1
RESULT 501
A08781
LOCUS

DEFINITION reverse complement.
ACCESSION A08781
VERSION A08781.1 GI:489060
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 16)
AUTHORS
TITLE COMPLETE NUCLEOTIDIC SEQUENCE OF THE COMPLEMENTARY DNA OF THE
GENOMIC RNA OF THE POTYVIRUS, GENES CODING FOR THE POTYVIRUS
CAPSID PROTEIN AND APPLICATION OF SAID GENES TO THE CREATION OF
POTYVIRUS-RESISTANT TRANSGENIC PLANTS
JOURNAL Patent: WO 8912100-A 6 14-DEC-1989;
FEATURES Location/Qualifiers
source
1. .16
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
BASE COUNT 1 a 5 c 3 g 7 t
Query Match 1.0%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 4.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 901 CTGTGTTCTCTCTT 914
Db 1 CATGTTTCTCTT 14
RESULT 502
A88098/c
LOCUS A88098
DEFINITION Sequence 246 from Patent WO9833904.
ACCESSION A88098
VERSION A88098.1 GI:6736668
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 16)
AUTHORS Brysch,W. and Schlingensiepen,K.
TITLE AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
JOURNAL Patent: WO 9833904-A 246 06-AUG-1998;
BIOGNOSTIK GES (DE); BRYSCH WOLFGANG (DE)
FEATURES Location/Qualifiers
source
1. .16
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
BASE COUNT 9 a 2 c 1 g 4 t
Query Match 1.0%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 4.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1045 TATTATGTATTATTA 1058
Db 16 TATTATGTATTATTA 3
RESULT 503
A88522/c
LOCUS A88522
DEFINITION Sequence 670 from Patent WO9833904.
ACCESSION A88522
VERSION A88522.1 GI:6737092
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 16)
AUTHORS Brysch,W. and Schlingensiepen,K.

TITLE AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
JOURNAL Patent: WO 9833904-A 670 05-AUG-1998;
BIOGOSTIK GES (DE); BRYSCH WOLFGANG (DE)
FEATURES
source
1. .16
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
6 t
BASE COUNT 8 a 1 c 1 g 6 t
Query Match 1.0%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 4.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1171 TTTTATTAGTAAA 1184
Db 14 TTTTATTAGCTAAA 1
RESULT 504
LOCUS A88613 16 bp DNA linear PAT 22-JAN-2000
DEFINITION Sequence 761 from Patent WO9833904.
ACCESSION A88613
VERSION A88613.1 GI:6737183
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 16)
AUTHORS Brysch,W.D. and Schlingensiepen,K.D.
TITLE AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
JOURNAL Patent: WO 9833904-A 761 05-AUG-1998;
BIOGOSTIK GES (DE); BRYSCH WOLFGANG (DE)
FEATURES
source
1. .16
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
9 t
BASE COUNT 5 a 2 g 9 t
Query Match 1.0%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 4.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1204 ATTAACAAACAAA 1217
Db 14 ATTAACAACTCAAA 1
RESULT 505
LOCUS A90065 16 bp DNA linear PAT 22-JAN-2000
DEFINITION Sequence 246 from Patent EP0856579.
ACCESSION A90065
VERSION A90065.1 GI:6738579
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 16)
AUTHORS Brysch,W.D. and Schlingensiepen,K.D.
TITLE An antisense oligonucleotide preparation method
JOURNAL Patent: EP 0856579-A 246 05-AUG-1998;
BIOGOSTIK GES (DE)
FEATURES
source
1. .16
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
4 t
BASE COUNT 9 a 2 c 1 g 4 t
Query Match 1.0%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 4.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1045 TATTATGTATTAA 1058
Db 16 TATTGTGTTATTA 3
RESULT 506
LOCUS A90489 16 bp DNA linear PAT 22-JAN-2000
DEFINITION Sequence 670 from Patent EP0856579.
ACCESSION A90489
VERSION A90489.1 GI:6739003
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 16)
AUTHORS Brysch,W.D. and Schlingensiepen,K.D.
TITLE An antisense oligonucleotide preparation method
JOURNAL Patent: EP 0856579-A 670 05-AUG-1998;
BIOGOSTIK GES (DE)
FEATURES
source
1. .16
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
6 t
BASE COUNT 8 a 1 c 1 g 6 t
Query Match 1.0%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 4.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1171 TTTTATTAGTAAA 1184
Db 14 TTTTATTAGCTAAA 1
RESULT 507
LOCUS A90580 16 bp DNA linear PAT 22-JAN-2000
DEFINITION Sequence 761 from Patent EP0856579.
ACCESSION A90580
VERSION A90580.1 GI:6739094
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 16)
AUTHORS Brysch,W.D. and Schlingensiepen,K.D.
TITLE An antisense oligonucleotide preparation method
JOURNAL Patent: EP 0856579-A 761 05-AUG-1998;
BIOGOSTIK GES (DE)
FEATURES
source
1. .16
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
9 t
BASE COUNT 5 a 2 g 9 t
Query Match 1.0%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 4.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1204 ATTAACAAACAAA 1217
Db 14 ATTAACAACTCAAA 1
RESULT 508
LOCUS AX088232 16 bp DNA linear PAT 17-MAR-2001

```

DEFINITION Sequence 16 from Patent WO0114520.
ACCESSION AX088232
VERSION AX088232.1 GI:13397143
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1
AUTHORS Wadskov-Hansen,S.L., Hammer,K. and Martinussen,J.
TITLE Phage resistant lactic acid bacterial mutants
JOURNAL Patent: WO 0114520-A 16 01-MAR-2001;
Chr. Hansen A/S (DK)
FEATURES
source
Location/Qualifiers
1..16
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/note="Oligonucleotide SLH6 used for PCR"
BASE COUNT 8 a 2 c 3 g 3 t
Query Match 1.0%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 4.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1626 TTGCTGTCGAAGT 1639
Db 14 TTTTGTGCAAGT 1
RESULT 509
AX235073/c
LOCUS AX235073 16 bp DNA linear PAT 11-SEP-2001
DEFINITION Sequence 30 from Patent WO0163540.
ACCESSION AX235073
VERSION AX235073.1 GI:15593721
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1
AUTHORS Bureau,T.
TITLE Method for identifying transposons from a nucleic acid database
JOURNAL Patent: WO 0163540-A 30 30-AUG-2001;
McGILL UNIVERSITY (CA)
FEATURES
source
Location/Qualifiers
1..16
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/note="sequence from gi 2245031"
BASE COUNT 5 a 2 c 2 g 7 t
Query Match 1.0%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 4.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 798 TTGCATATAAGTCA 811
Db 15 TTGACATATAAGTCA 2
RESULT 510
AX235096/c
LOCUS AX235096 16 bp DNA linear PAT 11-SEP-2001
DEFINITION Sequence 53 from Patent WO0163540.
ACCESSION AX235096
VERSION AX235096.1 GI:15593744
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1
AUTHORS Bureau,T.

```

```

TITLE Method for identifying transposons from a nucleic acid database
JOURNAL Patent: WO 0163540-A 53 30-AUG-2001;
McGILL UNIVERSITY (CA)
FEATURES
source
Location/Qualifiers
1..16
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/note="sequence from gi 3243214"
BASE COUNT 8 a 0 c 2 g 6 t
Query Match 1.0%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 4.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 995 TTTCATCATAAACAT 1008
Db 15 TTTCATCATAAATAT 2
RESULT 511
BD065611/c
LOCUS BD065611 16 bp DNA linear PAT 27-AUG-2002
DEFINITION An antisense oligonucleotide preparation method.
ACCESSION BD065611
VERSION BD065611.1 GI:22611214
KEYWORDS JP 2001511000-A/246.
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Schlingensiefen,K.H. and Brysch,W.
TITLE An antisense oligonucleotide preparation method
JOURNAL Patent: JP 2001511000-A 246 07-AUG-2001;
BIOGNOSTIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MEH
COMMENT OS Unknown
PN JP 2001511000-A/246
PD 07-AUG-2001
PF 30-JAN-1998 JP 1998532533
PR 31-JAN-1997 EP 97101531.8
PI KARL HERMANN SCHLINGENSIEFEN,WOLFGANG BRYSCH
PC C12N15/11,C07H21/04,A61K31/70
CC An antisense oligonucleotide preparation method FH Key
Location/Qualifiers
FT source 1..16
PT /organism="Unknown".
FEATURES
source
Location/Qualifiers
1..16
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
BASE COUNT 9 a 2 c 1 g 4 t
Query Match 1.0%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 4.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1045 TATTATGATATTA 1058
Db 16 TATTGCTGATATTA 3
RESULT 512
BD066035/c
LOCUS BD066035 16 bp DNA linear PAT 27-AUG-2002
DEFINITION An antisense oligonucleotide preparation method.
ACCESSION BD066035
VERSION BD066035.1 GI:22611638
KEYWORDS JP 2001511000-A/670.
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 16)

```

```

AUTHORS Schlingensiepen,K.H. and Brysch,W.
TITLE An antisense oligonucleotide preparation method
JOURNAL Patent: JP 2001511000-A 670 07-AUG-2001;
COMMENT BIOGNOSTIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH
OS Unknown
PN JP 2001511000-A/670
PD 07-AUG-2001
PF 30-JAN-1998 JP 1998532533
PR 31-JAN-1997 EP 97101531.8
PI KARL HERMANN SCHLINGENSIEPEN,WOLFGANG BRYSCH
PC C12N15/11,C07H21/04,A61K31/70
CC An antisense oligonucleotide preparation method FH Key
FT Location/Qualifiers
FT 1..16 /organism='Unknown'.
FT source Location/Qualifiers
FT 1..16 /organism='Unknown'.
FT source Location/Qualifiers
FT 1..16 /organism='unidentified'
FT /mol_type='genomic DNA'
FT /db_xref='taxon:32644'
FT 8 a 1 c 1 g 6 t
BASE COUNT
Query Match 1.0%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 4.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1171 TTTTATTAGATAAA 1184
DB 14 TTTTATTAGCTAAA 1
RESULT 513
BD066126/c
LOCUS 16 bp DNA linear PAT 27-AUG-2002
DEFINITION An antisense oligonucleotide preparation method.
ACCESSION BD066126
VERSION BD066126.1 GI:22611729
KEYWORDS JP 2001511000-A/761.
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 16)
AUTHORS Schlingensiepen,K.H. and Brysch,W.
TITLE An antisense oligonucleotide preparation method
JOURNAL Patent: JP 2001511000-A 761 07-AUG-2001;
COMMENT BIOGNOSTIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH
OS Unknown
PN JP 2001511000-A/761
PD 07-AUG-2001
PF 30-JAN-1998 JP 1998532533
PR 31-JAN-1997 EP 97101531.8
PI KARL HERMANN SCHLINGENSIEPEN,WOLFGANG BRYSCH
PC C12N15/11,C07H21/04,A61K31/70
CC An antisense oligonucleotide preparation method FH Key
FT Location/Qualifiers
FT 1..16 /organism='Unknown'.
FT source Location/Qualifiers
FT 1..16 /organism='unidentified'
FT /mol_type='genomic DNA'
FT /db_xref='taxon:32644'
FT 5 a 0 c 2 g 9 t
BASE COUNT
Query Match 1.0%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 4.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1204 ATTAAACAAACAAA 1217
DB 14 ATTAAACAAATCAAA 1

```

```

RESULT 514
BD091246
LOCUS 16 bp RNA linear PAT 27-AUG-2002
DEFINITION RNase L activators and antisense oligonucleotides effective to
treat RSV infections.
ACCESSION BD091246
VERSION BD091246.1 GI:22636856
KEYWORDS JP 2001523636-A/21.
SOURCE Respiratory syncytial virus
ORGANISM Respiratory syncytial virus
REFERENCE 1 (bases 1 to 16)
AUTHORS Torrence,P.F., Silverman,R.H., Cirino,N.M., Li,G., Xiao,W. and
Player,M.R.
TITLE RNase L activators and antisense oligonucleotides effective to
treat RSV infections
JOURNAL Patent: JP 2001523636-A 21 27-NOV-2001;
COMMENT THE CLEVELAND CLINIC FOUNDATION,NATIONAL INSTITUTES OF HEALTH
OS Respiratory syncytial virus
PN JP 2001523636-A/21
PD 27-NOV-2001
PF 02-NOV-1998 JP 2000518674
PR 03-NOV-1997 US 08/962690
PI PAUL F TORRENCE,ROBERT H SILVERMAN,NICK M CIRINO,GUYING LI,
PI WEI XIAO,
PI MARK R PLAYER
PC A61K31/711,A61K9/12,A61K48/00,A61P31/14,C12N15/09,C12N15/00 CC
n=a,c,g, or u Location/Qualifiers
FT modified base (10).
FT Location/Qualifiers
FT 1..16 /organism='Respiratory syncytial virus'
FT /mol_type='genomic RNA'
FT /db_xref='taxon:12814'
FT 5 a 1 c 0 g 9 t 1 others
BASE COUNT
Query Match 1.0%; Score 12.4; DB 1; Length 16;
Best Local Similarity 86.7%; Pred. No. 4.7e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1521 TTTATATTTTAACT 1535
DB 2 TTTATATATTTAACT 16
RESULT 515
A89165
LOCUS 17 bp DNA linear PAT 22-JAN-2000
DEFINITION Sequence 1313 from Patent WO9833904.
ACCESSION A89165
VERSION A89165.1 GI:6737735
KEYWORDS unidentified
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Brysch,W. and Schlingensiepen,K.
TITLE AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
JOURNAL Patent: WO 9833904-A 1313 06-AUG-1998;
BIOGNOSTIK GES (DE); BRYSCH WOLFGANG (DE)
FEATURES Location/Qualifiers
FT 1..17 /organism='unidentified'
FT /mol_type='genomic DNA'
FT /db_xref='taxon:32644'
FT 4 a 2 c 4 g 7 t
BASE COUNT
Query Match 1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```


QY 720 CTTTAATTCAGGA 733
 Db 1 CTTTAATTCAGGA 14

RESULT 516
 LOCUS AR046644 17 bp DNA PAT 29-SEP-1999
 DEFINITION Sequence 1437 from patent US 5817796.
 ACCESSION AR046644
 VERSION AR046644.1 GI:5968109
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unclassified.
 REFERENCE 1 (bases 1 to 17)
 AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
 TITLE C-myb ribozymes having 2'-5'-linked adenylyate residues
 JOURNAL Patent: US 5817796-A 1437 06-OCT-1998;
 FEATURES Location/Qualifiers
 source 1..17
 BASE COUNT 7 a 6 c 2 g 2 t
 Query Match 1.0%; Score 12.4; DB 1; Length 17;
 Best Local Similarity 92.9%; Pred. No. 5.2e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1354 TGTGTGTGTAATGC 1367
 Db 17 TGTGTGTGTAATGC 4

RESULT 517
 LOCUS AR186350 17 bp DNA PAT 20-APR-2002
 DEFINITION Sequence 1838 from patent US 6346398.
 ACCESSION AR186350
 VERSION AR186350.1 GI:20232315
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unclassified.
 REFERENCE 1 (bases 1 to 17)
 AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
 TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
 JOURNAL Patent: US 6346398-A 1838 12-FEB-2002;
 FEATURES Location/Qualifiers
 source 1..17
 BASE COUNT 11 a 4 c 1 g 1 t
 Query Match 1.0%; Score 12.4; DB 1; Length 17;
 Best Local Similarity 92.9%; Pred. No. 5.2e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 616 ACAAAATACACAA 629
 Db 2 ACAAAATACACAA 15

RESULT 518
 LOCUS AR186590 17 bp DNA PAT 20-APR-2002
 DEFINITION Sequence 2078 from patent US 6346398.
 ACCESSION AR186590
 VERSION AR186590.1 GI:20232555
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unclassified.
 REFERENCE 1 (bases 1 to 17)

AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
 TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
 JOURNAL Patent: US 6346398-A 2078 12-FEB-2002;
 FEATURES Location/Qualifiers
 source 1..17
 BASE COUNT 5 a 3 c 3 g 6 t
 Query Match 1.0%; Score 12.4; DB 1; Length 17;
 Best Local Similarity 92.9%; Pred. No. 5.2e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 714 TCCGAACTTTAATT 727
 Db 1 TCCGAACTTTAATT 14

RESULT 519
 LOCUS AR186885 17 bp DNA PAT 20-APR-2002
 DEFINITION Sequence 2373 from patent US 6346398.
 ACCESSION AR186885
 VERSION AR186885.1 GI:20232850
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unclassified.
 REFERENCE 1 (bases 1 to 17)
 AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
 TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
 JOURNAL Patent: US 6346398-A 2373 12-FEB-2002;
 FEATURES Location/Qualifiers
 source 1..17
 BASE COUNT 5 a 5 c 2 g 5 t
 Query Match 1.0%; Score 12.4; DB 1; Length 17;
 Best Local Similarity 92.9%; Pred. No. 5.2e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 980 AAGCACTTTAAGTT 993
 Db 2 AAGCACTTTAAGTT 15

RESULT 520
 LOCUS AR186886 17 bp DNA PAT 20-APR-2002
 DEFINITION Sequence 2374 from patent US 6346398.
 ACCESSION AR186886
 VERSION AR186886.1 GI:20232851
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unclassified.
 REFERENCE 1 (bases 1 to 17)
 AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
 TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
 JOURNAL Patent: US 6346398-A 2374 12-FEB-2002;
 FEATURES Location/Qualifiers
 source 1..17
 BASE COUNT 5 a 5 c 2 g 5 t
 Query Match 1.0%; Score 12.4; DB 1; Length 17;
 Best Local Similarity 92.9%; Pred. No. 5.2e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 980 AAGCACTTTAAGTT 993
 Db 2 AAGCACTTTAAGTT 15

Db 1 AGCACTTTAAGCT 14 linear PAT 20-APR-2002

RESULT 521
LOCUS ARI188361 17 bp DNA
DEFINITION Sequence 3849 from patent US 6346398.
ACCESSION ARI188361
VERSION ARI188361.1 GI:20234326
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 3849 12-FEB-2002;
FEATURES Location/Qualifiers
source 1..17
BASE COUNT 5 a 3 c 2 g 7 t

Query Match 1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1457 GTTATTATGATCA 1470
Db 3 GTCTATTATGATCA 16

RESULT 522
LOCUS ARI188739 17 bp DNA
DEFINITION Sequence 4227 from patent US 6346398.
ACCESSION ARI188739
VERSION ARI188739.1 GI:20234704
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 4227 12-FEB-2002;
FEATURES Location/Qualifiers
source 1..17
BASE COUNT 8 a 2 c 1 g 6 t

Query Match 1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1118 ATAGTTATAAGAT 1131
Db 1 ATATTATAAGAT 14

RESULT 523
LOCUS ARI190158 17 bp DNA
DEFINITION Sequence 5646 from patent US 6346398.
ACCESSION ARI190158
VERSION ARI190158.1 GI:20236123
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.

TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 5646 12-FEB-2002;
FEATURES Location/Qualifiers
source 1..17
BASE COUNT 5 a 5 c 2 g 5 t

Query Match 1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 467 CATGTATTGTGTGG 480
Db 14 CATGTAAATGTGTGG 1

RESULT 524
LOCUS ARI192044 17 bp DNA
DEFINITION Sequence 7532 from patent US 6346398.
ACCESSION ARI192044
VERSION ARI192044.1 GI:20238009
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 7532 12-FEB-2002;
FEATURES Location/Qualifiers
source 1..17
BASE COUNT 11 a 4 c 1 g 1 t

Query Match 1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 616 ACAAAAACACACAA 629
Db 2 ACAAAATACACAA 15

RESULT 525
LOCUS ARI192329/c 17 bp DNA
DEFINITION Sequence 7817 from patent US 6346398.
ACCESSION ARI192329
VERSION ARI192329.1 GI:20238294
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 7817 12-FEB-2002;
FEATURES Location/Qualifiers
source 1..17
BASE COUNT 0 a 1 c 3 g 13 t

Query Match 1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 617 CAAAAACACACAA 630
Db 17 CAAAAACACAAAA 4

```

RESULT 526
AR192331/c
LOCUS       AR192331        17 bp    DNA          linear          PAT 20-APR-2002
DEFINITION   Sequence 7819 from patent US 6346398.
ACCESSION    AR192331
VERSION      AR192331.1   GI:20238296
KEYWORDS     Unknown.
SOURCE       Unknown.
ORGANISM     Unclassified.
REFERENCE    1 (bases 1 to 17)
AUTHORS      Pavco, P., McSwiggen, J., Stinchcomb, D. and Bacabedo, J.
TITLE        Method and reagent for the treatment of diseases or conditions
             related to levels of vascular endothelial growth factor receptor
JOURNAL      Patent: US 6346398-A 7819 12-FEB-2002;
FEATURES     Location/Qualifiers
             source          1..17
             /organism="unknown"
BASE COUNT   0 a      0 c      2 g      15 t

Query Match      1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      616  ACAAACCAACCAACAA 629
Db      14  ACAAACCAACCAAAA 1

RESULT 527
AX215016/c
LOCUS       AX215016        17 bp    mRNA          linear          PAT 07-SEP-2001
DEFINITION   Sequence 458 from Patent WO0159103.
ACCESSION    AX215016
VERSION      AX215016.1   GI:15525059
KEYWORDS     synthetic construct
             synthetic construct
             artificial sequences.
ORGANISM     synthetic construct
REFERENCE    1
AUTHORS      Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE        Method and reagent for the modulation and diagnosis of cd20 and
             nogo gene expression
JOURNAL      Patent: WO 0159103-A 458 16-AUG-2001;
             RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
             McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES     Location/Qualifiers
             source          1..17
             /organism="synthetic construct"
             /mol_type="mRNA"
             /db_xref="taxon:32630"
             /note="Nucleic Acid"
BASE COUNT   5 a      2 c      1 g      9 t

Query Match      1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1096 TAGAAGATGAATCA 1109
Db      14  TAGAAGATGAATCA 1

RESULT 528
AX215685
LOCUS       AX215685        17 bp    mRNA          linear          PAT 07-SEP-2001
DEFINITION   Sequence 1127 from Patent WO0159103.
ACCESSION    AX215685
VERSION      AX215685.1   GI:15525728
KEYWORDS     synthetic construct
             synthetic construct
             artificial sequences.
ORGANISM     synthetic construct
REFERENCE    1
AUTHORS      Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE        Method and reagent for the modulation and diagnosis of cd20 and
             nogo gene expression
JOURNAL      Patent: WO 0159103-A 1127 16-AUG-2001;
             RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
             McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES     Location/Qualifiers
             source          1..17
             /organism="synthetic construct"
             /mol_type="mRNA"
             /db_xref="taxon:32630"
             /note="Nucleic Acid"
BASE COUNT   9 a      3 c      1 g      4 t

Query Match      1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      623  ACAACCAATAATTT 636
Db      2    ACAACCAATAATTT 15

RESULT 530
AX217082
LOCUS       AX217082        17 bp    mRNA          linear          PAT 07-SEP-2001
DEFINITION   Sequence 2524 from Patent WO0159103.
ACCESSION    AX217082
VERSION      AX217082.1   GI:15527143
KEYWORDS     synthetic construct
             synthetic construct
             artificial sequences.
ORGANISM     synthetic construct
REFERENCE    1
AUTHORS      Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE        Method and reagent for the modulation and diagnosis of cd20 and
             nogo gene expression
JOURNAL      Patent: WO 0159103-A 2182 16-AUG-2001;
             RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
             McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES     Location/Qualifiers
             source          1..17
             /organism="synthetic construct"
             /mol_type="mRNA"
             /db_xref="taxon:32630"
             /note="Nucleic Acid"
BASE COUNT   9 a      3 c      1 g      4 t

Query Match      1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      623  ACAACCAATAATTT 636
Db      2    ACAACCAATAATTT 15

RESULT 530
AX217082
LOCUS       AX217082        17 bp    mRNA          linear          PAT 07-SEP-2001
DEFINITION   Sequence 2524 from Patent WO0159103.
ACCESSION    AX217082
VERSION      AX217082.1   GI:15527143
KEYWORDS     synthetic construct
             synthetic construct
             artificial sequences.
ORGANISM     synthetic construct
REFERENCE    1
AUTHORS      Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE        Method and reagent for the modulation and diagnosis of cd20 and
             nogo gene expression
JOURNAL      Patent: WO 0159103-A 2182 16-AUG-2001;
             RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
             McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES     Location/Qualifiers
             source          1..17
             /organism="synthetic construct"
             /mol_type="mRNA"
             /db_xref="taxon:32630"
             /note="Nucleic Acid"
BASE COUNT   9 a      3 c      1 g      4 t

Query Match      1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      623  ACAACCAATAATTT 636
Db      2    ACAACCAATAATTT 15

```

```

ORGANISM     synthetic construct
             artificial sequences.
REFERENCE    1
AUTHORS      Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE        Method and reagent for the modulation and diagnosis of cd20 and
             nogo gene expression
JOURNAL      Patent: WO 0159103-A 1127 16-AUG-2001;
             RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
             McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES     Location/Qualifiers
             source          1..17
             /organism="synthetic construct"
             /mol_type="mRNA"
             /db_xref="taxon:32630"
             /note="Nucleic Acid"
BASE COUNT   7 a      3 c      2 g      5 t

Query Match      1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      523  ACACCAATAATTT 536
Db      4    ACACCAATAATTT 17

RESULT 529
AX216740
LOCUS       AX216740        17 bp    mRNA          linear          PAT 07-SEP-2001
DEFINITION   Sequence 2182 from Patent WO0159103.
ACCESSION    AX216740
VERSION      AX216740.1   GI:15526801
KEYWORDS     synthetic construct
             synthetic construct
             artificial sequences.
ORGANISM     synthetic construct
REFERENCE    1
AUTHORS      Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE        Method and reagent for the modulation and diagnosis of cd20 and
             nogo gene expression
JOURNAL      Patent: WO 0159103-A 2182 16-AUG-2001;
             RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
             McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES     Location/Qualifiers
             source          1..17
             /organism="synthetic construct"
             /mol_type="mRNA"
             /db_xref="taxon:32630"
             /note="Nucleic Acid"
BASE COUNT   9 a      3 c      1 g      4 t

Query Match      1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      623  ACAACCAATAATTT 636
Db      2    ACAACCAATAATTT 15

RESULT 530
AX217082
LOCUS       AX217082        17 bp    mRNA          linear          PAT 07-SEP-2001
DEFINITION   Sequence 2524 from Patent WO0159103.
ACCESSION    AX217082
VERSION      AX217082.1   GI:15527143
KEYWORDS     synthetic construct
             synthetic construct
             artificial sequences.
ORGANISM     synthetic construct
REFERENCE    1
AUTHORS      Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE        Method and reagent for the modulation and diagnosis of cd20 and
             nogo gene expression
JOURNAL      Patent: WO 0159103-A 2182 16-AUG-2001;
             RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
             McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES     Location/Qualifiers
             source          1..17
             /organism="synthetic construct"
             /mol_type="mRNA"
             /db_xref="taxon:32630"
             /note="Nucleic Acid"
BASE COUNT   9 a      3 c      1 g      4 t

Query Match      1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      623  ACAACCAATAATTT 636
Db      2    ACAACCAATAATTT 15

```

```

nogo gene expression
Patent: WO 0159103-A 2524 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US);
McSwiggen, James (US); Chowrira, Bharat M. (US)
Location/Qualifiers
1. .17
/organism="synthetic construct"
/mol_type="mRNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"
BASE COUNT      8 a      3 c      1 g      5 t
Query Match      1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 623 ACAACAGATAATT 536
|||||
DB 3 ACAACAGATAATT 16

RESULT 531
AX217114      17 bp mRNA linear PAT 07-SEP-2001
LOCUS
DEFINITION Sequence 2556 from Patent WO0159103.
ACCESSION AX217114
VERSION AX217114.1 GI:15527175
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE
1 Blatt, L., McSwiggen, J. and Chowrira, B.M.
AUTHORS Method and reagent for the modulation and diagnosis of cd20 and
TITLE nogo gene expression
JOURNAL RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US);
McSwiggen, James (US); Chowrira, Bharat M. (US)
FEATURES
1. .17
Location/Qualifiers
/organism="synthetic construct"
/mol_type="mRNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"
BASE COUNT      11 a      1 c      2 g      3 t
Query Match      1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1204 ATTAAAGAACAAA 1217
|||||
DB 3 ATTAAAGAACAAA 16

RESULT 532
AX226925      17 bp mRNA linear PAT 10-SEP-2001
LOCUS
DEFINITION Sequence 297 from Patent WO0157206.
ACCESSION AX226925
VERSION AX226925.1 GI:15556066
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE
1 Fattaey, A.R., Jarvis, T., McSwiggen, J., Boohar, R.N. and Holman, P.S.
AUTHORS Method and reagent for the inhibition of checkpoint kinase-1 (chk
TITLE 1) enzyme
JOURNAL RIBOZYME PHARMACEUTICALS, INC. (US); Fattaey, Ali R. (US)
FEATURES
1. .17
Location/Qualifiers
/organism="synthetic construct"
/mol_type="mRNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"
BASE COUNT      3 a      0 c      2 g      12 t
Query Match      1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

nogo gene expression
Patent: WO 0159103-A 2524 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US);
McSwiggen, James (US); Chowrira, Bharat M. (US)
Location/Qualifiers
1. .17
/organism="synthetic construct"
/mol_type="mRNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"
BASE COUNT      3 a      2 c      1 g      11 t
Query Match      1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1141 AATTATTATTATT 1154
|||||
DB 4 AATTATTATTATT 17

RESULT 533
AX226926      17 bp mRNA linear PAT 10-SEP-2001
LOCUS
DEFINITION Sequence 298 from Patent WO0157206.
ACCESSION AX226926
VERSION AX226926.1 GI:15556067
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE
1 Fattaey, A.R., Jarvis, T., McSwiggen, J., Boohar, R.N. and Holman, P.S.
AUTHORS Method and reagent for the inhibition of checkpoint kinase-1 (chk
TITLE 1) enzyme
JOURNAL RIBOZYME PHARMACEUTICALS, INC. (US); Fattaey, Ali R. (US)
FEATURES
1. .17
Location/Qualifiers
/organism="synthetic construct"
/mol_type="mRNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"
BASE COUNT      3 a      1 c      2 g      11 t
Query Match      1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1141 AATTATTATTATT 1154
|||||
DB 2 AATTATTATTATT 15

RESULT 534
AX226927      17 bp mRNA linear PAT 10-SEP-2001
LOCUS
DEFINITION Sequence 299 from Patent WO0157206.
ACCESSION AX226927
VERSION AX226927.1 GI:15556068
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE
1 Fattaey, A.R., Jarvis, T., McSwiggen, J., Boohar, R.N. and Holman, P.S.
AUTHORS Method and reagent for the inhibition of checkpoint kinase-1 (chk
TITLE 1) enzyme
JOURNAL RIBOZYME PHARMACEUTICALS, INC. (US); Fattaey, Ali R. (US)
FEATURES
1. .17
Location/Qualifiers
/organism="synthetic construct"
/mol_type="mRNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"
BASE COUNT      3 a      0 c      2 g      12 t
Query Match      1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

nogo gene expression
Patent: WO 0157206-A 297 09-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); Fattaey, Ali R. (US)
Location/Qualifiers
1. .17
/organism="synthetic construct"
/mol_type="mRNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"
BASE COUNT      3 a      0 c      2 g      12 t
Query Match      1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

QY 1141 AATTATTTTATTT 1154
 Db 1 AATTATTTTGT 14

RESULT 535
 AX263192
 LOCUS AX263192 17 bp DNA linear PAT 26-OCT-2001
 DEFINITION Sequence 583 from Patent WO0173002.
 ACCESSION AX263192
 VERSION AX263192.1 GI:16511991
 KEYWORDS Homo sapiens (human)
 SOURCE
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1
 AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
 TITLE Targeted chromosomal genomic alterations with modified single stranded oligonucleotides
 JOURNAL Patent: WO 0173002-A 583 04-OCT-2001;
 UNIVERSITY OF DELAWARE (US)
 FEATURES Location/Qualifiers
 source 1..17
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"
 BASE COUNT 9 a 2 c 1 g 5 t
 Query Match 1.0%; Score 12.4; DB 1; Length 17;
 Best Local Similarity 92.9%; Pred. No. 5.2e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1204 ATTAACACAA 1217
 Db 3 ATTAACACAA 16

RESULT 536
 AX263193/c
 LOCUS AX263193 17 bp DNA linear PAT 26-OCT-2001
 DEFINITION Sequence 584 from Patent WO0173002.
 ACCESSION AX263193
 VERSION AX263193.1 GI:16511992
 KEYWORDS Homo sapiens (human)
 SOURCE
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1
 AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
 TITLE Targeted chromosomal genomic alterations with modified single stranded oligonucleotides
 JOURNAL Patent: WO 0173002-A 584 04-OCT-2001;
 UNIVERSITY OF DELAWARE (US)
 FEATURES Location/Qualifiers
 source 1..17
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"
 BASE COUNT 5 a 1 c 2 g 9 t
 Query Match 1.0%; Score 12.4; DB 1; Length 17;
 Best Local Similarity 92.9%; Pred. No. 5.2e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1204 ATTAACACAA 1217
 Db 15 ATTAACACAA 2

RESULT 537
 AX265663

LOCUS AX265663 17 bp DNA linear PAT 26-OCT-2001
 DEFINITION Sequence 3054 from Patent WO0173002.
 ACCESSION AX265663
 VERSION AX265663.1 GI:16514462
 KEYWORDS Homo sapiens (human)
 SOURCE
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1
 AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
 TITLE Targeted chromosomal genomic alterations with modified single stranded oligonucleotides
 JOURNAL Patent: WO 0173002-A 3054 04-OCT-2001;
 UNIVERSITY OF DELAWARE (US)
 FEATURES Location/Qualifiers
 source 1..17
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"
 BASE COUNT 6 a 3 c 3 g 5 t
 Query Match 1.0%; Score 12.4; DB 1; Length 17;
 Best Local Similarity 92.9%; Pred. No. 5.2e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 533 TTCAGTAAACAATG 546
 Db 4 TTCAGTAAACAATG 17

RESULT 538
 AX265664/c
 LOCUS AX265664 17 bp DNA linear PAT 26-OCT-2001
 DEFINITION Sequence 3055 from Patent WO0173002.
 ACCESSION AX265664
 VERSION AX265664.1 GI:16514463
 KEYWORDS Homo sapiens (human)
 SOURCE
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1
 AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
 TITLE Targeted chromosomal genomic alterations with modified single stranded oligonucleotides
 JOURNAL Patent: WO 0173002-A 3055 04-OCT-2001;
 UNIVERSITY OF DELAWARE (US)
 FEATURES Location/Qualifiers
 source 1..17
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"
 BASE COUNT 5 a 3 c 3 g 6 t
 Query Match 1.0%; Score 12.4; DB 1; Length 17;
 Best Local Similarity 92.9%; Pred. No. 5.2e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 533 TTCAGTAAACAATG 546
 Db 14 TTCAGTAAACAATG 1

RESULT 539
 AX272720
 LOCUS AX272720 17 bp mRNA linear PAT 29-OCT-2001
 DEFINITION Sequence 289 from Patent WO0162911.
 ACCESSION AX272720
 VERSION AX272720.1 GI:16545457
 KEYWORDS Homo sapiens (human)
 SOURCE
 ORGANISM Homo sapiens

```

REFERENCE
AUTHORS      Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
TITLE        Jarvis, T., von Carlowitz, I., Mcswiggen, J.A., Hamblin, P.A. and
              Ellis, J.H.
JOURNAL      Method and reagent for the inhibition of grid
              Patent: WO 0162911-A 289 30-AUG-2001;
              RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
source       Location/Qualifiers
              1..17
              /organism="Homo sapiens"
              /mol_type="mRNA"
              /db_xref="taxon:9606"
BASE COUNT   5 a 5 c 3 g 4 t

Query Match   1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 457 TTCAACACCTTCATG 470
Db 3 TTCAACACCTTCAG 16

RESULT 540
AX272721
LOCUS        AX272721 17 bp mRNA linear PAT 29-OCT-2001
DEFINITION   Sequence 290 from Patent WO0162911.
ACCESSION    AX272721
VERSION      AX272721.1 GI:16545458
KEYWORDS     Homo sapiens (human)
SOURCE       Homo sapiens
ORGANISM     Homo sapiens
              Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE    1
AUTHORS      Jarvis, T., von Carlowitz, I., Mcswiggen, J.A., Hamblin, P.A. and
              Ellis, J.H.
TITLE        Method and reagent for the inhibition of grid
JOURNAL      Patent: WO 0162911-A 290 30-AUG-2001;
              RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
source       Location/Qualifiers
              1..17
              /organism="Homo sapiens"
              /mol_type="mRNA"
              /db_xref="taxon:9606"
BASE COUNT   5 a 5 c 2 g 5 t

Query Match   1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 457 TTCAACACCTTCATG 470
Db 1 TTCAACACCTTCAG 14

RESULT 541
AX383942
LOCUS        AX383942 17 bp DNA linear PAT 19-MAR-2002
DEFINITION   Sequence 45 from Patent WO0214546.
ACCESSION    AX383942
VERSION      AX383942.1 GI:19577513
KEYWORDS     Plasmodium falciparum (malaria parasite P. falciparum)
SOURCE       Plasmodium falciparum
ORGANISM     Eukaryota; Alveolata; Apicomplexa; Haemosporida; Plasmodium.
REFERENCE    1
AUTHORS      Fritzsche, M.
TITLE        Use of microbial dna sequences for the identification of human
              diseases
JOURNAL      Patent: WO 0214546-A 45 21-FEB-2002;
              Fritzsche, Markus (CH)

```

```

FEATURES
source       Location/Qualifiers
              1..17
              /organism="Plasmodium falciparum"
              /mol_type="genomic DNA"
              /db_xref="taxon:5833"
BASE COUNT   8 a 1 c 1 g 7 t

Query Match   1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1604 ATATGAAACATTTA 1617
Db 1 ATATGAAACATTTA 14

RESULT 542
AX421941/c
LOCUS        AX421941 17 bp mRNA linear PAT 18-JUN-2002
DEFINITION   Sequence 277 from Patent WO0188124.
ACCESSION    AX421941
VERSION      AX421941.1 GI:21525323
KEYWORDS     Homo sapiens (human)
SOURCE       Homo sapiens
ORGANISM     Homo sapiens
              Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE    1
AUTHORS      Jarvis, T., von Carlowitz, I., Mcswiggen, J.A., McLaughlin, P.G. and
              Randi, A.M.
TITLE        Method and reagent for the inhibition of erg
JOURNAL      Patent: WO 0188124-A 277 22-NOV-2001;
              RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
source       Location/Qualifiers
              1..17
              /organism="Homo sapiens"
              /mol_type="mRNA"
              /db_xref="taxon:9606"
BASE COUNT   7 a 3 c 1 g 6 t

Query Match   1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1505 TTTTAAATACAG 1518
Db 17 TTTTAAATACAG 4

RESULT 543
AX423390/c
LOCUS        AX423390 17 bp mRNA linear PAT 18-JUN-2002
DEFINITION   Sequence 1726 from Patent WO0188124.
ACCESSION    AX423390
VERSION      AX423390.1 GI:21526772
KEYWORDS     Homo sapiens (human)
SOURCE       Homo sapiens
ORGANISM     Homo sapiens
              Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE    1
AUTHORS      Jarvis, T., von Carlowitz, I., Mcswiggen, J.A., McLaughlin, P.G. and
              Randi, A.M.
TITLE        Method and reagent for the inhibition of erg
JOURNAL      Patent: WO 0188124-A 1726 22-NOV-2001;
              RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
source       Location/Qualifiers
              1..17
              /organism="Homo sapiens"
              /mol_type="mRNA"
              /db_xref="taxon:9606"
BASE COUNT   9 a 1 c 1 g 6 t

```

```

Query Match          1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1233 TTAATTTTCATTT 1246
Db 14 TAAATTTTCATTT 1

RESULT 544
AX500362/c
LOCUS          AX500362          17 bp  DNA    linear    PAT 27-SEP-2002
DEFINITION     Sequence 1669 from Patent EPI229046.
ACCESSION      AX500362
VERSION        AX500362.1 GI:23382655
KEYWORDS
SOURCE         Homo sapiens (human)
ORGANISM
REFERENCE
AUTHORS        Zhan,J.
TITLE          Human testis expressed patched like protein
JOURNAL        Patent: EP 1229046-A 1669 07-AUG-2002;
Aeomica, Inc. (US)
FEATURES       Location/Qualifiers
source         1..17
                /organism="Homo sapiens"
                /mol_type="genomic DNA"
                /db_xref="taxon:9606"
                /db_xref="taxon:9606"
BASE COUNT     2 a 1 c 2 g 12 t

Query Match          1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 678 ACAATAGCAAAAT 691
Db 17 AAAAATAGCAAAAT 4

RESULT 545
AX500368/c
LOCUS          AX500368          17 bp  DNA    linear    PAT 27-SEP-2002
DEFINITION     Sequence 1675 from Patent EPI229046.
ACCESSION      AX500368
VERSION        AX500368.1 GI:23382661
KEYWORDS
SOURCE         Homo sapiens (human)
ORGANISM
REFERENCE
AUTHORS        Zhan,J.
TITLE          Human testis expressed patched like protein
JOURNAL        Patent: EP 1229046-A 1675 07-AUG-2002;
Aeomica, Inc. (US)
FEATURES       Location/Qualifiers
source         1..17
                /organism="Homo sapiens"
                /mol_type="genomic DNA"
                /db_xref="taxon:9606"
                /db_xref="taxon:9606"
BASE COUNT     5 a 2 c 1 g 9 t

Query Match          1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 675 TATACAAATAGCAA 688
Db 14 TATACAAATAGCAA 1

```

```

RESULT 546
AX500620/c
LOCUS          AX500620          17 bp  DNA    linear    PAT 27-SEP-2002
DEFINITION     Sequence 1927 from Patent EPI229046.
ACCESSION      AX500620
VERSION        AX500620.1 GI:23382913
KEYWORDS
SOURCE         Homo sapiens (human)
ORGANISM
REFERENCE
AUTHORS        Zhan,J.
TITLE          Human testis expressed patched like protein
JOURNAL        Patent: EP 1229046-A 1927 07-AUG-2002;
Aeomica, Inc. (US)
FEATURES       Location/Qualifiers
source         1..17
                /organism="Homo sapiens"
                /mol_type="genomic DNA"
                /db_xref="taxon:9606"
                /db_xref="taxon:9606"
BASE COUNT     5 a 2 c 2 g 8 t

Query Match          1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1459 TTATTATGTACAA 1472
Db 17 TTATGATGTACAA 4

RESULT 547
AX500621/c
LOCUS          AX500621          17 bp  DNA    linear    PAT 27-SEP-2002
DEFINITION     Sequence 1928 from Patent EPI229046.
ACCESSION      AX500621
VERSION        AX500621.1 GI:23382914
KEYWORDS
SOURCE         Homo sapiens (human)
ORGANISM
REFERENCE
AUTHORS        Zhan,J.
TITLE          Human testis expressed patched like protein
JOURNAL        Patent: EP 1229046-A 1928 07-AUG-2002;
Aeomica, Inc. (US)
FEATURES       Location/Qualifiers
source         1..17
                /organism="Homo sapiens"
                /mol_type="genomic DNA"
                /db_xref="taxon:9606"
                /db_xref="taxon:9606"
BASE COUNT     5 a 2 c 3 g 7 t

Query Match          1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1459 TTATTATGTACAA 1472
Db 16 TTATGATGTACAA 3

RESULT 548
AX578723/c
LOCUS          AX578723          17 bp  mRNA    linear    PAT 10-JAN-2003
DEFINITION     Sequence 561 from Patent WO0211674.
ACCESSION      AX578723
VERSION        AX578723.1 GI:27647925
KEYWORDS
SOURCE         Homo sapiens (human)
ORGANISM

```

```

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS
Thompson, J., McSwiggen, J., McKenzie, T., Ayers, D., Szymkowski, D.E.
and Grupe, A.
TITLE
Method and reagent for the inhibition of calcium activated chloride
channel-1 (clca-1)
JOURNAL
Patent: WO 0211674-A 561 14-FEB-2002;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
Thompson, James (US)
FEATURES
source
Location/Qualifiers
1. .17
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
7 a 1 c 1 g 8 t
BASE COUNT
Query Match 1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. NO. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1134 TATAGTAAATTTAT 1147
|||||
Db 3 TATAGTACATTTAT 16

RESULT 549
AX579367
LOCUS
DEFINITION
Sequence 1205 from Patent WO0211674.
ACCESSION
AX579367
VERSION
AX579367.1 GI:27648569
KEYWORDS
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS
Thompson, J., McSwiggen, J., McKenzie, T., Ayers, D., Szymkowski, D.E.
and Grupe, A.
TITLE
Method and reagent for the inhibition of calcium activated chloride
channel-1 (clca-1)
JOURNAL
Patent: WO 0211674-A 1205 14-FEB-2002;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
Thompson, James (US)
FEATURES
source
Location/Qualifiers
1. .17
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
6 a 2 c 1 g 8 t
BASE COUNT
Query Match 1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. NO. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1134 TATAGTAAATTTAT 1147
|||||
Db 1 TATAGTACATTTAT 14

RESULT 550
AX671564/c
LOCUS
DEFINITION
Sequence 9 from Patent WO03004526.
ACCESSION
AX671564
VERSION
AX671564.1 GI:29322912
KEYWORDS
Homo sapiens (human)
SOURCE
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE

```

```

Telerman, A., Anson, R. and Tuijnder, M.
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines
Patent: WO 03004526-A 9 16-JAN-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
Location/Qualifiers
1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
7 a 2 c 3 g 5 t
BASE COUNT
Query Match 1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. NO. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 627 CAAATATTTTGA 640
|||||
Db 16 CAAATATTTTGA 3

RESULT 551
AX671663/c
LOCUS
DEFINITION
Sequence 108 from Patent WO03004526.
ACCESSION
AX671663
VERSION
AX671663.1 GI:29330011
KEYWORDS
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS
Telerman, A., Anson, R. and Tuijnder, M.
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines
Patent: WO 03004526-A 108 16-JAN-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
Location/Qualifiers
1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
9 a 3 c 4 g 1 t
BASE COUNT
Query Match 1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. NO. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1438 TTCTTCTGCTGA 1451
|||||
Db 16 TTCTTCTGCTGA 3

RESULT 552
AX672450/c
LOCUS
DEFINITION
Sequence 895 from Patent WO03004526.
ACCESSION
AX672450
VERSION
AX672450.1 GI:29330798
KEYWORDS
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS
Telerman, A., Anson, R. and Tuijnder, M.
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines
Patent: WO 03004526-A 895 16-JAN-2003;
Molecular Engines Laboratories (FR)
JOURNAL

```


FEATURES source
1. .17
Molecular Engines Laboratories (FR)
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 6 a 2 c 1 g 8 t
Query Match 1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1156 AGATATTATATGAT 1169
Db 15 ATATATTATATGAT 2
RESULT 553
AX672835/c
LOCUS AX672835 17 bp DNA linear PAT 27-MAR-2003
DEFINITION Sequence 1280 from Patent WO03004526.
ACCESSION AX672835
VERSION AX672835.1 GI:29331183
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines
JOURNAL Patent: WO 03004526-A 1280 16-JAN-2003;
Molecular Engines Laboratories (FR)
FEATURES source
1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 5 a 4 c 3 g 5 t
Query Match 1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1101 GATCAATCATGAT 1114
Db 15 GATCAATCATGAT 2
RESULT 554
AX673316/c
LOCUS AX673316 17 bp DNA linear PAT 27-MAR-2003
DEFINITION Sequence 1761 from Patent WO03004526.
ACCESSION AX673316
VERSION AX673316.1 GI:29331664
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines
JOURNAL Patent: WO 03004526-A 1761 16-JAN-2003;
Molecular Engines Laboratories (FR)
FEATURES source
1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"

BASE COUNT 6 a 3 g 2 t
Query Match 1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 959 TGATGTTGTGAGGA 972
Db 16 TGCTGTGTGAGGA 3
RESULT 555
AX673453/c
LOCUS AX673453 17 bp DNA linear PAT 27-MAR-2003
DEFINITION Sequence 1898 from Patent WO03004526.
ACCESSION AX673453
VERSION AX673453.1 GI:29331801
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines
JOURNAL Patent: WO 03004526-A 1898 16-JAN-2003;
Molecular Engines Laboratories (FR)
FEATURES source
1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 5 a 3 c 5 g 4 t
Query Match 1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 864 TGCTAGCCAGGATC 877
Db 14 TTCTAGCCAGGATC 1
RESULT 556
AX674582
LOCUS AX674582 17 bp DNA linear PAT 27-MAR-2003
DEFINITION Sequence 3027 from Patent WO03004526.
ACCESSION AX674582
VERSION AX674582.1 GI:29332930
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines
JOURNAL Patent: WO 03004526-A 3027 16-JAN-2003;
Molecular Engines Laboratories (FR)
FEATURES source
1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 7 a 5 c 2 g 3 t
Query Match 1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;

Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
QY 1399 TATTAAACAGCCA 1412	
DB 3 TCTTAAACAGCCA 16	
RESULT 557	
AX674587/c	
LOCUS	17 bp DNA linear PAT 27-MAR-2003
DEFINITION	Sequence 3032 from Patent WO03004526.
ACCESSION	AX674587
VERSION	AX674587.1 GI:29332935
KEYWORDS	Hom sapiens (human)
SOURCE	ORGANISM
REFERENCE	
AUTHORS	Hom sapiens
TITLE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
JOURNAL	1
TELERMAN, A., AMSON, R. and TUIJNDER, M.	
SEQUENCES INVOLVED IN PHENOMENA OF TUMOUR SUPPRESSION, TUMOUR REVERSION, APOPTOSIS AND/OR RESISTANCE TO VIRUSES AND THEIR USE AS MEDICINES	
PATENT: WO 03004526-A 3032 16-JAN-2003;	
MOLECULAR ENGINES LABORATORIES (FR)	
FEATURES	source
1..17	
/organism="Homo sapiens"	
/mol_type="genomic DNA"	
/db_xref="taxon:9606"	
BASE COUNT 8 a 1 c 1 g 7 t	
Query Match 1.0%; Score 12.4; DB 1; Length 17;	
Best Local Similarity 92.9%; Pred. No. 5.2e+02;	
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
QY 1146 ATTATTTTATGAT 1159	
DB 15 ATTTTATTTAGAT 2	
RESULT 558	
AX722326/c	
LOCUS	17 bp DNA linear PAT 08-MAY-2003
DEFINITION	Sequence 13 from Patent WO03025176.
ACCESSION	AX722326
VERSION	AX722326.1 GI:30422827
KEYWORDS	Mus musculus (house mouse)
SOURCE	ORGANISM
REFERENCE	
AUTHORS	Mus musculus
TITLE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
JOURNAL	1
TELERMAN, A., AMSON, R. and TUIJNDER, M.	
SEQUENCES INVOLVED IN PHENOMENA OF TUMOUR SUPPRESSION, TUMOUR REVERSION, APOPTOSIS AND/OR VIRUS RESISTANCE AND THEIR USE AS MEDICINES	
PATENT: WO 03025176-A 13 27-MAR-2003;	
MOLECULAR ENGINES LABORATORIES (FR)	
FEATURES	source
1..17	
/organism="Mus musculus"	
/mol_type="genomic DNA"	
/db_xref="taxon:10090"	
BASE COUNT 6 a 3 c 3 g 5 t	
Query Match 1.0%; Score 12.4; DB 1; Length 17;	
Best Local Similarity 92.9%; Pred. No. 5.2e+02;	
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
QY 1076 TGTGCAAGATTG 1089	
DB 17 TGTCCAAGATTG 4	
RESULT 561	
AX724038	
LOCUS	17 bp DNA linear PAT 08-MAY-2003

RESULT 559	
AX722545	
LOCUS	17 bp DNA linear PAT 08-MAY-2003
DEFINITION	Sequence 232 from Patent WO03025176.
ACCESSION	AX722545
VERSION	AX722545.1 GI:30423046
KEYWORDS	Mus musculus (house mouse)
SOURCE	ORGANISM
REFERENCE	
AUTHORS	Mus musculus
TITLE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
JOURNAL	1
TELERMAN, A., AMSON, R. and TUIJNDER, M.	
SEQUENCES INVOLVED IN PHENOMENA OF TUMOUR SUPPRESSION, TUMOUR REVERSION, APOPTOSIS AND/OR VIRUS RESISTANCE AND THEIR USE AS MEDICINES	
PATENT: WO 03025176-A 232 27-MAR-2003;	
MOLECULAR ENGINES LABORATORIES (FR)	
FEATURES	source
1..17	
/organism="Mus musculus"	
/mol_type="genomic DNA"	
/db_xref="taxon:10090"	
BASE COUNT 9 a 1 c 4 g 3 t	
Query Match 1.0%; Score 12.4; DB 1; Length 17;	
Best Local Similarity 92.9%; Pred. No. 5.2e+02;	
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
QY 414 CAAGATCAAGTGAA 427	
DB 4 CAAGATAAGTGAA 17	
RESULT 560	
AX723257/c	
LOCUS	17 bp DNA linear PAT 08-MAY-2003
DEFINITION	Sequence 944 from Patent WO03025176.
ACCESSION	AX723257
VERSION	AX723257.1 GI:30423758
KEYWORDS	Mus musculus (house mouse)
SOURCE	ORGANISM
REFERENCE	
AUTHORS	Mus musculus
TITLE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
JOURNAL	1
TELERMAN, A., AMSON, R. and TUIJNDER, M.	
SEQUENCES INVOLVED IN PHENOMENA OF TUMOUR SUPPRESSION, TUMOUR REVERSION, APOPTOSIS AND/OR VIRUS RESISTANCE AND THEIR USE AS MEDICINES	
PATENT: WO 03025176-A 944 27-MAR-2003;	
MOLECULAR ENGINES LABORATORIES (FR)	
FEATURES	source
1..17	
/organism="Mus musculus"	
/mol_type="genomic DNA"	
/db_xref="taxon:10090"	
BASE COUNT 7 a 2 c 1 g 7 t	
Query Match 1.0%; Score 12.4; DB 1; Length 17;	
Best Local Similarity 92.9%; Pred. No. 5.2e+02;	
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
QY 1613 ATTAAATATATAT 1626	
DB 15 ATTTAAATATATGAT 2	
RESULT 561	
AX724038	
LOCUS	17 bp DNA linear PAT 08-MAY-2003

```

DEFINITION      Sequence 1725 from Patent WO03025176.
ACCESSION       AX724038
VERSION         AX724038.1 GI:305033381
KEYWORDS
SOURCE
ORGANISM        Mus musculus (house mouse)
REFERENCE
AUTHORS         Telerman,A., Anson,R. and Tuijnder,M.
TITLE           Sequences involved in phenomena of tumour suppression, tumour
                reversion, apoptosis and/or virus resistance and their use as
                medicines
JOURNAL         Patent: WO 03025176-A 1725 27-MAR-2003;
                Molecular Engines Laboratories (FR)
FEATURES        Location/Qualifiers
source          1..17
                /organism="Mus musculus"
                /mol_type="genomic DNA"
                /db_xref="taxon:10090"
BASE COUNT      6 a 4 c 2 g 5 t
                Query Match      1.0%; Score 12.4; DB 1; Length 17;
                Best Local Similarity 92.9%; Pred. No. 5.2e+02;
                Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1419 CACAGTCAATATTA 1432
Db 4 CACAGTCACTATTA 17

RESULT 562
AX724983
LOCUS           AX724983 17 bp DNA linear PAT 08-MAY-2003
DEFINITION     Sequence 2670 from Patent WO03025176.
ACCESSION      AX724983
VERSION        AX724983.1 GI:30504326
KEYWORDS
SOURCE         Mus musculus (house mouse)
ORGANISM       Mus musculus
                Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
                Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE
AUTHORS        Telerman,A., Anson,R. and Tuijnder,M.
TITLE          Sequences involved in phenomena of tumour suppression, tumour
                reversion, apoptosis and/or virus resistance and their use as
                medicines
JOURNAL        Patent: WO 03025176-A 2670 27-MAR-2003;
                Molecular Engines Laboratories (FR)
FEATURES        Location/Qualifiers
source          1..17
                /organism="Mus musculus"
                /mol_type="genomic DNA"
                /db_xref="taxon:10090"
BASE COUNT      8 a 2 c 1 g 6 t
                Query Match      1.0%; Score 12.4; DB 1; Length 17;
                Best Local Similarity 92.9%; Pred. No. 5.2e+02;
                Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 802 CATAAAGTCAAAATT 815
Db 4 CATAAATTCAAATT 17

RESULT 563
AX725250
LOCUS           AX725250 17 bp DNA linear PAT 08-MAY-2003
DEFINITION     Sequence 2937 from Patent WO03025176.
ACCESSION      AX725250
VERSION        AX725250.1 GI:30504593
KEYWORDS
SOURCE         Mus musculus (house mouse)

```

```

ORGANISM        Mus musculus
                Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
                Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE
AUTHORS         Telerman,A., Anson,R. and Tuijnder,M.
TITLE           Sequences involved in phenomena of tumour suppression, tumour
                reversion, apoptosis and/or virus resistance and their use as
                medicines
JOURNAL         Patent: WO 03025176-A 2937 27-MAR-2003;
                Molecular Engines Laboratories (FR)
FEATURES        Location/Qualifiers
source          1..17
                /organism="Mus musculus"
                /mol_type="genomic DNA"
                /db_xref="taxon:10090"
BASE COUNT      7 a 4 c 2 g 4 t
                Query Match      1.0%; Score 12.4; DB 1; Length 17;
                Best Local Similarity 92.9%; Pred. No. 5.2e+02;
                Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 451 AACTACTTCAACAC 464
Db 2 AACTACTTAAACAC 15

RESULT 564
AX726061
LOCUS           AX726061 17 bp DNA linear PAT 08-MAY-2003
DEFINITION     Sequence 3748 from Patent WO03025176.
ACCESSION      AX726061
VERSION        AX726061.1 GI:30505404
KEYWORDS
SOURCE         Mus musculus (house mouse)
ORGANISM       Mus musculus
                Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
                Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE
AUTHORS        Telerman,A., Anson,R. and Tuijnder,M.
TITLE          Sequences involved in phenomena of tumour suppression, tumour
                reversion, apoptosis and/or virus resistance and their use as
                medicines
JOURNAL        Patent: WO 03025176-A 3748 27-MAR-2003;
                Molecular Engines Laboratories (FR)
FEATURES        Location/Qualifiers
source          1..17
                /organism="Mus musculus"
                /mol_type="genomic DNA"
                /db_xref="taxon:10090"
BASE COUNT      1 a 4 c 5 g 7 t
                Query Match      1.0%; Score 12.4; DB 1; Length 17;
                Best Local Similarity 92.9%; Pred. No. 5.2e+02;
                Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 895 CTGTGCTTGCTTT 908
Db 4 CTGTGCTTGCTTT 17

RESULT 565
AX726396
LOCUS           AX726396 17 bp DNA linear PAT 08-MAY-2003
DEFINITION     Sequence 4083 from Patent WO03025176.
ACCESSION      AX726396
VERSION        AX726396.1 GI:30505739
KEYWORDS
SOURCE         Mus musculus (house mouse)
ORGANISM       Mus musculus
                Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
                Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE
AUTHORS        Telerman,A., Anson,R. and Tuijnder,M.

```

TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines

JOURNAL Patent: WO 03025176-A 4083 27-MAR-2003; Molecular Engines Laboratories (FR)

FEATURES
source
1. .17
/organism="Mus musculus"
/mol_type="genomic DNA"
/db_xref="taxon:10090"

BASE COUNT 8 a 4 c 1 g 4 t

Query Match 1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 612 ATCTACAAACAA 625
|||||

Db 2 ATCTACAAACAA 15

RESULT 566
AX727438/c
LOCUS 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 5125 from Patent WO03025176.
ACCESSION AX727438
VERSION AX727438.1 GI:30506781
KEYWORDS Mus musculus (house mouse)
SOURCE Mus musculus
ORGANISM Mus musculus
REFERENCE 1
AUTHORS Telerman, A., Anson, R. and Tuijinder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines

JOURNAL Patent: WO 03025176-A 5125 27-MAR-2003; Molecular Engines Laboratories (FR)

FEATURES
source
1. .17
/organism="Mus musculus"
/mol_type="genomic DNA"
/db_xref="taxon:10090"

BASE COUNT 8 a 2 c 2 g 5 t

Query Match 1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1489 TATTTAAATGACTG 1502
|||||

Db 17 TATTTAAATGACTG 4

RESULT 567
AX729724/c
LOCUS 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 1358 from Patent WO03025175.
ACCESSION AX729724
VERSION AX729724.1 GI:30509067
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Telerman, A., Anson, R. and Tuijinder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines

JOURNAL Patent: WO 03025175-A 1358 27-MAR-2003; Molecular Engines Laboratories (FR)

FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

BASE COUNT 10 a 3 c 1 g 3 t

Query Match 1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1146 ATTTTATTTTATGAT 1159
|||||

Db 15 ATTTTATTTTATGAT 2

RESULT 568
AX730214
LOCUS 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 1848 from Patent WO03025175.
ACCESSION AX730214
VERSION AX730214.1 GI:30509557
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Telerman, A., Anson, R. and Tuijinder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines

JOURNAL Patent: WO 03025175-A 1848 27-MAR-2003; Molecular Engines Laboratories (FR)

FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

BASE COUNT 5 a 2 c 6 g 4 t

Query Match 1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 953 TCACAGTGTGATGTTG 966
|||||

Db 3 TCACAGTGTGATGTTG 16

RESULT 569
AX730221/c
LOCUS 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 1855 from Patent WO03025175.
ACCESSION AX730221
VERSION AX730221.1 GI:30509564
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Telerman, A., Anson, R. and Tuijinder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines

JOURNAL Patent: WO 03025175-A 1855 27-MAR-2003; Molecular Engines Laboratories (FR)

FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

```

BASE COUNT      3 a      4 c      4 g      6 t

Query Match      1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 413 CCAAGATCAGTGA 426
Db 16 CCAAGATCAGTGA 3

RESULT 570
AX730379          AX730379          17 bp DNA linear PAT 08-MAY-2003
LOCUS
DEFINITION      Sequence 2013 from Patent WO03025175.
ACCESSION      AX730379
VERSION        AX730379.1 GI:30509722
KEYWORDS
SOURCE
ORGANISM        Homo sapiens (human)
REFERENCE
AUTHORS         Telerman,A., Amson,R. and Tuijnder,M.
TITLE           Sequences involved in phenomena of tumour suppression, tumour
                reversion, apoptosis and/or virus resistance and their use as
                medicines
JOURNAL         Patent: WO 03025175-A 2013 27-MAR-2003;
                Molecular Engines Laboratories (FR)
FEATURES
source          1..17
                /organism="Homo sapiens"
                /mol_type="genomic DNA"
                /db_xref="taxon:9606"
                /db_xref="taxon:9606"
BASE COUNT      4 a      1 c      1 g      11 t

Query Match      1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1142 ATTATTTATTTT 1155
Db 2 ATCTATTTATTT 15

RESULT 571
AX731157          AX731157          17 bp DNA linear PAT 08-MAY-2003
LOCUS
DEFINITION      Sequence 2791 from Patent WO03025175.
ACCESSION      AX731157
VERSION        AX731157.1 GI:30510500
KEYWORDS
SOURCE
ORGANISM        Homo sapiens (human)
REFERENCE
AUTHORS         Telerman,A., Amson,R. and Tuijnder,M.
TITLE           Sequences involved in phenomena of tumour suppression, tumour
                reversion, apoptosis and/or virus resistance and their use as
                medicines
JOURNAL         Patent: WO 03025175-A 2791 27-MAR-2003;
                Molecular Engines Laboratories (FR)
FEATURES
source          1..17
                /organism="Homo sapiens"
                /mol_type="genomic DNA"
                /db_xref="taxon:9606"
                /db_xref="taxon:9606"
BASE COUNT      2 a      3 c      1 g      11 t

Query Match      1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

QY 908 TCTCTTTATTTCT 921
Db 3 TCTCTTTATTTCT 16

RESULT 572
AX731513          AX731513          17 bp DNA linear PAT 08-MAY-2003
LOCUS
DEFINITION      Sequence 3147 from Patent WO03025175.
ACCESSION      AX731513
VERSION        AX731513.1 GI:30510856
KEYWORDS
SOURCE
ORGANISM        Homo sapiens (human)
REFERENCE
AUTHORS         Telerman,A., Amson,R. and Tuijnder,M.
TITLE           Sequences involved in phenomena of tumour suppression, tumour
                reversion, apoptosis and/or virus resistance and their use as
                medicines
JOURNAL         Patent: WO 03025175-A 3147 27-MAR-2003;
                Molecular Engines Laboratories (FR)
FEATURES
source          1..17
                /organism="Homo sapiens"
                /mol_type="genomic DNA"
                /db_xref="taxon:9606"
                /db_xref="taxon:9606"
BASE COUNT      4 a      3 c      2 g      8 t

Query Match      1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 910 TCTTTATTTCTGA 923
Db 3 TCTTTATTTCTGA 16

RESULT 573
AX731889          AX731889          17 bp DNA linear PAT 08-MAY-2003
LOCUS
DEFINITION      Sequence 3523 from Patent WO03025175.
ACCESSION      AX731889
VERSION        AX731889.1 GI:30511232
KEYWORDS
SOURCE
ORGANISM        Homo sapiens (human)
REFERENCE
AUTHORS         Telerman,A., Amson,R. and Tuijnder,M.
TITLE           Sequences involved in phenomena of tumour suppression, tumour
                reversion, apoptosis and/or virus resistance and their use as
                medicines
JOURNAL         Patent: WO 03025175-A 3523 27-MAR-2003;
                Molecular Engines Laboratories (FR)
FEATURES
source          1..17
                /organism="Homo sapiens"
                /mol_type="genomic DNA"
                /db_xref="taxon:9606"
                /db_xref="taxon:9606"
BASE COUNT      6 a      2 c      4 g      5 t

Query Match      1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 839 TCTGTAAATCTCG 852
Db 3 TCTGTAAATCTCG 16

```

[illegible]

RESULT 574	AX732329/c	AX732329	17 bp	DNA	linear	PAT 08-MAY-2003
LOCUS	Sequence 3963 from Patent WO03025175.					
DEFINITION	AX732329					
ACCESSION	AX732329					
VERSION	AX732329.1	GI:30511672				
KEYWORDS	Homo sapiens (human)					
SOURCE	Homo sapiens					
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.					
REFERENCE	1	Telerman, A., Anson, R. and Tuijinder, M.				
AUTHORS	Sequences involved in phenomena of tumour suppression, tumour					
TITLE	reversion, apoptosis and/or virus resistance and their use as					
JOURNAL	Patent: WO 03025175-A 3963 27-MAR-2003;					
FEATURES	Molecular Engines Laboratories (FR)					
source	Location/Qualifiers					
BASE COUNT	1. .17					
	8 a 1 c 1 g 7 t					
Query Match	1.0%; Score 12.4; DB 1; Length 17;					
Best Local Similarity	92.9%; Pred. No. 5.2e+02;					
Matches	13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;					
QY	1146 ATTATTTTATGAT 1159					
Db	15 ATTATTTTATGAT 2					
RESULT 575	AX7333592	AX7333592	17 bp	DNA	linear	PAT 08-MAY-2003
LOCUS	Sequence 5226 from Patent WO03025175.					
DEFINITION	AX7333592					
ACCESSION	AX7333592					
VERSION	AX7333592.1	GI:30512935				
KEYWORDS	Homo sapiens (human)					
SOURCE	Homo sapiens					
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.					
REFERENCE	1	Telerman, A., Anson, R. and Tuijinder, M.				
AUTHORS	Sequences involved in phenomena of tumour suppression, tumour					
TITLE	reversion, apoptosis and/or virus resistance and their use as					
JOURNAL	Patent: WO 03025175-A 5226 27-MAR-2003;					
FEATURES	Molecular Engines Laboratories (FR)					
source	Location/Qualifiers					
BASE COUNT	1. .17					
	4 a 2 c 4 g 7 t					
Query Match	1.0%; Score 12.4; DB 1; Length 17;					
Best Local Similarity	92.9%; Pred. No. 5.2e+02;					
Matches	13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;					
QY	809 TCAAAATTAGCTGG 822					
Db	3 TCAAAATTAGCTGG 16					
RESULT 576	AX735084	AX735084	17 bp	DNA	linear	PAT 08-MAY-2003
LOCUS	Sequence 674 from Patent WO03025177.					
DEFINITION	AX735084					
ACCESSION	AX735084					
VERSION	AX735084.1	GI:30515846				
KEYWORDS	Homo sapiens (human)					
SOURCE	Homo sapiens					
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.					
REFERENCE	1	Telerman, A., Anson, R. and Tuijinder, M.				
AUTHORS	Sequences involved in phenomena of tumour suppression, tumour					
TITLE	reversion, apoptosis and/or resistance to viruses and the use					
JOURNAL	Patent: WO 03025177-A 674 27-MAR-2003;					
FEATURES	Molecular Engines Laboratories (FR)					
source	Location/Qualifiers					
BASE COUNT	1. .17					
	6 a 3 c 3 g 5 t					
Query Match	1.0%; Score 12.4; DB 1; Length 17;					
Best Local Similarity	92.9%; Pred. No. 5.2e+02;					
Matches	13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;					
QY	1317 ATCTAGTTTGATA 1330					
Db	2 ATCTAGTTTGATA 15					
RESULT 578	AX736558/c	AX736558	17 bp	DNA	linear	PAT 08-MAY-2003
LOCUS	Sequence 2148 from Patent WO03025177.					
DEFINITION	AX736558					
ACCESSION	AX736558					
VERSION	AX736558.1	GI:30515846				
KEYWORDS	Homo sapiens (human)					
SOURCE	Homo sapiens					
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.					
REFERENCE	1	Telerman, A., Anson, R. and Tuijinder, M.				
AUTHORS	Sequences involved in phenomena of tumour suppression, tumour					
TITLE	reversion, apoptosis and/or resistance to viruses and the use					
JOURNAL	Patent: WO 03025177-A 1067 27-MAR-2003;					
FEATURES	Molecular Engines Laboratories (FR)					
source	Location/Qualifiers					

```

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL Patent: WO 03025177-A 2148 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source 1. .17
Location/Qualifiers
BASE COUNT 2 a 7 c 3 g 5 t
Query Match 1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 425 GAAGATGCCAGTGA 438
Db 16 GAAGAGGCCAGTGA 3

RESULT 579
AX736937/c
LOCUS 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 2527 from Patent WO03025177.
ACCESSION AX736937
VERSION AX736937.1 GI:30516225
KEYWORDS Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL Patent: WO 03025177-A 2527 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source 1. .17
Location/Qualifiers
BASE COUNT 8 a 1 c 4 g 4 t
Query Match 1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1238 TTTTCATTTCAGAT 1251
Db 15 TTTTCATTTCAGAT 2

RESULT 580
AX737227/c
LOCUS 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 2817 from Patent WO03025177.
ACCESSION AX737227
VERSION AX737227.1 GI:30516515
KEYWORDS Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour

```

```

reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
Patent: WO 03025177-A 2817 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source 1. .17
Location/Qualifiers
BASE COUNT 8 a 2 c 1 g 6 t
Query Match 1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1146 ATTATTATTAGAT 1159
Db 15 ATTATTATTAGAT 2

RESULT 581
AX738005/c
LOCUS 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 3595 from Patent WO03025177.
ACCESSION AX738005
VERSION AX738005.1 GI:30517293
KEYWORDS Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL Patent: WO 03025177-A 3595 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source 1. .17
Location/Qualifiers
BASE COUNT 10 a 1 c 2 g 4 t
Query Match 1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1146 ATTATTATTAGAT 1159
Db 15 ATTATTATTAGAT 2

RESULT 582
AX738018/c
LOCUS 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 3608 from Patent WO03025177.
ACCESSION AX738018
VERSION AX738018.1 GI:30517306
KEYWORDS Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL Patent: WO 03025177-A 3608 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
Location/Qualifiers

```

```
source
1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
7 a 3 c 1 g 6 t
BASE COUNT 7 a 3 c 1 g 6 t

Query Match
Best Local Similarity 1.0%; Score 12.4; DB 1; Length 17;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1538 AAGATGTTTTATG 1551
Db 17 AAGATGTTTTATG 4

RESULT 583
AX738565
LOCUS AX738565 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 4155 from Patent WO03025177.
ACCESSION AX738565
VERSION AX738565.1 GI:30517855
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
TITLE Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Telerman,A., Anson,R. and Tuijinder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL Patent: WO 03025177-A 4155 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
Location/Qualifiers
1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
2 a 2 c 6 g 7 t
BASE COUNT 2 a 2 c 6 g 7 t

Query Match
Best Local Similarity 1.0%; Score 12.4; DB 1; Length 17;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 478 TGGGTCTGTGTAG 491
Db 3 TCGGTCTGTGTAG 16

RESULT 584
AX739077/c
LOCUS AX739077/c 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 4667 from Patent WO03025177.
ACCESSION AX739077
VERSION AX739077.1 GI:30518374
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
TITLE Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Telerman,A., Anson,R. and Tuijinder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL Patent: WO 03025177-A 4667 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
Location/Qualifiers
1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
5 a 3 c 5 g 4 t
BASE COUNT 5 a 3 c 5 g 4 t
```

```
Query Match
Best Local Similarity 1.0%; Score 12.4; DB 1; Length 17;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 864 TGCTAGCCAGGATC 877
Db 14 TTCTAGCCAGGATC 1

RESULT 585
AX739138
LOCUS AX739138 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 4728 from Patent WO03025177.
ACCESSION AX739138
VERSION AX739138.1 GI:30518435
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
TITLE Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Telerman,A., Anson,R. and Tuijinder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL Patent: WO 03025177-A 4728 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
Location/Qualifiers
1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
8 a 3 c 1 g 5 t
BASE COUNT 8 a 3 c 1 g 5 t

Query Match
Best Local Similarity 1.0%; Score 12.4; DB 1; Length 17;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 612 ATCTACAAAACA 625
Db 2 ATCTACAAAACA 15

RESULT 586
AX739438/c
LOCUS AX739438/c 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 5028 from Patent WO03025177.
ACCESSION AX739438
VERSION AX739438.1 GI:30518735
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
TITLE Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Telerman,A., Anson,R. and Tuijinder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL Patent: WO 03025177-A 5028 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
Location/Qualifiers
1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
7 a 2 c 3 g 5 t
BASE COUNT 7 a 2 c 3 g 5 t

Query Match
Best Local Similarity 1.0%; Score 12.4; DB 1; Length 17;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```


QY 627 CAAATAATTTTGA 640
Db 16 CAAATAGTTTGA 3

RESULT 587
AX739515/c
LOCUS 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 5105 from Patent WO03025177.
ACCESSION AX739515
VERSION AX739515.1 GI:30518812
KEYWORDS Homo sapiens (human)
SOURCE
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments
JOURNAL Patent: WO 03025177-A 5105 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 9 a 3 c 4 g 1 t
Query Match 1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1438 TTCTGCTGTTGA 1451
Db 16 TTCTGCTGTTGA 3

RESULT 588
AX739551/c
LOCUS 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 5141 from Patent WO03025177.
ACCESSION AX739551
VERSION AX739551.1 GI:30518848
KEYWORDS Homo sapiens (human)
SOURCE
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments
JOURNAL Patent: WO 03025177-A 5141 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 5 a 1 c 5 g 5 t
Query Match 1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1444 CTGCTGAACTTG 1457
Db 4 CTGCTGAACTTG 17

RESULT 589
AX739830/c
LOCUS 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 5420 from Patent WO03025177.
ACCESSION AX739830
VERSION AX739830.1 GI:30519127
KEYWORDS Homo sapiens (human)
SOURCE
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments
JOURNAL Patent: WO 03025177-A 5420 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 8 a 1 c 1 g 7 t
Query Match 1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1146 ATTTTATTAGAT 1159
Db 15 ATTTTATTAGAT 2

RESULT 590
BD066678
LOCUS 17 bp DNA linear PAT 27-AUG-2002
DEFINITION An antisense oligonucleotide preparation method.
ACCESSION BD066678
VERSION BD066678.1 GI:22612281
KEYWORDS JP 2001511000-A/1313.
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 17)
AUTHORS Schlingensiepen,K.H. and Brysch,W.
TITLE An antisense oligonucleotide preparation method
JOURNAL Patent: JP 2001511000-A 1313 07-AUG-2001;
BIOGNOSTIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH
COMMENT OS Unknown
FN JP 2001511000-A/1313
PD 07-AUG-2001
PF 30-JAN-1998 JP 198532533
PI 31-JAN-1997 EP 97101531.8
PC KARL HERMANN SCHLINGENSIEPEN,WOLFGANG BRYSCH
CC Cl2N15/11,C07H21/04,A61K31/70
CC An antisense oligonucleotide preparation method FH Key
FEATURES
source
1..16
/organism="Unknown"
Location/Qualifiers
1..17
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
BASE COUNT 4 a 2 c 4 g 7 t
Query Match 1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 720 CTTTATTTTCAGGA 733
Db 720 CTTTATTTTCAGGA 733

QY 1354 TGTGTTGGTAGTC 1367
 |||||
 Db 17 TGTGTTGGTAATGC 4

RESULT 595

A04265/c
 LOCUS 194265 17 bp DNA linear PAT 01-DEC-1998
 DEFINITION Sequence 428 from patent US 5731295.
 ACCESSION I94265
 VERSION I94265.1 GI:3938735

KEYWORDS

Unknown.

SOURCE

ORGANISM

Unclassified.

REFERENCE 1 (bases 1 to 17)

AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and

Stinchcomb,D.T.

TITLE Method of reducing stromelysin RNA via ribozymes

JOURNAL Patent: US 5731295-A 428 24-MAR-1998;

FEATURES

source

1. 17

/organism="unknown"

BASE COUNT 12 a 2 c 1 g 2 t

Query Match 1.0%; Score 12.4; DB 1; Length 17;

Best Local Similarity 92.9%; Pred. No. 5.2e+02;

Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 826 TCCTGGATTTTTT 839

|||
 Db 14 TCTTGGATTTTTT 1

RESULT 596

BD182174/c
 LOCUS BD182174 30 bp DNA linear PAT 15-MAY-2003
 DEFINITION Method for synthesizing of nucleic acid.
 ACCESSION BD182174

VERSION BD182174.1 GI:30793092

KEYWORDS WO 02090538-A/6.

SOURCE synthetic construct

ORGANISM artificial sequences.

REFERENCE 1 (bases 1 to 30)

AUTHORS Nagamine,K.

TITLE Method for synthesizing of nucleic acid

JOURNAL Patent: WO 02090538-A 6 14-NOV-2002;

COMMENT EIKEN CHEMICAL CO LTD, KENTARO NAGAMINE

OS Artificial Sequence

PN WO 02090538-A/6

PD 14-NOV-2002

PP 08-MAY-2002 WO 2002JP004479

PR 08-MAY-2001 JP 01P 137060,18-JUN-2001 JP 01P 184131 PI

KENTARO NAGAMINE

PC C12N15/09,C12Q1/68

CC Description of Artificial Sequence:an artificially synthesized

CC primer

CC sequence

EH Key

FT source

1. 30

/organism="Artificial Sequence".

FEATURES

source

1. 30

/organism="synthetic construct"

/mol_type="genomic DNA"

/db_xref="taxon:32630"

BASE COUNT 13 a 3 c 5 g 9 t

Query Match 1.0%; Score 12.4; DB 1; Length 30;

Best Local Similarity 72.7%; Pred. No. 9e+02;

Matches 16; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 1068 CAAATATTTGCAACAATTTC 1089

|||||
 Db 25 CAAATCTTGCACAAATATTTC 4

RESULT 597

A04026/c
 LOCUS A04026 17 bp DNA linear PAT 09-JUL-1993
 DEFINITION Synthetic probe P6.
 ACCESSION A04026

VERSION A04026.1 GI:412366

KEYWORDS

synthetic construct

SOURCE synthetic construct

ORGANISM artificial sequences.

REFERENCE 1 (bases 1 to 17)

AUTHORS

JOURNAL

FEATURES

source

1. 17

/organism="synthetic construct"

/mol_type="genomic DNA"

/db_xref="taxon:32630"

BASE COUNT 8 a 0 c 4 g 5 t

Query Match 1.0%; Score 12.2; DB 1; Length 17;

Best Local Similarity 82.4%; Pred. No. 5.8e+02;

Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1231 AGTAAATTTTCATTC 1247

|||||
 Db 17 ACTTCAATTTTCATTC 1

RESULT 598

A04027
 LOCUS A04027 17 bp DNA linear PAT 09-JUL-1993
 DEFINITION Synthetic sequence P6 (Reverse complement).
 ACCESSION A04027

VERSION A04027.1 GI:410971

KEYWORDS

synthetic construct

SOURCE synthetic construct

ORGANISM artificial sequences.

REFERENCE 1 (bases 1 to 17)

AUTHORS

JOURNAL

FEATURES

source

1. 17

/organism="synthetic construct"

/mol_type="genomic DNA"

/db_xref="taxon:32630"

BASE COUNT 5 a 4 c 0 g 8 t

Query Match 1.0%; Score 12.2; DB 1; Length 17;

Best Local Similarity 82.4%; Pred. No. 5.8e+02;

Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1231 AGTAAATTTTCATTC 1247

|||||
 Db 1 ACTTCAATTTTCATTC 17

RESULT 599

A09201
 LOCUS A09201 17 bp DNA linear PAT 23-AUG-1993
 DEFINITION Nucleotide sequence 17 from patent number EP0365894.
 ACCESSION A09201

VERSION A09201.1 GI:411948

KEYWORDS

unidentified

SOURCE

```

ORGANISM      unidentified
REFERENCE      1 (bases 1 to 17)
AUTHORS      Brandazza,A., Sarmientos,P. and Orsini,G.
TITLE        Production of human prourokinase
JOURNAL      FARMITALIA CARLO ERBA S.r.L
FEATURES      Location/Qualifiers
source
1..17
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
BASE COUNT    5 a      4 c      0 g      8 t

Query Match    1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1231 AGTTAAATTTTCATTC 1247
DB 1 ACTTCAATTTTCATTC 17

RESULT 600
A64296/c
LOCUS      A64296      17 bp      DNA      linear      PAT 29-MAR-1999
DEFINITION Sequence 84 from Patent WO9727332.
ACCESSION  A64296
VERSION     A64296.1 GI:3717727
KEYWORDS
SOURCE      unidentified
ORGANISM    unclassified.
REFERENCE 1
AUTHORS     Stuyver,L., Louwagie,J. and Rossau,R.
TITLE       METHOD FOR DETECTION OF DRUG-INDUCED MUTATIONS IN THE REVERSE
            TRANSCRIPTASE GENE
JOURNAL     Patent: WO 9727332-A 84 31-JUL-1997;
            INNOGENETICS NV (BE)
COMMENT     Other publication AU 144397 19970820.
FEATURES    Location/Qualifiers
source
1..17
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
BASE COUNT    8 a      2 c      2 g      5 t

Query Match    1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1043 ATTATTATGATTTAT 1059
DB 17 ATCTCAATTTTCATTC 17

RESULT 601
A88483/c
LOCUS      A88483      17 bp      DNA      linear      PAT 22-JAN-2000
DEFINITION Sequence 631 from Patent WO9833904.
ACCESSION  A88483
VERSION     A88483.1 GI:6737053
KEYWORDS
SOURCE      unidentified
ORGANISM    unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS     Brysch,W. and Schlingensiepen,K.
TITLE       AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
JOURNAL     Patent: WO 9833904-A 631 06-AUG-1998;
            BIOGOSTIK GES (DE); BRYSCH WOLFGANG (DE)
FEATURES    Location/Qualifiers
source
1..17
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
BASE COUNT    5 a      4 c      0 g      8 t

Query Match    1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1619 AATATAATTTGTGTCA 1635
DB 17 GCATACAGGATCTTCC 17

```

```

/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
BASE COUNT    4 a      3 c      5 g      5 t

Query Match    1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 639 GAATATAGGATTTTCC 655
DB 17 GCATACAGGATCTTCC 17

RESULT 602
A90450/c
LOCUS      A90450      17 bp      DNA      linear      PAT 22-JAN-2000
DEFINITION Sequence 631 from Patent EP0856579.
ACCESSION  A90450
VERSION     A90450.1 GI:6738964
KEYWORDS
SOURCE      unidentified
ORGANISM    unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS     Brysch,W.D. and Schlingensiepen,K.D.
TITLE       An antisense oligonucleotide preparation method
JOURNAL     Patent: EP 0856579-A 631 05-AUG-1998;
            BIOGOSTIK GES (DE)
FEATURES    Location/Qualifiers
source
1..17
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
BASE COUNT    4 a      3 c      5 g      5 t

Query Match    1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 639 GAATATAGGATTTTCC 655
DB 17 GCATACAGGATCTTCC 17

RESULT 603
A97833
LOCUS      A97833      17 bp      DNA      linear      PAT 26-JAN-2000
DEFINITION Sequence 110 from Patent WO9914377.
ACCESSION  A97833
VERSION     A97833.1 GI:6781071
KEYWORDS
SOURCE      unidentified
ORGANISM    unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS     Quint,W. and Kleter,B.
TITLE       DETECTION AND IDENTIFICATION OF HUMAN PAPILLOMAVIRUS BY PCR AND
            TYPE-SPECIFIC REVERSE HYBRIDIZATION
JOURNAL     Patent: WO 9914377-A 110 25-MAR-1999;
            INNOGENETICS NV (BE); DELETS DIAGNOSTIC LAB B V (NL)
FEATURES    Location/Qualifiers
source
1..17
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
BASE COUNT    5 a      1 c      5 g      6 t

Query Match    1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1619 AATATAATTTGTGTCA 1635
DB 17 GCATACAGGATCTTCC 17

```

JOURNAL	Patent: US 5817796-A 792 06-OCT-1998;
FEATURES	Location/Qualifiers
SOURCE	1. .17 /organism="unknown"
BASE COUNT	11 a 1 c 1 g 4 t
Query Match	1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity	82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative	0; Mismatches 3; Indels 0; Gaps 0;
QY	980 AAGCACCTTTAAGTTTTT 996 17 AATCAATTGATGTITT 1
Db	
RESULT 607	PAT 29-SEP-1999
AR046167/c	linear
LOCUS	17 bp DNA
DEFINITION	Sequence 960 from patent US 5817796.
ACCESSION	AR046167
VERSION	AR046167.1 GI:5967632
KEYWORDS	
SOURCE	Unknown.
ORGANISM	Unclassified. 1 (bases 1 to 17) Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T. C-myb ribozymes having 2'-5'-linked adenylylate residues
TITLE	C-myb ribozymes having 2'-5'-linked adenylylate residues
JOURNAL	Patent: US 5817796-A 960 06-OCT-1998;
FEATURES	Location/Qualifiers
SOURCE	1. .17 /organism="unknown"
BASE COUNT	8 a 0 c 2 g 7 t
Query Match	1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity	82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative	0; Mismatches 3; Indels 0; Gaps 0;
QY	1030 TATTAACCTATTATTATA 1046 17 TATAAAACTATTTCCTTA 1
Db	
RESULT 608	PAT 29-SEP-1999
AR046169/c	linear
LOCUS	17 bp DNA
DEFINITION	Sequence 962 from patent US 5817796.
ACCESSION	AR046169
VERSION	AR046169.1 GI:5967634
KEYWORDS	
SOURCE	Unknown.
ORGANISM	Unclassified. 1 (bases 1 to 17) Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T. C-myb ribozymes having 2'-5'-linked adenylylate residues
TITLE	C-myb ribozymes having 2'-5'-linked adenylylate residues
JOURNAL	Patent: US 5817796-A 962 06-OCT-1998;
FEATURES	Location/Qualifiers
SOURCE	1. .17 /organism="unknown"
BASE COUNT	10 a 0 c 1 g 6 t
Query Match	1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity	82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative	0; Mismatches 3; Indels 0; Gaps 0;
QY	1477 TTCTTATATATTATTATT 1493 17 TTTTATAAACTATTTT 1
Db	
RESULT 609	
AR046255	

Query Match	1.0%	Score 12.2;	DB 1;	Length 17;
Best Local Similarity	82.4%;	Pred. No. 5.8e+02;		
Matches 14;	Conservative 0;	Mismatches 3;	Indels 0;	Gaps 0;
Qy 1583	TGTATGCAATAAAAA	1599		
Db 17	TGTATATATATAAAA	1		
<p>RESULT 612</p> <p>AR047078 17 bp DNA linear PAT 29-SEP-1999</p> <p>LOCUS AR047078</p> <p>DEFINITION Sequence 1871 from patent US 5817796.</p> <p>ACCESSION AR047078</p> <p>VERSION AR047078.1 GI:5968543</p> <p>KEYWORDS</p> <p>SOURCE Unknown.</p> <p>ORGANISM Unknown.</p> <p>REFERENCE 1 (bases 1 to 17)</p> <p>AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.</p> <p>TITLE C-myb ribozymes having 2'-5'-linked adenylate residues</p> <p>JOURNAL Patent: US 5817796-A 1871 06-OCT-1998;</p> <p>FEATURES</p> <p>source 1..17</p> <p>BASE COUNT 6 a 0 c 2 g 9 t</p>				
Query Match	1.0%	Score 12.2;	DB 1;	Length 17;
Best Local Similarity	82.4%;	Pred. No. 5.8e+02;		
Matches 14;	Conservative 0;	Mismatches 3;	Indels 0;	Gaps 0;
Qy 1259	AAATAATTTTTTAGTAT	1275		
Db 1	AAATGATTTATTTGAT	17		
<p>RESULT 613</p> <p>AR047092 17 bp DNA linear PAT 29-SEP-1999</p> <p>LOCUS AR047092</p> <p>DEFINITION Sequence 1885 from patent US 5817796.</p> <p>ACCESSION AR047092</p> <p>VERSION AR047092.1 GI:5968557</p> <p>KEYWORDS</p> <p>SOURCE Unknown.</p> <p>ORGANISM Unknown.</p> <p>REFERENCE 1 (bases 1 to 17)</p> <p>AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.</p> <p>TITLE C-myb ribozymes having 2'-5'-linked adenylate residues</p> <p>JOURNAL Patent: US 5817796-A 1885 06-OCT-1998;</p> <p>FEATURES</p> <p>source 1..17</p> <p>BASE COUNT 6 a 0 c 3 g 8 t</p>				
Query Match	1.0%	Score 12.2;	DB 1;	Length 17;
Best Local Similarity	82.4%;	Pred. No. 5.8e+02;		
Matches 14;	Conservative 0;	Mismatches 3;	Indels 0;	Gaps 0;
Qy 1147	TTTTTATTTTAGATATTA	1163		
Db 1	TTGTATTTTAGAATA	17		
<p>RESULT 614</p> <p>AR047108/c 17 bp DNA linear PAT 29-SEP-1999</p> <p>LOCUS AR047108</p> <p>DEFINITION Sequence 1901 from patent US 5817796.</p> <p>ACCESSION AR047108</p> <p>VERSION AR047108.1 GI:5968573</p> <p>KEYWORDS</p> <p>SOURCE Unknown.</p>				

```

ORGANISM      Unknown.
Unclassified.
REFERENCE      1 (bases 1 to 17)
AUTHORS      Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE        C-myb ribozymes having 2'-5'-linked adenylyate residues
JOURNAL      Patent: US 5817796-A 1901 06-OCT-1998;
FEATURES      Location/Qualifiers
source        1..17
              /organism="unknown"
BASE COUNT    3 a      1 c      5 g      8 t

Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      1418 CCACAGTCATATTAAGT 1434
Db      17 CCACAGTCAAAATAACT 1

RESULT 615
AR047190/c
LOCUS      AR047190      17 bp      DNA      linear      PAT 29-SEP-1999
DEFINITION      Sequence 1983 from patent US 5817796.
ACCESSION      AR047190
VERSION      AR047190.1 GI:5968655
KEYWORDS      .
SOURCE      Unknown.
ORGANISM      Unknown.
Unclassified.
REFERENCE      1 (bases 1 to 17)
AUTHORS      Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE        C-myb ribozymes having 2'-5'-linked adenylyate residues
JOURNAL      Patent: US 5817796-A 1983 06-OCT-1998;
FEATURES      Location/Qualifiers
source        1..17
              /organism="unknown"
BASE COUNT    4 a      2 c      3 g      8 t

Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      929 AAAAGTATTAGCCACCA 945
Db      17 AAGATTATTAGCCACAA 1

RESULT 616
AR047354
LOCUS      AR047354      17 bp      DNA      linear      PAT 29-SEP-1999
DEFINITION      Sequence 2147 from patent US 5817796.
ACCESSION      AR047354
VERSION      AR047354.1 GI:5968819
KEYWORDS      .
SOURCE      Unknown.
ORGANISM      Unknown.
Unclassified.
REFERENCE      1 (bases 1 to 17)
AUTHORS      Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE        C-myb ribozymes having 2'-5'-linked adenylyate residues
JOURNAL      Patent: US 5817796-A 2147 06-OCT-1998;
FEATURES      Location/Qualifiers
source        1..17
              /organism="unknown"
BASE COUNT    3 a      1 c      0 g      13 t

Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      1035 ACCTATTATTATTAT 1051

```

```

FEATURES
  source
    BASE COUNT      5 a      0 c      0 g      12 t
    Query Match      1.0%; Score 12.2; DB 1; Length 17;
    Best Local Similarity 82.4%; Pred. No. 5.8e+02;
    Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1041 TTATTATTATATATTT 1057
Db 1 TTATTATTATATATAT 17

RESULT 620
AR047604/c
LOCUS AR047604 17 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 2397 from patent US 5817796.
ACCESSION AR047604
VERSION AR047604.1 GI:5969069
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myc ribozymes having 2'-5'-linked adenylate residues
JOURNAL Patent: US 5817796-A 2397 06-OCT-1998;
FEATURES
  source
    BASE COUNT      8 a      1 c      2 g      6 t
    Query Match      1.0%; Score 12.2; DB 1; Length 17;
    Best Local Similarity 82.4%; Pred. No. 5.8e+02;
    Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 640 AATATAGAGATTTCCT 656
Db 17 AATATAGATTTCCT 1

RESULT 621
AR057620
LOCUS AR057620 17 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 1824 from patent US 5837542.
ACCESSION AR057620
VERSION AR057620.1 GI:5983197
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and Draper,K.G.
TITLE Intercellular adhesion molecule-1 (ICAM-1) ribozymes
JOURNAL Patent: US 5837542-A 1824 17-NOV-1998;
FEATURES
  source
    BASE COUNT      4 a      4 c      4 g      5 t
    Query Match      1.0%; Score 12.2; DB 1; Length 17;
    Best Local Similarity 82.4%; Pred. No. 5.8e+02;
    Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 977 TGGAGCAGCTTCAGTT 993
Db 1 TGGAGCAGCTTCAGCT 17

RESULT 622
AR057641
LOCUS AR057641 17 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 1845 from patent US 5837542.
ACCESSION AR057641
VERSION AR057641.1 GI:5983218
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and Draper,K.G.
TITLE Intercellular adhesion molecule-1 (ICAM-1) ribozymes
JOURNAL Patent: US 5837542-A 1845 17-NOV-1998;
FEATURES
  source
    BASE COUNT      6 a      1 c      1 g      9 t
    Query Match      1.0%; Score 12.2; DB 1; Length 17;
    Best Local Similarity 82.4%; Pred. No. 5.8e+02;
    Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1050 ATGTATTATTATTAAGCA 1066
Db 1 ATGTATTATTATTAATCA 17

RESULT 623
AR057785
LOCUS AR057785 17 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 1989 from patent US 5837542.
ACCESSION AR057785
VERSION AR057785.1 GI:5983362
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and Draper,K.G.
TITLE Intercellular adhesion molecule-1 (ICAM-1) ribozymes
JOURNAL Patent: US 5837542-A 1989 17-NOV-1998;
FEATURES
  source
    BASE COUNT      6 a      1 c      1 g      9 t
    Query Match      1.0%; Score 12.2; DB 1; Length 17;
    Best Local Similarity 82.4%; Pred. No. 5.8e+02;
    Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1050 ATGTATTATTATTAAGCA 1066
Db 1 ATGTATTATTATTAATCA 17

RESULT 624
AR057803
LOCUS AR057803 17 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 2007 from patent US 5837542.
ACCESSION AR057803
VERSION AR057803.1 GI:5983380
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and Draper,K.G.
TITLE Intercellular adhesion molecule-1 (ICAM-1) ribozymes
JOURNAL Patent: US 5837542-A 2007 17-NOV-1998;
FEATURES
  source
    BASE COUNT      6 a      1 c      1 g      9 t
    Query Match      1.0%; Score 12.2; DB 1; Length 17;
    Best Local Similarity 82.4%; Pred. No. 5.8e+02;
    Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1050 ATGTATTATTATTAAGCA 1066
Db 1 ATGTATTATTATTAATCA 17

```



```

BASE COUNT      4 a      4 c      4 g      5 t
Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 977 TGAAGACACTTTAAGTT 993
Db 1 TGAAGACTCTTCAAGCT 17

RESULT 625
AR057805
LOCUS AR057805 17 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 2009 from patent US 5837542.
ACCESSION AR057805
VERSION AR057805.1 GI:5983382
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
BASE COUNT      4 a      4 c      4 g      5 t
Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 977 TGAAGACACTTTAAGTT 993
Db 1 TGAAGACTCTTCAAGCT 17

RESULT 626
AR065109
LOCUS AR065109 17 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 1 from patent US 5849486.
ACCESSION AR065109
VERSION AR065109.1 GI:5995325
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
BASE COUNT      9 a      0 c      0 g      8 t
Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1610 AACATTAAATATAT 1626
Db 1 AAATTATATATATAT 17

RESULT 627
AR080426
LOCUS AR080426 17 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 84 from patent US 6087093.
ACCESSION AR102595
VERSION AR102595.1 GI:12814183
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL

```

```

LOCUS AR080426 17 bp DNA linear PAT 31-AUG-2000
DEFINITION Sequence 30 from patent US 5968776.
ACCESSION AR080426
VERSION AR080426.1 GI:10007161
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
BASE COUNT      5 a      4 c      2 g      6 t
Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1307 TGAACCTAACATCTCTAG 1323
Db 1 TGAACCTAACATCTCTAG 17

RESULT 628
AR092550
LOCUS AR092550 17 bp DNA linear PAT 08-SEP-2000
DEFINITION Sequence 30 from patent US 5998169.
ACCESSION AR092550
VERSION AR092550.1 GI:10019304
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
BASE COUNT      5 a      4 c      2 g      6 t
Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1307 TGAACCTAACATCTCTAG 1323
Db 1 TGAACCTAACATCTCTAG 17

RESULT 629
AR102595/c
LOCUS AR102595/c 17 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 84 from patent US 6087093.
ACCESSION AR102595
VERSION AR102595.1 GI:12814183
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL

```


Draper, K.G.
Ribozyme treatment of diseases or conditions related to levels of
intercellular adhesion molecule-1 (ICAM-1)
Patent: US 613967-A 2009 17-OCT-2000;
JOURNAL
FEATURES
source
1. .17
Location/Qualifiers
BASE COUNT 4 a 4 c 4 g 5 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 977 TGAAGCCTTTAAGTT 993
Db 1 TGAAGCCTTTAAGTT 17
RESULT 635
ARI157370
LOCUS
DEFINITION Sequence 1 from patent US 6245508.
ACCESSION ARI157370
VERSION ARI157370.1 GI:16218305
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Heller, M.James. and Soenowski, R.George.
TITLE Method for fingerprinting utilizing an electronically addressable
array
JOURNAL Patent: US 6245508-A 1 12-JUN-2001;
FEATURES Location/Qualifiers
source 1. .17
/organism="unknown"
BASE COUNT 9 a 0 c 0 g 8 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 1610 AACATTAAATATAAT 1626
Db 1 AAATTTAATATAAT 17
RESULT 636
ARI186327
LOCUS
DEFINITION Sequence 1815 from patent US 6346398.
ACCESSION ARI186327
VERSION ARI186327.1 GI:20232292
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco, P., McSwiggen, J., Stinchcomb, D. and Escobedo, J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 1815 12-FEB-2002;
FEATURES Location/Qualifiers
source 1. .17
/organism="unknown"
BASE COUNT 10 a 2 c 2 g 3 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 1178 ACATTAATTCATCAG 1194
Db 1 ACATTAATTCATCAG 17

Db 1 AAAGAAATTAACATCAG 17
RESULT 637
ARI186562/C
LOCUS
DEFINITION Sequence 2050 from patent US 6346398.
ACCESSION ARI186562
VERSION ARI186562.1 GI:20232527
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco, P., McSwiggen, J., Stinchcomb, D. and Escobedo, J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 2050 12-FEB-2002;
FEATURES Location/Qualifiers
source 1. .17
/organism="unknown"
BASE COUNT 4 a 2 c 5 g 6 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 441 CTTCAAGCAATCTACT 457
Db 17 CTTCAAGCAATCACCT 1
RESULT 638
ARI186699
LOCUS
DEFINITION Sequence 2187 from patent US 6346398.
ACCESSION ARI186699
VERSION ARI186699.1 GI:20232664
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco, P., McSwiggen, J., Stinchcomb, D. and Escobedo, J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 2187 12-FEB-2002;
FEATURES Location/Qualifiers
source 1. .17
/organism="unknown"
BASE COUNT 1 a 2 c 2 g 12 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 1519 GCTTTATATTTTAACT 1535
Db 1 GCTTTATTTTGTACT 17
RESULT 639
ARI186816
LOCUS
DEFINITION Sequence 2304 from patent US 6346398.
ACCESSION ARI186816
VERSION ARI186816.1 GI:20232781
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco, P., McSwiggen, J., Stinchcomb, D. and Escobedo, J.

TITLE		Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor	
JOURNAL		Patent: US 6346398-A 2304 12-FEB-2002;	
FEATURES		Location/Qualifiers	
source		1. .17	
BASE COUNT		3 a 1 c 3 g 10 t	
Query Match		1.0%; Score 12.2; DB 1; Length 17;	
Best Local Similarity		82.4%; Pred. No. 5.8e+02;	
Matches		14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;	
Qy		1146 ATTTATTATAGATT 1162	
Db		1 ATTTATTATGGTATT 17	
RESULT 640			
LOCUS		AR186817 17 bp DNA linear PAT 20-APR-2002	
DEFINITION		Sequence 2305 from patent US 6346398.	
ACCESSION		AR186817	
VERSION		AR186817.1 GI:20232782	
KEYWORDS		Unknown.	
SOURCE		Unknown.	
ORGANISM		Unclassified.	
REFERENCE		1 (bases 1 to 17)	
AUTHORS		Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.	
TITLE		Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor	
JOURNAL		Patent: US 6346398-A 2305 12-FEB-2002;	
FEATURES		Location/Qualifiers	
source		1. .17	
BASE COUNT		3 a 1 c 3 g 10 t	
Query Match		1.0%; Score 12.2; DB 1; Length 17;	
Best Local Similarity		82.4%; Pred. No. 5.8e+02;	
Matches		14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;	
Qy		1147 TTTTATTTAGATT 1163	
Db		1 TTCTATTTGGGTATTA 17	
RESULT 641			
LOCUS		AR186851 17 bp DNA linear PAT 20-APR-2002	
DEFINITION		Sequence 2339 from patent US 6346398.	
ACCESSION		AR186851	
VERSION		AR186851.1 GI:20232816	
KEYWORDS		Unknown.	
SOURCE		Unknown.	
ORGANISM		Unclassified.	
REFERENCE		1 (bases 1 to 17)	
AUTHORS		Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.	
TITLE		Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor	
JOURNAL		Patent: US 6346398-A 2339 12-FEB-2002;	
FEATURES		Location/Qualifiers	
source		1. .17	
BASE COUNT		9 a 1 c 4 g 3 t	
Query Match		1.0%; Score 12.2; DB 1; Length 17;	
Best Local Similarity		82.4%; Pred. No. 5.8e+02;	
Matches		14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;	
Qy		1026 AACTATTACCTATT 1042	
Db		17 ACCTATTGACCTTTT 1	
RESULT 642			
LOCUS		AR186887 17 bp DNA linear PAT 20-APR-2002	
DEFINITION		Sequence 2375 from patent US 6346398.	
ACCESSION		AR186887	
VERSION		AR186887.1 GI:20232852	
KEYWORDS		Unknown.	
SOURCE		Unknown.	
ORGANISM		Unclassified.	
REFERENCE		1 (bases 1 to 17)	
AUTHORS		Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.	
TITLE		Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor	
JOURNAL		Patent: US 6346398-A 2375 12-FEB-2002;	
FEATURES		Location/Qualifiers	
source		1. .17	
BASE COUNT		4 a 5 c 2 g 6 t	
Query Match		1.0%; Score 12.2; DB 1; Length 17;	
Best Local Similarity		82.4%; Pred. No. 5.8e+02;	
Matches		14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;	
Qy		981 AGCACTTTAAGTTT 997	
Db		1 AGCACTTTAAGTCCTT 17	
RESULT 643			
LOCUS		AR187067 17 bp DNA linear PAT 20-APR-2002	
DEFINITION		Sequence 2555 from patent US 6346398.	
ACCESSION		AR187067	
VERSION		AR187067.1 GI:20233032	
KEYWORDS		Unknown.	
SOURCE		Unknown.	
ORGANISM		Unclassified.	
REFERENCE		1 (bases 1 to 17)	
AUTHORS		Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.	
TITLE		Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor	
JOURNAL		Patent: US 6346398-A 2555 12-FEB-2002;	
FEATURES		Location/Qualifiers	
source		1. .17	
BASE COUNT		3 a 2 c 0 g 12 t	
Query Match		1.0%; Score 12.2; DB 1; Length 17;	
Best Local Similarity		82.4%; Pred. No. 5.8e+02;	
Matches		14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;	
Qy		1086 TTTCGAAAAATAGAAGA 1102	
Db		17 TTTCGAAAAAATAAAAA 1	
RESULT 644			
LOCUS		AR187212 17 bp DNA linear PAT 20-APR-2002	
DEFINITION		Sequence 2700 from patent US 6346398.	
ACCESSION		AR187212	
VERSION		AR187212.1 GI:20233177	
KEYWORDS		Unknown.	
SOURCE		Unknown.	
ORGANISM		Unclassified.	
REFERENCE		1 (bases 1 to 17)	
AUTHORS		Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.	
TITLE		Method and reagent for the treatment of diseases or conditions	

Db 1 TTGGTCCTAATTTCTA 17

```

JOURNAL Patent: US 6346398-A 2857 12-FEB-2002;
FEATURES Location/Qualifiers
source 1..17
BASE COUNT 2 a 3 c 3 g 9 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 803 ATAAAGTCAAAATTAGC 819
DB 17 ATAAAGGCAAAATAGC 1

RESULT 650
AR188360
LOCUS AR188360 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 3848 from patent US 6346398.
ACCESSION AR188360
VERSION AR188360.1 GI:20234325
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 3848 12-FEB-2002;
FEATURES Location/Qualifiers
source 1..17
BASE COUNT 5 a 4 c 2 g 6 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1453 ACTGTTTATTATGTAC 1469
DB 1 ACCAGTCTATTATGTAC 17

RESULT 651
AR188498/c
LOCUS AR188498 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 3996 from patent US 6346398.
ACCESSION AR188498
VERSION AR188498.1 GI:20234463
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 3986 12-FEB-2002;
FEATURES Location/Qualifiers
source 1..17
BASE COUNT 7 a 3 c 1 g 6 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1133 TTATAGTAAATTTATT 1149
DB 17 TTAGAGCAAAATGTATT 1

RESULT 652
AR188771/c
LOCUS AR188771 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 4259 from patent US 6346398.
ACCESSION AR188771
VERSION AR188771.1 GI:20234736
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 4259 12-FEB-2002;
FEATURES Location/Qualifiers
source 1..17
BASE COUNT 2 a 6 c 7 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 969 AGGCATGTGGAGCAC 985
DB 17 AGGATATGGAGAGCAC 1

RESULT 653
AR192457
LOCUS AR192457 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 7945 from patent US 6346398.
ACCESSION AR192457
VERSION AR192457.1 GI:20238422
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 7945 12-FEB-2002;
FEATURES Location/Qualifiers
source 1..17
BASE COUNT 5 a 2 c 1 g 9 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 586 TTATATGTAAGTATTA 602
DB 1 TTTTATCTCAAGTATTA 17

RESULT 654
AR192474
LOCUS AR192474 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 7962 from patent US 6346398.
ACCESSION AR192474
VERSION AR192474.1 GI:20238439
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 7962 12-FEB-2002;
FEATURES Location/Qualifiers
source 1..17
```

LOCUS	17 bp	DNA	linear	PAT 20-JUN-2002
AR207848	Sequence 22 from patent US 6379928.			
AR207848	AR207848.1 GI:21507708			
LOCUS	Unknown.			
ORGANISM	Unclassified.			
REFERENCE	1 (bases 1 to 17)			
AUTHORS	Berka,R.Michael., Cullen,D., Gray,G.Lawrence., Hayenga,K.James. and Lawlis,V.Bryan.			
TITLE	Heterologous polypeptides expressed in filamentous fungi, processes for making same, and vectors for making same			
JOURNAL	Patent: US 6379928-A 22 30-APR-2002;			
FEATURES	Location/Qualifiers			
source	1..17			
BASE COUNT	8 a 1 c 0 g 5 t 3 others			
Query Match	1.0%; Score 12.2; DB 1; Length 17;			
Best Local Similarity	73.3%; Pred. No. 5.8e+02;			
Matches	11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;			
QY	1271 AGTATAAGTACATTA 1285			
Db	2 ARTAYAARTATATTA 16			
RESULT 658				
AR207851	Sequence 25 from patent US 6379928.	17 bp	DNA	linear
LOCUS	Unknown.			
ORGANISM	Unclassified.			
REFERENCE	1 (bases 1 to 17)			
AUTHORS	Berka,R.Michael., Cullen,D., Gray,G.Lawrence., Hayenga,K.James. and Lawlis,V.Bryan.			
TITLE	Heterologous polypeptides expressed in filamentous fungi, processes for making same, and vectors for making same			
JOURNAL	Patent: US 6379928-A 25 30-APR-2002;			
FEATURES	Location/Qualifiers			
source	1..17			
BASE COUNT	8 a 3 c 0 g 3 t 3 others			
Query Match	1.0%; Score 12.2; DB 1; Length 17;			
Best Local Similarity	73.3%; Pred. No. 5.8e+02;			
Matches	11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;			
QY	1271 AGTATAAGTACATTA 1285			
Db	2 ARTAYAARTATATTA 16			
RESULT 659				
AR207853	Sequence 27 from patent US 6379928.	17 bp	DNA	linear
LOCUS	Unknown.			
ORGANISM	Unclassified.			
REFERENCE	1 (bases 1 to 17)			
AUTHORS	Berka,R.Michael., Cullen,D., Gray,G.Lawrence., Hayenga,K.James. and Lawlis,V.Bryan.			
TITLE	Heterologous polypeptides expressed in filamentous fungi, processes for making same, and vectors for making same			
JOURNAL	Patent: US 6379928-A 27 30-APR-2002;			
FEATURES	Location/Qualifiers			
source	1..17			
BASE COUNT	8 a 3 c 0 g 3 t 3 others			
Query Match	1.0%; Score 12.2; DB 1; Length 17;			
Best Local Similarity	73.3%; Pred. No. 5.8e+02;			
Matches	11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;			
QY	1271 AGTATAAGTACATTA 1285			
Db	2 ARTAYAARTATATTA 16			
RESULT 660				
AR207855	Sequence 29 from patent US 6379928.	17 bp	DNA	linear
LOCUS	Unknown.			
ORGANISM	Unclassified.			
REFERENCE	1 (bases 1 to 17)			
AUTHORS	Berka,R.Michael., Cullen,D., Gray,G.Lawrence., Hayenga,K.James. and Lawlis,V.Bryan.			
TITLE	Heterologous polypeptides expressed in filamentous fungi, processes for making same, and vectors for making same			
JOURNAL	Patent: US 6379928-A 29 30-APR-2002;			
FEATURES	Location/Qualifiers			
source	1..17			
BASE COUNT	8 a 3 c 0 g 3 t 3 others			
Query Match	1.0%; Score 12.2; DB 1; Length 17;			
Best Local Similarity	73.3%; Pred. No. 5.8e+02;			
Matches	11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;			
QY	1271 AGTATAAGTACATTA 1285			
Db	2 ARTAYAARTATATTA 16			

JOURNAL Patent: US 6313189-A 84 18-DEC-2001;
 FEATURES Location/Qualifiers
 source 1. .17
 BASE COUNT 8 a 2 c 2 g 5 t
 Query Match 1.0%; Score 12.2; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 5.8e+02;
 Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 Qy 1043 ATTATTATGTTATTTAT 1059
 Db 17 ATCATCTATGTTATGAT 1
 RESULT 665
 AR266625/c
 LOCUS 17 bp DNA linear PAT 10-APR-2003
 DEFINITION Sequence 63 from patent US 6495319.
 ACCESSION AR266625
 VERSION AR266625.1 GI:29695689
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 17)
 AUTHORS McClelland, M., Welsh, J. and Trenkle, T.
 TITLE Reduced complexity nucleic acid targets and methods of using same
 JOURNAL Patent: US 6495319-A 63 17-DEC-2002;
 FEATURES Location/Qualifiers
 source 1. .17
 BASE COUNT 2 a 0 c 0 g 15 t
 Query Match 1.0%; Score 12.2; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 5.8e+02;
 Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 Qy 615 TACAAAAAACACCAAT 631
 Db 17 TAAAAAATAAAAAAAT 1
 RESULT 666
 AR286163
 LOCUS 17 bp RNA linear PAT 10-APR-2003
 DEFINITION Sequence 535 from patent US 6528640.
 ACCESSION AR286163
 VERSION AR286163.1 GI:29723759
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 17)
 AUTHORS Beigelman, L., Burgin, A., Beaudry, A., Karpeisky, A.,
 Matulic-Adamic, J., Swedler, D. and Zinnen, S.
 TITLE Synthetic ribonucleic acids with RNase activity
 JOURNAL Patent: US 6528640-A 535 04-MAR-2003;
 FEATURES Location/Qualifiers
 source 1. .17
 BASE COUNT 4 a 0 c 0 g 6 t
 Query Match 1.0%; Score 12.2; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 5.8e+02;
 Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 Qy 1363 AGTGCTGTGTTGAATTA 1379
 Db 1 AGTGATGTGTGAGTTA 17
 RESULT 667

AX029315/c
 LOCUS 17 bp DNA linear PAT 16-SEP-2000
 DEFINITION Sequence 18 from Patent WO9902694.
 ACCESSION AX029315
 VERSION AX029315.1 GI:10190166
 KEYWORDS
 SOURCE synthetic construct
 ORGANISM synthetic construct
 REFERENCE 1
 AUTHORS Zhou, J. and Frazer, I.
 TITLE Nucleic acid sequence and method for selectively expressing a
 protein in a target cell or tissue
 JOURNAL Patent: WO 9902694-A 18 21-JAN-1999;
 ZHOU JIAN (AU) ; FRAZER IAN (AU) ; UNIV QUEENSLAND (AU)
 FEATURES Location/Qualifiers
 source 1. .17
 BASE COUNT 5 a 4 c 1 g 7 t
 Query Match 1.0%; Score 12.2; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 5.8e+02;
 Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 Qy 1363 AGTGCTGTGTTGAATTA 1379
 Db 17 AATGCTGTGTAGAATA 1
 RESULT 668
 AX206986/c
 LOCUS 17 bp DNA linear PAT 30-AUG-2001
 DEFINITION Sequence 9 from Patent WO0155214.
 ACCESSION AX206986
 VERSION AX206986.1 GI:15394743
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 REFERENCE 1
 AUTHORS Whittaker, P.A., Jones, S.J. and Hanley, M.T.
 TITLE Disease-associated gene
 JOURNAL Patent: WO 0155214-A 9 02-AUG-2001;
 FEATURES Location/Qualifiers
 source 1. .17
 BASE COUNT 3 a 4 c 7 g 3 t
 Query Match 1.0%; Score 12.2; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 5.8e+02;
 Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 Qy 862 TCTGCTAGCCAGGATCC 878
 Db 17 TCTGCGAACCCGGATCC 1
 RESULT 669
 AX214665
 LOCUS 17 bp mRNA linear PAT 07-SEP-2001
 DEFINITION Sequence 107 from Patent WO0159103.
 ACCESSION AX214665
 VERSION AX214665.1 GI:15524708
 KEYWORDS
 SOURCE synthetic construct
 ORGANISM synthetic construct
 REFERENCE 1
 AUTHORS Zhou, J. and Frazer, I.
 TITLE Nucleic acid sequence and method for selectively expressing a
 protein in a target cell or tissue
 JOURNAL Patent: WO 9902694-A 18 21-JAN-1999;
 ZHOU JIAN (AU) ; FRAZER IAN (AU) ; UNIV QUEENSLAND (AU)
 FEATURES Location/Qualifiers
 source 1. .17
 BASE COUNT 5 a 4 c 1 g 7 t
 Query Match 1.0%; Score 12.2; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 5.8e+02;
 Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 Qy 1363 AGTGCTGTGTTGAATTA 1379
 Db 17 AATGCTGTGTAGAATA 1

```

REFERENCE
AUTHORS      Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE        Method and reagent for the modulation and diagnosis of cd20 and
              nogo gene expression
JOURNAL      Patent: WO 0159103-A 107 16-AUG-2001;
              RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
              McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
source
BASE COUNT   7 a      2 c      5 g      3 t
              1. .17
              /organism="synthetic construct"
              /mol_type="mRNA"
              /db_xref="taxon:32630"
              /note="Nucleic Acid"
Query Match   1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 425 GAAGATGCCAGTGAAC 441
Db 1 GAAATGTCAGTGAAGC 17

RESULT 670
LOCUS      AX215017/c      17 bp      mRNA      linear      PAT 07-SEP-2001
DEFINITION Sequence 459 from Patent WO0159103.
ACCESSION  AX215017
VERSION     AX215017.1 GI:15525060
KEYWORDS   .
SOURCE     synthetic construct
           synthetic construct
           artificial sequences.
REFERENCE  1
AUTHORS    Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE      Method and reagent for the modulation and diagnosis of cd20 and
           nogo gene expression
JOURNAL    Patent: WO 0159103-A 459 16-AUG-2001;
           RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
           McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
source
BASE COUNT   5 a      2 c      1 g      9 t
              1. .17
              /organism="synthetic construct"
              /mol_type="mRNA"
              /db_xref="taxon:32630"
              /note="Nucleic Acid"
Query Match   1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1092 AAAATAGAGATGAATC 1108
Db 17 AAATAGAAATGAATC 1

RESULT 671
LOCUS      AX215079/c      17 bp      mRNA      linear      PAT 07-SEP-2001
DEFINITION Sequence 521 from Patent WO0159103.
ACCESSION  AX215079
VERSION     AX215079.1 GI:15525122
KEYWORDS   .
SOURCE     synthetic construct
           synthetic construct
           artificial sequences.
REFERENCE  1
AUTHORS    Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE      Method and reagent for the modulation and diagnosis of cd20 and
           nogo gene expression
JOURNAL    Patent: WO 0159103-A 521 16-AUG-2001;

```

```

RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
source
BASE COUNT   4 a      4 c      1 g      8 t
              1. .17
              /organism="synthetic construct"
              /mol_type="mRNA"
              /db_xref="taxon:32630"
              /note="Nucleic Acid"
Query Match   1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1088 TGGAAATATAGAGATG 1104
Db 17 TGGAAATATAGCAGATG 1

RESULT 672
LOCUS      AX215156      17 bp      mRNA      linear      PAT 07-SEP-2001
DEFINITION Sequence 598 from Patent WO0159103.
ACCESSION  AX215156
VERSION     AX215156.1 GI:15525199
KEYWORDS   .
SOURCE     synthetic construct
           synthetic construct
           artificial sequences.
REFERENCE  1
AUTHORS    Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE      Method and reagent for the modulation and diagnosis of cd20 and
           nogo gene expression
JOURNAL    Patent: WO 0159103-A 598 16-AUG-2001;
           RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
           McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
source
BASE COUNT   3 a      2 c      3 g      9 t
              1. .17
              /organism="synthetic construct"
              /mol_type="mRNA"
              /db_xref="taxon:32630"
              /note="Nucleic Acid"
Query Match   1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1286 TTGTTTATCTGAATTT 1302
Db 1 TTGATTCTCTGAATTT 17

RESULT 673
LOCUS      AX215198/c      17 bp      mRNA      linear      PAT 07-SEP-2001
DEFINITION Sequence 640 from Patent WO0159103.
ACCESSION  AX215198
VERSION     AX215198.1 GI:15525241
KEYWORDS   .
SOURCE     synthetic construct
           synthetic construct
           artificial sequences.
REFERENCE  1
AUTHORS    Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE      Method and reagent for the modulation and diagnosis of cd20 and
           nogo gene expression
JOURNAL    Patent: WO 0159103-A 640 16-AUG-2001;
           RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
           McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
source
BASE COUNT   1. .17
              /organism="synthetic construct"

```

```

/mol_type="mRNA"
/db xref="taxon:32630"
/notes="Nucleic Acid"
BASE COUNT      7 a      1 c      3 g      6 t

Query Match
Best Local Similarity 1.0%; Score 12.2; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 579 AACATCTTATATGTA 595
|||||
Db 17 AACATCTTATATGCAA 1

RESULT 674
AX215220
LOCUS AX215220 17 bp mRNA linear PAT 07-SEP-2001
DEFINITION Sequence 662 from Patent WO0159103.
ACCESSION AX215220
VERSION AX215220.1 GI:15525263
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
JOURNAL nogo gene expression
PATENT: WO 0159103-A 662 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
Location/Qualifiers
source
1..17
/organism="synthetic construct"
/mol_type="mRNA"
/db xref="taxon:32630"
/notes="Nucleic Acid"
BASE COUNT      5 a      2 c      1 g      9 t

Query Match
Best Local Similarity 1.0%; Score 12.2; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 601 TATTTCATTGATCTAC 617
|||||
Db 1 TATTTCATTGATATAC 17

RESULT 675
AX215570
LOCUS AX215570 17 bp mRNA linear PAT 07-SEP-2001
DEFINITION Sequence 1012 from Patent WO0159103.
ACCESSION AX215570
VERSION AX215570.1 GI:15525613
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
JOURNAL nogo gene expression
PATENT: WO 0159103-A 1012 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
Location/Qualifiers
source
1..17
/organism="synthetic construct"
/mol_type="mRNA"
/db xref="taxon:32630"
/notes="Nucleic Acid"
BASE COUNT      7 a      2 c      4 g      4 t

```

```

Query Match
Best Local Similarity 1.0%; Score 12.2; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 426 AGATGCCAGTGAAC 442
|||||
Db 1 AAAATGTCAGTGAAGCT 17

RESULT 676
AX216249
LOCUS AX216249 17 bp mRNA linear PAT 07-SEP-2001
DEFINITION Sequence 1691 from Patent WO0159103.
ACCESSION AX216249
VERSION AX216249.1 GI:15526292
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
JOURNAL nogo gene expression
PATENT: WO 0159103-A 1691 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
Location/Qualifiers
source
1..17
/organism="synthetic construct"
/mol_type="mRNA"
/db xref="taxon:32630"
/notes="Nucleic Acid"
BASE COUNT      8 a      1 c      4 g      4 t

Query Match
Best Local Similarity 1.0%; Score 12.2; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1104 GAATCATTGATTGATA 1120
|||||
Db 1 GAGTCATGATAGATA 17

RESULT 677
AX216420
LOCUS AX216420 17 bp mRNA linear PAT 07-SEP-2001
DEFINITION Sequence 1862 from Patent WO0159103.
ACCESSION AX216420
VERSION AX216420.1 GI:15526481
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
JOURNAL nogo gene expression
PATENT: WO 0159103-A 1862 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
Location/Qualifiers
source
1..17
/organism="synthetic construct"
/mol_type="mRNA"
/db xref="taxon:32630"
/notes="Nucleic Acid"
BASE COUNT      6 a      2 c      4 g      5 t

Query Match
Best Local Similarity 1.0%; Score 12.2; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 427 AGATGCCAGTGAAC 443

```

AX217250	LOCUS	AX217250	17 bp	mRNA	linear	PAT 07-SEP-2001
	DEFINITION	Sequence 2692 from Patent WO0159103.				
	ACCESSION	AX217250				
	VERSION	AX217250.1	GI:15527311			
	KEYWORDS					
	SOURCE	synthetic construct				
	ORGANISM	synthetic construct				
		artificial sequences.				
	REFERENCE	1				
	AUTHORS	Blatt, L., McSwiggen, J. and Chowrira, B.M.				
	TITLE	Method and reagent for the modulation and diagnosis of cd20 and				
	JOURNAL	nogo gene expression				
		Patent: WO 0159103-A 2692 16-AUG-2001;				
		RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;				
		McSwiggen, James (US) ; Chowrira, Bharat M. (US)				
	FEATURES	Location/Qualifiers				
	source	1..17				
		/organism="synthetic construct"				
		/mol type="mRNA"				
		/db xref="taxon:32630"				
		/note="Nucleic Acid"				
	BASE COUNT	6 a 1 c 3 g 7 t				
QY		1049 TATGATTTTATTACG 1065				
Db		1 TATGATGGATTAAAC 17				
	RESULT 681					
AX217422/c	LOCUS	AX217422	17 bp	mRNA	linear	PAT 07-SEP-2001
	DEFINITION	Sequence 2864 from Patent WO0159103.				
	ACCESSION	AX217422				
	VERSION	AX217422.1	GI:15527483			
	KEYWORDS					
	SOURCE	synthetic construct				
	ORGANISM	synthetic construct				
		artificial sequences.				
	REFERENCE	1				
	AUTHORS	Blatt, L., McSwiggen, J. and Chowrira, B.M.				
	TITLE	Method and reagent for the modulation and diagnosis of cd20 and				
	JOURNAL	nogo gene expression				
		Patent: WO 0159103-A 2864 16-AUG-2001;				
		RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;				
		McSwiggen, James (US) ; Chowrira, Bharat M. (US)				
	FEATURES	Location/Qualifiers				
	source	1..17				
		/organism="synthetic construct"				
		/mol type="mRNA"				
		/db xref="taxon:32630"				
		/note="Nucleic Acid"				
	BASE COUNT	7 a 2 c 1 g 7 t				
Query Match		1.0%; Score 12.2; DB 1; Length 17;				
Best Local Similarity		82.4%; Pred. No. 5.8e+02;				
Matches		14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;				
QY		1175 ATTGATTAATTTCAAT 1191				
Db		17 ATTGGAATATTTCAT 1				
	RESULT 682					
AX218022	LOCUS	AX218022	17 bp	mRNA	linear	PAT 07-SEP-2001
	DEFINITION	Sequence 3464 from Patent WO0159103.				
	ACCESSION	AX218022				
	VERSION	AX218022.1	GI:15528083			

[illegible]

<p>AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M. TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression JOURNAL Patent: WO 0159103-A 3608 16-AUG-2001; RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ; McSwiggen, James (US) ; Chowrira, Bharat M. (US) FEATURES Location/Qualifiers source 1..17 /mol_type="synthetic construct" /db_xref="taxon:32630" /note="Nucleic Acid"</p>		<p>1.0%; Score 12.2; DB 1; Length 17; Best Local Similarity 82.4%; Pred. No. 5.8e+02; Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;</p>	
<p>BASE COUNT 9 a 1 c 4 g 3 t</p>			
QY	424 TGAAGATGCCAGTGA 440	17 bp	linear
Db	1 TGAAGATGCCAGTGA 17		
<p>RESULT 685 LOCUS AX227049 DEFINITION Sequence 421 from Patent WO0157206. ACCESSION AX227049 VERSION AX227049.1 GI:15556190 KEYWORDS synthetic construct SOURCE synthetic construct ORGANISM artificial sequences.</p>			
<p>REFERENCE 1 Fattaeey A.R., Jarvis T., McSwiggen, J., Bocher, R.N. and Holman, P.S. AUTHORS Method and reagent for the inhibition of checkpoint kinase-1 (chk TITLE 1) enzyme JOURNAL Patent: WO 0157206-A 421 09-AUG-2001; RIBOZYME PHARMACEUTICALS, INC. (US) ; Fattaeey, Ali R. (US)</p>			
<p>FEATURES source 1..17 /mol_type="synthetic construct" /db_xref="taxon:32630"</p>		<p>1.0%; Score 12.2; DB 1; Length 17; Best Local Similarity 82.4%; Pred. No. 5.8e+02; Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;</p>	
<p>BASE COUNT 6 a 3 c 3 g 5 t</p>			
QY	949 TACCTCACAGTGATTT 965	17 bp	linear
Db	1 TAACTCACAGGATATT 17		
<p>RESULT 686 LOCUS AX227468 DEFINITION Sequence 840 from Patent WO0157206. ACCESSION AX227468 VERSION AX227468.1 GI:15556609 KEYWORDS synthetic construct SOURCE synthetic construct ORGANISM artificial sequences.</p>			
<p>REFERENCE 1 Fattaeey A.R., Jarvis T., McSwiggen, J., Bocher, R.N. and Holman, P.S. AUTHORS Method and reagent for the inhibition of checkpoint kinase-1 (chk TITLE 1) enzyme JOURNAL Patent: WO 0157206-A 840 09-AUG-2001; RIBOZYME PHARMACEUTICALS, INC. (US) ; Fattaeey, Ali R. (US)</p>			
<p>FEATURES source 1..17 /mol_type="synthetic construct" /db_xref="taxon:32630"</p>		<p>1.0%; Score 12.2; DB 1; Length 17; Best Local Similarity 82.4%; Pred. No. 5.8e+02; Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;</p>	

```

/organism="synthetic construct"
/mol_type="rRNA"
/db_xref="taxon:32630"
2 a 3 c 6 g 6 t
BASE COUNT
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 462 CACTTCATGTTGTTGTT 478
Db 1 CACTTCATGTTGTTGTT 17

RESULT 687
AX263172
LOCUS AX263172 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 563 from Patent WO0173002.
ACCESSION AX263172
VERSION AX263172.1 GI:16511971
KEYWORDS Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
JOURNAL Patent: WO 0173002-A 563 04-OCT-2001;
FEATURES LOCATION/Qualifiers
source 1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
5 a 2 c 4 g 6 t
BASE COUNT
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1373 TGAATTACCGAATAATG 1389
Db 1 TGAATTACCGAATAATG 17

RESULT 688
AX263173/c
LOCUS AX263173 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 564 from Patent WO0173002.
ACCESSION AX263173
VERSION AX263173.1 GI:16511972
KEYWORDS Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
JOURNAL Patent: WO 0173002-A 564 04-OCT-2001;
FEATURES LOCATION/Qualifiers
source 1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
6 a 4 c 2 g 5 t
BASE COUNT
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;

```

```

Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1373 TGAATTACCGAATAATG 1389
Db 1 TGAATTACCGAATAATG 1

RESULT 689
AX263380
LOCUS AX263380 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 771 from Patent WO0173002.
ACCESSION AX263380
VERSION AX263380.1 GI:16512179
KEYWORDS Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
JOURNAL Patent: WO 0173002-A 771 04-OCT-2001;
FEATURES LOCATION/Qualifiers
source 1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
6 a 0 c 7 g 4 t
BASE COUNT
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 921 TAAGTGGAAAAAGTATT 937
Db 1 TAAGTGGAAAAAGTATT 17

RESULT 690
AX263381/c
LOCUS AX263381 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 772 from Patent WO0173002.
ACCESSION AX263381
VERSION AX263381.1 GI:16512180
KEYWORDS Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
JOURNAL Patent: WO 0173002-A 772 04-OCT-2001;
FEATURES LOCATION/Qualifiers
source 1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
4 a 7 c 0 g 6 t
BASE COUNT
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 921 TAAGTGGAAAAAGTATT 937
Db 1 TAAGTGGAAAAAGTATT 1

```

```

RESULT 691
AX264332      17 bp      DNA      linear      PAT 26-OCT-2001
LOCUS
DEFINITION   Sequence 1723 from Patent WO0173002.
ACCESSION   AX264332
VERSION     AX264332.1 GI:16513131
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Kniec,E.B., Gamper,H.B. and Rice,M.C.
TITLE       Targeted chromosomal genomic alterations with modified single
            stranded oligonucleotides
JOURNAL     Patent: WO 0173002-A 1723 04-OCT-2001;
            UNIVERSITY OF DELAWARE (US)
FEATURES    Location/Qualifiers
            source
            1..17
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"
BASE COUNT   8 a 6 c 2 g 1 t
Query Match  1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 1404 AAACAGCCAAACTCCA 1420
Db 1 AGACACCCAAAGTCCA 17
RESULT 692
AX264333/c
LOCUS
DEFINITION   Sequence 1724 from Patent WO0173002.
ACCESSION   AX264333
VERSION     AX264333.1 GI:16513132
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Kniec,E.B., Gamper,H.B. and Rice,M.C.
TITLE       Targeted chromosomal genomic alterations with modified single
            stranded oligonucleotides
JOURNAL     Patent: WO 0173002-A 1724 04-OCT-2001;
            UNIVERSITY OF DELAWARE (US)
FEATURES    Location/Qualifiers
            source
            1..17
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"
BASE COUNT   1 a 2 c 6 g 8 t
Query Match  1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 1404 AAACAGCCAAACTCCA 1420
Db 17 AGACACCCAAAGTCCA 1
RESULT 693
AX264767
LOCUS
DEFINITION   Sequence 2158 from Patent WO0173002.
ACCESSION   AX264767
VERSION     AX264767.1 GI:16513566
KEYWORDS

```

```

SOURCE      Homo sapiens (human)
ORGANISM    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Kniec,E.B., Gamper,H.B. and Rice,M.C.
TITLE       Targeted chromosomal genomic alterations with modified single
            stranded oligonucleotides
JOURNAL     Patent: WO 0173002-A 2158 04-OCT-2001;
            UNIVERSITY OF DELAWARE (US)
FEATURES    Location/Qualifiers
            source
            1..17
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"
BASE COUNT   8 a 2 c 3 g 4 t
Query Match  1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 1604 ATATGAACACTTTAAAA 1620
Db 1 AGATGAACCTTTAAGA 17
RESULT 694
AX264768/c
LOCUS
DEFINITION   Sequence 2159 from Patent WO0173002.
ACCESSION   AX264768
VERSION     AX264768.1 GI:16513567
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Kniec,E.B., Gamper,H.B. and Rice,M.C.
TITLE       Targeted chromosomal genomic alterations with modified single
            stranded oligonucleotides
JOURNAL     Patent: WO 0173002-A 2159 04-OCT-2001;
            UNIVERSITY OF DELAWARE (US)
FEATURES    Location/Qualifiers
            source
            1..17
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"
BASE COUNT   4 a 3 c 2 g 8 t
Query Match  1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 1604 ATATGAACACTTTAAAA 1620
Db 17 AGATGAACCTTTAAGA 1
RESULT 695
AX265047
LOCUS
DEFINITION   Sequence 2438 from Patent WO0173002.
ACCESSION   AX265047
VERSION     AX265047.1 GI:16513846
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Kniec,E.B., Gamper,H.B. and Rice,M.C.
TITLE       Targeted chromosomal genomic alterations with modified single

```

```
stranded oligonucleotides
Patent: WO 0173002-A 2438 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
  source
    1..17
      /organism="Homo sapiens"
      /mol_type="genomic DNA"
      /db_xref="taxon:9606"
BASE COUNT      6 a      2 c      4 g      5 t
Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 980 AAGCAGCTTTAAGTTT 996
Db 1 AAGCAGCAGAGTTT 17

RESULT 696
AX265048/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
  Homo sapiens (human)
REFERENCE
  Kniec,E.B., Gamper,H.B. and Rice,M.C.
  Targeted chromosomal genomic alterations with modified single
  stranded oligonucleotides
  Patent: WO 0173002-A 2439 04-OCT-2001;
  UNIVERSITY OF DELAWARE (US)
  Location/Qualifiers
    1..17
      /organism="Homo sapiens"
      /mol_type="genomic DNA"
      /db_xref="taxon:9606"
BASE COUNT      5 a      4 c      2 g      6 t
Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 980 AAGCAGCTTTAAGTTT 996
Db 17 AAGCAGCAGAGTTT 1

RESULT 697
AX265051
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
  Homo sapiens (human)
REFERENCE
  Kniec,E.B., Gamper,H.B. and Rice,M.C.
  Targeted chromosomal genomic alterations with modified single
  stranded oligonucleotides
  Patent: WO 0173002-A 2442 04-OCT-2001;
  UNIVERSITY OF DELAWARE (US)
  Location/Qualifiers
    1..17
      /organism="Homo sapiens"
      /mol_type="genomic DNA"
      /db_xref="taxon:9606"
BASE COUNT      4 a      2 c      5 g      6 t
Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 980 AAGCAGCTTTAAGTTT 996
Db 17 AAGCAGCAGAGTTT 1

RESULT 698
AX265052
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
  Homo sapiens (human)
REFERENCE
  Kniec,E.B., Gamper,H.B. and Rice,M.C.
  Targeted chromosomal genomic alterations with modified single
  stranded oligonucleotides
  Patent: WO 0173002-A 2443 04-OCT-2001;
  UNIVERSITY OF DELAWARE (US)
  Location/Qualifiers
    1..17
      /organism="Homo sapiens"
      /mol_type="genomic DNA"
      /db_xref="taxon:9606"
BASE COUNT      5 a      4 c      2 g      6 t
Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 980 AAGCAGCTTTAAGTTT 996
Db 17 AAGCAGCAGAGTTT 1

RESULT 699
AX265147
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
  Homo sapiens (human)
REFERENCE
  Kniec,E.B., Gamper,H.B. and Rice,M.C.
  Targeted chromosomal genomic alterations with modified single
  stranded oligonucleotides
  Patent: WO 0173002-A 2538 04-OCT-2001;
  UNIVERSITY OF DELAWARE (US)
  Location/Qualifiers
    1..17
      /organism="Homo sapiens"
      /mol_type="genomic DNA"
      /db_xref="taxon:9606"
BASE COUNT      4 a      2 c      5 g      6 t
Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```



```

QY 1491 TTTAAATGACTGCATTT 1507
Db 1 TTTAAATGGCGCAGTT 17

RESULT 700
AX265148/c
LOCUS AX265148 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2539 from Patent WO0173002.
ACCESSION AX265148
VERSION AX265148.1 GI:16513947
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
REFERENCE
AUTHORS Kniec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
JOURNAL stranded oligonucleotides
PATENT: WO 0173002-A 2539 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
BASE COUNT 6 a 5 c 2 g 4 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1491 TTTAAATGACTGCATTT 1507
Db 17 TTTAAATGGCGCAGTT 1

RESULT 701
AX265151/c
LOCUS AX265151 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2542 from Patent WO0173002.
ACCESSION AX265151
VERSION AX265151.1 GI:16513950
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
REFERENCE
AUTHORS Kniec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
JOURNAL stranded oligonucleotides
PATENT: WO 0173002-A 2542 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
BASE COUNT 4 a 2 c 5 g 6 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1491 TTTAAATGACTGCATTT 1507
Db 1 TTTAAATGGCGCAGTT 17

RESULT 702
AX265152/c
LOCUS AX265152 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2543 from Patent WO0173002.
ACCESSION AX265152
VERSION AX265152.1 GI:16513951
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
REFERENCE
AUTHORS Kniec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
JOURNAL stranded oligonucleotides
PATENT: WO 0173002-A 2543 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
BASE COUNT 6 a 5 c 2 g 4 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1491 TTTAAATGACTGCATTT 1507
Db 17 TTTAAATGGCGCAGTT 1

RESULT 703
AX266795/c
LOCUS AX266795 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 4186 from Patent WO0173002.
ACCESSION AX266795
VERSION AX266795.1 GI:16515596
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
REFERENCE
AUTHORS Kniec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
JOURNAL stranded oligonucleotides
PATENT: WO 0173002-A 4186 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
BASE COUNT 5 a 3 c 0 g 9 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1124 ATAAAGATCTTATAGTA 1140
Db 17 ATAGAGATGATATAATA 1

RESULT 704
AX266796/c
LOCUS AX266796 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 4187 from Patent WO0173002.
ACCESSION AX266796
VERSION AX266796.1 GI:16515597
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM

```

```

LOCUS AX265152 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2543 from Patent WO0173002.
ACCESSION AX265152
VERSION AX265152.1 GI:16513951
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
REFERENCE
AUTHORS Kniec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
JOURNAL stranded oligonucleotides
PATENT: WO 0173002-A 2543 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
BASE COUNT 6 a 5 c 2 g 4 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1491 TTTAAATGACTGCATTT 1507
Db 17 TTTAAATGGCGCAGTT 1

RESULT 703
AX266795/c
LOCUS AX266795 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 4186 from Patent WO0173002.
ACCESSION AX266795
VERSION AX266795.1 GI:16515596
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
REFERENCE
AUTHORS Kniec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
JOURNAL stranded oligonucleotides
PATENT: WO 0173002-A 4186 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
BASE COUNT 5 a 3 c 0 g 9 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1124 ATAAAGATCTTATAGTA 1140
Db 17 ATAGAGATGATATAATA 1

RESULT 704
AX266796/c
LOCUS AX266796 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 4187 from Patent WO0173002.
ACCESSION AX266796
VERSION AX266796.1 GI:16515597
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM

```

```

REFERENCE
AUTHORS      Bukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
TITLE        Knies, E.B., Gamber, H.B. and Rice, M.C.
              Targeted chromosomal genomic alterations with modified single
              stranded oligonucleotides
JOURNAL      Patent: WO 0173002-A 4187 04-OCT-2001;
              UNIVERSITY OF DELAWARE (US)
FEATURES
source       Location/Qualifiers
            1..17
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"
BASE COUNT   9 a 0 c 3 g 5 t

Query Match
Best Local Similarity 1.0%; Score 12.2; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1124 ATAGAGATGATATAGTA 1140
|||||
Db 1 ATAGAGATGATATAATA 17

RESULT 705
AX272674
LOCUS       AX272674
DEFINITION Sequence 243 from Patent WO0162911.
ACCESSION  AX272674
VERSION    AX272674.1 GI:16545411
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
REFERENCE  1 Jarvis, T., von Carlowitz, I., Mcswiggen, J.A., Hamblin, P.A. and
            Ellis, J.H.
            Method and reagent for the inhibition of grid
            Patent: WO 0162911-A 243 30-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US); GLAXO GROUP LIMITED (GB)
FEATURES
source      Location/Qualifiers
            1..17
            /organism="Homo sapiens"
            /mol_type="mRNA"
            /db_xref="taxon:9606"
BASE COUNT   6 a 3 c 3 g 5 t

Query Match
Best Local Similarity 1.0%; Score 12.2; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1071 ATATTGTGCAAGAATT 1087
|||||
Db 1 ATATGTGCCCAAGAATT 17

RESULT 706
AX272675
LOCUS       AX272675
DEFINITION Sequence 244 from Patent WO0162911.
ACCESSION  AX272675
VERSION    AX272675.1 GI:16545412
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
REFERENCE  1 Jarvis, T., von Carlowitz, I., Mcswiggen, J.A., Hamblin, P.A. and
            Ellis, J.H.
            Method and reagent for the inhibition of grid
            Patent: WO 0162911-A 244 30-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US); GLAXO GROUP LIMITED (GB)
FEATURES
source      Location/Qualifiers
            1..17
            /organism="Homo sapiens"
            /mol_type="mRNA"
            /db_xref="taxon:9606"
BASE COUNT   6 a 3 c 3 g 5 t

Query Match
Best Local Similarity 1.0%; Score 12.2; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1071 ATATTGTGCAAGAATT 1087
|||||
Db 1 ATATGTGCCCAAGAATT 17

RESULT 705
AX272674
LOCUS       AX272674
DEFINITION Sequence 243 from Patent WO0162911.
ACCESSION  AX272674
VERSION    AX272674.1 GI:16545411
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
REFERENCE  1 Jarvis, T., von Carlowitz, I., Mcswiggen, J.A., Hamblin, P.A. and
            Ellis, J.H.
            Method and reagent for the inhibition of grid
            Patent: WO 0162911-A 243 30-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US); GLAXO GROUP LIMITED (GB)
FEATURES
source      Location/Qualifiers
            1..17
            /organism="Homo sapiens"
            /mol_type="mRNA"
            /db_xref="taxon:9606"
BASE COUNT   6 a 3 c 3 g 5 t

Query Match
Best Local Similarity 1.0%; Score 12.2; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1071 ATATTGTGCAAGAATT 1087
|||||
Db 1 ATATGTGCCCAAGAATT 17

RESULT 706
AX272675
LOCUS       AX272675
DEFINITION Sequence 244 from Patent WO0162911.
ACCESSION  AX272675
VERSION    AX272675.1 GI:16545412
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
REFERENCE  1 Jarvis, T., von Carlowitz, I., Mcswiggen, J.A., Hamblin, P.A. and
            Ellis, J.H.
            Method and reagent for the inhibition of grid
            Patent: WO 0162911-A 244 30-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US); GLAXO GROUP LIMITED (GB)
FEATURES
source      Location/Qualifiers
            1..17
            /organism="Homo sapiens"
            /mol_type="mRNA"
            /db_xref="taxon:9606"
BASE COUNT   6 a 3 c 3 g 5 t

Query Match
Best Local Similarity 1.0%; Score 12.2; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1071 ATATTGTGCAAGAATT 1087
|||||
Db 1 ATATGTGCCCAAGAATT 17

RESULT 707
AX272989
LOCUS       AX272989
DEFINITION Sequence 558 from Patent WO0162911.
ACCESSION  AX272989
VERSION    AX272989.1 GI:16545726
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
REFERENCE  1 Jarvis, T., von Carlowitz, I., Mcswiggen, J.A., Hamblin, P.A. and
            Ellis, J.H.
            Method and reagent for the inhibition of grid
            Patent: WO 0162911-A 558 30-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US); GLAXO GROUP LIMITED (GB)
FEATURES
source      Location/Qualifiers
            1..17
            /organism="Homo sapiens"
            /mol_type="mRNA"
            /db_xref="taxon:9606"
BASE COUNT   6 a 3 c 4 g 4 t

Query Match
Best Local Similarity 1.0%; Score 12.2; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1072 TATTGTGCAAGAATT 1088
|||||
Db 1 TATGTGCCCAAGAATT 17

RESULT 707
AX272989
LOCUS       AX272989
DEFINITION Sequence 558 from Patent WO0162911.
ACCESSION  AX272989
VERSION    AX272989.1 GI:16545726
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
REFERENCE  1 Jarvis, T., von Carlowitz, I., Mcswiggen, J.A., Hamblin, P.A. and
            Ellis, J.H.
            Method and reagent for the inhibition of grid
            Patent: WO 0162911-A 558 30-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US); GLAXO GROUP LIMITED (GB)
FEATURES
source      Location/Qualifiers
            1..17
            /organism="Homo sapiens"
            /mol_type="mRNA"
            /db_xref="taxon:9606"
BASE COUNT   5 a 3 c 6 t

Query Match
Best Local Similarity 1.0%; Score 12.2; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1072 TATTGTGCAAGAATT 1088
|||||
Db 1 TATGTGCCCAAGAATT 17

RESULT 708
AX273017
LOCUS       AX273017
DEFINITION Sequence 586 from Patent WO0162911.
ACCESSION  AX273017
VERSION    AX273017.1 GI:16545754
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
REFERENCE  1 Jarvis, T., von Carlowitz, I., Mcswiggen, J.A., Hamblin, P.A. and
            Ellis, J.H.
            Method and reagent for the inhibition of grid
            Patent: WO 0162911-A 586 30-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US); GLAXO GROUP LIMITED (GB)
FEATURES
source      Location/Qualifiers
            1..17
            /organism="Homo sapiens"
            /mol_type="mRNA"
            /db_xref="taxon:9606"
BASE COUNT   4 a 8 c 4 g 1 t

```



```

RESULT 713
AX326013/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
AX326013
Sequence 2151 from Patent WO0192512.
AX326013
Helianthus annuus (common sunflower)
Eukaryota; Viridiplantae; Streptophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
Asteridae; campanulids; Asterales; Asteraceae; Asteroideae;
Heliantheae; Helianthus.
1
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
1.17
/organism="Helianthus annuus"
/mol_type="genomic DNA"
/db_xref="taxon:4232"
BASE COUNT
4 a 9 c 0 g 4 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 966 GTGAGGACATGTGGAG 982
Db 17 GTGAGGATATGGGAG 1

RESULT 714
AX326014
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
AX326014
Sequence 2152 from Patent WO0192512.
AX326014
Helianthus annuus (common sunflower)
Eukaryota; Viridiplantae; Streptophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
Asteridae; campanulids; Asterales; Asteraceae; Asteroideae;
Heliantheae; Helianthus.
1
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
1.17
/organism="Helianthus annuus"
/mol_type="genomic DNA"
/db_xref="taxon:4232"
BASE COUNT
4 a 0 c 9 g 4 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 966 GTGAGGACATGTGGAG 982
Db 1 GTGAGGATATGGGAG 17

RESULT 715
AX326015/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
AX326015
Sequence 2153 from Patent WO0192512.
AX326015
Helianthus annuus (common sunflower)
Eukaryota; Viridiplantae; Streptophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
Asteridae; campanulids; Asterales; Asteraceae; Asteroideae;
Heliantheae; Helianthus.
1
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
1.17
/organism="Helianthus annuus"
/mol_type="genomic DNA"
/db_xref="taxon:4232"
BASE COUNT
4 a 0 c 9 g 4 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 966 GTGAGGACATGTGGAG 982
Db 1 GTGAGGATATGGGAG 17

```

```

AX326473
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
AX326473
Sequence 2611 from Patent WO0192512.
AX326473
Glycine max (soybean)
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
Rosids; eurosids I; Fabales; Fabaceae; Papilionoideae; Phaseoleae;
Glycine.
1
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
1.17
/organism="Glycine max"
/mol_type="genomic DNA"
/db_xref="taxon:3847"
BASE COUNT
4 a 4 c 3 g 6 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1315 CAATCCTAGTTTGATAC 1331
Db 1 CAAGCTTAGTTTGATCC 17

RESULT 716
AX326474/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
AX326474
Sequence 2612 from Patent WO0192512.
AX326474
Glycine max (soybean)
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
Rosids; eurosids I; Fabales; Fabaceae; Papilionoideae; Phaseoleae;
Glycine.
1
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
1.17
/organism="Glycine max"
/mol_type="genomic DNA"
/db_xref="taxon:3847"
BASE COUNT
6 a 3 c 4 g 4 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1315 CAATCCTAGTTTGATAC 1331
Db 1 CAAGCTTAGTTTGATCC 17

RESULT 717
AX326475/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
AX326475
Sequence 2613 from Patent WO0192512.
AX326475
Glycine max (soybean)
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
Rosids; eurosids I; Fabales; Fabaceae; Papilionoideae; Phaseoleae;
Glycine.
1
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
1.17
/organism="Glycine max"
/mol_type="genomic DNA"
/db_xref="taxon:3847"
BASE COUNT
6 a 3 c 4 g 4 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1315 CAATCCTAGTTTGATAC 1331
Db 1 CAAGCTTAGTTTGATCC 17

RESULT 718
AX326476/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
AX326476
Sequence 2614 from Patent WO0192512.
AX326476
Glycine max (soybean)
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
Rosids; eurosids I; Fabales; Fabaceae; Papilionoideae; Phaseoleae;
Glycine.
1
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
1.17
/organism="Glycine max"
/mol_type="genomic DNA"
/db_xref="taxon:3847"
BASE COUNT
6 a 3 c 4 g 4 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1315 CAATCCTAGTTTGATAC 1331
Db 1 CAAGCTTAGTTTGATCC 17

```

ACCESSION AX393409
VERSION AX393409.1 GI:19701391
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS St Croix, B., Kinzler, K.W. and Vogelstein, B.
TITLE Endothelial cell expression patterns
JOURNAL Patent: WO 0210217-A 339 07-FEB-2002;
The Johns Hopkins University (US)
FEATURES
source
1. .17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 7 a 3 c 2 g 5 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1621 TATAATTGTTGTCAAA 1637
Db 1 TACAAATCGTGTCAAA 17
RESULT 718
AX421792
LOCUS AX421792 17 bp mRNA linear PAT 18-JUN-2002
DEFINITION Sequence 128 from Patent WO0188124.
ACCESSION AX421792
VERSION AX421792.1 GI:21525174
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Jarvis, T., von Carlowitz, I., Mcswiggen, J.A., McLaughlin, F.G. and
Randi, A.M.
TITLE Method and reagent for the inhibition of erg
JOURNAL Patent: WO 0188124-A 128 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); GLAXO GROUP LIMITED (GB)
FEATURES
source
1. .17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
BASE COUNT 5 a 3 c 2 g 7 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1473 TAGATCTTATAATATT 1489
Db 1 TAGATCTTATCAGATT 17
RESULT 719
AX421950
LOCUS AX421950 17 bp mRNA linear PAT 18-JUN-2002
DEFINITION Sequence 286 from Patent WO0188124.
ACCESSION AX421950
VERSION AX421950.1 GI:21525332
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Jarvis, T., von Carlowitz, I., Mcswiggen, J.A., McLaughlin, F.G. and
Randi, A.M.
TITLE Method and reagent for the inhibition of erg
JOURNAL Patent: WO 0188124-A 286 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); GLAXO GROUP LIMITED (GB)
FEATURES
source
1. .17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
BASE COUNT 9 a 3 c 0 g 5 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1244 TTTCAGATAAACACAA 1260
Db 1 TTTCATATCAAAACAA 17
RESULT 720
AX421950/c
LOCUS AX421950 17 bp mRNA linear PAT 18-JUN-2002
DEFINITION Sequence 286 from Patent WO0188124.
ACCESSION AX421950
VERSION AX421950.1 GI:21525332
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Jarvis, T., von Carlowitz, I., Mcswiggen, J.A., McLaughlin, F.G. and
Randi, A.M.
TITLE Method and reagent for the inhibition of erg
JOURNAL Patent: WO 0188124-A 286 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); GLAXO GROUP LIMITED (GB)
FEATURES
source
1. .17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
BASE COUNT 9 a 3 c 0 g 5 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1244 TTTCAGATAAACACAA 1260
Db 1 TTTCATATCAAAACAA 17
RESULT 721
AX422015/c
LOCUS AX422015 17 bp mRNA linear PAT 18-JUN-2002
DEFINITION Sequence 351 from Patent WO0188124.
ACCESSION AX422015
VERSION AX422015.1 GI:21525397
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Jarvis, T., von Carlowitz, I., Mcswiggen, J.A., McLaughlin, F.G. and
Randi, A.M.
TITLE Method and reagent for the inhibition of erg
JOURNAL Patent: WO 0188124-A 351 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); GLAXO GROUP LIMITED (GB)
FEATURES
source
1. .17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
BASE COUNT 9 a 3 c 0 g 5 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1149 TTATTTTATGATATATA 1165
Db 1 TTGTTTTCATATGAAA 1
RESULT 721
AX422015/c
LOCUS AX422015 17 bp mRNA linear PAT 18-JUN-2002
DEFINITION Sequence 351 from Patent WO0188124.
ACCESSION AX422015
VERSION AX422015.1 GI:21525397
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Jarvis, T., von Carlowitz, I., Mcswiggen, J.A., McLaughlin, F.G. and
Randi, A.M.
TITLE Method and reagent for the inhibition of erg
JOURNAL Patent: WO 0188124-A 351 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); GLAXO GROUP LIMITED (GB)
FEATURES
source
1. .17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"

AUTHORS Jarvis, T., von Carlowitz, I., Mcswiggen, J.A., McLaughlin, F.G. and
Randi, A.M.
TITLE Method and reagent for the inhibition of erg
JOURNAL Patent: WO 0188124-A 286 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); GLAXO GROUP LIMITED (GB)
FEATURES
source
1. .17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
BASE COUNT 9 a 3 c 0 g 5 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1244 TTTCAGATAAACACAA 1260
Db 1 TTTCATATCAAAACAA 17
RESULT 720
AX421950/c
LOCUS AX421950 17 bp mRNA linear PAT 18-JUN-2002
DEFINITION Sequence 286 from Patent WO0188124.
ACCESSION AX421950
VERSION AX421950.1 GI:21525332
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Jarvis, T., von Carlowitz, I., Mcswiggen, J.A., McLaughlin, F.G. and
Randi, A.M.
TITLE Method and reagent for the inhibition of erg
JOURNAL Patent: WO 0188124-A 286 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); GLAXO GROUP LIMITED (GB)
FEATURES
source
1. .17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
BASE COUNT 9 a 3 c 0 g 5 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1149 TTATTTTATGATATATA 1165
Db 1 TTGTTTTCATATGAAA 1
RESULT 721
AX422015/c
LOCUS AX422015 17 bp mRNA linear PAT 18-JUN-2002
DEFINITION Sequence 351 from Patent WO0188124.
ACCESSION AX422015
VERSION AX422015.1 GI:21525397
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Jarvis, T., von Carlowitz, I., Mcswiggen, J.A., McLaughlin, F.G. and
Randi, A.M.
TITLE Method and reagent for the inhibition of erg
JOURNAL Patent: WO 0188124-A 351 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); GLAXO GROUP LIMITED (GB)
FEATURES
source
1. .17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"

```

/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
3 a 2 c 2 g 10 t

Query Match
Best Local Similarity 1.0%; Score 12.2; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

BASE COUNT
1204 ATTAACAAACAAACAA 1220
Db 17 ATTGACAAACAAAGAA 1

RESULT 722
AX422082
LOCUS AX422082 17 bp mRNA linear PAT 18-JUN-2002
DEFINITION Sequence 418 from Patent WO0188124.
ACCESSION AX422082
VERSION AX422082.1 GI:21525464
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Jarvis, T., von Carlowitz, I., Mcswiggen, J.A., McLaughlin, F.G. and
Randi, A.M.
TITLE Method and reagent for the inhibition of erg
JOURNAL Patent: WO 0188124-A 418 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); GLAXO GROUP LIMITED (GB)
FEATURES
source
1. .17
/db_xref="taxon:9606"
6 a 2 c 1 g 8 t

Query Match
Best Local Similarity 1.0%; Score 12.2; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

BASE COUNT
1042 TATATTTTGTATTTA 1058
Db 1 TATAACTTATGCAATTA 17

RESULT 723
AX422103/c
LOCUS AX422103 17 bp mRNA linear PAT 18-JUN-2002
DEFINITION Sequence 439 from Patent WO0188124.
ACCESSION AX422103
VERSION AX422103.1 GI:21525485
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Jarvis, T., von Carlowitz, I., Mcswiggen, J.A., McLaughlin, F.G. and
Randi, A.M.
TITLE Method and reagent for the inhibition of erg
JOURNAL Patent: WO 0188124-A 439 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); GLAXO GROUP LIMITED (GB)
FEATURES
source
1. .17
/db_xref="taxon:9606"
6 a 2 c 1 g 8 t

Query Match
Best Local Similarity 1.0%; Score 12.2; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```

```

Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1524 ATATTTTAACTTTAAG 1540
Db 17 ATATTTGAAACATTAAG 1

RESULT 724
AX422116/c
LOCUS AX422116 17 bp mRNA linear PAT 18-JUN-2002
DEFINITION Sequence 452 from Patent WO0188124.
ACCESSION AX422116
VERSION AX422116.1 GI:21525498
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Jarvis, T., von Carlowitz, I., Mcswiggen, J.A., McLaughlin, F.G. and
Randi, A.M.
TITLE Method and reagent for the inhibition of erg
JOURNAL Patent: WO 0188124-A 452 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); GLAXO GROUP LIMITED (GB)
FEATURES
source
1. .17
/db_xref="taxon:9606"
9 a 2 g 6 t

Query Match
Best Local Similarity 1.0%; Score 12.2; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

BASE COUNT
1169 TGTTTTATTAGATAAAT 1185
Db 17 TATTTTATTACATCAT 1

RESULT 725
AX422708/c
LOCUS AX422708 17 bp mRNA linear PAT 18-JUN-2002
DEFINITION Sequence 1044 from Patent WO0188124.
ACCESSION AX422708
VERSION AX422708.1 GI:21526090
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Jarvis, T., von Carlowitz, I., Mcswiggen, J.A., McLaughlin, F.G. and
Randi, A.M.
TITLE Method and reagent for the inhibition of erg
JOURNAL Patent: WO 0188124-A 1044 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); GLAXO GROUP LIMITED (GB)
FEATURES
source
1. .17
/db_xref="taxon:9606"
7 a 4 c 2 g 4 t

Query Match
Best Local Similarity 1.0%; Score 12.2; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1107 TCATTGATTGAATAGTT 1123
Db 17 TCATTGCTTGAGAGTT 1

```

```

RESULT 726
AX423057/c
LOCUS AX423057 17 bp mRNA linear PAT 18-JUN-2002
DEFINITION Sequence 1393 from Patent WO0188124.
ACCESSION AX423057
VERSION AX423057.1 GI:21526439
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
REFERENCE
AUTHORS Jarvis, T., von Carlowitz, I., Mcswiggen, J.A., McLaughlin, F.G. and
Randi, A.M.
TITLE Method and reagent for the inhibition of erg
JOURNAL Patent: WO 0188124-A 1393 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
source
BASE COUNT 6 a 6 c 3 g 2 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 1341 TGTCTATTCAGCTGTG 1357
Db 17 TGTCTATTCAGCTGTG 1
RESULT 727
AX423166
LOCUS AX423166 17 bp mRNA linear PAT 18-JUN-2002
DEFINITION Sequence 1502 from Patent WO0188124.
ACCESSION AX423166
VERSION AX423166.1 GI:21526548
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
REFERENCE
AUTHORS Jarvis, T., von Carlowitz, I., Mcswiggen, J.A., McLaughlin, F.G. and
Randi, A.M.
TITLE Method and reagent for the inhibition of erg
JOURNAL Patent: WO 0188124-A 1502 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
source
BASE COUNT 8 a 1 c 1 g 7 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 1467 TACAAATAGATCTTAT 1483
Db 1 TACAAATAGATCTTAT 17
RESULT 728
AX423293/c
LOCUS AX423293 17 bp mRNA linear PAT 18-JUN-2002
DEFINITION Sequence 1629 from Patent WO0188124.
ACCESSION AX423293
VERSION AX423293.1 GI:21526675
KEYWORDS

```

```

SOURCE
ORGANISM Homo sapiens (human)
REFERENCE
AUTHORS Jarvis, T., von Carlowitz, I., Mcswiggen, J.A., McLaughlin, F.G. and
Randi, A.M.
TITLE Method and reagent for the inhibition of erg
JOURNAL Patent: WO 0188124-A 1629 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
source
BASE COUNT 4 a 3 c 3 g 7 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 412 TCCAAGATCAGTGAAG 428
Db 17 TCCAAGATCAGTGAAG 1
RESULT 729
AX423315/c
LOCUS AX423315 17 bp mRNA linear PAT 18-JUN-2002
DEFINITION Sequence 1651 from Patent WO0188124.
ACCESSION AX423315
VERSION AX423315.1 GI:21526697
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
REFERENCE
AUTHORS Jarvis, T., von Carlowitz, I., Mcswiggen, J.A., McLaughlin, F.G. and
Randi, A.M.
TITLE Method and reagent for the inhibition of erg
JOURNAL Patent: WO 0188124-A 1651 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
source
BASE COUNT 7 a 3 c 3 g 4 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 392 AAAATTCATCTCTGTG 408
Db 17 AAAATTCATCTCTGTG 1
RESULT 730
AX423389/c
LOCUS AX423389 17 bp mRNA linear PAT 18-JUN-2002
DEFINITION Sequence 1725 from Patent WO0188124.
ACCESSION AX423389
VERSION AX423389.1 GI:21526771
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
REFERENCE
AUTHORS Jarvis, T., von Carlowitz, I., Mcswiggen, J.A., McLaughlin, F.G. and
Randi, A.M.

```

TITLE Method and reagent for the inhibition of erg
JOURNAL Patent: WO 0188124-A 1725 22-NOV-2001; GLAXO GROUP LIMITED (GB)
RIBOZYME PHARMACEUTICALS, INC. (US);
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
BASE COUNT 7 a 1 c 2 g 7 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1236 AATTTCATTTCAGATA 1252
Db 17 AATTTCATTTCAGAA 1
RESULT 731
AX423598/c
LOCUS AX423598 17 bp mRNA linear PAT 18-JUN-2002
DEFINITION Sequence 1934 from Patent WO0188124.
ACCESSION AX423598
VERSION AX423598.1 GI:21526980
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Jarvis, T., von Carlowitz, I., McSwiggen, J.A., McLaughlin, F.G. and Randi, A.M.
TITLE Method and reagent for the inhibition of erg
JOURNAL Patent: WO 0188124-A 1934 22-NOV-2001; GLAXO GROUP LIMITED (GB)
RIBOZYME PHARMACEUTICALS, INC. (US);
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
BASE COUNT 7 a 4 c 3 g 3 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 393 AAATTCATTCTCTGG 409
Db 17 AAGTTCATTCTCTGG 1
RESULT 732
AX428711
LOCUS AX428711 17 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 110 from Patent EP1201771.
ACCESSION AX428711
VERSION AX428711.1 GI:21538622
KEYWORDS unidentified
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Van Doorn, I.J., Kletter, B. and Ter Schegget, J.
TITLE Detection and identification of human papillomavirus by pcr and type-specific reverse hybridization
JOURNAL Patent: EP 1201771-A 110 02-MAY-2002;
INNOGENETICS N.V. (BE) Delft Diagnostic laboratory B.V. (NL)
FEATURES Location/Qualifiers
source 1..17
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

BASE COUNT 5 a 1 c 5 g 6 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1619 AATATAATTGTGTCA 1635
Db 1 AATGGAATTGTGTGCA 17
RESULT 733
AX499533
LOCUS AX499533 17 bp DNA linear PAT 27-SEP-2002
DEFINITION Sequence 840 from Patent EP1229046.
ACCESSION AX499533
VERSION AX499533.1 GI:23381826
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Zhan, J.
TITLE Human testis expressed patched like protein
JOURNAL Patent: EP 1229046-A 840 07-AUG-2002;
Aeomica, Inc. (US)
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 5 a 6 c 4 g 2 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 496 GCCAGATGCAATACAAAG 512
Db 1 GCCAGATCCAGTACCAG 17
RESULT 734
AX499867/c
LOCUS AX499867 17 bp DNA linear PAT 27-SEP-2002
DEFINITION Sequence 1174 from Patent EP1229046.
ACCESSION AX499867
VERSION AX499867.1 GI:23382160
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Zhan, J.
TITLE Human testis expressed patched like protein
JOURNAL Patent: EP 1229046-A 1174 07-AUG-2002;
Aeomica, Inc. (US)
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 8 a 1 c 4 g 4 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1006 CATAAATTATTTTCAAG 1022
Db 17 CCTCAATTATTTTCAAG 1

RESULT 735	AX499868	17 bp	DNA	linear	PAT 27-SEP-2002
LOCUS	Sequence 1175 from Patent EPI229046.				
DEFINITION	AX499868				
ACCESSION	AX499868.1	GI:23382161			
VERSION					
KEYWORDS					
SOURCE	Homo sapiens (human)				
ORGANISM	Homo sapiens				
REFERENCE	Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi; Mammalia; Butheria; Primates; Catarrhini; Hominidae; Homo.				
AUTHORS	Zhan,J.				
TITLE	Human testis expressed patched like protein				
JOURNAL	Patent: EP 1229046-A 1175 07-AUG-2002;				
FEATURES	Neomica, Inc. (US)				
source	1..17				
	/organism="Homo sapiens"				
	/mol_type="genomic DNA"				
	/db_xref="taxon:9606"				
BASE COUNT	8 a 0 c 4 g 5 t				
Query Match	1.0%; Score 12.2; DB 1; Length 17;				
Best Local Similarity	82.4%; Pred. No. 5.8e+02;				
Matches	14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;				
QY	1005 ACATAAATTATTTCAA 1021				
DB	17 ACCTCAATTTTTTCAA 1				
RESULT 736	AX499997	17 bp	DNA	linear	PAT 27-SEP-2002
LOCUS	Sequence 1304 from Patent EPI229046.				
DEFINITION	AX499997				
ACCESSION	AX499997.1	GI:23382290			
VERSION					
KEYWORDS	Homo sapiens (human)				
SOURCE	Homo sapiens				
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.				
REFERENCE	Zhan,J.				
AUTHORS	Human testis expressed patched like protein				
TITLE	Patent: EP 1229046-A 1304 07-AUG-2002;				
JOURNAL	Neomica, Inc. (US)				
FEATURES	Location/Qualifiers				
source	1..17				
	/organism="Homo sapiens"				
	/mol_type="genomic DNA"				
	/db_xref="taxon:9606"				
BASE COUNT	2 a 2 c 5 g 8 t				
Query Match	1.0%; Score 12.2; DB 1; Length 17;				
Best Local Similarity	82.4%; Pred. No. 5.8e+02;				
Matches	14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;				
QY	433 CAGTCGAACCTTCAGCA 449				
DB	17 CAGTCGAACCTTCAGCA 1				
RESULT 737	AX502719	17 bp	DNA	linear	PAT 27-SEP-2002
LOCUS	Sequence 4026 from Patent EPI229046.				
DEFINITION	AX502719				
ACCESSION	AX502719.1	GI:23385012			
VERSION					
KEYWORDS					

```

FEATURES
  source
    Location/Qualifiers
      1..17
        /organism="Homo sapiens"
        /mol_type="genomic DNA"
        /db_xref="taxon:9606"
      4 a 3 c 3 g 7 t
BASE COUNT
  4 a 3 c 3 g 7 t
Query Match
  1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1188 CAATCAGGGTTTGTAGA 1204
Db ||||| ||||| |||||
17 CAATCAGGAATCTAGA 1

RESULT 740
AX527053/c
LOCUS AX527053 17 bp DNA linear PAT 21-NOV-2002
DEFINITION Sequence 83 from Patent WO0226818.
ACCESSION AX527053
VERSION AX527053.1 GI:25171668
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
  1 Gu, Y. and Corrigan, A.
AUTHORS Human nedd-1
TITLE Patent: WO 0226818-A 83 04-APR-2002;
JOURNAL Aecomica, Inc. (US)
FEATURES
  source
    Location/Qualifiers
      1..17
        /organism="Homo sapiens"
        /mol_type="genomic DNA"
        /db_xref="taxon:9606"
      7 a 4 c 1 g 5 t
BASE COUNT
  7 a 4 c 1 g 5 t
Query Match
  1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1095 ATAGAGGATGAATCAT 1111
Db ||||| ||||| |||||
17 ATAGAGGATGAATCTTT 1

RESULT 741
AX527175
LOCUS AX527175 17 bp DNA linear PAT 21-NOV-2002
DEFINITION Sequence 205 from Patent WO0226818.
ACCESSION AX527175
VERSION AX527175.1 GI:25171790
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
  1 Gu, Y. and Corrigan, A.
AUTHORS Human nedd-1
TITLE Patent: WO 0226818-A 205 04-APR-2002;
JOURNAL Aecomica, Inc. (US)
FEATURES
  source
    Location/Qualifiers
      1..17
        /organism="Homo sapiens"
        /mol_type="genomic DNA"
        /db_xref="taxon:9606"
      9 a 1 c 3 g 4 t
BASE COUNT
  9 a 1 c 3 g 4 t
Query Match
  1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;

FEATURES
  source
    Location/Qualifiers
      1..17
        /organism="Homo sapiens"
        /mol_type="genomic DNA"
        /db_xref="taxon:9606"
      4 a 3 c 3 g 7 t
BASE COUNT
  4 a 3 c 3 g 7 t
Query Match
  1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 668 GGGAGATATATCAATA 684
Db ||||| ||||| |||||
1 GGGAAATATATCAATA 17

RESULT 742
AX531355/c
LOCUS AX531355 17 bp DNA linear PAT 22-NOV-2002
DEFINITION Sequence 864 from Patent EP1239051.
ACCESSION AX531355
VERSION AX531355.1 GI:25254493
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
  1 Shannon, M.
AUTHORS Human posh-like protein 1
TITLE Patent: EP 1239051-A 864 11-SEP-2002;
JOURNAL Aecomica, Inc. (US)
FEATURES
  source
    Location/Qualifiers
      1..17
        /organism="Homo sapiens"
        /mol_type="genomic DNA"
        /db_xref="taxon:9606"
      7 a 2 c 7 g 1 t
BASE COUNT
  7 a 2 c 7 g 1 t
Query Match
  1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1333 CCCAGTCTTGTCATTC 1349
Db ||||| ||||| |||||
17 CTCACCTCTTGCTTC 1

RESULT 743
AX531356/c
LOCUS AX531356 17 bp DNA linear PAT 22-NOV-2002
DEFINITION Sequence 865 from Patent EP1239051.
ACCESSION AX531356
VERSION AX531356.1 GI:25254495
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
  1 Shannon, M.
AUTHORS Human posh-like protein 1
TITLE Patent: EP 1239051-A 865 11-SEP-2002;
JOURNAL Aecomica, Inc. (US)
FEATURES
  source
    Location/Qualifiers
      1..17
        /organism="Homo sapiens"
        /mol_type="genomic DNA"
        /db_xref="taxon:9606"
      8 a 2 c 6 g 1 t
BASE COUNT
  8 a 2 c 6 g 1 t
Query Match
  1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1332 TCCAGTCTTGTCATTC 1348
Db ||||| ||||| |||||
17 TCTCACTCTTGCTTC 1

RESULT 744
AX531483/c

```

LOCUS AX531483 17 bp DNA linear PAT 22-NOV-2002
 DEFINITION Sequence 992 from Patent EP1239051.
 ACCESSION AX531483
 VERSION AX531483.1 GI:25254743
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1
 AUTHORS Shannon, M.
 TITLE Human pash-like protein 1
 JOURNAL Patent: EP 1239051-A 992 11-SEP-2002;
 Aeomica, Inc. (US)
 FEATURES
 source Location/Qualifiers
 1..17
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"
 BASE COUNT 5 a 2 c 4 g 6 t
 Query Match 1.0%; Score 12.2; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 5.8e+02;
 Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 607 TTGGAATCTCAAAAA 623
 |||||
 Db 17 TTGGCTCTACAAACA 1
 RESULT 745
 AX532080/c
 LOCUS AX532080 17 bp DNA linear PAT 22-NOV-2002
 DEFINITION Sequence 1589 from Patent EP1239051.
 ACCESSION AX532080
 VERSION AX532080.1 GI:25255923
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1
 AUTHORS Shannon, M.
 TITLE Human pash-like protein 1
 JOURNAL Patent: EP 1239051-A 1589 11-SEP-2002;
 Aeomica, Inc. (US)
 FEATURES
 source Location/Qualifiers
 1..17
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"
 BASE COUNT 3 a 5 c 2 g 7 t
 Query Match 1.0%; Score 12.2; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 5.8e+02;
 Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 1083 GAATTCGAAAATAGA 1099
 |||||
 Db 17 GAGCTCGAAACTAGA 1
 RESULT 746
 AX572026/c
 LOCUS AX572026 17 bp DNA linear PAT 29-NOV-2002
 DEFINITION Sequence 66 from Patent WO02055741.
 ACCESSION AX572026
 VERSION AX572026.1 GI:26004116
 KEYWORDS
 SOURCE Human immunodeficiency virus
 ORGANISM Human immunodeficiency virus
 Viruses; Retroviridae; Lentivirus; Primate
 lentivirus group.

REFERENCE 1
 AUTHORS de Smet, K. and Stuyver, L.
 TITLE Method for detection of drug-induced mutations in the hiv reverse transcriptase gene
 JOURNAL Patent: WO 02055741-A 66 18-JUL-2002;
 INNOGENETICS N.V. (BE)
 FEATURES
 source Location/Qualifiers
 1..17
 /organism="Human immunodeficiency virus"
 /mol_type="genomic DNA"
 /db_xref="taxon:12721"
 BASE COUNT 9 a 2 c 3 g 3 t
 Query Match 1.0%; Score 12.2; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 5.8e+02;
 Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 1571 ACTGTTCTCGATTGTAT 1587
 |||||
 Db 17 ACTGTTACTGATTCATT 1
 RESULT 747
 AX572825/c
 LOCUS AX572825 17 bp DNA linear PAT 29-NOV-2002
 DEFINITION Sequence 865 from Patent WO02055741.
 ACCESSION AX572825
 VERSION AX572825.1 GI:26004915
 KEYWORDS
 SOURCE Human immunodeficiency virus
 ORGANISM Human immunodeficiency virus
 Viruses; Retroviridae; Lentivirus; Primate
 lentivirus group.
 REFERENCE 1
 AUTHORS de Smet, K. and Stuyver, L.
 TITLE Method for detection of drug-induced mutations in the hiv reverse transcriptase gene
 JOURNAL Patent: WO 02055741-A 865 18-JUL-2002;
 INNOGENETICS N.V. (BE)
 FEATURES
 source Location/Qualifiers
 1..17
 /organism="Human immunodeficiency virus"
 /mol_type="genomic DNA"
 /db_xref="taxon:12721"
 BASE COUNT 10 a 2 c 2 g 3 t
 Query Match 1.0%; Score 12.2; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 5.8e+02;
 Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 1571 ACTGTTCTCGATTGTAT 1587
 |||||
 Db 17 ACTGTTACTGATTCATT 1
 RESULT 748
 AX578220/c
 LOCUS AX578220 17 bp mRNA linear PAT 10-JAN-2003
 DEFINITION Sequence 58 from Patent WO0211674.
 ACCESSION AX578220
 VERSION AX578220.1 GI:27647422
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1
 AUTHORS Thompson, J., Mcswiggen, J., Mckenzie, T., Ayers, D., Szymkowski, D.E. and Grupe, A.
 TITLE Method and reagent for the inhibition of calcium activated chloride channel-1 (clca-1)
 JOURNAL Patent: WO 0211674-A 58 14-FEB-2002;
 RIBOZYME PHARMACEUTICALS, INC. (US); Syntex (U.S.A.) LLC (US);

```
Thompson, James (US)
Location/Qualifiers
1. .17
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
BASE COUNT      5 a      2 c      1 g      9 t
Query Match
Best Local Similarity 1.0%; Score 12.2; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 675 TATACAAATAGCAAAAT 691
Db 17 TATACAGATATGAAAT 1

RESULT 749
AX578273
LOCUS      AX578273      17 bp      mRNA      linear      PAT 10-JAN-2003
DEFINITION Sequence 111 from Patent WO0211674.
ACCESSION AX578273
VERSION    AX578273.1 GI:27647475
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
REFERENCE  1
AUTHORS    Zukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
          Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
TITLE      Thompson, J., Mcswiggen, J., McKenzie, T., Ayers, D., Szymkowski, D.E.
          Method and reagent for the inhibition of calcium activated chloride
          channel-1 (clca-1)
JOURNAL    Patent: WO 0211674-A 111 14-FEB-2002;
          RIBOZYME PHARMACEUTICALS, INC. (US); Syntex (U.S.A.) LLC (US);
          Thompson, James (US)
FEATURES   source
            Location/Qualifiers
            1. .17
            /organism="Homo sapiens"
            /mol_type="mRNA"
            /db_xref="taxon:9606"
BASE COUNT      4 a      3 c      3 g      7 t
Query Match
Best Local Similarity 1.0%; Score 12.2; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 601 TATTATTGAACTAC 617
Db 1 TATCTGTTTGAGCTAC 17

RESULT 750
AX578687
LOCUS      AX578687      17 bp      mRNA      linear      PAT 10-JAN-2003
DEFINITION Sequence 525 from Patent WO0211674.
ACCESSION AX578687
VERSION    AX578687.1 GI:27647889
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
REFERENCE  1
AUTHORS    Zukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
          Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
TITLE      Thompson, J., Mcswiggen, J., McKenzie, T., Ayers, D., Szymkowski, D.E.
          Method and reagent for the inhibition of calcium activated chloride
          channel-1 (clca-1)
JOURNAL    Patent: WO 0211674-A 525 14-FEB-2002;
          RIBOZYME PHARMACEUTICALS, INC. (US); Syntex (U.S.A.) LLC (US);
          Thompson, James (US)
FEATURES   source
            Location/Qualifiers
            1. .17
            /organism="Homo sapiens"
            /mol_type="mRNA"
            /db_xref="taxon:9606"
BASE COUNT      6 a      1 c      2 g      8 t
Query Match
Best Local Similarity 1.0%; Score 12.2; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 832 ATTATTTCTGTAAAT 848
Db 1 ATTTTGTCAATAAT 17

RESULT 751
AX578733
LOCUS      AX578733      17 bp      mRNA      linear      PAT 10-JAN-2003
DEFINITION Sequence 571 from Patent WO0211674.
ACCESSION AX578733
VERSION    AX578733.1 GI:27647935
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
REFERENCE  1
AUTHORS    Thompson, J., Mcswiggen, J., McKenzie, T., Ayers, D., Szymkowski, D.E.
          Method and reagent for the inhibition of calcium activated chloride
          channel-1 (clca-1)
JOURNAL    Patent: WO 0211674-A 571 14-FEB-2002;
          RIBOZYME PHARMACEUTICALS, INC. (US); Syntex (U.S.A.) LLC (US);
          Thompson, James (US)
FEATURES   source
            Location/Qualifiers
            1. .17
            /organism="Homo sapiens"
            /mol_type="mRNA"
            /db_xref="taxon:9606"
BASE COUNT      7 a      1 c      2 g      7 t
Query Match
Best Local Similarity 1.0%; Score 12.2; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1132 GTTATAGTAAATTTATT 1148
Db 1 GATATACTAAATGATT 17

RESULT 752
AX578825
LOCUS      AX578825      17 bp      mRNA      linear      PAT 10-JAN-2003
DEFINITION Sequence 663 from Patent WO0211674.
ACCESSION AX578825
VERSION    AX578825.1 GI:27648027
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
REFERENCE  1
AUTHORS    Thompson, J., Mcswiggen, J., McKenzie, T., Ayers, D., Szymkowski, D.E.
          Method and reagent for the inhibition of calcium activated chloride
          channel-1 (clca-1)
JOURNAL    Patent: WO 0211674-A 663 14-FEB-2002;
          RIBOZYME PHARMACEUTICALS, INC. (US); Syntex (U.S.A.) LLC (US);
          Thompson, James (US)
FEATURES   source
            Location/Qualifiers
            1. .17
            /organism="Homo sapiens"
            /mol_type="mRNA"
            /db_xref="taxon:9606"
```

```

BASE COUNT      7 a      2 c      4 g      4 t

Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      607 TTTCATCTACAAAAA 623
Db      1 TTTCAGCTACAGGAA 17

RESULT 753
AX579184/c
LOCUS      AX579184      17 bp      mRNA      linear      PAT 10-JAN-2003
DEFINITION Sequence 1022 from Patent WO0211674.
ACCESSION AX579184
VERSION    AX579184.1 GI:27648386
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
REFERENCE  1
AUTHORS    Thompson,J., McSwiggen,J., Mckenzie,T., Ayers,D., Szymkowski,D.E.
TITLE      Method and reagent for the inhibition of calcium activated chloride
channel-1 (clca-1)
JOURNAL    Patent: WO 0211674-A 1022 14-FEB-2002;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
Thompson, James (US)
FEATURES   source
            Location/Qualifiers
            1..17
            /organism="Homo sapiens"
            /mol_type="mRNA"
            /db_xref="taxon:9606"
BASE COUNT      5 a      5 c      3 g      4 t

Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1186 TTCAATCAGGCTTTTA 1202
Db      17 TTCAATCAGGCTGTGA 1

RESULT 754
AX579358/c
LOCUS      AX579358      17 bp      mRNA      linear      PAT 10-JAN-2003
DEFINITION Sequence 1196 from Patent WO0211674.
ACCESSION AX579358
VERSION    AX579358.1 GI:27648560
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
REFERENCE  1
AUTHORS    Thompson,J., McSwiggen,J., Mckenzie,T., Ayers,D., Szymkowski,D.E.
TITLE      Method and reagent for the inhibition of calcium activated chloride
channel-1 (clca-1)
JOURNAL    Patent: WO 0211674-A 1196 14-FEB-2002;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
Thompson, James (US)
FEATURES   source
            Location/Qualifiers
            1..17
            /organism="Homo sapiens"
            /mol_type="mRNA"
            /db_xref="taxon:9606"
BASE COUNT      7 a      4 c      0 g      6 t

Query Match      1.0%; Score 12.2; DB 1; Length 17;

```

```

Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1099 AAGATGATCAATGATT 1115
Db      17 AAGATGATCAATATT 1

RESULT 755
AX579392/c
LOCUS      AX579392      17 bp      mRNA      linear      PAT 10-JAN-2003
DEFINITION Sequence 1230 from Patent WO0211674.
ACCESSION AX579392
VERSION    AX579392.1 GI:27648594
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
REFERENCE  1
AUTHORS    Thompson,J., McSwiggen,J., Mckenzie,T., Ayers,D., Szymkowski,D.E.
TITLE      Method and reagent for the inhibition of calcium activated chloride
channel-1 (clca-1)
JOURNAL    Patent: WO 0211674-A 1230 14-FEB-2002;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
Thompson, James (US)
FEATURES   source
            Location/Qualifiers
            1..17
            /organism="Homo sapiens"
            /mol_type="mRNA"
            /db_xref="taxon:9606"
BASE COUNT      5 a      3 c      3 g      6 t

Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      602 ATTATTGCAATCTACA 618
Db      1 ATCTGTTGAAGCTACA 17

RESULT 756
AX579804/c
LOCUS      AX579804      17 bp      mRNA      linear      PAT 10-JAN-2003
DEFINITION Sequence 1642 from Patent WO0211674.
ACCESSION AX579804
VERSION    AX579804.1 GI:27649006
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
REFERENCE  1
AUTHORS    Thompson,J., McSwiggen,J., Mckenzie,T., Ayers,D., Szymkowski,D.E.
TITLE      Method and reagent for the inhibition of calcium activated chloride
channel-1 (clca-1)
JOURNAL    Patent: WO 0211674-A 1642 14-FEB-2002;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
Thompson, James (US)
FEATURES   source
            Location/Qualifiers
            1..17
            /organism="Homo sapiens"
            /mol_type="mRNA"
            /db_xref="taxon:9606"
BASE COUNT      7 a      4 c      3 g      3 t

Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```

```

QY 3281 CATTATGCTTCTCAAGCT 1297
Db 17 CATTATGCTTCTCAAGCT 1

RESULT 757
AX579811
LOCUS AX579811 17 bp mRNA linear PAT 10-JAN-2003
DEFINITION Sequence 1649 from Patent WO0211674.
ACCESSION AX579811
VERSION AX579811.1 GI:27649013
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
REFERENCE
AUTHORS Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
1
TITLE Thompson, J., McSwiggen, J., McKenzie, T., Ayers, D., Szykowski, D.E.
and Grube, A.
METHOD and reagent for the inhibition of calcium activated chloride
channel-1 (clca-1)
JOURNAL Patent: WO 0211674-A 1649 14-FEB-2002;
RIBOZYME PHARMACEUTICALS, INC. (US); Syntex (U.S.A.) LLC (US);
Thompson, James (US)
FEATURES
source
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
BASE COUNT 8 a 3 c 2 g 4 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1099 AGATGCAATCATGATT 1115
Db 1 AGATGCAATCATGATT 17

RESULT 758
AX634690
LOCUS AX634690 17 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 1829 from Patent EP1260586.
ACCESSION AX634690
VERSION AX634690.1 GI:28470304
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Stinchcomb, D.T., Dudycz, L.W., Chowrira, B., Grimm, S., Drenzo, A.,
Karpeisky, A., Draper, K.G., Kisich, K., Matulic-Adamic, J.,
McSwiggen, J.A., Modak, A., Pavco, P., Beigelman, L., Sullivan, S.M.,
Sweedler, D., Thompson, J.D., Tracz, D., Usman, N., Wincott, F.E. and
Woolf, T.
TITLE Method and reagent for inhibiting the expression of disease related
genes
JOURNAL Patent: EP 1260586-A 1829 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
source
Location/Qualifiers
1..17
/organism="unidentified"
/mol_type="mRNA"
/db_xref="taxon:32644"
BASE COUNT 4 a 4 c 4 g 5 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 977 TGAAGCCTTAAAGTT 993
Db 17 TGAAGCCTTAAAGTT 17

RESULT 759
AX634732
LOCUS AX634732 17 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 1871 from Patent EP1260586.
ACCESSION AX634732
VERSION AX634732.1 GI:28470346
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Stinchcomb, D.T., Dudycz, L.W., Chowrira, B., Grimm, S., Drenzo, A.,
Karpeisky, A., Draper, K.G., Kisich, K., Matulic-Adamic, J.,
McSwiggen, J.A., Modak, A., Pavco, P., Beigelman, L., Sullivan, S.M.,
Sweedler, D., Thompson, J.D., Tracz, D., Usman, N., Wincott, F.E. and
Woolf, T.
TITLE Method and reagent for inhibiting the expression of disease related
genes
JOURNAL Patent: EP 1260586-A 1871 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
source
Location/Qualifiers
1..17
/organism="unidentified"
/mol_type="mRNA"
/db_xref="taxon:32644"
BASE COUNT 6 a 1 c 1 g 9 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1050 ATGTATTATTATTAAAGCA 1066
Db 1 ATGTATTATTATTAAAGCA 17

RESULT 760
AX634825
LOCUS AX634825 17 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 1964 from Patent EP1260586.
ACCESSION AX634825
VERSION AX634825.1 GI:28470439
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Stinchcomb, D.T., Dudycz, L.W., Chowrira, B., Grimm, S., Drenzo, A.,
Karpeisky, A., Draper, K.G., Kisich, K., Matulic-Adamic, J.,
McSwiggen, J.A., Modak, A., Pavco, P., Beigelman, L., Sullivan, S.M.,
Sweedler, D., Thompson, J.D., Tracz, D., Usman, N., Wincott, F.E. and
Woolf, T.
TITLE Method and reagent for inhibiting the expression of disease related
genes
JOURNAL Patent: EP 1260586-A 1964 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
source
Location/Qualifiers
1..17
/organism="unidentified"
/mol_type="mRNA"
/db_xref="taxon:32644"
BASE COUNT 6 a 1 c 1 g 9 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1050 ATGTATTATTATTAAAGCA 1066
Db 1 ATGTATTATTATTAAAGCA 17

```

```

RESULT 761
AX634861
LOCUS AX634861 17 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 2000 from Patent EP1260586.
ACCESSION AX634861
VERSION AX634861.1 GI:28470475
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
SOURCE
BASE COUNT 4 a 4 c 4 g 5 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 977 TGGAGCCTTTAAGTT 993
Db 1 TGGAGCCTTTAAGCT 17

RESULT 762
AX634864
LOCUS AX634864 17 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 2003 from Patent EP1260586.
ACCESSION AX634864
VERSION AX634864.1 GI:28470478
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
SOURCE
BASE COUNT 4 a 4 c 4 g 5 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 977 TGGAGCCTTTAAGTT 993
Db 1 TGGAGCCTTTAAGCT 17

RESULT 763
AX648466/c
LOCUS AX648466/c 17 bp DNA linear PAT 22-MAR-2003
DEFINITION Sequence 306 from Patent EP1273660.
ACCESSION AX648466
VERSION AX648466.1 GI:29151284
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
SOURCE
BASE COUNT 6 a 1 c 5 g 5 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1418 CCACAGTCATATTTAGT 1434
Db 17 CCACCTTTCATATTCAGT 1

RESULT 764
AX648467/c
LOCUS AX648467/c 17 bp DNA linear PAT 22-MAR-2003
DEFINITION Sequence 307 from Patent EP1273660.
ACCESSION AX648467
VERSION AX648467.1 GI:29151285
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
SOURCE
BASE COUNT 6 a 1 c 5 g 5 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1417 TCCACAGTCATATTTAGT 1433
Db 17 TCCACTTTCATATTCAGT 1

RESULT 765
AX648579/c
LOCUS AX648579/c 17 bp DNA linear PAT 22-MAR-2003
DEFINITION Sequence 419 from Patent EP1273660.
ACCESSION AX648579
VERSION AX648579.1 GI:29151397
KEYWORDS
SOURCE

```

```

RESULT 763
AX648466/c
LOCUS AX648466/c 17 bp DNA linear PAT 22-MAR-2003
DEFINITION Sequence 306 from Patent EP1273660.
ACCESSION AX648466
VERSION AX648466.1 GI:29151284
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
SOURCE
BASE COUNT 6 a 1 c 5 g 5 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1418 CCACAGTCATATTTAGT 1434
Db 17 CCACCTTTCATATTCAGT 1

RESULT 764
AX648467/c
LOCUS AX648467/c 17 bp DNA linear PAT 22-MAR-2003
DEFINITION Sequence 307 from Patent EP1273660.
ACCESSION AX648467
VERSION AX648467.1 GI:29151285
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
SOURCE
BASE COUNT 6 a 1 c 5 g 5 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1417 TCCACAGTCATATTTAGT 1433
Db 17 TCCACTTTCATATTCAGT 1

RESULT 765
AX648579/c
LOCUS AX648579/c 17 bp DNA linear PAT 22-MAR-2003
DEFINITION Sequence 419 from Patent EP1273660.
ACCESSION AX648579
VERSION AX648579.1 GI:29151397
KEYWORDS
SOURCE

```

[illegible]


```

Query Match          1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1203 GATTAAACAACAACA 1219
Db 1 GATCAACAAGCAAGCA 17

RESULT 770
AX671657
LOCUS AX671657 17 bp DNA linear PAT 27-MAR-2003
DEFINITION Sequence 102 from Patent WO03004526.
ACCESSION AX671657
VERSION AX671657.1 GI:29330005
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines
JOURNAL Patent: WO 03004526-A 102 16-JAN-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1..17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 6 a 3 c 2 g 6 t

Query Match          1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 519 GGTAAATTTGAATTC 535
Db 1 GATCAATTTGAATTC 17

RESULT 771
AX672578
LOCUS AX672578 17 bp DNA linear PAT 27-MAR-2003
DEFINITION Sequence 1023 from Patent WO03004526.
ACCESSION AX672578
VERSION AX672578.1 GI:29330926
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines
JOURNAL Patent: WO 03004526-A 1023 16-JAN-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1..17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 5 a 6 c 2 g 4 t

Query Match          1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```

```

Qy 874 GATCCACAAGTCTCTGT 890
Db 1 GATCCACAAGTCTCTCT 17

RESULT 772
AX672799/c
LOCUS AX672799 17 bp DNA linear PAT 27-MAR-2003
DEFINITION Sequence 1244 from Patent WO03004526.
ACCESSION AX672799
VERSION AX672799.1 GI:29331147
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines
JOURNAL Patent: WO 03004526-A 1244 16-JAN-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1..17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 4 a 2 c 2 g 9 t

Query Match          1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1596 AAAAGTAATATCAAC 1612
Db 17 AAAAGTAATATCAATC 1

RESULT 773
AX672898
LOCUS AX672898 17 bp DNA linear PAT 27-MAR-2003
DEFINITION Sequence 1343 from Patent WO03004526.
ACCESSION AX672898
VERSION AX672898.1 GI:29331246
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines
JOURNAL Patent: WO 03004526-A 1343 16-JAN-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1..17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 2 a 4 c 3 g 8 t

Query Match          1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 874 GATCCACAAGTCTCTGT 890
Db 1 GATCCATTTGCTCTGT 17

```

RESULT 774
AX673031
LOCUS AX673031 17 bp DNA linear PAT 27-MAR-2003
DEFINITION Sequence 1476 from Patent WO03004526.
ACCESSION AX673031
VERSION AX673031.1 GI:293331379
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Telerman,A., Amson,R. and Tuijinder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines
JOURNAL Patent: WO 03004526-A 1476 16-JAN-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 5 a 5 c 2 g 5 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1224 GGTACCCAGTCAATT 1240
Db 1 GATCCCGAGTCAATT 17
RESULT 775
AX673430/c
LOCUS AX673430 17 bp DNA linear PAT 27-MAR-2003
DEFINITION Sequence 1875 from Patent WO03004526.
ACCESSION AX673430
VERSION AX673430.1 GI:293331778
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Telerman,A., Amson,R. and Tuijinder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines
JOURNAL Patent: WO 03004526-A 1875 16-JAN-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 3 a 7 c 3 g 4 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 861 GTCGTGACCGAGGATC 877
Db 17 GTCGTGAGCGGAGGATC 1
RESULT 776
AX674727
LOCUS AX674727 17 bp DNA linear PAT 27-MAR-2003
DEFINITION Sequence 3172 from Patent WO03004526.
ACCESSION AX674727

VERSION AX674727.1 GI:29333075
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Telerman,A., Amson,R. and Tuijinder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines
JOURNAL Patent: WO 03004526-A 3172 16-JAN-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 5 a 3 c 2 g 7 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 717 GAACCTTAATTCAGGA 733
Db 1 GATCTTTAATCTCATGA 17
RESULT 777
AX674800
LOCUS AX674800 17 bp DNA linear PAT 27-MAR-2003
DEFINITION Sequence 3245 from Patent WO03004526.
ACCESSION AX674800
VERSION AX674800.1 GI:293331148
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Telerman,A., Amson,R. and Tuijinder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines
JOURNAL Patent: WO 03004526-A 3245 16-JAN-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 6 a 1 c 1 g 9 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 831 GATTTTTCGTTAAA 847
Db 1 GATCTTTTATATATAA 17
RESULT 778
AX687406/c
LOCUS AX687406 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 138 from Patent EP1281758.
ACCESSION AX687406
VERSION AX687406.1 GI:29410100
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

REFERENCE 1
AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12
JOURNAL Patent: EP 1281758-A 138 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES source
Location/Qualifiers 1..17
1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
BASE COUNT 7 a 4 c 3 g 3 t

Qy 975 TGTGGAGCCTTTAAG 991
|||||
Db 17 TCTGGAGCCTTTAAG 1

RESULT 779
AX687451
LOCUS AX687451 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 183 from Patent EP1281758.
ACCESSION AX687451
VERSION AX687451.1 GI:29410145
KEYWORDS Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12
JOURNAL Patent: EP 1281758-A 183 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES source
Location/Qualifiers 1..17
1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
BASE COUNT 3 a 2 c 6 g 6 t

Qy 1360 GGTAGTCTGTGTGAA 1376
|||||
Db 1 GGTATTCCTGTGTGAA 17

RESULT 780
AX691337
LOCUS AX691337 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 4069 from Patent EP1281758.
ACCESSION AX691337
VERSION AX691337.1 GI:29414273
KEYWORDS Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12
JOURNAL Patent: EP 1281758-A 4069 05-FEB-2003;
Aeomica, Inc. (US)

FEATURES source
Location/Qualifiers 1..17
1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
BASE COUNT 7 a 2 c 3 g 5 t

Qy 1060 TTAAGCATCAATATTT 1076
|||||
Db 1 TTAAGCATCAAGATT 17

RESULT 781
AX692522/c
LOCUS AX692522 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 5254 from Patent EP1281758.
ACCESSION AX692522
VERSION AX692522.1 GI:29415480
KEYWORDS Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12
JOURNAL Patent: EP 1281758-A 5254 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES source
Location/Qualifiers 1..17
1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
BASE COUNT 1 a 1 c 0 g 15 t

Qy 618 AAAAAACAACAATAAT 634
|||||
Db 17 AAAAAAAGAGAAAT 1

RESULT 782
AX692526/c
LOCUS AX692526 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 5258 from Patent EP1281758.
ACCESSION AX692526
VERSION AX692526.1 GI:29415484
KEYWORDS Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12
JOURNAL Patent: EP 1281758-A 5258 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES source
Location/Qualifiers 1..17
1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
BASE COUNT 0 a 0 c 1 g 16 t

Thu Dec 18 07:29:18 2003

```
Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 617 CAATAAACAACAATAA 633
Db 17 CAATAAACAACAATAA 1

RESULT 783
AX722376/c
LOCUS AX722376 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 63 from Patent WO03025176.
ACCESSION AX722376
VERSION AX722376.1 GI:30422877
KEYWORDS Mus musculus (house mouse)
SOURCE Mus musculus
ORGANISM Mus musculus
REFERENCE 1
AUTHORS Telerman,A., Anson,R. and Tuijinder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025176-A 63 27-MAR-2003;
FEATURES Molecular Engines Laboratories (FR)
source Location/Qualifiers
1..17
/organism="Mus musculus"
/mol_type="genomic DNA"
/db_xref="taxon:10090"
BASE COUNT 5 a 1 c 6 g 5 t

Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1328 ATACTCCAGTCCTGTGTC 1344
Db 17 ATACTCCAGTCGTGATC 1

RESULT 784
AX722391/c
LOCUS AX722391 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 78 from Patent WO03025176.
ACCESSION AX722391
VERSION AX722391.1 GI:30422892
KEYWORDS Mus musculus (house mouse)
SOURCE Mus musculus
ORGANISM Mus musculus
REFERENCE 1
AUTHORS Telerman,A., Anson,R. and Tuijinder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025176-A 78 27-MAR-2003;
FEATURES Molecular Engines Laboratories (FR)
source Location/Qualifiers
1..17
/organism="Mus musculus"
/mol_type="genomic DNA"
/db_xref="taxon:10090"
BASE COUNT 4 a 3 c 3 g 7 t

Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 831 GATTTTTCGCTGATAA 847
```

```
Db 1 GATCTGTTTCGCTAAA 17

RESULT 785
AX723177/c
LOCUS AX723177 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 864 from Patent WO03025176.
ACCESSION AX723177
VERSION AX723177.1 GI:30423678
KEYWORDS Mus musculus (house mouse)
SOURCE Mus musculus
ORGANISM Mus musculus
REFERENCE 1
AUTHORS Telerman,A., Anson,R. and Tuijinder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025176-A 864 27-MAR-2003;
FEATURES Molecular Engines Laboratories (FR)
source Location/Qualifiers
1..17
/organism="Mus musculus"
/mol_type="genomic DNA"
/db_xref="taxon:10090"
BASE COUNT 4 a 7 c 3 g 3 t

Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 405 TGTGGTATCCAGGATC 421
Db 17 TGTGGGCTCCAAGGATC 1

RESULT 786
AX723495/c
LOCUS AX723495 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 1182 from Patent WO03025176.
ACCESSION AX723495
VERSION AX723495.1 GI:30423996
KEYWORDS Mus musculus (house mouse)
SOURCE Mus musculus
ORGANISM Mus musculus
REFERENCE 1
AUTHORS Telerman,A., Anson,R. and Tuijinder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025176-A 1182 27-MAR-2003;
FEATURES Molecular Engines Laboratories (FR)
source Location/Qualifiers
1..17
/organism="Mus musculus"
/mol_type="genomic DNA"
/db_xref="taxon:10090"
BASE COUNT 4 a 5 c 3 g 5 t

Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 425 GAAGATGCCAGTGAAC 441
Db 17 GAAGATGCCATTGGATC 1

RESULT 787
```

```

AX723876/c
LOCUS       AX723876               17 bp    DNA          linear          PAT 08-MAY-2003
DEFINITION   Sequence 1563 from Patent WO03025176.
ACCESSION   AX723876
VERSION     AX723876.1 GI:30503219
KEYWORDS
SOURCE      Mus musculus (house mouse)
ORGANISM    Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE   1
AUTHORS     Telerman,A., Amson,R. and Tuijinder,M.
TITLE       Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
JOURNAL     Patent: WO 03025176-A 1563 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES
source      1..17
            /organism="Mus musculus"
            /mol_type="genomic DNA"
            /db_xref="taxon:10090"
BASE COUNT  11 a          3 g          2 t
            Query Match      1.0%; Score 12.2; DB 1; Length 17;
            Best Local Similarity 82.4%; Pred. No. 5.8e+02;
            Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      833 TTTTTCCTGTTAAATC 849
Db      17 TTTTTCCTTCAGATC 1

RESULT 788
AX724563
LOCUS       AX724563               17 bp    DNA          linear          PAT 08-MAY-2003
DEFINITION   Sequence 2250 from Patent WO03025176.
ACCESSION   AX724563
VERSION     AX724563.1 GI:30503906
KEYWORDS
SOURCE      Mus musculus (house mouse)
ORGANISM    Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE   1
AUTHORS     Telerman,A., Amson,R. and Tuijinder,M.
TITLE       Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
JOURNAL     Patent: WO 03025176-A 2250 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES
source      1..17
            /organism="Mus musculus"
            /mol_type="genomic DNA"
            /db_xref="taxon:10090"
BASE COUNT  4 a          3 g          5 t
            Query Match      1.0%; Score 12.2; DB 1; Length 17;
            Best Local Similarity 82.4%; Pred. No. 5.8e+02;
            Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      874 GATCCAGACGCTCTGT 890
Db      1 GATCCAGACGCTCTGT 17

RESULT 789
AX726475/c
LOCUS       AX726475               17 bp    DNA          linear          PAT 08-MAY-2003
DEFINITION   Sequence 4162 from Patent WO03025176.
ACCESSION   AX726475
VERSION     AX726475.1 GI:30505818

```

```

KEYWORDS
SOURCE      Mus musculus (house mouse)
ORGANISM    Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE   1
AUTHORS     Telerman,A., Amson,R. and Tuijinder,M.
TITLE       Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
JOURNAL     Patent: WO 03025176-A 4162 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES
source      1..17
            /organism="Mus musculus"
            /mol_type="genomic DNA"
            /db_xref="taxon:10090"
BASE COUNT  5 a          3 g          4 t
            Query Match      1.0%; Score 12.2; DB 1; Length 17;
            Best Local Similarity 82.4%; Pred. No. 5.8e+02;
            Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      405 TGTGGTATCCAGATC 421
Db      17 TGTGGATCCAGGATC 1

RESULT 790
AX726611/c
LOCUS       AX726611               17 bp    DNA          linear          PAT 08-MAY-2003
DEFINITION   Sequence 4298 from Patent WO03025176.
ACCESSION   AX726611
VERSION     AX726611.1 GI:30505954
KEYWORDS
SOURCE      Mus musculus (house mouse)
ORGANISM    Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE   1
AUTHORS     Telerman,A., Amson,R. and Tuijinder,M.
TITLE       Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
JOURNAL     Patent: WO 03025176-A 4298 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES
source      1..17
            /organism="Mus musculus"
            /mol_type="genomic DNA"
            /db_xref="taxon:10090"
BASE COUNT  10 a          3 c          1 g          3 t
            Query Match      1.0%; Score 12.2; DB 1; Length 17;
            Best Local Similarity 82.4%; Pred. No. 5.8e+02;
            Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      1052 GTATTATTATGATC 1068
Db      17 GTTTTATTTAGGATC 1

RESULT 791
AX726698
LOCUS       AX726698               17 bp    DNA          linear          PAT 08-MAY-2003
DEFINITION   Sequence 4385 from Patent WO03025176.
ACCESSION   AX726698
VERSION     AX726698.1 GI:30506041
KEYWORDS
SOURCE      Mus musculus (house mouse)
ORGANISM    Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

```

```

REFERENCE
AUTHORS      1
TITLE        Telerman,A., Anson,R. and Tuijnder,M.
JOURNAL      Sequences involved in phenomena of tumour suppression, tumour
FEATURES     reversion, apoptosis and/or virus resistance and their use as
              medicines
              Patent: WO 03025176-A 4385 27-MAR-2003;
              Molecular Engines Laboratories (FR)
              Location/Qualifiers
              1..17
              /organism="Mus musculus"
              /mol_type="genomic DNA"
              /db_xref="taxon:10090"
BASE COUNT   2 a      3 g      9 t
              1..17
              Query Match      1.0%; Score 12.2; DB 1; Length 17;
              Best Local Similarity 82.4%; Pred. No. 5.8e+02;
              Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1540 GATGTTTATGTCGTC 1556
Db 1 GATCTTTATGTCGTC 17

RESULT 792
AX727922/c
LOCUS      AX727922      17 bp      DNA      linear      PAT 08-MAY-2003
DEFINITION Sequence 5609 from Patent WO03025176.
ACCESSION AX727922
VERSION   AX727922.1 GI:30507265
KEYWORDS  Mus musculus (house mouse)
SOURCE    Mus musculus
ORGANISM  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
          Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE
AUTHORS      1
TITLE        Telerman,A., Anson,R. and Tuijnder,M.
JOURNAL      Sequences involved in phenomena of tumour suppression, tumour
FEATURES     reversion, apoptosis and/or virus resistance and their use as
              medicines
              Patent: WO 03025176-A 5609 27-MAR-2003;
              Molecular Engines Laboratories (FR)
              Location/Qualifiers
              1..17
              /organism="Mus musculus"
              /mol_type="genomic DNA"
              /db_xref="taxon:10090"
BASE COUNT   6 a      4 c      3 g      4 t
              1..17
              Query Match      1.0%; Score 12.2; DB 1; Length 17;
              Best Local Similarity 82.4%; Pred. No. 5.8e+02;
              Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 861 GTCTGTAGCAGGATC 877
Db 17 GTCTGTATACAGGATC 1

RESULT 793
AX728060/c
LOCUS      AX728060      17 bp      DNA      linear      PAT 08-MAY-2003
DEFINITION Sequence 5747 from Patent WO03025176.
ACCESSION AX728060
VERSION   AX728060.1 GI:30507403
KEYWORDS  Mus musculus (house mouse)
SOURCE    Mus musculus
ORGANISM  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
          Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE
AUTHORS      1
TITLE        Telerman,A., Anson,R. and Tuijnder,M.
JOURNAL      Sequences involved in phenomena of tumour suppression, tumour
FEATURES     reversion, apoptosis and/or virus resistance and their use as
              medicines

```

```

JOURNAL      Patent: WO 03025176-A 5747 27-MAR-2003;
FEATURES     Molecular Engines Laboratories (FR)
              Location/Qualifiers
              1..17
              /organism="Mus musculus"
              /mol_type="genomic DNA"
              /db_xref="taxon:10090"
BASE COUNT   5 a      1 c      1 g      10 t
              1..17
              Query Match      1.0%; Score 12.2; DB 1; Length 17;
              Best Local Similarity 82.4%; Pred. No. 5.8e+02;
              Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1475 GATCTTTATGTCGTC 1491
Db 1 GATCTTTATGTCGTC 17

RESULT 794
AX728122/c
LOCUS      AX728122      17 bp      DNA      linear      PAT 08-MAY-2003
DEFINITION Sequence 5809 from Patent WO03025176.
ACCESSION AX728122
VERSION   AX728122.1 GI:30507465
KEYWORDS  Mus musculus (house mouse)
SOURCE    Mus musculus
ORGANISM  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
          Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE
AUTHORS      1
TITLE        Telerman,A., Anson,R. and Tuijnder,M.
JOURNAL      Sequences involved in phenomena of tumour suppression, tumour
FEATURES     reversion, apoptosis and/or virus resistance and their use as
              medicines
              Patent: WO 03025176-A 5809 27-MAR-2003;
              Molecular Engines Laboratories (FR)
              Location/Qualifiers
              1..17
              /organism="Mus musculus"
              /mol_type="genomic DNA"
              /db_xref="taxon:10090"
BASE COUNT   4 a      2 c      2 g      9 t
              1..17
              Query Match      1.0%; Score 12.2; DB 1; Length 17;
              Best Local Similarity 82.4%; Pred. No. 5.8e+02;
              Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1596 AAAGTAAATATGGAAC 1612
Db 17 AAAGTAAATATGGAAC 1

RESULT 795
AX728315/c
LOCUS      AX728315      17 bp      DNA      linear      PAT 08-MAY-2003
DEFINITION Sequence 6002 from Patent WO03025176.
ACCESSION AX728315
VERSION   AX728315.1 GI:30507658
KEYWORDS  Mus musculus (house mouse)
SOURCE    Mus musculus
ORGANISM  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
          Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE
AUTHORS      1
TITLE        Telerman,A., Anson,R. and Tuijnder,M.
JOURNAL      Sequences involved in phenomena of tumour suppression, tumour
FEATURES     reversion, apoptosis and/or virus resistance and their use as
              medicines
              Patent: WO 03025176-A 6002 27-MAR-2003;
              Molecular Engines Laboratories (FR)
              Location/Qualifiers
              1..17
              /organism="Mus musculus"

```

```

Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1203 GATTAAACAAACAAACA 1219
|||||
Db 1 GATCAAGAACCAAAA 17

RESULT 798
AX728945/c 17 bp DNA linear PAT 08-MAY-2003
LOCUS
DEFINITION Sequence 579 from Patent WO03025175.
ACCESSION AX728945
VERSION AX728945.1 GI:30508288
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025175-A 579 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
location/Qualifiers
1..17
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 5 a 4 c 4 g 4 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 861 GTCTGCTGCCAGGATC 877
|||||
Db 17 GCTTCAGTCAGGATC 1

RESULT 799
AX730965/c 17 bp DNA linear PAT 08-MAY-2003
LOCUS
DEFINITION Sequence 2599 from Patent WO03025175.
ACCESSION AX730965
VERSION AX730965.1 GI:30510308
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025175-A 2599 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
location/Qualifiers
1..17
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 4 a 5 c 2 g 6 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1382 GAATATGAGTTAGAAC 1398
|||||

```

```

/mol_type="genomic DNA"
/db_xref="taxon:10090"
BASE COUNT 9 a 6 c 1 g 1 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1203 GATTAAACAAACAAACA 1219
|||||
Db 1 GATCAACAAACCAACA 17

RESULT 796
AX728823 17 bp DNA linear PAT 08-MAY-2003
LOCUS
DEFINITION Sequence 457 from Patent WO03025175.
ACCESSION AX728823
VERSION AX728823.1 GI:30508166
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025175-A 457 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
location/Qualifiers
1..17
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 9 a 5 c 2 g 1 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1203 GATTAAACAAACAAACA 1219
|||||
Db 1 GATCAACAAACCAACA 17

RESULT 797
AX728846 17 bp DNA linear PAT 08-MAY-2003
LOCUS
DEFINITION Sequence 480 from Patent WO03025175.
ACCESSION AX728846
VERSION AX728846.1 GI:30508189
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025175-A 480 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
location/Qualifiers
1..17
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 12 a 2 c 2 g 1 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;

```

```

Db      17 GAATACTAGGAGTAGATC 1
RESULT 800
AX731415
LOCUS      AX731415      17 bp      DNA
DEFINITION Sequence 3049 from Patent WO03025175.
ACCESSION AX731415
VERSION    AX731415.1 GI:30510758
KEYWORDS
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS    Telerman,A., Anson,R. and Tuijinder,M.
TITLE      Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
JOURNAL    Patent: WO 03025175-A 3049 27-MAR-2003;
FEATURES   Molecular Engines Laboratories (FR)
            source
            1. .17
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"
BASE COUNT      6 a      1 c      3 g      7 t
Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1129 GATGTTATAGTAATTT 1145
Db      1 GATCTTGTAGAAATTT 17

RESULT 801
AX732425
LOCUS      AX732425      17 bp      DNA
DEFINITION Sequence 4059 from Patent WO03025175.
ACCESSION AX732425
VERSION    AX732425.1 GI:30511768
KEYWORDS
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS    Telerman,A., Anson,R. and Tuijinder,M.
TITLE      Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
JOURNAL    Patent: WO 03025175-A 4059 27-MAR-2003;
FEATURES   Molecular Engines Laboratories (FR)
            source
            1. .17
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"
BASE COUNT      11 a      3 c      1 g      2 t
Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1203 GATTAACAACAACA 1219
Db      1 GATCAAAATTAACAACA 17

RESULT 802
AX733105/c
LOCUS      AX733105      17 bp      DNA
DEFINITION Sequence 4739 from Patent WO03025175.
ACCESSION AX733105
VERSION    AX733105.1 GI:30512448
KEYWORDS
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS    Telerman,A., Anson,R. and Tuijinder,M.
TITLE      Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
JOURNAL    Patent: WO 03025175-A 4739 27-MAR-2003;
FEATURES   Molecular Engines Laboratories (FR)
            source
            1. .17
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"
BASE COUNT      8 a      4 c      1 g      4 t
Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1052 GTATTATTAGGATC 1068
Db      17 GTATTATTAGGATC 1

RESULT 803
AX733543
LOCUS      AX733543      17 bp      DNA
DEFINITION Sequence 5177 from Patent WO03025175.
ACCESSION AX733543
VERSION    AX733543.1 GI:30512886
KEYWORDS
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS    Telerman,A., Anson,R. and Tuijinder,M.
TITLE      Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
JOURNAL    Patent: WO 03025175-A 5177 27-MAR-2003;
FEATURES   Molecular Engines Laboratories (FR)
            source
            1. .17
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"
BASE COUNT      6 a      3 c      2 g      6 t
Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      519 GGTAAATTTGAATTC 535
Db      1 GATCAAAATTTGAATTC 17

RESULT 804
AX735047
LOCUS      AX735047      17 bp      DNA
DEFINITION Sequence 637 from Patent WO03025177.
ACCESSION AX735047
VERSION    AX735047.1 GI:30514324
KEYWORDS

```


SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
 AUTHORS Telerman, A., Amson, R. and Tuijinder, M.
 TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments
 JOURNAL Patent: WO 03025177-A 637 27-MAR-2003;
 Moлекулярные Инженерные Лаборатории (FR)

FEATURES source
 1..17
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"
 6 a 2 c 2 g 7 t

BASE COUNT
 Query Match 1.0%; Score 12.2; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 5.8e+02;
 Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1457 GTTATTATGTCACAAAT 1473
 Db 1 GATCATATGTCACATAT 17

RESULT 805
 AX735909/c
 LOCUS AX735909 17 bp DNA linear PAT 08-MAY-2003
 DEFINITION Sequence 1499 from Patent WO03025177.
 ACCESSION AX735909
 VERSION AX735909.1 GI:30515186
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
 AUTHORS Telerman, A., Amson, R. and Tuijinder, M.
 TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments
 JOURNAL Patent: WO 03025177-A 1499 27-MAR-2003;
 Moлекулярные Инженерные Лаборатории (FR)

FEATURES source
 1..17
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"
 8 a 3 c 2 g 4 t

BASE COUNT
 Query Match 1.0%; Score 12.2; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 5.8e+02;
 Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 598 TATTATTATTGATGC 614
 Db 17 TATTATTATTGGGATC 1

RESULT 806
 AX735978/c
 LOCUS AX735978 17 bp DNA linear PAT 08-MAY-2003
 DEFINITION Sequence 1568 from Patent WO03025177.
 ACCESSION AX735978
 VERSION AX735978.1 GI:30515255
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1

AUTHORS Telerman, A., Amson, R. and Tuijinder, M.
 TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments
 JOURNAL Patent: WO 03025177-A 1568 27-MAR-2003;
 Moлекулярные Инженерные Лаборатории (FR)

FEATURES source
 1..17
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"
 7 a 2 c 3 g 5 t

BASE COUNT
 Query Match 1.0%; Score 12.2; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 5.8e+02;
 Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1239 TTTCATTTTCAGATAAAC 1255
 Db 17 TTTCATTTTCAGAGAATC 1

RESULT 807
 AX736175/c
 LOCUS AX736175 17 bp DNA linear PAT 08-MAY-2003
 DEFINITION Sequence 1765 from Patent WO03025177.
 ACCESSION AX736175
 VERSION AX736175.1 GI:30515452
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
 AUTHORS Telerman, A., Amson, R. and Tuijinder, M.
 TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments
 JOURNAL Patent: WO 03025177-A 1765 27-MAR-2003;
 Moлекулярные Инженерные Лаборатории (FR)

FEATURES source
 1..17
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"
 5 a 4 c 2 g 6 t

BASE COUNT
 Query Match 1.0%; Score 12.2; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 5.8e+02;
 Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 559 TTGTACCATGAAATATC 575
 Db 17 TTGTACCATGGAAGATC 1

RESULT 808
 AX736626/c
 LOCUS AX736626 17 bp DNA linear PAT 08-MAY-2003
 DEFINITION Sequence 2216 from Patent WO03025177.
 ACCESSION AX736626
 VERSION AX736626.1 GI:30515914
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
 AUTHORS Telerman, A., Amson, R. and Tuijinder, M.
 TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments
 JOURNAL Patent: WO 03025177-A 2216 27-MAR-2003;

```
FEATURES
  source
    Molecular Engines Laboratories (FR)
      Location/Qualifiers
        1..17
          /organism="Homo sapiens"
          /mol_type="genomic DNA"
          /db_xref="taxon:9606"
BASE COUNT      5 a      1 c      1 g      10 t
Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1475 GATCTTTAATATAT 1491
Db 1 GATCTTTAATATAT 17

RESULT 809
AX737074/c
LOCUS      AX737074      17 bp      DNA      linear      PAT 08-MAY-2003
DEFINITION Sequence 2664 from Patent WO03025177.
ACCESSION  AX737074
VERSION     AX737074.1 GI:30516362
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
REFERENCE
  AUTHORS    Telerman,A., Amson,R. and Tuijnder,M.
  TITLE      Sequences involved in phenomena of tumour suppression, tumour
             reversion, apoptosis and/or resistance to viruses and the use
             thereof as medicaments
  JOURNAL    Patent: WO 03025177-A 2664 27-MAR-2003;
             Molecular Engines Laboratories (FR)
FEATURES
  source
    1..17
      /organism="Homo sapiens"
      /mol_type="genomic DNA"
      /db_xref="taxon:9606"
BASE COUNT      8 a      4 c      1 g      4 t
Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1052 GTATTATTATGATC 1068
Db 17 GTATTATTATGATC 1

RESULT 810
AX738139/c
LOCUS      AX738139      17 bp      DNA      linear      PAT 08-MAY-2003
DEFINITION Sequence 3729 from Patent WO03025177.
ACCESSION  AX738139
VERSION     AX738139.1 GI:30517427
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
REFERENCE
  AUTHORS    Telerman,A., Amson,R. and Tuijnder,M.
  TITLE      Sequences involved in phenomena of tumour suppression, tumour
             reversion, apoptosis and/or resistance to viruses and the use
             thereof as medicaments
  JOURNAL    Patent: WO 03025177-A 3729 27-MAR-2003;
             Molecular Engines Laboratories (FR)
FEATURES
  source
    1..17
      /organism="Homo sapiens"
      /mol_type="genomic DNA"
      /db_xref="taxon:9606"
BASE COUNT      8 a      2 c      1 g      6 t
Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1052 GTATTATTATGATC 1068
Db 17 GTATTATTATGATC 1

RESULT 811
AX738829
LOCUS      AX738829      17 bp      DNA      linear      PAT 08-MAY-2003
DEFINITION Sequence 4419 from Patent WO03025177.
ACCESSION  AX738829
VERSION     AX738829.1 GI:30518119
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
REFERENCE
  AUTHORS    Telerman,A., Amson,R. and Tuijnder,M.
  TITLE      Sequences involved in phenomena of tumour suppression, tumour
             reversion, apoptosis and/or resistance to viruses and the use
             thereof as medicaments
  JOURNAL    Patent: WO 03025177-A 4419 27-MAR-2003;
             Molecular Engines Laboratories (FR)
FEATURES
  source
    1..17
      /organism="Homo sapiens"
      /mol_type="genomic DNA"
      /db_xref="taxon:9606"
BASE COUNT      4 a      5 c      3 g      5 t
Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 874 GATCCACAGTCCTTGT 890
Db 1 GATCCACAGTCCTTGT 17

RESULT 812
AX738984/c
LOCUS      AX738984      17 bp      DNA      linear      PAT 08-MAY-2003
DEFINITION Sequence 4574 from Patent WO03025177.
ACCESSION  AX738984
VERSION     AX738984.1 GI:30518274
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
REFERENCE
  AUTHORS    Telerman,A., Amson,R. and Tuijnder,M.
  TITLE      Sequences involved in phenomena of tumour suppression, tumour
             reversion, apoptosis and/or resistance to viruses and the use
             thereof as medicaments
  JOURNAL    Patent: WO 03025177-A 4574 27-MAR-2003;
             Molecular Engines Laboratories (FR)
FEATURES
  source
    1..17
      /organism="Homo sapiens"
      /mol_type="genomic DNA"
      /db_xref="taxon:9606"
BASE COUNT      7 a      2 c      4 g      4 t
Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 874 GATCCACAGTCCTTGT 890
Db 1 GATCCACAGTCCTTGT 17
```

Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1278 GTACATTTTGTTCATC 1294
 |||||
 DB 17 GTACATCATCTTGATC 1

RESULT 813
 AX744141

LOCUS AX744141 17 bp DNA linear PAT 14-MAY-2003
 DEFINITION Sequence 106 from Patent WO03031621.
 ACCESSION AX744141
 VERSION AX744141.1 GI:30722808
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
 AUTHORS Zhang, J.
 TITLE A human G protein coupled receptor
 JOURNAL Patent: WO 03031621-A 106 17-APR-2003;
 Amersham Biosciences (SV) Corp. (US)
 FEATURES Location/Qualifiers
 source
 1..17
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"

BASE COUNT 4 a 3 c 4 g 6 t

Query Match 1.0%; Score 12.2; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 5.8e+02;
 Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1513 TACAGGCTTATATT 1529
 |||||
 DB 1 TACAGGCTGTCATT 17

RESULT 814
 AX745054

LOCUS AX745054 17 bp DNA linear PAT 15-MAY-2003
 DEFINITION Sequence 1019 from Patent WO03031621.
 ACCESSION AX745054
 VERSION AX745054.1 GI:30723721
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
 AUTHORS Zhang, J.
 TITLE A human G protein coupled receptor
 JOURNAL Patent: WO 03031621-A 1019 17-APR-2003;
 Amersham Biosciences (SV) Corp. (US)
 FEATURES Location/Qualifiers
 source
 1..17
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"

BASE COUNT 9 a 1 c 1 g 6 t

Query Match 1.0%; Score 12.2; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 5.8e+02;
 Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 630 ATAATTTTGAATATA 646
 |||||
 DB 1 AAAATTTTGAATCAAA 17

RESULT 815
 AX745056

LOCUS AX745056 17 bp DNA linear PAT 14-MAY-2003
 DEFINITION Sequence 1021 from Patent WO03031621.
 ACCESSION AX745056
 VERSION AX745056.1 GI:30723723
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
 AUTHORS Zhang, J.
 TITLE A human G protein coupled receptor
 JOURNAL Patent: WO 03031621-A 1021 17-APR-2003;
 Amersham Biosciences (SV) Corp. (US)
 FEATURES Location/Qualifiers
 source
 1..17
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"

BASE COUNT 8 a 1 c 2 g 6 t

Query Match 1.0%; Score 12.2; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 5.8e+02;
 Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 632 AAATTTTGAATATAAGG 648
 |||||
 DB 1 AAATTTTGAATCAAAAG 17

RESULT 816
 BD065996/c

LOCUS BD065996 17 bp DNA linear PAT 27-AUG-2002
 DEFINITION An antisense oligonucleotide preparation method.
 ACCESSION BD065996
 VERSION BD065996.1 GI:22611599
 KEYWORDS
 SOURCE unidentified
 ORGANISM unclassified.

REFERENCE 1 (bases 1 to 17)
 AUTHORS Schlingensiefen, K.H. and Brysch, W.
 TITLE An antisense oligonucleotide preparation method
 JOURNAL Patent: JP 2001511000-A 631 07-AUG-2001;
 BIOGNOSTIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH

COMMENT OS Unknown
 PN JP 2001511000-A/631
 PD 07-AUG-2001
 PF 30-JAN-1998 JP 1998532533
 PR 31-JAN-1997 EP 97101531.8
 PI KARL HERMANN SCHLINGENSIEFEN, WOLFGANG BRYSCH
 PC C12N15/11.C07H21/04.A61K31/70
 CC An antisense oligonucleotide preparation method FH Key
 FT source 1..17
 /organism="Unknown".
 FEATURES Location/Qualifiers
 source
 1..17
 /organism="unidentified"
 /mol_type="genomic DNA"
 /db_xref="taxon:32644"

BASE COUNT 4 a 3 c 5 g 5 t

Query Match 1.0%; Score 12.2; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 5.8e+02;
 Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 639 GAATATAAGGATTTCC 655
 |||||
 DB 17 GCATACAGGATCTTCC 1

RESULT 817

```

BD067425/c
LOCUS      BD067425          17 bp    RNA    linear    PAT 27-AUG-2002
DEFINITION Enzymatic nucleic acid treatment of diseases or conditions related
            to levels of epidermal growth factor receptors.
ACCESSION  BD067425
VERSION    JP 2001511003-A/265.
KEYWORDS   unidentifed
SOURCE     unidentifed
ORGANISM   unclassified.
REFERENCE  1. (bases 1 to 17)
AUTHORS    Akhtar,S., Fell,P. and Mcswiggen,J.A.
TITLE      Enzymatic nucleic acid treatment of diseases or conditions related
            to levels of epidermal growth factor receptors
JOURNAL    Patent: JP 2001511003-A 265 07-AUG-2001;
            RIBOZYME PHARMACEUTICALS INC,ASTON UNIV
COMMENT    OS Unidentified
            PN JP 2001511003-A/265
            PD 07-AUG-2001
            PF 14-JAN-1998 JP 1998532913
            PR 31-JAN-1997 US 60/036476,04-DEC-1997 US 08/985162 PI
            SAGHIR AKHTAR,PATRICIA FELL,JAMES A MCSWIGGEN PC
            C12N9/00,C07K14/71
            CC Strandedness: Single;
            CC Topology: linear;
            CC Enzymatic nucleic acid treatment of diseases or conditions CC
            related to
            CC levels of epidermal growth factor receptors
            FH Key Location/Qualifiers
            FT source 1. .17
            FEATURES
            source 1. .17
            /organism="unidentified"
            /mol_type="genomic RNA"
            /db_xref="taxon:32644"
            BASE COUNT 9 a 2 c 3 g 3 t
            Query Match 1.0%; Score 12.2; DB 1; Length 17;
            Best Local Similarity 82.4%; Pred. No. 5.8e+02;
            Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
            QY 981 AGCACTTTAGTTT 997
            Db 17 AGCACTTTGATCTTTT 1
            RESULT 818
            BD067935/c
            LOCUS      BD067935          17 bp    RNA    linear    PAT 27-AUG-2002
            DEFINITION Enzymatic nucleic acid treatment of diseases or conditions related
            to levels of epidermal growth factor receptors.
            ACCESSION  BD067935
            VERSION    JP 2001511003-A/775.
            KEYWORDS   unidentifed
            SOURCE     unidentifed
            ORGANISM   unclassified.
            REFERENCE  1. (bases 1 to 17)
            AUTHORS    Akhtar,S., Fell,P. and Mcswiggen,J.A.
            TITLE      Enzymatic nucleic acid treatment of diseases or conditions related
            to levels of epidermal growth factor receptors
            JOURNAL    Patent: JP 2001511003-A 775 07-AUG-2001;
            RIBOZYME PHARMACEUTICALS INC,ASTON UNIV
            COMMENT    OS Unidentified
            PN JP 2001511003-A/775
            PD 07-AUG-2001
            PF 14-JAN-1998 JP 1998532913
            PR 31-JAN-1997 US 60/036476,04-DEC-1997 US 08/985162 PI
            SAGHIR AKHTAR,PATRICIA FELL,JAMES A MCSWIGGEN PC
            C12N9/00,C07K14/71
            CC Strandedness: Single;
            CC Topology: linear;

```

```

            CC Enzymatic nucleic acid treatment of diseases or conditions CC
            related to
            CC levels of epidermal growth factor receptors
            FH Key Location/Qualifiers
            FT source 1. .17
            /organism="unidentified".
            FEATURES
            source 1. .17
            Location/Qualifiers
            /organism="unidentified"
            /mol_type="genomic RNA"
            /db_xref="taxon:32644"
            BASE COUNT 7 a 3 c 2 g 5 t
            Query Match 1.0%; Score 12.2; DB 1; Length 17;
            Best Local Similarity 82.4%; Pred. No. 5.8e+02;
            Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
            QY 514 TTCCTGTTAAATTGA 530
            Db 17 TTCCTTGATAAATTGA 1
            RESULT 819
            BD073195/c
            LOCUS      BD073195          17 bp    DNA    linear    PAT 27-AUG-2002
            DEFINITION Nucleic acid sequence and method for selectively expressing protein
            in target cell and tissue.
            ACCESSION  BD073195
            VERSION    BD073195.1 GI:22618798
            KEYWORDS   JP 2001509388-A/12.
            SOURCE     synthetic construct
            ORGANISM   synthetic construct
            REFERENCE  1. (bases 1 to 17)
            AUTHORS    Flaese,I. and Joe,J.
            TITLE      Nucleic acid sequence and method for selectively expressing protein
            in target cell and tissue
            JOURNAL    Patent: JP 2001509388-A 12 24-JUL-2001;
            THE UNIVERSITY OF QUEENSLAND
            COMMENT    OS Artificial Sequence
            PN JP 2001509388-A/12
            PD 24-JUL-2001
            PF 09-JUL-1998 JP 2000502189
            PR 09-JUL-1997 AU PO 7765,11-SEP-1997 AU PO 9467 PI
            IAN FLASER,JEAN JOE
            PC C12N15/09,A61K48/00,A61P35/00,A61P43/00,C12N5/10,C12N7/00// PC
            A61K35/76,
            PC C12N15/00,C12N5/00
            CC Description of Artificial Sequence: Oligonucleotide specific
            for Glu(GAA)
            FH Key Location/Qualifiers
            FT source 1. .17
            /organism="Artificial Sequence".
            FEATURES
            source 1. .17
            Location/Qualifiers
            /organism="synthetic construct"
            /mol_type="genomic DNA"
            /db_xref="taxon:32630"
            BASE COUNT 5 a 4 c 1 g 7 t
            Query Match 1.0%; Score 12.2; DB 1; Length 17;
            Best Local Similarity 82.4%; Pred. No. 5.8e+02;
            Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
            QY 1363 AGTGCTGTGTTGAATTA 1379
            Db 17 AATGCTGTGAGAATA 1
            RESULT 820
            BD087253
            LOCUS      BD087253          17 bp    DNA    linear    PAT 27-AUG-2002
            DEFINITION Hyaluronan synthase gene and utilization thereof.

```

```

ACCESSION BD087253
VERSION BD087253.1 GI:22632863
KEYWORDS JP 2001521741-A/5.
SOURCE Streptococcus dysgalactiae subsp. equisimilis
ORGANISM Streptococcus dysgalactiae subsp. equisimilis
        Bacteria; Firmicutes; Lactobacillales; Streptococcaceae;
        Streptococcus.
REFERENCE 1 (bases 1 to 17)
AUTHORS Weigel,P.H., Kumari,K. and Deangelis,P.
TITLE Hyaluronan synthase gene and utilization thereof
JOURNAL Patent: JP 2001521741-A 5 13-NOV-2001;
        THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA
COMMENT OS Streptococcus equisimilis
        PN JP 2001521741-A/5
        PD 13-NOV-2001
        PP 30-OCT-1998 JP 2000519083
        PR 31-OCT-1997 US 607064435,26-OCT-1998 US 09/178951 PI
        PC C12N15/09,A61K31/728,A61P43/00,C12N1/21,C12N9/10,C12P19/04, PC
          C12Q1/68//
        PC (C12N15/09,C12R1:46),C12N15/00,(C12N15/00,C12R1:46) CC
          Hyaluronan synthase gene and utilization thereof PH Key
          Location/Qualifiers
            1..17
            source
            1..17
            /organism="Streptococcus equisimilis".
FEATURES
  source
    location/Qualifiers
      1..17
      /organism="Streptococcus dysgalactiae subsp. equisimilis"
      /mol_type="genomic DNA"
      /sub_species="subsp. equisimilis"
      /db_xref="taxon:119602"
BASE COUNT 2 a 5 c 2 g 8 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 1544 TTTTATGCTGCTCCCA 1560
      ||||| ||||| |||||
Db 1 TTTTACGTGCTCCCA 17
RESULT 821
I32318
LOCUS I32318 17 bp DNA linear PAT 06-FEB-1997
DEFINITION Sequence 10 from patent US 5587300.
ACCESSION I32318
VERSION I32318.1 GI:1823109
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Malter,J.S.
TITLE Method to increase regulatory molecule production
JOURNAL Patent: US 5587300-A 10 24-DEC-1996;
        Location/Qualifiers
  source
    1..17
    /organism="unknown"
BASE COUNT 5 a 0 c 4 g 8 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 1046 ATTATGATTTATTTA 1062
      ||||| ||||| |||||
Db 1 ATGATGATGATGATGTA 17
RESULT 822
I32319/c
LOCUS I32319 17 bp DNA linear PAT 06-FEB-1997
DEFINITION Sequence 10 from patent US 5587300.
ACCESSION I32319
VERSION I32319.1 GI:1823110
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Malter,J.S.
TITLE Method to increase regulatory molecule production
JOURNAL Patent: US 5587300-A 11 24-DEC-1996;
        Location/Qualifiers
  source
    1..17
    /organism="unknown"
BASE COUNT 8 a 4 c 0 g 5 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 1046 ATTATGATTTATTTA 1062
      ||||| ||||| |||||
Db 1 ATGATGATGATGATGTA 17

```

```

DEFINITION Sequence 11 from patent US 5587300.
ACCESSION I32319
VERSION I32319.1 GI:1823110
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Malter,J.S.
TITLE Method to increase regulatory molecule production
JOURNAL Patent: US 5587300-A 11 24-DEC-1996;
        Location/Qualifiers
  source
    1..17
    /organism="unknown"
BASE COUNT 8 a 4 c 0 g 5 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 1046 ATTATGATTTATTTA 1062
      ||||| ||||| |||||
Db 1 ATGATGATGATGATGTA 17
RESULT 823
I53001
LOCUS I53001 17 bp DNA linear PAT 07-OCT-1997
DEFINITION Sequence 742 from patent US 5646042.
ACCESSION I53001
VERSION I53001.1 GI:2474204
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myb targeted ribozymes
JOURNAL Patent: US 5646042-A 742 08-JUL-1997;
        Location/Qualifiers
  source
    1..17
    /organism="unknown"
BASE COUNT 9 a 0 c 2 g 6 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 1081 AAGAAATTTGAAAAATA 1097
      ||||| ||||| |||||
Db 1 AAGAAATTTTAAAAATA 17
RESULT 824
I53051
LOCUS I53051 17 bp DNA linear PAT 07-OCT-1997
DEFINITION Sequence 792 from patent US 5646042.
ACCESSION I53051
VERSION I53051.1 GI:2474254
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myb targeted ribozymes
JOURNAL Patent: US 5646042-A 792 08-JUL-1997;
        Location/Qualifiers
  source
    1..17
    /organism="unknown"
BASE COUNT 11 a 1 c 1 g 4 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;

```

```
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 619 AAAACACACAAATAAT 635
|||||
Db 1 AAAACACATAATGATT 17

RESULT 825
I53051/c
LOCUS 153051 17 bp DNA linear PAT 07-OCT-1997
DEFINITION Sequence 792 from patent US 5646042.
ACCESSION I53051
VERSION I53051.1 GI:2474254
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myb targeted ribozymes
JOURNAL Patent: US 5646042-A 792 08-JUL-1997;
FEATURES Location/Qualifiers
1..17
/organism="unknown"
BASE COUNT 11 a 1 c 1 g 4 t

Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 980 AAGCACTTAAAGTTT 996
|||||
Db 17 AATCATTTATGTTT 1

RESULT 826
I53219/c
LOCUS 153219 17 bp DNA linear PAT 07-OCT-1997
DEFINITION Sequence 960 from patent US 5646042.
ACCESSION I53219
VERSION I53219.1 GI:2474422
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myb targeted ribozymes
JOURNAL Patent: US 5646042-A 960 08-JUL-1997;
FEATURES Location/Qualifiers
1..17
/organism="unknown"
BASE COUNT 8 a 0 c 2 g 7 t

Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1030 TATTAACCTATTATTA 1046
|||||
Db 17 TATAAACTATTCCTA 1

RESULT 827
I53221/c
LOCUS 153221 17 bp DNA linear PAT 07-OCT-1997
DEFINITION Sequence 962 from patent US 5646042.
ACCESSION I53221
VERSION I53221.1 GI:2474424
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
```

```
Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myb targeted ribozymes
JOURNAL Patent: US 5646042-A 962 08-JUL-1997;
FEATURES Location/Qualifiers
1..17
/organism="unknown"
BASE COUNT 10 a 0 c 1 g 6 t

Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1477 TTCTTATATATATTT 1493
|||||
Db 17 TTTTATAAACTATT 1

RESULT 828
I53307
LOCUS 153307 17 bp DNA linear PAT 07-OCT-1997
DEFINITION Sequence 1048 from patent US 5646042.
ACCESSION I53307
VERSION I53307.1 GI:2474510
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myb targeted ribozymes
JOURNAL Patent: US 5646042-A 1048 08-JUL-1997;
FEATURES Location/Qualifiers
1..17
/organism="unknown"
BASE COUNT 5 a 0 c 0 g 12 t

Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1145 TATTTTATTTAGATAT 1161
|||||
Db 1 TTTTAAATTTATATAT 17

RESULT 829
I53307/c
LOCUS 153307 17 bp DNA linear PAT 07-OCT-1997
DEFINITION Sequence 1048 from patent US 5646042.
ACCESSION I53307
VERSION I53307.1 GI:2474510
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myb targeted ribozymes
JOURNAL Patent: US 5646042-A 1048 08-JUL-1997;
FEATURES Location/Qualifiers
1..17
/organism="unknown"
BASE COUNT 5 a 0 c 0 g 12 t

Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1590 AAATATAAACTAAATA 1606
|||||
Db 17 ATATATAAAATTAATAA 1
```

```

RESULT 830
153317/c
LOCUS
DEFINITION Sequence 1058 from patent US 5646042.
ACCESSION 153317
VERSION 153317.1 GI:2474520
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myb targeted ribozymes
JOURNAL Patent: US 5646042-A 1058 08-JUL-1997;
FEATURES
source
BASE COUNT 7 a 1 c 0 g 9 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1583 TGTATGGAATATATAAA 1599
|||||
Db 17 TGTATATATATATAAA 1

RESULT 831
154130
LOCUS
DEFINITION Sequence 1871 from patent US 5646042.
ACCESSION 154130
VERSION 154130.1 GI:2475333
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myb targeted ribozymes
JOURNAL Patent: US 5646042-A 1871 08-JUL-1997;
FEATURES
source
BASE COUNT 6 a 0 c 2 g 9 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1259 AAATAATTTTATGAT 1275
|||||
Db 1 AAATGATTTATTTGAT 17

RESULT 832
154144
LOCUS
DEFINITION Sequence 1885 from patent US 5646042.
ACCESSION 154144
VERSION 154144.1 GI:2475347
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myb targeted ribozymes
JOURNAL Patent: US 5646042-A 1885 08-JUL-1997;
FEATURES
Location/Qualifiers

```

```

source 1..17
/organism="unknown"
BASE COUNT 6 a 0 c 3 g 8 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1147 TTTATTTTAGATATTA 1163
|||||
Db 1 TTGTATTTTAGAGATA 17

RESULT 833
154160/c
LOCUS
DEFINITION Sequence 1901 from patent US 5646042.
ACCESSION 154160
VERSION 154160.1 GI:2475363
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myb targeted ribozymes
JOURNAL Patent: US 5646042-A 1901 08-JUL-1997;
FEATURES
Location/Qualifiers
source 1..17
/organism="unknown"
BASE COUNT 3 a 1 c 5 g 8 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1418 CCACAGTCATATATAGT 1434
|||||
Db 17 CCACAGTCATAAATACT 1

RESULT 834
154242/c
LOCUS
DEFINITION Sequence 1993 from patent US 5646042.
ACCESSION 154242
VERSION 154242.1 GI:2475445
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myb targeted ribozymes
JOURNAL Patent: US 5646042-A 1993 08-JUL-1997;
FEATURES
Location/Qualifiers
source 1..17
/organism="unknown"
BASE COUNT 4 a 2 c 3 g 8 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 929 AAAAGTATTAGCCACCA 945
|||||
Db 17 AAGATTATTAGCCACCA 1

RESULT 835
154406
LOCUS
DEFINITION Sequence 2147 from patent US 5646042.

```

```

ACCESSION I54406
VERSION I54406.1 GI:2475609
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myb targeted ribozymes
JOURNAL Patent: US 5646042-A 2147 08-JUL-1997;
FEATURES
source Location/Qualifiers
1..17
/organism="unknown"
BASE COUNT 3 a 1 c 0 g 13 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1035 ACCTATTATTATTTAT 1051
Db 1 ACTTTTATTTTATAT 17
RESULT 836
I54408
LOCUS
DEFINITION Sequence 2149 from patent US 5646042.
ACCESSION I54408
VERSION I54408.1 GI:2475611
KEYWORDS
SOURCE Unknown.
REFERENCE
1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myb targeted ribozymes
JOURNAL Patent: US 5646042-A 2149 08-JUL-1997;
FEATURES
source Location/Qualifiers
1..17
/organism="unknown"
BASE COUNT 3 a 0 c 0 g 14 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1145 TATTATTATTAGATAT 1161
Db 1 TTTTATTATTTTATAT 17
RESULT 837
I54410
LOCUS
DEFINITION Sequence 2151 from patent US 5646042.
ACCESSION I54410
VERSION I54410.1 GI:2475613
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myb targeted ribozymes
JOURNAL Patent: US 5646042-A 2151 08-JUL-1997;
FEATURES
source Location/Qualifiers
1..17
/organism="unknown"
BASE COUNT 4 a 0 c 0 g 13 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1038 TATTATTATTATGTA 1054
Db 1 TTTTATTATTTATATA 17
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1038 TATTATTATTATGTA 1054
Db 1 TTTTATTATTTATATA 17
RESULT 838
I54416
LOCUS
DEFINITION Sequence 2157 from patent US 5646042.
ACCESSION I54416
VERSION I54416.1 GI:2475619
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myb targeted ribozymes
JOURNAL Patent: US 5646042-A 2157 08-JUL-1997;
FEATURES
source Location/Qualifiers
1..17
/organism="unknown"
BASE COUNT 5 a 0 c 0 g 12 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1041 TTATTATTATGTAATTT 1057
Db 1 TTATTATTTATATATAT 17
RESULT 839
I54656/c
LOCUS
DEFINITION Sequence 2397 from patent US 5646042.
ACCESSION I54656
VERSION I54656.1 GI:2475859
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myb targeted ribozymes
JOURNAL Patent: US 5646042-A 2397 08-JUL-1997;
FEATURES
source Location/Qualifiers
1..17
/organism="unknown"
BASE COUNT 8 a 1 c 2 g 6 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 640 AATATAAGGATTTTCCT 656
Db 17 AATATATGTAATTTTCCT 1
RESULT 840
ATH529445
LOCUS
DEFINITION Arabidopsis thaliana T-DNA flanking sequence, left border, clone 187B12.
ACCESSION AJ529445
VERSION AJ529445.1 GI:26797705
KEYWORDS
SOURCE Arabidopsis thaliana (chale cress)
ORGANISM Arabidopsis thaliana

```


Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsid.

REFERENCE

1 Brunaud, V., Balzergue, S., Dubreucq, B., Aubourg, S., Samson, F., Chauvin, S., Bechtold, N., Cruaud, C., Derose, R., Pelletier, G., Lepoint, L., Caboche, M. and Lecharny, A.
T-DNA integration into the Arabidopsis genome depends on sequences of pre-insertion sites
EMBO Rep. 3 (12), 1152-1157 (2002)

JOURNAL

MEDLINE

PUBMED

REFERENCE

AUTHORS

TITLE

JOURNAL

COMMENT

Submitted (21-NOV-2002) Balzergue S., UMRGV, INRA/CNRS, 2 rue Gaston Cremieux, 91057 Evry cedex, FRANCE
PCR was performed on DNA from transformants of Arabidopsis thaliana plants from INRA (Versailles). The DNA fragment(s) resulting from the PCR were directly sequenced from the left or the right border to determine the genomic sequence flanking the insertion. T-DNA derived sequences were removed. Information to order the corresponding mutant line and a link to a database providing a graphical display of the insertion site are available at <http://dbgap.versailles.inra.fr/publiclines/>. This sequence has been generated in the framework of the French plant genomics program 'Genoplante' (<http://www.genoplante.com> and <http://genoplante-info.infobiogen.fr>).

FEATURES

source

misc_feature

BASE COUNT

Query Match

Best Local Similarity

Matches

Indels

Gaps

Length

DB

Score

Pred.

Mismatches

Indels

Gaps

Length

DB

Score

Pred.

Mismatches

Indels

Gaps

Length

DB

Score

Pred.

Mismatches

Indels

Gaps

Length

DB

Score

Pred.

Mismatches

Indels

Gaps

QY 1247 CAGATAAACCAATA 1263

Db 17 CAGATAAACCAATA 1

RESULT 842

LOCUS AR285276/c

DEFINITION Sequence 22 from patent US 6528296.

ACCESSION AR285276

VERSION AR285276.1 GI:29722376

KEYWORDS Unknown.

SOURCE Unknown.

ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 18)

AUTHORS Morishima, N., Mizumura, H. and Shibata, T.

TITLE Endonuclease

JOURNAL Patent: US 6528296-A 22 04-MAR-2003;

FEATURES Location/Qualifiers

source 1..18

BASE COUNT 4 a 1 c 4 g 9 t

Query Match 1.0%; Score 12.2; DB 1; Length 18;

Best Local Similarity 82.4%; Pred. No. 6.3e+02;

Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1247 CAGATAAACCAATA 1263

Db 17 CAGATAAACCAATA 1

RESULT 843

LOCUS AX643248

DEFINITION Sequence 114 from Patent WO209099.

ACCESSION AX643248

VERSION AX643248.1 GI:28550445

KEYWORDS synthetic construct

SOURCE synthetic construct

ORGANISM artificial sequences.

REFERENCE 1

AUTHORS Penger, A., Sprenger, R. and Brinkmann, U.

TITLE Polymorphisms in the human gene for cytochrome p450 polypeptide 2c8

JOURNAL and their use in diagnostic and therapeutic applications

Patent: WO 0209099-A 114 12-DEC-2002;

FEATURES Epidauros Biotechnologie AG (DE)

Location/Qualifiers

source 1..18

BASE COUNT 4 a 0 c 3 g 11 t

Query Match 1.0%; Score 12.2; DB 1; Length 18;

Best Local Similarity 82.4%; Pred. No. 6.3e+02;

Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1045 TATTATGTATTATT 1061

Db 2 TATTATGTATTATT 18

RESULT 844

LOCUS AX643251/c

DEFINITION Sequence 117 from Patent WO209099.

ACCESSION AX643251

VERSION AX643251.1 GI:28550449

KEYWORDS synthetic construct

SOURCE synthetic construct

Location/Qualifiers

source 1..18

BASE COUNT 4 a 1 c 4 g 9 t

Query Match 1.0%; Score 12.2; DB 1; Length 18;

Best Local Similarity 82.4%; Pred. No. 6.3e+02;

Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```

ORGANISM      synthetic construct
SOURCE        artificial sequences.
REFERENCE
AUTHORS      Panger, A., Spranger, R. and Brinkmann, U.
TITLE        Polymorphisms in the human gene for cytochrome p450 polypeptide 2c8
              and their use in diagnostic and therapeutic applications
JOURNAL      Patent: WO 02099099-A 117 12-DEC-2002;
              Epidauros Biotechnology AG (DE)
FEATURES
source       1. .18
              /organism="synthetic construct"
              /mol_type="genomic DNA"
              /db_xref="taxon:32630"
BASE COUNT   11 a 3 c 0 g 4 t
Query Match  1.0%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 6.3e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1045 TATTATGTTATTATT 1061
Db 17 TATTATGTTATTATG 1
RESULT 845
E60081/c
LOCUS      E60081
DEFINITION Endonuclease.
ACCESSION  E60081
VERSION     1 GI:13023331
KEYWORDS   JP 2000041686-A/21.
SOURCE     synthetic construct
ORGANISM   artificial sequences.
REFERENCE  1 (bases 1 to 18)
AUTHORS    Kobuhiro, M., Hikaru, M. and Takehiko, S.
TITLE      Endonuclease
COMMENT    Patent: JP 2000041686-A 21 15-FEB-2000;
              RIKAGAKU KENKYUSHO
              OS Artificial Sequence
              PN JP 2000041686-A/21
              PD 15-FEB-2000
              PF 24-MAY-1999 JP 1999144005
              PR NOBUHIRO MORISHIMA, HIKARU MIZUMURA, TAKEHIKO SHIBATA PC
              C12N15/09, C12N1/15, C12N1/19, C12N1/21, C12N5/10, C12N9/16// PC
              CC (C12N9/16, C12R1:19), C12N15/00, C12N5/00
              FH Key Location/Qualifiers
              FT source 1. .18
              FT /organism='Artificial Sequence'.
FEATURES
source     1. .18
              /organism="synthetic construct"
              /mol_type="genomic DNA"
              /db_xref="taxon:32630"
BASE COUNT  4 a 1 c 4 g 9 t
Query Match  1.0%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 6.3e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1247 CAGATAACCAACAATA 1263
Db 17 CAGATAACCAATATTA 1
RESULT 846
AX599396
LOCUS      AX599396
DEFINITION Sequence 736 from Patent WO02077272.
ACCESSION  AX599396
VERSION     1 GI:28399540
AUTHORS    Mireglia, L.J., Nero, P., Graham, M.J., Monia, B.P. and Cowsett, L.M.

```

```

KEYWORDS     synthetic construct
SOURCE       synthetic construct
ORGANISM     artificial sequences.
REFERENCE
AUTHORS      Berlin, K., Braun, A., Distler, J., Guetig, D., Howe, A., Mueller, J.,
              Olek, A., Piepenbrock, C., Adorian, P., Grabs, G., Lesche, R., Leu, E.,
              Lewin, A., Lipbacher, E., Maier, S., Model, F., Mueller, V., Otto, T.,
              Pelet, C. and Ziebarth, H.
TITLE        Methods and nucleic acids for the analysis of hematopoietic cell
              proliferative disorders
JOURNAL      Patent: WO 02077272-A 736 03-OCT-2002;
              Epigenomics AG (DE)
FEATURES
source       1. .18
              /organism="synthetic construct"
              /mol_type="genomic DNA"
              /db_xref="taxon:32630"
              /note="Detection oligonucleotide for DAPKI"
BASE COUNT   3 a 0 c 4 g 11 t
Query Match  1.0%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 6.3e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1286 TTGTTTATCTGAATT 1302
Db 1 TTGTTTATCTGAATT 17
RESULT 847
AX419972/c
LOCUS      AX419972
DEFINITION Sequence 309 from Patent WO0198537.
ACCESSION  AX419972
VERSION     AX419972.1 GI:21524339
KEYWORDS   synthetic construct
SOURCE     synthetic construct
ORGANISM   artificial sequences.
REFERENCE  1
AUTHORS    Lyamichev, V., Allawi, H., Dong, P., Neri, B.P. and Vener, I.T.
TITLE      Nucleic acid accessible hybridization sites
JOURNAL    Patent: WO 0198537-A 309 27-DEC-2001;
              THIRD WAVE TECHNOLOGIES, INC. (US)
FEATURES
source     1. .20
              /organism="synthetic construct"
              /mol_type="genomic DNA"
              /db_xref="taxon:32630"
BASE COUNT   7 a 5 c 2 g 6 t
Query Match  1.0%; Score 12.2; DB 1; Length 20;
Best Local Similarity 82.4%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 552 TTTCATGTTACCATG 568
Db 17 TATTCATGTTACCATG 1
RESULT 848
BD138313
LOCUS      BD138313
DEFINITION Antisense modulation of human MDM2 expression.
ACCESSION  BD138313
VERSION     BD138313.1 GI:23233258
KEYWORDS   JP 2002508944-A/239.
SOURCE     unidentified
ORGANISM   unclassified.
REFERENCE  1 (bases 1 to 20)
AUTHORS    Mireglia, L.J., Nero, P., Graham, M.J., Monia, B.P. and Cowsett, L.M.

```

TITLE Antisense modulation of human MDM2 expression
JOURNAL Patent: JP 2002508944-A 239 26-MAR-2002;
COMMENT ISIS PHARMACEUTICALS INC
OS Unidentified
PN JP 2002508944-A/239
PD 26-MAR-2002
PF 26-MAR-1999 JP 2000538025
PR 26-MAR-1998 US 09/048810
PI LOREN J MTRAGLIA, PAMELA NERO, MARK J GRAHAM, BRETT P MONIA, LEX M
PI CONSENT
PC C12N15/09, A61K48/00, A61P9/10, A61P17/06, A61P35/00, C07H21/04//
PC C12Q1/68,
PC C12N15/00
CC Strandedness: Single;
CC Topology: Linear;
CC Antisense modulation of human MDM2 expression FH Key
CC Location/Qualifiers
FT source 1..20
FT Location/Qualifiers
FT 1..20 /organism="Unidentified".
FEATURES
source Location/Qualifiers
1..20
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
BASE COUNT 9 a 1 c 2 g 8 t
Query Match 1.0%; Score 12.2; DB 1; Length 20;
Best Local Similarity 82.4%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1603 AATATGAACATTTAAA 1619
Db 2 AATAGTTACATTTAAA 18
RESULT 849
ATH552863/c
LOCUS Arabidopsis thaliana 20 bp DNA linear PLN 29-MAR-2003
DEFINITION Arabidopsis thaliana T-DNA flanking sequence, left border, clone 345E09.
ACCESSION Au552863
VERSION Au552863.1 GI:29369014
KEYWORDS left border; T-DNA flanking sequence.
SOURCE Arabidopsis thaliana (thale cress)
ORGANISM Arabidopsis thaliana
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
REFERENCE 1
AUTHORS Brunaud, V., Balzergue, S., Dubreucq, B., Aubourg, S., Samson, P., Chauvin, S., Bechtold, N., Cruaud, C., Dekosse, R., Pelletier, G., Lepiniec, L., Caboche, M. and Lecharny, A.
TITLE T-DNA integration into the Arabidopsis genome depends on sequences of pre-insertion sites
JOURNAL ENBO Rep. 3 (12), 1152-1157 (2002)
MEDLINE 22363535
PUBMED 12446565
REFERENCE 2 (bases 1 to 20)
AUTHORS Balzergue, S.
TITLE Direct Submission
JOURNAL Submitted (21-NOV-2002) Balzergue S., UMRGV, INRA/CNRS, 2 rue Gaston Cremieux, 91057 Evry cedex, FRANCE
COMMENT PCR was performed on DNA from transformants of Arabidopsis thaliana plants from INRA (Versailles). The DNA fragment(s) resulting from the PCR were directly sequenced from the left or the right border to determine the genomic sequence flanking the insertion. T-DNA derived sequences were removed. Information to order the corresponding mutant line and a link to a database providing a graphical display of the insertion site are available at <http://dbsgap.versailles.inra.fr/publiclines/>. This sequence has been generated in the framework of the French plant genomics program 'Genoplante' (<http://www.genoplante.com> and

http://genoplante-info.infobiogen.fr).
FEATURES
source Location/Qualifiers
1..20
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"
/cultivar="Wassiljewskija"
/db_xref="taxon:3702"
/clone="345E09"
/clone_lib="Arabidopsis thaliana T-DNA insertion lines"
misc_feature 1..20
/note="T-DNA flanking sequence
left border"
BASE COUNT 13 a 4 c 0 g 3 t
Query Match 1.0%; Score 12.2; DB 1; Length 20;
Best Local Similarity 82.4%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 594 AAAGTATTATTATTG 610
Db 20 AAAGTTTGTGTTGTTG 4
RESULT 850
AR236360/c
LOCUS Arabidopsis thaliana 21 bp RNA linear PAT 20-DEC-2002
DEFINITION Sequence 8 from patent US 6465176.
ACCESSION AR236360
VERSION AR236360.1 GI:27280288
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 21)
AUTHORS Giordano, T., Beach, D.L. and Temeles, G.L.
TITLE Method for identifying compounds RNA/RNA binding protein interactions
JOURNAL Patent: US 6465176-A 8 15-OCT-2002;
FEATURES
source Location/Qualifiers
1..21
/organism="unknown"
BASE COUNT 6 a 0 c 0 g 15 t
Query Match 1.0%; Score 12.2; DB 1; Length 21;
Best Local Similarity 82.4%; Pred. No. 7.6e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1590 AAATATAAAGTAAATA 1606
Db 20 AAATAAATAAATAAATA 4
RESULT 851
A61502
LOCUS Arabidopsis thaliana 12 bp DNA linear PAT 09-MAR-1998
DEFINITION Sequence 71 from Patent WO9710332.
ACCESSION A61502
VERSION A61502.1 GI:3715885
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Schmidt, G.
TITLE CHINAERIC OLIGONUCLEOTIDES AND USES THEREOF IN THE IDENTIFICATION OF ANTISENSE BINDING SITES
JOURNAL Patent: WO 9710332-A 71 20-MAR-1997;
COMMENT BRAX GENOMICS LTD (GB)
FEATURES
source Location/Qualifiers
1..12
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

```

BASE COUNT      3 a      0 c      0 g      9 t

Query Match
Best Local Similarity 1.0%; Score 12; DB 1; Length 12;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1038 TATTTATTATTT 1049
Db 1 TATTTATTATTT 12

RESULT 852
AR199094 AR199094 12 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 42 from patent US 6355418.
ACCESSION AR199094
VERSION AR199094.1 GI:20249168
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 12)
AUTHORS Schmidt,G.
TITLE Chimeric oligonucleotides and uses thereof in the identification of
JOURNAL antisense binding sites
FEATURES Patent: US 6355418-A 42 12-MAR-2002;
Location/Qualifiers
source 1..12
/organism="unknown"
BASE COUNT      3 a      0 c      0 g      9 t

Query Match
Best Local Similarity 1.0%; Score 12; DB 1; Length 12;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1038 TATTTATTATTT 1049
Db 1 TATTTATTATTT 12

RESULT 853
AR241715 AR241715 13 bp DNA linear PAT 20-DEC-2002
DEFINITION Sequence 3 from patent US 6472154.
ACCESSION AR241715
VERSION AR241715.1 GI:27287527
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 13)
AUTHORS Garner,H.R., Wren,J.D., Minna,J.D. and Fondon,J.W. III.
TITLE Polymorphic repeats in human genes
JOURNAL Patent: US 6472154-A 3 29-OCT-2002;
FEATURES Location/Qualifiers
source 1..13
/organism="unknown"
BASE COUNT     10 a      3 c      0 g      0 t

Query Match
Best Local Similarity 1.0%; Score 12; DB 1; Length 13;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 616 ACAAAAACAC 627
Db 2 ACAAAAACAC 13

RESULT 854
A88495 A88495 14 bp DNA linear PAT 22-JAN-2000
DEFINITION Sequence 643 from Patent WO9833904.
ACCESSION A88495

```

```

VERSION A88495.1 GI:6737065
KEYWORDS unidentified
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 14)
AUTHORS Brysch,W. and Schlingensiepen,K.
TITLE AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
JOURNAL Patent: WO 9833904-A 643 06-AUG-1998; (DE)
FEATURES BIOGNOSTIK GES (DE); BRYSCH WOLFGANG (DE)
Location/Qualifiers
source 1..14
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
BASE COUNT      5 a      1 c      7 t

Query Match
Best Local Similarity 1.0%; Score 12; DB 1; Length 14;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 635 TTTTGAATATAA 646
Db 3 TTTTGAATATAA 14

RESULT 855
A88649 A88649 14 bp DNA linear PAT 22-JAN-2000
DEFINITION Sequence 797 from Patent WO9833904.
ACCESSION A88649
VERSION A88649.1 GI:6737219
KEYWORDS unidentified
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 14)
AUTHORS Brysch,W. and Schlingensiepen,K.
TITLE AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
JOURNAL Patent: WO 9833904-A 797 06-AUG-1998;
FEATURES BIOGNOSTIK GES (DE); BRYSCH WOLFGANG (DE)
Location/Qualifiers
source 1..14
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
BASE COUNT      7 a      0 c      2 g      5 t

Query Match
Best Local Similarity 1.0%; Score 12; DB 1; Length 14;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1156 AGATATTAAATG 1167
Db 2 AGATATTAAATG 13

RESULT 856
A90462 A90462 14 bp DNA linear PAT 22-JAN-2000
DEFINITION Sequence 643 from Patent EP0856579.
ACCESSION A90462
VERSION A90462.1 GI:6738976
KEYWORDS unidentified
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 14)
AUTHORS Brysch,W.D. and Schlingensiepen,K.D.
TITLE An antisense oligonucleotide preparation method
JOURNAL Patent: EP 0856579-A 643 05-AUG-1998;
FEATURES BIOGNOSTIK GES (DE)
Location/Qualifiers

```

```

source      1..14
            /organism="unidentified"
            /mol_type="genomic DNA"
            /db_xref="taxon:32644"
BASE COUNT  5 a 1 c 1 g 7 t

Query Match      1.0%; Score 12; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 635 TTTTGAATATAA 646
Db 3 TTTTGAATATAA 14

RESULT 857
A90616
LOCUS      14 bp DNA linear PAT 22-JAN-2000
DEFINITION Sequence 797 from Patent EP0856579.
ACCESSION  A90616
VERSION     A90616.1 GI:6739130
KEYWORDS   unidentified
SOURCE      unidentified
ORGANISM    unclassified.
REFERENCE   1 (bases 1 to 14)
AUTHORS     Brysch,W.D. and Schlingensiepen,K.D.
TITLE       An antisense oligonucleotide preparation method
JOURNAL     Patent: EP 0856579-A 797 05-AUG-1998;
            BIOGNOSTIK GES (DE)
FEATURES    Location/Qualifiers
            source      1..14
                        /organism="unidentified"
                        /mol_type="genomic DNA"
                        /db_xref="taxon:32644"
BASE COUNT  7 a 0 c 2 g 5 t

Query Match      1.0%; Score 12; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1156 AGATATTAAATG 1167
Db 2 AGATATTAAATG 13

RESULT 858
BD066008
LOCUS      14 bp DNA linear PAT 27-AUG-2002
DEFINITION An antisense oligonucleotide preparation method.
ACCESSION  BD066008
VERSION     BD066008.1 GI:22611611
KEYWORDS   JP 2001511000-A/643.
SOURCE      unidentified
ORGANISM    unclassified.
REFERENCE   1 (bases 1 to 14)
AUTHORS     Schlingensiepen,K.H. and Brysch,W.
TITLE       An antisense oligonucleotide preparation method
JOURNAL     Patent: JP 2001511000-A 643 07-AUG-2001;
            BIOGNOSTIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH
COMMENT     OS Unknown
            PN JP 2001511000-A/643
            PD 07-AUG-2001
            PP 30-JAN-1998 JP 1998532533
            PR 31-JAN-1997 EP 97101531.8
            PI KARL HERMANN SCHLINGENSIEPEN,WOLFGANG BRYSCH
            PC C12N15/11,C07H21/04,A61K31/70
            CC An antisense oligonucleotide preparation method FH Key
            FT source      1..14
                        Location/Qualifiers
FEATURES
source      1..14
            /organism="unidentified"
            /mol_type="genomic DNA"
            /db_xref="taxon:32644"
BASE COUNT  7 a 0 c 2 g 5 t

Query Match      1.0%; Score 12; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1156 AGATATTAAATG 1167
Db 2 AGATATTAAATG 13

RESULT 860
A15311
LOCUS      15 bp DNA linear PAT 23-MAR-1994
DEFINITION Oligonucleotide Cdl.
ACCESSION  A15311
VERSION     A15311.1 GI:512714
KEYWORDS   .
SOURCE      synthetic construct
ORGANISM    synthetic construct
            artificial sequences.
REFERENCE   1 (bases 1 to 15)
AUTHORS     Ueda,I., Niwa,M., Saito,Y., Yamada,H. and Ishii,Y.
TITLE       A process for the production of alpha-human atrial natriuretic
            polypeptide
JOURNAL     Patent: EP 0206769-A 50 30-DEC-1986;
            FUJISAWA PHARMACEUTICAL CO., LTD

```

```

source      1..14
            /organism="unidentified"
            /mol_type="genomic DNA"
            /db_xref="taxon:32644"
BASE COUNT  5 a 1 c 1 g 7 t

Query Match      1.0%; Score 12; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 635 TTTTGAATATAA 646
Db 3 TTTTGAATATAA 14

RESULT 859
BD066162
LOCUS      14 bp DNA linear PAT 27-AUG-2002
DEFINITION An antisense oligonucleotide preparation method.
ACCESSION  BD066162
VERSION     BD066162.1 GI:22611765
KEYWORDS   JP 2001511000-A/797.
SOURCE      unidentified
ORGANISM    unidentified
            unclassified.
REFERENCE   1 (bases 1 to 14)
AUTHORS     Schlingensiepen,K.H. and Brysch,W.
TITLE       An antisense oligonucleotide preparation method
JOURNAL     Patent: JP 2001511000-A 797 07-AUG-2001;
            BIOGNOSTIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH
COMMENT     OS Unknown
            PN JP 2001511000-A/797
            PD 07-AUG-2001
            PP 30-JAN-1998 JP 1998532533
            PR 31-JAN-1997 EP 97101531.8
            PI KARL HERMANN SCHLINGENSIEPEN,WOLFGANG BRYSCH
            PC C12N15/11,C07H21/04,A61K31/70
            CC An antisense oligonucleotide preparation method FH Key
            FT source      1..14
                        Location/Qualifiers
FEATURES
source      1..14
            /organism="unidentified"
            /mol_type="genomic DNA"
            /db_xref="taxon:32644"
BASE COUNT  7 a 0 c 2 g 5 t

Query Match      1.0%; Score 12; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1156 AGATATTAAATG 1167
Db 2 AGATATTAAATG 13

RESULT 860
A15311
LOCUS      15 bp DNA linear PAT 23-MAR-1994
DEFINITION Oligonucleotide Cdl.
ACCESSION  A15311
VERSION     A15311.1 GI:512714
KEYWORDS   .
SOURCE      synthetic construct
ORGANISM    synthetic construct
            artificial sequences.
REFERENCE   1 (bases 1 to 15)
AUTHORS     Ueda,I., Niwa,M., Saito,Y., Yamada,H. and Ishii,Y.
TITLE       A process for the production of alpha-human atrial natriuretic
            polypeptide
JOURNAL     Patent: EP 0206769-A 50 30-DEC-1986;
            FUJISAWA PHARMACEUTICAL CO., LTD

```

FEATURES	source	Location/Qualifiers
BASE COUNT	6 a 4 c 0 g 5 t	
Query Match	1.0%; Score 12; DB 1; Length 15;	
Best Local Similarity	100.0%; Pred. No. 5.2e+02;	
Matches	12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
QY	452 TCTACTTCAACA 463	
Db		
LOCUS	A16511	15 bp DNA linear PAT 17-MAR-1994
DEFINITION	oligonucleotide Cdl.	
ACCESSION	A16511	
VERSION	A16511.1	GI:498989
KEYWORDS		
SOURCE		
ORGANISM		
REFERENCE		
AUTHORS	Ueda,I., Niwa,M., Saito,Y., Yamada,H. and Ishii,Y.	
TITLE	A process for the production of alpha-human atrial natriuretic	
JOURNAL	polypeptide	
	Patent: EP 0440311-A 67 07-AUG-1991;	
	FUJISAWA PHARMACEUTICAL CO., LTD	
FEATURES	Location/Qualifiers	
source	1. .15	
BASE COUNT	6 a 4 c 0 g 5 t	
Query Match	1.0%; Score 12; DB 1; Length 15;	
Best Local Similarity	100.0%; Pred. No. 5.2e+02;	
Matches	12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
QY	452 TCTACTTCAACA 463	
Db		
LOCUS	A88496	15 bp DNA linear PAT 22-JAN-2000
DEFINITION	Sequence 644 from Patent WO9833904.	
ACCESSION	A88496	
VERSION	A88496.1	GI:6737066
KEYWORDS		
SOURCE	unidentified	
ORGANISM	unidentified	
REFERENCE	unclassified.	
AUTHORS	1 (bases 1 to 15)	
TITLE	Brysch,W. and Schlingensiepen,K.	
JOURNAL	AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD	
	Patent: WO 9833904-A 644 06-AUG-1998;	
	BIOGNOSTIK GBS (DE); ERSICH WOLFGANG (DE)	
FEATURES	Location/Qualifiers	
source	1. .15	
BASE COUNT	5 a 1 c 1 g 8 t	
Query Match	1.0%; Score 12; DB 1; Length 15;	
Best Local Similarity	100.0%; Pred. No. 5.2e+02;	
Matches	12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	

```

VERSION      A90613.1  GI:6739127
KEYWORDS
SOURCE       unidentified
ORGANISM     unclassified.
REFERENCE    1 (bases 1 to 15)
AUTHORS      Brysch,W.D. and Schlingensiepen,K.D.
TITLE        An antisense oligonucleotide preparation method
JOURNAL      Patent: EP 0856579-A 794 05-AUG-1998;
              BIOGNOSTIK GES (DE)
FEATURES     Location/Qualifiers
              source
                1..15
                /organism="unidentified"
                /mol_type="genomic DNA"
                /db_xref="taxon:32644"
BASE COUNT   5 a 1 c 1 g 8 t

Query Match  1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1293 TCTGAATTTTA 1304
Db 1 TCTGAATTTTA 12

RESULT 866
AR041397
LOCUS        AR041397 15 bp DNA linear PAT 29-SEP-1999
DEFINITION   Sequence 187 from patent US 5811300.
ACCESSION    AR041397
VERSION      AR041397.1 GI:5961893
KEYWORDS
SOURCE       Unknown.
ORGANISM     Unclassified.
REFERENCE    1 (bases 1 to 15)
AUTHORS      Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE        TNF-.alpha. ribozymes
JOURNAL      Patent: US 5811300-A 187 22-SEP-1998;
              Location/Qualifiers
FEATURES     source
                1..15
                /organism="unknown"
BASE COUNT   4 a 0 c 1 g 10 t

Query Match  1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1038 TATTATTATTT 1049
Db 4 TATTATTATTT 15

RESULT 867
AR041405
LOCUS        AR041405 15 bp DNA linear PAT 29-SEP-1999
DEFINITION   Sequence 195 from patent US 5811300.
ACCESSION    AR041405
VERSION      AR041405.1 GI:5961901
KEYWORDS
SOURCE       Unknown.
ORGANISM     Unclassified.
REFERENCE    1 (bases 1 to 15)
AUTHORS      Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE        TNF-.alpha. ribozymes
JOURNAL      Patent: US 5811300-A 195 22-SEP-1998;
              Location/Qualifiers
FEATURES     source
                1..15
                /organism="unknown"
BASE COUNT   4 a 0 c 0 g 11 t

```

```

Query Match  1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1038 TATTATTATTT 1049
Db 4 TATTATTATTT 15

RESULT 868
AR041418
LOCUS        AR041418 15 bp DNA linear PAT 29-SEP-1999
DEFINITION   Sequence 208 from patent US 5811300.
ACCESSION    AR041418
VERSION      AR041418.1 GI:5961914
KEYWORDS
SOURCE       Unknown.
ORGANISM     Unclassified.
REFERENCE    1 (bases 1 to 15)
AUTHORS      Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE        TNF-.alpha. ribozymes
JOURNAL      Patent: US 5811300-A 208 22-SEP-1998;
              Location/Qualifiers
FEATURES     source
                1..15
                /organism="unknown"
BASE COUNT   4 a 0 c 2 g 9 t

Query Match  1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1050 ATGTATTATTT 1061
Db 4 ATGTATTATTT 15

RESULT 869
AR041419
LOCUS        AR041419 15 bp DNA linear PAT 29-SEP-1999
DEFINITION   Sequence 209 from patent US 5811300.
ACCESSION    AR041419
VERSION      AR041419.1 GI:5961915
KEYWORDS
SOURCE       Unknown.
ORGANISM     Unclassified.
REFERENCE    1 (bases 1 to 15)
AUTHORS      Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE        TNF-.alpha. ribozymes
JOURNAL      Patent: US 5811300-A 209 22-SEP-1998;
              Location/Qualifiers
FEATURES     source
                1..15
                /organism="unknown"
BASE COUNT   4 a 0 c 3 g 8 t

Query Match  1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1050 ATGTATTATTT 1061
Db 2 ATGTATTATTT 13

RESULT 870
AR041420
LOCUS        AR041420 15 bp DNA linear PAT 29-SEP-1999
DEFINITION   Sequence 210 from patent US 5811300.
ACCESSION    AR041420
VERSION      AR041420.1 GI:5961916
KEYWORDS
SOURCE       Unknown.

```

```

ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE TNF- $\alpha$ .alpha. ribozymes
JOURNAL Patent: US 5811300-A 210 22-SEP-1998;
FEATURES Location/Qualifiers
source 1..15
BASE COUNT 3 a 0 c 4 g 8 t
Query Match 1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1050 ATGTTATTATT 1061
Db 1 ATGTTATTATT 12
RESULT 871
AR041913
LOCUS AR041913 15 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 703 from patent US 5811300.
ACCESSION AR041913
VERSION AR041913.1 GI:5962409
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE TNF- $\alpha$ .alpha. ribozymes
JOURNAL Patent: US 5811300-A 703 22-SEP-1998;
FEATURES Location/Qualifiers
source 1..15
BASE COUNT 4 a 0 c 0 g 11 t
Query Match 1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1038 TATTTATTATT 1049
Db 4 TATTTATTATT 15
RESULT 872
AR041914
LOCUS AR041914 15 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 704 from patent US 5811300.
ACCESSION AR041914
VERSION AR041914.1 GI:5962410
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE TNF- $\alpha$ .alpha. ribozymes
JOURNAL Patent: US 5811300-A 704 22-SEP-1998;
FEATURES Location/Qualifiers
source 1..15
BASE COUNT 4 a 0 c 0 g 11 t
Query Match 1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1038 TATTTATTATT 1049
Db 4 TATTTATTATT 15
RESULT 873
AR041929
LOCUS AR041929 15 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 719 from patent US 5811300.
ACCESSION AR041929
VERSION AR041929.1 GI:5962425
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE TNF- $\alpha$ .alpha. ribozymes
JOURNAL Patent: US 5811300-A 719 22-SEP-1998;
FEATURES Location/Qualifiers
source 1..15
BASE COUNT 4 a 0 c 0 g 11 t
Query Match 1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1038 TATTTATTATT 1049
Db 4 TATTTATTATT 15
RESULT 874
AR041939
LOCUS AR041939 15 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 729 from patent US 5811300.
ACCESSION AR041939
VERSION AR041939.1 GI:5962435
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE TNF- $\alpha$ .alpha. ribozymes
JOURNAL Patent: US 5811300-A 729 22-SEP-1998;
FEATURES Location/Qualifiers
source 1..15
BASE COUNT 4 a 0 c 2 g 9 t
Query Match 1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1050 ATGTTATTATT 1061
Db 4 ATGTTATTATT 15
RESULT 875
AR041940
LOCUS AR041940 15 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 730 from patent US 5811300.
ACCESSION AR041940
VERSION AR041940.1 GI:5962436
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE TNF- $\alpha$ .alpha. ribozymes
JOURNAL Patent: US 5811300-A 730 22-SEP-1998;
FEATURES Location/Qualifiers
source 1..15
BASE COUNT 4 a 0 c 0 g 11 t
Query Match 1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1038 TATTTATTATT 1049
Db 4 TATTTATTATT 15

```


FEATURES source Location/Qualifiers
1. .15
BASE COUNT 4 a 0 c 3 g 8 t
Query Match 1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1050 ATGTATTATT 1061
Db 2 ATGTATTATT 13
RESULT 876
AR041941
LOCUS 15 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 731 from patent US 5811300.
ACCESSION AR041941
VERSION AR041941.1 GI:5962437
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Sullivan, S., Draper, K., Kisich, K., Stinchcomb, D.T., and McSwiggen, J.
TITLE TNF- α ribozymes
JOURNAL Patent: US 5811300-A 731 22-SEP-1998;
FEATURES Location/Qualifiers
source 1. .15
/organism="unknown"
BASE COUNT 4 a 0 c 3 g 8 t
Query Match 1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1050 ATGTATTATT 1061
Db 1 ATGTATTATT 12
RESULT 877
AR056012
LOCUS 15 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 216 from patent US 5837542.
ACCESSION AR056012
VERSION AR056012.1 GI:5981589
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Grimm, S., Stinchcomb, D.T., McSwiggen, J., Sullivan, S. and Draper, K.G.
TITLE Intercellular adhesion molecule-1 (ICAM-1) ribozymes
JOURNAL Patent: US 5837542-A 216 17-NOV-1998;
FEATURES Location/Qualifiers
source 1. .15
/organism="unknown"
BASE COUNT 4 a 1 c 2 g 8 t
Query Match 1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1049 TATGTATTATT 1060
Db 3 TATGTATTATT 14
RESULT 878
AR056294/c

LOCUS AR056294 15 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 498 from patent US 5837542.
ACCESSION AR056294
VERSION AR056294.1 GI:5981871
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Grimm, S., Stinchcomb, D.T., McSwiggen, J., Sullivan, S. and Draper, K.G.
TITLE Intercellular adhesion molecule-1 (ICAM-1) ribozymes
JOURNAL Patent: US 5837542-A 498 17-NOV-1998;
FEATURES Location/Qualifiers
source 1. .15
/organism="unknown"
BASE COUNT 3 a 3 c 7 g 2 t
Query Match 1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 862 TCTGCTAGCCAG 873
Db 13 TCTGCTAGCCAG 2
RESULT 879
AR056374/c
LOCUS 15 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 578 from patent US 5837542.
ACCESSION AR056374
VERSION AR056374.1 GI:5981951
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Grimm, S., Stinchcomb, D.T., McSwiggen, J., Sullivan, S. and Draper, K.G.
TITLE Intercellular adhesion molecule-1 (ICAM-1) ribozymes
JOURNAL Patent: US 5837542-A 578 17-NOV-1998;
FEATURES Location/Qualifiers
source 1. .15
/organism="unknown"
BASE COUNT 3 a 3 c 7 g 2 t
Query Match 1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 862 TCTGCTAGCCAG 873
Db 13 TCTGCTAGCCAG 2
RESULT 880
AR113770
LOCUS 15 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 216 from patent US 6132967.
ACCESSION AR113770
VERSION AR113770.1 GI:14094092
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Grimm, S., Stinchcomb, D.T., McSwiggen, J., Sullivan, S. and Draper, K.G.
TITLE Ribozyme treatment of diseases or conditions related to levels of intercellular adhesion molecule-1 (ICAM-1)
JOURNAL Patent: US 6132967-A 216 17-OCT-2000;
FEATURES Location/Qualifiers

```

source 1..15
BASE COUNT 4 a 1 c 2 g 8 t
Query Match 1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1049 TATGTATTATT 1060
Db 3 TATGTATTATT 14

RESULT 881
AR114052/c
LOCUS AR114052 15 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 498 from patent US 6132967.
ACCESSION AR114052
VERSION AR114052.1 GI:14094374
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and Draper,K.G.
TITLE Ribozyme treatment of diseases or conditions related to levels of intercellular adhesion molecule-1 (ICAM-1)
JOURNAL Patent: US 6132967-A 498 17-OCT-2000;
FEATURES
source 1..15
BASE COUNT 3 a 3 c 7 g 2 t
Query Match 1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 862 TCTGCTAGCCAG 873
Db 13 TCTGCTAGCCAG 2

RESULT 882
AR114132/c
LOCUS AR114132 15 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 578 from patent US 6132967.
ACCESSION AR114132
VERSION AR114132.1 GI:14094454
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and Draper,K.G.
TITLE Ribozyme treatment of diseases or conditions related to levels of intercellular adhesion molecule-1 (ICAM-1)
JOURNAL Patent: US 6132967-A 578 17-OCT-2000;
FEATURES
source 1..15
BASE COUNT 3 a 3 c 7 g 2 t
Query Match 1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 862 TCTGCTAGCCAG 873
Db 13 TCTGCTAGCCAG 2

RESULT 883
AX633102
LOCUS AX633102 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 241 from Patent EP1260586.
ACCESSION AX633102
VERSION AX633102.1 GI:28468716
KEYWORDS unidentified
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Direnzo,A., Karpeisky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J., McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M., Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,P.E. and Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related genes
JOURNAL Patent: EP 1260586-A 241 27-NOV-2002;
FEATURES
source 1..15
BASE COUNT 4 a 1 c 2 g 8 t
Query Match 1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1049 TATGTATTATT 1060
Db 3 TATGTATTATT 14

RESULT 884
AX633446/c
LOCUS AX633446 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 585 from Patent EP1260586.
ACCESSION AX633446
VERSION AX633446.1 GI:28469060
KEYWORDS unidentified
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Direnzo,A., Karpeisky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J., McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M., Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,P.E. and Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related genes
JOURNAL Patent: EP 1260586-A 585 27-NOV-2002;
FEATURES
source 1..15
BASE COUNT 3 a 3 c 7 g 2 t
Query Match 1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 862 TCTGCTAGCCAG 873
Db 13 TCTGCTAGCCAG 2

RESULT 885

```

```

AX633616/c
LOCUS      AX633616          15 bp  mRNA          linear          PAT 21-FEB-2003
DEFINITION Sequence 755 from Patent EP1260586.
ACCESSION  AX633616
VERSION     AX633616.1  GI:28469230
KEYWORDS   .
SOURCE      unidentified
ORGANISM    unidentified
REFERENCE   1
AUTHORS     Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
            Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
            McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
            Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
            Woolf,T.
TITLE       Method and reagent for inhibiting the expression of disease related
            genes
JOURNAL     Patent: EP 1260586-A 755 27-NOV-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES    source
            1..15
            /organism="unidentified"
            /mol_type="mRNA"
            /db_xref="taxon:32644"
BASE COUNT  3 a      3 c      7 g      2 t

Query Match      1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      862  TCTGCTAGCCAG 873
Db       13  TCTGCTAGCCAG 2

RESULT 886
AX635389
LOCUS      AX635389          15 bp  mRNA          linear          PAT 21-FEB-2003
DEFINITION Sequence 2528 from Patent EP1260586.
ACCESSION  AX635389
VERSION     AX635389.1  GI:28471003
KEYWORDS   .
SOURCE      unidentified
ORGANISM    unidentified
REFERENCE   1
AUTHORS     Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
            Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
            McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
            Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
            Woolf,T.
TITLE       Method and reagent for inhibiting the expression of disease related
            genes
JOURNAL     Patent: EP 1260586-A 2528 27-NOV-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES    source
            1..15
            /organism="unidentified"
            /mol_type="mRNA"
            /db_xref="taxon:32644"
BASE COUNT  5 a      0 c      1 g      9 t

Query Match      1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1052 GTATTATTATTA 1063
Db       4  GTATTATTATTA 15

RESULT 887
AX635391
LOCUS      AX635391          15 bp  mRNA          linear          PAT 21-FEB-2003
DEFINITION Sequence 2530 from Patent EP1260586.
ACCESSION  AX635391
VERSION     AX635391.1  GI:28471005
KEYWORDS   .
SOURCE      unidentified
ORGANISM    unidentified
REFERENCE   1
AUTHORS     Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
            Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
            McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
            Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
            Woolf,T.
TITLE       Method and reagent for inhibiting the expression of disease related
            genes
JOURNAL     Patent: EP 1260586-A 2530 27-NOV-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES    source
            1..15
            /organism="unidentified"
            /mol_type="mRNA"
            /db_xref="taxon:32644"
BASE COUNT  5 a      0 c      1 g      9 t

Query Match      1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1052 GTATTATTATTA 1063
Db       2  GTATTATTATTA 13

RESULT 888
AX635393
LOCUS      AX635393          15 bp  mRNA          linear          PAT 21-FEB-2003
DEFINITION Sequence 2532 from Patent EP1260586.
ACCESSION  AX635393
VERSION     AX635393.1  GI:28471007
KEYWORDS   .
SOURCE      unidentified
ORGANISM    unidentified
REFERENCE   1
AUTHORS     Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
            Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
            McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
            Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
            Woolf,T.
TITLE       Method and reagent for inhibiting the expression of disease related
            genes
JOURNAL     Patent: EP 1260586-A 2532 27-NOV-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES    source
            1..15
            /organism="unidentified"
            /mol_type="mRNA"
            /db_xref="taxon:32644"
BASE COUNT  5 a      0 c      2 g      8 t

Query Match      1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1052 GTATTATTATTA 1063
Db       3  GTATTATTATTA 14

```

```

DEFINITION Sequence 2552 from Patent EP1260586.
ACCESSION AX635413
VERSION AX635413.1 GI:28471027
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Direnzo,A.,
Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
McSwiggan,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related
genes
JOURNAL Patent: EP 1260586-A 2552 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
source
1..15
/organism="unidentified"
/mol_type="mRNA"
/db_xref="taxon:32644"
BASE COUNT 9 a 2 c 0 g 4 t
Query Match 1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1169 TCTTTATTAGA 1180
Db 13 TGTTTATTAGA 2
RESULT 890
AX636853
LOCUS AX636853 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 3992 from Patent EP1260586.
ACCESSION AX636853
VERSION AX636853.1 GI:28472467
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Direnzo,A.,
Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
McSwiggan,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related
genes
JOURNAL Patent: EP 1260586-A 3992 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
source
1..15
/organism="unidentified"
/mol_type="mRNA"
/db_xref="taxon:32644"
BASE COUNT 4 a 0 c 1 g 10 t
Query Match 1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1038 TATTATTATT 1049
Db 4 TATTATTATT 15
RESULT 891
AX636868
LOCUS AX636868 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 4007 from Patent EP1260586.
ACCESSION AX636868
VERSION AX636868.1 GI:28472482
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Direnzo,A.,
Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
McSwiggan,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related
genes
JOURNAL Patent: EP 1260586-A 4007 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
source
1..15
/organism="unidentified"
/mol_type="mRNA"
/db_xref="taxon:32644"
BASE COUNT 4 a 0 c 0 g 11 t
Query Match 1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1038 TATTATTATT 1049
Db 4 TATTATTATT 15
RESULT 892
AX636894
LOCUS AX636894 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 4033 from Patent EP1260586.
ACCESSION AX636894
VERSION AX636894.1 GI:28472508
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Direnzo,A.,
Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
McSwiggan,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related
genes
JOURNAL Patent: EP 1260586-A 4033 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
source
1..15
/organism="unidentified"
/mol_type="mRNA"
/db_xref="taxon:32644"
BASE COUNT 4 a 0 c 2 g 9 t
Query Match 1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1050 ATGTATTATT 1061
Db 4 ATGTATTATT 15
RESULT 893
AX636896
LOCUS AX636896 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 4035 from Patent EP1260586.
ACCESSION AX636896

```

```

VERSION      AX636896.1  GI:28472510
KEYWORDS
SOURCE       unidentified
ORGANISM     unidentified
REFERENCE    1
AUTHORS      Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Direnzo,A.,
              Karpelsky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
              Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
              Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
              Woolf,T.
TITLE        Method and reagent for inhibiting the expression of disease related
genes
JOURNAL      Patent: EP 1260586-A 4035 27-NOV-2002;
RIBOZYME     PHARMACEUTICALS, INC. (US)
FEATURES
source       1. .15
              /organism="unidentified"
              /mol_type="mRNA"
              /db_xref="taxon:32644"
BASE COUNT   4 a - 0 c 3 g 8 t
              Query Match 1.0%; Score 12; DB 1; Length 15;
              Best Local Similarity 100.0%; Pred. No. 5.2e+02;
              Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1050 ATGTATTATT 1061
Db 2 ATGTATTATT 13

RESULT 894
AX636898
LOCUS        AX636898 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION   Sequence 4037 from Patent EP1260586.
ACCESSION    AX636898
VERSION      AX636898.1 GI:28472512
KEYWORDS
SOURCE       unidentified
ORGANISM     unidentified
REFERENCE    1
AUTHORS      Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Direnzo,A.,
              Karpelsky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
              Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
              Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
              Woolf,T.
TITLE        Method and reagent for inhibiting the expression of disease related
genes
JOURNAL      Patent: EP 1260586-A 4037 27-NOV-2002;
RIBOZYME     PHARMACEUTICALS, INC. (US)
FEATURES
source       1. .15
              /organism="unidentified"
              /mol_type="mRNA"
              /db_xref="taxon:32644"
BASE COUNT   3 a - 0 c 4 g 8 t
              Query Match 1.0%; Score 12; DB 1; Length 15;
              Best Local Similarity 100.0%; Pred. No. 5.2e+02;
              Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1050 ATGTATTATT 1061
Db 1 ATGTATTATT 12

RESULT 895
AX637375
LOCUS        AX637375 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION   Sequence 4514 from Patent EP1260586.
ACCESSION    AX637375
VERSION      AX637375.1 GI:28472989

```

```

KEYWORDS
SOURCE       unidentified
ORGANISM     unidentified
REFERENCE    1
AUTHORS      Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Direnzo,A.,
              Karpelsky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
              Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
              Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
              Woolf,T.
TITLE        Method and reagent for inhibiting the expression of disease related
genes
JOURNAL      Patent: EP 1260586-A 4514 27-NOV-2002;
RIBOZYME     PHARMACEUTICALS, INC. (US)
FEATURES
source       1. .15
              /organism="unidentified"
              /mol_type="mRNA"
              /db_xref="taxon:32644"
BASE COUNT   4 a - 0 c 0 g 11 t
              Query Match 1.0%; Score 12; DB 1; Length 15;
              Best Local Similarity 100.0%; Pred. No. 5.2e+02;
              Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1038 TATTATTATT 1049
Db 4 TATTATTATT 15

RESULT 896
AX637377
LOCUS        AX637377 15 bp mRNA linear PAT 24-FEB-2003
DEFINITION   Sequence 4516 from Patent EP1260586.
ACCESSION    AX637377
VERSION      AX637377.1 GI:28472991
KEYWORDS
SOURCE       unidentified
ORGANISM     unidentified
REFERENCE    1
AUTHORS      Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Direnzo,A.,
              Karpelsky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
              Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
              Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
              Woolf,T.
TITLE        Method and reagent for inhibiting the expression of disease related
genes
JOURNAL      Patent: EP 1260586-A 4516 27-NOV-2002;
RIBOZYME     PHARMACEUTICALS, INC. (US)
FEATURES
source       1. .15
              /organism="unidentified"
              /mol_type="mRNA"
              /db_xref="taxon:32644"
BASE COUNT   4 a - 0 c 0 g 11 t
              Query Match 1.0%; Score 12; DB 1; Length 15;
              Best Local Similarity 100.0%; Pred. No. 5.2e+02;
              Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1038 TATTATTATT 1049
Db 4 TATTATTATT 15

RESULT 897
AX637407
LOCUS        AX637407 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION   Sequence 4546 from Patent EP1260586.
ACCESSION    AX637407
VERSION      AX637407.1 GI:28473021

```

```

SOURCE      unidentified
ORGANISM    unclassified
REFERENCE   1
AUTHORS     Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
            Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
            McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
            Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
            Woolf,T.
TITLE       Method and reagent for inhibiting the expression of disease related
            genes
JOURNAL     Patent: EP 1260586-A 4546 27-NOV-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES    source
            1..15
            /organism="unidentified"
            /mol_type="mRNA"
            /db_xref="taxon:32644"
BASE COUNT  4 a 0 c 0 g 11 t
Query Match 1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1038 TATTATTATT 1049
Db 4 TATTATTATT 15

RESULT 898
AX637423
LOCUS      AX637423 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 4562 from Patent EP1260586.
ACCESSION  AX637423
VERSION     AX637423.1 GI:28473037
KEYWORDS
SOURCE      unidentified
ORGANISM    unclassified
REFERENCE   1
AUTHORS     Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
            Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
            McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
            Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
            Woolf,T.
TITLE       Method and reagent for inhibiting the expression of disease related
            genes
JOURNAL     Patent: EP 1260586-A 4562 27-NOV-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES    source
            1..15
            /organism="unidentified"
            /mol_type="mRNA"
            /db_xref="taxon:32644"
BASE COUNT  4 a 0 c 2 g 9 t
Query Match 1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1050 ATGTATTATT 1061
Db 4 ATGTATTATT 15

RESULT 899
AX637424
LOCUS      AX637424 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 4563 from Patent EP1260586.
ACCESSION  AX637424
VERSION     AX637424.1 GI:28473038
KEYWORDS
SOURCE      unidentified

```

```

ORGANISM    unidentified
REFERENCE   1
AUTHORS     Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
            Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
            McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
            Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
            Woolf,T.
TITLE       Method and reagent for inhibiting the expression of disease related
            genes
JOURNAL     Patent: EP 1260586-A 4563 27-NOV-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES    source
            1..15
            /organism="unidentified"
            /mol_type="mRNA"
            /db_xref="taxon:32644"
BASE COUNT  4 a 0 c 3 g 8 t
Query Match 1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1050 ATGTATTATT 1061
Db 2 ATGTATTATT 13

RESULT 900
AX637425
LOCUS      AX637425 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 4564 from Patent EP1260586.
ACCESSION  AX637425
VERSION     AX637425.1 GI:28473039
KEYWORDS
SOURCE      unidentified
ORGANISM    unclassified
REFERENCE   1
AUTHORS     Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
            Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
            McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
            Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
            Woolf,T.
TITLE       Method and reagent for inhibiting the expression of disease related
            genes
JOURNAL     Patent: EP 1260586-A 4564 27-NOV-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES    source
            1..15
            /organism="unidentified"
            /mol_type="mRNA"
            /db_xref="taxon:32644"
BASE COUNT  4 a 0 c 3 g 8 t
Query Match 1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1050 ATGTATTATT 1061
Db 1 ATGTATTATT 12

RESULT 901
AX638328/c
LOCUS      AX638328 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 5467 from Patent EP1260586.
ACCESSION  AX638328
VERSION     AX638328.1 GI:28473942
KEYWORDS
SOURCE      unidentified

```

unclassified.

REFERENCE 1
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A., Karpeisky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J., McSwiggan,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M., Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related genes
JOURNAL RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
source 1. 15
/organism="unidentified"
/mol_type="mRNA"
/db_xref="taxon:32644"
BASE COUNT 8 a 2 c 1 g 4 t
Query Match 1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 525 ATTTGAATTTC A 536
Db 12 ATTTGAATTTC A 1

RESULT 902
AX638404/c
LOCUS AX638404 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 5543 from Patent EP1260586.
ACCESSION AX638404
VERSION AX638404.1 GI:28474018
KEYWORDS
SOURCE unidentified
ORGANISM unclassified.

REFERENCE 1
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A., Karpeisky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J., McSwiggan,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M., Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related genes
JOURNAL RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
source 1. 15
/organism="unidentified"
/mol_type="mRNA"
/db_xref="taxon:32644"
BASE COUNT 8 a 1 c 1 g 5 t
Query Match 1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1524 ATATTTTAACT 1535
Db 15 ATATTTTAACT 4

RESULT 903
BD066009
LOCUS BD066009 15 bp DNA linear PAT 27-AUG-2002
DEFINITION An antisense oligonucleotide preparation method.
ACCESSION BD066009
VERSION BD066009.1 GI:22611612
KEYWORDS JP 2001511000-A/644.
SOURCE unidentified
ORGANISM unclassified.

REFERENCE 1 (bases 1 to 15)
AUTHORS Schlingensiefen,K.H. and Brysch,W.
TITLE An antisense oligonucleotide preparation method
JOURNAL Patent: JP 2001511000-A 644 07-AUG-2001;
COMMENT BIOGNOSTIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH
OS Unknown
PN JP 2001511000-A/644
PD 07-AUG-2001
PF 30-JAN-1998 JP 1998532533
PR 31-JAN-1997 EP 97101531.8
PI KARL HERMANN SCHLINGENSIEFEN,WOLFGANG BRYSCH
PC C12N15/11,C07H21/04,A61K31/70
CC An antisense oligonucleotide preparation method FH Key
Location/Qualifiers
FT source 1. 15
/organism="Unknown".
FEATURES
source 1. 15
Location/Qualifiers
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
BASE COUNT 5 a 1 c 1 g 8 t
Query Match 1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 635 TTTTGAATATAA 646
Db 4 TTTTGAATATAA 15

RESULT 904
BD066159
LOCUS BD066159 15 bp DNA linear PAT 27-AUG-2002
DEFINITION An antisense oligonucleotide preparation method.
ACCESSION BD066159
VERSION BD066159.1 GI:22611762
KEYWORDS JP 2001511000-A/794.
SOURCE unidentified
ORGANISM unclassified.

REFERENCE 1 (bases 1 to 15)
AUTHORS Schlingensiefen,K.H. and Brysch,W.
TITLE An antisense oligonucleotide preparation method
JOURNAL Patent: JP 2001511000-A 794 07-AUG-2001;
COMMENT BIOGNOSTIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH
OS Unknown
PN JP 2001511000-A/794
PD 07-AUG-2001
PF 30-JAN-1998 JP 1998532533
PR 31-JAN-1997 EP 97101531.8
PI KARL HERMANN SCHLINGENSIEFEN,WOLFGANG BRYSCH
PC C12N15/11,C07H21/04,A61K31/70
CC An antisense oligonucleotide preparation method FH Key
Location/Qualifiers
FT source 1. 15
/organism="Unknown".
FEATURES
source 1. 15
Location/Qualifiers
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
BASE COUNT 5 a 1 c 1 g 8 t
Query Match 1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1293 TCTGAATTTTAA 1304
Db 1 TCTGAATTTTAA 12

BASE COUNT 5 a 0 c 1 g 9 t

Query Match 1.0%; Score 12; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 5.2e+02;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1052 GTATTATTAA 1063
 |||||
 Db 3 GTATTATTAA 14

RESULT 908
 I39130
 LOCUS I39130 15 bp DNA linear PAT 13-MAY-1997
 DEFINITION Sequence 168 from patent US 5616488.
 ACCESSION I39130
 VERSION I39130.1 GI:2083610
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unclassified.
 REFERENCE 1 (bases 1 to 15)
 AUTHORS Sullivan, S., Draper, K.G., McSwiggen, J. and Stinchcomb, D.T.
 TITLE IL-5 targeted ribozymes
 JOURNAL Patent: US 5616488-A 188 01-APR-1997;
 FEATURES Location/Qualifiers
 1..15
 source

BASE COUNT 5 a 0 c 2 g 8 t

Query Match 1.0%; Score 12; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 5.2e+02;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1052 GTATTATTAA 1063
 |||||
 Db 2 GTATTATTAA 13

RESULT 909
 I39140/c
 LOCUS I39140 15 bp DNA linear PAT 13-MAY-1997
 DEFINITION Sequence 178 from patent US 5616488.
 ACCESSION I39140
 VERSION I39140.1 GI:2083620
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unclassified.
 REFERENCE 1 (bases 1 to 15)
 AUTHORS Sullivan, S., Draper, K.G., McSwiggen, J. and Stinchcomb, D.T.
 TITLE IL-5 targeted ribozymes
 JOURNAL Patent: US 5616488-A 178 01-APR-1997;
 FEATURES Location/Qualifiers
 1..15
 source

BASE COUNT 9 a 2 c 0 g 4 t

Query Match 1.0%; Score 12; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 5.2e+02;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1169 TGTATTATAGA 1180
 |||||
 Db 13 TGTATTATAGA 2

RESULT 910
 I77804/c
 LOCUS I77804 15 bp DNA linear PAT 03-APR-1998
 DEFINITION Sequence 511 from patent US 5693532.
 ACCESSION I77804

RESULT 905
 I35095/c
 LOCUS I35095 15 bp DNA linear PAT 13-MAY-1997
 DEFINITION Sequence 63 from patent US 559706.
 ACCESSION I35095
 VERSION I35095.1 GI:2088063
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unclassified.
 REFERENCE 1 (bases 1 to 15)
 AUTHORS Stinchcomb, D.T., McSwiggen, J., Newton, R.S. and Ramharack, R.
 TITLE Ribozymes targeted to apo(a) mRNA
 JOURNAL Patent: US 559706-A 63 04-FEB-1997;
 FEATURES Location/Qualifiers
 1..15
 source

BASE COUNT 3 a 6 c 2 g 4 t

Query Match 1.0%; Score 12; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 5.2e+02;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 963 GTGTGAGGACA 974
 |||||
 Db 13 GTGTGAGGACA 2

RESULT 906
 I39128
 LOCUS I39128 15 bp DNA linear PAT 13-MAY-1997
 DEFINITION Sequence 166 from patent US 5616488.
 ACCESSION I39128
 VERSION I39128.1 GI:2083608
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unclassified.
 REFERENCE 1 (bases 1 to 15)
 AUTHORS Sullivan, S., Draper, K.G., McSwiggen, J. and Stinchcomb, D.T.
 TITLE IL-5 targeted ribozymes
 JOURNAL Patent: US 5616488-A 166 01-APR-1997;
 FEATURES Location/Qualifiers
 1..15
 source

BASE COUNT 5 a 0 c 1 g 9 t

Query Match 1.0%; Score 12; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 5.2e+02;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1052 GTATTATTAA 1063
 |||||
 Db 4 GTATTATTAA 15

RESULT 907
 I39129
 LOCUS I39129 15 bp DNA linear PAT 13-MAY-1997
 DEFINITION Sequence 167 from patent US 5616488.
 ACCESSION I39129
 VERSION I39129.1 GI:2083609
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unclassified.
 REFERENCE 1 (bases 1 to 15)
 AUTHORS Sullivan, S., Draper, K.G., McSwiggen, J. and Stinchcomb, D.T.
 TITLE IL-5 targeted ribozymes
 JOURNAL Patent: US 5616488-A 167 01-APR-1997;
 FEATURES Location/Qualifiers
 1..15
 source

VERSION I77804.1 GI:3013958
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS McSwiggen,J., Draper,K., Pavco,P. and Woolf,T.
TITLE Respiratory syncytial virus ribozymes
JOURNAL Patent: US 5693532-A 511 02-DEC-1997;
FEATURES Location/Qualifiers
source 1..15
/organism="unknown"
BASE COUNT 8 a 2 c 1 g 4 t
Query Match 1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 525 ATTGAATTTC 536
Db 12 ATTGAATTTC 1
RESULT 911
LOCUS I77891/c 15 bp DNA linear PAT 03-APR-1998
DEFINITION Sequence 598 from patent US 5693532.
ACCESSION I77891
VERSION I77891.1 GI:3014045
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS McSwiggen,J., Draper,K., Pavco,P. and Woolf,T.
TITLE Respiratory syncytial virus ribozymes
JOURNAL Patent: US 5693532-A 598 02-DEC-1997;
FEATURES Location/Qualifiers
source 1..15
/organism="unknown"
BASE COUNT 8 a 1 c 1 g 5 t
Query Match 1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1524 ATATTTTAACT 1535
Db 15 ATATTTTAACT 4
RESULT 912
LOCUS A88497 16 bp DNA linear PAT 22-JAN-2000
DEFINITION Sequence 645 from Patent WO9833904.
ACCESSION A88497
VERSION A88497.1 GI:6737067
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 16)
AUTHORS Brysch,W. and Schlingensiepen,K.
TITLE AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
JOURNAL Patent: WO 9833904-A 645 06-AUG-1998;
FEATURES Location/Qualifiers
source 1..16
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
BASE COUNT 5 a 1 c 1 g 9 t

Query Match 1.0%; Score 12; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 5.8e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 635 TTTTGAATATAA 646
Db 5 TTTTGAATATAA 16
RESULT 913
LOCUS A88647 16 bp DNA linear PAT 22-JAN-2000
DEFINITION Sequence 795 from Patent WO9833904.
ACCESSION A88647
VERSION A88647.1 GI:6737217
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 16)
AUTHORS Brysch,W. and Schlingensiepen,K.
TITLE AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
JOURNAL Patent: WO 9833904-A 795 06-AUG-1998;
FEATURES Location/Qualifiers
source 1..16
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
BASE COUNT 5 a 1 c 1 g 9 t
Query Match 1.0%; Score 12; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 5.8e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1293 TCTGAATTTTA 1304
Db 2 TCTGAATTTTA 13
RESULT 914
LOCUS A90464 16 bp DNA linear PAT 22-JAN-2000
DEFINITION Sequence 645 from Patent EP0858579.
ACCESSION A90464
VERSION A90464.1 GI:6738978
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 16)
AUTHORS Brysch,W.D. and Schlingensiepen,K.D.
TITLE An antisense oligonucleotide preparation method
JOURNAL Patent: EP 0858579-A 645 05-AUG-1998;
FEATURES Location/Qualifiers
source 1..16
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
BASE COUNT 5 a 1 c 1 g 9 t
Query Match 1.0%; Score 12; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 5.8e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 635 TTTTGAATATAA 646
Db 5 TTTTGAATATAA 16
RESULT 915
A90614

```
LOCUS       A90614                      15 bp    DNA             linear             PAT 22-JAN-2000
DEFINITION   Sequence 795 from Patent BP0856579.
ACCESSION    A90614
VERSION      A90614.1  GI:6739128
SOURCE       unidentified
ORGANISM     unidentified
REFERENCE    1 (bases 1 to 16)
AUTHORS      Brysch,W.D. and Schlingensiefen,K.D.
TITLE        An antisense oligonucleotide preparation method
JOURNAL      Patent: EP 0856579-A 795 05-AUG-1998;
             BIOGENOSTIK GES (DE)
FEATURES     source
             1..16
             /organism="unidentified"
             /mol_type="genomic DNA"
             /db_xref="taxon:32644"
BASE COUNT   5 a      1 c      1 g      9 t
Query Match      1.0%; Score 12; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 5.8e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY      1293 TCTGAAATTTTA 1304
Db      2 TCTGAAATTTTA 13
RESULT 916
AR165130/c
LOCUS       AR165130                      16 bp    DNA             linear             PAT 17-OCT-2001
DEFINITION   Sequence 3 from patent US 6274373.
ACCESSION    AR165130
VERSION      AR165130.1  GI:16238557
SOURCE       unidentified
ORGANISM     unclassified.
REFERENCE    1 (bases 1 to 16)
AUTHORS      Virtanen,J.
TITLE        Gene sequencer and methods
JOURNAL      Patent: US 6274373-A 3 14-AUG-2001;
FEATURES     source
             1..16
             /organism="unknown"
BASE COUNT     8 a      0 c      2 g      6 t
Query Match      1.0%; Score 12; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 5.8e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY      1560 AAATTTTTTT 1571
Db      15 AAATTTTTTT 4
RESULT 917
BD066010
LOCUS       BD066010                      15 bp    DNA             linear             PAT 27-AUG-2002
DEFINITION   An antisense oligonucleotide preparation method.
ACCESSION    BD066010
VERSION      BD066010.1  GI:22611613
SOURCE       unidentified
ORGANISM     unidentified
REFERENCE    1 (bases 1 to 16)
AUTHORS      Schlingensiefen,K.H. and Brysch,W.
TITLE        An antisense oligonucleotide preparation method
JOURNAL      Patent: JP 2001511000-A 645 07-AUG-2001;
             BIOGENOSTIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH
OS          UNKNOWN
LOCUS       A90614                      15 bp    DNA             linear             PAT 22-JAN-2000
DEFINITION   Sequence 795 from Patent BP0856579.
ACCESSION    A90614
VERSION      A90614.1  GI:6739128
SOURCE       unidentified
ORGANISM     unidentified
REFERENCE    1 (bases 1 to 16)
AUTHORS      Brysch,W.D. and Schlingensiefen,K.D.
TITLE        An antisense oligonucleotide preparation method
JOURNAL      Patent: EP 0856579-A 795 05-AUG-1998;
             BIOGENOSTIK GES (DE)
FEATURES     source
             1..16
             /organism="unidentified"
             /mol_type="genomic DNA"
             /db_xref="taxon:32644"
BASE COUNT   5 a      1 c      1 g      9 t
Query Match      1.0%; Score 12; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 5.8e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY      1293 TCTGAAATTTTA 1304
Db      2 TCTGAAATTTTA 13
RESULT 918
BD066160
LOCUS       BD066160                      16 bp    DNA             linear             PAT 27-AUG-2002
DEFINITION   An antisense oligonucleotide preparation method.
ACCESSION    BD066160
VERSION      BD066160.1  GI:22611763
SOURCE       unidentified
ORGANISM     unclassified.
REFERENCE    1 (bases 1 to 16)
AUTHORS      Schlingensiefen,K.H. and Brysch,W.
TITLE        An antisense oligonucleotide preparation method
JOURNAL      Patent: JP 2001511000-A 795 07-AUG-2001;
             BIOGENOSTIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH
OS          UNKNOWN
LOCUS       A90614                      15 bp    DNA             linear             PAT 22-JAN-2000
DEFINITION   Sequence 795 from Patent BP0856579.
ACCESSION    A90614
VERSION      A90614.1  GI:6739128
SOURCE       unidentified
ORGANISM     unidentified
REFERENCE    1 (bases 1 to 16)
AUTHORS      Brysch,W.D. and Schlingensiefen,K.D.
TITLE        An antisense oligonucleotide preparation method
JOURNAL      Patent: EP 0856579-A 795 05-AUG-1998;
             BIOGENOSTIK GES (DE)
FEATURES     source
             1..16
             /organism="unidentified"
             /mol_type="genomic DNA"
             /db_xref="taxon:32644"
BASE COUNT   5 a      1 c      1 g      9 t
Query Match      1.0%; Score 12; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 5.8e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY      1293 TCTGAAATTTTA 1304
Db      2 TCTGAAATTTTA 13
RESULT 919
AX736998
LOCUS       AX736998                      17 bp    DNA             linear             PAT 08-MAY-2003
DEFINITION   Sequence 2588 from Patent WO03025177.
ACCESSION    AX736998
VERSION      AX736998.1  GI:100000000
SOURCE       unidentified
ORGANISM     unidentified
REFERENCE    1 (bases 1 to 17)
AUTHORS      Schlingensiefen,K.H. and Brysch,W.
TITLE        An antisense oligonucleotide preparation method
JOURNAL      Patent: JP 2001511000-A 645 07-AUG-2001;
             BIOGENOSTIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH
OS          UNKNOWN
```

VERSION AX736998.1 GI:30516286
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Rukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Telesman,A., Anson,R. and Tuijinder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments
JOURNAL Patent: WO 03025177-A 2588 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES source
1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 8 a 3 c 1 g 5 t
Query Match 1.0%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 6.4e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 769 ATCATATAAAAA 780
Db 2 ATCATATAAAAA 13
RESULT 920
A88498
LOCUS A88498 17 bp DNA linear PAT 22-JAN-2000
DEFINITION Sequence 646 from Patent WO9833904.
ACCESSION A88498
VERSION A88498.1 GI:6737068
KEYWORDS unidentified
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Brysch,W. and Schlingensiepen,K.
TITLE AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
JOURNAL Patent: WO 9833904-A 646 06-AUG-1998;
BIOGNOSTIK GES (DE); BRYSCH WOLFGANG (DE)
FEATURES source
1. .17
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
BASE COUNT 5 a 1 c 1 g 10 t
Query Match 1.0%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 6.4e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 635 TTTTGAATATAA 646
Db 6 TTTTGAATATAA 17
RESULT 921
A90465
LOCUS A90465 17 bp DNA linear PAT 22-JAN-2000
DEFINITION Sequence 646 from Patent EP0856579.
ACCESSION A90465
VERSION A90465.1 GI:6738979
KEYWORDS unidentified
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Brysch,W.D. and Schlingensiepen,K.D.
TITLE An antisense oligonucleotide preparation method

JOURNAL Patent: EP 0856579-A 646 05-AUG-1998;
BIOGNOSTIK GES (DE)
FEATURES source
1. .17
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
BASE COUNT 5 a 1 c 1 g 10 t
Query Match 1.0%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 6.4e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 635 TTTTGAATATAA 646
Db 6 TTTTGAATATAA 17
RESULT 922
AR047246
LOCUS AR047246 17 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 2039 from patent US 5817796.
ACCESSION AR047246
VERSION AR047246.1 GI:5968711
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myp ribozymes having 2'-5'-linked adenylate residues
JOURNAL Patent: US 5817796-A 2039 06-OCT-1998;
FEATURES source
1. .17
/organism="unknown"
BASE COUNT 5 a 0 c 3 g 9 t
Query Match 1.0%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 6.4e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 544 ATGAATAGTTTT 555
Db 3 ATGAATAGTTTT 14
RESULT 923
AR186564
LOCUS AR186564 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 2052 from patent US 6346398.
ACCESSION AR186564
VERSION AR186564.1 GI:20232529
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 2052 12-FEB-2002;
FEATURES source
1. .17
/organism="unknown"
BASE COUNT 6 a 3 c 2 g 6 t
Query Match 1.0%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 6.4e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 441 CTTCAAGCAAT 452
Db 6 CTTCAAGCAAT 17

related to levels of vascular endothelial growth factor receptor

JOURNAL Patent: US 6346398-A 5930 12-FEB-2002;
FEATURES Location/Qualifiers
1. .17
source

BASE COUNT 4 a 2 c 3 g 8 t

Query Match 1.0%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 6.4e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1014 ATTTTCAAGTGT 1025
|||||
Db 6 ATTTTCAAGTGT 17

RESULT 927
AR190443
LOCUS
DEFINITION Sequence 5931 from patent US 6346398.
ACCESSION AR190443
VERSION AR190443.1 GI:20236408
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 5931 12-FEB-2002;
FEATURES Location/Qualifiers
1. .17
source

BASE COUNT 4 a 1 c 3 g 9 t

Query Match 1.0%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 6.4e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1014 ATTTTCAAGTGT 1025
|||||
Db 5 ATTTTCAAGTGT 16

RESULT 928
AR190444
LOCUS
DEFINITION Sequence 5932 from patent US 6346398.
ACCESSION AR190444
VERSION AR190444.1 GI:20236409
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 5932 12-FEB-2002;
FEATURES Location/Qualifiers
1. .17
source

BASE COUNT 4 a 1 c 4 g 8 t

Query Match 1.0%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 6.4e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1014 ATTTTCAAGTGT 1025
|||||
Db 4 ATTTTCAAGTGT 15

related to levels of vascular endothelial growth factor receptor

JOURNAL Patent: US 6346398-A 5930 12-FEB-2002;
FEATURES Location/Qualifiers
1. .17
source

BASE COUNT 3 a 1 c 7 g 6 t

Query Match 1.0%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 6.4e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1578 CTGATTGTATGG 1589
|||||
Db 4 CTGATTGTATGG 15

RESULT 925
AR187326
LOCUS
DEFINITION Sequence 2814 from patent US 6346398.
ACCESSION AR187326
VERSION AR187326.1 GI:202333291
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 2814 12-FEB-2002;
FEATURES Location/Qualifiers
1. .17
source

BASE COUNT 2 a 1 c 6 g 8 t

Query Match 1.0%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 6.4e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1578 CTGATTGTATGG 1589
|||||
Db 1 CTGATTGTATGG 12

RESULT 926
AR190442
LOCUS
DEFINITION Sequence 5930 from patent US 6346398.
ACCESSION AR190442
VERSION AR190442.1 GI:20236407
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions

RESULT 929
AX214676/c
LOCUS AX214676 17 bp mRNA linear PAT 07-SEP-2001
DEFINITION Sequence 118 from Patent WO0159103.
ACCESSION AX214676
VERSION AX214676.1 GI:15524719
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
JOURNAL Patent: WO 0159103-A 118 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US); McSwiggen, James (US); Chowrira, Bharat M. (US)
FEATURES
source
location/Qualifiers
1. .17
/organism="synthetic construct"
/mol_type="mRNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"
BASE COUNT 8 a 1 c 4 g 4 t
Query Match 1.0%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 6.4e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 839 TCTGTTAAATCT 850
Db 16 TCTGTTAAATCT 5
RESULT 930
AX214677/c
LOCUS AX214677 17 bp mRNA linear PAT 07-SEP-2001
DEFINITION Sequence 119 from Patent WO0159103.
ACCESSION AX214677
VERSION AX214677.1 GI:15524720
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
JOURNAL Patent: WO 0159103-A 119 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US); McSwiggen, James (US); Chowrira, Bharat M. (US)
FEATURES
source
location/Qualifiers
1. .17
/organism="synthetic construct"
/mol_type="mRNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"
BASE COUNT 7 a 1 c 4 g 5 t
Query Match 1.0%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 6.4e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 839 TCTGTTAAATCT 850
Db 15 TCTGTTAAATCT 4
RESULT 931
AX214678/c
LOCUS AX214678 17 bp mRNA linear PAT 07-SEP-2001
DEFINITION Sequence 120 from Patent WO0159103.

ACCESSION AX214678
VERSION AX214678.1 GI:15524721
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
JOURNAL Patent: WO 0159103-A 120 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US); McSwiggen, James (US); Chowrira, Bharat M. (US)
FEATURES
source
location/Qualifiers
1. .17
/organism="synthetic construct"
/mol_type="mRNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"
BASE COUNT 7 a 1 c 4 g 5 t
Query Match 1.0%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 6.4e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 839 TCTGTTAAATCT 850
Db 14 TCTGTTAAATCT 3
RESULT 932
AX214795
LOCUS AX214795 17 bp mRNA linear PAT 07-SEP-2001
DEFINITION Sequence 237 from Patent WO0159103.
ACCESSION AX214795
VERSION AX214795.1 GI:15524838
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
JOURNAL Patent: WO 0159103-A 237 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US); McSwiggen, James (US); Chowrira, Bharat M. (US)
FEATURES
source
location/Qualifiers
1. .17
/organism="synthetic construct"
/mol_type="mRNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"
BASE COUNT 14 a 0 c 2 g 1 t
Query Match 1.0%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 6.4e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1091 AAAAATAGAAGA 1102
Db 3 AAAAATAGAAGA 14
RESULT 933
AX214989
LOCUS AX214989 17 bp mRNA linear PAT 07-SEP-2001
DEFINITION Sequence 431 from Patent WO0159103.
ACCESSION AX214989
VERSION AX214989.1 GI:15525032
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM

artificial sequences.

REFERENCE 1
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B. M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
JOURNAL Patent: WO 0159103-A 433 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US);
McSwiggen, James (US); Chowrira, Bharat M. (US)
FEATURES
source
Location/Qualifiers
1. .17
/organism="synthetic construct"
/mol_type="mRNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"
5 a 1 c 9 t

BASE COUNT 5 a 1 c 9 t

Query Match 1.0%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 6.4e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 913 TTTATTTCTAAG 924
|||||
Db 4 TTTATTTCTAAG 15

RESULT 934
AX214990
LOCUS AX214990 17 bp mRNA linear PAT 07-SEP-2001
DEFINITION Sequence 433 from Patent WO0159103.
ACCESSION AX214990
VERSION AX214990.1 GI:15525033
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B. M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
JOURNAL Patent: WO 0159103-A 432 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US);
McSwiggen, James (US); Chowrira, Bharat M. (US)
FEATURES
source
Location/Qualifiers
1. .17
/organism="synthetic construct"
/mol_type="mRNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"
6 a 1 c 8 t

BASE COUNT 6 a 1 c 8 t

Query Match 1.0%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 6.4e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 913 TTTATTTCTAAG 924
|||||
Db 3 TTTATTTCTAAG 14

RESULT 935
AX214991
LOCUS AX214991 17 bp mRNA linear PAT 07-SEP-2001
DEFINITION Sequence 433 from Patent WO0159103.
ACCESSION AX214991
VERSION AX214991.1 GI:15525034
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B. M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression

JOURNAL Patent: WO 0159103-A 433 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US);
McSwiggen, James (US); Chowrira, Bharat M. (US)
FEATURES
source
Location/Qualifiers
1. .17
/organism="synthetic construct"
/mol_type="mRNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"
6 a 1 c 7 t

BASE COUNT 6 a 1 c 7 t

Query Match 1.0%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 6.4e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 913 TTTATTTCTAAG 924
|||||
Db 2 TTTATTTCTAAG 13

RESULT 936
AX215858
LOCUS AX215858 17 bp mRNA linear PAT 07-SEP-2001
DEFINITION Sequence 1300 from Patent WO0159103.
ACCESSION AX215858
VERSION AX215858.1 GI:15525901
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B. M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
JOURNAL Patent: WO 0159103-A 1300 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US);
McSwiggen, James (US); Chowrira, Bharat M. (US)
FEATURES
source
Location/Qualifiers
1. .17
/organism="synthetic construct"
/mol_type="mRNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"
5 a 2 c 7 t

BASE COUNT 5 a 2 c 7 t

Query Match 1.0%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 6.4e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 913 TTTATTTCTAAG 924
|||||
Db 2 TTTATTTCTAAG 13

RESULT 937
AX216684/c
LOCUS AX216684 17 bp mRNA linear PAT 07-SEP-2001
DEFINITION Sequence 2126 from Patent WO0159103.
ACCESSION AX216684
VERSION AX216684.1 GI:15526745
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B. M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
JOURNAL Patent: WO 0159103-A 2126 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US);
McSwiggen, James (US); Chowrira, Bharat M. (US)
FEATURES
source
Location/Qualifiers
1. .17

Query Match 1.0%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 6.4e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
BASE COUNT 6 a 1 c 4 g 6 t

QY 839 TCTGTTAAATCT 850
Db 13 TCTGTTAAATCT 2

RESULT 938
AX216730
LOCUS AX216730 17 bp mRNA linear PAT 07-SEP-2001
DEFINITION Sequence 2172 from Patent WO0159103.
ACCESSION AX216730
VERSION AX216730.1 GI:15526791
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
JOURNAL nogo gene expression
PATENT: WO 0159103-A 2172 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US);
McSwiggen, James (US); Chowrira, Bharat M. (US)
FEATURES
source
1..17
/organism="synthetic construct"
/mol_type="mRNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

BASE COUNT 14 a 0 c 2 g 1 t

Query Match 1.0%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 6.4e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
BASE COUNT 14 a 0 c 2 g 1 t

QY 1091 AAAAATAGAAGA 1102
Db 5 AAAAATAGAAGA 16

RESULT 939
AX217071
LOCUS AX217071 17 bp mRNA linear PAT 07-SEP-2001
DEFINITION Sequence 2513 from Patent WO0159103.
ACCESSION AX217071
VERSION AX217071.1 GI:15527132
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
JOURNAL nogo gene expression
PATENT: WO 0159103-A 2513 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US);
McSwiggen, James (US); Chowrira, Bharat M. (US)
FEATURES
source
1..17
/organism="synthetic construct"
/mol_type="mRNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

BASE COUNT 13 a 0 c 3 g 1 t

Query Match 1.0%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 6.4e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
BASE COUNT 1091 AAAAATAGAAGA 1102
Db 2 AAAAATAGAAGA 13

RESULT 940
AX263260/c
LOCUS AX263260 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 651 from Patent WO0173002.
ACCESSION AX263260
VERSION AX263260.1 GI:16512059
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Knies, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
JOURNAL stranded oligonucleotides
PATENT: WO 0173002-A 651 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

BASE COUNT 7 a 2 c 3 g 5 t

Query Match 1.0%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 6.4e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
BASE COUNT 1293 TCTGAAATTTTA 1304
Db 12 TCTGAAATTTTA 1

RESULT 941
AX263261
LOCUS AX263261 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 652 from Patent WO0173002.
ACCESSION AX263261
VERSION AX263261.1 GI:16512060
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Knies, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
JOURNAL stranded oligonucleotides
PATENT: WO 0173002-A 652 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

BASE COUNT 5 a 3 c 2 g 7 t

Query Match 1.0%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 6.4e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
BASE COUNT 1293 TCTGAAATTTTA 1304
Db 12 TCTGAAATTTTA 1

```

Db      6 TCTGAATTTA 17
RESULT 942
AX264543
LOCUS      AX264543
DEFINITION Sequence 1934 from Patent WO0173002.
ACCESSION  AX264543
VERSION     AX264543.1 GI:16513342
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Knies, E.B., Gamper, H.B. and Rice, M.C.
TITLE       Targeted chromosomal genomic alterations with modified single
            stranded oligonucleotides
JOURNAL     Patent: WO 0173002-A 1934 04-OCT-2001;
            UNIVERSITY OF DELAWARE (US)
FEATURES    Location/Qualifiers
            source
            1..17
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"
BASE COUNT  3 a 7 c 2 g 5 t
Query Match 1.0%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 6.4e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      892 CCACTGTGCCTT 903
Db      1 CCACTGTGCCTT 12
RESULT 943
AX264544/c
LOCUS      AX264544
DEFINITION Sequence 1935 from Patent WO0173002.
ACCESSION  AX264544
VERSION     AX264544.1 GI:16513343
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Knies, E.B., Gamper, H.B. and Rice, M.C.
TITLE       Targeted chromosomal genomic alterations with modified single
            stranded oligonucleotides
JOURNAL     Patent: WO 0173002-A 1935 04-OCT-2001;
            UNIVERSITY OF DELAWARE (US)
FEATURES    Location/Qualifiers
            source
            1..17
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"
BASE COUNT  5 a 2 c 7 g 3 t
Query Match 1.0%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 6.4e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      892 CCACTGTGCCTT 903
Db      17 CCACTGTGCCTT 6
RESULT 944
AX272719
LOCUS      AX272719
DEFINITION Sequence 288 from Patent WO0162911.
ACCESSION  AX272719
VERSION     AX272719.1 GI:16545456
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Jarvis, T., von Carlowitz, I., Mcswiggen, J.A., Hamblin, P.A. and
            Ellis, J.H.
TITLE       Method and reagent for the inhibition of grid
            RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
JOURNAL     Patent: WO 0162911-A 288 30-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES    Location/Qualifiers
            source
            1..17
            /organism="Homo sapiens"
            /mol_type="mRNA"
            /db_xref="taxon:9606"
BASE COUNT  5 a 2 g 5 t
Query Match 1.0%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 6.4e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      457 TTCACACTTCA 468
Db      6 TTCACACTTCA 17
RESULT 945
AX273119
LOCUS      AX273119
DEFINITION Sequence 688 from Patent WO0162911.
ACCESSION  AX273119
VERSION     AX273119.1 GI:16545856
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Jarvis, T., von Carlowitz, I., Mcswiggen, J.A., Hamblin, P.A. and
            Ellis, J.H.
TITLE       Method and reagent for the inhibition of grid
            RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
JOURNAL     Patent: WO 0162911-A 688 30-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES    Location/Qualifiers
            source
            1..17
            /organism="Homo sapiens"
            /mol_type="mRNA"
            /db_xref="taxon:9606"
BASE COUNT  6 a 2 g 4 t
Query Match 1.0%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 6.4e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      457 TTCACACTTCA 468
Db      5 TTCACACTTCA 16
RESULT 946
AX500360/c
LOCUS      AX500360
DEFINITION Sequence 1667 from Patent EP1229046.
ACCESSION  AX500360
VERSION     AX500360.1 GI:23382653
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

```


REFERENCE 1
 AUTHORS Zhan,J.
 TITLE Human testis expressed patched like protein
 JOURNAL Patent: EP 1229046-A 1667 07-AUG-2002;
 Aeomica, Inc. (US)
 FEATURES Location/Qualifiers
 source 1..17
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"

BASE COUNT 2 a 2 c 2 g 11 t

Query Match 1.0%; Score 12; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 6.4e+02;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 680 AAATAGCAAAAT 691

Db 17 AAATAGCAAAAT 6

RESULT 947

AX500361/C
 LOCUS AX500361 17 bp DNA linear PAT 27-SEP-2002
 DEFINITION Sequence 1668 from Patent EP1229046.
 ACCESSION AX500361
 VERSION AX500361.1 GI:23382654
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
 AUTHORS Zhan,J.
 TITLE Human testis expressed patched like protein
 JOURNAL Patent: EP 1229046-A 1668 07-AUG-2002;
 Aeomica, Inc. (US)
 FEATURES Location/Qualifiers
 source 1..17
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"

BASE COUNT 2 a 1 c 2 g 12 t

Query Match 1.0%; Score 12; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 6.4e+02;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 680 AAATAGCAAAAT 691

Db 16 AAATAGCAAAAT 5

RESULT 948

AX500436
 LOCUS AX500436 17 bp DNA linear PAT 27-SEP-2002
 DEFINITION Sequence 1743 from Patent EP1229046.
 ACCESSION AX500436
 VERSION AX500436.1 GI:23382729
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
 AUTHORS Zhan,J.
 TITLE Human testis expressed patched like protein
 JOURNAL Patent: EP 1229046-A 1743 07-AUG-2002;
 Aeomica, Inc. (US)
 FEATURES Location/Qualifiers
 source 1..17
 /organism="Homo sapiens"
 /mol_type="genomic DNA"

BASE COUNT 4 a 3 c 5 g 5 t

Query Match 1.0%; Score 12; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 6.4e+02;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1442 TGCTGTTGAAA 1453

Db 6 TGCTGTTGAAA 17

RESULT 949

AX500437
 LOCUS AX500437 17 bp DNA linear PAT 27-SEP-2002
 DEFINITION Sequence 1744 from Patent EP1229046.
 ACCESSION AX500437
 VERSION AX500437.1 GI:23382730
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
 AUTHORS Zhan,J.
 TITLE Human testis expressed patched like protein
 JOURNAL Patent: EP 1229046-A 1744 07-AUG-2002;
 Aeomica, Inc. (US)
 FEATURES Location/Qualifiers
 source 1..17
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"

BASE COUNT 5 a 3 c 4 g 5 t

Query Match 1.0%; Score 12; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 6.4e+02;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1442 TGCTGTTGAAA 1453

Db 5 TGCTGTTGAAA 16

RESULT 950

AX500438
 LOCUS AX500438 17 bp DNA linear PAT 27-SEP-2002
 DEFINITION Sequence 1745 from Patent EP1229046.
 ACCESSION AX500438
 VERSION AX500438.1 GI:23382731
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
 AUTHORS Zhan,J.
 TITLE Human testis expressed patched like protein
 JOURNAL Patent: EP 1229046-A 1745 07-AUG-2002;
 Aeomica, Inc. (US)
 FEATURES Location/Qualifiers
 source 1..17
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"

BASE COUNT 6 a 2 c 4 g 5 t

Query Match 1.0%; Score 12; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 6.4e+02;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1442 TGCTGTTGAAA 1453

|||||

FEATURES		source		Molecular Engines Laboratories (FR)	
Location/Qualifiers		1. .17		/organism="Homo sapiens"	
/mol_type="genomic DNA"		/db_xref="taxon:9606"		11 t	
BASE COUNT	4 a 1 c 1 g 11 t				
Query Match	1.0%; Score 12; DB 1; Length 17;				
Best Local Similarity	100.0%; Pred. NO. 6.4e-02;				
Matches 12; Conservative	0; Mismatches 0; Indels 0; Gaps 0;				
QY	1144 TTATTTTATTTT 1155				
Db	6 TTATTTTATTTT 17				
RESULT 958					
AX672536/c					
LOCUS	17 bp DNA linear PAT 27-MAR-2003				
DEFINITION	Sequence 981 from Patent WO03004526.				
ACCESSION	AX672536				
VERSION	AX672536.1 GI:29330884				
KEYWORDS					
SOURCE	Homo sapiens (human)				
ORGANISM					
REFERENCE					
AUTHORS	Teerman,A., Anson,R. and Tuijnder,M.				
TITLE	Sequences involved in phenomena of tumour suppression, tumour				
	reversion, apoptosis and/or resistance to viruses and their use as				
	medicines				
JOURNAL	Patent: WO 03004526-A 981 16-JAN-2003;				
	Molecular Engines Laboratories (FR)				
FEATURES					
source	1. .17				
	/organism="Homo sapiens"				
	/mol_type="genomic DNA"				
	/db_xref="taxon:9606"				
BASE COUNT	7 a 3 c 3 g 4 t				
Query Match	1.0%; Score 12; DB 1; Length 17;				
Best Local Similarity	100.0%; Pred. NO. 6.4e-02;				
Matches 12; Conservative	0; Mismatches 0; Indels 0; Gaps 0;				
QY	1432 AGTAATTTCTTG 1443				
Db	16 AGTAATTTCTTG 5				
RESULT 959					
AX673577					
LOCUS	17 bp DNA linear PAT 27-MAR-2003				
DEFINITION	Sequence 2022 from Patent WO03004526.				
ACCESSION	AX673577				
VERSION	AX673577.1 GI:29331925				
KEYWORDS					
SOURCE	Homo sapiens (human)				
ORGANISM					
REFERENCE					
AUTHORS	Teerman,A., Anson,R. and Tuijnder,M.				
TITLE	Sequences involved in phenomena of tumour suppression, tumour				
	reversion, apoptosis and/or resistance to viruses and their use as				
	medicines				
JOURNAL	Patent: WO 03004526-A 2022 16-JAN-2003;				
	Molecular Engines Laboratories (FR)				
FEATURES					
source	1. .17				
	/organism="Homo sapiens"				
	/mol_type="genomic DNA"				

```
BASE COUNT      3 a      4 c      2 g      8 t
Query Match      1.0%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 6.4e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 910 TCCTTTATTTCT 921
DB 3 TCCTTTATTTCT 14

RESULT 960
AX723158
LOCUS      AX723158      17 bp      DNA
DEFINITION Sequence 845 from Patent WO03025176.
ACCESSION  AX723158
VERSION     AX723158.1 GI:30423659
KEYWORDS
SOURCE      Mus musculus (house mouse)
ORGANISM    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1
AUTHORS     Telerman,A., Amson,R. and Tuijnder,M.
TITLE       Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
JOURNAL     Patent: WO 03025176-A 845 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES    source
            1..17
            Location/Qualifiers
            6 a      1 c      2 g      8 t
Query Match      1.0%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 6.4e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 601 TATTTATTTGAA 612
DB 5 TATTTATTTGAA 16

RESULT 961
AX723252
LOCUS      AX723252      17 bp      DNA
DEFINITION Sequence 939 from Patent WO03025176.
ACCESSION  AX723252
VERSION     AX723252.1 GI:30423753
KEYWORDS
SOURCE      Mus musculus (house mouse)
ORGANISM    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1
AUTHORS     Telerman,A., Amson,R. and Tuijnder,M.
TITLE       Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
JOURNAL     Patent: WO 03025176-A 939 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES    source
            1..17
            Location/Qualifiers
            8 a      2 c      3 g      4 t
Query Match      1.0%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 6.4e+02;

BASE COUNT      8 a      2 c      3 g      4 t

QY 1521 TTTATATTTTGA 1532
DB 17 TTTATATTTTGA 6

Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1246 TCAGATAAACAA 1257
DB 3 TCAGATAAACAA 14

RESULT 962
AX723252/c
LOCUS      AX723252/c      17 bp      DNA
DEFINITION Sequence 939 from Patent WO03025176.
ACCESSION  AX723252
VERSION     AX723252.1 GI:30423753
KEYWORDS
SOURCE      Mus musculus (house mouse)
ORGANISM    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1
AUTHORS     Telerman,A., Amson,R. and Tuijnder,M.
TITLE       Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
JOURNAL     Patent: WO 03025176-A 939 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES    source
            1..17
            Location/Qualifiers
            8 a      2 c      3 g      4 t
Query Match      1.0%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 6.4e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1286 TTGTTTATCTGA 1297
DB 14 TTGTTTATCTGA 3

RESULT 963
AX725994/c
LOCUS      AX725994/c      17 bp      DNA
DEFINITION Sequence 3681 from Patent WO03025176.
ACCESSION  AX725994
VERSION     AX725994.1 GI:30505337
KEYWORDS
SOURCE      Mus musculus (house mouse)
ORGANISM    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1
AUTHORS     Telerman,A., Amson,R. and Tuijnder,M.
TITLE       Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
JOURNAL     Patent: WO 03025176-A 3681 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES    source
            1..17
            Location/Qualifiers
            11 a     1 c      1 g      4 t
Query Match      1.0%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 6.4e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1521 TTTATATTTTGA 1532
DB 17 TTTATATTTTGA 6
```

RESULT 964
AX726152/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
BASE COUNT
Query Match
Best Local Similarity
Matches
12; Conservative
0; Mismatches
0; Indels
0; Gaps
0;
QY 626 ACAATAATTTT 637
Db 16 ACAATAATTTT 5

RESULT 965
AX727032
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
BASE COUNT
Query Match
Best Local Similarity
Matches
12; Conservative
0; Mismatches
0; Indels
0; Gaps
0;
QY 1503 CATTTTTAAATA 1514
Db 4 CATTTTTAAATA 15

RESULT 966
AX727182/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
BASE COUNT
Query Match
Best Local Similarity
Matches
12; Conservative
0; Mismatches
0; Indels
0; Gaps
0;
QY 1503 CATTTTTAAATA 1514
Db 4 CATTTTTAAATA 15

RESULT 967
AX727214/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
BASE COUNT
Query Match
Best Local Similarity
Matches
12; Conservative
0; Mismatches
0; Indels
0; Gaps
0;
QY 1240 TTCATTTCAGAT 1251
Db 13 TTCATTTCAGAT 2

RESULT 968
AX728795/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
BASE COUNT
Query Match
Best Local Similarity
Matches
12; Conservative
0; Mismatches
0; Indels
0; Gaps
0;
QY 1158 ATATTAAATGAT 1169
Db 13 ATATTAAATGAT 2

RESULT 969
AX728795/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
BASE COUNT
Query Match
Best Local Similarity
Matches
12; Conservative
0; Mismatches
0; Indels
0; Gaps
0;
QY 1158 ATATTAAATGAT 1169
Db 13 ATATTAAATGAT 2

DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
BASE COUNT
Query Match
Best Local Similarity
Matches
12; Conservative
0; Mismatches
0; Indels
0; Gaps
0;
QY 1240 TTCATTTCAGAT 1251
Db 13 TTCATTTCAGAT 2

DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
BASE COUNT
Query Match
Best Local Similarity
Matches
12; Conservative
0; Mismatches
0; Indels
0; Gaps
0;
QY 1240 TTCATTTCAGAT 1251
Db 13 TTCATTTCAGAT 2

DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
BASE COUNT
Query Match
Best Local Similarity
Matches
12; Conservative
0; Mismatches
0; Indels
0; Gaps
0;
QY 1240 TTCATTTCAGAT 1251
Db 13 TTCATTTCAGAT 2

DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
BASE COUNT
Query Match
Best Local Similarity
Matches
12; Conservative
0; Mismatches
0; Indels
0; Gaps
0;
QY 1240 TTCATTTCAGAT 1251
Db 13 TTCATTTCAGAT 2

DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
BASE COUNT
Query Match
Best Local Similarity
Matches
12; Conservative
0; Mismatches
0; Indels
0; Gaps
0;
QY 1240 TTCATTTCAGAT 1251
Db 13 TTCATTTCAGAT 2

ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS Telerman, A., Anson, R. and Tuijinder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025175-A 429 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
7 a 2 c 2 g 6 t
BASE COUNT
Query Match 1.0%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 6.4e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1006 CATAAATTATTT 1017
Db 17 CATAAATTATTT 6
RESULT 969
LOCUS AX730870 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 2504 from Patent WO03025175.
ACCESSION AX730870
VERSION AX730870.1 GI:30510213
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
REFERENCE
AUTHORS Telerman, A., Anson, R. and Tuijinder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025175-A 2504 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
3 a 3 c 3 g 8 t
BASE COUNT
Query Match 1.0%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 6.4e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1572 CTGTTTCTGATT 1583
Db 4 CTGTTTCTGATT 15
RESULT 970
LOCUS AX731363 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 2997 from Patent WO03025175.
ACCESSION AX731363
VERSION AX731363.1 GI:30510706
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
REFERENCE
AUTHORS Telerman, A., Anson, R. and Tuijinder, M.

TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025175-A 2997 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
4 a 1 c 1 g 11 t
BASE COUNT
Query Match 1.0%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 6.4e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1144 TTATTTATTTT 1155
Db 6 TTATTTATTTT 17
RESULT 971
LOCUS AX732412 17 bp DNA linear PAT 09-MAY-2003
DEFINITION Sequence 4046 from Patent WO03025175.
ACCESSION AX732412
VERSION AX732412.1 GI:30511755
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
REFERENCE
AUTHORS Telerman, A., Anson, R. and Tuijinder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025175-A 4046 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
8 a 3 c 1 g 5 t
BASE COUNT
Query Match 1.0%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 6.4e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1457 GTTATTATGTA 1468
Db 17 GTTATTATGTA 6
RESULT 972
LOCUS AX732979 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 4613 from Patent WO03025175.
ACCESSION AX732979
VERSION AX732979.1 GI:30512322
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
REFERENCE
AUTHORS Telerman, A., Anson, R. and Tuijinder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025175-A 4613 27-MAR-2003;
Molecular Engines Laboratories (FR)

FEATURES source Location/Qualifiers

1..17 /organism="Homo sapiens" /mol_type="genomic DNA" /db_xref="taxon:9606" 6 t

BASE COUNT 9 a 1 c 1 g 6 t

Query Match 1.0%; Score 12; DB 1; Length 17; Best Local Similarity 100.0%; Pred. No. 6.4e+02; Mismatches 0; Indels 0; Gaps 0; Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1148 TTATTATTAGAT 1159
|||||

Db 13 TTATTATTAGAT 2

RESULT 973
AX733611
LOCUS AX733611 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 5245 from Patent WO03025175.
ACCESSION AX733611
VERSION AX733611.1 GI:30512954
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
JOURNAL Patent: WO 03025175-A 5245 27-MAR-2003; Molecular Engines Laboratories (FR)
FEATURES source Location/Qualifiers
1..17 /organism="Homo sapiens" /mol_type="genomic DNA" /db_xref="taxon:9606" 4 t

BASE COUNT 8 a 4 c 1 g 4 t

Query Match 1.0%; Score 12; DB 1; Length 17; Best Local Similarity 100.0%; Pred. No. 6.4e+02; Mismatches 0; Indels 0; Gaps 0; Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 612 ATCTACAAAAA 623
|||||

Db 2 ATCTACAAAAA 13

RESULT 974
AX734657/c
LOCUS AX734657 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 247 from Patent WO03025177.
ACCESSION AX734657
VERSION AX734657.1 GI:30513934
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments
JOURNAL Patent: WO 03025177-A 247 27-MAR-2003; Molecular Engines Laboratories (FR)
FEATURES source Location/Qualifiers
1..17 /organism="Homo sapiens" /mol_type="genomic DNA" /db_xref="taxon:9606"

BASE COUNT 7 a 1 c 4 g 5 t

Query Match 1.0%; Score 12; DB 1; Length 17; Best Local Similarity 100.0%; Pred. No. 6.4e+02; Mismatches 0; Indels 0; Gaps 0; Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1240 TTCATTTCAGAT 1251
|||||

Db 13 TTCATTTCAGAT 2

RESULT 975
BD066011
LOCUS BD066011 17 bp DNA linear PAT 27-AUG-2002
DEFINITION An antisense oligonucleotide preparation method.
ACCESSION BD066011
VERSION BD066011.1 GI:22611614
KEYWORDS JP 2001511000-A/646.
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 17)
AUTHORS Schlingensiepen,K.H. and Brysch,W.
TITLE An antisense oligonucleotide preparation method
JOURNAL Patent: JP 2001511000-A 646 07-AUG-2001; BIOLOGISCHES INSTITUT FÜR BIOMOLEKULARE DIAGNOSTIK MBH
COMMENT OS Unknown
FN JP 2001511000-A/646
PD 07-AUG-2001
PP 30-JAN-1998 JP 1998532533
PR 31-JAN-1997 EP 97101531.8
PI KARL HERMANN SCHLINGENSIEPEN WOLFGANG BRYSCH
PC C12N15/11,C07H21/04,A61K31/70
CC An antisense oligonucleotide preparation method FH Key
FEATURES source Location/Qualifiers
1..17 /organism="Unknown".
1..17 Location/Qualifiers
1..17 /organism="unidentified" /mol_type="genomic DNA" /db_xref="taxon:32644"

BASE COUNT 5 a 1 c 1 g 10 t

Query Match 1.0%; Score 12; DB 1; Length 17; Best Local Similarity 100.0%; Pred. No. 6.4e+02; Mismatches 0; Indels 0; Gaps 0; Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 635 TTTTGAATATAA 646
|||||

Db 6 TTTTGAATATAA 17

RESULT 976
BD067356
LOCUS BD067356 17 bp RNA linear PAT 27-AUG-2002
DEFINITION Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors.
ACCESSION BD067356
VERSION BD067356.1 GI:22612959
KEYWORDS JP 2001511003-A/196.
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 17)
AUTHORS Akhtar,S., Fell,P. and McSwiggen,J.A.
TITLE Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors
JOURNAL Patent: JP 2001511003-A 196 07-AUG-2001; RIBOZYME PHARMACEUTICALS INC,ASTON UNIV
COMMENT OS Unidentified
FN JP 2001511003-A/196
PD 07-AUG-2001

PF	14-JAN-1998	JP	1998532913	
PR	31-JAN-1997	US	60/036476,04-DEC-1997	US 08/985162 PI
SAGHIR AKHTAR,PATRICIA FELL,JAMES A MCSWIGGEN PC				
C12N9/00,C07K14/71				
CC	Strandedness: Single;			
CC	Topology: Linear;			
CC	Enzymatic nucleic acid treatment of diseases or conditions related to			
CC	levels of epidermal growth factor receptors			
PH	Key	Location/Qualifiers		
FT	source	1..17		
FT		/organism='Unidentified'.		
FEATURES				
source				
1..17				
Location/Qualifiers				
/organism='unidentified'				
/mol_type='genomic RNA'				
/db_xref='taxon:32644'				
7 a 1 c 4 g 5 t				
BASE COUNT				
Query Match 1.0%; Score 12; DB 1; Length 17;				
Best Local Similarity 100.0%; Pred. No. 6.4e+02;				
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;				
Qy	723	TAATTCAGGAA	734	
Db	5	TAATTCAGGAA	16	
RESULT 977				
BD067357				
LOCUS	17 bp RNA linear PAT 27-AUG-2002			
DEFINITION	Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors.			
ACCESSION	BD067357			
VERSION	BD067357.1 GI:22612960			
KEYWORDS	JP 2001511003-A/197.			
SOURCE	unidentified			
ORGANISM	unclassified.			
REFERENCES	1 (bases 1 to 17)			
AUTHORS	Akhtar,S., Fell,P. and Mcswiggen,J.A.			
TITLE	Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors			
JOURNAL	Patent: JP 2001511003-A 197 07-AUG-2001;			
COMMENT	RIBOZYME PHARMACEUTICALS INC,ASTON UNIV			
	EN	JP	2001511003-A/197	
	PD	07-AUG-2001		
	PP	14-JAN-1998	JP 1998532913	
	PR	31-JAN-1997	US 60/036476,04-DEC-1997	US 08/985162 PI
SAGHIR AKHTAR,PATRICIA FELL,JAMES A MCSWIGGEN PC				
C12N9/00,C07K14/71				
CC	Strandedness: Single;			
CC	Topology: Linear;			
CC	Enzymatic nucleic acid treatment of diseases or conditions related to			
CC	levels of epidermal growth factor receptors			
PH	Key	Location/Qualifiers		
FT	source	1..17		
FT		/organism='Unidentified'.		
FEATURES				
source				
1..17				
Location/Qualifiers				
/organism='unidentified'				
/mol_type='genomic RNA'				
/db_xref='taxon:32644'				
7 a 2 c 3 g 5 t				
BASE COUNT				
Query Match 1.0%; Score 12; DB 1; Length 17;				
Best Local Similarity 100.0%; Pred. No. 6.4e+02;				
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;				
Qy	723	TAATTCAGGAA	734	

SAGHIR AKHTAR, PATRICIA FELL, JAMES A MCSWIGGEN PC
 C12N9/00, C07K14/71
 CC Strandedness: Single;
 CC Topology: Linear;
 CC Enzymatic nucleic acid treatment of diseases or conditions CC
 related to
 CC levels of epidermal growth factor receptors
 FT Key
 FT source
 FT 1. .17
 Location/Qualifiers
 /organism="Unidentified".
 1. .17
 Location/Qualifiers
 /organism="unidentified"
 /mol_type="genomic RNA"
 /db_xref="taxon:32644"
 8 a 1 c 4 g 4 t
 BASE COUNT 5 a 0 c 3 g 9 t

Query Match 1.0%; Score 12; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 6.4e+02;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1599 AGTAATATGAA 1610
 |||||
 Db 6 AGTAATATGAA 17

RESULT 980
 I54298
 LOCUS 17 bp DNA linear PAT 07-OCT-1997
 DEFINITION Sequence 2039 from patent US 5646042.
 ACCESSION I54298
 VERSION I54298.1 GI:2475501
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 Unclassified.
 1 (bases 1 to 17)
 AUTHORS Stinchcomb, D.T., Draper, K., McSwiggen, J. and Jarvis, T.
 TITLE C-myc targeted ribozymes
 JOURNAL Patent: US 5646042-A 2039 08-JUL-1997;
 LOCATION/Qualifiers
 1. .17
 /organism="unknown"
 5 a 0 c 3 g 9 t
 BASE COUNT 5 a 0 c 3 g 9 t

Query Match 1.0%; Score 12; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 6.4e+02;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 544 ATGAATAGTTT 555
 |||||
 Db 3 ATGAATAGTTT 14

RESULT 981
 AR041398/c
 LOCUS 15 bp DNA linear PAT 29-SEP-1999
 DEFINITION Sequence 188 from patent US 5811300.
 ACCESSION AR041398
 VERSION AR041398.1 GI:5961894
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 Unclassified.
 1 (bases 1 to 15)
 AUTHORS Sullivan, S., Draper, K., Kisich, K., Stinchcomb, D.T. and McSwiggen, J.
 TITLE TNF- α ribozymes
 JOURNAL Patent: US 5811300-A 188 22-SEP-1998;
 LOCATION/Qualifiers
 1. .15
 /organism="unknown"
 5 a 0 c 0 g 10 t
 BASE COUNT 5 a 0 c 0 g 10 t

Query Match 0.9%; Score 11.8; DB 1; Length 15;
 Best Local Similarity 86.7%; Pred. No. 5.8e+02;
 Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1251 TAAACACAAATAAT 1265
 |||||
 Db 15 TAAATAATAATAAT 1

RESULT 982
 AR041915/c
 LOCUS 15 bp DNA linear PAT 29-SEP-1999
 DEFINITION Sequence 705 from patent US 5811300.
 ACCESSION AR041915
 VERSION AR041915.1 GI:5962411
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 Unclassified.
 1 (bases 1 to 15)
 AUTHORS Sullivan, S., Draper, K., Kisich, K., Stinchcomb, D.T. and McSwiggen, J.
 TITLE TNF- α ribozymes
 JOURNAL Patent: US 5811300-A 705 22-SEP-1998;
 LOCATION/Qualifiers
 1. .15
 /organism="unknown"
 5 a 0 c 0 g 10 t
 BASE COUNT 5 a 0 c 0 g 10 t

Query Match 0.9%; Score 11.8; DB 1; Length 15;
 Best Local Similarity 86.7%; Pred. No. 5.8e+02;
 Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1251 TAAACACAAATAAT 1265
 |||||
 Db 15 TAAATAATAATAAT 1

RESULT 983
 AX636855/c
 LOCUS 15 bp mRNA linear PAT 21-FEB-2003
 DEFINITION Sequence 3994 from Patent EP1260586.
 ACCESSION AX636855
 VERSION AX636855.1 GI:28472469
 KEYWORDS
 SOURCE unidentified
 ORGANISM unidentified
 Unclassified.
 1
 REFERENCE 1
 AUTHORS Stinchcomb, D.T., Dudycz, L.W., Chowrira, B., Grimm, S., Drenzo, A., Karpeisky, A., Draper, K.G., Kisich, K., Matulic-Adamic, J., McSwiggen, J.A., Modak, A., Pavco, P., Beigelman, L., Sullivan, S.M., Sweedler, D., Thompson, J.D., Tracz, D., Usman, N., Wincott, P.E. and Woolf, T.
 TITLE Method and reagent for inhibiting the expression of disease related genes
 JOURNAL Patent: EP 1260586-A 3994 27-NOV-2002;
 RIBOZYME PHARMACEUTICALS, INC. (US)
 LOCATION/Qualifiers
 1. .15
 /organism="unidentified"
 /mol_type="mRNA"
 /db_xref="taxon:32644"
 5 a 0 c 0 g 10 t
 BASE COUNT 5 a 0 c 0 g 10 t

Query Match 0.9%; Score 11.8; DB 1; Length 15;
 Best Local Similarity 86.7%; Pred. No. 5.8e+02;
 Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1251 TAAACACAAATAAT 1265
 |||||
 Db 15 TAAATAATAATAAT 1

RESULT 984
AX637379/c AX637379 15 bp mRNA linear PAT 21-FEB-2003
LOCUS Sequence 4518 from Patent EP1260586.
DEFINITION AX637379
ACCESSION AX637379
VERSION AX637379.1 GI:28472993
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
unclassified.
REFERENCE
1 Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Direnzo,A.,
Karpeisky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J.,
McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
Wolf,T.
TITLE Method and reagent for inhibiting the expression of disease related
genes
JOURNAL Patent: EP 1260586-A 4518 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
Source 1..15
/organism="unidentified"
/mol_type="mRNA"
/db_xref="taxon:32644"
BASE COUNT 5 a 0 c 0 g 10 t
Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. NO. 5.8e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1251 TAAACACAAATAT 1265
Db 15 TAAATATATATAT 1

Search completed: December 18, 2003, 07:17:26
Job time : 19 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: December 18, 2003, 07:20:09 ; Search time 13 Seconds
(without alignments)
2.704 Million cell updates/sec

Title: us-09-960-143-3

Perfect score: 1249

Sequence: 1 aaaaattctctctgtgtggt.....atataattgtgtcaaat 1249

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 0.5

Searched: 835 seqs, 14073 residues

Total number of hits satisfying chosen parameters: 1670

Minimum DB seq length: 8

Maximum DB seq length: 50

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 984 summaries

Database : rng.seq.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	50	4.0	50	1	ABZ00185
2	50	4.0	50	1	ABZ01793
3	50	4.0	50	1	ABL01980
4	30	2.4	30	1	ABL04338
5	30	2.4	30	1	ABL55125
6	30	2.4	30	1	ABL55126
7	28.4	2.3	18	1	AAH51650
8	26	2.1	26	1	AAH21908
9	25	2.0	26	1	AAH21907
10	24	1.9	24	1	ABS98731
11	24	1.9	24	1	AAH39937
12	24	1.9	24	1	AAH79046
13	21	1.7	21	1	AAH06866
14	21	1.7	21	1	AAH62016
15	21	1.7	21	1	AAH62018
16	21	1.7	21	1	ABL46343
17	21	1.7	21	1	ABL46345
18	20.8	1.7	24	1	AAH76783
19	20	1.6	20	1	AAV44676
20	20	1.6	20	1	AAV44678
21	20	1.6	20	1	AAZ30727
22	20	1.6	20	1	ABL46342
23	19	1.5	19	1	AAH76367
24	19	1.5	19	1	AAH54168
25	19	1.5	19	1	AAH19734
26	19	1.5	19	1	AAA33612
27	19	1.5	27	1	ABX11405
28	19	1.5	27	1	ABQ77073
29	18.6	1.5	25	1	AAH66457
30	18.2	1.5	24	1	AAH66531
31	17.6	1.4	25	1	AAH45430
32	17.4	1.4	21	1	AAH14463
33	17.4	1.4	21	1	AAH49639

34	17.4	1.4	21	1	AAH50228	Human ARE-mRNA seq
35	17.4	1.4	21	1	AAH53707	Adenylate Uridylat
36	17.4	1.4	24	1	AAH54044	Human MADP protein
37	17	1.4	17	1	AAH76273	Human MDCNF antise
38	17	1.4	17	1	AAH54070	Monocyte-derived n
39	17	1.4	17	1	AAH19636	Human monocyte der
40	17	1.4	17	1	AAH33514	Low adenosine anti
41	17	1.4	17	1	ABH46341	Human interleukin-
42	16.8	1.3	24	1	AAH45792	Human MGC-2413-31
43	16.8	1.3	24	1	AAH02441	Human CCR4 protein
44	16.6	1.3	26	1	AAH21908	PCR primer, 2767T
45	16.4	1.3	20	1	AAH21908	Human PI3 kinase p
46	16.4	1.3	22	1	AAH01237	Human chromosome 1
47	16.2	1.3	23	1	AAH10028	Human biallelic po
48	16.2	1.3	23	1	AAH33029	Human BRCA2 gene p
49	16.2	1.3	23	1	AAH32150	BRCA2 gene specifi
50	16.2	1.3	23	1	AAH22211	Aurone glycosyl tr
51	15.8	1.3	20	1	AAH27999	Human biallelic ma
52	15.8	1.3	20	1	AAH26837	Human osteoregulin
53	15.8	1.3	21	1	AAH67374	Nucleotide fragmen
54	15.8	1.3	21	1	AAH69186	Human ABC1 gene ex
55	15.8	1.3	21	1	AAH93051	ABC1 polymorphism
56	15.8	1.3	22	1	AAH37635	Porcine PERV locus
57	15.6	1.2	22	1	AAH64706	2',5'-linked tetra
58	15.6	1.2	26	1	AAH21907	PCR primer, 2767A
59	15.4	1.2	17	1	AAH22696	Integrin subunit b
60	15.4	1.2	17	1	AAH22697	Integrin subunit b
61	15.4	1.2	17	1	AAH22698	Integrin subunit b
62	15.4	1.2	17	1	AAH22699	Integrin subunit b
63	15.4	1.2	17	1	AAH22700	Integrin subunit b
64	15.4	1.2	17	1	AAH22701	Integrin subunit b
65	15.4	1.2	17	1	AAH22702	Integrin subunit b
66	15.4	1.2	17	1	AAH22703	Integrin subunit b
67	15.4	1.2	17	1	AAH22704	Integrin subunit b
68	15.4	1.2	17	1	AAH22705	Integrin subunit b
69	15.4	1.2	17	1	AAH22706	Integrin subunit b
70	15.4	1.2	17	1	AAH22899	Integrin subunit b
71	15.4	1.2	17	1	AAH22900	Integrin subunit b
72	15.4	1.2	17	1	AAH22901	Integrin subunit b
73	15.4	1.2	17	1	AAH22902	Integrin subunit b
74	15.4	1.2	17	1	AAH22903	Integrin subunit b
75	15.4	1.2	17	1	AAH80426	Human HTPPL scannin
76	15.4	1.2	17	1	AAH49440	Human adenylate ur
77	15.4	1.2	17	1	AAH50229	Human ARE-mRNA seq
78	15.4	1.2	17	1	AAH53708	Adenylate Uridylat
79	15.4	1.2	18	1	AAH41044	Cellular inhibitor
80	15.4	1.2	18	1	AAH22138	Human c-IAP-2 mRNA
81	15.4	1.2	19	1	AAH37308	3' primer #5 used
82	15.4	1.2	20	1	AAH09117	Human MEK3 antise
83	15.4	1.2	22	1	AAH22289	Human COL9A2 PCR p
84	15.2	1.2	22	1	AAH32809	Microsatellite rep
85	15.2	1.2	20	1	AAH57832	Primer pair 10A CD
86	15.2	1.2	20	1	AAH67914	Human/mouse casein
87	15.2	1.2	20	1	ABH85435	Oligonucleotide #1
88	15.2	1.2	21	1	AAH20077	HIV-1 DNA probe (g
89	15.2	1.2	21	1	AAH20043	Cross-linking olig
90	15.2	1.2	21	1	AAH30406	Oligomer IL2R503 f
91	15.2	1.2	21	1	AAH30408	Oligomer IL2R505 f
92	15.2	1.2	21	1	AAH75643	Reverse transcript
93	15.2	1.2	21	1	AAH29560	PCR primer E475783
94	15.2	1.2	21	1	AAH74938	Human CD40L promot
95	15	1.2	15	1	ABH46344	Human interleukin-
96	15	1.2	17	1	ABH07608	Human GMPLP-1 17-m
97	15	1.2	17	1	ABH07609	Human GMPLP-1 17-m
98	15	1.2	17	1	ABH07610	Human GMPLP-1 17-m
99	15	1.2	20	1	AAH55403	Acromionum chrysog
100	15	1.2	21	1	AAH79313	Human c-raf-1 onco
101	14.8	1.2	18	1	AAH14087	Probe HBP253 for
102	14.8	1.2	18	1	AAH90243	GRK4 allele specifi
103	14.8	1.2	18	1	ABH55998	Collagenase recogn
104	14.8	1.2	19	1	AAH82895	cdk4 ribozyme bind
105	14.8	1.2	19	1	AAH58057	Cell-cycle depende
106	14.8	1.2	20	1	AAH11919	Hepatocyte growth

C 107 14.8 1.2 20 1 AA237709 Human mdm2 phospho
C 108 14.8 1.2 20 1 AA298583 Human MAPK kinase
C 109 14.8 1.2 20 1 AA95269 Neurogulin-1 gene
C 110 14.8 1.2 20 1 AA96762 Neurogulin-1 gene
C 111 14.8 1.2 20 1 AA921759 Mouse Survivin ant
C 112 14.8 1.2 20 1 AA521760 Mouse Survivin ant
C 113 14.8 1.2 20 1 AA521760 Human mdm2 antisen
C 114 14.8 1.2 20 1 AA294788 Human mdm2 phospho
C 115 14.8 1.2 20 1 AA567849 Casein kinase-2 an
C 116 14.8 1.2 20 1 AA700039 Human neurogulin-1
C 117 14.8 1.2 20 1 AA701532 Human neurogulin-1
C 118 14.8 1.2 20 1 AB511148 Human TNF inducibl
C 119 14.8 1.2 20 1 AA732456 Neuroblastoma-rela
C 120 14.8 1.2 20 1 AB210278 Haematopoietic cel
C 121 14.8 1.2 21 1 AA710936 B. burgdorferi exp
C 122 14.8 1.2 21 1 AA226565 Human polymorphic
C 123 14.8 1.2 21 1 AA276395 Human biallelic ma
C 124 14.8 1.2 21 1 AA84289 Human cell death p
C 125 14.8 1.2 21 1 AA84289 Per tyrosine kinase
C 126 14.8 1.2 21 1 AA62464 CytochromeP19 poly
C 127 14.8 1.2 24 1 AA166531 Human pterin-molyb
C 128 14.4 1.2 16 1 AA74329 Leblolly pine SSR
C 129 14.4 1.2 16 1 AA74330 Leblolly pine SSR
C 130 14.4 1.2 16 1 AA703399 Human ovary specif
C 131 14.4 1.2 17 1 AA22707 Integrin subunit b
C 132 14.4 1.2 17 1 AA711138 Detection probe SE
C 133 14.4 1.2 17 1 ABV80425 Human HTPL scannin
C 134 14.4 1.2 17 1 ABV80427 Human HTPL scannin
C 135 14.4 1.2 17 1 ABT37900 Tumour suppression
C 136 14.4 1.2 18 1 AA732141 DNA sequencing 'pr
C 137 14.4 1.2 18 1 AB210520 Haematopoietic cel
C 138 14.4 1.2 20 1 AA089232 Rat opioid recepto
C 139 14.4 1.2 20 1 AA56684 Streptococcus pyog
C 140 14.4 1.2 20 1 AA683325 Human SAPL CDNA sp
C 141 14.4 1.2 19 1 AA62676 Cry2A family gene
C 142 14.2 1.1 19 1 AA883135 cdk7 ribozyme bind
C 143 14.2 1.1 19 1 AA58297 Cell-cycle depende
C 144 14.2 1.1 19 1 ABX93225 PCR primer Lp132r
C 145 14.2 1.1 19 1 AB210313 Haematopoietic cel
C 146 14.2 1.1 20 1 AAQ75568 Reverse transcript
C 147 14.2 1.1 20 1 AAQ91529 Tyrosinase gene 3'
C 148 14.2 1.1 20 1 AA74234 Mouse bg critical
C 149 14.2 1.1 20 1 AA747265 5' fragment #2 of
C 150 14.2 1.1 20 1 AA206093 PCR primer used to
C 151 14.2 1.1 20 1 AA201504 PCR primer used to
C 152 14.2 1.1 20 1 AA96384 PCR primer used to
C 153 14.2 1.1 20 1 AA915294 PCR primer RF-S4.
C 154 14.2 1.1 20 1 AA15295 PCR primer RF-S5.
C 155 14.2 1.1 20 1 AA38895 PCR primer SEQ ID
C 156 14.2 1.1 20 1 AA80900 Oligonucleotide hy
C 157 14.2 1.1 20 1 AA80901 Oligonucleotide hy
C 158 14.2 1.1 20 1 AA80905 Oligonucleotide hy
C 159 14.2 1.1 20 1 AA80906 Oligonucleotide hy
C 160 14.2 1.1 20 1 AA856708 S. aureus groG ope
C 161 14.2 1.1 20 1 ABQ79871 Nucleotide sequenc
C 162 14.2 1.1 20 1 ABS67672 Casein kinase-2 an
C 163 14.2 1.1 20 1 ABS59257 Human CAS gene ant
C 164 14.2 1.1 20 1 ABQ62328 Human syntaxin 4 i
C 165 14.2 1.1 20 1 AA518578 Human translocatin
C 166 14.2 1.1 20 1 ACC47011 Mouse phospholipas
C 167 14.2 1.1 20 1 AA522331 Human IFNGR2 antis
C 168 14.2 1.1 20 1 AA521486 3' end of the cott
C 169 14.2 1.1 15 1 AA756320 Mouse TNF-a hammer
C 170 14.2 1.1 15 1 AA755811 Human TNF-alpha ha
C 171 14.2 1.1 15 1 AA755796 Human TNF-alpha ha
C 172 14.2 1.1 16 1 AB734305 Hypocretin recepto
C 173 14.2 1.1 17 1 AA957934 Human EGF-R target
C 174 14.2 1.1 17 1 AA222807 Integrin subunit b
C 175 14.2 1.1 17 1 AA222808 Integrin subunit b
C 176 14.2 1.1 17 1 AA222809 Integrin subunit b
C 177 14.2 1.1 17 1 AA22810 Integrin subunit b
C 178 14.2 1.1 17 1 AA336306 Human genomic SNP
C 179 14.2 1.1 17 1 ABN07607 Human GDMLP-1 17-m

17 1 ABN07611 Human GDMLP-1 17-m
18 1 AA724944 PCR primer used to
19 1 AAQ82529 Chromosome 11 (loc
20 1 AA96450 PCR primer used to
20 1 AA298592 Human MAPK kinase
20 1 AA513722 Simple sequence re
50 1 AB201980 Human leukocyte ge
17 1 AA781506 Human c-myc hammer
17 1 AA966639 Potato citrate syn
17 1 AA19037 Human TIR-2 substr
17 1 AA11468 Integrin alpha 6 s
17 1 AA21475 Integrin alpha 6 s
17 1 AA22904 Integrin subunit b
17 1 AA91422 Human C-raf target
17 1 AA202426 Hammerhead ribozym
17 1 AA25364 Oestrogen receptor
17 1 AA25367 Oestrogen receptor
17 1 AA35990 Oestrogen receptor
17 1 ABV80684 Human HTPL scannin
17 1 ABK57491 Human CLCA1 gene e
17 1 AB261055 Human K-Ras DNazym
18 1 AA762126 A. thaliana plant
18 1 AA909459 Human biallelic po
18 1 AA717951 Chlamydia Genus sp
18 1 AA275038 Human biallelic ma
18 1 AA275043 Human biallelic ma
18 1 AA86606 Human 2 kinase hamme
18 1 AA717639 Human GCPII gene e
18 1 AA61772 Cdc 2 kinase hamme
18 1 AB210595 Haematopoietic cel
19 1 AAQ47991 PCR primer used in
19 1 AAQ52249 Ligase Chain React
19 1 AAQ62250 Ligase Chain React
19 1 AA74905 5' end fragment of
19 1 AA49298 Capped RNA influen
19 1 AA47269 Capped RNA influen
19 1 AA47270 Capped RNA influen
19 1 AA47271 Capped RNA influen
19 1 AA47272 Capped RNA influen
19 1 AA47267 Capped RNA influen
19 1 AA47276 5' fragment of ali
19 1 AA47277 Capped RNA influen
19 1 AA47278 Capped RNA influen
19 1 AA47279 Capped RNA influen
19 1 AA49123 rb gene antisense
19 1 AA26328 Human prostate can
19 1 AA274461 Human biallelic ma
19 1 AA83681 cdk-we-hu ribozyme
19 1 AA58843 Cdk-we-hu ribozyme
19 1 AB201793 Human leukocyte ge
15 1 AD26678 Human GPR31 gene p
20 1 ABQ79871 Nucleotide sequenc
20 1 AAQ64706 Nucleic acid synth
30 1 AA55126 Mouse TNF-a hammer
15 1 AA56350 Mouse TNF-a hammer
15 1 AA56326 Mouse TNF-a hammer
15 1 AA56332 Mouse TNF-a hammer
15 1 AA56338 Mouse TNF-alpha ha
15 1 AA55813 Human TNF-alpha ha
15 1 AA55817 Human TNF-alpha ha
15 1 AA55819 Human TNF-alpha ha
15 1 AA55797 Human TNF-alpha ha
15 1 AA55799 Human TNF-alpha ha
15 1 AA55801 Human TNF-alpha ha
15 1 AA40324 Primer 1a used to
15 1 AA40327 Group 1 intron sub
15 1 AA16099 Probe ATT-3. Sync
15 1 AA90942 Primer 1a for tetr
15 1 AA826597 Human interferon-a
15 1 AA80978 PTGS2 allele speci

253	13.4	1.1	15	1	AAF48964	IGFBP3 oligonucleo	IGFBP3 oligonucleo	13.2	1.1	18	1	ABZ33767	HIV-1 reverse tran
254	13.4	1.1	15	1	AAF48965	IGFBP3 oligonucleo	IGFBP3 oligonucleo	13.2	1.1	18	1	ABL30677	Human HLA gnotyp
255	13.4	1.1	15	1	AAF48966	IGFBP3 oligonucleo	IGFBP3 oligonucleo	13.2	1.1	18	1	ABX79935	EST polymorphic DN
256	13.4	1.1	15	1	AAF48967	IGFBP3 oligonucleo	IGFBP3 oligonucleo	13.2	1.1	18	1	ABZ10470	Haematopoietic cel
257	13.4	1.1	16	1	AAF40332	DNA cleavage subst	DNA cleavage subst	13	1.0	13	1	ABC00856	Oligonucleotide SE
258	13.4	1.1	16	1	AAF40329	Improved cleavage	Improved cleavage	13	1.0	13	1	ABC00857	Oligonucleotide SE
259	13.4	1.1	16	1	AAV03052	Primer 1 for tetra	Primer 1 for tetra	13	1.0	13	1	ABC02380	Oligonucleotide SE
260	13.4	1.1	16	1	AAV03052	Human uteroglobin	Human uteroglobin	13	1.0	13	1	ABC02381	Oligonucleotide SE
261	13.4	1.1	17	1	AAQ92084	Humicola grisea gl	Humicola grisea gl	13	1.0	13	1	ABC08775	Oligonucleotide SE
262	13.4	1.1	17	1	AAQ92084	Renilla reniformis	Renilla reniformis	13	1.0	13	1	ABC08775	Oligonucleotide SE
263	13.4	1.1	17	1	AAQ92084	Human c-myc hamper	Human c-myc hamper	13	1.0	13	1	ABC18133	Oligonucleotide SE
264	13.4	1.1	17	1	AAQ92084	Mouse flt-1 VEGF r	Mouse flt-1 VEGF r	13	1.0	13	1	ABC18133	Oligonucleotide SE
265	13.4	1.1	17	1	AAQ92084	Human flt-1 VEGF re	Human flt-1 VEGF re	13	1.0	13	1	ABC19108	Oligonucleotide SE
266	13.4	1.1	17	1	AAQ92084	Human flt-1 VEGF re	Human flt-1 VEGF re	13	1.0	13	1	ABC19109	Oligonucleotide SE
267	13.4	1.1	17	1	AAQ92084	ASO 2184dAN wild-t	ASO 2184dAN wild-t	13	1.0	13	1	ABC19440	Oligonucleotide SE
268	13.4	1.1	17	1	AAQ92084	Integrin alpha 6 s	Integrin alpha 6 s	13	1.0	13	1	ABC19441	Oligonucleotide SE
269	13.4	1.1	17	1	AAQ92084	Integrin alpha 6 s	Integrin alpha 6 s	13	1.0	13	1	ABC20820	Oligonucleotide SE
270	13.4	1.1	17	1	AAQ92084	Integrin alpha 6 s	Integrin alpha 6 s	13	1.0	13	1	ABC20821	Oligonucleotide SE
271	13.4	1.1	17	1	AAQ92084	Integrin alpha 6 s	Integrin alpha 6 s	13	1.0	13	1	ABC27496	Oligonucleotide SE
272	13.4	1.1	17	1	AAQ92084	Integrin subunit b	Integrin subunit b	13	1.0	13	1	ABC27497	Oligonucleotide SE
273	13.4	1.1	17	1	AAQ92084	Hammerhead ribozym	Hammerhead ribozym	13	1.0	13	1	ABC27750	Oligonucleotide SE
274	13.4	1.1	17	1	AAQ92084	Hammerhead ribozym	Hammerhead ribozym	13	1.0	13	1	ABC27751	Oligonucleotide SE
275	13.4	1.1	17	1	AAQ92084	Human HTPL scannin	Human HTPL scannin	13	1.0	13	1	ABC28094	Oligonucleotide SE
276	13.4	1.1	17	1	AAQ92084	Human HTPL scannin	Human HTPL scannin	13	1.0	13	1	ABC28095	Oligonucleotide SE
277	13.4	1.1	17	1	AAQ92084	Human HTPL scannin	Human HTPL scannin	13	1.0	13	1	ABC29508	Oligonucleotide SE
278	13.4	1.1	17	1	AAQ92084	Human ERG hamperhe	Human ERG hamperhe	13	1.0	13	1	ABC29509	Oligonucleotide SE
279	13.4	1.1	17	1	AAQ92084	Human ERG hamperhe	Human ERG hamperhe	13	1.0	13	1	ABC30110	Oligonucleotide SE
280	13.4	1.1	17	1	AAQ92084	Human ADAMTS-M PCR	Human ADAMTS-M PCR	13	1.0	13	1	ABC30111	Oligonucleotide SE
281	13.4	1.1	17	1	AAQ92084	Tumour suppression	Tumour suppression	13	1.0	13	1	ABC37546	Oligonucleotide SE
282	13.4	1.1	17	1	AAQ92084	Tumour suppression	Tumour suppression	13	1.0	13	1	ABC37547	Oligonucleotide SE
283	13.4	1.1	17	1	AAQ92084	Tumour suppression	Tumour suppression	13	1.0	13	1	ABC37938	Oligonucleotide SE
284	13.4	1.1	17	1	AAQ92084	Human K-Ras DNazym	Human K-Ras DNazym	13	1.0	13	1	ABC37939	Oligonucleotide SE
285	13.4	1.1	17	1	AAQ92084	Human K-Ras DNazym	Human K-Ras DNazym	13	1.0	13	1	ABC40557	Oligonucleotide SE
286	13.4	1.1	17	1	AAQ92084	PCR primer used to	PCR primer used to	13	1.0	13	1	ABC40557	Oligonucleotide SE
287	13.4	1.1	17	1	AAQ92084	Human sentrin phos	Human sentrin phos	13	1.0	13	1	ABC55322	Oligonucleotide SE
288	13.4	1.1	17	1	AAQ92084	Wild type sequence	Wild type sequence	13	1.0	13	1	ABC55323	Oligonucleotide SE
289	13.4	1.1	17	1	AAQ92084	PAF-AH DNA related	PAF-AH DNA related	13	1.0	13	1	ABC61518	Oligonucleotide SE
290	13.4	1.1	17	1	AAQ92084	Primer #2 to ampli	Primer #2 to ampli	13	1.0	13	1	ABC61519	Oligonucleotide SE
291	13.4	1.1	17	1	AAQ92084	Human IVS17 3'-acc	Human IVS17 3'-acc	13	1.0	13	1	ABC61822	Oligonucleotide SE
292	13.4	1.1	17	1	AAQ92084	Human biallelic ma	Human biallelic ma	13	1.0	13	1	ABC61823	Oligonucleotide SE
293	13.4	1.1	17	1	AAQ92084	Cyclin C ribozyme	Cyclin C ribozyme	13	1.0	13	1	ABC67270	Oligonucleotide SE
294	13.4	1.1	17	1	AAQ92084	Rat adenosine rece	Rat adenosine rece	13	1.0	13	1	ABC67271	Oligonucleotide SE
295	13.4	1.1	17	1	AAQ92084	Human inflammatory	Human inflammatory	13	1.0	13	1	ABC72812	Oligonucleotide SE
296	13.4	1.1	17	1	AAQ92084	S. aureus groB ope	S. aureus groB ope	13	1.0	13	1	ABC72813	Oligonucleotide SE
297	13.4	1.1	17	1	AAQ92084	Cyclin C ribozyme	Cyclin C ribozyme	13	1.0	13	1	ABC78656	Oligonucleotide SE
298	13.4	1.1	17	1	AAQ92084	Low abundance nucl	Low abundance nucl	13	1.0	13	1	ABC78657	Oligonucleotide SE
299	13.4	1.1	17	1	AAQ92084	Human CYP4501A2 Ex	Human CYP4501A2 Ex	13	1.0	13	1	ABC81442	Oligonucleotide SE
300	13.4	1.1	17	1	AAQ92084	Human CCR4 protein	Human CCR4 protein	13	1.0	13	1	ABC81443	Oligonucleotide SE
301	13.4	1.1	17	1	AAQ92084	Cross-linking olig	Cross-linking olig	13	1.0	13	1	ABC83552	Oligonucleotide SE
302	13.4	1.1	17	1	AAQ92084	Cross-linking olig	Cross-linking olig	13	1.0	13	1	ABC83553	Oligonucleotide SE
303	13.4	1.1	17	1	AAQ92084	Oligomer HSV723 fo	Oligomer HSV723 fo	13	1.0	13	1	ABC83568	Oligonucleotide SE
304	13.4	1.1	17	1	AAQ92084	Oligomer HSV702 fo	Oligomer HSV702 fo	13	1.0	13	1	ABC83569	Oligonucleotide SE
305	13.4	1.1	17	1	AAQ92084	Oligomer HUM beta	Oligomer HUM beta	13	1.0	13	1	ABF01934	Oligonucleotide SE
306	13.4	1.1	17	1	AAQ92084	Probe HBP257 for	Probe HBP257 for	13	1.0	13	1	ABF01935	Oligonucleotide SE
307	13.4	1.1	17	1	AAQ92084	Probe HBP254 for	Probe HBP254 for	13	1.0	13	1	ABF12532	Oligonucleotide SE
308	13.4	1.1	17	1	AAQ92084	Probe HBP254 for	Probe HBP254 for	13	1.0	13	1	ABF12533	Oligonucleotide SE
309	13.4	1.1	17	1	AAQ92084	Probe HBP255 for	Probe HBP255 for	13	1.0	13	1	ABF15742	Oligonucleotide SE
310	13.4	1.1	17	1	AAQ92084	Sense primer 1 for	Sense primer 1 for	13	1.0	13	1	ABF15743	Oligonucleotide SE
311	13.4	1.1	17	1	AAQ92084	Antisense oligonuc	Antisense oligonuc	13	1.0	13	1	ABF16637	Oligonucleotide SE
312	13.4	1.1	17	1	AAQ92084	GRK4 allele specif	GRK4 allele specif	13	1.0	13	1	ABF20442	Oligonucleotide SE
313	13.4	1.1	17	1	AAQ92084	PCR primer for con	PCR primer for con	13	1.0	13	1	ABF20443	Oligonucleotide SE
314	13.4	1.1	17	1	AAQ92084	PCR primer for Hum	PCR primer for Hum	13	1.0	13	1	ABF20500	Oligonucleotide SE
315	13.4	1.1	17	1	AAQ92084	Human biallelic ma	Human biallelic ma	13	1.0	13	1	ABF20501	Oligonucleotide SE
316	13.4	1.1	17	1	AAQ92084	Yersinia YopE mRNA	Yersinia YopE mRNA	13	1.0	13	1	ABF33284	Oligonucleotide SE
317	13.4	1.1	17	1	AAQ92084	Yersinia YopE spon	Yersinia YopE spon	13	1.0	13	1	ABF33285	Oligonucleotide SE
318	13.4	1.1	17	1	AAQ92084	Yersinia YopE spon	Yersinia YopE spon	13	1.0	13	1	ABF50618	Oligonucleotide SE
319	13.4	1.1	17	1	AAQ92084	Yersinia YopE spon	Yersinia YopE spon	13	1.0	13	1	ABF50619	Oligonucleotide SE
320	13.4	1.1	17	1	AAQ92084	Human GCPII gene e	Human GCPII gene e	13	1.0	13	1	ABF53014	Oligonucleotide SE
321	13.4	1.1	17	1	AAQ92084	Parathyroid hormon	Parathyroid hormon	13	1.0	13	1	ABF53015	Oligonucleotide SE
322	13.4	1.1	17	1	AAQ92084	Shrimp white spot	Shrimp white spot	13	1.0	13	1	ABF50866	Oligonucleotide SE
323	13.4	1.1	17	1	AAQ92084	Human Akt-3 antise	Human Akt-3 antise	13	1.0	13	1	ABF60867	Oligonucleotide SE
324	13.4	1.1	17	1	AAQ92084	Binary encoded seq	Binary encoded seq	13	1.0	13	1	ABF65362	Oligonucleotide SE
325	13.4	1.1	17	1	AAQ92084			13	1.0	13	1		

399	13	1.0	1	13	1	ABP65363	Oligonucleotide SE	472	13	1.0	17	1	ABN07606	Human GDMPLP-1 17-m
400	13	1.0	1	13	1	ABP68618	Oligonucleotide SE	473	13	1.0	17	1	ABN07612	Human ERG hammerhe
401	13	1.0	1	13	1	ABP68619	Oligonucleotide SE	474	13	1.0	17	1	ABX17633	Tumour suppression
402	13	1.0	1	13	1	ABF71788	Oligonucleotide SE	475	13	1.0	17	1	AA374689	Primer NGA63-F for
403	13	1.0	1	13	1	ABF71789	Oligonucleotide SE	476	13	1.0	18	1	AA379107	TEIL random bindin
404	13	1.0	1	13	1	ABF83258	Oligonucleotide SE	477	13	1.0	18	1	AA295455	EGF-R mRNA specifi
405	13	1.0	1	13	1	ABF83259	Oligonucleotide SE	478	13	1.0	18	1	AAH22863	EGF-R mRNA specifi
406	13	1.0	1	13	1	ABF83902	Oligonucleotide SE	479	13	1.0	18	1	AAH22864	Human genetic mark
407	13	1.0	1	13	1	ABF83903	Oligonucleotide SE	480	13	1.0	18	1	AAH22864	Corynebacterium th
408	13	1.0	1	13	1	ABF88502	Oligonucleotide SE	481	13	1.0	18	1	AAH22864	Corynebacterium th
409	13	1.0	1	13	1	ABF88503	Oligonucleotide SE	482	13	1.0	18	1	AAH22864	Corynebacterium th
410	13	1.0	1	13	1	ABF94864	Oligonucleotide SE	483	13	1.0	18	1	AAH22864	Corynebacterium th
411	13	1.0	1	13	1	ABF94865	Oligonucleotide SE	484	13	1.0	18	1	AAH22864	Corynebacterium th
412	13	1.0	1	13	1	ABH13810	Oligonucleotide SE	485	13	1.0	18	1	AAH22864	Corynebacterium th
413	13	1.0	1	13	1	ABH13811	Oligonucleotide SE	486	13	1.0	18	1	AAH22864	Corynebacterium th
414	13	1.0	1	13	1	ABH231148	Oligonucleotide SE	487	13	1.0	30	1	AAH22864	Corynebacterium th
415	13	1.0	1	13	1	ABH231149	Oligonucleotide SE	488	12.8	1.0	16	1	AAH22864	Corynebacterium th
416	13	1.0	1	13	1	ABH27672	Oligonucleotide SE	489	12.8	1.0	16	1	AAH22864	Corynebacterium th
417	13	1.0	1	13	1	ABH27673	Oligonucleotide SE	490	12.8	1.0	16	1	AAH22864	Corynebacterium th
418	13	1.0	1	13	1	ABH29395	Oligonucleotide SE	491	12.8	1.0	16	1	AAH22864	Corynebacterium th
419	13	1.0	1	13	1	ABH29397	Oligonucleotide SE	492	12.8	1.0	17	1	AAH22864	Corynebacterium th
420	13	1.0	1	13	1	ABH37864	Oligonucleotide SE	493	12.8	1.0	17	1	AAH22864	Corynebacterium th
421	13	1.0	1	13	1	ABH37865	Oligonucleotide SE	494	12.8	1.0	17	1	AAH22864	Corynebacterium th
422	13	1.0	1	13	1	ABH48890	Oligonucleotide SE	495	12.8	1.0	17	1	AAH22864	Corynebacterium th
423	13	1.0	1	13	1	ABH48891	Oligonucleotide SE	496	12.8	1.0	17	1	AAH22864	Corynebacterium th
424	13	1.0	1	13	1	ABH49485	Oligonucleotide SE	497	12.8	1.0	17	1	AAH22864	Corynebacterium th
425	13	1.0	1	13	1	ABH49487	Oligonucleotide SE	498	12.8	1.0	17	1	AAH22864	Corynebacterium th
426	13	1.0	1	13	1	ABH53272	Oligonucleotide SE	499	12.8	1.0	17	1	AAH22864	Corynebacterium th
427	13	1.0	1	13	1	ABH53273	Oligonucleotide SE	500	12.8	1.0	17	1	AAH22864	Corynebacterium th
428	13	1.0	1	13	1	ABH53668	Oligonucleotide SE	501	12.8	1.0	17	1	AAH22864	Corynebacterium th
429	13	1.0	1	13	1	ABH53669	Oligonucleotide SE	502	12.8	1.0	17	1	AAH22864	Corynebacterium th
430	13	1.0	1	13	1	ABH55558	Oligonucleotide SE	503	12.8	1.0	17	1	AAH22864	Corynebacterium th
431	13	1.0	1	13	1	ABH55559	Oligonucleotide SE	504	12.8	1.0	17	1	AAH22864	Corynebacterium th
432	13	1.0	1	13	1	ABH57674	Oligonucleotide SE	505	12.8	1.0	17	1	AAH22864	Corynebacterium th
433	13	1.0	1	13	1	ABH57675	Oligonucleotide SE	506	12.8	1.0	17	1	AAH22864	Corynebacterium th
434	13	1.0	1	13	1	ABH58412	Oligonucleotide SE	507	12.8	1.0	17	1	AAH22864	Corynebacterium th
435	13	1.0	1	13	1	ABH58413	Oligonucleotide SE	508	12.8	1.0	17	1	AAH22864	Corynebacterium th
436	13	1.0	1	13	1	ABH62638	Oligonucleotide SE	509	12.8	1.0	17	1	AAH22864	Corynebacterium th
437	13	1.0	1	13	1	ABH62639	Oligonucleotide SE	510	12.8	1.0	17	1	AAH22864	Corynebacterium th
438	13	1.0	1	13	1	ABH66082	Oligonucleotide SE	511	12.8	1.0	17	1	AAH22864	Corynebacterium th
439	13	1.0	1	13	1	ABH66083	Oligonucleotide SE	512	12.8	1.0	17	1	AAH22864	Corynebacterium th
440	13	1.0	1	15	1	AAT56348	Mouse TNF-a hammer	513	12.8	1.0	17	1	AAH22864	Corynebacterium th
441	13	1.0	1	15	1	AAT56318	Mouse TNF-a hammer	514	12.8	1.0	17	1	AAH22864	Corynebacterium th
442	13	1.0	1	15	1	AAT55809	Human TNF-alpha ha	515	12.8	1.0	17	1	AAH22864	Corynebacterium th
443	13	1.0	1	15	1	AAT55794	Human TNF-alpha ha	516	12.8	1.0	17	1	AAH22864	Corynebacterium th
444	13	1.0	1	15	1	AAT57265	RSV N hammerhead r	517	12.8	1.0	17	1	AAH22864	Corynebacterium th
445	13	1.0	1	15	1	AAT91825	Antitumoural phosph	518	12.8	1.0	17	1	AAH22864	Corynebacterium th
446	13	1.0	1	15	1	AAT91826	Human TNFRSF11B ge	519	12.8	1.0	17	1	AAH22864	Corynebacterium th
447	13	1.0	1	15	1	AAH70068	Human TNFRSF11B ge	520	12.8	1.0	17	1	AAH22864	Corynebacterium th
448	13	1.0	1	15	1	AAH70070	Human ovary specif	521	12.8	1.0	17	1	AAH22864	Corynebacterium th
449	13	1.0	1	15	1	ABT04008	Pro-UK probe T6 (T	522	12.8	1.0	17	1	AAH22864	Corynebacterium th
450	13	1.0	1	17	1	AAQ23015	Type II procollage	523	12.8	1.0	17	1	AAH22864	Corynebacterium th
451	13	1.0	1	17	1	AAQ23015	Human EGF-R target	524	12.8	1.0	17	1	AAH22864	Corynebacterium th
452	13	1.0	1	17	1	AAV97734	Human EGF-R target	525	12.8	1.0	17	1	AAH22864	Corynebacterium th
453	13	1.0	1	17	1	AAV97735	Human EGF-R target	526	12.8	1.0	17	1	AAH22864	Corynebacterium th
454	13	1.0	1	17	1	AAV97736	Human EGF-R target	527	12.8	1.0	17	1	AAH22864	Corynebacterium th
455	13	1.0	1	17	1	AAH22686	Integrin subunit b	528	12.8	1.0	17	1	AAH22686	Corynebacterium th
456	13	1.0	1	17	1	AAH22687	Integrin subunit b	529	12.8	1.0	17	1	AAH22686	Corynebacterium th
457	13	1.0	1	17	1	AAH22688	Integrin subunit b	530	12.8	1.0	17	1	AAH22686	Corynebacterium th
458	13	1.0	1	17	1	AAH22689	Integrin subunit b	531	12.8	1.0	17	1	AAH22686	Corynebacterium th
459	13	1.0	1	17	1	AAH22806	Integrin subunit b	532	12.8	1.0	17	1	AAH22686	Corynebacterium th
460	13	1.0	1	17	1	AAH22811	Integrin subunit b	533	12.8	1.0	17	1	AAH22686	Corynebacterium th
461	13	1.0	1	17	1	AAH23569	Human B-raf substr	534	12.8	1.0	17	1	AAH23569	Corynebacterium th
462	13	1.0	1	17	1	AAH23570	Human B-raf substr	535	12.8	1.0	17	1	AAH23569	Corynebacterium th
463	13	1.0	1	17	1	AAH23571	Hammerhead ribozym	536	12.8	1.0	17	1	AAH23569	Corynebacterium th
464	13	1.0	1	17	1	AAH23572	Hammerhead ribozym	537	12.8	1.0	17	1	AAH23569	Corynebacterium th
465	13	1.0	1	17	1	AAH23573	Hammerhead ribozym	538	12.8	1.0	17	1	AAH23569	Corynebacterium th
466	13	1.0	1	17	1	AAH23574	Hammerhead ribozym	539	12.8	1.0	17	1	AAH23569	Corynebacterium th
467	13	1.0	1	17	1	AAH23575	Factor V mutation	540	12.8	1.0	17	1	AAH23569	Corynebacterium th
468	13	1.0	1	17	1	AAH23576	Factor V mutation	541	12.8	1.0	17	1	AAH23569	Corynebacterium th
469	13	1.0	1	17	1	AAH23577	Factor V mutation	542	12.8	1.0	17	1	AAH23569	Corynebacterium th
470	13	1.0	1	17	1	AAH23578	Human CLCA1 gene e	543	12.8	1.0	17	1	AAH23569	Corynebacterium th
471	13	1.0	1	17	1	AAH23579	Human CLCA1 gene e	544	12.8	1.0	17	1	AAH23569	Corynebacterium th

C 545	12.8	1.0	17	1	AAH61737	Cdc 2 kinase hamme
C 546	12.8	1.0	17	1	AAH56150	Staphylococcus aur
C 547	12.8	1.0	17	1	ABK00430	Human NQO Hammerh
C 548	12.8	1.0	17	1	ABK00457	Human NQO Hammerh
C 549	12.8	1.0	17	1	ABK01316	Human NQO Inozyme
C 550	12.8	1.0	17	1	ABK01612	Human NQO G-cleav
C 551	12.8	1.0	17	1	ABK02193	Human NQO DNazyme
C 552	12.8	1.0	17	1	ABV80693	Human HTPL scannin
C 553	12.8	1.0	17	1	ABV80693	Human HTPL scannin
C 554	12.8	1.0	17	1	ABV83076	Human HTPL scannin
C 555	12.8	1.0	17	1	ABV83077	Human HTPL scannin
C 556	12.8	1.0	17	1	ABV90149	Human POSHL1 scann
C 557	12.8	1.0	17	1	ABV90150	Human POSHL1 scann
C 558	12.8	1.0	17	1	ABK56195	Human CLCA1 gene e
C 559	12.8	1.0	17	1	ABK56693	Human CLCA1 gene e
C 560	12.8	1.0	17	1	ABK56852	Human CLCA1 gene e
C 561	12.8	1.0	17	1	ABK56963	Human CLCA1 gene e
C 562	12.8	1.0	17	1	ABK57058	Human CLCA1 gene e
C 563	12.8	1.0	17	1	ABK18668	Human ERG G-cleave
C 564	12.8	1.0	17	1	ABK18697	Human ERG G-cleave
C 565	12.8	1.0	17	1	ABT34683	Tumour suppression
C 566	12.8	1.0	17	1	ABT34698	Tumour suppression
C 567	12.8	1.0	17	1	ABT35053	Tumour suppression
C 568	12.8	1.0	17	1	ABT35977	Tumour suppression
C 569	12.8	1.0	17	1	ABT36351	Tumour suppression
C 570	12.8	1.0	17	1	ABT36416	Tumour suppression
C 571	12.8	1.0	17	1	ABT37756	Tumour suppression
C 572	12.8	1.0	17	1	ABT38062	Tumour suppression
C 573	12.8	1.0	17	1	ABT38413	Tumour suppression
C 574	12.8	1.0	17	1	ABT39158	Tumour suppression
C 575	12.8	1.0	17	1	ABT39376	Tumour suppression
C 576	12.8	1.0	17	1	ABT39378	Tumour suppression
C 577	12.8	1.0	17	1	ABT39979	Tumour suppression
C 578	12.8	1.0	17	1	ABT40081	Tumour suppression
C 579	12.8	1.0	17	1	ABT60208	Human K-Ras DNazym
C 580	12.8	1.0	17	1	ABT60265	Human K-Ras DNazym
C 581	12.8	1.0	17	1	ABT60471	Human K-Ras DNazym
C 582	12.8	1.0	17	1	ABT60554	Human K-Ras DNazym
C 583	12.8	1.0	17	1	ABT60733	Human K-Ras DNazym
C 584	12.8	1.0	17	1	ABT61054	Human K-Ras DNazym
C 585	12.8	1.0	17	1	ABT61098	Human K-Ras DNazym
C 586	12.8	1.0	17	1	ABT61149	Human K-Ras DNazym
C 587	12.8	1.0	17	1	ABT61155	Human K-Ras DNazym
C 588	12.8	1.0	17	1	ABT61203	Human K-Ras DNazym
C 589	12.8	1.0	17	1	ABT61621	Human H-Ras DNazym
C 590	12.8	1.0	18	1	AAH43555	HUMTH01 microsatel
C 591	12.8	1.0	18	1	AAV60776	HIV-1 strain YB30
C 592	12.8	1.0	18	1	AAV49122	rb gene antisense
C 593	12.8	1.0	18	1	AAV36410	Antisense oligonuc
C 594	12.8	1.0	18	1	AAV36411	Sense oligonucleot
C 595	12.8	1.0	18	1	AAV34526	Chemokine receptor
C 596	12.8	1.0	18	1	AAZ41004	Human RhoC phospho
C 597	12.8	1.0	18	1	AAZ56787	WO9222023 probe 23
C 598	12.8	1.0	18	1	AAH37761	Staphylococcus sp.
C 599	12.8	1.0	18	1	AAV82030	Moraxella lactofer
C 600	12.8	1.0	18	1	AAV82031	Moraxella lactofer
C 601	12.8	1.0	18	1	AAZ25754	RT-PCR primer RT-N
C 602	12.8	1.0	18	1	AAZ70894	Human biallelic ma
C 603	12.8	1.0	18	1	AAZ71730	Human biallelic ma
C 604	12.8	1.0	18	1	AAH86605	Cdc 2 kinase hamme
C 605	12.8	1.0	18	1	AAH86607	Cdc 2 kinase hamme
C 606	12.8	1.0	18	1	AAH86759	Cdc 2 kinase hamme
C 607	12.8	1.0	18	1	AAH10824	G-alpha-11 antisen
C 608	12.8	1.0	18	1	AAZ294449	Human Ship-2 phosph
C 609	12.8	1.0	18	1	AAZ37341	Interleukin-15 ant
C 610	12.8	1.0	18	1	AAH61773	Cdc 2 kinase hamme
C 611	12.8	1.0	18	1	AAH61773	Cdc 2 kinase hamme
C 612	12.8	1.0	18	1	AAH61925	Cdc 2 kinase hamme
C 613	12.8	1.0	18	1	AAH61925	Cdc 2 kinase hamme
C 614	12.8	1.0	18	1	AAH61925	Primer T-PA2. Uni
C 615	12.8	1.0	18	1	AAH61925	Genomic DNA methyl
C 616	12.8	1.0	18	1	AAH61925	Mixed element RESI
C 617	12.8	1.0	18	1	ABS54314	P. falciparum DHFR
C 618	12.8	1.0	18	1	ABS54315	P. falciparum DHFR
C 619	12.8	1.0	18	1	ABO65395	Human gene methyl
C 620	12.8	1.0	18	1	ABK34044	Human NFI probe #2
C 621	12.8	1.0	18	1	ABK40096	Human super oxide
C 622	12.8	1.0	18	1	ABK40096	Human super oxide
C 623	12.8	1.0	18	1	ABK40096	Human super oxide
C 624	12.8	1.0	18	1	ABZ70969	Human bcl-2 relate
C 625	12.8	1.0	18	1	ABZ10410	Haematopoietic cel
C 626	12.8	1.0	18	1	ABZ10519	Haematopoietic cel
C 627	12.8	1.0	18	1	ABZ10596	Haematopoietic cel
C 628	12.8	1.0	18	1	ABZ10922	Haematopoietic cel
C 629	12.8	1.0	19	1	AAH81135	cdk7 ribozyme bind
C 630	12.8	1.0	19	1	AAH82297	Cell-cycle depende
C 631	12.6	1.0	13	1	ABC05468	Oligonucleotide SE
C 632	12.6	1.0	13	1	ABC05469	Oligonucleotide SE
C 633	12.6	1.0	13	1	ABC12854	Oligonucleotide SE
C 634	12.6	1.0	13	1	ABC12855	Oligonucleotide SE
C 635	12.6	1.0	13	1	ABC13828	Oligonucleotide SE
C 636	12.6	1.0	13	1	ABC13829	Oligonucleotide SE
C 637	12.6	1.0	13	1	ABC23680	Oligonucleotide SE
C 638	12.6	1.0	13	1	ABC23681	Oligonucleotide SE
C 639	12.6	1.0	13	1	ABC26934	Oligonucleotide SE
C 640	12.6	1.0	13	1	ABC26935	Oligonucleotide SE
C 641	12.6	1.0	13	1	ABC45016	Oligonucleotide SE
C 642	12.6	1.0	13	1	ABC45017	Oligonucleotide SE
C 643	12.6	1.0	13	1	ABC52710	Oligonucleotide SE
C 644	12.6	1.0	13	1	ABC52711	Oligonucleotide SE
C 645	12.6	1.0	13	1	ABC59940	Oligonucleotide SE
C 646	12.6	1.0	13	1	ABC72766	Oligonucleotide SE
C 647	12.6	1.0	13	1	ABC72767	Oligonucleotide SE
C 648	12.6	1.0	13	1	ABC75212	Oligonucleotide SE
C 649	12.6	1.0	13	1	ABC75213	Oligonucleotide SE
C 650	12.6	1.0	13	1	ABC80810	Oligonucleotide SE
C 651	12.6	1.0	13	1	ABC80811	Oligonucleotide SE
C 652	12.6	1.0	13	1	ABC93680	Oligonucleotide SE
C 653	12.6	1.0	13	1	ABC93681	Oligonucleotide SE
C 654	12.6	1.0	13	1	ABC95530	Oligonucleotide SE
C 655	12.6	1.0	13	1	ABC95531	Oligonucleotide SE
C 656	12.6	1.0	13	1	ABC95532	Oligonucleotide SE
C 657	12.6	1.0	13	1	ABF24642	Oligonucleotide SE
C 658	12.6	1.0	13	1	ABF24643	Oligonucleotide SE
C 659	12.6	1.0	13	1	ABF46540	Oligonucleotide SE
C 660	12.6	1.0	13	1	ABF46541	Oligonucleotide SE
C 661	12.6	1.0	13	1	ABF52838	Oligonucleotide SE
C 662	12.6	1.0	13	1	ABF52839	Oligonucleotide SE
C 663	12.6	1.0	13	1	ABF53002	Oligonucleotide SE
C 664	12.6	1.0	13	1	ABF53003	Oligonucleotide SE
C 665	12.6	1.0	13	1	ABF54452	Oligonucleotide SE
C 666	12.6	1.0	13	1	ABF54453	Oligonucleotide SE
C 667	12.6	1.0	13	1	ABF57444	Oligonucleotide SE
C 668	12.6	1.0	13	1	ABF57445	Oligonucleotide SE
C 669	12.6	1.0	13	1	ABF59176	Oligonucleotide SE
C 670	12.6	1.0	13	1	ABF59177	Oligonucleotide SE
C 671	12.6	1.0	13	1	ABF72046	Oligonucleotide SE
C 672	12.6	1.0	13	1	ABF72047	Oligonucleotide SE
C 673	12.6	1.0	13	1	ABF76626	Oligonucleotide SE
C 674	12.6	1.0	13	1	ABF76627	Oligonucleotide SE
C 675	12.6	1.0	13	1	ABF78844	Oligonucleotide SE
C 676	12.6	1.0	13	1	ABF78845	Oligonucleotide SE
C 677	12.6	1.0	13	1	ABP79012	Oligonucleotide SE
C 678	12.6	1.0	13	1	ABP79013	Oligonucleotide SE
C 679	12.6	1.0	13	1	ABP98558	Oligonucleotide SE
C 680	12.6	1.0	13	1	ABH23016	Oligonucleotide SE
C 681	12.6	1.0	13	1	ABH23017	Oligonucleotide SE
C 682	12.6	1.0	13	1	ABH36948	Oligonucleotide SE
C 683	12.6	1.0	13	1	ABH36949	Oligonucleotide SE
C 684	12.6	1.0	13	1	ABH40538	Oligonucleotide SE
C 685	12.6	1.0	13	1	ABH40539	Oligonucleotide SE
C 686	12.6	1.0	13	1	ABH50358	Oligonucleotide SE
C 687	12.6	1.0	13	1	ABH50359	Oligonucleotide SE
C 688	12.6	1.0	13	1	ABH58638	Oligonucleotide SE
C 689	12.6	1.0	13	1	ABH58639	Oligonucleotide SE
C 690	12.6	1.0	13	1	ABH60060	Oligonucleotide SE

c 691	12.6	1.0	13	1	ABH60061	Oligonucleotide SE	764	12.4	1.0	17	1	AAK69623	Human flt1 VEGF re
c 692	12.6	1.0	13	1	ABH64678	Oligonucleotide SE	765	12.4	1.0	17	1	AAK69624	Human flt1 VEGF re
c 693	12.6	1.0	13	1	ABH64679	Oligonucleotide SE	766	12.4	1.0	17	1	AAK69328	Human flt1 VEGF re
c 694	12.6	1.0	15	1	AAD49641	Human adenylate ur	767	12.4	1.0	17	1	AAK69088	Human EGF-R target
c 695	12.6	1.0	15	1	AAL50230	Human ARE-mRNA seq	768	12.4	1.0	17	1	AAV97418	Solanidine glucosy
c 696	12.6	1.0	15	1	AAL53709	Adenylate Uridylat	c 769	12.4	1.0	17	1	AAV95855	Solanidine glucosy
c 697	12.6	1.0	17	1	AAW71403	Sequence of hybrid	c 770	12.4	1.0	17	1	AAV95856	Primer C5 for Cyt
c 698	12.6	1.0	17	1	AAQ78885	Hemicola grisea gl	c 771	12.4	1.0	17	1	AAV58890	Primer CSR for Cyt
c 699	12.6	1.0	18	1	ABK85464	5'-degenerate sequ	772	12.4	1.0	17	1	AAV58891	Arly hydrocarbon n
c 700	12.6	1.0	14	1	AAV22349	A promoter regulat	773	12.4	1.0	17	1	AAAL7432	Integrin alpha 6 s
c 701	12.4	1.0	14	1	AAV22279	ISRE gene promoter	774	12.4	1.0	17	1	AAA20578	Integrin alpha 6 s
c 702	12.4	1.0	14	1	AAZ32432	8-mer minor groove	775	12.4	1.0	17	1	AAA20579	Integrin alpha 6 s
c 703	12.4	1.0	14	1	AAD20794	PNA16/DNA oligo, u	776	12.4	1.0	17	1	AAA21204	Integrin alpha 6 s
c 704	12.4	1.0	14	1	AAAS0742	Solid-state DNA se	777	12.4	1.0	17	1	AAA21208	Integrin alpha 6 s
c 705	12.4	1.0	14	1	AAD07293	PNA16/DNA primer.	c 778	12.4	1.0	17	1	AAA21356	Integrin alpha 6 s
c 706	12.4	1.0	14	1	ABK98758	Solid state sequen	c 779	12.4	1.0	17	1	AAA21375	Integrin alpha 6 s
c 707	12.4	1.0	14	1	ABL55256	Vector 1-8 Sleepin	780	12.4	1.0	17	1	AAA21375	Integrin alpha 6 s
c 708	12.4	1.0	14	1	ABZ21280	Fixa aptamer oligo	781	12.4	1.0	17	1	AAA21377	Integrin alpha 6 s
c 709	12.4	1.0	15	1	AAQ55455	Detection primer f	782	12.4	1.0	17	1	AAA21423	Integrin alpha 6 s
c 710	12.4	1.0	15	1	AAT56342	Mouse TNF-a hammer	783	12.4	1.0	17	1	AAA22894	Integrin subunit b
c 711	12.4	1.0	15	1	AAT54316	Human II-5 hammer	c 784	12.4	1.0	17	1	AAA22895	Integrin subunit b
c 712	12.4	1.0	15	1	AAT54316	Human II-5 hammer	c 785	12.4	1.0	17	1	AAK78370	Human BRCA2 5374de
c 713	12.4	1.0	15	1	AAT55821	Human TNF-alpha ha	c 786	12.4	1.0	17	1	AAK78370	Hammerhead ribozym
c 714	12.4	1.0	15	1	AAT55803	Human TNF-alpha ha	c 787	12.4	1.0	17	1	AAK78370	Hammerhead ribozym
c 715	12.4	1.0	15	1	AAT52043	Human ICAM hammerh	c 788	12.4	1.0	17	1	AAK78370	Hammerhead ribozym
c 716	12.4	1.0	15	1	AAT56823	RSV 1B hammerhead	c 789	12.4	1.0	17	1	AAK78370	Hammerhead ribozym
c 717	12.4	1.0	15	1	AAT52338	Mouse ICAM hammerh	c 790	12.4	1.0	17	1	AAK78370	Hammerhead ribozym
c 718	12.4	1.0	15	1	AAT52338	Mouse ICAM hammerh	c 791	12.4	1.0	17	1	AAK78370	Hammerhead ribozym
c 719	12.4	1.0	15	1	AAK66586	Human CD40 hammerh	c 792	12.4	1.0	17	1	AAK78370	Hammerhead ribozym
c 720	12.4	1.0	15	1	AAK65399	Mouse B7-1 hammerh	c 793	12.4	1.0	17	1	AAK78370	Hammerhead ribozym
c 721	12.4	1.0	15	1	AAK75738	Human flt-1 and KD	c 794	12.4	1.0	17	1	AAK78370	Hammerhead ribozym
c 722	12.4	1.0	15	1	AAV06916	Probe PP15-TGT-TO	c 795	12.4	1.0	17	1	AAK78370	Hammerhead ribozym
c 723	12.4	1.0	15	1	AAZ6372	Antisense oligonuc	c 796	12.4	1.0	17	1	AAK78370	Hammerhead ribozym
c 724	12.4	1.0	15	1	AAZ95561	Pyrene modified RN	c 797	12.4	1.0	17	1	AAK78370	Hammerhead ribozym
c 725	12.4	1.0	15	1	AAZ95562	Pyrene modified RN	c 798	12.4	1.0	17	1	AAK78370	Hammerhead ribozym
c 726	12.4	1.0	15	1	AAZ95563	Pyrene modified RN	c 799	12.4	1.0	17	1	AAK78370	Hammerhead ribozym
c 727	12.4	1.0	15	1	AAZ95564	Pyrene modified DN	c 800	12.4	1.0	17	1	AAK78370	Hammerhead ribozym
c 728	12.4	1.0	15	1	AAZ95565	Pyrene modified DN	c 801	12.4	1.0	17	1	AAK78370	Hammerhead ribozym
c 729	12.4	1.0	15	1	AAZ95566	Pyrene modified DN	c 802	12.4	1.0	17	1	AAK78370	Hammerhead ribozym
c 730	12.4	1.0	15	1	AAZ39954	Human interleukin-	c 803	12.4	1.0	17	1	AAK78370	Hammerhead ribozym
c 731	12.4	1.0	15	1	AAH20775	Complex PCR amplif	c 804	12.4	1.0	17	1	AAK78370	Hammerhead ribozym
c 732	12.4	1.0	15	1	AAH20782	Complex PCR amplif	c 805	12.4	1.0	17	1	AAK78370	Hammerhead ribozym
c 733	12.4	1.0	15	1	AAH20782	Human IGFBP3 allele	c 806	12.4	1.0	17	1	AAK78370	Hammerhead ribozym
c 734	12.4	1.0	15	1	AAH20782	Human IGFBP3 allele	c 807	12.4	1.0	17	1	AAK78370	Hammerhead ribozym
c 735	12.4	1.0	15	1	AAH20782	Human IGFBP3 allele	c 808	12.4	1.0	17	1	AAK78370	Hammerhead ribozym
c 736	12.4	1.0	15	1	AAH20782	Human IGFBP3 allele	c 809	12.4	1.0	17	1	AAK78370	Hammerhead ribozym
c 737	12.4	1.0	15	1	AAH20782	Human IGFBP3 allele	c 810	12.4	1.0	17	1	AAK78370	Hammerhead ribozym
c 738	12.4	1.0	15	1	AAH20782	Human IGFBP3 allele	c 811	12.4	1.0	17	1	AAH91169	Human inflammatory
c 739	12.4	1.0	15	1	AAH20782	Human IGFBP3 allele	c 812	12.4	1.0	17	1	AAH91169	Human inflammatory
c 740	12.4	1.0	15	1	AAH20782	Human IGFBP3 allele	c 813	12.4	1.0	17	1	AAH91169	Human Chk1 ribozym
c 741	12.4	1.0	15	1	AAH20782	Human IGFBP3 allele	c 814	12.4	1.0	17	1	AAH91169	Human Chk1 ribozym
c 742	12.4	1.0	15	1	AAH20782	Human IGFBP3 allele	c 815	12.4	1.0	17	1	AAH91169	Human Chk1 ribozym
c 743	12.4	1.0	15	1	AAH20782	Human IGFBP3 allele	c 816	12.4	1.0	17	1	AAH91169	Human Chk1 ribozym
c 744	12.4	1.0	15	1	AAH20782	Human IGFBP3 allele	c 817	12.4	1.0	17	1	AAH91169	Human Chk1 ribozym
c 745	12.4	1.0	15	1	AAH20782	Human IGFBP3 allele	c 818	12.4	1.0	17	1	AAH91169	Human Chk1 ribozym
c 746	12.4	1.0	15	1	AAH20782	Human IGFBP3 allele	c 819	12.4	1.0	17	1	AAH91169	Human Chk1 ribozym
c 747	12.4	1.0	15	1	AAH20782	Human IGFBP3 allele	c 820	12.4	1.0	17	1	AAH91169	Human Chk1 ribozym
c 748	12.4	1.0	15	1	AAH20782	Human IGFBP3 allele	c 821	12.4	1.0	17	1	AAH91169	Human Chk1 ribozym
c 749	12.4	1.0	15	1	AAH20782	Human IGFBP3 allele	c 822	12.4	1.0	17	1	AAH91169	Human Chk1 ribozym
c 750	12.4	1.0	15	1	AAH20782	Human IGFBP3 allele	c 823	12.4	1.0	17	1	AAH91169	Human Chk1 ribozym
c 751	12.4	1.0	15	1	AAH20782	Human IGFBP3 allele	c 824	12.4	1.0	17	1	AAH91169	Human Chk1 ribozym
c 752	12.4	1.0	15	1	AAH20782	Human IGFBP3 allele	c 825	12.4	1.0	17	1	AAH91169	Human Chk1 ribozym
c 753	12.4	1.0	15	1	AAH20782	Human IGFBP3 allele	c 826	12.4	1.0	17	1	AAH91169	Human Chk1 ribozym
c 754	12.4	1.0	15	1	AAH20782	Human IGFBP3 allele	c 827	12.4	1.0	17	1	AAH91169	Human Chk1 ribozym
c 755	12.4	1.0	15	1	AAH20782	Human IGFBP3 allele	c 828	12.4	1.0	17	1	AAH91169	Human Chk1 ribozym
c 756	12.4	1.0	15	1	AAH20782	Human IGFBP3 allele	c 829	12.4	1.0	17	1	AAH91169	Human Chk1 ribozym
c 757	12.4	1.0	15	1	AAH20782	Human IGFBP3 allele	c 830	12.4	1.0	17	1	AAH91169	Human Chk1 ribozym
c 758	12.4	1.0	15	1	AAH20782	Human IGFBP3 allele	c 831	12.4	1.0	17	1	AAH91169	Human Chk1 ribozym
c 759	12.4	1.0	15	1	AAH20782	Human IGFBP3 allele	c 832	12.4	1.0	17	1	AAH91169	Human Chk1 ribozym
c 760	12.4	1.0	15	1	AAH20782	Human IGFBP3 allele	c 833	12.4	1.0	17	1	AAH91169	Human Chk1 ribozym
c 761	12.4	1.0	15	1	AAH20782	Human IGFBP3 allele	c 834	12.4	1.0	17	1	AAH91169	Human Chk1 ribozym
c 762	12.4	1.0	15	1	AAH20782	Human IGFBP3 allele	c 835	12.4	1.0	17	1	AAH91169	Human Chk1 ribozym
c 763	12.4	1.0	15	1	AAH20782	Human IGFBP3 allele	c 836	12.4	1.0	17	1	AAH91169	Human Chk1 ribozym

c 837	12.4	1.0	17	1	ABT35721	Tumour suppression	c 910	11.6	0.9	20	1	ABK85435	Oligonucleotide #1
c 838	12.4	1.0	17	1	ABT36211	Tumour suppression	911	11.6	0.9	20	1	ABL51148	Human TNF inducibl
c 839	12.4	1.0	17	1	ABT36218	Tumour suppression	912	11.6	0.9	20	1	AAQ75568	Reverse transcript
840	12.4	1.0	17	1	ABT36376	Tumour suppression	c 913	11.6	0.9	20	1	AAAT47265	5' fragment #2 of
841	12.4	1.0	17	1	ABT37154	Tumour suppression	914	11.6	0.9	21	1	AAV67374	Nucleotide fragmen
842	12.4	1.0	17	1	ABT37510	Tumour suppression	915	11.6	0.9	21	1	AAQ20077	Hiv-1 DNA probe (g
843	12.4	1.0	17	1	ABT37886	Tumour suppression	916	11.6	0.9	21	1	AAQ75643	Reverse transcript
c 844	12.4	1.0	17	1	ABT38326	Tumour suppression	917	11.4	0.9	17	1	AAV91422	Human C-raf target
c 845	12.4	1.0	17	1	ABT39589	Tumour suppression	c 918	11.4	0.9	17	1	AAV70035	Human flt1 VEGF re
846	12.4	1.0	17	1	ACA06849	NFKB sub-unit modu	c 919	11.4	0.9	17	1	AAAT21376	Integrin alpha 6 s
847	12.4	1.0	17	1	ACA08322	Necrosis factor ka	920	11.4	0.9	20	1	AAQ09117	Human MEKK2 antise
848	12.4	1.0	17	1	ABZ60207	Human K-Ras DNazym	c 921	11.4	0.9	20	1	AAQ30406	Oligomer IL2R503 f
849	12.4	1.0	17	1	ABZ61180	Human X-Ras DNazym	c 922	11.4	0.9	21	1	AAZ26565	Human polymorphic
c 850	12.4	1.0	25	1	AAAG66457	Dog genomic marker	923	11.2	0.9	16	1	AAAT43329	Lobolilly pine SSR
c 851	12.4	1.0	30	1	AAAL55125	Nucleic acid synth	924	11.2	0.9	16	1	AAAT43330	Lobolilly pine SSR
c 852	12.2	1.0	17	1	AAAT22700	Integrin subunit b	c 925	11.2	0.9	16	1	AAV09052	Improved cleavage
c 853	12.2	1.0	17	1	AAAT22703	Integrin subunit b	c 926	11.2	0.9	17	1	AAAT40329	Primer 1 for tetra
c 854	12.2	1.0	17	1	AAAT22706	Integrin subunit b	c 927	11.2	0.9	17	1	AAAT22698	Integrin subunit b
855	12.2	1.0	17	1	AAAT22899	Integrin subunit b	c 928	11.2	0.9	17	1	AAAT22699	Integrin subunit b
856	12.2	1.0	17	1	AAAT22900	Integrin subunit b	c 929	11.2	0.9	17	1	AAAT22701	Integrin subunit b
857	12.2	1.0	17	1	AAAT22901	Integrin subunit b	c 930	11.2	0.9	17	1	AAAT22702	Integrin subunit b
858	12.2	1.0	17	1	AAAT22902	Integrin subunit b	c 931	11.2	0.9	17	1	AAAT22704	Integrin subunit b
859	12.2	1.0	17	1	AAAT22903	Integrin subunit b	c 932	11.2	0.9	17	1	AAAT22705	Integrin subunit b
c 860	12.2	1.0	17	1	AAAT22708	Integrin subunit b	c 933	11.2	0.9	17	1	AAAT49640	Human adenylate ur
c 861	12.2	1.0	18	1	ABSG7982	PAP-AH DNA related	c 934	11.2	0.9	17	1	AAAT50229	Human ARE-mRNA seq
c 862	12.2	1.0	18	1	AAQ20160	Cross-linking olig	c 935	11.2	0.9	17	1	AAAT50229	Adenylate Uridylat
c 863	12.2	1.0	18	1	AAQ30368	Oligomer HSV723 fo	c 936	11.2	0.9	17	1	AAAT50270	Integrin subunit b
c 864	12.2	1.0	18	1	AAQ30368	Oligomer HUM beta	c 937	11.2	0.9	17	1	AAAT37900	Tumour suppression
c 865	12.2	1.0	18	1	ABZ10596	Haematopoietic cel	c 938	11.2	0.9	17	1	AAV96639	Potato citrate syn
c 866	12.2	1.0	20	1	ABL46342	Human interleukin-	939	11.2	0.9	17	1	AAAT21468	Integrin alpha 6 s
c 867	12.2	1.0	20	1	ABZ37709	Human mdm2 phospho	c 940	11.2	0.9	17	1	AAAT22904	Integrin subunit b
868	12.2	1.0	20	1	AAAT29478	Human mdm2 antisen	c 941	11.2	0.9	17	1	AAV96640	Potato citrate syn
869	12.2	1.0	20	1	AAAF08663	Human mdm2 phospho	942	11.2	0.9	17	1	AAAT22898	Integrin subunit b
c 870	12.2	1.0	21	1	AAAL4463	AUUA RNA target s	943	11.2	0.9	17	1	AAAT34544	Oestrogen receptor
c 871	12.2	1.0	21	1	AAAD49639	Human adenylate ur	c 944	11.2	0.9	17	1	ABK56852	Human C-raf gene e
c 872	12.2	1.0	21	1	AAAL50228	Human ARB-mRNA seq	c 945	11.2	0.9	17	1	ABZ60733	Human K-Ras DNazym
c 873	12.2	1.0	21	1	AAAL53707	Adenylate Uridylat	c 946	11.2	0.9	17	1	ABZ61098	Human K-Ras DNazym
874	12	1.0	17	1	AAV58890	Primer C5 for Cyt	c 947	11.2	0.9	17	1	AAAT74782	Mouse flt-1 VEGF r
c 875	12	1.0	17	1	AAV58891	Primer CSR for Cyt	c 948	11.2	0.9	17	1	AAAT69088	Human flt1 VEGF re
876	12	1.0	20	1	AAAT52331	Human IFNGR2 antis	c 949	11.2	0.9	17	1	AAAT31377	Integrin alpha 6 s
c 877	12	1.0	21	1	AAAT74938	Human CD40L promot	c 950	11.2	0.9	17	1	ABSG4671	Human PAPP-Ba asso
c 878	11.8	0.9	15	1	AAAT56318	Mouse TNF-a hamme	c 951	11.2	0.9	17	1	ABSG4672	Human PAPP-Ba asso
c 879	11.8	0.9	15	1	AAAT5794	Human TNF-alpha ha	c 952	11.2	0.9	17	1	ABT36211	Tumour suppression
c 880	11.8	0.9	17	1	AAQ202084	Renilla reniformis	c 953	11.2	0.9	17	1	ABT38326	Tumour suppression
881	11.8	0.9	17	1	AAQ202054	Hammerhead ribozym	954	11.2	0.9	18	1	AAAT79673	Human Akt-3 antise
c 882	11.8	0.9	17	1	ABT39376	Tumour suppression	955	11.2	0.9	18	1	AAAT37761	Staphylococcus sp.
883	11.8	0.9	17	1	ABZ60465	Human K-Ras DNazym	c 956	11.2	0.9	18	1	ABK34044	Human NF1 probe #2
c 884	11.8	0.9	17	1	AAAF05526	Hammerhead ribozym	c 957	11.2	0.9	19	1	AAAT37308	3' primer #5 used
c 885	11.8	0.9	18	1	ABZ10595	Haematopoietic cel	c 958	11.2	0.9	19	1	AAH90994	Human inflammatory
c 886	11.8	0.9	18	1	AAV82030	Moraxella lactofer	959	11.2	0.9	24	1	AAAL54044	Human macroprotein
c 887	11.8	0.9	18	1	AAV82031	Moraxella lactofer	c 960	11	0.9	13	1	ABF53002	Oligonucleotide SE
888	11.8	0.9	19	1	ABH56758	S. aureus groE ope	961	11	0.9	13	1	ABF53003	Oligonucleotide SE
889	11.8	0.9	24	1	AAH76783	Human nuclear tran	962	11	0.9	17	1	AAAT81506	Human C-myb hamme
c 890	11.8	0.9	25	1	AAH45430	Glutamate tRNA syn	963	11	0.9	17	1	AAAT81507	Human C-myb hamme
c 891	11.8	0.9	38	1	AAAL51650	Interleukin 8 capt	c 964	11	0.9	17	1	AAV24553	PCR primer for DNA
892	11.6	0.9	18	1	AAH86606	Cdc 2 kinase hamme	c 965	11	0.9	17	1	AAV24555	PCR primer for DNA
893	11.6	0.9	18	1	AAH61772	Cdc 2 kinase hamme	c 966	11	0.9	17	1	AAAT71403	Sequence of hybrid
894	11.6	0.9	18	1	ABZ11062	Haematopoietic cel	c 967	11	0.9	17	1	AAV78885	Hemicola grisea gl
c 895	11.6	0.9	19	1	AAAT62676	Cry2A family gene	968	11	0.9	20	1	AAV44676	PCR primer for UC
c 896	11.6	0.9	19	1	AAAT49298	5' end fragment of	969	11	0.9	20	1	AAV44678	PCR primer for UC
c 897	11.6	0.9	19	1	AAAT49298	5' end fragment of	c 970	11	0.9	20	1	AAAT30727	Human interleukin-
c 898	11.6	0.9	19	1	AAAT47269	Capped RNA influen	c 971	11	0.9	20	1	AAAT31760	Mouse Surivin ant
c 899	11.6	0.9	19	1	AAAT47270	Capped RNA influen	972	11	0.9	20	1	AAH80901	Oligonucleotide by
c 900	11.6	0.9	19	1	AAAT47271	Capped RNA influen	c 973	11	0.9	21	1	AAQ79313	Human C-raf-1 onco
c 901	11.6	0.9	19	1	AAAT47272	Capped RNA influen	974	11	0.9	21	1	AAAG2202	Per tyrosine kinas
c 902	11.6	0.9	19	1	AAAT47273	Capped RNA influen	c 975	11	0.9	50	1	ABZ00185	Human leukocyte ge
c 903	11.6	0.9	19	1	AAAT47267	Capped RNA influen	c 976	10.8	0.9	15	1	AAAT56320	Mouse TNF-a hamme
c 904	11.6	0.9	19	1	AAAT47264	5' fragment of aif	c 977	10.8	0.9	15	1	AAAT55811	Human TNF-alpha ha
c 905	11.6	0.9	19	1	AAAT47276	Capped RNA influen	c 978	10.8	0.9	15	1	AAAT55796	Human TNF-alpha ha
c 906	11.6	0.9	19	1	AAAT47277	Capped RNA influen	c 979	10.8	0.9	15	1	AAAT56348	Mouse TNF-a hamme
c 907	11.6	0.9	19	1	AAAT47278	Capped RNA influen	c 980	10.8	0.9	15	1	AAAT55809	Human TNF-alpha ha
c 908	11.6	0.9	19	1	AAAT47279	Capped RNA influen	c 981	10.8	0.9	15	1	AAAT70070	Human TNFRSF11B ge
c 909	11.6	0.9	20	1	AAAT92878	Human PI3 kinase p	982	10.8	0.9	15	1	AAAT04008	Human ovary specif

RESULT 2
ABZ01793
ID ABZ01793 standard; DNA; 50 BP.

T7; leukocyte; gene expression profiling; allograft rejection;
 KW
 atherosclerosis; congestive heart failure; systemic lupus erythematosus;
 KW
 osteoarthritis; osteoarthritis; cytomegalovirus; infection;
 KW
 leukocyte; gene expression profiling; allograft rejection;
 KW

KW probe; ss.
XX Homo sapiens.
XX WO200257414-A2.
XX 25-JUL-2002.
XX 22-OCT-2001; 2001WO-USA7856.
XX 20-OCT-2000; 2000US-241994P.
XX 08-JUN-2001; 2001US-296764P.
XX (BIOC-) BIOCARDIA INC.
XX Wohlgemuth J, Fry K, Matcuk G, Altman P, Prentice J, Phillips J;
PI Ly N, Woodward R, Quartermours T, Johnson F;
XX WPI; 2002-636525/68.
XX New system for leukocyte expression profiling, diagnosing a disease, or
PT monitoring (the rate of) progression of a disease, e.g. atherosclerosis
PT or congestive heart failure, comprises diagnostic oligonucleotides -
XX Claim 1; Page 389; 2038pp; English.
XX The invention relates to a system for detecting gene expression, which
CC comprises one or two isolated DNA molecules that detect expression of a
CC gene, where the gene corresponds to any of 8143 oligonucleotides
CC (ABZ00010-ABZ08152) each having 50 base pairs (bp). The system is useful
CC for leukocyte expression profiling. It is particularly useful for
CC diagnosing a disease, monitoring (rate of) progression of a disease,
CC predicting therapeutic outcome, determining prognosis for a patient,
CC predicting disease complications in an individual or monitoring response
CC to treatment in an individual. The diseases include cardiac allograft
CC rejection, kidney allograft rejection, liver allograft rejection,
CC atherosclerosis, congestive heart failure, systemic lupus erythematosus,
CC rheumatoid arthritis, osteoarthritis or cytomegalovirus infection.
XX SQ Sequence 50 BP; 19 A; 10 C; 7 G; 14 T; 0 other;
Query Match 4.0%; Score 50; DB 1; Length 50;
Best Local Similarity 100.0%; Pred. No. 1.1e-05;
Matches 50; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1403 AAAACAGCCAAACTCCACAGTCATATAGTAATTTCTGCTGGTTGAA 1452
Db 1 AAAACAGCCAAACTCCACAGTCATATAGTAATTTCTGCTGGTTGAA 50
RESULT 4
ABL46338/c
ID ABL46338 standard; DNA; 30 BP.
XX ABL46338;
XX 26-APR-2002 (first entry)
XX Human interleukin-1 beta oligonucleotide SEQ ID NO:305.
XX Nucleic acid accessible hybridisation site; detection; hybridisation;
KW characterisation; identification; nucleic acid structure; diagnosis;
XX PCR primer; probe; ss.
XX Homo sapiens.
XX Synthetic.
XX WO200198537-A2.
XX 27-DEC-2001.
XX 15-JUN-2001; 2001WO-US19401.

PR 17-JUN-2000; 2000US-212308P.
PR 15-JUN-2001; 2001US-0212308.
XX (THIR-) THIRD WAVE TECHNOLOGIES INC.
XX Lyamichev V, Allawi H, Dong F, Neri BP, Vener IT;
XX WPI; 2002-049698/06.
XX Identifying oligonucleotides hybridizing to nucleic acids containing
PT secondary structure, useful in clinical diagnosis, comprises
PT identifying primers that interact with the target to form an extension
PT product under amplification conditions -
XX Claim 48; Fig 81A; 409pp; English.
XX The present invention describes a method for identifying oligonucleotides
CC with desired hybridisation properties to nucleic acid targets containing
CC secondary structure. The method comprises amplifying a target nucleic
CC acid having at least one accessible and one inaccessible site. Primers
CC that form an extension product are identified as the oligonucleotides
CC which can interact with the folded target nucleic acid. Oligonucleotides
CC from the present invention can be used in novel detection methods for
CC clinical diagnostic purposes, including the detection and identification
CC of pathogenic organisms (e.g. HIV). The method allows the ability to
CC rapidly analyse nucleic acid structures. ABL46034 to ABL46367 represent
CC sequences used in the exemplification of the present invention.
XX SQ Sequence 30 BP; 13 A; 4 C; 2 G; 11 T; 0 other;
Query Match 2.4%; Score 30; DB 1; Length 30;
Best Local Similarity 100.0%; Pred. No. 0.15;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1165 ATGATGTTTTATGATATAAATTTCAATCAG 1194
Db 30 ATGATGTTTTATGATATAAATTTCAATCAG 1
RESULT 5
AAL55125
ID AAL55125 standard; DNA; 30 BP.
XX AAL55125;
XX 16-APR-2003 (first entry)
XX Nucleic acid synthesising method related PCR primer, SEQ ID No 6.
XX Synthesising; target base sequence; annealing; genetic disease; SNP;
KW single nucleotide polymorphism; cancer; PCR; primer; ss.
XX Unidentified.
XX WO200290538-A1.
XX 14-NOV-2002.
XX 08-MAY-2002; 2002WO-JP04479.
XX 08-MAY-2001; 2001JP-0137060.
PR 18-JUN-2001; 2001JP-0184131.
XX (SIKE) EIKEN KAGAKU KK.
XX Nagamine K;
XX WPI; 2003-120547/11.
XX Synthesizing target base sequence-containing nucleic acids constituting
PT complementary base sequences against template by the LAMP method,
PT applicable in identifying genetic diseases, cancerization and
PT microorganisms -

XX Example 1; Page 62; 107pp; Japanese.
PS The invention relates to a novel method for synthesising a target base
CC sequence-containing nucleic acids. The method comprises the formation of
CC single-stranded nucleic acids; synthesis of complementary strand by
CC annealing; and producing single-stranded nucleic acid from a target base
CC sequence by the synthesis of a complementary strand by annealing of a
CC complementary base sequence. The method is useful for synthesising a
CC target base sequence-containing nucleic acids, which is applicable in
CC detecting SNP (single nucleotide polymorphism) in genes, identifying
CC genetic diseases, cancer and microorganisms. Such a method can be
CC easily, rapidly and freely carried out without being influenced by
CC contamination or complicated temperature control, but with improved
CC reaction specificity, high accuracy and efficiency, operable at low cost.
CC This polynucleotide sequence represents a PCR primer used in the
XX synthesising method of the invention.
XX SQ Sequence 30 BP; 13 A; 3 C; 5 G; 9 T; 0 other;
Query Match 2.4%; Score 30; DB 1; Length 30;
Best Local Similarity 100.0%; Pred. No. 0.15;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1065 CATCAATATTGTCAGAAATTGCAAAA 1094
DB 1 CATCAATATTGTCAGAAATTGCAAAA 30
RESULT 6
AAL55126/c
ID AAL55126 standard; DNA; 30 BP.
XX AAL55126;
AC AAL55126;
XX 16-APR-2003 (first entry)
XX Nucleic acid synthesising method related PCR primer, SEQ ID No 7.
XX Synthesising; target base sequence; annealing; genetic disease; SNP;
XX single nucleotide polymorphism; cancer; PCR; primer; ss.
XX Unidentified.
XX WO200290538-A1.
XX 14-NOV-2002.
XX 08-MAY-2002; 2002WO-JP04479.
XX 08-MAY-2001; 2001JP-0137060.
XX 18-JUN-2001; 2001JP-0184131.
XX (EIKS) EIKEN KAGAKU KK.
XX Nagamine K;
XX WPI; 2003-120547/11.
XX Synthesizing target base sequence-containing nucleic acids constituting
XX complementary base sequences against template by the LAMP method,
XX applicable in identifying genetic diseases, cancerization and
XX microorganisms -
XX Example 1; Page 62; 107pp; Japanese.
PS The invention relates to a novel method for synthesising a target base
CC sequence-containing nucleic acids. The method comprises the formation of
CC single-stranded nucleic acids; synthesis of complementary strand by
CC annealing; and producing single-stranded nucleic acid from a target base
CC sequence by the synthesis of a complementary strand by annealing of a
CC complementary base sequence. The method is useful for synthesising a
CC target base sequence-containing nucleic acids, which is applicable in

CC detecting SNP (single nucleotide polymorphism) in genes, identifying
CC genetic diseases, cancer and microorganisms. Such a method can be
CC easily, rapidly and freely carried out without being influenced by
CC contamination or complicated temperature control, but with improved
CC reaction specificity, high accuracy and efficiency, operable at low cost.
CC This polynucleotide sequence represents a PCR primer used in the
XX synthesising method of the invention.
XX SQ Sequence 30 BP; 15 A; 2 C; 2 G; 11 T; 0 other;
Query Match 2.4%; Score 30; DB 1; Length 30;
Best Local Similarity 100.0%; Pred. No. 0.15;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1045 TATTATGCTATTATTATTAAGCATCAAAATAT 1074
DB 30 TATTATGCTATTATTATTAAGCATCAAAATAT 1
RESULT 7
AAL51650
ID AAL51650 standard; DNA; 38 BP.
XX AAL51650;
AC AAL51650;
XX 17-APR-2003 (first entry)
XX Interleukin 8 capture probe.
XX Probe; ss; messenger RNA amplification; capture probe;
XX rolling circle replication; nucleic acid detection; disease detection;
XX mutation detection; gene expression profiling; RNA expression profiling;
XX gene discovery; gene mapping; agricultural research; virus detection;
XX cancer; cystic fibrosis; muscular dystrophy; diabetes; haemophilia;
XX sickle cell anaemia.
XX Unidentified.
XX Key Location/Qualifiers
XX modified_base 1 /*tag= a
XX /mod_base= OTHER
XX /note= "Modified with NH2-Cl2"
XX WO2003008538-A2.
XX 30-JAN-2003.
XX 10-MAY-2002; 2002WO-US15045.
XX 20-JUL-2001; 2001US-0910383.
XX (MOLE-) MOLECULAR STAGING INC.
XX Nallur GN, Luo C, Chowdhury K, Pinard R;
XX WPI; 2003-221847/21.
XX Amplifying messenger RNA for manipulating and detecting nucleic acid,
XX disease and mutation detection, gene or RNA expression profiling and
XX gene discovery, comprises associating a rolling circle replication
XX primer with a cDNA strand -
XX Example 3; Page 69; 103pp; English.
PS The invention comprises a method for amplifying messenger RNA (mRNA). The
CC method involves: mixing reverse transcription (RT) primers with a nucleic
CC acid sample and reverse transcribing to produce cDNA strands; mixing the
CC strands with capture probes, then with rolling circle replication
CC primers; mixing amplification target circles with the primers; and
CC incubating the circles to promote replication of the target circles - to
CC form tandem sequence DNA. The method of the invention is useful for
CC amplifying mRNA. The method is useful for manipulating and detecting

CC nucleic acids, disease and mutation detection, gene or RNA expression
 CC profiling, gene discovery, gene mapping, agricultural research and virus
 CC detection. Disorders which can be diagnosed by the method of the
 CC invention include: cancer; cystic fibrosis; muscular dystrophy; diabetes;
 CC haemophilia; sickle cell anaemia. The present DNA sequence represents a
 CC capture probe used in an example of the invention.

XX
 SQ Sequence 38 BP; 25 A; 1 C; 5 G; 7 T; 0 other;

Query Match 2.3%; Score 28.4; DB 1; Length 38;
 Best Local Similarity 96.7%; Pred. No. 0.46;
 Matches 29; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1091 AAAAATGAGATGAATCATTCATTGATTA 1120
 Db 9 AAAAAGAGAGATGAATCATTCATTGATTA 38

RESULT 8

AAAD21908
 ID AAD21908 standard; DNA; 26 BP.

XX
 AC AAD21908;

DT 12-FEB-2002 (first entry)

DE PCR primer, 2767T used to determine the genotype of human IL-8 gene.

KW Human; Genetic variant identification; interleukin 8; RSV bronchiolitis;
 KW respiratory syncytial virus; PCR primer; ss.

XX Homo sapiens.

XX WO200177382-A2.

PN 18-OCT-2001.

XX 11-APR-2001; 2001WO-GB01634.

PR 11-APR-2000; 2000GB-0008910.

XX (ISIS-) ISIS INNOVATION LTD.

PI Hull J, Kwiatkowski DP;

DR WPI; 2002-017472/02.

XX Nucleic acid comprising a sequence corresponding to variant allele of
 PT human interleukin 8 gene, useful for determining susceptibility to
 PT respiratory syncytial virus bronchiolitis in humans -

XX Claim 42; Page 47; 49pp; English.

XX The patent discloses methods for identification of genetic variants
 CC at the interleukin 8 (IL-8) locus. The invention relates to nucleic
 CC acid molecules corresponding to various alleles at the IL8 locus
 CC and kits for the detection of the presence of variant alleles. The
 CC polymorphic variants of the IL-8 locus are useful for screening a
 CC human subject for susceptibility to a disease such as respiratory
 CC syncytial virus (RSV) bronchiolitis for which increased production
 CC of IL-8 is a risk factor. The polymorphic variants of IL-8 locus are
 CC also useful for determining the likelihood that a patient previously
 CC identified as infected with RSV will develop severe disease. They are
 CC useful as probes and primers for genotyping. They are also useful for
 CC initiating DNA synthesis or amplification for detecting the presence
 CC of IL-8 genetic variants. The single nucleotide polymorphisms have a
 CC general utility as a genetic marker. The present DNA sequence is PCR
 CC primer, 2767T which is used to determine the genotype of human
 CC IL-8 gene.

XX Sequence 26 BP; 9 A; 5 C; 2 G; 10 T; 0 other;

Query Match 2.1%; Score 26; DB 1; Length 26;

Best Local Similarity 100.0%; Pred. No. 1;
 Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1228 CCAGTTAAATTTTCATTTCAGATAA 1253
 Db 1 CCAGTTAAATTTTCATTTCAGATAA 26

RESULT 9

AAAD21907
 ID AAD21907 standard; DNA; 26 BP.

XX
 AC AAD21907;

DT 12-FEB-2002 (first entry)

DE PCR primer, 2767A used to determine the genotype of human IL-8 gene.

KW Human; Genetic variant identification; interleukin 8; RSV bronchiolitis;
 KW respiratory syncytial virus; PCR primer; ss.

XX Homo sapiens.

XX WO200177382-A2.

PN 18-OCT-2001.

XX 11-APR-2001; 2001WO-GB01634.

PR 11-APR-2000; 2000GB-0008910.

XX (ISIS-) ISIS INNOVATION LTD.

PI Hull J, Kwiatkowski DP;

DR WPI; 2002-017472/02.

XX Nucleic acid comprising a sequence corresponding to variant allele of
 PT human interleukin 8 gene, useful for determining susceptibility to
 PT respiratory syncytial virus bronchiolitis in humans -

XX Claim 42; Page 47; 49pp; English.

XX The patent discloses methods for identification of genetic variants
 CC at the interleukin 8 (IL-8) locus. The invention relates to nucleic
 CC acid molecules corresponding to various alleles at the IL8 locus
 CC and kits for the detection of the presence of variant alleles. The
 CC polymorphic variants of the IL-8 locus are useful for screening a
 CC human subject for susceptibility to a disease such as respiratory
 CC syncytial virus (RSV) bronchiolitis for which increased production
 CC of IL-8 is a risk factor. The polymorphic variants of IL-8 locus are
 CC also useful for determining the likelihood that a patient previously
 CC identified as infected with RSV will develop severe disease. They are
 CC useful as probes and primers for genotyping. They are also useful for
 CC initiating DNA synthesis or amplification for detecting the presence
 CC of IL-8 genetic variants. The single nucleotide polymorphisms have a
 CC general utility as a genetic marker. The present DNA sequence is PCR
 CC primer, 2767A which is used to determine the genotype of human
 CC IL-8 gene.

XX Sequence 26 BP; 8 A; 5 C; 2 G; 11 T; 0 other;

Query Match 2.0%; Score 25; DB 1; Length 26;

Best Local Similarity 100.0%; Pred. No. 1.7;
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1228 CCAGTTAAATTTTCATTTCAGATA 1252
 Db 1 CCAGTTAAATTTTCATTTCAGATA 25

RESULT 10

ABS98731/c

CC expression of genes in organisms under various physiological conditions,
CC for studying the role of gene expression in diseases and oncogenesis,
CC physio-chemical cellular responses to stimuli, and cell growth and
CC differentiation, for titrating the amount of amplified mRNA present in a
CC sample, and to compare, side by side, the expression levels of mRNA in a
CC cell type that has undergone two physical or chemical stimuli.
CC The method uses primer extension and an active electronic microarray.
CC The present sequence is a gene specific primer used in the method
CC of the invention.

XX Sequence 24 BP; 9 A; 11 C; 3 G; 1 T; 0 other;
SQ Query Match 1.9%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 2.5;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 475 GTGTGGTCTGTGTAGGGTTGCC 498
DB 24 GTGTGGTCTGTGTAGGGTTGCC 1

RESULT 11
AAD39937/c
ID AAD39937 standard; DNA; 24 BP.
XX
AC AAD39937;
XX
XX 22-OCT-2002 (first entry)
XX
DE Human primer #2 to amplify beta-thromboglobulin-like protein target gene.
XX
XX Human; amplicon; electronic hybridisation; gene expression; oncogenesis;
KW physio-chemical cellular response; stimuli; cell growth; differentiation;
KW PCR; primer; beta-thromboglobulin-like protein; ss.
XX
XX Homo sapiens.
XX
XX US6379897-B1.
XX
XX 30-APR-2002.
XX
XX 09-NOV-2000; 2000US-0710200.
XX
XX 09-NOV-2000; 2000US-0710200.
XX
XX (NANO-) NANOGEN INC.
XX
XX Weidenhammer EM, Wang L, Xu X, Heller MJ, Kahl BP;
XX
XX WPI; 2002-424785/45.
XX
XX Detecting relative amounts of at least two different mRNAs in
XX biological samples by electronically hybridizing amplicons to probes,
XX useful to monitor gene expression in disease and in cell response
XX studies -
XX
XX Example 6; Column 51; 36pp; English.

XX The invention relates to a method for detecting the relative amounts of
XX at least two different mRNA sequences in biological samples. The method
XX comprising isolating sample mRNA, amplifying at least two mRNAs to
XX produce amplicons of not more than 300 bases, electronically hybridising
XX the amplicons to probes bound to a support at predetermined locations and
XX detecting amounts of hybridised amplicons. The method may be used to
XX monitor gene expression in the study of disease and oncogenesis, physio-
XX chemical cellular responses to stimuli and cell growth and
XX differentiation. The present sequence is a human PCR primer used for
XX amplifying beta-thromboglobulin-like protein target gene.

XX Sequence 24 BP; 9 A; 11 C; 3 G; 1 T; 0 other;
SQ Query Match 1.9%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 2.5;

Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 475 GTGTGGGTCGTGTGAGGGTTGCC 498
 DB 24 GTGTGGGTCGTGTGAGGGTTGCC 1

RESULT 12
 ABX79046/c
 ID ABX79046 standard; DNA; 24 BP.

AC ABX79046;
 XX
 XX
 XX 15-APR-2003 (first entry)
 DE Electronic microarray associated oligonucleotide #2.
 KW Electronic microarray; utilising gene expression experimental model;
 KW onogenesis; physio-chemical cellular response; cell growth;
 KW cell differentiation; ss.
 XX Homo sapiens.
 OS
 XX US2002150917-A1.
 FN
 XX 17-OCT-2002.
 PD
 XX 10-OCT-2001; 2001US-0975408.
 PF
 XX 09-NOV-2000; 2000US-0710200.
 PR
 XX (NANO-) NANOGEN INC.
 PA
 XX Weidenhammer EM, Wang L, Xu X, Heller MJ, Kahl BP;
 PI WPI; 2003-198284/19.
 DR
 XX Detecting relative amounts of at least two mRNA utilizing
 PT microelectronic arrays in a sample, useful for studying disease and
 PT onogenesis, physio-chemical cellular responses to stimuli, and cell
 PT growth and differentiation -
 XX Example 6; Page 15; 39pp; English.

The invention describes a method of detecting the relative amounts of at least two mRNA sequences in at least one biological sample, comprising:
 CC (a) isolating mRNA from the sample;
 CC (b) amplifying at least two mRNA transcripts to produce amplicons;
 CC (c) electronically hybridising the amplicons produced to at least two probes bound to a support at predetermined locations; and
 CC (d) detecting the amounts of each amplicon hybridised to the bound probes at the predetermined locations.
 CC The methods and compositions are useful for utilising gene expression experimental models for use in studying disease and onogenesis.
 CC Physio-chemical cellular responses to stimuli, and cell growth and differentiation. This sequence represents an oligonucleotide targeted to a human gene and used to demonstrate the methods described in the invention.

Sequence 24 BP; 9 A; 11 C; 3 G; 1 T; 0 other;
 Query Match 1.9%; Score 24; DB 1; Length 24;
 Best Local Similarity 100.0%; Pred.No. 2.5;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 475 GTGTGGGTCGTGTGAGGGTTGCC 498
 DB 24 GTGTGGGTCGTGTGAGGGTTGCC 1

RESULT 13
 AAT06866/c
 ID AAT06866 standard; DNA; 21 BP.

XX AAT06866;
 AC
 XX 27-JUN-1996 (first entry)
 DT
 XX Psoriasis susceptibility probe #10.
 DE
 XX Interleukin enhancer binding factor; ILF; probe; psoriasis; gene therapy;
 KW interleukin-8; IL-8; familial psoriasis; linkage analysis; chromosome 17;
 KW ss.
 XX Synthetic.
 OS
 XX W09533208-A1.
 FN
 XX 30-NOV-1995.
 PD
 XX 19-MAY-1995; 95WO-US06356.
 PF
 XX 20-MAY-1994; 94US-0246855.
 PR
 XX (TEXA) UNIV TEXAS SYSTEM.
 PA
 XX Bowcock A, Gaynor R, Menter A, Tomfohrde J;
 XX WPI; 1996-020600/02.
 DR
 XX Screening families for susceptibility to psoriasis - by hybridising
 PT DNA to probe corresponding to susceptibility locus, also new locus
 PT and psoriasis genes located on chromosome 17q
 XX Claim 18; Page 75; 93pp; English.

AAT06866 represent sequences used in the method of the invention for screening for psoriasis susceptibility. In the method, DNA is obtained from an unaffected and an affected family member. A family specific allele of a polymorphism present in the patients sample is identified. The polymorphism is linked with a gene for interleukin enhancer binding factor (ILF) or interleukin-8 (IL-8). This thereby identifies a familial psoriasis susceptibility locus. A probe sequence (such as this sequence) is prepared and used to screen nucleic acid samples from members of the family. This sequence represents a psoriasis susceptibility probe of the invention. The probes can be used in linkage analysis and hybridisation studies on chromosome 17 (where the psoriasis gene is located), and for detecting a genetic lesion or polymorphism in a 17q distal region. Polymorphism in a gene from this region indicates an inherited germ-line mutation related to familial psoriasis. Wild type forms of psoriasis genes may be used in gene therapy of this disease.

Sequence 21 BP; 6 A; 5 C; 4 G; 6 T; 0 other;
 Query Match 1.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred.No. 9.9;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 403 TCTGTGATATCCAGATATCAG 423
 DB 21 TCTGTGATATCCAGATATCAG 1

RESULT 14
 AAH62016
 ID AAH62016 standard; DNA; 21 BP.
 XX
 AC AAH62016;
 XX
 XX 10-SEP-2001 (first entry)
 DT
 XX IL8 hairpin/hammerhead ribozyme recognition site SEQ ID NO:4440.
 DE
 XX Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
 KW recognition site; target; ribozyme binding site; eye disease; vulvular;
 KW proliferative disease; skin disease; psoriasis; diabetic retinopathy;

KW cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;
 KW matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;
 KW antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;
 KW antickling; ophthalmological; keratolytic; gene therapy; viral wart;
 KW atopic dermatitis; actinic keratosis; squamous cell carcinoma;
 KW basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;
 KW sickle cell retinopathy; ss.
 OS Homo sapiens.
 OS Synthetic.
 XX WO200130362-A2.
 PN 03-MAY-2001.
 XX 26-OCT-2000; 2000WO-US29500.
 XX 26-OCT-1999; 99US-0161532.
 XX (IMMU-) IMMUSOL INC.
 PA Robbins JM, Tritz R;
 PI WPI; 2001-300427/31.
 DR Treating proliferative skin or eye diseases and scarring, using
 XX ribozymes that cleave RNA encoding cytokines involved in inflammation,
 PT matrix metalloproteinases, growth factors and cell-cycle dependent
 PT kinases -
 XX Example 1; Page 22; 408pp; English.
 XX The present invention describes a method for treating a proliferative
 CC skin or eye disease and scarring. The method involves administering a
 CC ribozyme (I) which cleaves RNA encoding a cytokine involved in
 CC inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
 CC dependent kinase, growth factor or a reductase, or administering a
 CC nucleic acid molecule (II) comprising a promoter operably linked to a
 CC nucleic acid segment encoding (I). (I) can have antipsoriatic,
 CC dermatological, cytostatic, antiseborrheic, antidiabetic, antickling,
 CC ophthalmological, vulnary, keratolytic and virucide activities, and
 CC cleaves RNA encoding cytokine involved in inflammation. (I) can be used
 CC in gene therapy. (I) and (II) are useful for treating proliferative
 CC skin diseases such as psoriasis, atopic dermatitis, actinic keratosis,
 CC squamous or basal cell carcinoma and viral or seborrheic wart. They can
 CC also be used for treating proliferative eye diseases such as diabetic
 CC retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
 CC prematurity and retinal detachment, and for treating and preventing
 CC scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
 CC scar. AAH57577 to AAH62099 represent sequences used in the
 CC exemplification of the present invention.
 XX Sequence 21 BP; 1 A; 1 C; 10 G; 9 T; 0 other;
 SQ Query Match 1.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 9.9;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 473 TTGTGCGGCTGTGTGAGG 493
 Db 1 TTGTGCGGCTGTGTGAGG 21
 RESULT 15
 ID AAH62018 standard; DNA; 21 BP.
 XX AAH62018;
 AC AAH62018;
 XX 10-SEP-2001 (first entry)
 DT IL6 hairpin/hammerhead ribozyme recognition site SEQ ID NO:4442.
 DE
 XX

KW Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
 KW recognition site; target; ribozyme binding site; eye disease; vulnary;
 KW proliferative disease; skin disease; psoriasis; diabetic retinopathy;
 KW cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;
 KW matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;
 KW antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;
 KW antickling; ophthalmological; keratolytic; gene therapy; viral wart;
 KW atopic dermatitis; actinic keratosis; squamous cell carcinoma;
 KW basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;
 KW sickle cell retinopathy; ss.
 XX Homo sapiens.
 OS Synthetic.
 XX WO200130362-A2.
 PN 03-MAY-2001.
 XX 26-OCT-2000; 2000WO-US29500.
 XX 26-OCT-1999; 99US-0161532.
 XX (IMMU-) IMMUSOL INC.
 PA Robbins JM, Tritz R;
 PI WPI; 2001-300427/31.
 DR Treating proliferative skin or eye diseases and scarring, using
 XX ribozymes that cleave RNA encoding cytokines involved in inflammation,
 PT matrix metalloproteinases, growth factors and cell-cycle dependent
 PT kinases -
 XX Example 1; Page 22; 408pp; English.
 XX The present invention describes a method for treating a proliferative
 CC skin or eye disease and scarring. The method involves administering a
 CC ribozyme (I) which cleaves RNA encoding a cytokine involved in
 CC inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
 CC dependent kinase, growth factor or a reductase, or administering a
 CC nucleic acid molecule (II) comprising a promoter operably linked to a
 CC nucleic acid segment encoding (I). (I) can have antipsoriatic,
 CC dermatological, cytostatic, antiseborrheic, antidiabetic, antickling,
 CC ophthalmological, vulnary, keratolytic and virucide activities, and
 CC cleaves RNA encoding cytokine involved in inflammation. (I) can be used
 CC in gene therapy. (I) and (II) are useful for treating proliferative
 CC skin diseases such as psoriasis, atopic dermatitis, actinic keratosis,
 CC squamous or basal cell carcinoma and viral or seborrheic wart. They can
 CC also be used for treating proliferative eye diseases such as diabetic
 CC retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
 CC prematurity and retinal detachment, and for treating and preventing
 CC scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
 CC scar. AAH57577 to AAH62099 represent sequences used in the
 CC exemplification of the present invention.
 XX Sequence 21 BP; 5 A; 8 C; 4 G; 4 T; 0 other;
 SQ Query Match 1.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 9.9;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 853 CAACCTAGTCTGTGAGG 873
 Db 1 CAACCTAGTCTGTGAGG 21
 RESULT 16
 ID ABL46343 standard; DNA; 21 BP.
 XX ABL46343;
 AC ABL46343;
 XX 26-APR-2002 (first entry)
 DT

XX DE Human interleukin-1 beta oligonucleotide SEQ ID NO:310.
XX KW Nucleic acid accessible hybridisation site; detection; hybridisation;
KW characterisation; identification; nucleic acid structure; diagnosis;
XX PCR primer; probe; ss.
XX OS Homo sapiens.
OS Synthetic.
XX PN WO200198537-A2.
XX PD 27-DEC-2001.
XX PF 15-JUN-2001; 2001WO-US19401.
XX PR 17-JUN-2000; 2000US-212308P.
XX PS 15-JUN-2001; 2001US-0212308.
XX PA (THIR-) THIRD WAVE TECHNOLOGIES INC.
XX PI Lyamichev V, Allawi H, Dong F, Neri BP, Vener IT;
XX MPI; 2002-049698/06.
XX PT Identifying oligonucleotides hybridizing to nucleic acids containing
PT secondary structure, useful in clinical diagnosis, comprises
PT identifying primers that interact with the target to form an extension
PT product under amplification conditions -
XX PS Claim 48; Fig 81A; 409pp; English.
XX CC The present invention describes a method for identifying oligonucleotides
CC with desired hybridisation properties to nucleic acid targets containing
CC secondary structure. The method comprises amplifying a target nucleic
CC acid having at least one accessible and one inaccessible site. Primers
CC that form an extension product are identified as the oligonucleotides
CC from the present invention can be used in novel detection methods for
CC clinical diagnostic purposes, including the detection and identification
CC of pathogenic organisms (e.g. HIV). The method allows the ability to
CC rapidly analyse nucleic acid structures. ABL46034 to ABL46367 represent
CC sequences used in the exemplification of the present invention.
XX SQ Sequence 21 BP; 7 A; 2 C; 4 G; 8 T; 0 other;
Query Match 1.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 9.9;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Oy 717 GAACCTTTAATTTCAGGAATTG 737
Db 1 GAACCTTTAATTTCAGGAATTG 21
RESULT 17
ABL46345
ID ABL46345 standard; DNA; 21 BP.
XX AC ABL46345;
XX DT 26-APR-2002 (first entry)
XX DE Human interleukin-1 beta oligonucleotide SEQ ID NO:312.
XX KW Nucleic acid accessible hybridisation site; detection; hybridisation;
KW characterisation; identification; nucleic acid structure; diagnosis;
XX PCR primer; probe; ss.
XX OS Homo sapiens.
OS Synthetic.
XX PN WO200198537-A2.

XX PD 27-DEC-2001.
XX PF 15-JUN-2001; 2001WO-US19401.
XX PR 17-JUN-2000; 2000US-212308P.
XX PS 15-JUN-2001; 2001US-0212308.
XX PA (THIR-) THIRD WAVE TECHNOLOGIES INC.
XX PI Lyamichev V, Allawi H, Dong F, Neri BP, Vener IT;
XX MPI; 2002-049698/06.
XX PT Identifying oligonucleotides hybridizing to nucleic acids containing
PT secondary structure, useful in clinical diagnosis, comprises
PT identifying primers that interact with the target to form an extension
PT product under amplification conditions -
XX PS Claim 48; Fig 81A; 409pp; English.
XX CC The present invention describes a method for identifying oligonucleotides
CC with desired hybridisation properties to nucleic acid targets containing
CC secondary structure. The method comprises amplifying a target nucleic
CC acid having at least one accessible and one inaccessible site. Primers
CC that form an extension product are identified as the oligonucleotides
CC from the present invention can be used in novel detection methods for
CC clinical diagnostic purposes, including the detection and identification
CC of pathogenic organisms (e.g. HIV). The method allows the ability to
CC rapidly analyse nucleic acid structures. ABL46034 to ABL46367 represent
CC sequences used in the exemplification of the present invention.
XX SQ Sequence 21 BP; 7 A; 4 C; 2 G; 8 T; 0 other;
Query Match 1.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 9.9;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Oy 1017 TTCAGTGTAACCTATTATACC 1037
Db 1 TTCAGTGTAACCTATTATACC 21
RESULT 18
AAH76783/c
ID AAH76783 standard; DNA; 24 BP.
XX AC AAH76783;
XX DT 14-DEC-2001 (first entry)
XX DE Human nuclear transforming protein 13 RT-PCR primer, SEQ ID NO:4.
XX KW Human; nuclear transforming protein 13; ATP/GTP binding domain;
KW recombinant production; malignant tumour; cancer; blood disease;
KW HIV infection; human immunodeficiency virus; immune disorder;
KW inflammatory condition; cytostatic; anti-HIV; antiinflammatory;
KW immunomodulator; reverse transcription-PCR; RT-PCR primer; ss.
XX OS Homo sapiens.
XX PN WO200172800-A1.
XX PD 04-OCT-2001.
XX PF 26-MAR-2001; 2001WO-CN00437.
XX PR 27-MAR-2000; 2000CN-0115183.
XX PA (SHAN-) SHANGHAI BIONDOWN GENE DEV INC.
XX PI Mao Y, Xie Y;

XX WPI; 2001-597103/67.
XX Human nuclear transforming protein 13 containing ATP/GTP binding domain
PT and encoded polynucleotide, applicable in diagnosis and treatment of
PT malignant neoplasm, hemopathy, HIV infection, immunological diseases
PT and inflammations
XX
XX Example 2; Page 18; 37pp; Chinese.
XX
XX The invention relates to human nuclear transforming protein 13
CC (AAG66744), nucleic acids encoding it (AAH76781), and a method for the
CC recombinant production of nuclear transforming protein 13. The protein
CC contains an ATP/GTP binding domain and has a molecular weight of 13 kD.
CC The present invention additionally discloses an antagonist of nuclear
CC transforming protein 13 for therapeutic use, and an antibody which
CC specifically binds to human nuclear transforming protein 13. Nuclear
CC transforming protein 13, and nucleotides which encode it may be used
CC for treating a variety of diseases, such as malignant tumours, blood
CC diseases, HIV (human immunodeficiency virus) infection, immune disorders
CC and inflammatory conditions. The protein may also be used to screen for
CC modulators of its activity or for peptide fingerprinting identification.
CC The polynucleotide can be used as a primer for nucleic acid amplification
CC reactions or as a probe for hybridisation reactions, or in producing gene
CC chips or microarrays. Sequences AAH76782-AAH76783 represent reverse
CC transcription-PCR (RT-PCR) primers used in an exemplification of the
CC invention to isolate human nuclear transforming protein 13 cDNA.
XX
SQ Sequence 24 BP; 6 A; 4 C; 1 G; 13 T; 0 other;
Query Match 1.7%; Score 20.8; DB 1; Length 24;
Best Local Similarity 91.7%; Pred. No. 13;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1062 AAGCATCAAAATATTGTGCAAGAA 1085
Db 24 AAGCAATAAAATATTGTGCAAGAA 1
RESULT 19
AAV44676/c
ID AAV44676 standard; DNA; 20 BP.
XX AAV44676;
AC
XX 08-OCT-1998 (first entry)
DT
XX PCR primer for UC Band#325-1.
DE
XX DNA marker; metastatic prostate cancer; human; detection; PCR primer;
KW disease marker identification; lupus erythematosus; rheumatoid arthritis;
KW multiple sclerosis; asthma; myasthenia gravis; autoimmune thyroiditis;
KW amyloid lateral sclerosis; interstitial cystitis; prostatitis;
KW UC Band#325-1; ss.
XX Synthetic.
OS Homo sapiens.
XX WO9824935-A1.
XX 11-JUN-1998.
PD
XX 05-DEC-1997; 97WO-US22105.
XX
XX 24-MAR-1997; 97US-0041576.
PR 06-DEC-1996; 96US-0032619.
PR 12-DEC-1996; 96US-0032701.
XX (UROC-) UROCOR INC.
XX An G, O'Hara M, Ralph D, Veltri R;
XX WPI; 1998-333350/29.

XX Identifying markers for disease states - by amplifying RNA from
PT peripheral blood and identifying RNA which is differential expressed
PT between normal and disease state subjects
XX
XX Example 3; Page 91; 158pp; English.
XX
XX This sequence is a PCR primer for the marker DNA sequence UC Band#325-1
CC and was used in the method of the invention. The method is for
CC identifying markers for a disease state, and comprises: (a) providing a
CC first set of peripheral blood mRNAs from one or more subjects known to
CC exhibit the disease state and a second set of peripheral blood mRNAs from
CC one or more normal subjects; (b) amplifying both sets of mRNAs to provide
CC nucleic acid amplification products; (c) comparing the sets of
CC amplification products; and (d) identifying those mRNAs that are
CC differentially expressed between normal subjects and subjects exhibiting
CC the disease state; where a difference in quantity of expression of an
CC mRNA is indicative of a disease marker. The identified marker
CC sequence can be used in a method of detecting a metastatic cancer disease
CC state, especially for detection prostate cancer. Using the methods, a
CC disease state may be detected, diagnosed, or a prognosis may be delivered
CC by examining a blood sample rather than relying on a more invasive, or
CC less sensitive test. In addition, a subject may be monitored for disease
CC progression, status and response to therapies through monitoring of
CC differentially expressed disease markers. The methods can be used for
CC diseases such as cancer (especially metastatic or prostate cancer),
CC asthma, lupus erythematosus, rheumatoid arthritis, multiple sclerosis,
CC myasthenia gravis, autoimmune thyroiditis, amyloid lateral sclerosis,
CC interstitial cystitis, prostatitis or other systemic or chronic conditions.
XX
SQ Sequence 20 BP; 7 A; 8 C; 3 G; 2 T; 0 other;
Query Match 1.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 480 GGTCTGTTGTAGGGTTGCCA 499
Db 20 GGTCTGTTGTAGGGTTGCCA 1
RESULT 20
AAV44678/c
ID AAV44678 standard; DNA; 20 BP.
XX AAV44678;
AC
XX 08-OCT-1998 (first entry)
DT
XX PCR primer for UC Band#325-2.
DE
XX DNA marker; metastatic prostate cancer; human; detection; PCR primer;
KW disease marker identification; lupus erythematosus; rheumatoid arthritis;
KW multiple sclerosis; asthma; myasthenia gravis; autoimmune thyroiditis;
KW amyloid lateral sclerosis; interstitial cystitis; prostatitis;
KW UC Band#325-2; ss.
XX Synthetic.
OS Homo sapiens.
XX WO9824935-A1.
XX 11-JUN-1998.
PD
XX 05-DEC-1997; 97WO-US22105.
XX
XX 24-MAR-1997; 97US-0041576.
PR 06-DEC-1996; 96US-0032619.
PR 12-DEC-1996; 96US-0032701.
XX (UROC-) UROCOR INC.
XX An G, O'Hara M, Ralph D, Veltri R;
XX WPI; 1998-333350/29.

XX DR WPI; 1998-333350/29.

XX DR

PT Identifying markers for disease states - by amplifying RNA from

PT peripheral blood and identifying RNA which is differential expressed

XX between normal and disease state subjects

XX PS

XX Example 3; Page 91; 158pp; English.

XX CC This sequence is a PCR primer for the marker DNA sequence UC Band#325-2

CC and was used in the method of the invention. The method is for

CC identifying markers for a disease state, and comprises: (a) providing a

CC first set of peripheral blood mRNAs from one or more subjects known to

CC exhibit the disease state and a second set of peripheral blood mRNAs from

CC one or more normal subjects; (b) amplifying both sets of mRNAs to provide

CC nucleic acid amplification products; (c) comparing the sets of

CC amplification products; and (d) identifying those mRNAs that are

CC differentially expressed between normal subjects and subjects exhibiting

CC the disease state; where a difference in quantity of expression of an

CC mRNA is indicative of a disease marker. The identified marker

CC sequence can be used in a method of detecting a metastatic cancer disease

CC state, especially for detection, diagnosis, or a prognosis may be delivered

CC by examining a blood sample rather than relying on a core invasive, or

CC less sensitive test. In addition, a subject may be monitored for disease

CC progression, status and response to therapies through monitoring of

CC differentially expressed disease markers. The methods can be used for

CC diseases such as cancer (especially metastatic or prostate cancer),

CC asthma, lupus erythematosus, rheumatoid arthritis, multiple sclerosis,

CC myasthenia gravis, autoimmune thyroiditis, amyloid lateral sclerosis,

CC interstitial cystitis, prostatitis or other systemic or chronic conditions.

XX SQ Sequence 20 BP; 7 A; 8 C; 3 G; 2 T; 0 other;

Query Match 1.6%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 15;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 480 GGTCTGTTGTAGGGTGGCA 499

DB 20 GGTCTGTTGTAGGGTGGCA 1

RESULT 21

AAZ30727/c

ID AAZ30727 standard; DNA; 20 BP.

AC AAZ30727;

DT 19-JAN-2000 (first entry)

DE Human interleukin-8 (IL-8) RT-PCR primer #11.

KW Interleukin-8; IL-8; marker; expression; diagnosis;

KW differential; disease; cancer; metastatic; breast cancer; prostate;

KW peripheral leukocyte; immune response; asthma; lupus erythematosus;

KW rheumatoid arthritis; multiple sclerosis; myasthenia gravis;

KW autoimmune thyroiditis; amyotrophic lateral sclerosis; ALS;

KW interstitial cystitis; prostatitis; mRNA; reverse transcriptase PCR;

KW RT-PCR; screening; early; diagnosis; prognosis; monitoring; primer; ss.

OS Synthetic.

OS Homo sapiens.

PN WO9949083-A1.

PD 30-SEP-1999.

XX 24-MAR-1999; 99WO-US06488.

XX 24-MAR-1998; 98US-0046894.

XX (UROC-) UROCOR INC.

XX PI Ralph D, An G, O'Hara SM, Veltri RW;

XX WPI; 1999-591105/50.

XX DR

PT Identifying markers of human disease, specifically for diagnosis of

PT metastatic prostatic and breast cancers -

XX PS

XX Example 3; Page 122; 225pp; English.

XX CC This sequence represents human interleukin-8 (IL-8) reverse

CC transcriptase-PCR (RT-PCR) primer #11, used with primers #10 (AAZ30726)

CC or #12 (AAZ30728) to amplify 2 different IL-8 cDNAs (AAZ30714-230715)

CC from peripheral leukocyte RNA. IL-8 cDNA is referred to in this

CC specification as UC Band #325-1, while an IL-8 cDNA containing intron #3

CC is referred to as UC Band #325-2. The IL-8 gene was found to be

CC differentially expressed between healthy subjects and patients with

CC metastatic cancers (especially those of the prostate or breast) and may

CC therefore be used as a marker for such diseases. Detecting levels of such

CC human disease markers is used for diagnosis (also prognosis and

CC monitoring) of diseases, including metastatic or organ-confined cancers,

CC and diseases which also elicit an immune response such as asthma, lupus

CC erythematosus, rheumatoid arthritis, multiple sclerosis, myasthenia

CC gravis, autoimmune thyroiditis, amyotrophic lateral sclerosis (ALS),

CC interstitial cystitis and prostatitis, but especially metastatic

CC prostatic and breast cancer. A particular use is differentiating between

CC prostatic cancer and benign prostatic hypertrophy, and between advanced

CC and localised prostatic cancer, by multivariate analysis of several

CC different markers. Cancers can be treated by administering sequences

CC antisense to sequences that encode human disease markers. This method

CC detects a leukocyte response to disease rather than products of diseased

CC cells, so is suitable for large-scale screening of asymptomatic subjects.

CC Disease can be detected at an early stage, when few, if any, diseased

CC cells are present in the circulation. Analysis of blood samples

CC eliminates the need for more invasive methods for obtaining samples.

XX SQ Sequence 20 BP; 7 A; 8 C; 3 G; 2 T; 0 other;

Query Match 1.6%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 15;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 480 GGTCTGTTGTAGGGTGGCA 499

DB 20 GGTCTGTTGTAGGGTGGCA 1

RESULT 22

ABL46342

ID ABL46342 standard; DNA; 20 BP.

AC ABL46342;

DT 26-APR-2002 (first entry)

DE Human interleukin-1 beta oligonucleotide SEQ ID NO:309.

KW Nucleic acid accessible hybridisation site; detection; hybridisation;

KW characterisation; identification; nucleic acid structure; diagnosis;

KW PCR primer; probe; ss.

OS Homo sapiens.

OS Synthetic.

PN WO200198537-A2.

PD 27-DEC-2001.

XX 15-JUN-2001; 2001WO-US19401.

XX 17-JUN-2000; 2000US-212308P.

XX 15-JUN-2001; 2001US-0212308.

PA (THIR-) THIRD WAVE TECHNOLOGIES INC.
 XX Lyamichev V, Allawi H, Dong F, Neri BP, Vener IT;
 XX WPI; 2002-049698/06.
 XX
 XX Identifying oligonucleotides hybridizing to nucleic acids containing
 PT secondary structure, useful in clinical diagnosis, comprises
 PT identifying primers that interact with the target to form an extension
 PT product under amplification conditions -
 XX
 XX Claim 48; Fig 81A; 409pp; English.
 XX
 XX The present invention describes a method for identifying oligonucleotides
 CC with desired hybridisation properties to nucleic acid targets containing
 CC secondary structure. The method comprises amplifying a target nucleic
 CC acid having at least one accessible and one inaccessible site. Primers
 CC that form an extension product are identified as the oligonucleotides
 CC which can interact with the folded target nucleic acid. Oligonucleotides
 CC from the present invention can be used in novel detection methods for
 CC clinical diagnostic purposes, including the detection and identification
 CC of pathogenic organisms (e.g. HIV). The method allows the ability to
 CC rapidly analyse nucleic acid structures. ABL46034 to ABL46367 represent
 CC sequences used in the exemplification of the present invention.
 XX
 XX Sequence 20 BP; 7 A; 5 C; 2 G; 6 T; 0 other;
 SQ
 Query Match 1.6%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 15;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 557 CATTGTACCATGAATATCC 576
 DB 1 CATTGTACCATGAATATCC 20
 RESULT 23
 AAT76367/c
 ID AAT76367 standard; DNA; 19 BP.
 XX
 XX AAT76367;
 AC
 XX
 DT 15-SEP-1997 (first entry)
 XX
 XX Human interleukin 8 antisense oligonucleotide HUMIL8AAS4.
 DE
 XX Asthma; airway epithelium; adenosine free; cystic fibrosis;
 KW chronic obstructive pulmonary disease; bronchitis; ss.
 KW
 XX Synthetic.
 OS
 XX WO9640162-A1.
 FN
 XX 19-DEC-1996.
 PD
 XX
 XX 06-JUN-1996; 96WO-US09306.
 PF
 XX
 XX 07-JUN-1995; 95US-0474497.
 PR
 XX (UYEC-) UNIV EAST CAROLINA.
 PA
 XX Metzger WJ, Nyce JW;
 PI
 XX WPI; 1997-051871/05.
 DR
 XX Treatment of airway diseases such as asthma - by topically applying
 PT adenosine-free antisense oligo:nucleotide to airway epithelium of
 PT subject
 PT
 XX Claim 5; Page 36; 71pp; English.
 PS
 XX A method for treating airway disease in a subject has been produced,
 CC which involves the topical administration of an essentially adenosine

CC free antisense oligonucleotide (ON) to the airway epithelium of the
 CC subject. The present sequence is an antisense oligonucleotide
 CC HUMIL8AAS4 specific for the human interleukin 8. The method can
 CC be used to treat airway diseases such as cystic fibrosis, asthma,
 CC chronic obstructive pulmonary disease, bronchitis and other
 CC airway diseases characterised by an inflammatory response. By
 CC eliminating adenosine from the antisense ON, its liberation upon
 CC antisense degradation is prevented, thereby preventing adenosine-
 CC induced bronchoconstriction in patients with hyper-reactive airways.
 XX
 XX Sequence 19 BP; 0 A; 8 C; 4 G; 7 T; 0 other;
 SQ
 Query Match 1.5%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 24;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 693 GGGCCACAGGGCCACAGAA 711
 DB 19 GGGCCACAGGGCCACAGAA 1
 RESULT 24
 AAX54168/c
 ID AAX54168 standard; DNA; 19 BP.
 XX
 XX AAX54168;
 AC
 XX
 DT 05-JUL-1999 (first entry)
 XX
 XX Human IL-8 antisense oligonucleotide fragment.
 DE
 XX
 XX Antisense oligonucleotide; multiple target; antisense treatment;
 KW impaired respiration; inflammation; lung disease;
 KW pulmonary vasoconstriction; inflammation; allergic rhinitis;
 KW acute asthma; allergy; asthma; impeded respiration;
 KW respiratory distress syndrome; pain; cystic fibrosis;
 KW pulmonary hypertension; pulmonary vasoconstriction; emphysema;
 KW chronic obstructive pulmonary disease; leukemia; lymphoma; carcinoma;
 KW colon cancer; breast cancer; lung cancer; pancreatic cancer;
 KW hepatocellular carcinoma; kidney cancer; melanoma; hepatic metastasis;
 KW prostate cancer; ss.
 KW
 XX Synthetic.
 OS
 XX WO9913886-A1.
 PN
 XX 25-MAR-1999.
 PD
 XX 17-SEP-1998; 98WO-US19419.
 PF
 XX 09-JUN-1998; 98US-0093972.
 PR
 XX 17-SEP-1997; 97US-0059160.
 PR
 XX (UYEC-) UNIV EAST CAROLINA.
 PA
 XX Nyce JW;
 PI
 XX WPI; 1999-229400/19.
 DR
 XX New antisense oligonucleotides used in treatment of, e.g. pulmonary
 PT vasoconstriction
 PT
 XX Disclosure; Page 55; 120pp; English.
 PS
 XX The specification describes antisense oligonucleotides (AAX52869-X55271)
 CC directed against at least 2 mRNAs selected from target genes, coding and
 CC non-coding regions of RNAs corresponding to target genes, gene
 CC initiation codons, genomic flanking regions, intron-exon borders, the
 CC 5'-end, the 3'-end and the junction between coding and non-coding
 CC regions and all segments of RNAs encoding proteins associated with one
 CC or more diseases, conditions or mixtures. The antisense oligonucleotides
 CC may be derived from sequences AAX5272-74. These multiple target
 CC oligonucleotides (specifically AAX55180-271) can be used for the

CC antineoplastic treatment of diseases and conditions. Typical diseases and
 CC conditions are those associated with impaired respiration and
 CC inflammation, including lung diseases, pulmonary vasoconstriction,
 CC inflammation, allergic rhinitis, acute asthma, allergies, asthma, impeded
 CC respiration, respiratory distress syndrome, pain, cystic fibrosis,
 CC pulmonary hypertension, pulmonary vasoconstriction, emphysema, chronic
 CC obstructive pulmonary disease (COPD), and cancers such as leukemias,
 CC lymphomas, carcinomas e.g. colon cancer, breast cancer, lung cancer,
 CC pancreatic cancer, hepatocellular carcinoma, kidney cancer, melanoma,
 CC hepatic metastases, as well as all types of cancers which may metastasize
 CC or have metastasized to the lungs, including breast and prostate cancer.
 CC
 XX Sequence 19 BP; 0 A; 8 C; 4 G; 7 T; 0 other;

Query Match 1.5%; Score 19; DB 1; Length 19;

Best Local Similarity 100.0%; Pred. No. 24;

Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 693 GGGCCAGGGCCAGAGAA 711

Db 19 GGGCCAGGGCCAGAGAA 1

RESULT 25

AAF19734/C

ID AAF19734 standard; DNA; 19 BP.

XX AAF19734;

AC AAF19734;

XX 14-MAR-2001 (first entry)

XX Human interleukin-8 polynucleotide fragment #1301.

XX

XX Low adenosine antisense oligonucleotide; phosphorothioate; allergy;

XX human; airway disorder; bronchoconstriction; lung inflammation;

XX surfactant depletion; respiratory bronchodilator; antiinflammatory;

XX immunosuppressive; antiasthmatic; analgesic; hypotensive; cytostatic;

XX respiratory obstruction; pulmonary obstruction; impeded respiration;

XX surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;

XX respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;

XX pulmonary hypertension; emphysema; pulmonary transplantation rejection;

XX chronic obstructive pulmonary disease; pulmonary infection; bronchitis;

XX cancer; ss.

XX

XX Homo sapiens.

XX

XX WO200062736-A2.

XX

XX 26-OCT-2000.

XX

XX 24-MAR-2000; 2000WO-US08020.

XX

XX 06-APR-1999; 99US-0127958.

XX

XX (UYEC-) UNIV EAST CAROLINA.

XX

XX (NYCE/) NYCE J W.

XX

XX Nyce JW;

XX

XX WPI; 2000-679539/66.

XX

XX Low adenosine (A) content antisense oligonucleotides which do not

XX trigger adenosine receptors during metabolism, useful e.g. for treating

XX cancers and respiratory obstructions -

XX

XX Claim 14; Page 236; 1592pp; English.

XX

XX The present invention describes low adenosine (A) content antisense

XX oligonucleotides and compositions (I) comprising them. In the antisense

XX oligonucleotides the A is replaced by a 'Universal' or alternative base.

XX (I) can have respiratory, bronchodilator, antiinflammatory, analgesic,

XX immunosuppressive, antiasthmatic, hypotensive and cytostatic activities.

XX The antisense oligonucleotides and (I) can be used to down-regulate the

CC expression and or activity of target polypeptides associated with
 CC lung/respiratory disorders and malignancies, such as stimulating and
 CC activating peptide factors and transmitters, transcription factors,
 CC immunoglobulins and antibodies, antibody receptors, cytokines and
 CC chemokines, endogenously produced specific and non-specific enzymes,
 CC binding proteins, adenosine molecules and their receptors, cytokine and
 CC chemokine receptors, adenosine receptors, bradykinin receptors, central
 CC nervous system (CNS) and peripheral nervous and non-nervous system
 CC receptors, CNS and peripheral nervous and non-nervous system peptide
 CC transmitters, defensins growth factors, vasoactive peptides and
 CC receptors, binding proteins and malignancy associated proteins. The
 CC antisense oligonucleotides may be used in this way to treat disorders
 CC including respiratory obstruction (especially pulmonary obstruction
 CC and/or bronchoconstriction) and/or lung inflammation, allergy(ies)
 CC condition selected from pulmonary vasoconstriction, inflammation,
 CC allergies, asthma, impeded respiration, respiratory distress syndrome
 CC (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease (COPD),
 CC pulmonary transplantation rejection, pulmonary infections, bronchitis,
 CC and/or cancer. AAF18434 to AAF21543 represent human polynucleotide
 CC fragments and antisense oligonucleotides used in the exemplification of
 CC the present invention.
 XX

SQ Sequence 19 BP; 0 A; 8 C; 4 G; 7 T; 0 other;

Query Match 1.5%; Score 19; DB 1; Length 19;

Best Local Similarity 100.0%; Pred. No. 24;

Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 693 GGGCCAGGGCCAGAGAA 711

Db 19 GGGCCAGGGCCAGAGAA 1

RESULT 26

AAF19734/C

ID AAF19734 standard; DNA; 19 BP.

XX AAF19734;

AC AAF19734;

XX 28-JUL-2000 (first entry)

XX Low adenosine antisense oligonucleotide SEQ ID NO:1301.

XX Human; adenosine receptor; low adenosine antisense oligonucleotide;

XX phosphorothioate; impaired respiration; inflammation; allergy;

XX allergic disease; bronchoconstriction; inhibitor; antiinflammatory;

XX antiallergic; antiasthmatic; cytostatic; analgesic; impaired airway;

XX lung disease; ischaemic condition; pulmonary vasoconstriction; asthma;

XX respiratory distress syndrome; pain; cystic fibrosis; emphysema;

XX pulmonary hypertension; chronic obstructive pulmonary disease; COPD;

XX cancer; leukaemia; lymphoma; carcinoma; metastasis; ss.

XX

XX Homo sapiens.

XX

XX WO200009525-A2.

XX

XX 24-FEB-2000.

XX

XX 03-AUG-1999; 99WO-US17712.

XX

XX 03-AUG-1999; 98US-0095212.

XX

XX (UYEC-) UNIV EAST CAROLINA.

XX

XX Nyce JW;

XX

XX WPI; 2000-205971/18.

XX

XX New antisense oligonucleotides useful for treating e.g. pulmonary

XX vasoconstriction, inflammation, allergies, asthma, hypertension,

XX bronchitis, emphysema, respiratory distress syndrome, ischemia or

XX

PT cancers -
 PS Claim 18; Page 427; 1343pp; English.
 XX
 CC The present invention describes a new composition comprising an
 CC antisense oligonucleotide (ON) with low adenosine (up to 15%), which
 CC targets nucleic acids involved in bronchoconstriction, allergies, and/or
 CC inflammation. The ON can have antiinflammatory, antiallergic,
 CC antasthmatic, cytosstatic and anagesic activities. The compositions are
 CC useful for the treatment of diseases associated with inflammation,
 CC impaired airways, including lung disease and diseases whose secondary
 CC effects afflict the lungs of a subject. They can be used for treating
 CC e.g. ischaemic conditions, pulmonary vasoconstriction, allergies,
 CC asthma, impeded respiration, respiratory distress syndrome, pain, cystic
 CC fibrosis, pulmonary hypertension, emphysema, chronic obstructive
 CC pulmonary disease (COPD), and cancers such as leukaemias, lymphomas,
 CC carcinomas, and cancers which may metastasise to the lungs, including
 CC breast and prostate cancer. The reduction of the adenosine content of
 CC the ONs reduces side effects. The A-containing ONs break down with the
 CC release of deoxyadenosine which activates adenosine receptors causing
 CC bronchoconstriction and inflammation. AAA32313 to AAA35312 represent the
 CC nucleotide sequences given in the sequence listing from the present
 CC invention, which correspond to SEQ ID NO:1 to 2815, and then the last
 CC 185 sequences are also called SEQ ID NO:1 to 185, but the sequences
 CC differ from the previously named sequences. SEQ ID NO:11 to 1680
 CC (AAA32323 to AAA3392) are specifically claimed ONs from the present
 CC invention. N.B. Sequences given in the disclosure of the present
 CC invention do not match up with their corresponding SEQ ID NO: sequences
 CC given in the sequence listing.

XX Sequence 19 BP; 0 A; 8 C; 4 G; 7 T; 0 other;

Query Match 1.5%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 24;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 693 GGGCCAGGCGCCAGAGAA 711
 DB 19 GGGCCAGGCGCCAGAGAA 1

RESULT 27

ID ABX11405

XX AC ABX11405;
 XX AC ABX11405;

DT 28-APR-2003 (first entry)

XX 3' primer used to amplify human chemokine alpha-3 for use in pQE-9.

XX ss; primer; human; chemokine alpha-3; gene therapy; chemotactic cytokine;
 XX chronic infection; mycobacterial infection; parasitic infection; asthma;
 XX T-cell mediated autoimmune disease; psoriasis; fibrotic disorder; sepsis;
 XX liver cirrhosis; osteoarthritis; pulmonary fibrosis; allergy; rhinitis;
 XX schistosomiasis; trichinosis; ascariasis; bone marrow protection; ARDS;
 XX haemopoiesis regulation; growth factor activity; stem cell mobilisation;
 XX angiogenesis inhibition; adult respiratory distress syndrome; silicosis;
 XX endotoxic shock; wound healing; multiple sclerosis; chronic urticaria;
 XX insulin-dependent diabetes; idiopathic hyperesoinophilic syndrome; PCR;
 XX sarcoidosis; idiopathic pulmonary fibrosis; atopic dermatitis; eczema;
 XX atherosclerosis; acute inflammatory pulmonary disease; aplastic anaemia;
 XX chronic inflammatory pulmonary disease; degenerative arthropathy; pQE-9;
 XX inflammatory arthropathy; prostaglandin-independent fever; leukaemia;
 XX myelodysplastic syndrome; subepithelial basement membrane fibrosis;
 XX tumour.

XX Homo sapiens.
 OS Synthetic.

XX US2002132305-A1.

PN 19-SEP-2002.

XX 10-MAY-2002; 2002US-0141938.

XX 18-MAR-1996; 96US-013615P.

PR 18-MAR-1997; 97US-0816772.

PA (HUMA-) HUMAN GENOME SCI INC.

XX Ni J, Li H, Su JY;

XX WPI; 2003-237898/23.

XX New human chemokine alpha-3 polypeptides and polynucleotides, useful in
 XX gene therapy, and for treating e.g. tumors, chronic infections,
 XX leukemia, T-cell mediated autoimmune diseases, parasitic infections,
 XX psoriasis, and allergy

XX Example 1; Page 17; 29pp; English.

XX The invention relates to an isolated polynucleotide which encodes a
 XX member of the (chemotactic cytokine) chemokine alpha subfamily. An
 XX antagonist of the polypeptide is useful in a method of treating a patient
 XX in need of inhibiting chemokine alpha-3 polypeptide. The polypeptide is
 XX useful in a method of treating a patient in need of chemokine alpha-3.
 XX The human chemokine alpha-3 polypeptides and polynucleotides are useful
 XX in gene therapy, for treating tumors, chronic infections (e.g.
 XX mycobacterial infections), leukaemia, T-cell mediated autoimmune
 XX diseases, parasitic infections, psoriasis, fibrotic disorders (e.g. liver
 XX cirrhosis, osteoarthritis and pulmonary fibrosis), allergy, trichinosis,
 XX schistosomiasis, ascariasis, asthma and sepsis, for protecting bone
 XX marrow during chemotherapy, for regulating haemopoiesis, for stimulating
 XX growth factor activity and stem cell mobilisation, for inhibiting
 XX angiogenesis and adult respiratory distress syndrome (ARDS) and for
 XX promoting wound healing. Human cytokine alpha-3 antagonists can be used
 XX to treat multiple sclerosis, insulin-dependent diabetes, silicosis,
 XX sarcoidosis, idiopathic pulmonary fibrosis, idiopathic hyperesoinophilic
 XX syndrome, rhinitis, endotoxic shock, chronic urticaria, atherosclerosis,
 XX atopic dermatitis, eczema, acute inflammatory pulmonary disease, chronic
 XX inflammatory pulmonary disease, degenerative arthropathy, inflammatory
 XX arthropathy, aplastic anaemia, prostaglandin-independent fever, fibrosis.
 XX The present sequence represents the 3' primer used to amplify human
 XX chemokine alpha-3 so that it can be cloned into the bacterial expression
 XX vector pQE-9.

XX Sequence 27 BP; 3 A; 10 C; 4 G; 10 T; 0 other;

Query Match 1.5%; Score 19; DB 1; Length 27;

Best Local Similarity 81.5%; Pred. No. 36;

Matches 22; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 870 CCAGATCCCAAGTCTCTGTTCCTACT 896

DB 1 CCGGATCCTCGTCTGTTCCTACT 27

RESULT 28

ABQ77073

ID ABQ77073 standard; DNA; 27 BP.

XX AC ABQ77073;

XX 27-MAR-2003 (first entry)

XX Human CKalpha-3 PCR primer SEQ ID 4.

XX Chemokine alpha-3; human; cytokine; antirheumatic; rheumatoid arthritis;
 XX antiinflammatory; antiarteriosclerotic; antiasthmatic; atopic dermatitis;
 XX chemokine antagonist; gene therapy; allergic rhinitis; PCR; primer; ss.

XX Homo sapiens.

XX US2002150994-A1.

```

XX PD 17-OCT-2002.
XX PF
XX PP
XX PR 10-MAY-2002; 2002US-0142046.
XX PR 18-MAR-1996; 96US-013615P.
XX PR 18-MAR-1997; 97US-0816772.
XX PA (HUMA-) HUMAN GENOME SCI INC.
XX PI Ni J, Li H, Su J;
XX PI WPI; 2003-182501/18.
XX DR
XX PF New polynucleotide human chemokine alpha-3 polynucleotide, useful for
XX PF producing a medicament for treating atherosclerosis, atopic dermatitis,
XX PT asthma, allergic rhinitis or rheumatoid arthritis -
XX PT
XX PS Example 1; Page 17; 31pp; English.
XX CC This invention describes a novel human chemotactic cytokine, chemokine
XX CC alpha-3 (CKalpha-3) which has anti-rheumatic, anti-inflammatory,
XX CC anti-atherosclerotic and antiasthmatic activity. CKalpha-3 is a chemokine
XX CC antagonist which can be used for gene therapy and for producing a
XX CC medicament to treat atherosclerosis, atopic dermatitis, asthma, allergic
XX CC rhinitis or rheumatoid arthritis. This sequence represents a PCR primer
XX CC used in the expression and purification of mature human CKalpha-3 using
XX CC bacteria.
XX SQ Sequence 27 BP; 3 A; 10 C; 4 G; 10 T; 0 other;

  Query Match      1.5%; Score 19; DB 1; Length 27;
  Best Local Similarity 81.5%; Pred. No. 36;
  Matches 22; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Oy 870 CCAGATCCACAAAGTCCTTGTTCCACT 896
Db 1 CCCGATCCTCAGTTCTTGTTCCACT 27

RESULT 29
AAA66457
ID AAA66457 standard; DNA; 25 BP.
XX AC AAA66457;
XX DT 09-OCT-2000 (first entry)
XX DE Dog genomic marker oligonucleotide sequence SEQ ID NO:319.
XX KW Dog; genome; genomic marker; radiation hybrid map; identification;
XX KW chromosome location; gene marker; polymorphic microsatellite marker;
XX KW phenotype; behaviour; pedigree; ss.
XX OS Canis familiaris.
XX PN WO200029615-A2.
XX PD 25-MAY-2000.
XX PF 15-NOV-1999; 99WO-IB01907.
XX PR 13-NOV-1998; 98US-0108193.
XX PA (CNRS ) CNRS CENT NAT RECH SCI.
XX PI Galibert F, Andre C;
XX PI WPI; 2000-387821/33.
XX DR
XX PF New radiation hybrid map of the dog, Canine familiaris, genome, useful
XX PF for e.g. identifying genes implicated in phenotypic and behavioral
XX PT traits or in genetic diseases and for studying dog pedigrees -

```

```

XX Claim 1; Page 66; 87pp; English.
XX CC The present invention describes a radiation hybrid map of the dog
XX CC (Canine familiaris) genome comprising the genome location of a marker
XX CC selected from AAA66139 to AAA66942. The radiation hybrid map is useful
XX CC for identifying and localising dog genes, since it covers approximately
XX CC 80 % of the dog genome and provides a dense map integrating different
XX CC types (i.e. Type I and Type II) of markers. The map and the dog genome
XX CC markers (or complementary sequences) are especially useful to identify
XX CC genes responsible for phenotypic and behavioural traits in dogs, to
XX CC identify morbid genes, to analyse diseases and identify implicated genes
XX CC in such diseases and their alleles, and to study dog pedigrees. They
XX CC may also be useful for isolating corresponding human gene sequences
XX CC e.g. genes involved in genetic diseases.
XX SQ Sequence 25 BP; 12 A; 5 C; 3 G; 5 T; 0 other;

  Query Match      1.5%; Score 18.6; DB 1; Length 25;
  Best Local Similarity 84.0%; Pred. No. 40;
  Matches 21; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Oy 431 GCCAGTCGAACCTTCAAGCAATCTA 455
Db 1 GCCAATGAGACTTCAAAAAAATCTA 25

RESULT 30
AAI66531/C
ID AAI66531 standard; DNA; 24 BP.
XX AC AAI66531;
XX DT 11-DEC-2001 (first entry)
XX DE Human pterin-molybdenum oxidoreductase 10 cDNA PCR primer #1.
XX KW Human; pterin-molybdenum oxidoreductase 10; cancer; haemopathy;
XX KW immunological disease; HIV infection; inflammation; gene therapy;
XX KW PCR primer; ss.
XX OS Homo sapiens.
XX PN WO200172788-A1.
XX PD 04-OCT-2001.
XX PF 23-MAR-2001; 2001WO-CN00393.
XX PR 24-MAR-2000; 2000CN-0115110.
XX PA (SHAN-) SHANGHAI BIOWINDOW GENE DEV INC.
XX PI Mao Y, Xie Y;
XX PI WPI; 2001-602841/68.
XX DR
XX PF New polypeptide for the diagnosis and treatment of malignant neoplasm,
XX PF hemopathy, HIV infection, immunological diseases and inflammations,
XX PF comprises the human pterin-molybdenum oxidoreductase 10 protein -
XX PF
XX PS Example 2; Page 17; 36pp; Chinese.
XX CC The present invention provides the protein and coding sequences of human
XX CC pterin-molybdenum oxidoreductase 10. The sequences can be used in the
XX CC treatment of cancer, haemopathy, HIV infection, immunological diseases
XX CC and inflammation. The present sequence is a PCR primer for the coding
XX CC sequence of the invention.
XX SQ Sequence 24 BP; 10 A; 2 C; 0 G; 12 T; 0 other;

  Query Match      1.5%; Score 18.2; DB 1; Length 24;
  Best Local Similarity 87.0%; Pred. No. 47;

```

Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 590 ATGTAAGTATTATTATTATTGAA 612
 DB 24 ATGTAAGTATTATTATTATTAAA 2

RESULT 31
 AAH45430
 ID AAH45430 standard; DNA; 25 BP.
 XX
 AC AAH45430;
 XX
 DT 06-SEP-2001 (first entry)
 XX
 DE Glutamate tRNA synthetase 58 cDNA specific PCR primer.
 XX
 KW Human; glutamate tRNA synthetase 58; malignant tumour; haemopathy;
 KW HIV infection; immunological disease; inflammatory condition; cytostatic;
 KW haemostatic; virucide; immunomodulatory; antiinflammatory;
 KW PCR primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200138371-A1.
 XX
 PD 31-MAY-2001.
 XX
 XX 20-NOV-2000; 2000WO-CN00475.
 XX
 XX 24-NOV-1999; 99CN-0124102.
 XX
 PA (BIOR-) BIORAD GENE DEV LTD SHANGHAI.
 XX
 PI Mao Y, Xie Y;
 XX
 DR WPI; 2001-355891/37.
 XX
 XX New human glutamate tRNA synthase 58 for diagnosing and treating
 PT cancer, hemopathy, human immunodeficiency virus (HIV) infection,
 PT immunological diseases and inflammation -
 XX
 XX Example 3; Page 12; 36pp; Chinese.

This invention relates to human glutamate tRNA synthetase 58, and the
 CC cDNA sequence encoding it. The invention includes a vector containing the
 CC cDNA sequence, a host cell transformed with the vector, and an antibody
 CC targeting the glutamate tRNA synthetase 58 protein. The glutamate tRNA
 CC synthetase 58 protein and cDNA may be used in the diagnosis and treatment
 CC of malignant tumours, haemopathy, human immunodeficiency virus (HIV)
 CC infection, immunological diseases and various inflammatory conditions.
 CC Use of the protein or cDNA for treatment, may result in cytostatic;
 CC haemostatic; virucide; immunomodulatory; or antiinflammatory activity.
 CC The present sequence represents a PCR primer specific for cDNA encoding
 CC human glutamate tRNA synthetase 58.

Sequence 25 BP; 5 A; 1 C; 0 G; 19 T; 0 other;
 Query Match 1.4%; Score 17.6; DB 1; Length 25;
 Best Local Similarity 83.3%; Pred. No. 66;
 Matches 20; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1139 TAAATTTATTATTATTAGATATT 1162
 DB 1 TCATTTTATTATTATTATTATTATT 24

RESULT 32
 AAA14463
 ID AAA14463 standard; RNA; 21 BP.
 XX
 AC AAA14463;
 XX

Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

DT 21-AUG-2000 (first entry)
 XX
 DE AUUUA RNA target sequence.
 XX
 KW AUUUA sequence; RNA target molecule; RNA binding protein identification;
 KW ss.
 XX
 OS Synthetic.
 XX
 PN WO200020637-A1.
 XX
 PD 13-APR-2000.
 XX
 PF 16-SEP-1999; 99WO-US21672.
 XX
 PR 02-OCT-1998; 98US-0165868.
 XX
 PA (MESS-) MESSAGE PHARM INC.
 XX
 PI Giordano T, Beach DL, Temeles GL;
 XX
 DR WPI; 2000-303802/26.
 XX
 XX Nucleic acid molecules useful for identifying compounds affecting
 PT interactions between RNA molecules and identifying RNA binding proteins
 PT -
 XX
 PS Example 1; Page 33; 58pp; English.

The invention relates to mRNA sequences which bind to RNA binding
 CC proteins, and their use for identifying RNA binding proteins and
 CC compounds which have an effect on the interactions between an RNA
 CC binding protein and an RNA molecule. The disclosed sequences are the 3',
 CC untranslated region (3' UTR) sequences APP-R1, APP-D3 and APP-I1 from
 CC the human amyloid precursor protein mRNA (AAAI4456-A14458); the 3' UTR
 CC of human interleukin-10 (IL-10) mRNA (AAAI4459); the 3' UTR of human
 CC erb-B2 mRNA (AAAI4460); and the 5' UTR of human insulin-like growth
 CC factor I receptor (IGF-IR) mRNA (AAAI4461). The disclosed mRNA sequences
 CC molecule comprising the sequence and an RNA binding protein. Such
 CC compounds can then be included with a carrier in pharmaceutical
 CC compositions for altering expression of a gene comprising the sequences,
 CC which can be administered to individuals or cells requiring altered
 CC expression of the gene. The mRNA sequences are also useful to identify
 CC RNA binding proteins which interact with them. Compounds identified as
 CC having the ability to affect such RNA binding interactions may therefore
 CC be useful as drugs for modulating protein levels in disease states. The
 CC present sequence represents an AUUUA RNA sequence used as a target
 CC molecule in an exemplification of the invention in an assay for
 CC detecting interactions between RNA molecules and RNA binding proteins.

Sequence 21 BP; 6 A; 0 C; 0 G; 15 U; 0 other;
 Query Match 1.4%; Score 17.4; DB 1; Length 21;
 Best Local Similarity 26.3%; Pred. No. 60;
 Matches 5; Conservative 13; Mismatches 1; Indels 0; Gaps 0;

QY 1044 TTATTATGTTATTATTATTA 1062
 DB 3 UUAUUUUUUUUUUUUUUUU 21

RESULT 33
 AAD49639
 ID AAD49639 standard; mRNA; 21 BP.
 XX
 AC AAD49639;
 XX
 XX 24-MAR-2003 (first entry)
 DT
 XX Human adenylate uridylylate-rich element (ARE) motif mRNA #1.
 DE
 XX Amyloidosis; haemophilia; Alzheimer's disease; atherosclerosis; cancer;
 KW

PT Identifying a test compound that binds to a target RNA molecule by
PT separating the detectably labeled target RNA: support-attached test
PT compound complex from uncomplexed target RNA molecules and test
PT compounds by flow cytometry -
XX
PS Disclosure; Page 16; 131pp; English.
XX
CC The invention relates to a novel method for identifying a test compound
CC that binds to a target RNA molecule comprising separating the detectably
CC labeled target RNA: support-attached test compound complex from
CC uncomplexed target RNA molecules and test compounds. The separating
CC process is carried out by flow cytometry and determining a structure of
CC the type of test compound of the RNA: support-attached test compound
CC complex by mass spectrometry. The method is useful for high-throughput
CC screening of libraries of compounds to identify pharmaceutical leads.
CC This polynucleotide sequence represents one of the target RNA motifs/
CC regions of the invention.
XX
SQ Sequence 21 BP; 6 A; 0 C; 0 G; 15 U; 0 other;

Query Match 1.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 26.3%; Pred. No. 60;
Matches 5; Conservative 13; Mismatches 1; Indels 0; Gaps 0;

QY 1044 TTATTATGTTATTATTA 1062
DB 3 UUAUUUUUUUUUUUUUU 21

RESULT 36
AAL54044/c
ID AAL54044 standard; DNA; 24 BP.
XX
AC AAL54044;
XX
XX 06-MAR-2003 (first entry)
XX Human macroprotein 16-39 PCR primer 1.
XX
XX Human macroprotein 16.39; embryotic development deformity; tumour;
XX DNA recombination; PCR; primer; ss.
XX Homo sapiens.
XX
XX CN1342711-A.
XX
XX 03-APR-2002.
XX
XX 12-SEP-2000; 2000CN-0125188.
XX
XX 12-SEP-2000; 2000CN-0125188.
XX (BODE-) BODE GENE DEV CO LTD SHANGHAI.
XX
XX Mao Y, Xie Y;
XX WPI; 2002-529786/57.
XX
XX Polypeptide-human macroprotein 16.39 and polynucleotide for coding it -
XX
XX Example 2; Page 19 (Disclosure); 35pp; Chinese.
XX
XX The invention relates to the novel human macroprotein 16.39. The
XX invention also relates to the polynucleotide for coding the protein, the
XX process for preparing the protein by DNA recombination technique, the
XX application of the protein in treating several diseases such as embryotic
XX development deformity and tumours, the antagonist against this protein
XX and its therapeutic action, and the application of the polynucleotide
XX coding this new human macroprotein 16.35. This polynucleotide sequence
XX represents a PCR primer of the human macroprotein 16.39 of the invention.
XX
XX Sequence 24 BP; 7 A; 2 C; 2 G; 13 T; 0 other;

Query Match 1.4%; Score 17.4; DB 1; Length 24;
Best Local Similarity 94.7%; Pred. No. 70;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1590 AAATATAAAGTAAATATG 1608
DB 21 AAAAATAAAGTAAATATG 3

RESULT 37
AAT76273/c
ID AAT76273 standard; DNA; 17 BP.
XX
AC AAT76273;
XX
XX 15-SEP-1997 (first entry)
XX Human MDNCF antisense oligonucleotide H5MDNCFAS3.
XX
XX Asthma; airway epithelium; adenosine free; cystic fibrosis;
XX chronic obstructive pulmonary disease; bronchitis;
XX monocyte-derived neutrophil chemotactic factor; ss.
XX Synthetic.
XX WO9640162-A1.
XX
XX 19-DEC-1996.
XX
XX 06-JUN-1996; 96WO-US09306.
XX
XX 07-JUN-1995; 95US-0474497.
XX (UYEC-) UNIV EAST CAROLINA.
XX
XX Metzger WJ, Nyce JW;
XX WPI; 1997-051871/05.
XX
XX Treatment of airway diseases such as asthma - by topically applying
XX adenosine-free antisense oligo:nucleotide to airway epithelium of
XX subject
XX
XX Claim 5; Page 33; 71pp; English.
XX
XX A method for treating airway disease in a subject has been produced,
XX which involves the topical administration of an essentially adenosine
XX free antisense oligonucleotide (ON) to the airway epithelium of the
XX subject. The present sequence is an antisense oligonucleotide of
XX H5MDNCFAS3 specific for the human monocyte-derived neutrophil
XX chemotactic factor. The method can be used to treat airway diseases
XX such as cystic fibrosis, asthma, chronic obstructive pulmonary disease,
XX bronchitis and other airway diseases characterised by an inflammatory
XX response. By eliminating adenosine from the antisense ON, its
XX liberation upon antisense degradation is prevented, thereby preventing
XX adenosine-induced bronchoconstriction in patients with hyper-reactive
XX airways.
XX
XX Sequence 17 BP; 0 A; 6 C; 4 G; 7 T; 0 other;

Query Match 1.4%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 58;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 695 GCCAAGGGGCCAAGAGAA 711
DB 17 GCCAAGGGGCCAAGAGAA 1

RESULT 38
AAK54070/c
ID AAK54070 standard; DNA; 17 BP.
XX

AC	AAX54070;
XX	
DT	05-JUL-1999 (first entry)
XX	
DE	Monocyte-derived neutrophil chemotactic factor antisense oligo.
XX	
KW	Antisense oligonucleotide; multiple target; antisense treatment;
KW	impaired respiration; inflammation; lung disease;
KW	pulmonary vasoconstriction; inflammation; allergic rhinitis;
KW	acute asthma; allergy; asthma; impeded respiration;
KW	respiratory distress syndrome; pain; cystic fibrosis;
KW	pulmonary hypertension; pulmonary vasoconstriction; emphysema;
KW	chronic obstructive pulmonary disease; leukemia; lymphoma; carcinoma;
KW	colon cancer; breast cancer; lung cancer; pancreatic cancer;
KW	hepatocellular carcinoma; kidney cancer; melanoma; hepatic metastasis;
KW	prostate cancer; ss.
OS	Synthetic.
XX	
PN	WO9913886-A1.
XX	
PD	25-MAR-1999.
XX	
PF	17-SBP-1998; 98WO-US19419.
XX	
PR	09-JUN-1998; 98US-0093972.
PR	17-SEP-1997; 97US-0059160.
XX	
PA	(UYEC-) UNIV EAST CAROLINA.
XX	
PI	Nyce JW;
XX	
DR	WI; 1999-229400/19.
XX	
PT	New antisense oligonucleotides used in treatment of, e.g. pulmonary
PT	vasoconstriction
XX	
PS	Disclosure; Page 51; 120pp; English.
XX	
CC	The specification describes antisense oligonucleotides (AAX52869-X55271)
CC	directed against at least 2 mRNAs selected from target genes, coding and
CC	non-coding regions of RNAs corresponding to target genes, gene
CC	initiation codons, genomic flanking regions, intron-exon borders, the
CC	5'-end, the 3'-end and the juxta-section between coding and non-coding
CC	regions and all segments of RNAs encoding proteins associated with one
CC	or more diseases, conditions or mixtures. The antisense oligonucleotides
CC	may be derived from sequences AAX5272-74. These multiple target
CC	oligonucleotides (specifically AAX5180-271) can be used for the
CC	antisense treatment of diseases and conditions. Typical diseases and
CC	conditions are those associated with impaired respiration and
CC	inflammation, including lung diseases, pulmonary vasoconstriction,
CC	allergic rhinitis, acute asthma, allergies, asthma, impeded
CC	respiration, respiratory distress syndrome, pain, cystic fibrosis.
CC	pulmonary hypertension, pulmonary vasoconstriction, emphysema, chronic
CC	obstructive pulmonary disease (COPD), and cancers such as leukemias,
CC	lymphomas, carcinomas e.g. colon cancer, breast cancer, lung cancer,
CC	pancreatic cancer, hepatocellular carcinoma, kidney cancer, melanoma,
CC	hepatic metastases, as well as all types of cancers which may metastasize
CC	or have metastasized to the lungs, including breast and prostate cancer.
XX	
SQ	Sequence 17 BP; 0 A; 6 C; 4 G; 7 T; 0 other;
	Query Match 1.4%; Score 17; DB 1; Length 17;
	Best Local Similarity 100.0%; Pred.No. 58;
	Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY	695 GCCAACGGGCCAAGAGA 711
Db	17 GCCAACGGGCCAAGAGA 1
RESULT 39	
AAFI9636/c	

CC		(AAA32323 to AAA33992) are specifically claimed ONs from the present invention. N.B. Sequences given in the disclosure of the present invention do not match up with their corresponding SEQ ID NO: sequences given in the sequence listing.	
XX	Sequence 17 BP; 0 A; 6 C; 4 G; 7 T; 0 other;	XX	Sequence 17 BP; 0 A; 6 C; 4 G; 7 T; 0 other;
Query Match		1.4%; Score 17; DB 1; Length 17;	
Best Local Similarity		100.0%; Pred. No. 58;	
Matches 17; Conservative		0; Mismatches 0; Indels 0; Gaps 0;	
QY	695 GCCAGGGCCACAGAGAA 711	QY	695 GCCAGGGCCACAGAGAA 711
DB	17 GCCAGGGCCACAGAGAA 1	DB	17 GCCAGGGCCACAGAGAA 1
RESULT 41		RESULT 41	
ID	ABL46341	ID	ABL46341
XX	ABL46341 standard; DNA; 17 BP.	XX	ABL46341 standard; DNA; 17 BP.
AC	ABL46341;	AC	ABL46341;
DT	26-APR-2002 (first entry)	DT	26-APR-2002 (first entry)
DB	Human interleukin-1 beta oligonucleotide SEQ ID NO:308.	DB	Human interleukin-1 beta oligonucleotide SEQ ID NO:308.
XX	Nucleic acid accessible hybridisation site; detection; hybridisation; characterisation; identification; nucleic acid structure; diagnosis;	XX	Nucleic acid accessible hybridisation site; detection; hybridisation; characterisation; identification; nucleic acid structure; diagnosis;
KW	PCR primer; probe; ss.	KW	PCR primer; probe; ss.
OS	Homo sapiens.	OS	Homo sapiens.
OS	Synthetic.	OS	Synthetic.
XX	WO200198537-A2.	XX	WO200198537-A2.
PD	27-DEC-2001.	PD	27-DEC-2001.
PF	15-JUN-2001; 2001WO-US19401.	PF	15-JUN-2001; 2001WO-US19401.
PR	17-JUN-2000; 2000US-212308P.	PR	17-JUN-2000; 2000US-212308P.
PR	15-JUN-2001; 2001US-0212308.	PR	15-JUN-2001; 2001US-0212308.
XX	(THIR-) THIRD WAVE TECHNOLOGIES INC.	XX	(THIR-) THIRD WAVE TECHNOLOGIES INC.
PI	Lyamichev V, Allawi H, Dong F, Neri BP, Vener IT;	PI	Lyamichev V, Allawi H, Dong F, Neri BP, Vener IT;
XX	WPI; 2002-049698/06.	XX	WPI; 2002-049698/06.
PT	Identifying oligonucleotides hybridizing to nucleic acids containing secondary structure, useful in clinical diagnosis, comprises identifying primers that interact with the target to form an extension product under amplification conditions -	PT	Identifying oligonucleotides hybridizing to nucleic acids containing secondary structure, useful in clinical diagnosis, comprises identifying primers that interact with the target to form an extension product under amplification conditions -
PS	Claim 48; Fig 81A; 409pp; English.	PS	Claim 48; Fig 81A; 409pp; English.
CC	The present invention describes a method for identifying oligonucleotides with desired hybridisation properties to nucleic acid targets containing secondary structure. The method comprises amplifying a target nucleic acid having at least one accessible and one inaccessible site. Primers that form an extension product are identified as the oligonucleotides which can interact with the folded target nucleic acid. Oligonucleotides from the present invention can be used in novel detection methods for clinical diagnostic purposes, including the detection and identification of pathogenic organisms (e.g. HIV). The method allows the ability to rapidly analyse nucleic acid structures. ABL46034 to ABL46367 represent sequences used in the exemplification of the present invention.	CC	The present invention describes a method for identifying oligonucleotides with desired hybridisation properties to nucleic acid targets containing secondary structure. The method comprises amplifying a target nucleic acid having at least one accessible and one inaccessible site. Primers that form an extension product are identified as the oligonucleotides which can interact with the folded target nucleic acid. Oligonucleotides from the present invention can be used in novel detection methods for clinical diagnostic purposes, including the detection and identification of pathogenic organisms (e.g. HIV). The method allows the ability to rapidly analyse nucleic acid structures. ABL46034 to ABL46367 represent sequences used in the exemplification of the present invention.
XX	Sequence 17 BP; 6 A; 3 C; 5 G; 3 T; 0 other;	XX	Sequence 17 BP; 6 A; 3 C; 5 G; 3 T; 0 other;
Query Match		1.4%; Score 17; DB 1; Length 17;	
Best Local Similarity		100.0%; Pred. No. 58;	
Matches 17; Conservative		0; Mismatches 0; Indels 0; Gaps 0;	

Query Match		1.4%; Score 17; DB 1; Length 17;	
Best Local Similarity		100.0%; Pred. No. 58;	
Matches 17; Conservative		0; Mismatches 0; Indels 0; Gaps 0;	
QY	695 GCCAGGGCCACAGAGAA 711	QY	695 GCCAGGGCCACAGAGAA 711
DB	17 GCCAGGGCCACAGAGAA 1	DB	17 GCCAGGGCCACAGAGAA 1
RESULT 40		RESULT 40	
ID	AAA33514/C	ID	AAA33514/C
XX	AAA33514 standard; DNA; 17 BP.	XX	AAA33514 standard; DNA; 17 BP.
AC	AAA33514;	AC	AAA33514;
DT	28-JUL-2000 (first entry)	DT	28-JUL-2000 (first entry)
DE	Low adenosine antisense oligonucleotide SEQ ID NO:1203.	DE	Low adenosine antisense oligonucleotide SEQ ID NO:1203.
XX	Human; adenosine receptor; low adenosine antisense oligonucleotide; phosphothioate; impaired respiration; inflammation; allergy;	XX	Human; adenosine receptor; low adenosine antisense oligonucleotide; phosphothioate; impaired respiration; inflammation; allergy;
KW	allergic disease; bronchoconstriction; inhibitor; antiinflammatory;	KW	allergic disease; bronchoconstriction; inhibitor; antiinflammatory;
KW	antiallergic; antiasthmatic; cytosolic; analgesic; impaired airway;	KW	antiallergic; antiasthmatic; cytosolic; analgesic; impaired airway;
KW	lung disease; ischaemic condition; pulmonary vasoconstriction; asthma;	KW	lung disease; ischaemic condition; pulmonary vasoconstriction; asthma;
KW	respiratory distress syndrome; pain; cystic fibrosis; emphysema;	KW	respiratory distress syndrome; pain; cystic fibrosis; emphysema;
KW	pulmonary hypertension; chronic obstructive pulmonary disease; COPD;	KW	pulmonary hypertension; chronic obstructive pulmonary disease; COPD;
KW	cancer; leukaemia; lymphoma; carcinoma; metastasis; ss.	KW	cancer; leukaemia; lymphoma; carcinoma; metastasis; ss.
OS	Homo sapiens.	OS	Homo sapiens.
XX	WO200009525-A2.	XX	WO200009525-A2.
PD	24-FEB-2000.	PD	24-FEB-2000.
PF	03-AUG-1999; 99WO-US17712.	PF	03-AUG-1999; 99WO-US17712.
PR	03-AUG-1998; 98US-0095212.	PR	03-AUG-1998; 98US-0095212.
PA	(UYEC-) UNIV EAST CAROLINA.	PA	(UYEC-) UNIV EAST CAROLINA.
XX	Nyce JW;	XX	Nyce JW;
XX	WPI; 2000-205971/18.	XX	WPI; 2000-205971/18.
PT	New antisense oligonucleotides useful for treating e.g. pulmonary vasoconstriction, inflammation, allergies, asthma, hypertension, or cancers -	PT	New antisense oligonucleotides useful for treating e.g. pulmonary vasoconstriction, inflammation, allergies, asthma, hypertension, or cancers -
PS	Claim 18; Page 415; 1343pp; English.	PS	Claim 18; Page 415; 1343pp; English.
CC	The present invention describes a new composition comprising an antisense oligonucleotide (ON) with low adenosine (up to 15%), which targets nucleic acids involved in bronchoconstriction, allergies, and/or inflammation. The ON can have antiinflammatory, antiallergic, antiasthmatic, cytosolic and analgesic activities. The compositions are useful for the treatment of diseases associated with inflammation, impaired airways, including lung disease and diseases whose secondary effects afflict the lungs of a subject. They can be used for treating e.g. ischaemic conditions, pulmonary vasoconstriction, allergies, asthma, impaired respiration, respiratory distress syndrome, pain, cystic fibrosis, pulmonary hypertension, emphysema, chronic obstructive pulmonary disease (COPD), and cancers such as leukaemias, lymphomas, carcinomas, and cancers which may metastasise to the lungs, including breast and prostate cancer. The reduction of the adenosine content of the ONs reduces side effects. The A-containing ONs break down with the release of deoxyadenosine which activates adenosine receptors causing the bronchoconstriction and inflammation. AAA32313 to AAA3312 represent nucleotide sequences given in the sequence listing from the present invention, which correspond to SEQ ID NO:1 to 2815, and then the last 185 sequences are also called SEQ ID NO:1 to 185, but the sequences differ from the previously named sequences. SEQ ID NO:11 to 1680	CC	The present invention describes a new composition comprising an antisense oligonucleotide (ON) with low adenosine (up to 15%), which targets nucleic acids involved in bronchoconstriction, allergies, and/or inflammation. The ON can have antiinflammatory, antiallergic, antiasthmatic, cytosolic and analgesic activities. The compositions are useful for the treatment of diseases associated with inflammation, impaired airways, including lung disease and diseases whose secondary effects afflict the lungs of a subject. They can be used for treating e.g. ischaemic conditions, pulmonary vasoconstriction, allergies, asthma, impaired respiration, respiratory distress syndrome, pain, cystic fibrosis, pulmonary hypertension, emphysema, chronic obstructive pulmonary disease (COPD), and cancers such as leukaemias, lymphomas, carcinomas, and cancers which may metastasise to the lungs, including breast and prostate cancer. The reduction of the adenosine content of the ONs reduces side effects. The A-containing ONs break down with the release of deoxyadenosine which activates adenosine receptors causing the bronchoconstriction and inflammation. AAA32313 to AAA3312 represent nucleotide sequences given in the sequence listing from the present invention, which correspond to SEQ ID NO:1 to 2815, and then the last 185 sequences are also called SEQ ID NO:1 to 185, but the sequences differ from the previously named sequences. SEQ ID NO:11 to 1680

QY 417 GAATCACTGAGATGCC 433
 DB 1 GAATCACTGAGATGCC 17

RESULT 42

AA145792
 ID AAL45792 standard; DNA; 24 BP.

AC AAL45792;
 XX 28-JUN-2002 (first entry)

DE Human MGC-2413-31 coding sequence PCR primer #2.

XX Human; MGC-2413.31; cancer; haemopathy; development disorder;
 KW cytostatic; haemostatic; virucide; immunomodulatory; antiinflammatory;
 KW immune disorder; HIV infection; inflammation; gene therapy; PCR;
 KW primer; ss.

OS Homo sapiens.

XX WO200220776-A1.

XX 14-MAR-2002.

XX 29-JUN-2001; 2001WO-CN01088.

XX 30-JUN-2000; 2000CN-0116945.

XX (SHAN-) SHANGHAI BIOWINDOW GENE DEV INC.

XX Mao Y, Xie Y;

XX WPI; 2002-258028/30.

XX Polypeptide-MGC-2413.31 and encoding polynucleotide, used in diagnosis
 PT and treatment of malignant tumors, hemopathy, human immunodeficiency
 PT virus infection, immunological diseases and inflammation -

XX Example 2; Page 17; 34pp; Chinese.

XX The present invention provides the protein and coding sequences of human
 CC MGC-2413.31. The sequences can be used in the treatment of cancer,
 CC haemopathy, development disorders, HIV infection, immune disorders and
 CC inflammation. The present sequence is a PCR primer for the coding
 CC sequence of the invention.

XX Sequence 24 BP; 8 A; 2 C; 1 G; 13 T; 0 other;

Query Match 1.3%; Score 16.8; DB 1; Length 24;
 Best Local Similarity 90.0%; Pred. No. 93;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1137 AGTAAATTTATTTATTTTA 1156
 DB 4 ATTGAATTTATTTATTTTA 23

RESULT 43

ABA02441
 ID ABA02441 standard; DNA; 24 BP.

XX ABA02441;

XX 04-MAR-2002 (first entry)

DE Human CCR4 protein 10 RT-PCR primer, SEQ ID NO:3.

XX Human; CCR4 protein 10; recombinant production;
 KW malignant tumour; cancer; blood disease; HIV infection;
 KW human immunodeficiency virus; immune disorder; inflammatory condition;
 KW gene therapy; cytostatic; anti-HIV; antiinflammatory; immunomodulator;

KW reverse transcription-PCR; RT-PCR primer; ss.

OS Homo sapiens.

XX WO200187947-A1.

XX 22-NOV-2001.

XX 08-MAY-2001; 2001WO-CN00700.

XX 09-MAY-2000; 2000CN-0115620.

XX (SHAN-) SHANGHAI BIOWINDOW GENE DEV INC.

XX Mao Y, Xie Y;

XX WPI; 2002-066676/09.

XX Human CCR4 protein 10 and encoding polynucleotide, used in diagnosis
 PT and treatment of malignant tumors, hemopathy, human immunodeficiency
 PT virus infection, immunological diseases and inflammation -

XX Example 2; Page 17; 37pp; Chinese.

XX The invention relates to human CCR4 protein 10 (AAME52938), nucleic acids
 CC encoding it (ABA02440), and a method for the recombinant production of
 CC CCR4 protein 10. The protein has a molecular weight of 10 kD. The
 CC present invention additionally discloses an antagonist of CCR4 protein
 CC 10 for therapeutic use, and an antibody which specifically binds to CCR4
 CC protein 10. CCR4 protein 10, and nucleotides which encode it may be used
 CC for treating a variety of diseases, such as malignant tumours, blood
 CC diseases, HIV (human immunodeficiency virus) infection, immune disorders
 CC and inflammatory conditions. The protein may also be used to screen for
 CC modulators of its activity or for peptide fingerprinting identification.
 CC The polynucleotide can be used as a primer for nucleic acid amplification
 CC reactions or as a probe for hybridisation reactions, or in producing gene
 CC chips or microarrays. Sequences ABA02441-ABA02442 represent reverse
 CC transcription-PCR (RT-PCR) primers used in an exemplification of the
 CC invention to isolate human CCR4 protein 10 cDNA.

XX Sequence 24 BP; 5 A; 3 C; 0 G; 16 T; 0 other;

Query Match 1.3%; Score 16.8; DB 1; Length 24;
 Best Local Similarity 90.0%; Pred. No. 93;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1042 TATTATTATGTTATTTATTT 1061
 DB 5 TTATTATTATTATTATTATT 24

RESULT 44

AAD21908/C

ID AAD21908 standard; DNA; 26 BP.

XX AAD21908;

XX 12-FEB-2002 (first entry)

DE PCR primer, 2767T used to determine the genotype of human IL-8 gene.

XX Human; genetic variant identification; interleukin 8; RSV bronchiolitis;
 KW respiratory syncytial virus; PCR primer; ss.

OS Homo sapiens.

XX WO200177382-A2.

XX 18-OCT-2001.

XX 11-APR-2001; 2001WO-GB01634.

XX 11-APR-2000; 2000GB-0008910.

```

XX PA (ISIS-) ISIS INNOVATION LTD.
XX PI Hull J, Kwiatkowski DP;
XX XX WPI; 2002-017472/02.
XX DR
XX PT Nucleic acid comprising a sequence corresponding to variant allele of
XX PT human interleukin 8 gene, useful for determining susceptibility to
XX PT respiratory syncytial virus bronchiolitis in humans -
XX XX Claim 42; Page 47; 49pp; English.
XX CC The patent discloses methods for identification of genetic variants
XX CC at the interleukin 8 (IL-8) locus. The invention relates to nucleic
XX CC acid molecules corresponding to various alleles at the IL8 locus
XX CC and kits for the detection of the presence of variant alleles. The
XX CC polymorphic variants of the IL-8 locus are useful for screening a
XX CC human subject for susceptibility to a disease such as respiratory
XX CC syncytial virus (RSV) bronchiolitis for which increased production
XX CC of IL-8 is a risk factor. The polymorphic variants of IL-8 locus are
XX CC also useful for determining the likelihood that a patient previously
XX CC identified as infected with RSV will develop severe disease. They are
XX CC useful as probes and primers for genotyping. They are also useful for
XX CC initiating DNA synthesis or amplification for detecting the presence
XX CC of IL-8 genetic variants. The single nucleotide polymorphisms have a
XX CC general utility as a genetic marker. The present DNA sequence is PCR
XX CC primer, 2767T which is used to determine the genotype of human
XX CC IL-8 Gene.
XX SQ Sequence 26 BP; 9 A; 5 C; 2 G; 10 T; 0 other;
    Query Match 1.3%; Score 16.6; DB 1; Length 26;
    Best Local Similarity 82.6%; Pred No. 1, 1e+02;
    Matches 19; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

XX QY 1290 TTATCTGAATTTTAAATGAAT 1312
XX DB 26 TTATCTGAATTTTAAATGAAT 4

RESULT 45
XX AAC92878/c
XX ID AAC92878 standard; DNA; 20 BP.
XX AC AAC92878;
XX DT 27-MAR-2001 (first entry)
XX DE Human PI3 kinase p55 gamma antisense oligonucleotide, SEQ ID NO:61.
XX KW Human phosphatidylinositol 3-kinase p55 gamma regulatory subunit;
XX KW PI3 kinase p55 gamma; hp55-gamma; p55-gamma; PIK3R3; p55PIK;
XX KW signal transduction; downstream effector; receptor tyrosine kinase;
XX KW insulin receptor; IR; insulin-like growth factor receptor; IGFRI;
XX KW cell growth; differentiation; apoptosis; developmental regulation;
XX KW alternative splicing; tumour formation; cancer; inflammation;
XX KW infection; expression inhibition; phosphorothioate;
XX KW antisense oligonucleotide; ss.
XX OS Homo sapiens.
XX XX US6165790-A.
XX PN 26-DEC-2000.
XX PD 03-NOV-1999; 99US-0433694.
XX PF 03-NOV-1999; 99US-0433694.
XX PR (ISIS-) ISIS PHARM INC.
XX PA Borchers AH, Cowseert LM, Ward DT;
XX PI

```

```

XX DR WPI; 2001-101697/11.
XX XX Novel antisense compound targeted to human PI3 kinase p55 gamma
XX PT specifically hybridizes with and inhibits the expression of human PI3
XX PT kinase p55 gamma, useful for modulating the expression of PI3 kinase
XX PT p55 gamma in cells -
XX XX Example 15; Column 41-42; 39pp; English.
XX CC Sequences AAC92827-C92906 represent phosphorothioate antisense
XX CC oligonucleotides targeted to the phosphatidylinositol 3-kinase p55
XX CC gamma regulatory subunit (PI3 kinase p55 gamma) gene, which inhibit its
XX CC expression. The antisense oligonucleotides were designed to target
XX CC different regions of human PI3 kinase p55 mRNA species, and were
XX CC analysed for their effect on PI3 kinase p55 mRNA levels by quantitative
XX CC real-time PCR. PI3 kinase p55 gamma (also known as hp55-gamma,
XX CC p55-gamma, PIK3R3 and p55PIK) is one of several PI3 kinase regulatory
XX CC subunits that may associate with the PI3 kinase catalytic subunit to form
XX CC a heterodimeric PI3 kinase holoenzyme. PI3 kinases act as downstream
XX CC effectors of receptor tyrosine kinases such as growth factor and
XX CC hormone receptors and oncogene products, and are found in association
XX CC with the cytoplasmic domains of such receptors. PI3 kinase p55 gamma
XX CC is able to interact with both the insulin receptor (IR) and the
XX CC insulin-like growth factor receptor (IGFR), which play important roles
XX CC in growth, differentiation and apoptosis. PI3 kinase p55 gamma is
XX CC thought to be developmentally regulated, as four distinct mRNA
XX CC species are found in adult tissues, while only the larger mRNA is
XX CC expressed in foetal tissues. The oligonucleotides of the invention are
XX CC useful for diagnosis, prevention and treatment of conditions associated
XX CC with PI3 kinase p55 expression, such as tumour formation, inflammation
XX CC and certain infections, and allow expression level modulation of the
XX CC alternatively spliced forms of PI3 kinase p55.
XX SQ Sequence 20 BP; 7 A; 1 C; 1 G; 11 T; 0 other;
    Query Match 1.3%; Score 16.4; DB 1; Length 20;
    Best Local Similarity 94.4%; Pred. No. 93;
    Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

XX QY 1606 ATGAACATTTAAATAT 1623
XX DB 20 ATGAACATTTAAATAT 3

RESULT 46
XX AAT01237/c
XX ID AAT01237 standard; DNA; 22 BP.
XX AC AAT01237;
XX DT 25-MAR-2003 (updated)
XX DT 07-DEC-1995 (first entry)
XX DE Human chromosome 13 gene based 13-STS11 antisense primer.
XX KW Normalised cDNA library; directionally cloned cDNA library;
XX KW screening; hybridisation; human chromosome 13; exon mapping; STS;
XX KW sequence tagged site; ss.
XX OS Synthetic.
XX XX WO9508647-A1.
XX PN 30-MAR-1995.
XX PD 23-SEP-1994; 94WO-US10821.
XX PF 24-SEP-1993; 93US-0126594.
XX PR (UYCO ) UNIV COLUMBIA NEW YORK.
XX PA Efstratiadis A, Soares MB;
XX PI

```

XX WPI; 1995-139615/18.
 XX New normalised directional cDNA libraries - used for isolating
 PT novel cDNA's, including tissue-specific and development-specific
 PT DNA.
 XX Disclosure; Page 125; 186pp; English.
 XX To initiate exon-mapping of human chromosome 13, cDNAs present in a
 CC normalised library were hybridised to arrayed chromosome-specific
 CC phage lambda clones. Part of the procedure involved PCR
 CC amplification of chromosome 13 sequences using primer pairs based
 CC on the 3' (and/or exceptionally the 5') terminal 300 nucleotides of
 CC each cDNA (see AAT01228-T01257).
 CC (Updated on 25-MAR-2003 to correct PN field.)
 XX Sequence 22 BP; 7 A; 2 C; 5 G; 8 T; 0 other;
 SQ Query Match 1.3%; Score 16.2; DB 1; Length 22;
 Best Local Similarity 85.7%; Pred. No. 1.1e+02;
 Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 1068 CAATATTTTGTGCAAGAAATTT 1088
 DB 21 CAAAAATTTGTCCCAAGATTT 1
 RESULT 47
 AAX10028/c
 ID AAX10028 standard; DNA; 23 BP.
 XX AC AAX10028;
 XX 24-MAR-1999 (first entry)
 XX Human biallelic polymorphic marker downstream primer #334.
 XX Polymorphism; biallelic; human; forensic; paternity testing; disease;
 KW detection; phenotypic typing; characteristic; infection; hereditary;
 KW autoimmune disease; cancer; inflammation; drug; therapy; medication;
 KW treatment; marker; primer; ss.
 XX Synthetic.
 OS Homo sapiens.
 XX WO9820165-A2.
 XX 14-MAY-1998.
 XX 05-NOV-1997; 97WO-US20313.
 XX 06-NOV-1996; 96US-0030455.
 XX (WHED) WHITEHEAD INST BIOMEDICAL RES.
 XX Hudson T, Lander ES, Wang D;
 XX WPI; 1998-286974/25.
 XX New isolated nucleic acid segments from the human genome - used for
 PT determining polymorphic forms for use in e.g. forensics, paternity
 PT testing or phenotypic typing for disease
 XX Claim 16; Page 93; 310pp; English.
 XX AAX09121-X10268 are allele-specific oligonucleotide primers used in the
 CC isolation of various biallelic polymorphic markers found in the human
 CC genome (represented in AAX10269-X12937). These primers can be used in a
 CC method for determining polymorphic forms in an individual for use in
 CC e.g. forensics, paternity testing or for phenotypic typing for diseases
 CC such as agammaglobulinemia, diabetes insipidus, Leech-Nyhan syndrome,
 CC muscular dystrophy, Wiskott-Aldrich syndrome, Fabry's disease, familial

CC hypercholesterolemia, polycystic kidney disease, hereditary
 CC spherocytosis, von Willebrand's disease, tuberous sclerosis, hereditary
 CC haemorrhagic telangiectasia, familial colonic polyposis, Ehlers-Danlos
 CC syndrome, osteogenesis imperfecta, acute intermittent porphyria,
 CC autoimmune diseases, inflammation, cancer, diseases of the nervous
 CC system, infection by pathogenic microorganisms, and characteristics such
 CC as longevity, appearance (e.g. baldness, obesity), strength, speed,
 CC endurance, fertility, and susceptibility or receptivity to particular
 CC drugs or therapeutic treatments. The isolated polymorphic nucleic acid
 CC segments can also be used to produce medicaments for the treatment or
 CC prophylaxis of such diseases.
 XX Sequence 23 BP; 6 A; 2 C; 7 G; 8 T; 0 other;
 SQ Query Match 1.3%; Score 16.2; DB 1; Length 23;
 Best Local Similarity 85.7%; Pred. No. 1.2e+02;
 Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 448 CAAATCTACTTCAACACTTCA 468
 DB 22 CAAATCCAGTTTAAACACTTCA 2
 RESULT 48
 AAX33029/c
 ID AAX33029 standard; DNA; 23 BP.
 XX AC AAX33029;
 XX 21-JUN-1999 (first entry)
 XX Human BRCA2 gene PCR primer SEQ ID NO:42.
 XX Human; BRCA2; genetic testing; protein therapy; haplotype; detection;
 KW gene therapy; breast cancer; ovarian cancer; PCR primer; ss.
 XX Synthetic.
 OS Homo sapiens.
 XX WO9909164-A1.
 XX 25-FEB-1999.
 XX 14-AUG-1998; 98WO-US16905.
 XX 22-MAY-1998; 98US-0084471.
 XX 15-AUG-1997; 97US-0055784.
 XX 07-NOV-1997; 97US-0064926.
 XX 12-NOV-1997; 97US-0065367.
 XX 01-MAY-1998; 98US-0071715.
 XX (ONCO-) ONCORMED INC.
 XX Ekandari T, Jackson GM, Murphy PD, Olson SJ, Park M;
 XX Rabin MB, Schryer B, White MB, Yoshikawa M;
 XX WPI; 1999-190163/16.
 XX New coding sequence haplotypes of the human BRCA2 gene - used to
 PT develop products for determining susceptibility to, detection and
 PT treatment of breast or ovarian cancer
 XX Example 1; Page 32; 236pp; English.
 XX The present invention describes genomic DNA which contains a BRCA2 gene
 CC where the first 12 nucleotides beginning exon 5 are 5'-TCCTGTTGTTCT-3',
 CC as in sequence (I) (see AAX03249), where nucleotides numbers
 CC 5782-5790 are GTTGTGTT as in sequence (IV) (see AAX10255), and where
 CC the last 20 nucleotides encoding exon 15 are 5'-CTGGGTGTTCTCAAAACAG-3',
 CC as in sequence (II) (see AAX30251) and the first 20 nucleotides
 CC beginning exon 16 are 5'-CTGTATACGATGCGTTC-3', as in sequence (III)
 CC (see AAX30253). Products and methods from the present invention can be
 CC used for identifying mutations in the BRCA2 gene leading to

CC predisposition or higher susceptibility to breast or ovarian cancer. They
CC can also be used for detection and gene therapy for breast and ovarian
CC cancers. They can be used in methods for monitoring disease progression,
CC for determining patients suited for gene and protein replacement
CC progression, or for detecting the presence or quantifying the amount of a
CC tumour growth inhibitor following such therapy. The BRCA2 protein,
CC polypeptides, their functional equivalents, antibodies, and FNs may also
CC be useful in the study of the characteristics of BRCA2 proteins, such as
CC structure and function of BRCA2 in oncogenesis or subcellular
CC localisation of BRCA2 protein in normal and cancerous cells. AAX33001 to
CC AAX33097 represent PCR primers used in the amplification of the human
CC BRCA2 gene.
XX
SQ Sequence 23 BP; 4 A; 4 C; 3 G; 12 T; 0 other;

Query Match 1.3%; Score 16.2; DB 1; Length 23;
Best Local Similarity 85.7%; Pred. No. 1.2e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 763 TGAAGCATCATATAAAATGA 783
DB 22 TAAAGCAGCATATAAAATGA 2

RESULT 49
AAX32150/C
ID AAX32150 standard; DNA; 23 BP.
XX
AC AAX32150;
XX
DT 14-JUN-1999 (first entry)
XX
DE BRCA2 gene specific primer.

XX Allele profile; diagnosis; treatment; pharmacogenetic; breast cancer;
KW CPTX; cystic fibrosis; dystrophin; Duchenne muscular dystrophy; p53;
KW Becker muscular dystrophy; Li-Fraumeni syndrome; neurofibromatosis;
KW colorectal cancer; MSH2 gene; MLH1 gene; BRCA1 gene; BRCA2 gene;
KW BAP1 gene; PCR primer; ss.
XX
OS Synthetic.

XX WO9906598-A2.
XX
PD 11-FEB-1999.
XX
PF 04-AUG-1998; 98WO-US16574.
XX
PR 22-MAY-1998; 98US-0084471.
PR 04-AUG-1997; 97US-0905772.
XX
PA (ONCO-) ONCOMED INC.

XX Murphy PD;
XX
DR WPI; 1999-153820/13.
XX
PT Determining common functional alleles in a population - useful in
PT the diagnosis of disease associated with allelic heterogeneity
XX
PS Example 5; Page 37; 78pp; English.

XX The invention relates to methods of determining a functional allele
CC profile of a gene in a population. Functional allele profiles comprise
CC the commonly occurring alleles in a population, and the relative
CC frequencies at which such alleles of a given gene occur. The methods
CC are used to identify and determine the frequency of the functional
CC alleles of genes which display extensive allelic heterogeneity,
CC particularly those implicated in disease or conditions, such as the
CC BRCA1 gene associated with breast cancer, CPTX associated with cystic
CC fibrosis, dystrophin associated with Duchenne muscular dystrophy and
CC Becker muscular dystrophy, and p53 associated with Li-Fraumeni syndrome.
CC The methods can also be employed for diseases where allelic and genetic

CC heterogeneity exist, such as breast cancer, neurofibromatosis, and
CC hereditary non-polyposis colorectal cancer. Identification of functional
CC alleles is necessary for identification of mutations which may be
CC implicated in the disease. Sequences AAX32001-172 represent primers for
CC determining the functional allele profiles of various genes. The
CC primers are specific for genes such as MSH2 gene, MLH1 gene, BRCA1 gene,
CC BRCA2 gene and BAP1 gene.

SQ Sequence 23 BP; 4 A; 4 C; 3 G; 12 T; 0 other;
Query Match 1.3%; Score 16.2; DB 1; Length 23;
Best Local Similarity 85.7%; Pred. No. 1.2e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 763 TGAAGCATCATATAAAATGA 783
DB 22 TAAAGCAGCATATAAAATGA 2

RESULT 50
AAX92211/C
ID AAX92211 standard; DNA; 23 BP.
XX
AC AAX92211;
XX
DT 05-JAN-2001 (first entry)
XX
DE Aurone glycosyl transferase related PCR primer SEQ ID NO:14.

XX Aurone; glycosyl transferase; plant; yellow pigment; flower;
KW PCR primer; ss.
XX
OS Synthetic.

XX WO200049155-A1.
XX
PD 24-AUG-2000.
XX
PF 16-FEB-2000; 2000WO-JP00876.
XX
PR 16-FEB-1999; 99JP-0036801.

XX (SUNR) SUNTORY LTD.
XX
PI Sakakibara K, Fukui Y, Tanaka Y, Kusumi T, Yoshikawa T;
XX
DR WPI; 2000-543757/49.
XX
PT Plant gene encoding an aurone glycosyltransferase for producing plant
PT varieties having stable yellow flower coloration -
XX
PS Example 8; Page 18; 51pp; Japanese.

XX The present invention describes a protein which has aurone glycosyl
CC transferase activity. Introduction of the aurone glycosyl transferase
CC gene into a plant in which it is absent results in the production of
CC the yellow pigment aurone in the flowers in a stable form. The gene is
CC used for the production of plants which have flowers with a stable
CC yellow colour. The present sequence represents a PCR primer which is
CC used in an example from the present invention.

SQ Sequence 23 BP; 7 A; 6 C; 3 G; 7 T; 0 other;
Query Match 1.3%; Score 15.2; DB 1; Length 23;
Best Local Similarity 85.7%; Pred. No. 1.2e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 546 GAATAGTTTTCATGTACCA 566
DB 22 GAATAGTTTTCATGTACCA 2

RESULT 51


```

AAZ72999
ID  AAZ72999 standard; DNA; 20 BP.
AC  AAZ72999;
DT  10-SEP-2001 (first entry)
DE  Human biallelic marker upstream amplification primer SEQ ID NO:7355.
KW  Human genome; biallelic marker; high density disequilibrium map;
KW  genomic map; haplotype; phenotype; polymorphic base; genotyping;
KW  haplotyping; hybridisation; identification; characterisation;
KW  amplification; single nucleotide polymorphism; SNP; PCR primer;
KW  diagnosis; ss.
XX  OS
XX  Homo sapiens.
XX  PN  WO9954500-A2.
XX  PD  28-OCT-1999.
XX  PF  21-APR-1999; 99WO-IB00822.
XX  PR  21-APR-1998; 98US-0082614.
XX  PR  23-NOV-1998; 98US-0109732.
XX  PA  (GEST ) GENSET.
XX  PI  Cohen D, Blumenfeld M, Chumakov I;
XX  DR  WPI; 2000-013267/01.
XX  PT  Novel biallelic markers used to construct a high density disequilibrium
XX  map of the human genome.
XX  PS  Claim 9; Page 1799; 2745pp; English.
XX  CC  AAZ65654 to AAZ69578 represent human biallelic markers from the present
XX  invention, which contain a polymorphic base at position 24 of their
XX  nucleotide sequences. AAZ69579 to AAZ77440 represent amplification
XX  primers for the biallelic markers. The biallelic markers of the
XX  invention have a variety of uses: they can be used for high density
XX  mapping of the human genome, and in complex association studies and
XX  haplotyping studies which are useful in determining the genetic basis
XX  for disease states. Compositions and methods of the invention can also
XX  be useful for the identification of the targets for the development of
XX  pharmaceutical agents and diagnostic methods, as well as the
XX  characterisation of the differential efficacious responses to and side
XX  effects from pharmaceutical agents acting on a disease as well as other
XX  treatment.
XX  N.B. the SEQ ID NOS 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297
XX  and 3367, are not actually given a sequence in the Sequence Listing
XX  from the present invention.
XX  SQ  Sequence 20 BP; 1 A; 3 C; 5 G; 11 T; 0 other;
      Query Match 1.3%; Score 15.8; DB 1; Length 20;
      Best Local Similarity 89.5%; Pred. No. 1.2e+02;
      Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY  901 CTGGTTTCTCTCTTTATT 919
Db  1 CTGGTTTCTCTCTTTATT 19

RESULT 52
AAH26837
ID  AAH26837 standard; DNA; 20 BP.
XX  AC  AAH26837;
XX  DT  21-DEC-2001 (first entry)
XX  OS
XX  Homo sapiens.

```

```

DE  Human osteoregulin gene PCR primer.
XX  OS
XX  Osteoregulin; human; bone; homeostasis; adipose; calcification;
XX  atherosclerosis; osteoporosis; osteopathic; antiarteriosclerotic;
XX  therapy; PCR primer; ss.
XX  OS
XX  Homo sapiens.
XX  PN  EP1130098-A2.
XX  PD  05-SEP-2001.
XX  PF  27-FEB-2001; 2001EP-0301768.
XX  PR  29-FEB-2000; 2000US-185617P.
XX  PR  22-SEP-2000; 2000US-234500P.
XX  PA  (PFIZ ) PFIZER PROD INC.
XX  PI  Brown TA, De Wet JR, Gowen LC, Hames LM;
XX  DR  WPI; 2001-604111/59.
XX  PT  Novel osteoregulin polypeptide useful for regulating bone homeostasis,
XX  adiposity and calcification of atherosclerotic plaques comprises
XX  measuring the activity of osteoregulin.
XX  PS  Example; Page 37; 90pp; English.
XX  CC  The present sequence is that of a human osteoregulin gene PCR
XX  primer, which is one of a set of primers (see AAH26837-40) used in
XX  first and second round PCR amplifications of human osteoregulin
XX  cDNA from human osteoblast SaOS cells. A 433 bp product was
XX  obtained, which allowed compilation of complete sequences for
XX  human osteoregulin splice variant cDNAs (see AAH26808 and
XX  AAH26809). Human osteoregulin (see AAH2620-21) is a novel protein
XX  that plays a role in regulating bone homeostasis, adiposity and the
XX  calcification of atherosclerotic plaques. The invention provides
XX  osteoregulin proteins, nucleic acids which encode them, vectors,
XX  antibodies, host cells, and animal cells and mammals with a targeted
XX  disruption of an osteoregulin gene. It also provides screening
XX  assays to identify modulators of osteoregulin activity useful for
XX  treating a mammal in need of regulation of bone mass and/or density,
XX  adiposity, vascular flexibility, and/or atherosclerotic plaque
XX  calcification, for treating and preventing osteoporosis, and for
XX  stimulating bone repair and regeneration.
XX  SQ  Sequence 20 BP; 9 A; 4 C; 1 G; 6 T; 0 other;
      Query Match 1.3%; Score 15.8; DB 1; Length 20;
      Best Local Similarity 89.5%; Pred. No. 1.2e+02;
      Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY  716 CGAACTTTAATTTCAGGAA 734
Db  1 CGAACTTTAATTTCAGGAA 19

RESULT 53
AAV67374/c
ID  AAV67374 standard; DNA; 21 BP.
XX  AC  AAV67374;
XX  DT  21-DEC-1998 (first entry)
XX  OS
XX  Nucleotide fragment containing polymorphic site, WI-5865 (i).
XX  ss; polymorphic site; nucleic acid analysis; diagnosis; monitoring;
XX  cancer; inflammation; heart disease; CNS disease.
XX  OS
XX  Homo sapiens.

```

PN WO9938846-A2.
 XX 11-SEP-1998.
 XX 06-MAR-1998; 98WO-US04571.
 XX 28-MAR-1997; 97US-0042125.
 PR 07-MAR-1997; 97US-0813159.
 XX (AFFY-) AFFYMETRIX INC.
 XX Berno A, Chee M, Fan J, Lipschutz RJ;
 XX WPI; 1998-495419/42.
 XX New nucleic acid segments containing polymorphic sites, or
 PT complements and methods of detecting a nucleic acid - for general
 PT use including diagnosis and monitoring of diseases
 XX Claim 1; Page 9; 42pp; English.
 XX New nucleic acid segment comprising one of the 10 - 100 bp sequences
 CC given in the specification (sequences of a polymorphic site), or the
 CC complement of the segment and a method of analysing a nucleic acid
 CC comprising determining the base occupying the polymorphic site of the
 CC polymorphic fragment sequences are disclosed in the specification. The
 CC information obtained from nucleic acid analysis by the method described
 CC is useful in diagnosis or monitoring of diseases like cancer,
 CC inflammation, heart disease, CNS diseases, and susceptibility to
 CC infection by microorganisms. In addition, the nucleic acid segments are
 CC useful in manufacturing medication in the treatment of prophylaxis of
 CC diseases, and also the use of the DNA segments as pharmaceutical.
 XX SQ Sequence 21 BP; 13 A; 2 C; 0 G; 5 T; 1 other;
 Query Match 1.3%; Score 15.8; DB 1; Length 21;
 Best Local Similarity 81.0%; Pred. No. 1.3e+02;
 Matches 17; Conservative 1; Mismatches 3; Indels 0; Gaps 0;
 QY 1140 AAATTATTTATTTATTTAGATA 1160
 DB 21 ATATTTCTTTATTTATTTAGATA 1
 RESULT 54
 ID AAC69186/c
 AC AAC69186 standard; DNA; 21 BP.
 AC AAC69186;
 XX 29-JAN-2001 (first entry)
 XX Human ABC1 gene exon 8 3' PCR primer, SEQ ID NO:85.
 XX Human ABC1 cholesterol transporter; chromosome 9q31;
 KW ATP-binding cassette; HDL deficiency disorder; high density lipoprotein;
 KW Tangier disease; TD; familial HDL deficiency; FHA; polymorphism;
 KW cerebrovascular disease; coronary artery disease; coronary restenosis;
 KW cerebrovascular disease; peripheral vascular disease;
 KW Alzheimer's disease; Niemann-Pick disease; Huntington's disease;
 KW X-linked adrenoleukodystrophy; cancer; gene therapy; genetic diagnosis;
 KW prognosis; prophylaxis; drug screening; transgenic animal; PCR primer;
 KW ss.
 XX Homo sapiens.
 OS
 XX WO200055318-A2.
 PN 21-SEP-2000.
 PD 15-MAR-2000; 2000WO-IB00532.
 XX 15-MAR-1999; 99US-0124702.
 PR

08-JUN-1999; 99US-0138048.
 17-JUN-1999; 99US-0139600.
 01-SEP-1999; 99US-0151977.
 (UYBR-) UNIV BRITISH COLUMBIA.
 (XENO-) XENON BIORESEARCH INC.
 Hayden MR, Wilson AR, Pimstone SN;
 WPI; 2000-587528/55.
 New ABC1 polypeptide is useful for treating diseases associated with
 ABC1 biological activity, e.g. Alzheimer's disease, Huntington's
 disease and cancer -
 Disclosure; Fig 10; 229pp; English.
 The invention relates to the human ABC1 cholesterol transporter protein
 (B38082) and to nucleic acid sequences (C69120) which encode it. ABC1 is
 a member of the ATP-binding cassette (ABC transporter) superfamily of
 proteins, and plays a crucial role in cholesterol transport, particularly
 intracellular cholesterol trafficking in monocytes and fibroblasts, being
 involved in cholesterol efflux from the cell. The gene encoding ABC1 is
 located on chromosome 9q31, and mutations in this gene are associated
 with two genetic HDL (high density lipoprotein) deficiency disorders,
 Tangier disease (TD) and familial HDL deficiency (FHA). These diseases
 are distinguishable in that TD is an autosomal recessive disorder, while
 FHA is inherited as an autosomal dominant trait. Low levels of HDL ("good
 cholesterol") in the blood correlate with a high risk of cardiovascular
 disease, particularly coronary artery disease, but also cerebrovascular
 disease, coronary restenosis, and peripheral vascular disease.
 Conversely, a high level of HDL has protective effects against
 cardiovascular disease. The invention provides genetic constructs and
 transgenic cells and non-human animals comprising human ABC1 nucleic
 acids, and methods of gene therapy for the treatment or prevention of
 cardiovascular disease comprising the administration of an expression
 vector encoding ABC1 or an active fragment thereof. The invention also
 encompasses compounds which mimic ABC1 activity, compounds which
 stimulate ABC1 expression and methods of screening for such compounds.
 It further relates to methods for determining whether a patient has an
 increased risk for cardiovascular disease due to polymorphisms in the
 ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat
 or prevent cardiovascular disease, especially coronary artery disease,
 cerebrovascular disease, coronary restenosis or peripheral vascular
 disease. They may also be used in the treatment of diseases associated
 with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick
 disease, Huntington's disease, X-linked adrenoleukodystrophy and cancer.
 The invention specifically excludes proteins with the exact amino acid
 sequences of GenBank Accession No: CAA10005.1 and X75926, and the nucleic
 acid with the exact sequence as GenBank Accession No: AJ012376.1. The
 present sequence represents a human ABC1 gene PCR primer which may be
 used to amplify an exon of the human ABC1 gene.
 Sequence 21 BP; 7 A; 5 C; 3 G; 6 T; 0 other;
 Query Match 1.3%; Score 15.8; DB 1; Length 21;
 Best Local Similarity 89.5%; Pred. No. 1.3e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 516 CTTGTTAAATTTGAATTT 534
 DB 21 CTTGCGAGAAATTTGAATTT 3
 RESULT 55
 ID AAF93051/c
 AC AAF93051 standard; DNA; 21 BP.
 AC AAF93051;
 XX 17-MAY-2001 (first entry)
 XX ABC1 polymorphism RFLP oligonucleotide #12.

```

XX KW High density lipoprotein-cholesterol; HDL-C; cardiovascular; ABC1; ds.
XX OS Homo sapiens.
XX FW WO200115676-A2.
XX PD 08-MAR-2001.
XX PF 01-SEP-2000; 2000WO-IB01492.
XX PR 01-SEP-1999; 95US-0151977.
XX PR 15-MAR-2000; 2000US-0526193.
XX PR 23-JUN-2000; 2000US-0213958.
XX PA (UYBR-) UNIV BRITISH COLUMBIA.
XX PA (XENO-) XENON GENETICS INC.
XX PI Hayden MR, Brooks-Wilson AR, Pimstone SN, Clee SM;
XX WPI; 2001-244356/25.
XX DR
XX XX Treating a lower than normal high density lipoprotein-cholesterol
XX (HDL-C) level, a higher than normal triglyceride level, or a
XX cardiovascular disease, by administering a compound that modulates LXR-
XX or RXR-mediated transcriptional activity.
XX PS Disclosure; Fig 17; 317pp; English.
XX CC The present invention relates to a method for treating a patient
XX diagnosed as having a lower than normal high density
XX lipoprotein-cholesterol (HDL-C) level, a higher than normal
XX triglyceride level, or a cardiovascular disease, involving
XX administering a compound that modulates LXR- or RXR-mediated
XX transcriptional activity or ABC1 expression or activity.
XX CC The LXR gene product may be used in an assay to identify
XX compounds useful for the treatment of a disease or condition selected a
XX lower than normal HDL cholesterol level, a higher than normal
XX triglyceride level, and a cardiovascular disease.
XX SQ Sequence 21 BP; 7 A; 5 C; 3 G; 6 T; 0 other;

Query Match 1.3%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 516 CCTGGTTAAATTGAAATT 534
Db 21 CCTGGAGAAATTGAAATT 3

RESULT 56
ABZ37635
ID ABZ37635 standard; DNA; 22 BP.
XX AC ABZ37635;
XX XX 26-FEB-2003 (first entry)
XX DT
XX DE Porcine PERV locus 3' flanking sequence PCR primer 5'G16.
XX XX Porcine; flanking sequence; porcine endogenous retrovirus; PERV; pig;
XX KW xenograft; insertion site; PCR; primer; ss.
XX OS Sus scrofa.
XX XX WO200283838-A2.
XX PN
XX PD 24-OCT-2002.
XX XX 28-MAR-2002; 2002WO-US10168.
XX PP
XX PR 28-MAR-2001; 2001US-279337P.

```

```

XX PA (NEXT-) NEXTRAN INC.
XX PI Cui C, Diamond LB, Logan JS;
XX DR WPI; 2003-093004/08.
XX XX New isolated porcine nucleic acid sequence comprising a 3' end or 5'
XX end flanking sequence of an infectious porcine endogenous retrovirus
XX (PERV) insertion site, useful for selectively breeding a pig for use as
XX a xenograft donor.
XX PS Disclosure; Page 75; 91pp; English.
XX CC The invention relates to a novel isolated porcine nucleic acid sequence
XX comprising a 3' end or 5' end flanking sequence of an infectious porcine
XX endogenous retrovirus (PERV) insertion site. A probe of the invention is
XX useful for detecting the presence of potentially infectious PERV in
XX biological sample. The method is useful for selectively breeding a pig
XX for use as a xenograft donor, thereby reducing the risk of transmission
XX of PERV from porcine tissues suitable for use as xenografts. The nucleic
XX acid sequences are useful for constructing the probes. The sequences
XX shown in ABZ37605 - ABZ37664 represent PCR primers used in the invention
XX to amplify probes corresponding to the 3' flanking PERV integration
XX sequences.
XX SQ Sequence 22 BP; 5 A; 9 C; 3 G; 5 T; 0 other;

Query Match 1.3%; Score 15.8; DB 1; Length 22;
Best Local Similarity 89.5%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 940 CCACCATCTTACCTCAG 958
Db 4 CCACCATCTTACCTCAG 22

RESULT 57
AAQ64706/c
ID AAQ64706 standard; cDNA to mRNA; 22 BP.
XX AC AAQ64706;
XX XX 25-MAR-2003 (updated)
XX DT 04-JAN-1995 (first entry)
XX DE 2',5'-linked tetraadenylate-antisense oligonucleotide chimeric mol.
XX XX antisense; 2',5'-tetraadenylate; 2-5A dependent RNase activator;
XX KW RNA cleavage; antiviral therapy; chimeric molecule; ss.
XX OS Synthetic.
XX XX
XX PH Key Location/Qualifiers
XX FT misc_feature 1...4
XX FT /tag= a
XX FT /label= 2',5'-linked tetraadenylate
XX FT /note= "nucleotides linked through phosphodiester
XX FT bonds at hydroxyl groups of 2' and 5'
XX FT carbons"
XX FT misc_feature 5..22
XX FT /tag= b
XX FT /note= "antisense region"
XX XX
XX PN WO9409129-A2.
XX XX 28-APR-1994.
XX XX 20-OCT-1993; 93WO-US10103.
XX PP
XX XX 21-OCT-1992; 92US-0965666.
XX PR 17-SEP-1993; 93US-0123449.
XX XX

```

PA (CLEV-) CLEVELAND CLINIC RES INST.
 PA (USSH) US DEPT HEALTH & HUMAN SERVICES.
 XX Lesiak K, Maitra R, Silverman R, Torrence P;
 XX WPI; 1994-151315/18.
 XX Specific cleavage of RNA, useful partic. for treating viral
 PT infection, cancers, etc. - by using anti-sense oligo:nucleotide
 PT coupled to activator of 2-5A dependent RNase
 XX Example 1; Page 68; 86pp; English.
 XX This sequence is an example of a 2-5A-antisense oligonucleotide
 CC chimeric molecule. The antisense region targets the chimeric
 CC molecule to a particular region of RNA to be specifically
 CC cleaved and the 2',5'-linked tetraadenylate tail activates
 CC the 2-5A RNase. Typical applications are treatment of viral
 CC infections (esp. for cleavage of an RNA virus genome), cancer;
 CC leukemia, cardiovascular disorders (e.g. restenosis after
 CC angioplasty), genetic disorders, osteoarthritis or rheumatoid
 CC arthritis.
 CC (Updated on 25-MAR-2003 to correct PN field.)
 XX
 XX Sequence 22 BP; 4 A; 0 C; 0 G; 18 T; 0 other;

Query Match 1.2%; Score 15.6; DB 1; Length 22;
 Best Local Similarity 81.8%; Pred. No. 1.5e+02;
 Matches 18; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 616 ACAAACACACAAATATTTT 637
 DB 22 AAAAAAAAAAAAAAAAAATTTT 1

RESULT 59
 AAD21907/C
 ID AAD21907 standard; DNA; 26 BP.
 XX
 AC AAD21907;
 XX
 DT 12-FEB-2002 (first entry)
 DE PCR primer, 2767A used to determine the genotype of human IL-8 gene.
 XX Human; genetic variant identification; interleukin 8; RSV bronchiolitis;
 XX respiratory syncytial virus; PCR primer; ss.
 XX Homo sapiens.
 XX WO200177382-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 11-APR-2001; 2001WO-GB01634.
 XX
 PR 11-APR-2000; 2000GB-0008910.
 XX
 PA (ISIS-) ISIS INNOVATION LTD.
 XX
 PI Hull J, Kwiatkowski DP;
 XX WPI; 2002-017472/02.

XX Nucleic acid comprising a sequence corresponding to variant allele of
 PT human interleukin 8 gene, useful for determining susceptibility to
 PT respiratory syncytial virus bronchiolitis in humans -
 XX
 XX Claim 42; Page 47; 49pp; English.
 XX The patent discloses methods for identification of genetic variants
 CC at the interleukin 8 (IL-8) locus. The invention relates to nucleic
 CC acid molecules corresponding to various alleles at the IL8 locus

CC and kits for the detection of the presence of variant alleles. The
 CC polymorphic variants of the IL-8 locus are useful for screening a
 CC human subject for susceptibility to a disease such as respiratory
 CC syncytial virus (RSV) bronchiolitis for which increased production
 CC of IL-8 is a risk factor. The polymorphic variants of IL-8 locus are
 CC also useful for determining the likelihood that a patient previously
 CC identified as infected with RSV will develop severe disease. They are
 CC useful as probes and primers for genotyping. They are also useful for
 CC initiating DNA synthesis or amplification for detecting the presence
 CC of IL-8 genetic variants. The single nucleotide polymorphisms have a
 CC general utility as a genetic marker. The present DNA sequence is PCR
 CC primer, 2767A which is used to determine the genotype of human
 CC IL-8 gene.

XX Sequence 26 BP; 8 A; 5 C; 2 G; 11 T; 0 other;

Query Match 1.2%; Score 15.6; DB 1; Length 26;
 Best Local Similarity 81.8%; Pred. No. 1.8e+02;
 Matches 18; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1291 TATCTGAAATTTTAATTGAACT 1312
 DB 25 TATCTGAAATGAAATTTAACT 4

RESULT 59
 AAA22696
 ID AAA22696 standard; RNA; 17 BP.

XX
 AC AAA22696;

XX 19-JUN-2000 (first entry)

XX Integrin subunit beta 3 substrate sequence SEQ ID NO:5922.

XX Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
 XX integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
 XX hammerhead ribozyme; angiogenic factor; cytostatic; antidiabetic;
 XX ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
 XX dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;
 XX age related macular degeneration; inflammation; neovascular glaucoma;
 XX myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;
 XX tuberosus sclerosis; pot-wine stain; Sturge Weber syndrome;
 XX Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.

XX Homo sapiens.

XX WO9950403-A2.

XX 07-OCT-1999.

XX 24-MAR-1999; 99WO-US06507.

XX 27-MAR-1998; 98US-0079678.

XX (RIBO-) RIBOZYME PHARM INC.

XX Pavco PA, Roberts B, Jarvis T, Coeshott C, McSwiggen JA;

XX WPI; 1999-591315/50.

XX Novel ribozymes for modulating the synthesis, expression and/or
 PT stability of an mRNA encoding an angiogenic factors -

XX Claim 54; Page 236; 305pp; English.

XX The present invention describes enzymatic nucleic acid molecules with
 CC RNA cleaving activity, which specifically cleave RNA encoded by an aryl
 CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
 CC gene, an integrin alpha 6 subunit gene, or a tie-2 gene. AAA16775 to
 CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
 CC and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their
 CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to

CC AA19154 represent ribozyme sequences for Tie-2, and AA18386 to AA19086
CC and AA19155 to AA19222 represent their corresponding target sequences;
CC AA19223 to AA20361 and AA21501 to AA21595 represent ribozyme
CC sequences for integrin alpha 6 subunit, and AA20362 to AA21500 and
CC AA21596 to AA21688 represent their corresponding target sequences;
CC AA21689 to AA22475 and AA22476 to AA22477 represent ribozyme sequences
CC for integrin subunit beta 3, and AA22478 to AA22479, AA22480 to
CC AA22481 represent their corresponding target sequences. The ribozymes of
CC the invention are used for modulating the synthesis, expression and/or
CC stability of an mRNA encoding angiogenic factor, especially ARNT,
CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
CC especially used to treat cancer, diabetic retinopathy, age related
CC macular degeneration (ARMD), inflammation, and arthritis, as well as
CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
CC angiofibroma of tuberous sclerosis, pot-wine stains, Sturge Weber
CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,
CC and other syndromes and diseases related to the levels of ARNT, Tie-2,
CC integrin subunit alpha-6, or integrin subunit beta-3.
SQ Sequence 17 BP; 4 A; 0 C; 0 G; 13 U; 0 other;

Query Match 1.2%; Score 15.4; DB 1; Length 17;
Best Local Similarity 23.5%; Pred. No. 1.3e+02;
Matches 4; Conservative 12; Mismatches 1; Indels 0; Gaps 0;

Qy 1040 TTATTATTATGTTT 1056
Db 1 UUAUUUUUUUUUUUUU 17
AA222697
AA222697 standard; RNA; 17 BP.
AA222697;
19-JUN-2000 (first entry)
Integrin subunit beta 3 substrate sequence SEQ ID NO:5923.

Human; aryl hydrocarbon nuclear transporter; ARNT; TIE-2; angiogenesis;
integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
hammerhead ribozyme; angiogenic factor; cytostatic; antidiabetic;
ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;
age related macular degeneration; inflammation; neovascular glaucoma;
myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;
tuberous sclerosis; pot-wine stain; Sturge Weber syndrome;
Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
Homo sapiens.
WO9950403-A2.
07-OCT-1999.
24-MAR-1999; 99WO-US06507.
27-MAR-1998; 98US-0079678.
(RIBO-) RIBOZYME PHARM INC.
Pavco PA, Roberts E, Jarvis T, Coeshott C, McSwiggen JA;
WPI; 1999-591315/50.

Novel ribozymes for modulating the synthesis, expression and/or
stability of an mRNA encoding an angiogenic factors -
Claim 54; Page 236; 305pp; English.
The present invention describes enzymatic cleave acid molecules with
RNA cleaving activity, which specifically cleave RNA encoded by an aryl

CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AA16775 to
CC AA17167 and AA17561 to AA17622 represent ribozyme sequences for ARNT,
CC and AA17168 to AA17560 and AA17623 to AA17684 represent their
CC corresponding target sequences; AA17685 to AA18385 and AA19087 to
CC AA19154 represent ribozyme sequences for Tie-2, and AA18386 to AA19086
CC and AA19155 to AA19222 represent their corresponding target sequences;
CC AA19223 to AA20361 and AA21501 to AA21595 represent ribozyme
CC sequences for integrin alpha 6 subunit, and AA20362 to AA21500 and
CC AA21596 to AA21688 represent their corresponding target sequences;
CC AA21689 to AA22475 and AA22476 to AA22477 represent ribozyme sequences
CC for integrin subunit beta 3, and AA22478 to AA22479, AA22480 to
CC AA22481 represent their corresponding target sequences. The ribozymes of
CC the invention are used for modulating the synthesis, expression and/or
CC stability of an mRNA encoding angiogenic factor, especially ARNT,
CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
CC especially used to treat cancer, diabetic retinopathy, age related
CC macular degeneration (ARMD), inflammation, and arthritis, as well as
CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
CC angiofibroma of tuberous sclerosis, pot-wine stains, Sturge Weber
CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,
CC and other syndromes and diseases related to the levels of ARNT, Tie-2,
CC integrin subunit alpha-6, or integrin subunit beta-3.
SQ Sequence 17 BP; 4 A; 0 C; 0 G; 13 U; 0 other;

Query Match 1.2%; Score 15.4; DB 1; Length 17;
Best Local Similarity 23.5%; Pred. No. 1.3e+02;
Matches 4; Conservative 12; Mismatches 1; Indels 0; Gaps 0;

Qy 1041 TTATTATTATGTTT 1057
Db 1 UUAUUUUUUUUUUUUU 17
AA222698
AA222698 standard; RNA; 17 BP.
AA222698;
19-JUN-2000 (first entry)
Integrin subunit beta 3 substrate sequence SEQ ID NO:5924.

Human; aryl hydrocarbon nuclear transporter; ARNT; TIE-2; angiogenesis;
integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
hammerhead ribozyme; angiogenic factor; cytostatic; antidiabetic;
ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;
age related macular degeneration; inflammation; neovascular glaucoma;
myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;
tuberous sclerosis; pot-wine stain; Sturge Weber syndrome;
Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
Homo sapiens.
WO9950403-A2.
07-OCT-1999.
24-MAR-1999; 99WO-US06507.
27-MAR-1998; 98US-0079678.
(RIBO-) RIBOZYME PHARM INC.
Pavco PA, Roberts E, Jarvis T, Coeshott C, McSwiggen JA;
WPI; 1999-591315/50.

Novel ribozymes for modulating the synthesis, expression and/or
stability of an mRNA encoding an angiogenic factors -


```

PR 27-MAR-1998; 98US-0079678.
XX (RIBO-) RIBOZYME PHARM INC.
XX PA
XX PI Pavco PA, Roberts E, Jarvis T, Coeshott C, McSwiggen JA;
XX DR WPI; 1999-591315/50.
XX XX
XX PT Novel ribozymes for modulating the synthesis, expression and/or
XX PT stability of an mRNA encoding an angiogenic factors
XX XX
XX PS Claim 54; Page 237; 305pp; English.
XX XX
XX CC The present invention describes enzymatic nucleic acid molecules with
XX CC RNA cleaving activity, which specifically cleave RNA encoded by an aryl
XX CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
XX CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
XX CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
XX CC and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their
XX CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
XX CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to
XX CC AAA19155 represent ribozyme sequences for integrin subunit beta-3.
XX CC AAA19155 to AAA19222 represent their corresponding target sequences;
XX CC and AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
XX CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
XX CC AAA21596 to AAA21688 represent their corresponding target sequences;
XX CC AAA21689 to AAA22475 and AAA23263 to AAA23442 represent ribozyme sequences
XX CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to
XX CC AAA23422 represent their corresponding target sequences. The ribozymes of
XX CC the invention are used for modulating the synthesis, expression and/or
XX CC stability of an mRNA encoding angiogenic factor, especially ARNT,
XX CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
XX CC especially used to treat cancer, diabetic retinopathy, age related
XX CC macular degeneration (ARMD), inflammation, and arthritis, as well as
XX CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
XX CC angiofibroma of tuberous sclerosis, pot-wine stains, Sturge Weber
XX CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,
XX CC and other syndromes and diseases related to the levels of ARNT, Tie-2,
XX CC integrin subunit alpha-6, or integrin subunit beta-3.
XX CC
XX CC Sequence 17 BP; 4 A; 0 C; 0 G; 13 U; 0 other;
XX
XX Query Match 1.2%; Score 15.4; DB 1; Length 17;
XX Best Local Similarity 23.5%; Pred. No. 1.3e+02;
XX Matches 4; Conservative 12; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 1045 TATTTATGTAATTTATTT 1061
XX Db 1 UAUUUUUUUUUUUUUUU 17
XX
XX RESULT 64
XX AAA222701
XX ID AAA222701 standard; RNA; 17 BP.
XX AC AAA22701;
XX XX
XX DT 19-JUN-2000 (first entry)
XX DE Integrin subunit beta 3 substrate sequence SEQ ID NO:5927.
XX
XX Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
XX integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
XX hammerhead ribozyme; angiogenic factor; cytostatic; antidiabetic;
XX ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
XX dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;
XX age related macular degeneration; inflammation; neovascular glaucoma;
XX myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;
XX Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
XX
XX Homo sapiens.
XX OS
XX PN WO9950403-A2.

```

```

XX PD 07-OCT-1999.
XX XX
XX PF 24-MAR-1999; 99WO-US06507.
XX XX
XX PR 27-MAR-1998; 98US-0079678.
XX XX
XX PA (RIBO-) RIBOZYME PHARM INC.
XX XX
XX PI Pavco PA, Roberts E, Jarvis T, Coeshott C, McSwiggen JA;
XX DR WPI; 1999-591315/50.
XX XX
XX PT Novel ribozymes for modulating the synthesis, expression and/or
XX PT stability of an mRNA encoding an angiogenic factors
XX XX
XX PS Claim 54; Page 237; 305pp; English.
XX XX
XX CC The present invention describes enzymatic nucleic acid molecules with
XX CC RNA cleaving activity, which specifically cleave RNA encoded by an aryl
XX CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
XX CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
XX CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
XX CC and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their
XX CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
XX CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to
XX CC AAA19155 represent ribozyme sequences for integrin subunit beta-3.
XX CC AAA19155 to AAA19222 represent their corresponding target sequences;
XX CC and AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
XX CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
XX CC AAA21596 to AAA21688 represent their corresponding target sequences;
XX CC AAA21689 to AAA22475 and AAA23263 to AAA23442 represent ribozyme sequences
XX CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to
XX CC AAA23422 represent their corresponding target sequences. The ribozymes of
XX CC the invention are used for modulating the synthesis, expression and/or
XX CC stability of an mRNA encoding angiogenic factor, especially ARNT,
XX CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
XX CC especially used to treat cancer, diabetic retinopathy, age related
XX CC macular degeneration (ARMD), inflammation, and arthritis, as well as
XX CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
XX CC angiofibroma of tuberous sclerosis, pot-wine stains, Sturge Weber
XX CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,
XX CC and other syndromes and diseases related to the levels of ARNT, Tie-2,
XX CC integrin subunit alpha-6, or integrin subunit beta-3.
XX CC
XX CC Sequence 17 BP; 5 A; 0 C; 0 G; 12 U; 0 other;
XX
XX Query Match 1.2%; Score 15.4; DB 1; Length 17;
XX Best Local Similarity 29.4%; Pred. No. 1.3e+02;
XX Matches 5; Conservative 11; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 1046 ATTATGTAATTTATTTA 1062
XX Db 1 AUUUUUUUUUUUUUUUUA 17
XX
XX RESULT 65
XX AAA22702
XX ID AAA22702 standard; RNA; 17 BP.
XX AC AAA22702;
XX XX
XX DT 19-JUN-2000 (first entry)
XX DE Integrin subunit beta 3 substrate sequence SEQ ID NO:5928.
XX
XX Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
XX integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
XX hammerhead ribozyme; angiogenic factor; cytostatic; antidiabetic;
XX ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
XX dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;
XX age related macular degeneration; inflammation; neovascular glaucoma;
XX myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;
XX tuberous sclerosis; psoriasis; verruca vulgaris; Sturge Weber syndrome;
XX

```

[illegible]

DE XX Integrin subunit beta 3 substrate sequence SEQ ID NO:5930.

KW Human; aryl hydrocarbon nuclear transport; ARNT; Tie-2; angiogenesis;

KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;

KW hammerhead ribozyme; angiogenic factor; cytosolic; antidiabetic;

KW ophthalmologic; antiinflammatory; antiarthritic; antipapillary; ARMD;

KW dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;

KW age related macular degeneration; inflammation; neovascular glaucoma;

KW myopic degeneration; psoriasis; verruca vulgaris; angiobroma;

KW tuberculous sclerosis; pot-wine stain; Sturge Weber syndrome;

KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.

OS Homo sapiens.

XX WO9950403-A2.

XX 07-OCT-1999.

XX 24-MAR-1999; 99WO-US06507.

XX 27-MAR-1998; 98US-0079678.

XX (RIBO-) RIBOZYME PHARM INC.

XX Pavco PA, Roberts E, Jarvis T, Coeshott C, McSwiggen JA;

XX WPI; 1999-591315/50.

XX Novel ribozymes for modulating the synthesis, expression and/or

XX stability of an mRNA encoding an angiogenic factors -

XX Claim 54; Page 237; 305pp; English.

XX The present invention describes enzymatic nucleic acid molecules with

XX RNA cleaving activity, which specifically cleave RNA encoded by an aryl

XX hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3

XX gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to

XX AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,

XX and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their

XX corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to

XX AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086

XX corresponding target sequences. The ribozymes of

XX for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to

XX AAA21596 to AAA21688 represent their corresponding target sequences;

XX AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme

XX sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and

XX AAA21596 to AAA21688 represent their corresponding target sequences;

XX AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme

XX sequences for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to

XX AAA23422 represent their corresponding target sequences. The ribozymes of

XX the invention are used for modulating the synthesis, expression and/or

XX stability of an mRNA encoding angiogenic factor, especially ARNT,

XX integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are

XX especially used to treat cancer, diabetic retinopathy, age related

XX macular degeneration (ARMD), inflammation, and arthritis, as well as

XX neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,

XX angiobroma of tuberculous sclerosis, pot-wine stains, Sturge Weber

XX syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,

XX and other syndromes and diseases related to the levels of ARNT, Tie-2,

XX integrin subunit alpha-6, or integrin subunit beta-3.

XX Sequence 17 BP; 5 A; 0 C; 0 G; 12 U; 0 other;

SQ

Query Match 1.2%; Score 15.4; DB 1; Length 17;

Best Local Similarity 29.4%; Pred. No. 1.3e+02;

Matches 5; Conservative 11; Mismatches 1; Indels 0; Gaps 0;

QY 1046 ATTATGATGATTTATTTA 1062

DB 1 AUUUUUUUUUUUUU 17

RESULT 68

AAA22705

ID AAA22705 standard; RNA; 17 BP.

XX AAA22705;

XX 19-JUN-2000 (first entry)

XX Integrin subunit beta 3 substrate sequence SEQ ID NO:5931.

XX Human; aryl hydrocarbon nuclear transport; ARNT; Tie-2; angiogenesis;

XX integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;

XX hammerhead ribozyme; angiogenic factor; cytosolic; antidiabetic;

XX ophthalmologic; antiinflammatory; antiarthritic; antipapillary; ARMD;

XX dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;

XX age related macular degeneration; inflammation; neovascular glaucoma;

XX myopic degeneration; psoriasis; verruca vulgaris; angiobroma;

XX tuberculous sclerosis; pot-wine stain; Sturge Weber syndrome;

XX Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.

XX Homo sapiens.

XX WO9950403-A2.

XX 07-OCT-1999.

XX 24-MAR-1999; 99WO-US06507.

XX 27-MAR-1998; 98US-0079678.

XX (RIBO-) RIBOZYME PHARM INC.

XX Pavco PA, Roberts E, Jarvis T, Coeshott C, McSwiggen JA;

XX WPI; 1999-591315/50.

XX Novel ribozymes for modulating the synthesis, expression and/or

XX stability of an mRNA encoding an angiogenic factors -

XX Claim 54; Page 237; 305pp; English.

XX The present invention describes enzymatic nucleic acid molecules with

XX RNA cleaving activity, which specifically cleave RNA encoded by an aryl

XX hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3

XX gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to

XX AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,

XX and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their

XX corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to

XX AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086

XX corresponding target sequences. The ribozymes of

XX for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to

XX AAA21596 to AAA21688 represent their corresponding target sequences;

XX AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme

XX sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and

XX AAA21596 to AAA21688 represent their corresponding target sequences;

XX AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme

XX sequences for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to

XX AAA23422 represent their corresponding target sequences. The ribozymes of

XX the invention are used for modulating the synthesis, expression and/or

XX stability of an mRNA encoding angiogenic factor, especially ARNT,

XX integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are

XX especially used to treat cancer, diabetic retinopathy, age related

XX macular degeneration (ARMD), inflammation, and arthritis, as well as

XX neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,

XX angiobroma of tuberculous sclerosis, pot-wine stains, Sturge Weber

XX syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,

XX and other syndromes and diseases related to the levels of ARNT, Tie-2,

XX integrin subunit alpha-6, or integrin subunit beta-3.

XX Sequence 17 BP; 4 A; 0 C; 0 G; 13 U; 0 other;

SQ

Query Match 1.2%; Score 15.4; DB 1; Length 17;

Best Local Similarity 23.5%; Pred. No. 1.3e+02;

Matches 4; Conservative 12; Mismatches 1; Indels 0; Gaps 0;

QY 1044 TTATTTATGATTTATTTT 1060

DB 1 UUAUUUUUUUUUUUU 17

RESULT 69
 ID AAA22706 standard; RNA; 17 BP.
 AC AAA22706;
 XX
 XX 19-JUN-2000 (first entry)
 DT
 DE Integrin subunit beta 3 substrate sequence SEQ ID NO:5932.
 KW Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
 KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
 KW hammerhead ribozyme; angiogenic factor; cytostatic; antidiabetic;
 KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
 KW dermatologic; RNA cleavage; cancer; diabetic retinopathy; arthritis;
 KW age related macular degeneration; psoriasis; verruca vulgaris; angiobroma;
 KW myopic degeneration; Sturge Weber syndrome;
 KW tuberous sclerosis; pot-wine stain; Sturge Weber syndrome;
 KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO9950403-A2.
 PN
 XX
 PD 07-OCT-1999.
 XX
 PF 24-MAR-1999; 99WO-US06507.
 XX
 XX 27-MAR-1998; 98US-0079678.
 PR
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 PI Pavco PA, Roberts E, Jarvis T, Coeshott C, McSwiggen JA;
 XX WPI; 1999-591315/50.
 DR
 XX Novel ribozymes for modulating the synthesis, expression and/or
 PT stability of an mRNA encoding an angiogenic factors -
 XX
 PS Claim 54; Page 237; 305pp; English.
 XX
 CC The present invention describes enzymatic cleave RNA molecules with
 CC RNA cleaving activity, which specifically cleave RNA encoded by an aryl
 CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
 CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
 CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
 CC and AAA17168 to AAA17560 and AAA17623 to AAA18385 and AAA19087 to
 CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
 CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
 CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
 CC AAA21596 to AAA22475 and AAA23263 to AAA23342 represent ribozyme
 CC sequences for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to
 CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to
 CC AAA23422 represent their corresponding target sequences. The ribozymes of
 CC the invention are used for modulating the synthesis, expression and/or
 CC stability of an mRNA encoding angiogenic factor, especially ARNT,
 CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
 CC especially used to treat cancer, diabetic retinopathy, age related
 CC macular degeneration (ARMD), inflammation, and arthritis, as well as
 CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
 CC angiobroma of tuberous sclerosis, pot-wine stains, Sturge Weber
 CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,
 CC and other syndromes and diseases related to the levels of ARNT, Tie-2,
 CC integrin subunit alpha-6, or integrin subunit beta-3.
 XX
 SQ Sequence 17 BP; 4 A; 0 C; 0 G; 13 U; 0 other;
 Query Match 1.2%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 23.5%; Pred. No. 1.3e+02;

Matches 4; Conservative 12; Mismatches 1; Indels 0; Gaps 0;
 QY 1045 TATTATGCTATTATTT 1061
 :|:::|:|:::|:::
 DB 1 UAGUUAUUUAUUUUU 17
 RESULT 70
 AAA22899/c
 ID AAA22899 standard; RNA; 17 BP.
 XX
 AC AAA22899;
 XX
 XX 19-JUN-2000 (first entry)
 DT
 DE Integrin subunit beta 3 substrate sequence SEQ ID NO:5125.
 KW Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
 KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
 KW hammerhead ribozyme; angiogenic factor; cytostatic; antidiabetic;
 KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
 KW dermatologic; RNA cleavage; cancer; diabetic retinopathy; arthritis;
 KW age related macular degeneration; psoriasis; verruca vulgaris; angiobroma;
 KW myopic degeneration; Sturge Weber syndrome;
 KW tuberous sclerosis; pot-wine stain; Sturge Weber syndrome;
 KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO9950403-A2.
 PN
 XX
 PD 07-OCT-1999.
 XX
 PF 24-MAR-1999; 99WO-US06507.
 XX
 XX 27-MAR-1998; 98US-0079678.
 PR
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 PI Pavco PA, Roberts E, Jarvis T, Coeshott C, McSwiggen JA;
 XX WPI; 1999-591315/50.
 DR
 XX Novel ribozymes for modulating the synthesis, expression and/or
 PT stability of an mRNA encoding an angiogenic factors -
 XX
 PS Claim 54; Page 249; 305pp; English.
 XX
 CC The present invention describes enzymatic cleave RNA molecules with
 CC RNA cleaving activity, which specifically cleave RNA encoded by an aryl
 CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
 CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
 CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
 CC and AAA17168 to AAA17560 and AAA17623 to AAA18385 and AAA19087 to
 CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
 CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
 CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
 CC AAA21596 to AAA22475 and AAA23263 to AAA23342 represent ribozyme
 CC sequences for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to
 CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to
 CC AAA23422 represent their corresponding target sequences. The ribozymes of
 CC the invention are used for modulating the synthesis, expression and/or
 CC stability of an mRNA encoding angiogenic factor, especially ARNT,
 CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
 CC especially used to treat cancer, diabetic retinopathy, age related
 CC macular degeneration (ARMD), inflammation, and arthritis, as well as
 CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
 CC angiobroma of tuberous sclerosis, pot-wine stains, Sturge Weber
 CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,
 CC and other syndromes and diseases related to the levels of ARNT, Tie-2,
 CC integrin subunit alpha-6, or integrin subunit beta-3.

XX SQ Sequence 17 BP; 13 A; 0 C; 0 G; 4 U; 0 other;
Query Match 1.2%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1045 TATTATGTTATTATT 1061
DB 17 TATTATTATTATTATT 1
RESULT 71
AAA22900/c
ID AAA22900 standard; RNA; 17 BP.
XX AAA22900;
AC
DT 19-JUN-2000 (first entry)
DE Integrin subunit beta 3 substrate sequence SEQ ID NO:6126.
XX Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
KW hammerhead ribozyme; angiogenic factor; cytosolic; antidiabetic;
KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
KW dermatologic; RNA cleavage; cancer; diabetic retinopathy; arthritis;
KW age related macular degeneration; inflammation; neovascular glaucoma;
KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;
KW tuberosus sclerosis; pot-wine stain; Sturge Weber syndrome;
KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
XX OS Homo sapiens.
XX WO9950403-A2.
XX 07-OCT-1999.
XX 24-MAR-1999; 99WO-US06507.
XX 27-MAR-1998; 98US-0079678.
XX (RIBO-) RIBOZYME PHARM INC.
XX Pavco PA, Roberts B, Jarvis T, Coeshott C, McSwiggen JA;
XX WPI; 1999-591315/50.
XX Novel ribozymes for modulating the synthesis, expression and/or
XX stability of an mRNA encoding an angiogenic factors -
XX Claim 54; Page 249; 305pp; English.
XX The present invention describes enzymatic cleave RNA molecules with
XX RNA cleaving activity, which specifically cleave RNA encoded by an aryl
XX hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
XX gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
XX AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
XX and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their
XX corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
XX AAA21596 to AAA21688 represent their corresponding target sequences;
XX AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
XX and AAA19155 to AAA19222 represent their corresponding target sequences;
XX AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
XX sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
XX AAA21596 to AAA21688 represent their corresponding target sequences;
XX AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme
XX sequences for integrin subunit beta 3, and AAA22476 to AAA23262, and
XX AAA23343 to
XX AAA23422 represent their corresponding target sequences. The ribozymes of

CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
CC angiofibroma of tuberosus sclerosis, pot-wine stains, Sturge Weber
CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,
CC and other syndromes and diseases related to the levels of ARNT, Tie-2,
CC integrin subunit alpha-6, or integrin subunit beta-3.
XX SQ Sequence 17 BP; 13 A; 0 C; 0 G; 4 U; 0 other;
Query Match 1.2%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1045 TATTATGTTATTATT 1061
DB 17 TATTATTATTATTATT 1
RESULT 72
AAA22901/c
ID AAA22901 standard; RNA; 17 BP.
XX AAA22901;
AC
DT 19-JUN-2000 (first entry)
DE Integrin subunit beta 3 substrate sequence SEQ ID NO:6127.
XX Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
KW hammerhead ribozyme; angiogenic factor; cytosolic; antidiabetic;
KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
KW dermatologic; RNA cleavage; cancer; diabetic retinopathy; arthritis;
KW age related macular degeneration; inflammation; neovascular glaucoma;
KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;
KW tuberosus sclerosis; pot-wine stain; Sturge Weber syndrome;
KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
XX OS Homo sapiens.
XX WO9950403-A2.
XX 07-OCT-1999.
XX 24-MAR-1999; 99WO-US06507.
XX 27-MAR-1998; 98US-0079678.
XX (RIBO-) RIBOZYME PHARM INC.
XX Pavco PA, Roberts B, Jarvis T, Coeshott C, McSwiggen JA;
XX WPI; 1999-591315/50.
XX Novel ribozymes for modulating the synthesis, expression and/or
XX stability of an mRNA encoding an angiogenic factors -
XX Claim 54; Page 249; 305pp; English.
XX The present invention describes enzymatic cleave RNA molecules with
XX RNA cleaving activity, which specifically cleave RNA encoded by an aryl
XX hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
XX gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
XX AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
XX and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their
XX corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
XX AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
XX and AAA19155 to AAA19222 represent their corresponding target sequences;
XX AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
XX sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
XX AAA21596 to AAA21688 represent their corresponding target sequences;
XX AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme
XX sequences for integrin subunit beta 3, and AAA22476 to AAA23262, and
XX AAA23343 to
XX AAA23422 represent their corresponding target sequences. The ribozymes of

CC the invention are used for modulating the synthesis, expression and/or
 CC stability of an mRNA encoding angiogenic factor, especially ARNT,
 CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
 CC especially used to treat cancer, diabetic retinopathy, age related
 CC macular degeneration (ARMD), inflammation, and arthritis, as well as
 CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
 CC angiofibroma of tuberosus sclerosis, pot-wine stains, Sturge Weber
 CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,
 CC and other syndromes and diseases related to the levels of ARNT, Tie-2,
 CC integrin subunit alpha-6, or integrin subunit beta-3.

XX Sequence 17 BP; 13 A; 0 C; 0 G; 4 U; 0 other;

Query Match 1.2%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 1.3e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1045 TATTTATGTTATTTATTT 1061

Db 17 TATTTATTTATTTATTT 1

RESULT 73

AAA22902/c

ID AAA22902 standard; RNA; 17 BP.

XX AAA22902;

DT 19-JUN-2000 (first entry)

DE Integrin subunit beta 3 substrate sequence SEQ ID NO:6128.

XX Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
 XX integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
 XX hammerhead ribozyme; angiogenic factor; cytosolic; antidiabetic;
 XX ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
 XX dermatologic; RNA cleavage; cancer; diabetic retinopathy; arthritis;
 XX age related macular degeneration; inflammation; neovascular glaucoma;
 XX myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;
 XX tuberosus sclerosis; pot-wine stain; Sturge Weber syndrome;
 XX Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.

XX Homo sapiens.

XX WO9950403-A2.

XX 07-OCT-1999.

XX 24-MAR-1999; 99WO-US06507.

XX 27-MAR-1998; 98US-0079678.

XX (RIBO-) RIBOZYME PHARM INC.

XX Pavco PA, Roberts E, Jarvis T, Coeshott C, McSwiggen JA;

XX WPI; 1999-591315/50.

XX Novel ribozymes for modulating the synthesis, expression and/or
 PT stability of an mRNA encoding an angiogenic factors -

XX Claim 54; Page 249; 305pp; English.

XX The present invention describes enzymatic nucleic acid molecules with
 CC RNA cleaving activity, which specifically cleave RNA encoded by an aryl
 CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
 CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
 CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
 CC and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their
 CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
 CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
 CC and AAA19155 to AAA19222 represent their corresponding target sequences;
 CC AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme

CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
 CC AAA21596 to AAA21688 represent their corresponding target sequences;
 CC AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence
 CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to
 CC AAA23422 represent their corresponding target sequences. The ribozymes of
 CC the invention are used for modulating the synthesis, expression and/or
 CC stability of an mRNA encoding angiogenic factor, especially ARNT,
 CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
 CC especially used to treat cancer, diabetic retinopathy, age related
 CC macular degeneration (ARMD), inflammation, and arthritis, as well as
 CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
 CC angiofibroma of tuberosus sclerosis, pot-wine stains, Sturge Weber
 CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,
 CC and other syndromes and diseases related to the levels of ARNT, Tie-2,
 CC integrin subunit alpha-6, or integrin subunit beta-3.

XX Sequence 17 BP; 13 A; 0 C; 0 G; 4 U; 0 other;

Query Match 1.2%; Score 15.4; DB 1; Length 17;

Best Local Similarity 94.1%; Pred. No. 1.3e+02;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1045 TATTTATGTTATTTATTT 1061

Db 17 TATTTATTTATTTATTT 1

RESULT 74

AAA22902/c

ID AAA22903 standard; RNA; 17 BP.

XX AAA22903;

XX 19-JUN-2000 (first entry)

DE Integrin subunit beta 3 substrate sequence SEQ ID NO:6129.

XX Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
 XX integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
 XX hammerhead ribozyme; angiogenic factor; cytosolic; antidiabetic;
 XX ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
 XX dermatologic; RNA cleavage; cancer; diabetic retinopathy; arthritis;
 XX age related macular degeneration; inflammation; neovascular glaucoma;
 XX myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;
 XX tuberosus sclerosis; pot-wine stain; Sturge Weber syndrome;
 XX Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.

XX Homo sapiens.

XX WO9950403-A2.

XX 07-OCT-1999.

XX 24-MAR-1999; 99WO-US06507.

XX 27-MAR-1998; 98US-0079678.

XX (RIBO-) RIBOZYME PHARM INC.

XX Pavco PA, Roberts E, Jarvis T, Coeshott C, McSwiggen JA;

XX WPI; 1999-591315/50.

XX Novel ribozymes for modulating the synthesis, expression and/or
 PT stability of an mRNA encoding an angiogenic factors -

XX Claim 54; Page 249; 305pp; English.

XX The present invention describes enzymatic nucleic acid molecules with
 CC RNA cleaving activity, which specifically cleave RNA encoded by an aryl
 CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
 CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
 CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,

CC and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their
 CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
 CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
 CC and AAA19155 to AAA19222 represent their corresponding target sequences;
 CC AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
 CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
 CC AAA21596 to AAA21688 represent their corresponding target sequences;
 CC AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence
 CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to
 CC AAA23422 represent their corresponding target sequences. The ribozymes of
 CC the invention are used for modulating the synthesis, expression and/or
 CC stability of an mRNA encoding angiogenic factor, especially ARNT,
 CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
 CC especially used to treat cancer, diabetic retinopathy, age related
 CC macular degeneration (AMD), inflammation, and arthritis, as well as
 CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
 CC angiofibroma of tuberous sclerosis, pot-wine stains, Sturge Weber
 CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,
 CC and other syndromes and diseases related to the levels of ARNT, Tie-2,
 CC integrin subunit alpha-6, or integrin subunit beta-3.
 XX
 SQ Sequence 17 BP; 13 A; 0 C; 0 G; 4 U; 0 other;
 Query Match 1.2%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 1.3e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1045 TATTTATGATTTATTT 1051
 Db 17 TATTTATTTATTTATTT 1
 RESULT 75
 ABV80426/c
 ID ABV80426 standard; DNA; 17 BP.
 AC ABV80426;
 XX
 DT 03-JAN-2003 (first entry)
 XX
 DE Human HTPL scanning oligonucleotide SEQ ID 1672.
 XX
 KW Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;
 KW human testis expressed patched like protein; testis; adrenal; liver;
 KW male germ cell development; bone marrow; brain; kidney; lung; placenta;
 KW prostate; skeletal muscle; colon; male infertility; cancer; ss.
 XX
 OS Homo sapiens.
 XX
 FN EP1229046-A2.
 XX
 PD 07-AUG-2002.
 XX
 PF 28-JAN-2002; 2002EP-0001167.
 XX
 PR 30-JAN-2001; 2001WO-US00663.
 PR 30-JAN-2001; 2001WO-US00664.
 PR 30-JAN-2001; 2001WO-US00665.
 PR 30-JAN-2001; 2001WO-US00667.
 PR 30-JAN-2001; 2001WO-US00668.
 PR 30-JAN-2001; 2001WO-US00669.
 PR 23-MAY-2001; 2001US-0864761.
 PR 09-OCT-2001; 2001US-0327898.
 XX
 PA (ABOM-) ABOMICA INC.
 XX
 PI Zhan J;
 XX
 DR WPI; 2002-676582/73.
 XX
 PT Novel isolated human testis expressed patched like protein (HTPL),
 PT useful for identifying agonist and antagonist and specific binding
 PT partners, and for treating subjects having defects in HTPL -

XX Example 2; Page 283; 718pp; English.
 PS
 XX The present invention relates to human testis expressed Patched like
 CC protein (HTPL, see ABV78759 to ABV78762 and ABV98519 to ABV98520). HTPL
 CC has two isoforms, with a few single base pair differences between the
 CC two. One of the single base pair changes introduces a premature stop
 CC codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL
 CC shares an overall structure organisation with the Patched protein. The
 CC shared structural features strongly imply that HTPL plays a role similar
 CC to that of Patched, and is a potential tumour suppressor. HTPL is
 CC important in regulating male germ cell development, and the HTPL gene was
 CC mapped to human chromosome 10p12.1. HTPL and its coding sequence are
 CC useful for diagnosing a disorder caused by mutation in HTPL, and in
 CC therapy and manufacture of a medicament for treatment or prevention of
 CC such disorder associated with decreased expression or activity of human
 CC HTPL. Such disorders include disorders of testis, or adrenal, adult and
 CC foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,
 CC skeletal muscle or colon function. HTPL proteins and nucleic acids are
 CC clinically useful diagnostic markers and potential therapeutic agents for
 CC male infertility and cancer. The present oligonucleotide was used in an
 CC example from the invention.
 XX
 SQ Sequence 17 BP; 4 A; 1 C; 1 G; 11 T; 0 other;
 Query Match 1.2%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 1.3e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 675 TATACAAATAGCAAAT 691
 Db 17 TATACAAATAGCAAAT 1
 RESULT 76
 AAD49640
 ID AAD49640 standard; mRNA; 17 BP.
 AC AAD49640;
 XX
 DT 24-MAR-2003 (first entry)
 XX
 DE Human adenylylate uridylylate-rich element (ARE) motif mRNA #2.
 XX
 KW Amyloidosis; haemophilia; Alzheimer's disease; atherosclerosis; cancer;
 KW gigantism; dwarfism; hypothyroidism; hyperthyroidism; cystic fibrosis;
 KW autoimmune disorder; aging; inflammation; diabetes; obesity; anorectic;
 KW neurodegenerative disorder; Parkinson's disease; gene therapy; virucide;
 KW haemostatic; antibacterial; nootropic; neuroprotective; cytostatic;
 KW fungicide; human; adenylylate uridylylate-rich element; ARE; ss.
 XX
 OS Homo sapiens.
 XX
 FN WO200283953-A1.
 XX
 PD 24-OCT-2002.
 XX
 PR 11-APR-2002; 2002WO-US11757.
 PR 11-APR-2001; 2001US-282965P.
 XX
 PA (PTCT-) PTC THERAPEUTICS INC.
 XX
 PI Rando R, Welch E;
 XX
 DR WPI; 2003-075561/07.
 XX
 PT Identifying a test compound that binds to a target RNA molecule for
 PT treating or preventing amyloidosis, hemophilia, cancer, gigantism,
 PT diabetes, by contacting a detectably labeled target RNA molecule with a
 PT library of test compounds -
 XX
 PS Disclosure; Page 18; 152pp; English.

XX The invention relates to a method for identifying a test compound that
 CC binds to a target RNA molecule, which comprises contacting a detectably
 CC labelled target RNA molecule with a library of test compounds under
 CC conditions that permit direct binding of the labelled target RNA to a
 CC member of the library of test compounds so that a detectably labeled
 CC target RNA: test compound complex is formed. The method is useful for
 CC screening libraries of compounds for those that are selectively bind to
 CC a pre-selected target RNA. The compounds are useful for inhibiting the
 CC formation of a specific bound RNA: host cell factor complexes in vivo.
 CC They are also useful for treating or preventing diseases associated
 CC with overproduction or decreased protein function, such as amyloidosis,
 CC haemophilia, Alzheimer's disease, atherosclerosis, cancer, gigantism,
 CC dwarfism, hypothyroidism, hyperthyroidism, autoimmune disorders, aging,
 CC inflammation, cystic fibrosis, diabetes, obesity, neurodegenerative
 CC disorders, Parkinson's disease or infections (bacterial, viral, fungal).
 CC The invention is also used in gene therapy. The present sequence is
 CC human adenylate uridylylate-rich element (ARE) motif mRNA. This sequence
 CC is used to illustrate the method of the invention.

XX Sequence 17 BP; 5 A; 0 C; 0 G; 12 U; 0 other;

Query Match 1.2%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 29.4%; Pred. No. 1.3e+02;
 Matches 5; Conservative 11; Mismatches 1; Indels 0; Gaps 0;

OY 1046 ATTATGCTATTATTATTA 1062
 |:::|:|:::|:::|
 Db 1 AUUUUUUUUUUUUUUA 17

RESULT 77
 AAL50229
 ID AAL50229 standard; mRNA; 17 BP.

XX AAL50229;

XX 13-FEB-2003 (first entry)

XX Human ARE-mRNA sequence #2.

XX ARE-mRNA; protein secretion inhibition; ARE-mRNA regulation;
 XX inflammation; arthritis; autoimmune disease; septic shock; blood clot;
 XX stroke; TNFalpha; tumour necrosis factor alpha; antiinflammatory;
 XX antiarthritic; antibacterial; immunosuppressive; cerebroprotective;
 XX antipyretic; immunomodulator; adenylate-uridylylate rich element; ss.

XX Homo sapiens.

XX WO200283842-A2.

XX 24-OCT-2002.

XX 08-APR-2002; 2002WO-US10898.

XX 10-APR-2001; 2001US-282974P.

XX (MESS-) MESSAGE PHARM INC.

XX Giordano T, Sturges MA;

XX WPI; 2003-046924/04.

XX Modulating Adenylate-Uridylate Rich element-mRNA regulation involves
 PT administering new amide compound that inhibits secretion of protein
 PT encoded by ARE-mRNA, useful for treating inflammation, arthritis and
 PT autoimmune diseases -

PS Disclosure; Fig 5; 147pp; English.

XX The present invention relates to a method of modulating the regulation of
 CC an adenylate-uridylylate rich element (ARE)-mRNA, which involves
 CC administering new compounds that inhibits secretion of a protein encoded

CC by an ARE-mRNA. This can be used in the treatment of inflammation, fever,
 CC arthritis, autoimmune diseases, septic shock, blood clot, stroke, fever,
 CC acute respiratory distress syndrome (ARDS) and cachexia. The present
 CC sequence is an ARE-mRNA shown in the exemplification of the invention.

XX Sequence 17 BP; 5 A; 0 C; 0 G; 12 U; 0 other;

Query Match 1.2%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 29.4%; Pred. No. 1.3e+02;
 Matches 5; Conservative 11; Mismatches 1; Indels 0; Gaps 0;

OY 1046 ATTATGCTATTATTATTA 1062
 |:::|:|:::|:::|
 Db 1 AUUUUUUUUUUUUUUA 17

RESULT 78

AAL53708

ID AAL53708 standard; RNA; 17 BP.

XX AAL53708;

XX 07-FEB-2003 (first entry)

XX Adenylate Uridylate-rich element motif SEQ ID No 2.

XX Target RNA; target RNA: support-attached test compound; flow cytometry;

XX mass spectrometry; high-throughput screening; RNA motif; ss.

XX Homo sapiens.

XX WO200283837-A1.

XX 24-OCT-2002.

XX 11-APR-2002; 2002WO-US11758.

XX 11-APR-2001; 2001US-282966P.

XX (PTCT-) PTC THERAPEUTICS INC.

XX Almstead NG;

XX WPI; 2003-075534/07.

XX Identifying a test compound that binds to a target RNA molecule by
 PT separating the detectably labeled target RNA: support-attached test
 PT compound complex from uncomplexed target RNA molecules and test
 PT compounds by flow cytometry -

PS Disclosure; Page 16; 131pp; English.

XX The invention relates to a novel method for identifying a test compound
 CC that binds to a target RNA molecule comprising separating the detectably
 CC labeled target RNA: support-attached test compound complex from
 CC uncomplexed target RNA molecules and test compounds. The separating
 CC process is carried out by flow cytometry and determining a structure of
 CC the type of test compound of the RNA: support-attached test compound
 CC complex by mass spectrometry. The method is useful for high-throughput
 CC screening of libraries of compounds to identify pharmaceutical leads.
 CC This polynucleotide sequence represents one of the target RNA motifs/
 CC regions of the invention.

XX Sequence 17 BP; 5 A; 0 C; 0 G; 12 U; 0 other;

Query Match 1.2%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 29.4%; Pred. No. 1.3e+02;
 Matches 5; Conservative 11; Mismatches 1; Indels 0; Gaps 0;

OY 1046 ATTATGCTATTATTATTA 1062
 |:::|:|:::|:::|
 Db 1 AUUUUUUUUUUUUUUA 17

RESULT 79
AAZ41044
ID AAZ41044 standard; DNA; 18 BP.
XX
AC AAZ41044;
XX
DT 26-JAN-2000 (first entry)
XX
DE Cellular inhibitor of apoptosis-2 phosphorothioate antisense oligo #36.
XX
KW Identification; genetic target; gene modulation; human; probe;
KW antisense oligonucleotide; phosphorothioate; PCR primer;
KW nucleotide sequence-based technology; antisense drug discovery;
KW target validation; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO9953101-A1.
XX
PD 21-OCT-1999.
XX
PF 13-APR-1999; 99WO-US08268.
XX
PR 13-APR-1998; 98US-0081483.
PR 28-APR-1998; 98US-0067638.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Cowseert LM, Baker BF, McNeill J, Freier SM, Sasmor HM, Brooks DG;
PI Ohasi C, Wyatt JR, Borchers AH, Vickers TA;
XX
DR WPI; 1999-620446/53.
XX
PT Identifying compounds which modulate expression of nucleic acids, used
PT to provide compounds having defined physical, chemical or bioactive
PT properties, e.g. antisense activity -
XX
PS Example 21; Page 101; 264pp; English.
XX
CC A method has been developed of defining a set of compounds that modulate
CC the expression of a target nucleic acid (tNA) sequence via binding of
CC the compounds with the tNA sequence. The method comprises generating a
CC library of virtual compounds in silico according to defined criteria,
CC and evaluating in silico the binding of the virtual compounds with the
CC tNA according to defined criteria. Also described are: (1) a method of
CC defining a set of oligonucleotides (ONs) that modulate the expression of
CC a tNA sequence via binding of the ONs with the tNA sequence comprising
CC generating a library of virtual compounds in silico according to defined
CC criteria, and evaluating in silico the binding of the virtual ONs with
CC the tNA according to defined criteria; and (2) a method of defining a
CC set of compounds that modulate the expression of a tNA sequence via
CC binding of the compounds with the tNA. The methods can be used for the
CC generation and identification of synthetic compounds having defined
CC physical, chemical or bioactive properties. Information gathered from
CC assays of such compounds is used to identify nucleic acid sequences that
CC are tractable to a variety of nucleotide sequence-based technologies,
CC e.g. antisense drug discovery and target validation. AAZ40852 to
CC AAZ41220, and AAY52701 to AAY52706, represent sequences used in the
CC exemplification of the present invention.
XX
SQ Sequence 18 BP; 6 A; 1 C; 3 G; 8 T; 0 other;

Query Match 1.2%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 1.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1294 CTGAATTTTAAATGAA 1310
DB 1 CTGAATTTTAAATGAA 17

RESULT 80
AAZ22138
ID AAZ22138 standard; DNA; 18 BP.
XX
AC AAZ22138;
XX
DT 26-NOV-1999 (first entry)
XX
DE Human c-IAP-2 mRNA inhibiting antisense oligo ISIS #23447.
XX
KW Cellular inhibitor of Apoptosis-2; antisense; diagnostic; therapeutic;
KW c-IAP-2; prophylaxis; infection; inflammation; tumor formation; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN US5958771-A.
XX
PD 28-SEP-1999.
XX
PF 03-DEC-1998; 98US-0205144.
XX
PR 03-DEC-1998; 98US-0205144.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Bennett CF, Cowseert LM, Ackermann EJ;
XX
DR WPI; 1999-561046/47.
XX
PT Antisense compounds complementary to Cellular Inhibitor of Apoptosis-2
PT useful for e.g. diagnostics, therapeutics, and as research reagents -
XX
PS Example 15; Column 39; 33pp; English.
XX
CC The invention provides antisense compounds of 8-30 nucleotides that
CC inhibit the expression of human Cellular Inhibitor of Apoptosis-2
CC (c-IAP-2). The antisense compounds may be used for diagnostics,
CC therapeutics (for modulating the expression of c-IAP-2), prophylaxis
CC (e.g. to prevent or delay infection, inflammation, or tumor formation),
CC as research reagents (e.g. to distinguish between members of a
CC biological pathway) and in kits. Sequences AAZ22103-142 represent
CC phosphorothioate oligonucleotides used for antisense inhibition of
CC cellular inhibitor of apoptosis-2.
XX
SQ Sequence 18 BP; 6 A; 1 C; 3 G; 8 T; 0 other;

Query Match 1.2%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 1.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1294 CTGAATTTTAAATGAA 1310
DB 1 CTGAATTTTAAATGAA 17

RESULT 81
AAD37308/c
ID AAD37308 standard; DNA; 19 BP.
XX
AC AAD37308;
XX
DT 21-AUG-2002 (first entry)
XX
DE 3' primer #5 used for selective amplification of human ARE mRNAs.
XX
KW Human; untranslated region; UTR; adenylate uridylylate-rich element; ARE;
KW cancer; gene expression; PCR; primer; ss.
XX
OS Homo sapiens.
XX
PN WO200183691-A2.

```

PD 08-NOV-2001.
XX
XX 12-APR-2001; 2001WO-US11993.
XX
XX 12-APR-2000; 2000US-196870P.
XX
XX (CLEV-) CLEVELAND CLINIC FOUND.
XX (KING-) KING FAISAL SPECIALIST HOSPITAL & RES CR.
XX
XX Abu-Khabar KS, Williams BRG, Frevel M, Silverman RH,
XX
XX WPI; 2002-055473/07.
XX
XX Selecting adenylate uridylylate-rich element (ARE) coding sequences from
XX databases, comprises extracting nucleic acids with protein coding
XX sequences upstream, contiguous with a 3' untranslated region having a
XX specific ARE sequence.
XX
XX Disclosure; Page 12; 106pp; English.
XX
XX The invention relates to a gene discovery system and gene expression
XX systems specific for genes encoding adenylate uridylylate-rich element
XX (ARE)-containing mRNAs. The invention relates to a method of selecting
XX nucleic acids which involves extracting protein coding sequences from
XX a database which contains several nucleic acids, each of which comprises
XX full-length or partial protein coding sequences and a 3' untranslated
XX region (UTR) sequence downstream and contiguous with protein coding
XX sequences by identifying protein coding sequences located upstream and
XX contiguous with a 3' UTR which has an adenylate uridylylate-rich element
XX (ARE) search sequence. The method is used for selecting a set of nucleic
XX acids for analysing gene expression in a cell. Nucleic acids of the
XX invention are useful for preparing a customised array of ARE genes. The
XX microarrays produced are useful for obtaining an ARE expression profile
XX in a subject. The microarrays are useful for obtaining an ARE expression
XX profile, particularly a subject with a disease such as cancer. The ARE
XX genes identified by the above mentioned method are useful for generation
XX of polymerase chain reaction (PCR) products or oligonucleotides for use
XX as immobilised probes in cDNA or oligonucleotide microarrays. The present
XX sequence is a PCR primer which is used for the selective amplification of
XX human ARE mRNAs by reverse transcription.
XX
XX Sequence 19 BP; 14 A; 0 C; 0 G; 5 T; 0 other;
XX
XX Query Match 1.2%; Score 15.4; DB 1; Length 19;
XX Best Local Similarity 94.1%; Pred. No. 1.4e+02;
XX Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1046 ATTATGCTATTATTATTA 1062
DB 19 ATTATTTATTATTATTA 3

RESULT 82
AAS09117/c
ID AAS09117 standard; DNA; 20 BP.
XX
XX AAS09117;
XX
XX 26-SEP-2001 (first entry)
XX
XX Human MEK2 antisense oligonucleotide 113923.
XX
XX Human; mitogen-activated protein kinase kinase kinase 2; MAP; MEK2;
XX MEK kinase 2; MAP/ERK kinase kinase 2; immunological disorder;
XX inflammatory disorder; hyperproliferative disorder; cancer; antisense;
XX phosphorothioate; ss.
XX
XX Homo sapiens.
XX
XX Key Location/Qualifiers
XX modified_base 1..20
XX /tag= a
XX /mod_base= "OTHER"

```

```

FT /note= "OTHER= phosphorothioate internucleotide linkages.
FT some bases especially bases 1-5 and bases 16-20
FT are 2'-methoxyethyl (2'-MOE) bases, bases 6-15
FT are 2'-deoxynucleotides and all cytidine bases
FT are 5'-methylcytidines"
XX
XX WO200152863-A1.
XX
XX 26-JUL-2001.
XX
XX 16-JAN-2001; 2001WO-US01361.
XX
XX 20-JAN-2000; 2000US-0488744.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Monia BP, Gaarde WA, Ward DT, Freier SM, Wyatt JR,
XX
XX WPI; 2001-442246/47.
XX
XX Antisense compound 8 to 30 nucleobases in length targeted to a nucleic
XX acid molecule encoding MEK2, useful for the treatment of an
XX immunological, inflammatory of hyperproliferative disorder.
XX
XX Example 15; Page 80; 105pp; English.
XX
XX The present sequence for human MEK2 antisense oligonucleotide 113923
XX is 1 of various novel human mitogen-activated protein (MAP)
XX kinase kinase kinase 2 (MEK2), also known as MEK kinase 2 and
XX MAP/ERK kinase kinase 2) antisense oligonucleotides (AAS09045-AAS09122)
XX which specifically hybridise with and inhibit the expression of MEK2.
XX The antisense oligonucleotides can be used in a composition to modulate
XX the expression of MEK2 (AAU03598). The antisense oligonucleotides are
XX useful for inhibiting the expression of MEK2 in the treatment of
XX immunological disorders, inflammatory disorders and hyperproliferative
XX disorders e.g. cancer.
XX
XX Sequence 20 BP; 11 A; 3 C; 2 G; 4 T; 0 other;
XX
XX Query Match 1.2%; Score 15.4; DB 1; Length 20;
XX Best Local Similarity 94.1%; Pred. No. 1.5e+02;
XX Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 512 GATTCCTGGTTAAATTT 528
DB 17 GATTCCTGGTTAAATTT 1

RESULT 83
AAS22289
ID AAS22289 standard; DNA; 22 BP.
XX
XX AAS22289;
XX
XX 24-OCT-2001 (first entry)
XX
XX Human COL9A2 PCR primer 2 for Exon 4.
XX
XX Human; collagen; COL1A1; COL1A2; COL9A1; COL9A2; COL9A3; ss;
XX osteoporosis; multiple epiphyseal dysplasia; osteogenesis imperfecta;
XX shortness of stature; low bone density; gene therapy; PCR primer.
XX
XX Homo sapiens.
XX
XX US6265157-B1.
XX
XX 24-JUL-2001.
XX
XX 03-OCT-1997; 97US-0943731.
XX
XX 03-DEC-1991; 91US-0803628.
XX 13-MAR-1994; 94US-0212322.
XX

```


PA (UYAL-) UNIV ALLEGHENY HEALTH SCI.
 PA (UYOE-) UNIV JEFFERSON THOMAS.
 PA (UYOU-) UNIV OULU.
 XX
 PI Prockop DJ, Spotila LD, Deltas CD, Sareda L, Westerhausen Larson A;
 PI Pack M, Collge A, Early J, Koerkke J, Ala-kokko L, Annunen S;
 PI Pihlajamaa T, Vuorisalo M, Paasilta P;
 XX
 DR MPI; 2001-432201/46.
 XX
 PT Detecting collagen gene alteration, useful for diagnosing osteoporosis,
 PT multiple epiphyseal dysplasia, osteogenesis imperfecta, shortness of
 PT stature and low bone density in humans -
 XX
 PS Claim 8; Fig 24; 617pp; English.
 XX
 CC The invention relates to Detecting a collagen gene alteration associated
 CC with a pathological condition in a human subject by obtaining from the
 CC subject a sample nucleic acid containing a portion of at least 15
 CC consecutive nucleotides of the segment of the COL1A1 gene extending in
 CC the 5' to 3' direction from 78 nucleotides of intron 27 located adjacent
 CC exon 28 through the 3' end of intron 51, where the portion contains an
 CC intronic nucleotide and a first and second site, determining the sequence
 CC of the portion and comparing the sequence of the portion with the
 CC corresponding consensus sequence of the COL1A1 gene where a difference
 CC between the sequence of the portion and the consensus sequence indicates
 CC the presence of the collagen alteration in the subject. The method is
 CC used for detecting abnormalities in a COL1 or COL9 gene is useful for
 CC determining whether a subject is afflicted with pathological conditions
 CC associated with an altered collagen gene such as osteoporosis, multiple
 CC epiphyseal dysplasia, osteogenesis imperfecta, shortness of stature and
 CC low bone density. Identification of an abnormality in a collagen gene is
 CC also useful for designing a therapeutic nucleotide or gene therapy agent
 CC which can be administered to the subject to correct or alleviate the
 CC abnormality. The method is useful for detecting mutations in both the
 CC coding and non-coding sequences of any of the COL1 or COL9 genes.
 CC Therefore the method can be used to detect collagen gene alterations
 CC which affect either the primary sequence of a collagen protein chain,
 CC splicing of the mRNA encoding such chains or regulation of expression of
 CC the genes encoding such chains. The present sequence is a PCR primer
 CC which amplifies a nucleic acid from a collagen gene of the invention.
 XX
 SQ Sequence 22 BP; 7 A; 5 C; 8 G; 2 T; 0 other;
 Query Match 1.2%; Score 15.4; DB 1; Length 22;
 Best Local Similarity 94.1%; Pred. No. 1.7e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 421 CAGTGAAGATGCCAGTG 437
 DB 1 CAGTGAAGATGCCAGAG 17
 RESULT 84
 AAQ32809/c
 ID AAQ32809 standard; DNA; 20 BP.
 XX
 AC AAQ32809;
 XX
 DT 25-MAR-2003 (updated)
 DT 05-MAY-1993 (first entry)
 XX
 DE Microsatellite repeat polymorphic DNA marker PCR primer.
 XX
 KW PIC; high polymorphism information content; forensic; screening;
 KW polymerase chain reaction; genetic mapping; paternity; prenatal.
 XX
 OS Synthetic.
 XX
 FN WO9221693-A1.
 XX
 PD 10-DEC-1992.
 XX

PF 27-MAY-1992; 92WO-US04195.
 XX
 PR 29-MAY-1991; 91US-0707501.
 PR 27-NOV-1991; 91US-0799828.
 XX
 PA (USSH) US DEPT HEALTH & HUMAN SERVICE.
 XX
 PI Merrill CR, Polymeropoulos MH;
 XX
 DR MPI; 1992-433606/52.
 XX
 PT Oligo-nucleotide primers for polymerase chain reaction
 PT amplification - which detect DNA polymorphisms and are useful for
 PT prenatal and paternity screening, and genetic mapping
 XX
 PS Disclosure; Fig 29; 44pp; English.
 XX
 CC This is a PCR primer which is used (with AAQ32808) to characterise
 CC a unique microsatellite repeat polymorphic DNA marker which has a
 CC high polymorphism information content. The marker is useful for
 CC human individualisation, in forensic screening, in paternity and
 CC prenatal screening as well as in genetic mapping.
 CC (Updated on 25-MAR-2003 to correct PN field.)
 XX
 SQ Sequence 20 BP; 4 A; 3 C; 7 G; 6 T; 0 other;
 Query Match 1.2%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.7e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 OY 427 AGATGCCAGTGAAACTTCAA 446
 DB 20 ACATGCCAGTGACACTTCCA 1
 RESULT 85
 AAQ57832/c
 ID AAQ57832 standard; DNA; 20 BP.
 XX
 AC AAQ57832;
 XX
 DT 25-MAR-2003 (updated)
 DT 21-AUG-1994 (first entry)
 XX
 XX Primer pair 10A CD-19 detection primer #2.
 XX
 KW Primer; assay; subtle difference; dinucleotide; tetranucleotide;
 KW repeat; polymorphism; PCR; polymerase chain reaction; amplify; PAGE;
 KW autoradiography; migration pattern; length variation; genetic mapping;
 KW forensic screening; paternity; prenatal; screening; microsatellite;
 KW human; ss.
 XX
 OS Synthetic.
 XX
 FN WO9403640-A1.
 XX
 PD 17-FEB-1994.
 XX
 PF 30-JUL-1993; 93WO-US07183.
 XX
 PR 31-JUL-1992; 92US-0922723.
 PR 28-SEP-1992; 92US-0952277.
 XX
 PA (USSH) US DEPT HEALTH & HUMAN SERVICES.
 XX
 PI Merrill CR, Polymeropoulos MH;
 XX
 DR MPI; 1994-065727/08.
 XX
 FT New polynucleotide sequences - derived from polymorphic
 FT microsatellite repeats, used for characterising human
 FT individuals for forensic, paternity and prenatal screening and
 FT genetic mapping

XX PS Disclosure; Page 39; 72pp; English.

XX CC The sequences given in AAQ57782-866 are primers which were used in

XX CC an assay for measuring the subtle differences in genetic material

XX CC regarding an added or omitted set of dinucleotide or tetranucleotide

XX CC repeat polymorphisms. The method comprises obtaining polynucleotide

XX CC segments comprising the repeat polymorphisms in an amount effective

XX CC for testing and amplifying the segments by a PCR procedure using a

XX CC pair of oligonucleotide primers capable of amplifying the polymorphism

XX CC containing sequence. The amplified sequences are resolved using PAGE

XX CC and the resolved sequences are compared by autoradiography to observe

XX CC the differences in migration pattern due to length variation. The

XX CC polynucleotides provide a fast and accurate test for measuring the

XX CC subtle differences in individuals in eg. forensic screening, paternity

XX CC and prenatal screening and genetic mapping. The polynucleotides are

XX CC specific for polymorphic microsatellite repeats based on previously

XX CC sequenced human genes.

XX CC (Updated on 25-MAR-2003 to correct PN field.)

SQ Sequence 20 BP; 4 A; 3 C; 7 G; 6 T; 0 other;

Query Match 1.2%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 1.7e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 427 AGATGCCAGTGAACCTTCAA 446

DB 20 ACATGCCAGTGAACCTTCAA 1

RESULT 86

ABS67914/C

ID ABS67914 standard; DNA; 20 BP.

AC ABS67914;

XX 29-NOV-2002 (first entry)

DT Human/mouse casein kinase 2-alpha prime antisense oligonucleotide #62.

DE Human; mouse; casein kinase 2-alpha prime; diabetes mellitus;

XX hyperproliferative disorder; breast cancer; prostate cancer;

XX liver cancer; infection; inflammation; tumour formation;

XX cytosolic; antidiabetic; antiinflammatory; antimicrobial;

XX phosphorothioate; antisense therapy; ss.

OS Homo sapiens.

OS Mus musculus.

XX WO200262951-A2.

PN 15-AUG-2002.

XX 01-FEB-2002; 2002WO-US02772.

XX 08-FEB-2001; 2001US-0780173.

XX (ISIS-) ISIS PHARM INC.

XX McKay R, Freier SM, Wyatt JR;

XX WPI; 2002-627539/67.

XX New antisense oligonucleotides targeted to nucleic acid encoding casein

XX kinase 2-alpha prime, useful for diagnosing and/or treating a disease

XX or condition associated with expression of casein kinase 2-alpha prime

XX

XX Example 15; Page 96; 129pp; English.

XX The present invention relates to antisense oligonucleotides and

XX methods for modulating the expression of human or mouse casein

CC kinase 2-alpha prime. The antisense oligonucleotides are useful

CC for inhibiting the expression of casein kinase 2-alpha prime, and

CC for treating diseases or conditions associated with aberrant

CC expression of casein kinase 2-alpha prime. Such diseases include

CC diabetes mellitus, and hyperproliferative disorders (particularly

CC cancers e.g. breast cancer, prostate cancer, or liver cancer).

CC The antisense compounds are also useful for diagnostics,

CC therapeutics, prophylaxis, e.g. to prevent or delay infection,

CC inflammation or tumour formation, as research reagents and kits,

CC and in distinguishing between functions of various members of a

CC biological pathway. ABS67840-ABS67917 represent human or mouse

CC casein kinase 2-alpha prime antisense oligonucleotides which

CC comprise a phosphorothioate backbone.

XX Sequence 20 BP; 9 A; 3 C; 0 G; 8 T; 0 other;

SQ

Query Match 1.2%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 1.7e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 633 ATTATTGAATATAAGGATTT 652

DB 20 ATTATTGAATATAAGGATTT 1

RESULT 87

ABK85435

ID ABK85435 standard; DNA; 20 BP.

AC ABK85435;

XX 14-AUG-2002 (first entry)

DT Oligonucleotide #13 binding to specific site of HIV-1 RNA.

DE Human immunodeficiency virus type 1; HIV-1 detection method;

XX primer; probe; ss.

XX Human immunodeficiency virus type 1.

OS BP1203826-A2.

PN 08-MAY-2002.

XX 30-OCT-2001; 2001EP-0125378.

XX 30-OCT-2000; 2000JP-0334937.

XX (TOYJ) TOSOH CORP.

XX Ishizuka T, Ishiguro T, Saitoh J;

XX WPI; 2002-473032/51.

XX An oligonucleotide useful for detection of an RNA derived from HIV-1 in

XX clinical tests and diagnosis -

XX Claim 1; Page 16; 34pp; English.

XX The present invention relates to oligonucleotides binding to specific

XX sites of human immunodeficiency virus type 1 (HIV-1) RNA. The

XX oligonucleotides are useful for detecting HIV-1 in clinical tests

XX and diagnosis. The oligonucleotides provide simple, speedy and

XX sensitive detection of HIV-1 RNA which can bind to an intramolecularly

XX free region of the genomic RNA of HIV-1 at relatively low and constant

XX temperatures. The detection method comprises synthesising a cDNA by

XX the action of an RNA-dependent DNA polymerase by using a specific

XX sequence in an RNA derived from HIV-1 anticipated in a sample as a

XX template, a first primer containing a sequence complementary to the

XX specific sequence and a second primer containing a sequence homologous

XX to the specific sequence (either of which additionally has a promoter

XX sequence for the RNA polymerase at the 5' end). ABK85423-ABK85440

XX represent oligonucleotides binding to specific sites of HIV-1 RNA.

CC They can be used either as first primers or probes.

XX Sequence 20 BP; 6 A; 2 C; 0 G; 12 T; 0 other;
SQ
Query Match 1.2%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.7e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1476 ATTCTTATATATTATTAA 1495
|||||
Db 1 ATTCTTACTATTATTATTAA 20

RESULT 88

AAQ20077/c
ID AAQ20077 standard; DNA; 21 BP.
XX
AC AAQ20077;
XX
DT 25-MAR-2003 (updated)
DT 24-MAR-1992 (first entry)
XX
DE HIV-1 DNA probe (gag region).
XX
XX Styrene glycol; reagent; spacer; polymer; primer; probe; ss.
XX
OS Synthetic.
XX
PN EP462644-A.
XX
PD 27-DEC-1991.
XX
PF 10-JUN-1991; 91EP-0201420.
XX
PR 18-JUN-1990; 90US-0539774.
XX
XX (EAST) EASTMAN KODAK CO.
PA (CLIN-) CLINICAL DIAGNOSTIC SYSTEMS INC.
PA (JOHJ) JOHNSON & JOHNSON CLINICAL DIAGNOSTICS INC.
XX
PI Sutton RC, Danielson SJ, Findlay JB, Oakes FT, Oenick MDB;
PI Ponticello IS, Warren HC;
XX
DR WPI; 1992-001022/01.
XX
XX Insoluble particles of copolymer with reactive surface carboxy
FT sps. - derived from monomers with long spacer between carboxy and
FT unsaturated site, covalently attached to biological cpd.
XX
PS Example 12; Page 23; 53pp; English.
XX

CC The 5' end comprises an ethylene glycol spacer which has been
CC attached according to US-A-4914210. The sequence is complementary
CC to a portion of HIV-1 DNA in the gag region. The oligonucleotide was
CC covalently bound to polymeric particles and used in nucleic assays
CC to detect HIV-1 DNA, beta-globin DNA or both.
CC Primers used in the amplification of HIV-1 and beta-globin DNA are
CC represented in Q2078-81.
CC See also AAQ20075-95.
CC (Updated on 25-MAR-2003 to correct PA field.)
XX
SQ Sequence 21 BP; 13 A; 0 C; 2 G; 6 T; 0 other;

Query Match 1.2%; Score 15.2; DB 1; Length 21;
Best Local Similarity 85.0%; Pred. No. 1.8e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1476 ATTCTTATATATTATTAA 1495
|||||
Db 21 ATTCTTACTATTATTATTAA 2

RESULT 89

AAQ20043
ID AAQ20043 standard; DNA; 21 BP.
XX
AC AAQ20043;
XX
DT 01-APR-1992 (first entry)
XX
DE Cross-linking oligomer 505 for targeting human IL-2 receptor gene.
XX
XX deoxyribonucleic acid; major groove; ethanoamino group;
KW interleukin; IL-2R; aziridinylcytosine; cross-linking group; ss.
XX
OS Synthetic.
XX
XX
PH Key Location/Qualifiers
FT modified_base 1
FT /*tag= a
FT /mod_base= OTHER
FT /note= "N4N4-ethanocytosine"
FT modified_base 2
FT /*tag= b
FT /mod_base= OTHER
FT /note= "N-methyl-8-oxo-2'-deoxyadenine"
FT modified_base 5
FT /*tag= c
FT /mod_base= OTHER
FT /note= "N-methyl-8-oxo-2'-deoxyadenine"
FT modified_base 6
FT /*tag= d
FT /mod_base= OTHER
FT /note= "N-methyl-8-oxo-2'-deoxyadenine"
FT modified_base 10
FT /*tag= e
FT /mod_base= OTHER
FT /note= "N-methyl-8-oxo-2'-deoxyadenine"
FT modified_base 14
FT /*tag= f
FT /mod_base= OTHER
FT /note= "N-methyl-8-oxo-2'-deoxyadenine"
FT modified_base 17
FT /*tag= g
FT /mod_base= OTHER
FT /note= "N-methyl-8-oxo-2'-deoxyadenine"
FT modified_base 18
FT /*tag= h
FT /mod_base= OTHER
FT /note= "N-methyl-8-oxo-2'-deoxyadenine"
FT modified_base 21
FT /*tag= i
FT /mod_base= OTHER
FT /note= "N-methyl-8-oxo-2'-deoxyadenine"
FT
XX W09118997-A.
XX
XX 12-DEC-1991.
PD
XX 24-MAY-1991; 91WO-1003680.
XX
XX 14-JAN-1991; 91US-0640654.
XX
XX 25-MAY-1990; 90US-0529346.
XX
XX (GILB-) GILB- SCIE INC.
XX
XX Matteucci MD, Krawczyk S;
XX
XX WPI; 1992-007480/01.
XX
XX New sequence-specific non-photo-activated crosslinking agents -
PT bind to the major groove of duplex DNA and are esp. useful for
PT treating latent infections e.g. HIV
XX
PS Example 4; Page 26; 42pp; English.
XX

```
CC The oligomer is an example of several which were designed to target
CC the Human interleukin-2 receptor gene, the exon 8 target and
CC flanks, specifically beginning at nucleotide 1114, and to covalently
CC cross-link to the target via the N4N4-ethanocytosine group.
CC See also AAQ20041-Q20045.
XX
SQ Sequence 21 BP; 8 A; 1 C; 0 G; 12 T; 0 other;

  Query Match      1.2%; Score 15.2; DB 1; Length 21;
  Best Local Similarity 85.0%; Pred. No. 1.8e+02;
  Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1031 ATTAACCTATTATTATTATTA 1050
Db 2 ATTAATTATTATTATTATTA 21

RESULT 91
AAQ30406
ID AAQ30406 standard; DNA; 21 BP.
XX
AC AAQ30406;
XX
DT 25-MAR-2003 (updated)
DT 07-DEC-1992 (first entry)
XX
XX Oligomer IL2R503 for forming triplex with HUMIL2 receptor target duplex.
XX
XX Human interleukin- 2 receptor gene; HUMIL2R8; herpes simplex; AIDS;
XX modified; HIV; RSV; HPV; malignancy; hepatitis; inflammation; ss.
XX
XX Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1 /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= N6 methyl-8-oxo 2' deoxyadenine"
FT
FT modified_base 2 /*tag= b
FT /mod_base= OTHER
FT /note= "OTHER= N6 methyl-8-oxo 2' deoxyadenine"
FT
FT modified_base 5 /*tag= c
FT /mod_base= OTHER
FT /note= "OTHER= N6 methyl-8-oxo 2' deoxyadenine"
FT
FT modified_base 6 /*tag= d
FT /mod_base= OTHER
FT /note= "OTHER= N6 methyl-8-oxo 2' deoxyadenine"
FT
FT modified_base 10 /*tag= e
FT /mod_base= OTHER
FT /note= "OTHER= N6 methyl-8-oxo 2' deoxyadenine"
FT
FT modified_base 14 /*tag= f
FT /mod_base= OTHER
FT /note= "OTHER= N6 methyl-8-oxo 2' deoxyadenine"
FT
FT modified_base 17 /*tag= g
FT /mod_base= OTHER
FT /note= "OTHER= N6 methyl-8-oxo 2' deoxyadenine"
FT
FT modified_base 18 /*tag= h
FT /mod_base= OTHER
FT /note= "OTHER= N6 methyl-8-oxo 2' deoxyadenine"
FT
FT modified_base 21 /*tag= i
FT /mod_base= OTHER
FT /note= "OTHER= N6 methyl-8-oxo 2' deoxyadenine"
FT
XX
XX W09209705-A1.
XX
```

```
PD 11-JUN-1992.
XX
PF 25-NOV-1991; 91WO-US08811.
XX
PR 23-NOV-1990; 90US-0617907.
PR 18-JAN-1991; 91US-0643382.
PR 08-APR-1991; 91US-0683420.
PR 17-APR-1991; 91US-0686544.
PR 17-APR-1991; 91US-0686546.
PR 17-APR-1991; 91US-0686547.
PR 27-SEP-1991; 91US-0766733.
XX
XX (GILE-) GILEAD SCI INC.
XX
XX Froehler B, Krawczyk S, Matteucci MD, Milligan J;
XX WPI; 1992-217083/26.
XX
XX New oligomers contg. modified bases - which form a triplex with
XX G-C doublet in a DNA duplex, for treating and diagnosing HIV,
XX hepatitis, herpes, malignancy and inflammation
XX
XX Claim 12; Page 71; 77pp; English.
XX
XX The synthetic oligomer is capable of forming a triplex at
XX physiological pH with a purine rich target sequence by coupling
XX into the major groove of the duplex. The specific target sequence
XX of this oligomer is the human interleukin-2 receptor gene exon 8
XX target and flanks beginning at nucleotide 1114 contg. a purine rich
XX sequence contd. on one strand of the duplex. The oligomer, and others
XX like it are useful in diagnosis and therapy of diseases characterised
XX by specific DNA duplex targets, e.g. HPV, HEP; HIV, hepatitis B, herpes,
XX malignant tumours and inflammation. The triple helices form under mild
XX conditions thus assays may be carried out without subjecting the test
XX specimen to harsh conditions.
XX See also AAQ25452-25501 and AAQ30226-448.
XX (Updated on 25-MAR-2003 to correct PN field.)
XX
XX Sequence 21 BP; 9 A; 0 C; 0 G; 12 T; 0 other;
SQ
  Query Match      1.2%; Score 15.2; DB 1; Length 21;
  Best Local Similarity 85.0%; Pred. No. 1.8e+02;
  Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1031 ATTAACCTATTATTATTATTA 1050
Db 2 ATTAATTATTATTATTATTA 21

RESULT 91
AAQ30408
ID AAQ30408 standard; DNA; 21 BP.
XX
AC AAQ30408;
XX
DT 25-MAR-2003 (updated)
DT 07-DEC-1992 (first entry)
XX
XX Oligomer IL2R505 for forming triplex with HUMIL2 receptor target duplex.
XX
XX Human interleukin- 2 receptor gene; HUMIL2R8; herpes simplex; AIDS;
XX modified; HIV; RSV; HPV; malignancy; hepatitis; inflammation; ss.
XX
XX Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1 /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= N4 N4 ethanocytosine"
FT
FT modified_base 2 /*tag= b
FT /mod_base= OTHER
FT
```


XX nosocomial infection; screening; hybridisation probe; ortholog; ss.
XX Synthetic.
OS Moraxella catarrhalis.
XX
XX
XX WO964448-A2.
XX
XX 16-DEC-1999.
XX
XX 31-MAY-1999; 99WO-EP03823.
XX
XX 05-JUN-1998; 98GB-0012163.
XX
XX (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.
XX
XX Ruelle J, Tommassen JPM, Vinals-Basseols C;
XX
XX WPI; 2000-116523/10.
XX
XX Novel polypeptides used as vaccines for treating Moraxella catarrhalis
XX infections like otitis media and pneumonia -
XX
XX Example 1; Page 49; 121pp; English.
XX
XX The present sequence is the PCR Primer E475783, used for amplification
XX of the BASB031 genomic DNA. This is done to experimentally confirm the
XX sequence of BASB031 gene, from Moraxella catarrhalis, strain ATCC 43617.
XX
XX Sequence 21 BP; 8 A; 5 C; 2 G; 6 T; 0 other;
XX
Query Match 1.2%; Score 15.2; DB 1; Length 21;
Best Local Similarity 85.0%; Pred. No. 1.8e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1420 ACAGTCATATATTAGTAATT 1439
DB 20 ACTGTCATATGGTAATT 1
RESULT 94
AAAF74938
ID AAF74938 standard; DNA; 21 BP.
XX
XX AAF74938;
XX
XX 23-MAY-2001 (first entry)
XX
XX Human CD40L promoter sequence PCR primer Pad3 SEQ ID NO:35.
XX
XX Human; CD40L; promoter; CD40 ligand promoter; rheumatoid arthritis;
XX diagnosis; antiarthritis; antirheumatic; immunosuppressive;
XX antinflammatory; inflammatory disease; autoimmune disease;
XX PCR primer; ss.
XX
XX Homo sapiens.
XX
XX WO200119844-A1.
XX
XX 22-MAR-2001.
XX
XX 13-SEP-2000; 2000WO-US24966.
XX
XX 13-SEP-1999; 99US-0153625.
XX
XX (NYRE-) NEW YORK SOC RELIEF RUPTURED & CRIPPLED.
XX
XX Crow MK, Li Y;
XX
XX WPI; 2001-244776/25.
XX
XX New altered CD40L promoter for use in the study, diagnosis and
XX treatment of a variety of inflammatory disorders and autoimmune
XX diseases, such as rheumatoid arthritis -

XX Example 1; Fig 2; 90pp; English.
XX
XX The present invention describes an isolated, purified nucleic acid,
XX which is an altered CD40 ligand (CD40L) promoter (I) for CD40 ligand,
XX having residues 331-455 of the sequence comprising 455 nucleotides given
XX in AAF74905 where A in the wild type sequence at position 331
XX (corresponding to position -125) is replaced with C. (I) has
XX antiarthritis, antirheumatic, immunosuppressive and antinflammatory
XX activities, and can be used in gene therapy. (I) is useful in the study,
XX diagnosis and treatment of inflammatory and autoimmune diseases, as well
XX as diseases in which elevated expression of CD40L is a factor,
XX e.g., rheumatoid arthritis. The present sequence represents a PCR primer
XX for the human CD40L promoter sequence, which is used in an example from
XX the present invention.
XX
XX Sequence 21 BP; 5 A; 4 C; 2 G; 10 T; 0 other;
XX
Query Match 1.2%; Score 15.2; DB 1; Length 21;
Best Local Similarity 85.0%; Pred. No. 1.8e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1450 GAACTTCTTTATTATGTAC 1469
DB 2 GAACTTCTTTCTTCTTTAC 21
RESULT 95
ABL46344
ID ABL46344 standard; DNA; 15 BP.
XX
XX ABL46344;
XX
XX 26-APR-2002 (first entry)
XX
XX Human interleukin-1 beta oligonucleotide SEQ ID NO:311.
XX
XX Nucleic acid accessible hybridisation site; detection; hybridisation;
XX characterisation; identification; nucleic acid structure; diagnosis;
XX PCR primer; probe; ss.
XX
XX Homo sapiens.
XX
XX Synthetic.
XX
XX WO200198537-A2.
XX
XX 27-DEC-2001.
XX
XX 15-JUN-2001; 2001WO-US19401.
XX
XX 17-JUN-2000; 2000US-212308P.
XX
XX 15-JUN-2001; 2001US-0212308.
XX
XX (THIR-) THIRD WAVE TECHNOLOGIES INC.
XX
XX Iyamichev V, Allawi H, Dong P, Neri BP, Vener IT;
XX
XX WPI; 2002-049698/06.
XX
XX Identifying oligonucleotides hybridizing to nucleic acids containing
XX secondary structure, useful in clinical diagnosis, comprises
XX identifying primers that interact with the target to form an extension
XX product under amplification conditions -
XX
XX Claim 48; Fig 81A; 409pp; English.
XX
XX The present invention describes a method for identifying oligonucleotides
XX with desired hybridisation properties to nucleic acid targets containing
XX secondary structure. The method comprises amplifying a target nucleic
XX acid having at least one accessible and one inaccessible site. Primers
XX that form an extension product are identified as the oligonucleotides
XX which can interact with the folded target nucleic acid. Oligonucleotides
XX from the present invention can be used in novel detection methods for

CC clinical diagnostic purposes, including the detection and identification
 CC of pathogenic organisms (e.g. HIV). The method allows the ability to
 CC rapidly analyse nucleic acid structures. ABL46034 to ABL46367 represent
 CC sequences used in the exemplification of the present invention.

XX Sequence 15 BP; 2 A; 6 C; 3 G; 4 T; 0 other;

SQ Query Match 1.2%; Score 15; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 856 CCTAGTCTGCTAGC 870

Db 1 CCTAGTCTGCTAGC 15

RESULT 96

ABN07608

ID ABN07608 standard; DNA; 17 BP.

XX AC ABN07608;

XX XX 29-MAY-2002 (first entry)

XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7600.

XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; ampiclon; screening; ss.

XX OS Homo sapiens.

XX XX WO200192524-A2.

XX XX 06-DEC-2001.

XX XX 25-MAY-2001; 2001WO-US16981.

XX XX 26-MAY-2000; 2000US-207456P.

XX XX 21-SEP-2000; 2000US-234687P.

XX XX 27-SEP-2000; 2000US-236359P.

XX XX 04-OCT-2000; 2000GB-0024263.

XX XX 30-JAN-2001; 2001WO-US00661.

XX XX 30-JAN-2001; 2001WO-US00662.

XX XX 30-JAN-2001; 2001WO-US00663.

XX XX 30-JAN-2001; 2001WO-US00664.

XX XX 30-JAN-2001; 2001WO-US00665.

XX XX 30-JAN-2001; 2001WO-US00666.

XX XX 30-JAN-2001; 2001WO-US00667.

XX XX 30-JAN-2001; 2001WO-US00668.

XX XX 30-JAN-2001; 2001WO-US00669.

XX XX 05-FEB-2001; 2001US-266860P.

XX XX (ABOM-) ABOMICA INC.

XX XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;

XX XX WPI; 2002-179446/23.

XX XX New polypeptide, for raising antibodies that recognize hGDMPLP-1

XX XX proteins, or as specific biomolecule capture probes for human

XX XX surface-enhanced laser desorption/ionization, comprises human

XX XX myosin-like protein hGDMPLP-1 -

XX XX Disclosure; SEQ ID 7600; 214pp; English.

XX XX The present invention describes a human genome-derived myosin-like

XX XX protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of

XX XX hGDMPLP-1 can be used in gene therapy and vaccine production. The

XX XX hGDMPLP-1 nucleic acids can be used as probes to detect, characterise

XX XX and quantify hGDMPLP-1 nucleic acids in samples, as amplification

XX XX substrates, to provide initial substrates for the recombinant engineering

CC of hGDMPLP-1 protein variants having desired phenotypic improvements, and
 CC for expressing the proteins. The hGDMPLP-1 proteins or polypeptides may
 CC be used as immunogens to raise antibodies that specifically recognise
 CC hGDMPLP-1 proteins, as standards in assays used to determine the
 CC concentration and/or amount specifically of hGDMPLP proteins, as specific
 CC biomolecule capture probes for surface-enhanced laser desorption
 CC ionisation, as therapeutic supplement in patients having specific
 CC deficiency in hGDMPLP-1 production, and in vaccines or for replacement
 CC therapy. The polynucleotide sequences encoding hGDMPLP-1 may be used for
 CC diagnosing a disorder associated with the expression of hGDMPLP-1, in
 CC particular heart and skeletal muscle disorders. hGDMPLP-1 is localised to
 CC chromosome 22. The present sequence represents an oligomer used in the
 CC screening of the hGDMPLP-1 sequence in the exemplification of the present
 CC invention.
 CC N.B. The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence.

XX SQ Sequence 17 BP; 3 A; 7 C; 2 G; 5 T; 0 other;

Query Match 1.2%; Score 15; DB 1; Length 17;

Best Local Similarity 100.0%; Pred. No. 1.5e+02;

Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 939 GCCACCATCTTACT 953

Db 3 GCCACCATCTTACT 17

RESULT 97

ABN07609

ID ABN07609 standard; DNA; 17 BP.

XX AC ABN07609;

XX XX 29-MAY-2002 (first entry)

XX XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7601.

XX XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; ampiclon; screening; ss.

XX OS Homo sapiens.

XX XX WO200192524-A2.

XX XX 06-DEC-2001.

XX XX 25-MAY-2001; 2001WO-US16981.

XX XX 26-MAY-2000; 2000US-207456P.

XX XX 21-SEP-2000; 2000US-234687P.

XX XX 27-SEP-2000; 2000US-236359P.

XX XX 04-OCT-2000; 2000GB-0024263.

XX XX 30-JAN-2001; 2001WO-US00661.

XX XX 30-JAN-2001; 2001WO-US00662.

XX XX 30-JAN-2001; 2001WO-US00663.

XX XX 30-JAN-2001; 2001WO-US00664.

XX XX 30-JAN-2001; 2001WO-US00665.

XX XX 30-JAN-2001; 2001WO-US00666.

XX XX 30-JAN-2001; 2001WO-US00667.

XX XX 30-JAN-2001; 2001WO-US00668.

XX XX 30-JAN-2001; 2001WO-US00669.

XX XX 05-FEB-2001; 2001US-266860P.

XX XX (ABOM-) ABOMICA INC.

XX XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;

XX XX WPI; 2002-179446/23.

PT New polypeptide, for raising antibodies that recognize hGDMPLP-1
PT proteins, or as specific biomolecule capture probes for
PT surface-enhanced laser desorption/ionization, comprises human
PT myosin-like protein hGDMPLP-1 -
XX
XX Disclosure; SEQ ID 7601; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of
CC hGDMPLP-1 can be used in gene therapy and vaccine production. The
CC hGDMPLP-1 nucleic acids can be used as probes to detect, characterise
CC and quantify hGDMPLP-1 nucleic acids in samples, as amplification
CC substrates, to provide initial substrates for the recombinant engineering
CC of hGDMPLP-1 protein variants having desired phenotypic improvements, and
CC for expressing the proteins. The hGDMPLP-1 proteins or polypeptides may
CC be used as immunogens to raise antibodies that specifically recognise
CC hGDMPLP-1 proteins, as standards in assays used to determine the
CC concentration and/or amount specifically of hGDMPLP proteins, as specific
CC biomolecule capture probes for surface-enhanced laser desorption
CC ionisation, as therapeutic supplement in patients having specific
CC deficiency in hGDMPLP-1 production, and in vaccines or for replacement
CC therapy. The polynucleotide sequences encoding hGDMPLP-1 may be used for
CC diagnosing a disorder associated with the expression of hGDMPLP-1, in
CC particular heart and skeletal muscle disorders. hGDMPLP-1 is localised to
CC chromosome 22. The present sequence represents an oligomer used in the
CC screening of the hGDMPLP-1 sequence in the exemplification of the present
CC invention.
CC N.B. The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence.
XX
XX Sequence 17 BP; 3 A; 7 C; 2 G; 5 T; 0 other;
XX
XX Query Match 1.2%; Score 15; DB 1; Length 17;
XX Best Local Similarity 100.0%; Pred. No. 1.5e+02;
XX Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 939 GCCACCATCTTACCT 953
DB 2 GCCACCATCTTACCT 16
XX
RESULT 98
ABN07610
ID ABN07610 standard; DNA; 17 BP.
XX
XX AC ABN07610;
XX
XX 29-MAY-2002 (first entry)
XX
XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7602.
XX
XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
XX muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX skeletal muscle disorder; amplicon; screening; ss.
XX
XX Homo sapiens.
XX
XX WO2001192524-A2.
XX
XX 06-DEC-2001.
XX
XX 25-MAY-2001; 2001WO-US16981.
XX
XX 26-MAY-2000; 2000US-207456P.
XX 21-SEP-2000; 2000US-234687P.
XX 27-SEP-2000; 2000US-236359P.
XX 04-OCT-2000; 2000GB-0024263.
XX 30-JAN-2001; 2001WO-US00661.
XX 30-JAN-2001; 2001WO-US00662.
XX 30-JAN-2001; 2001WO-US00663.
XX 30-JAN-2001; 2001WO-US00664.
XX 30-JAN-2001; 2001WO-US00665.
XX
XX 30-JAN-2001; 2001WO-US00666.
XX 30-JAN-2001; 2001WO-US00667.
XX 30-JAN-2001; 2001WO-US00668.
XX 30-JAN-2001; 2001WO-US00669.
XX 30-JAN-2001; 2001WO-US00670.
XX 05-FEB-2001; 2001US-268860P.
XX
XX (ABOM-) ABOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1
PT proteins, or as specific biomolecule capture probes for
PT surface-enhanced laser desorption/ionization, comprises human
PT myosin-like protein hGDMPLP-1 -
XX
XX Disclosure; SEQ ID 7602; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of
CC hGDMPLP-1 can be used in gene therapy and vaccine production. The
CC hGDMPLP-1 nucleic acids can be used as probes to detect, characterise
CC and quantify hGDMPLP-1 nucleic acids in samples, as amplification
CC substrates, to provide initial substrates for the recombinant engineering
CC of hGDMPLP-1 protein variants having desired phenotypic improvements, and
CC for expressing the proteins. The hGDMPLP-1 proteins or polypeptides may
CC be used as immunogens to raise antibodies that specifically recognise
CC hGDMPLP-1 proteins, as standards in assays used to determine the
CC concentration and/or amount specifically of hGDMPLP proteins, as specific
CC biomolecule capture probes for surface-enhanced laser desorption
CC ionisation, as therapeutic supplement in patients having specific
CC deficiency in hGDMPLP-1 production, and in vaccines or for replacement
CC therapy. The polynucleotide sequences encoding hGDMPLP-1 may be used for
CC diagnosing a disorder associated with the expression of hGDMPLP-1, in
CC particular heart and skeletal muscle disorders. hGDMPLP-1 is localised to
CC chromosome 22. The present sequence represents an oligomer used in the
CC screening of the hGDMPLP-1 sequence in the exemplification of the present
CC invention.
CC N.B. The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence.
XX
XX Sequence 17 BP; 3 A; 7 C; 2 G; 5 T; 0 other;
XX
XX Query Match 1.2%; Score 15; DB 1; Length 17;
XX Best Local Similarity 100.0%; Pred. No. 1.5e+02;
XX Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 939 GCCACCATCTTACCT 953
DB 2 GCCACCATCTTACCT 16
XX
RESULT 99
AAQ55403
ID AAQ55403 standard; DNA; 20 BP.
XX
XX AC AAQ55403;
XX
XX 22-FEB-1994 (first entry)
XX
XX Acremonium chrysogenum beta-tubulin gene PCR primer TU-1.
XX
XX Beta tubulin; mutant; chemical resistance; selective marker;
XX cephalosporin; antibiotic production; Phage M13;
XX polymerase chain reaction; ds.
XX
XX Acremonium chrysogenum.
XX
XX JP05192157-A.
XX

PD 03-AUG-1993.
 XX
 PF 26-MAY-1992; 92JP-0133384.
 XX
 PR 27-MAY-1991; 91JP-0121276.
 XX
 PA (TAKE) TAKEDA CHEM IND LTD.
 XX
 DR WPI; 1993-277472/35.
 XX
 XX DNA fragment contg. DNA coding mutant beta-tubulin - originates
 PT from Acremonium chrysogenum, used as selective marker for
 PT transformation of A.chrysogenum
 XX
 XX Example 2; Fig 1; 16pp; Japanese.
 PS
 XX PCR primers TU-1 and TU-2 (AAQ55403 and AAQ55404, respectively) were
 CC used on A.chrysogenum DNA as a template to amplify a fragment of
 CC the beta-tubulin coding sequence. The amplified fragment was used
 CC as a probe to clone the full-length beta-tubulin sequence in M13.
 CC The positive insert from one recombinant phage (pTUS) was used as
 CC the template in a second PCR amplification, this time using primer
 CC TU-1 with the M13 primer M3 (AAQ48229). The wild-type coding sequence
 CC for beta-tubulin from Acremonium chrysogenum ATCC 11550 was
 CC subsequently sequenced (see AAQ48230).
 XX
 SQ Sequence 20 BP; 7 A; 4 C; 6 G; 1 T; 2 other;
 Query Match 1.2%; Score 15; DB 1; Length 20;
 Best Local Similarity 78.9%; Pred. No. 1.8e+02;
 Matches 15; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
 XX
 QY 687 AAAATTGGGCGCAAGGGCCA 705
 DB 2 ACACTGGGCGAGGGYCA 20
 RESULT 100
 AAQ79313
 ID AAQ79313 standard; DNA; 21 BP.
 XX
 AC AAQ79313;
 XX
 DT 25-MAR-2003 (updated)
 DT 23-JUN-1995 (first entry)
 XX
 XX Human c-raf-1 oncogene mRNA 2819-2798 antisense oligonucleotide DK-23.
 DE
 XX Antisense oligonucleotide; ras-activated cancer cells;
 KW anti-raf-1 oncogene; antisense inhibition of translation; ss.
 XX
 OS Synthetic.
 XX
 PN WO9423755-A1.
 XX
 PD 27-OCT-1994.
 XX
 XX 11-APR-1994; 94WO-US04091.
 PF
 XX 09-APR-1993; 93US-0045374.
 PR
 XX (UYNE-) UNIV NEBRASKA.
 PA
 XX Iversen PL;
 PI
 XX WPI; 1994-341496/42.
 DR
 XX New heterotypic anti-raf antisense oligonucleotide(s) - for
 PT killing ras-activated cancer cells.
 PT
 XX Disclosure; Page 61; 81pp; English.
 PS
 XX Anti-raf antisense oligonucleotides can be used to kill cancer cells
 CC

CC which contain an activated ras oncogene. This is one of a group of
 CC antisense oligonucleotides which are exemplified in the
 CC specification; they are 8-50 nucleotides long and are antisense to
 CC regions of the A-raf-1 or the c-raf-1 genes obtained from the
 CC "EUGENE" gene library.
 CC (Updated on 25-MAR-2003 to correct PN field.)
 XX
 SQ Sequence 21 BP; 14 A; 6 C; 0 G; 1 T; 0 other;
 Query Match 1.2%; Score 15; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 1.9e+02;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1207 AAACAACCAACCAAT 1221
 DB 6 AAACAACCAACCAAT 20
 RESULT 101
 AAV14087
 ID AAV14087 standard; DNA; 18 BP.
 XX
 AC AAV14087;
 XX
 DT 19-MAY-1998 (first entry)
 DT
 XX Probe HBPr253 for RT pol region of HBV.
 DE
 XX Probe; hepatitis b virus; HBV detection; RT pol region; genetic analysis;
 KW preCore region; HBsAg region; genotype specific target;
 KW mutation detection; ss.
 XX
 OS Synthetic.
 OS Hepatitis b virus.
 XX
 PN WO9740193-A2.
 XX
 PD 30-OCT-1997.
 XX
 XX 21-APR-1997; 97WO-EP02002.
 PF
 XX 19-APR-1996; 96EP-0870053.
 PR
 XX (INNO-) INNOGENETICS NV.
 PA
 XX Maertens G, Rosaau R, Stuyver L;
 PI WPI; 1997-535867/49.
 XX
 XX Detection and/or genetic analysis of hepatitis B virus -
 PT specifically genotype, preCore mutations, vaccine escape mutations
 PT and RT gene mutations selected by treatment with drugs
 XX
 XX Claim 5; Page 32; 80pp; English.
 PS
 XX This sequence represents a probe for the RT pol region of hepatitis
 CC b virus (HBV). This sequence can be used in the method of the invention
 CC for detection and/or genetic analysis of hepatitis B virus (HBV) in a
 CC sample. The method comprises: (a) optionally releasing, isolating or
 CC concentrating polynucleic acids (1) in the sample, and amplifying the
 CC relevant part of a suitable HBV gene in the sample with at least 1
 CC suitable primer pair; (b) hybridising (1) with a combination of at least
 CC 2 nucleotide probes, which are applied to known locations on a solid
 CC support and hybridise specifically to mutant target sequences chosen from
 CC the HBV RT pol gene region, HBV preCore region, HBsAg region and/or HBV
 CC genotype specific target sequences, or their complements or 1' for T
 CC homologues; (c) detecting the hybrids formed in step (b), and inferring
 CC the HBV genotype and/or mutants present in the sample from the
 CC differential hybridisation signal(s). The composition can be used to
 CC diagnose and/or monitor HBV mutants and/or genotypes in a sample,
 CC specifically genotype, preCore mutations, vaccine escape mutations and
 CC RT gene mutations selected by treatment with drugs, e.g. lamivudine and
 CC penciclovir.

XX SQ Sequence 18 BP; 8 A; 0 C; 3 G; 7 T; 0 other;

Query Match 1.2%; Score 14.8; DB 1; Length 18;
 Best Local Similarity 88.9%; Pred. No. 1.8e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1123 TATAAGATGTTATAGTA 1140
 |||||
 DB 1 TATATAGATGATATAGTA 18

RESULT 102
 AAX90243
 ID AAX90243 standard; DNA; 18 BP.
 AC AAX90243;
 XX
 DT 23-SEP-1999 (first entry)
 DE GRK4 allele specific probe #10.
 XX
 KW Human; antibody; G-protein-related kinase; GRK4; mutant; hypertension;
 XX probe; ss.
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN W09935279-A1.
 XX
 PD 15-JUL-1999.
 XX
 PF 12-JAN-1999; 99WO-US00663.
 XX
 PR 28-AUG-1998; 98US-0098279.
 PR 12-JAN-1998; 98US-0071199.
 XX
 XX (GEOU) UNIV GEORGETOWN MEDICAL CENT.
 PA (UYVI-) UNIV VIRGINIA PATENT FOUND.
 XX
 PI Felder R, Jose P;
 XX
 DR WPI; 1999-444199/37.
 XX
 PT G protein-coupled receptor kinase 4 mutants associated with
 essential hypertension, useful for identifying anti-hypertensive
 drugs
 XX
 PS Disclosure; Page 20; 54pp; English.
 XX
 CC The present invention describes an isolated nucleic acid molecule
 encoding a G protein-coupled receptor kinase (GRK) 4 protein having an
 R65L, A142V or R65L, A486 double mutation or an R65L, A142V, A486V
 triple mutation. A transgenic animal, comprising a diploid genome
 comprising a transgene encoding a GRK4 protein which is expressed in
 renal cells to produce the GRK4 protein, and where expression of the
 transgene causes the transgenic animal to exhibit a state of essential
 hypertension compared to a normotensive animal whose renal cells do not
 express the GRK4 protein. The transgenic animal, especially a mouse, is
 useful as a model for essential hypertension. The transgenic animal's
 renal cells have a decreased ability to reject sodium compared to a
 normotensive animal whose renal cells do not express GRK4. The animal
 model, and reconstituted whole cell system, can be used to identify
 putative anti-hypertensive agents. The GRK4 protein complex and
 immortalized kidney cell cultures can also be used to identify putative
 anti-hypertensive agents. Drugs, e.g. antisense GRK4 RNA, a GRK4
 ribozyme or a GRK4 dominant negative mutant DNA molecule, that interact
 with GRK4 can be used to increase natriuresis (decrease sodium
 transport) in essential hypertensive individuals. The present sequence
 represents a GRK4 allele specific probe from the present invention.
 XX
 XX Sequence 18 BP; 2 A; 3 C; 7 G; 6 T; 0 other;

Query Match 1.2%; Score 14.8; DB 1; Length 18;
 Best Local Similarity 88.9%; Pred. No. 1.8e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 484 TGTGTAGGCTTCCAGA 501
 |||||
 DB 1 TGTGTAGGCTTCCAGA 18

RESULT 103
 ABL55998
 ID ABL55998 standard; DNA; 18 BP.
 XX
 AC ABL55998;
 XX
 DT 17-JUN-2002 (first entry)
 DE Collagenase recognition site related PCR primer 2.
 XX
 KW Human; growth hormone; collagenase; recognition site; PCR; primer; ss.
 XX
 OS Synthetic.
 XX
 PN KR289691-B.
 XX
 PD 15-MAY-2001.
 XX
 PF 28-DEC-1993; 93KR-0030318.
 XX
 PR 28-DEC-1993; 93KR-0030318.
 XX
 PA (GLDS) LG CHEM LTD.
 XX
 PI Yoo JG, Song YH;
 XX
 DR WPI; 2002-185396/24.
 XX
 PT Recombinant human growth hormone having collagenase recognition region -
 XX
 PS Disclosure; Page 3; 8pp; Korean.
 XX
 CC The invention relates to recombinant human growth hormone having a
 collagenase recognition region. The present sequence is that of a PCR
 primer, useful to the invention.
 XX
 XX Sequence 18 BP; 7 A; 2 C; 2 G; 7 T; 0 other;

Query Match 1.2%; Score 14.8; DB 1; Length 18;
 Best Local Similarity 88.9%; Pred. No. 1.8e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1507 TTTAAATACAGGCTTTA 1524
 |||||
 DB 1 TTTAAATCCAGACTTTA 18

RESULT 104
 AAA82895/c
 ID AAA82895 standard; DNA; 19 BP.
 XX
 AC AAA82895;
 XX
 DT 04-DEC-2000 (first entry)
 DE cdk4 ribozyme binding site #76.
 XX
 KW Ribozyme; hairpin; hammerhead; gene therapy; vasotropic;
 XX restenosis; ss.
 XX
 OS Mammalia.
 XX
 PN W0200032765-A2.
 XX

PD 08-JUN-2000.
 XX PF 06-DEC-1999; 99WO-US28772.
 XX PR 04-DEC-1998; 98US-0110954.
 XX PA (IMMU-) IMMUSOL INC.
 XX PI Tritz R, Welch PJ, Barber JR, Robbins JM;
 XX WPI; 2000-412314/35.
 XX DR WPI; 2000-412314/35.
 XX PT New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
 XX RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
 XX PCNA and Cyclin B1
 XX PS Disclosure; Page 53; 109pp; English.
 XX CC The present invention relates to a hairpin or hammerhead ribozyme,
 XX designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
 XX other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
 XX CC Representative examples of ribozyme recognition sites are given in
 XX AA82415 to AA86787. The ribozyme of the invention is useful for
 XX inhibiting restenosis by introduction of the ribozyme into cells.
 XX CC The ribozyme is resistant to endonuclease activity and hence is
 XX efficient in restenosis treatment.
 XX SQ Sequence 19 BP; 2 A; 2 C; 8 G; 7 T; 0 other;
 Query Match 1.2%; Score 14.8; DB 1; Length 19;
 Best Local Similarity 88.9%; Pred. No. 1.9e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1404 AAACAGCCAAACTCCAC 1421
 DB 18 ATACAGCCAAACTCCAC 1
 RESULT 105
 AAH58057/C
 ID AAH58057 standard; DNA; 19 BP.
 XX AC AAH58057;
 XX DT 10-SEP-2001 (first entry)
 XX DE Cell-cycle dependent kinase cdk4 ribozyme binding site SEQ ID NO:481.
 KW Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
 KW recognition site; target; ribozyme binding site; eye disease; vulnary;
 KW proliferative disease; skin disease; psoriasis; diabetic retinopathy;
 KW cytokine; inflammation; cell-cycle dependent kinase; cyclin; WMP;
 KW matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;
 KW antiproliferative; dermatological; antiseborrheic; antidiabetic; virucide;
 KW antisickling; ophthalmological; keratolytic; gene therapy; viral wart;
 KW atopic dermatitis; actinic keratosis; squamous cell carcinoma;
 KW basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;
 KW sickle cell retinopathy; ss.
 XX OS Homo sapiens.
 XX OS Synthetic.
 XX FN WO200130362-A2.
 XX PD 03-MAY-2001.
 XX PF 26-OCT-2000; 2000WO-US29500.
 XX PR 26-OCT-1999; 99US-0161532.
 XX PA (IMMU-) IMMUSOL INC.
 XX PI Robbins JM, Tritz R;

XX WPI; 2001-300427/31.
 XX Treating proliferative skin or eye diseases and scarring, using
 XX ribozymes that cleave RNA encoding cytokines involved in inflammation,
 XX matrix metalloproteinases, growth factors and cell-cycle dependent
 XX kinases -
 XX Example 1; Page 107; 409pp; English.
 XX The present invention describes a method for treating a proliferative
 XX skin or eye disease and scarring. The method involves administering a
 XX ribozyme (I) which cleaves RNA encoding a cytokine involved in
 XX inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
 XX dependent kinase, growth factor or a reductase, or administering a
 XX nucleic acid molecule (II) comprising a promoter operably linked to a
 XX nucleic acid segment encoding (I). (I) can have antiproliferative,
 XX dermatological, cytostatic, antiseborrheic, antidiabetic activities, and
 XX ophthalmological, vulnary, keratolytic and virucide activities, and
 XX cleaves RNA encoding cytokine involved in inflammation. (I) can be used
 XX in gene therapy. (I) and (II) are useful for treating proliferative
 XX skin diseases such as psoriasis, atopic dermatitis, actinic keratosis,
 XX squamous or basal cell carcinoma and viral or seborrheic wart. They can
 XX also be used for treating proliferative eye diseases such as diabetic
 XX retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
 XX prematurity and retinal detachment, and for treating and preventing
 XX scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
 XX scar. AAH57577 to AAH62093 represent sequences used in the
 XX exemplification of the present invention.
 XX SQ Sequence 19 BP; 2 A; 2 C; 8 G; 7 T; 0 other;
 Query Match 1.2%; Score 14.8; DB 1; Length 19;
 Best Local Similarity 88.9%; Pred. No. 1.9e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1404 AAACAGCCAAACTCCAC 1421
 DB 18 ATACAGCCAAACTCCAC 1
 RESULT 106
 AAH11919
 ID AAH11919 standard; DNA; 20 BP.
 XX AC AAH11919;
 XX DT 13-AUG-1998 (first entry)
 XX DE Hepatocyte growth factor inhibiting oligonucleotide #11.
 XX Hepatocyte growth factor; HGF; c-Met; modulator; inhibitor;
 XX antitumour agent; anti-metastasis agent; primer; ss.
 XX OS Synthetic.
 XX JPI0127286-A.
 XX PD 19-MAY-1998.
 XX PF 01-NOV-1996; 96JP-0291499.
 XX PR 01-NOV-1996; 96JP-0291499.
 XX PA (TERU) TERUMO CORP.
 XX DR WPI; 1998-340665/30.
 XX PT Oligo-nucleotide inhibiting HGF production - useful as antitumour
 XX and anti-metastatic agent
 XX PS Disclosure; Page 10; 15pp; Japanese.
 XX

CC AAV11909-V11925, AAV11927 and AAV11928 are oligonucleotide primers used
 CC to identify sequences which modulate or inhibit expression, production
 CC or reception of hepatocyte growth factor (HGF) or expression of c-Met.
 CC Such oligonucleotides are useful as antitumour or anti-metastasis
 CC agents.
 XX
 XX Sequence 20 BP; 0 A; 0 C; 11 G; 9 T; 0 other;
 SQ
 Query Match 1.2%; Score 14.8; DB 1; Length 20;
 Best Local Similarity 88.9%; Pred. No. 2e+02; 2; Indels 0; Gaps 0;
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 477 GTGGGTCGTGTGAGCGT 494
 DB 1 GTGGGTCGTGTGAGCGT 18
 RESULT 107
 AAZ37709/C
 ID AAZ37709 standard; DNA; 20 BP.
 XX
 AC AAZ37709;
 XX
 DT 07-JAN-2000 (first entry)
 DE Human mdm2 phosphorothioate oligodeoxynucleotide #239.
 XX
 XX Human mdm2 gene; proliferation; tumour; phosphorothioate; p53;
 KW cancer; antisense; modulation; oligonucleotide; expression;
 KW inhibition; hyperproliferation; blood cancer; brain cancer;
 KW breast cancer; lung cancer; soft tissue cancer; psoriasis; fibrosis;
 KW atherosclerosis; restenosis; ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 XX W09949065-A1.
 PN
 XX 30-SEP-1999.
 PD
 XX 26-MAR-1999; 99WO-US06702.
 PF
 XX 26-MAR-1998; 98US-0048810.
 PR
 XX (ISIS-) ISIS PHARM INC.
 PA
 XX Miraglia LJ, Nero P, Graham MJ, Monia BP, Cowsett LM;
 PI WPI; 1999-610754/52.
 XX
 XX New antisense compounds used to treat eg. hyperproliferative conditions
 PT
 XX
 PS Example 9; Page 54; 157pp; English.
 XX
 XX AAZ37473-237738 represent human mdm2 phosphorothioate oligonucleotides.
 CC AAZ37471, AAZ37472, AAZ37739, AAZ37740 and AAZ37741 are used in the
 CC exemplification of the present invention. The present invention
 CC describes novel nucleotide antisense compounds, targeted to the 5'
 CC untranslated, translation termination codon, or 3' untranslated region
 CC of a nucleic acid encoding human mdm2, that modulates expression of
 CC human mdm2. The oligonucleotides mediate their effect by antisense
 CC inhibition of hyperproliferative gene expression. The antisense compound
 CC is used to treat an animal having a disease or condition associated
 CC with mdm2, particularly a hyperproliferative condition, more
 CC particularly cancer, especially of the blood, brain, breast, lung or soft
 CC tissue, or psoriasis, fibrosis, atherosclerosis or restenosis.
 XX
 XX Sequence 20 BP; 9 A; 1 C; 2 G; 8 T; 0 other;
 SQ
 Query Match 1.2%; Score 14.8; DB 1; Length 20;
 Best Local Similarity 88.9%; Pred. No. 2e+02; 2; Indels 0; Gaps 0;
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1017 TTCAAGTGAACCTATTATTA 1034
 DB 18 TTAAATGTAACCTATTATTA 1
 RESULT 108
 AAZ98583
 ID AAZ98583 standard; DNA; 20 BP.
 XX
 AC AAZ98583;
 XX
 DT 19-JUN-2000 (first entry)
 DE Human MAPK kinase 6 inhibiting antisense oligo ISIS# 101504.
 XX
 XX Mitogen-activated protein kinase; MAPK; MAPK kinase 6; antisense;
 KW sandwich assay; human; ss.
 KW Homo sapiens.
 OS
 XX US6033910-A.
 PN
 XX 07-MAR-2000.
 PD
 XX 19-JUL-1999; 99US-0357073.
 PF
 XX 19-JUL-1999; 99US-0357073.
 PR
 XX (ISIS-) ISIS PHARM INC.
 PA Monia BP, Cowsett LM;
 PI WPI; 2000-269479/23.
 XX
 XX Novel antisense oligonucleotides used for inhibition of
 PT Mitogen-activated protein kinase 6 expression -
 XX Claim 11; Column 41; 33pp; English.
 XX
 XX The invention provides antisense oligonucleotides which are targeted to
 CC a nucleic acid encoding a mitogen-activated protein kinase (MAPK) kinase
 CC 6. The antisense oligonucleotides are used to inhibit MAPK kinase 6
 CC expression, and so are used to treat diseases mediated by MAPK kinase 6
 CC expression. They may also be used to detect MAPK kinase 6, e.g. in
 CC sandwich assays. Sequences AAZ98583-597 represent antisense oligos
 CC inhibiting human MAPK kinase 6 mRNA.
 XX
 XX Sequence 20 BP; 6 A; 4 C; 3 G; 7 T; 0 other;
 SQ
 Query Match 1.2%; Score 14.8; DB 1; Length 20;
 Best Local Similarity 88.9%; Pred. No. 2e+02; 2; Indels 0; Gaps 0;
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 407 TCGTATCCAGATCAGT 424
 DB 2 TAGTCTCCAGATCAGT 19
 RESULT 109
 AAZ95269/C
 ID AAZ95269 standard; DNA; 20 BP.
 XX
 AC AAZ95269;
 XX
 DT 17-DEC-2001 (first entry)
 DE Neuregulin-1 gene polymorphic microsatellite marker 473C15-533 forward.
 XX
 XX Human; neuregulin-1 associated gene 1; NRG1AG1; Schizophrenia gene;
 KW gene therapy; microsatellite marker; ds.
 XX
 XX Homo sapiens.
 OS

```

XX FN WO200164876-A2.
XX PD 07-SEP-2001.
XX PR 28-FEB-2001; 2001WO-US06376.
XX PF 28-FEB-2000; 2000US-0515715.
XX PR (DECO-) DECODE GENETICS EHP.
XX FA Stefansson H, Steinthorsdottir V, Gulcher JR;
XX PI WPI; 2001-550179/61.
XX DR
XX PT Neuregulin-1 associated gene 1 nucleic acids and fragments, useful for
XX PT preventing diagnosing and treating schizophrenia -
XX PS Disclosure; Page 504; 750pp; English.
XX CC This sequence represents a microsatellite marker from the human
XX CC neuregulin-1 associated gene 1 (NRG1AG1) of the invention. The NRG1AG1
XX CC gene is also referred to as the human Schizophrenia gene. The invention
XX CC also relates to fragments or variants of the gene and the NRG1AG1
XX CC polypeptides they encode. The NRG1AG1 nucleic acids and polypeptides may
XX CC be used in the prevention, diagnosis and treatment of diseases associated
XX CC with inappropriate NRG1AG1 expression. For example, they may be used to
XX CC treat disorders associated with decreased expression by rectifying
XX CC mutations or deletions in a patient's genome that affect the activity of
XX CC NRG1AG1 by expressing inactive proteins or to supplement the patients own
XX CC production of NRG1AG1. Additionally, the gene may be used to produce
XX CC NRG1AG1 polypeptides, by inserting the nucleic acids into a host cell and
XX CC culturing the cell to express the protein. The gene may also be used as
XX CC DNA probes and primers in diagnostic assays to detect and quantitate the
XX CC presence of similar nucleic acids in samples, and therefore which
XX CC patients may be in need of restorative therapy. The NRG1AG1 polypeptides
XX CC may also be used as antigens in the production of antibodies against
XX CC NRG1AG1 and in assays to identify modulators of NRG1AG1 expression and
XX CC activity. Anti-NRG1AG1 antibodies and antagonists may also be used to
XX CC down regulate expression and activity. Anti-NRG1AG1 antibodies may
XX CC also be used as diagnostic agents for detecting the presence of NRG1AG1
XX CC polypeptides in samples. NRG1AG1 is associated with schizophrenia which
XX CC may be prevented, diagnosed and/or treated by the above methods.
XX SQ Sequence 20 BP; 9 A; 6 C; 4 G; 1 T; 0 other;
      Query Match      1.2%; Score 14.8; DB 1; Length 20;
      Best Local Similarity 88.9%; Pred. No. 2e+02;
      Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1352 GCTGTGTTGGTAGTCTG 1369
DB 20 GCTGTGTTGGTAGTCTG 3
      ||||| ||||| |||||
RESULT 110
ID AAK96762/c
AC AAK96762;
AC AAK96762;
DT 17-DEC-2001 (first entry)
DE Neuregulin-1 gene polymorphic microsatellite marker 473C15-533 forward.
KW Human; neuregulin 1 gene; schizophrenia; gene therapy;
KW microsatellite marker; ds.
OS Homo sapiens.
XX WO200164877-A2.
XX PN
XX PD 07-SEP-2001.

```

```

XX PF 28-FEB-2001; 2001WO-US06377.
XX XX
XX PR 28-FEB-2000; 2000US-0515716.
XX PA (DECO-) DECODE GENETICS EHP.
XX PI Stefansson H, Steinthorsdottir V, Gulcher JR;
XX DR WPI; 2001-514841/56.
XX PT Neuregulin 1 nucleic acids and proteins useful for diagnosing
XX PT preventing and treating schizophrenia -
XX PS Disclosure; Page 89; 756pp; English.
XX CC This sequence represents a microsatellite marker from the human
XX CC neuregulin 1 gene of the invention. The invention also relates to
XX CC fragments or variants of the neuregulin 1 gene. The gene and its proteins
XX CC may be used in the prevention, diagnosis and treatment of diseases
XX CC associated with inappropriate neuregulin 1 expression, such as
XX CC schizophrenia. For example they may be used to treat disorders associated
XX CC with decreased neuregulin 1 expression by rectifying mutations or
XX CC deletions in a patient's genome that affect the activity of neuregulin 1
XX CC by expressing inactive proteins or to supplement the patients own
XX CC production of polypeptides. Additionally, the gene may be used to produce
XX CC the neuregulin 1 protein, by inserting the nucleic acids into a host cell
XX CC and culturing the cell to express the protein. The gene and its
XX CC complementary sequences may also be used as DNA probes in diagnostic
XX CC assays to detect and quantitate the presence of similar nucleic acids in
XX CC samples, and therefore which patients may be in need of restorative
XX CC therapy. The protein may also be used as antigens in the production of
XX CC antibodies against neuregulin 1 and in assays to identify modulators of
XX CC neuregulin 1 expression and activity. The antibodies and antagonists may
XX CC also be used to down regulate expression and activity. The antibodies may
XX CC also be used as diagnostic agents for detecting the presence of
XX CC neuregulin 1 in samples.
XX SQ Sequence 20 BP; 9 A; 6 C; 4 G; 1 T; 0 other;
      Query Match      1.2%; Score 14.8; DB 1; Length 20;
      Best Local Similarity 88.9%; Pred. No. 2e+02;
      Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1352 GCTGTGTTGGTAGTCTG 1369
DB 20 GCTGTGTTGGTAGTCTG 3
      ||||| ||||| |||||
RESULT 111
ID AAS21759
AC AAS21759 standard; DNA; 20 BP.
AC AAS21759;
DT 21-NOV-2001 (first entry)
DE Mouse Survivin antisense oligonucleotide #61.
KW Survivin; human; mouse; cytostatic; antisense oligonucleotide;
KW hyperproliferative condition; cancer; apoptosis; cytokinesis; ss.
OS Mus musculus.
OS Synthetic.
XX WO200157059-A1.
XX PN
XX PD 09-AUG-2001.
XX PR 30-JAN-2001; 2001WO-US02939.
XX PR 02-FEB-2000; 2000US-0496694.
XX XX

```

```

PA (ISIS-) ISIS PHARM INC.
XX Bennett CF, Ackermann EJ, Swayze EE, Cowsett LM;
PI WPI; 2001-488863/53.
XX
DR Novel antisense compounds for modulating the expression of Survivin and
PT treatment of cancer -
PT
PS Example 18; Page 62; 120pp; English.
XX
CC The invention relates to antisense oligonucleotides targeted to a nucleic
CC acid molecule encoding human Survivin, where the antisense
CC oligonucleotide inhibits the expression of human Survivin. These
CC antisense oligonucleotides are used in the treatment of an animal
CC suffering from a disease or condition associated with Survivin, e.g. a
CC hyperproliferative condition such as cancer, and comprises administering
CC a therapeutically or prophylactically effective amount of the antisense
CC oligonucleotide so that expression of Survivin is inhibited. The
CC oligonucleotides can also be used to treat a human suffering from a
CC disease or condition characterised by a reduction in apoptosis
CC comprising administering the antisense oligonucleotide to a human. In
CC addition, the antisense oligonucleotide and a cytotoxic chemotherapeutic
CC agent e.g. taxol or cisplatin, can be used to modulate apoptosis,
CC cytokinesis or the cell cycle, or inhibit the proliferation in a cancer
CC cell by contacting the cell with the antisense oligonucleotide.
CC AAS21521-AAS21768 represent Survivin nucleic acids, and antisense
CC oligonucleotides targeted to Survivin, used in the method of the
CC invention.
XX
SQ Sequence 20 BP; 5 A; 0 C; 3 G; 12 T; 0 other;
Query Match 1.2%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 2e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1039 ATTATTATTATTGTTT 1056
DB 2 AGTTATTATTGTTT 19

RESULT 112
AAS21760
ID AAS21760 standard; DNA; 20 BP.
XX
AC AAS21760;
XX
DT 21-NOV-2001 (first entry)
XX
DE Mouse Survivin antisense oligonucleotide #62.
XX
KW Survivin; human; mouse; cytostatic; antisense oligonucleotide;
KW hyperproliferative condition; cancer; apoptosis; cytokinesis; ss.
XX
OS Mus musculus.
OS Synthetic.
XX
PN WO200157059-A1.
XX
XX 09-AUG-2001.
XX
XX 30-JAN-2001; 2001WO-US02939.
XX
XX 02-FEB-2000; 2000US-0496694.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Bennett CF, Ackermann EJ, Swayze EE, Cowsett LM;
XX WPI; 2001-488863/53.
XX
DR Novel antisense compounds for modulating the expression of Survivin and
PT treatment of cancer -
PT

```

```

XX Example 18; Page 62; 120pp; English.
XX
CC The invention relates to antisense oligonucleotides targeted to a nucleic
CC acid molecule encoding human Survivin, where the antisense
CC oligonucleotide inhibits the expression of human Survivin. These
CC antisense oligonucleotides are used in the treatment of an animal
CC suffering from a disease or condition associated with Survivin, e.g. a
CC hyperproliferative condition such as cancer, and comprises administering
CC a therapeutically or prophylactically effective amount of the antisense
CC oligonucleotide so that expression of Survivin is inhibited. The
CC oligonucleotides can also be used to treat a human suffering from a
CC disease or condition characterised by a reduction in apoptosis
CC comprising administering the antisense oligonucleotide to a human. In
CC addition, the antisense oligonucleotide and a cytotoxic chemotherapeutic
CC agent e.g. taxol or cisplatin, can be used to modulate apoptosis,
CC cytokinesis or the cell cycle, or inhibit the proliferation in a cancer
CC cell by contacting the cell with the antisense oligonucleotide.
CC AAS21521-AAS21768 represent Survivin nucleic acids, and antisense
CC oligonucleotides targeted to Survivin, used in the method of the
CC invention.
XX
SQ Sequence 20 BP; 6 A; 0 C; 2 G; 12 T; 0 other;
Query Match 1.2%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 2e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1039 ATTATTATTATTGTTT 1056
DB 3 AGTTATTATTGTTT 20

RESULT 113
AAS29478/c
ID AAS29478 standard; DNA; 20 BP.
XX
AC AAS29478;
XX
DT 21-NOV-2001 (first entry)
XX
DE Human mdm2 antisense oligonucleotide 31618.
XX
KW Human; mdm2; hyperproliferative disorder; cancer; psoriasis;
KW atherosclerosis; tumour; cytostatic; anti psoriatic;
KW anti arteriosclerotic; vasotropic; antisense; phosphorothioate; ss.
XX
OS Homo sapiens.
XX
XX Key Location/Qualifiers
XX modified_base 1..20
XX /tag= a
XX /mod_base= OTHER
XX /note= "OTHER- All phosphorothioate linkages,
XX additionally bases 1-6 and bases 15-20 are
XX 2'-O-methoxyethyl bases, and bases 7-14 are
XX deoxynucleotides"
XX
XX US2001016575-A1.
XX
XX 23-AUG-2001.
XX
XX 02-JAN-2001; 2001US-0752983.
XX
XX 26-MAR-1999; 99US-0280805.
XX
XX 26-MAR-1998; 98US-0048810.
XX
XX (MIRA/) MIRAGLIA L J.
XX (NERO/) NERO P.
XX (GRAH/) GRAHAM M J.
XX (MONI/) MONIA B P.
XX (COWS/) COWSETT L M.
XX

```

PI Miraglia LJ, Nero P, Graham MJ, Monia BP, Cowseert LM;
 DR WPI; 2001-535565/59.
 XX
 XX An antisense compound, useful for treating e.g. cancer, comprises
 PT nucleobases targeted a region (e.g. translation termination codon
 PT region) of a nucleic acid encoding human mdm2 -
 XX
 XX Example 9; Page 18; 81pp; English.
 PS
 XX The present invention relates to antisense compounds, 8-30 nucleobases
 CC in length targeted to the 5' untranslated region, translation
 CC termination codon region, 3' untranslated region, coding region or
 CC translation start site of a nucleic acid encoding human mdm2, where
 CC the antisense compound modulates the expression of human mdm2. The
 CC antisense oligonucleotides of the invention are useful for encoding
 CC human mdm2 and for inhibiting the expression of human mdm2. They may be
 CC used for treating an animal having a disease or condition associated
 CC with amplification of mdm2 gene or overexpression of mdm2 e.g. a
 CC hyperproliferative disorder such as cancer (blood, brain, breast, lung,
 CC or a soft tissue cancer) and psoriasis, fibrosis, atherosclerosis or
 CC restenosis, tumours, colorectal carcinoma and chronic myelogenous
 CC leukemia. The antisense compound may be administered with a
 CC chemotherapeutic agent to overcome drug resistance. The antisense
 CC compound reduces hyperproliferation of human cells. The method, which
 CC involves the use of the antisense compound, is also useful for detecting
 CC the role of mdm2 expression in various cell functions and physiological
 CC processes and useful in both clinical research and diagnostic tools.
 CC AAS29242-AAS29507 represent the human mdm2 antisense oligonucleotides
 CC of the present invention.
 XX
 XX Sequence 20 BP; 9 A; 1 C; 2 G; 8 T; 0 other;
 SQ
 Query Match 1.2%; Score 14.8; DB 1; Length 20;
 Best Local Similarity 88.9%; Pred. No. 2e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1017 TTCAAGTGTAACTTATTA 1034
 DB |||||
 18 TTTAAATGTAACTTATTA 1
 RESULT 114
 AAF80863/C
 ID AAF80863 standard; DNA; 20 BP.
 XX
 XX AAF80863;
 AC
 XX 02-MAY-2001 (first entry)
 DT Human mdm2 phosphorothioate oligonucleotide #237.
 XX
 XX Antisense; mdm2; hyperproliferation; cancer; psoriasis; ss.
 KW Homo sapiens.
 OS US6184212-B1.
 PN
 XX 06-FEB-2001.
 PD
 XX 26-MAR-1999; 99US-0280805.
 PF
 XX 26-MAR-1998; 98US-0048810.
 PR
 XX (ISIS-) ISIS PHARM INC.
 PA
 XX Miraglia LJ, Nero P, Graham MJ, Monia BP, Cowseert LM;
 PI WPI; 2001-190948/19.
 DR
 XX Novel antisense compound 8-30 nucleobases in length targeted to a
 PT nucleic acid molecule encoding human mdm-2 useful for modulating the
 PT expression of human mdm-2 and reducing hyperproliferation of human

PT cells -
 XX Example 9; Column 31; 77pp; English.
 PS
 XX The present invention relates to an antisense compound 8-30
 CC nucleobases in length targeted to nucleobases 1-308 of the
 CC 5' untranslated region, 1776-1806 of the translation termination
 CC codon region or 1818-2370 of the 3' untranslated region of a
 CC nucleic acid molecule encoding human mdm-2. The invention is
 CC useful for reducing hyperproliferation of human cells,
 CC modulating the expression of mdm2 in human cells or tissues
 CC or in vitro. The hyperproliferative disorder includes cancer or
 CC psoriasis.
 XX
 XX Sequence 20 BP; 9 A; 1 C; 2 G; 8 T; 0 other;
 SQ
 Query Match 1.2%; Score 14.8; DB 1; Length 20;
 Best Local Similarity 88.9%; Pred. No. 2e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1017 TTCAAGTGTAACTTATTA 1034
 DB |||||
 18 TTTAAATGTAACTTATTA 1
 RESULT 115
 ABS67649
 ID ABS67649 standard; DNA; 20 BP.
 XX
 XX ABS67649;
 AC
 XX 29-NOV-2002 (first entry)
 DT Casein kinase-2 antisense oligonucleotide ISIS127149.
 XX
 XX ss; antisense therapy; casein kinase-2 alpha; cytostatic; antidiabetic;
 KW antinflammatory; diabetes; hyperproliferative disorder; cancer; human;
 KW breast cancer; prostate cancer; liver cancer; infection; inflammation;
 KW tumour.
 XX
 XX Homo sapiens.
 OS
 XX Key Location/Qualifiers
 FH modified_base 1..20
 FT /tag= a
 FT /label= OTHER
 FT /note= "All cytidines are 5-methylcytidine.
 FT Phosphorothioate backbone"
 FT modified_base 1..5
 FT /tag= b
 FT /label= OTHER
 FT /note= "2'-methoxyethyl nucleotides"
 FT modified_base 16..20
 FT /tag= c
 FT /label= OTHER
 FT /note= "2'-methoxyethyl nucleotides"
 XX
 XX WO200262818-A2.
 PN
 XX 15-AUG-2002.
 PD
 XX 31-JAN-2002; 2002WO-US03942.
 PF
 XX 08-FEB-2001; 2001US-0780172.
 PR
 XX (ISIS-) ISIS PHARM INC.
 PA
 XX McKay R, Freier SM, Wyatt JR;
 PI WPI; 2002-627521/67.
 DR
 XX New antisense oligonucleotides targeted to nucleic acid encoding casein
 PT kinase 2-alpha, useful in diagnostic and research applications, or for

PT treating a disease or condition associated with expression of casein
 PT kinase 2-alpha
 XX
 XX Claim 3; Page 95; 166pp; English.
 PS
 CC The invention relates to a compound 8-50 nucleobases in length targeted
 CC to a nucleic acid molecule encoding casein kinase 2-alpha. The compound
 CC specifically hybridizes with and inhibits the expression of casein
 CC kinase 2-alpha, or specifically hybridizes with at least an
 CC 8-nucleobase portion of an active site on a nucleic acid molecule
 CC encoding casein kinase 2-alpha i.e. an antisense oligonucleotide.
 CC Also included are: (1) a composition comprising the compound and a
 CC carrier or diluent; (2) inhibiting the expression of casein kinase
 CC 2-alpha in cells or tissues by contacting the cells or tissues with the
 CC novel compound; and (3) treating an animal having a disease or condition
 CC associated with casein kinase 2-alpha by administering to the animal the
 CC compound cited above so that expression of casein kinase 2-alpha is
 CC inhibited. The antisense compounds are useful for modulating the
 CC expression of casein kinase 2-alpha and for treating diseases or
 CC conditions associated with expression of casein kinase 2-alpha, e.g.
 CC diabetes or hyperproliferative disorder, particularly cancer, such as
 CC breast cancer, prostate cancer, or liver cancer. The antisense
 CC compounds are also useful for diagnostics, therapeutics, prophylaxis,
 CC e.g. to prevent or delay infection, inflammation or tumour formation, as
 CC research reagents and kits, and in distinguishing between functions of
 CC various members of a biological pathway. The present sequence is a
 CC casein kinase-2 alpha antisense oligonucleotide of the invention.
 XX
 SQ Sequence 20 BP; 2 A; 7 C; 3 G; 8 T; 0 other;
 Query Match 1.2%; Score 14.8; DB 1; Length 20;
 Best Local Similarity 88.9%; Pred. No. 2e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 393 AATTCATTCCTCTGGT 410
 DB 3 ACATTCCTCTCTGGT 20
 RESULT 116
 ABT00039/c
 ID ABT00039 standard; DNA; 20 BP.
 XX
 AC ABT00039;
 DT 07-NOV-2002 (first entry)
 XX
 DE Human neuregulin-1-associated gene 1 microsatellite marker #29.
 XX
 KW Human; neuregulin 1; neuregulin-1-associated gene 1; NRGL1; NRGL1G1;
 KW schizophrenia; chromosome 8p12; single nucleotide polymorphism; SNP;
 KW neuroleptic; gene therapy; splice variant; microsatellite marker; ds.
 XX
 OS Homo sapiens.
 XX
 PN US2002045577-A1.
 XX
 PD 18-APR-2002.
 XX
 PF 28-FEB-2001; 2001US-0795668.
 XX
 PR 28-FEB-2000; 2000US-0515716.
 XX
 PA (DECO-) DECODE GENETICS EHP.
 XX
 PI Stefansson H, Steinthorsdottir V, Gulcher JR;
 XX WPI; 2002-425447/45.
 DR
 XX New neuregulin 1 gene, schizophrenia gene residing in 1.5 Mb segment on
 XX human chromosome 8p12, useful for diagnosing susceptibility to or
 XX treating schizophrenia and for screening schizophrenia treating agents

XX Disclosure; Page 445; 700pp; English.
 XX
 CC The present invention relates to the human neuregulin 1 gene (NRG1),
 CC single nucleotide polymorphisms within which were identified as being
 CC associated with an increased susceptibility to schizophrenia, which is
 CC located on chromosome 8p12. Also found within the same sequence is the
 CC neuregulin-1-associated gene 1 (NRG1G1). The gene is useful for treating
 CC schizophrenia in an individual, for diagnosing susceptibility to
 CC schizophrenia, and for screening for agents useful in the treatment of
 CC the disease. The present sequence is a microsatellite marker identified
 CC within the gene of the invention.
 XX
 SQ Sequence 20 BP; 9 A; 6 C; 4 G; 1 T; 0 other;
 Query Match 1.2%; Score 14.8; DB 1; Length 20;
 Best Local Similarity 88.9%; Pred. No. 2e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1352 GCTGTGTGGTGGTGGTGG 1369
 DB 20 GCTGTGTGGTGGTGGTGG 3
 RESULT 117
 ABT01532/c
 ID ABT01532 standard; DNA; 20 BP.
 XX
 AC ABT01532;
 DT 07-NOV-2002 (first entry)
 XX
 DE Human neuregulin-1-associated gene 1 microsatellite marker #29.
 XX
 KW Human; neuregulin 1; neuregulin-1-associated gene 1; NRGL1; NRGL1G1;
 KW schizophrenia; chromosome 8p12; single nucleotide polymorphism; SNP;
 KW neuroleptic; gene therapy; splice variant; microsatellite marker; ds.
 XX
 OS Homo sapiens.
 XX
 PN US2002094954-A1.
 XX
 PD 18-JUL-2002.
 XX
 PF 28-FEB-2001; 2001US-0795686.
 XX
 PR 28-FEB-2000; 2000US-0515715.
 XX
 PA (DECO-) DECODE GENETICS EHP.
 XX
 PI Stefansson H, Steinthorsdottir V, Gulcher JR;
 XX WPI; 2002-665799/71.
 DR
 XX NRG1G1, useful for treating or diagnosing susceptibility to
 XX schizophrenia, or for assaying a sample for the presence of NRG1G1
 XX nucleic acid
 PT
 PT Disclosure; Page 444; 700pp; English.
 PS
 CC The present invention relates to the human neuregulin-1-associated gene
 CC 1 (NRG1G1), single nucleotide polymorphisms within which were identified
 CC as being associated with an increased susceptibility to schizophrenia,
 CC which is located on chromosome 8p12. Also found within the same sequence
 CC is the neuregulin 1 gene (NRG1). The gene is useful for treating
 CC schizophrenia in an individual, for diagnosing susceptibility to
 CC schizophrenia, and for screening for agents useful in the treatment of
 CC the disease. The present sequence is a microsatellite marker identified
 CC within the gene of the invention.
 XX
 SQ Sequence 20 BP; 9 A; 6 C; 4 G; 1 T; 0 other;
 Query Match 1.2%; Score 14.8; DB 1; Length 20;

CC prevent or delay infection, inflammation or tumour formation. (1) is
CC also useful as therapeutic, diagnostic and research reagent, for
CC distinguishing functions of various members of a biological pathway, and
CC in antisense gene therapy. The present sequence represents an antisense
CC oligonucleotide for human TNF inducible protein A20, from the present
CC invention.
XX
SQ Sequence 20 BP; 7 A; 2 C; 4 G; 7 T; 0 other;
Query Match 1.2%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 2e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1237 ATTTCATTTCAGATAAA 1254
DB 18 ATTGCATTTCAGACAAA 1
RESULT 119
ABT32456
ID ABT32456 standard; DNA; 20 BP.
XX
XX AC ABT32456;
XX
XX DT 08-MAY-2003 (first entry)
XX DE Neuroblastoma-related oligonucleotide #233.
XX KW Neuroblastoma; prognosis; spontaneous regression; primer; probe; ds;
XX KW high malignancy.
XX OS Unidentified.
XX FN WO200297093-A1.
XX PD 05-DEC-2002.
XX PF 30-MAY-2002; 2002WO-JP05294.
XX PR 30-MAY-2001; 2001JP-0162775.
XX PR 24-AUG-2001; 2001JP-0255226.
XX PA (CHIB-) CHIBA PREFECTURE.
XX PA (HISM) HISAMITSU PHARM CO LTD.
XX PI Nakagawara A;
XX DR WPI; 2003-140476/13.
XX PT Nucleic acids having higher expression in human neuroblastoma with poor
XX PT prognosis for diagnostic prediction of neuroblastoma prognosis -
XX PS Example 5; Page 27; 111pp; Japanese.
XX CC The invention comprises nucleic acids that show increased expression in
XX CC human neuroblastomas with poor prognosis over those with a good
XX CC prognosis. The nucleic acids of the invention are useful as a tool for
XX CC distinguishing neuroblastomas with a favourable prognosis (spontaneous
XX CC regression) from neuroblastomas with a poor prognosis (high malignancy).
XX CC The DNA sequences ABT32224 - ABT32571 represent oligonucleotides used in
XX CC an example of the invention.
XX
SQ Sequence 20 BP; 7 A; 3 C; 5 G; 5 T; 0 other;
Query Match 1.2%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 2e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1076 TGTGCGAGATTTCGAAA 1093
DB 1 TGGGCAATATTTGAAA 18

Best Local Similarity 88.9%; Pred. No. 2e+02; 0; Gaps 0;
Matches 16; Conservative 0; Mismatches 2; Indels 0;
QY 1352 GCTGCTGTGCTAGCTGCG 1369
DB 20 GCTGCTGTGCTAGCTGCTG 3
RESULT 118
ABL51148/c
ID ABL51148 standard; DNA; 20 BP.
XX
XX AC ABL51148;
XX
XX DT 27-JUN-2002 (first entry)
XX DE Human TNF inducible protein A20 antisense oligonucleotide SEQ ID:26.
XX KW Human; tumour necrosis factor inducible protein A20; phosphorothioate;
XX KW antisense modulation; antisense oligonucleotide; antiinflammatory;
XX KW cytostatic; antiviral; gene therapy; TNF inducible protein A20;
XX KW inflammatory disorder; viral infection; hyperproliferative disorder;
XX KW cancer; inflammation; tumour formation; ss.
XX OS Homo sapiens.
XX OS Synthetic.
XX
XX Key Location/Qualifiers
XX modified_base 1..20
XX /*tag= a
XX /mod_base= OTHER
XX /note= "2'-methoxyethyl (MOE) nucleotide wings and a
XX deoxy gap with a phosphorothioate backbone"
XX modified_base 1..5
XX /*tag= b
XX /mod_base= OTHER
XX /note= "2'-O-methoxyethyl nucleotides"
XX modified_base 15..20
XX /*tag= c
XX /mod_base= OTHER
XX /note= "2'-O-methoxyethyl nucleotides"
XX WO200220545-A1.
XX
XX PD 14-MAR-2002.
XX PF 07-SEP-2001; 2001WO-US28116.
XX PR 08-SEP-2000; 2000US-0658687.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Bennett CP, Wyatt JR;
XX DR WPI; 2002-362238/39.
XX PT New antisense compound useful for preventing or delaying infection,
XX PT inflammation or tumor formation, hybridizes and inhibits a nucleic acid
XX PT molecule encoding tumor necrosis factor inducible protein, A20 -
XX PS Claim 3; Page 91; 121pp; English.
XX
XX CC The present invention describes a compound (I) of 8 - 50 nucleotides
XX CC targeted to a nucleic acid molecule (II) encoding tumour necrosis factor
XX CC (TNF) inducible protein, A20, and which specifically hybridises with and
XX CC inhibits expression of A20, or a compound (Ia) of 8 - 50 nucleotides
XX CC which specifically hybridises with an 8-nucleotide portion of an active
XX CC site on (II). (I) have antiinflammatory, cytostatic and antiviral
XX CC activities. (I) can be used as inhibitors of TNF inducible protein, A20.
XX CC (I) is useful for inhibiting the expression of A20 in cells or tissues,
XX CC and for treating an animal having a disease condition associated with
XX CC A20, e.g. a inflammatory disorder, viral infection and hyperproliferative
XX CC disorder e.g. cancer. (I) is also useful prophylactically, e.g. to

```
RESULT 120
ABZ10278
ID ABZ10278 standard; DNA; 20 BP.
XX
AC
XX
AC ABZ10278;
XX
DT
XX
16-JAN-2003 (first entry)
XX
DE Haematopoietic cell proliferation disorder related primer SEQ ID NO:418.
XX
DE Human; haematopoietic cell proliferation disorder; cytostatic;
KW gene therapy; lymphocytic leukaemia; acute myelogenous leukaemia;
KW cytosine methylation state; probe; primer; ss.
XX
XX
OS Homo sapiens.
OS Synthetic.
XX
FN WO200277272-A2.
XX
PD
XX
03-OCT-2002.
XX
PD
XX
26-MAR-2002; 2002WO-EP03401.
XX
PF
XX
26-MAR-2001; 2001US-278333P.
XX
PR
XX
(PBIG-) EPIGENOMICS AG.
XX
PA
XX
Berlin K, Braun A, Distler J, Guetig D, Howe A, Mueller J;
PI Olek A, Piepenbrock C, Adorjan P, Grabs G, Lesche R, Leu E;
PI Lewin A, Lipscher E, Maier S, Model F, Mueller V, Otto T;
PI Pelet C, Schwöpe I, Ziebarth H;
XX
XX
WPI; 2003-018942/01.
XX
XX
Detecting and differentiating between hematopoietic cell proliferative
PT disorders, comprises contacting a target nucleic acid with a reagent
PT that distinguishes between methylated and non-methylated CpG
PT dinucleotides -
XX
XX
Claim 11; Page 33; 117pp; English.
XX
XX
The present invention describes a method for detecting and
CC differentiating between haematopoietic cell proliferative disorders
CC associated with at least 1 gene and/or their regulatory regions in a
CC subject. The method comprises contacting a target nucleic acid in a
CC biological sample obtained from the subject with at least 1 reagent,
CC which distinguishes between methylated and non-methylated CpG
CC dinucleotides within the target nucleic acid. ABZ09861 to ABZ1118
CC represent specifically claimed nucleotide sequences from the present
CC invention. Oligonucleotides from the present invention can be used: for
CC differentiating between healthy haematopoietic cells and proliferative
CC disorder haematopoietic cells; for differentiating between acute
CC lymphocytic leukaemia and acute myelogenous leukaemia; as probes for
CC determining the cytosine methylation state and/or single nucleotide
CC polymorphisms (SNPs) of haematopoietic cell proliferation disorder
CC related sequences and their complements; and as primers for the
CC amplification of haematopoietic cell proliferation disorder related
CC DNA sequences. The nucleotide sequences from the present invention can
CC also be used for detecting a predisposition to, differentiation between
CC subclasses, diagnosis, prognosis, treatment and/or monitoring of
CC haematopoietic cell proliferative disorders. The present method enables
CC a highly specific classification of haematopoietic cell proliferative
CC disorders allowing for improved and informed treatment of patients.
XX
XX
Sequence 20 BP; 8 A; 8 C; 0 G; 4 T; 0 other;
SQ
Query Match 1.2%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 2e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 439 AACTTCAGCAATCTCC 456
DB 3 AACTTCAGCAATCTCC 20
```

```
RESULT 121
AAT10936/C
ID AAT10936 standard; DNA; 21 BP.
XX
AC
XX
AC AAT10936;
XX
DT
XX
31-JUL-1996 (first entry)
XX
DE B. burgdorferi exported plasmid protein A (EppA) gene PCR primer.
XX
KW EppA; Lyme disease; antigenic; immune response; detection; virulent;
KW infection; polymerase chain reaction; ss.
XX
XX
OS Synthetic.
OS
XX
FN WO9535114-A1.
XX
PD
XX
28-DEC-1995.
XX
PD
XX
16-JUN-1995; 95WO-US07748.
XX
PF
XX
17-JUN-1994; 94US-0261825.
XX
PR
XX
(RESC ) UNIV CALIFORNIA.
XX
PA
XX
Blanco DR, Champion CI, Haake DA, Lovett MA, Miller JN;
XX
WPI; 1996-058208/06.
XX
XX
Borrelia burgdorferi exported plasmid protein A - used to develop
PT prods. to induce an immune response to B.burgdorferi and as
PT diagnostic markers for Lyme disease
XX
XX
Example 5; Page 34; 67pp; English.
XX
XX
AAT10933-T10937 are PCR primers used for the amplification of a DNA
CC sequence from Borrelia burgdorferi which encodes the exported plasmid
CC protein A (EppA). EppA is a virulent protein of about 17 kD. EppA and
CC its active fragments can be used to induce an immune response to
CC pathogenic Borrelia burgdorferi (BB) in an animal. The sequence may
CC be used to produce recombinant EppA expressed in E. coli. EppA is
CC exported beyond the inner membrane and is present during the
CC infectious, in vivo stages of virulent BB growth. Polynucleotides
CC encoding EppA and anti-EppA antibodies can be used for the detection
CC of pathogenic BB in a sample.
XX
XX
Sequence 21 BP; 10 A; 0 C; 4 G; 7 T; 0 other;
SQ
Query Match 1.2%; Score 14.8; DB 1; Length 21;
Best Local Similarity 88.9%; Pred. No. 2.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 542 CAATCAATAGTTTTCAT 559
DB 18 CAATAAATATTTTTCAT 1

RESULT 122
AAZ26565
ID AAZ26565 standard; DNA; 21 BP.
XX
AC
XX
AAZ26565;
XX
XX
30-NOV-1999 (first entry)
XX
DE Human polymorphic region 754.
XX
XX
Polymorphism; human; inhibitor; cancer; treatment; cell growth; LOH;
KW cell viability; loss of heterozygosity; precancerous condition; ASI;
KW allele specific inhibitor; somatic cell; diagnosis; prevention;
KW atherosclerotic plaque; premalignant metaplastic lesion; endometriosis;
KW
```

KW dysplastic lesion; benign tumour; polycystic kidney disease; transplant;
 KW graft versus host disease; malignant cell removal; bone marrow; ss.
 XX Homo sapiens.

XX WO9841648-A2.

XX 24-SEP-1998.

XX 19-MAR-1998; 98WO-US05419.

XX 20-MAR-1997; 97US-0041057.

XX (VARI-) VARIAGENICS INC.

XX Housman D, Ledley FD, Stanton VP;

XX WPI; 1998-521232/44.

XX Identifying target genes for allele-specific drugs - used for

XX diagnosis, prevention and treatment of, e.g. cancers, atherosclerotic

XX plaque, dysplastic lesions, endometriosis or graft versus host disease

XX Disclosure; Figure 7; 60pp; English.

XX This invention describes a novel method for identifying an inhibitor

XX potentially useful for treatment of cancer, where the inhibitor is

XX active on a gene vital for cell growth or viability, and where the gene

XX is subject to loss of heterozygosity (LOH) in a cancer. The inhibitor is

XX used for preventing the development of cancer in a patient having a

XX precancerous condition, by administering to the patient a first allele

XX specific inhibitor (ASI) targeted to an allele of a first essential gene

XX present in cells of the precancerous condition, where the normal somatic

XX cells of the patient are heterozygous for the first gene, the inhibitor

XX is active on at least one but less than all allelic forms of the gene

XX present in a population and targets only one allelic form present in the

XX normal somatic cells, and the first gene. The products and methods can

XX be used in the diagnosis, prevention and treatment of LOH disorders,

XX e.g. cancers, atherosclerotic plaques, premalignant metaplastic or

XX dysplastic lesions, benign tumours, endometriosis, polycystic kidney

XX disease, and graft versus host disease. The method can also be used to

XX remove malignant cells from bone marrow transplants. AA225812-226825

XX represent human polymorphic sites described in the method of the

XX invention.

XX SQ Sequence 21 BP; 8 A; 1 C; 0 G; 12 T; 0 other;

Query Match 1.2%; Score 14.8; DB 1; Length 21;

Best Local Similarity 88.9%; Pred. No. 2.1e+02;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1521 TTTATATTTTAACTTTA 1538

DB 4 TTTATATTTTAACTAA 21

RESULT 123

ID AA276395/C

XX AA276395 standard; DNA; 21 BP.

XX AA276395;

XX 10-SEP-2001 (first entry)

XX Human biallelic marker downstream amplification primer SEQ ID NO:10751.

XX Human genome; biallelic marker; high density disequilibrium map;

XX genomic map; haplotype; phenotype; polymorphic base; genotyping;

KW dysplastic lesion; benign tumour; polycystic kidney disease; transplant;
 KW graft versus host disease; malignant cell removal; bone marrow; ss.
 XX Homo sapiens.

XX WO9841648-A2.

XX 24-SEP-1998.

XX 19-MAR-1998; 98WO-US05419.

XX 20-MAR-1997; 97US-0041057.

XX (VARI-) VARIAGENICS INC.

XX Housman D, Ledley FD, Stanton VP;

XX WPI; 1998-521232/44.

XX Identifying target genes for allele-specific drugs - used for

XX diagnosis, prevention and treatment of, e.g. cancers, atherosclerotic

XX plaque, dysplastic lesions, endometriosis or graft versus host disease

XX Disclosure; Figure 7; 60pp; English.

XX This invention describes a novel method for identifying an inhibitor

XX potentially useful for treatment of cancer, where the inhibitor is

XX active on a gene vital for cell growth or viability, and where the gene

XX is subject to loss of heterozygosity (LOH) in a cancer. The inhibitor is

XX used for preventing the development of cancer in a patient having a

XX precancerous condition, by administering to the patient a first allele

XX specific inhibitor (ASI) targeted to an allele of a first essential gene

XX present in cells of the precancerous condition, where the normal somatic

XX cells of the patient are heterozygous for the first gene, the inhibitor

XX is active on at least one but less than all allelic forms of the gene

XX present in a population and targets only one allelic form present in the

XX normal somatic cells, and the first gene. The products and methods can

XX be used in the diagnosis, prevention and treatment of LOH disorders,

XX e.g. cancers, atherosclerotic plaques, premalignant metaplastic or

XX dysplastic lesions, benign tumours, endometriosis, polycystic kidney

XX disease, and graft versus host disease. The method can also be used to

XX remove malignant cells from bone marrow transplants. AA225812-226825

XX represent human polymorphic sites described in the method of the

XX invention.

XX SQ Sequence 21 BP; 8 A; 1 C; 0 G; 12 T; 0 other;

Query Match 1.2%; Score 14.8; DB 1; Length 21;

Best Local Similarity 88.9%; Pred. No. 2.1e+02;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1521 TTTATATTTTAACTTTA 1538

DB 4 TTTATATTTTAACTAA 21

RESULT 123

ID AA276395/C

XX AA276395 standard; DNA; 21 BP.

XX AA276395;

XX 10-SEP-2001 (first entry)

XX Human biallelic marker downstream amplification primer SEQ ID NO:10751.

XX Human genome; biallelic marker; high density disequilibrium map;

XX genomic map; haplotype; phenotype; polymorphic base; genotyping;

KW dysplastic lesion; benign tumour; polycystic kidney disease; transplant;
 KW graft versus host disease; malignant cell removal; bone marrow; ss.
 XX Homo sapiens.

XX WO9841648-A2.

XX 24-SEP-1998.

XX 19-MAR-1998; 98WO-US05419.

XX 20-MAR-1997; 97US-0041057.

XX (VARI-) VARIAGENICS INC.

XX Housman D, Ledley FD, Stanton VP;

XX WPI; 1998-521232/44.

XX Identifying target genes for allele-specific drugs - used for

XX diagnosis, prevention and treatment of, e.g. cancers, atherosclerotic

XX plaque, dysplastic lesions, endometriosis or graft versus host disease

XX Disclosure; Figure 7; 60pp; English.

XX This invention describes a novel method for identifying an inhibitor

XX potentially useful for treatment of cancer, where the inhibitor is

XX active on a gene vital for cell growth or viability, and where the gene

XX is subject to loss of heterozygosity (LOH) in a cancer. The inhibitor is

XX used for preventing the development of cancer in a patient having a

XX precancerous condition, by administering to the patient a first allele

XX specific inhibitor (ASI) targeted to an allele of a first essential gene

XX present in cells of the precancerous condition, where the normal somatic

XX cells of the patient are heterozygous for the first gene, the inhibitor

XX is active on at least one but less than all allelic forms of the gene

XX present in a population and targets only one allelic form present in the

XX normal somatic cells, and the first gene. The products and methods can

XX be used in the diagnosis, prevention and treatment of LOH disorders,

XX e.g. cancers, atherosclerotic plaques, premalignant metaplastic or

XX dysplastic lesions, benign tumours, endometriosis, polycystic kidney

XX disease, and graft versus host disease. The method can also be used to

XX remove malignant cells from bone marrow transplants. AA225812-226825

XX represent human polymorphic sites described in the method of the

XX invention.

XX SQ Sequence 21 BP; 8 A; 1 C; 0 G; 12 T; 0 other;

Query Match 1.2%; Score 14.8; DB 1; Length 21;

Best Local Similarity 88.9%; Pred. No. 2.1e+02;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1521 TTTATATTTTAACTTTA 1538

DB 4 TTTATATTTTAACTAA 21

RESULT 123

ID AA276395/C

XX AA276395 standard; DNA; 21 BP.

XX AA276395;

XX 10-SEP-2001 (first entry)

XX Human biallelic marker downstream amplification primer SEQ ID NO:10751.

XX Human genome; biallelic marker; high density disequilibrium map;

XX genomic map; haplotype; phenotype; polymorphic base; genotyping;

KW dysplastic lesion; benign tumour; polycystic kidney disease; transplant;
 KW graft versus host disease; malignant cell removal; bone marrow; ss.
 XX Homo sapiens.

XX WO9841648-A2.

XX 24-SEP-1998.

XX 19-MAR-1998; 98WO-US05419.

XX 20-MAR-1997; 97US-0041057.

XX (VARI-) VARIAGENICS INC.

XX Housman D, Ledley FD, Stanton VP;

XX WPI; 1998-521232/44.

XX Identifying target genes for allele-specific drugs - used for

XX diagnosis, prevention and treatment of, e.g. cancers, atherosclerotic

XX plaque, dysplastic lesions, endometriosis or graft versus host disease

XX Disclosure; Figure 7; 60pp; English.

XX This invention describes a novel method for identifying an inhibitor

XX potentially useful for treatment of cancer, where the inhibitor is

XX active on a gene vital for cell growth or viability, and where the gene

XX is subject to loss of heterozygosity (LOH) in a cancer. The inhibitor is

XX used for preventing the development of cancer in a patient having a

XX precancerous condition, by administering to the patient a first allele

XX specific inhibitor (ASI) targeted to an allele of a first essential gene

XX present in cells of the precancerous condition, where the normal somatic

XX cells of the patient are heterozygous for the first gene, the inhibitor

XX is active on at least one but less than all allelic forms of the gene

XX present in a population and targets only one allelic form present in the

XX normal somatic cells, and the first gene. The products and methods can

XX be used in the diagnosis, prevention and treatment of LOH disorders,

XX e.g. cancers, atherosclerotic plaques, premalignant metaplastic or

XX dysplastic lesions, benign tumours, endometriosis, polycystic kidney

XX disease, and graft versus host disease. The method can also be used to

XX remove malignant cells from bone marrow transplants. AA225812-226825

XX represent human polymorphic sites described in the method of the

XX invention.

XX SQ Sequence 21 BP; 8 A; 1 C; 0 G; 12 T; 0 other;

Query Match 1.2%; Score 14.8; DB 1; Length 21;

Best Local Similarity 88.9%; Pred. No. 2.1e+02;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1521 TTTATATTTTAACTTTA 1538

DB 4 TTTATATTTTAACTAA 21

RESULT 123

ID AA276395/C

XX AA276395 standard; DNA; 21 BP.

XX AA276395;

XX 10-SEP-2001 (first entry)

XX Human biallelic marker downstream amplification primer SEQ ID NO:10751.

XX Human genome; biallelic marker; high density disequilibrium map;

XX genomic map; haplotype; phenotype; polymorphic base; genotyping;

KW dysplastic lesion; benign tumour; polycystic kidney disease; transplant;
 KW graft versus host disease; malignant cell removal; bone marrow; ss.
 XX Homo sapiens.

XX WO9841648-A2.

XX 24-SEP-1998.

XX 19-MAR-1998; 98WO-US05419.

XX 20-MAR-1997; 97US-0041057.

XX (VARI-) VARIAGENICS INC.

XX Housman D, Ledley FD, Stanton VP;

XX WPI; 1998-521232/44.

XX Identifying target genes for allele-specific drugs - used for

XX diagnosis, prevention and treatment of, e.g. cancers, atherosclerotic

XX plaque, dysplastic lesions, endometriosis or graft versus host disease

XX Disclosure; Figure 7; 60pp; English.

XX This invention describes a novel method for identifying an inhibitor

XX potentially useful for treatment of cancer, where the inhibitor is

XX active on a gene vital for cell growth or viability, and where the gene

XX is subject to loss of heterozygosity (LOH) in a cancer. The inhibitor is

XX used for preventing the development of cancer in a patient having a

XX precancerous condition, by administering to the patient a first allele

XX specific inhibitor (ASI) targeted to an allele of a first essential gene

XX present in cells of the precancerous condition, where the normal somatic

XX cells of the patient are heterozygous for the first gene, the inhibitor

XX is active on at least one but less than all allelic forms of the gene

XX present in a population and targets only one allelic form present in the

XX normal somatic cells, and the first gene. The products and methods can

XX be used in the diagnosis, prevention and treatment of LOH disorders,

XX e.g. cancers, atherosclerotic plaques, premalignant metaplastic or

XX dysplastic lesions, benign tumours, endometriosis, polycystic kidney

XX disease, and graft versus host disease. The method can also be used to

XX remove malignant cells from bone marrow transplants. AA225812-226825

XX represent human polymorphic sites described in the method of the

XX invention.

XX SQ Sequence 21 BP; 8 A; 1 C; 0 G; 12 T; 0 other;

Query Match 1.2%; Score 14.8; DB 1; Length 21;

Best Local Similarity 88.9%; Pred. No. 2.1e+02;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1521 TTTATATTTTAACTTTA 1538

DB 4 TTTATATTTTAACTAA 21

RESULT 123

ID AA276395/C

XX AA276395 standard; DNA; 21 BP.

XX AA276395;

XX 10-SEP-2001 (first entry)

XX Human biallelic marker downstream amplification primer SEQ ID NO:10751.

XX Human genome; biallelic marker; high density disequilibrium map;

XX genomic map; haplotype; phenotype; polymorphic base; genotyping;

KW dysplastic lesion; benign tumour; polycystic kidney disease; transplant;
 KW graft versus host disease; malignant cell removal; bone marrow; ss.
 XX Homo sapiens.

XX WO9841648-A2.

XX 24-SEP-1998.

XX 19-MAR-1998; 98WO-US05419.

urticaria; immune disorder; acquired immunodeficiency syndrome; AIDS;
open reading frame; ORF; ss.
Homo sapiens.
WO2000145638-A2.
28-JUN-2001.
11-DEC-2000; 2000WO-US33547.
14-DEC-1999; 99US-0461697.
(COGE-) COGENT NEUROSCIENCE INC.
Lo DC, Barney S, Thomas MB, Portbury SD, Puranam K, Katz LC;
WPI; 2001-390297/41.
P-PSDB; AAG98756.
Novel protective sequence polynucleotides and polypeptides, used to
identify modulators of their expression and activity, which are used in
to treat central nervous system conditions, diseases and disorders -
Claim 2; Fig 11H; 325pp; English.
Sequences AAH84132-AAH84370 represent human nucleic acid sequences which
protect against cell death (i.e., apoptosis or necrosis). Sequences
AAH84132, AAH84145, AAH84170, AAH84201, AAH84226, AAH84265,
AAH84281, AAH84315 and AAH84367 represent 10 full-length cDNA clones,
while the remaining nucleic acid sequences within the range given above
represent the open reading frames (ORFs) of these cDNA clones. Sequences
AAG98610-AAG98829 represent the polypeptides encoded by the cell death
protective ORFs. The cell death protective cDNA clones are able to
prevent, delay or reverse progression through the apoptotic or necrotic
pathways when injected into a cell predisposed to or undergoing cell
death. The cell death protective nucleic acids and polypeptides can be
used in the diagnosis and treatment of disorders associated with cell
death, and to screen for compounds which modulate their activity or
expression. Such modulators, preferably a small organic molecule, an
antibody, a ribozyme, or an antisense molecule, can also be used to treat
cell death-related diseases. Such diseases include those associated with
the central nervous system including psychiatric or neurological
disorders, especially ischaemia-related conditions such as strokes, and
also includes neurodegenerative disorders such as Alzheimer's disease,
Huntington's disease, or Parkinson's disease. The modulators may also be
used to treat infections such as meningitis, malaria, or trypanosomiasis;
vascular diseases such as ischaemic encephalopathy or cerebral
infarction; eye conditions such as diabetic retinopathy or macular
degeneration; hypertension; myocardial infarction; atherosclerosis;
respiratory conditions such as asthma or chronic obstructive pulmonary
disease; neoplastic conditions such as cancers or benign tumours; blood
cell conditions such as anaemia; gastrointestinal conditions such as biliary
gastroitis or ulcerative colitis; liver conditions such as biliary
cirrhosis; kidney disorders such as glomerulonephritis; cystitis;
endometriosis; endocrine disorders such as Grave's disease or Hashimoto's
thyroiditis; skin conditions such as dermatitis or urticaria; or immune
system disorders such as acquired immunodeficiency syndrome (AIDS). The
nucleic acids may additionally be used to generate animal models of
cell death-associated disorders. The present sequence represents a
cell death protective ORF.
Sequence 21 BP; 4 A; 1 C; 5 G; 11 T; 0 other;
Query Match 1.2%; Score 14.8; DB 1; Length 21;
Best Local Similarity 88.9%; Pred. No. 2.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 830 CGATTTCCTCTGTTAAA 847
|||||
DB 4 CGATTTCCTCTGTTAAA 21

RESULT 125
AAH62202/c
ID AAH62202 standard; DNA; 21 BP.
XX
XX AC AAH62202;
XX
XX DT 12-SEP-2001 (first entry)
XX
XX DE Per tyrosine kinase polymorphism containing DNA fragment #103.
XX
XX KW Single nucleotide polymorphism; SNP; human; cancer; inflammation;
XX
XX KW heart disease; paternity testing; forensic science; ds.
XX
XX OS Homo sapiens.
XX
XX FH Key Location/Qualifiers
XX
XX FT Variation replace(11,G)
XX
XX FT /*tag= a
XX
XX FT /standard_name= "single nucleotide polymorphism"
XX
XX PN WO200138576-A2.
XX
XX XX 31-MAY-2001.
XX
XX PF 17-NOV-2000; 2000WO-US91639.
XX
XX PF 24-NOV-1999; 99US-0167334.
XX
XX PA (WHEED) WHITEHEAD INST BIOMEDICAL RES.
XX
XX FI Cargill M, Ireland JS, Lander BS;
XX
XX DR WPI; 2001-367705/38.
XX
XX XX New nucleic acid segments of the human genome, particularly from genes
XX
XX PT including polymorphic sites, for phenotype correlation, forensics,
XX
XX PT paternity testing, medicine and genetic analysis -
XX
XX PS Claim 1; Page 38; 80pp; English.
XX
XX CC DNA sequences AAH62100 - AAH62688 represent segments of human genes which
XX
XX CC contain single nucleotide polymorphisms (SNPs). A method is included in
XX
XX CC the invention for analysing a nucleic acid sample, which consists of
XX
XX CC determining the base occupying any one of the polymorphic sites given in
XX
XX CC the SNP containing sequences. The nucleotide sequences can be used in the
XX
XX CC diagnosis or monitoring of diseases, such as cancer, inflammation, heart
XX
XX CC diseases, diseases of the cardiovascular system, and infection by
XX
XX CC microorganisms. The oligonucleotides are also useful in the manufacture
XX
XX CC of a medicament for the treatment or prophylaxis of the diseases, and as
XX
XX CC a pharmaceutical. SNP containing oligonucleotides are useful in
XX
XX CC applications such as phenotype correlation, forensics, paternity testing,
XX
XX CC medicine and genetic analysis.
XX
XX SQ Sequence 21 BP; 11 A; 1 C; 4 G; 5 T; 0 other;
Query Match 1.2%; Score 14.8; DB 1; Length 21;
Best Local Similarity 88.9%; Pred. No. 2.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1561 AATTTCCTCTGTTTC 1578
|||||
DB 20 AATTTCCTCTGTTTC 3
RESULT 126
AAH62464/c
ID AAH62464 standard; DNA; 21 BP.
XX
XX AC AAH62464;
XX
XX XX 12-SEP-2001 (first entry)
XX
XX DE CytochromeP19 polymorphism containing DNA fragment #365.

```

XX Single nucleotide polymorphism; SNP, human; cancer; inflammation;
KW heart disease; paternity testing; forensic science; ds.
XX
XX Homo sapiens.
XX
XX Key Location/Qualifiers
XX Variation replace(11,C)
XX /tag= a
XX /standard_name= "single nucleotide polymorphism"
XX
XX WO200138576-A2.
XX
XX 31-MAY-2001.
XX
XX 17-NOV-2000; 2000WO-US31639.
XX
XX 24-NOV-1999; 99US-0167334.
XX
XX (WHED ) WHITEHEAD INST BIOMEDICAL RES.
XX
XX Cargill M, Ireland JS, Lander ES;
XX
XX WPI; 2001-367705/38.
XX
XX New nucleic acid segments of the human genome, particularly from genes
XX including polymorphic sites, for phenotype correlation, forensics,
XX paternity testing, medicine and genetic analysis -
XX
XX Claim 1; Page 58; 80pp; English.
XX
XX DNA sequences AAH62100 - AAH62688 represent segments of human genes which
XX contain single nucleotide polymorphisms (SNPs). A method is included in
XX the invention for analysing a nucleic acid sample, which consists of
XX determining the base occupying any one of the polymorphic sites given in
XX the SNP containing sequences. The nucleotide sequences can be used in the
XX diagnosis or monitoring of diseases, such as cancer, inflammation, heart
XX diseases, diseases of the cardiovascular system, and infection by
XX microorganisms. The oligonucleotides are also useful in the manufacture
XX of a medicament for the treatment or prophylaxis of the diseases, and as
XX a pharmaceutical. SNP containing oligonucleotides are useful in
XX applications such as phenotype correlation, forensics, paternity testing,
XX medicine and genetic analysis.
XX
XX Sequence 21 BP; 10 A; 2 C; 5 G; 4 T; 0 other;
XX
XX Query Match 1.2%; Score 14.8; DB 1; Length 21;
XX Best Local Similarity 88.9%; Pred. No. 2.1e+02;
XX Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 822 GAATCTCGATTTT 839
XX ||||| |||||
XX 21 GAATCTCGATCTTTT 4
XX
XX
XX RESULT 127
XX AA166531
XX ID AA166531 standard; DNA; 24 BP.
XX
XX AC AA166531;
XX
XX 11-DEC-2001 (first entry)
XX
XX Human pterin-molybdenum oxidoreductase 10 cDNA PCR primer #1.
XX
XX Human; pterin-molybdenum oxidoreductase 10; cancer; haemopathy;
XX immunological disease; HIV infection; inflammation; gene therapy;
XX PCR primer; ss.
XX
XX Homo sapiens.
XX
XX WO200172788-A1.
XX

```

```

PD 04-OCT-2001.
XX
XX 23-MAR-2001; 2001WO-CN00393.
XX
XX 24-MAR-2000; 2000CN-0115110.
XX
XX (SHAN-) SHANGHAI BIOWINDOW GENE DEV INC.
XX
XX Mao Y, Xie Y;
XX
XX WPI; 2001-602841/58.
XX
XX New polypeptide for the diagnosis and treatment of malignant neoplasm,
XX hemopathy, HIV infection, immunological diseases and inflammations,
XX comprises the human pterin-molybdenum oxidoreductase 10 protein -
XX
XX Example 2; Page 17; 36pp; Chinese.
XX
XX The present invention provides the protein and coding sequences of human
XX pterin-molybdenum oxidoreductase 10. The sequences can be used in the
XX treatment of cancer, haemopathy, HIV infection, immunological diseases
XX and inflammation. The present sequence is a PCR primer for the coding
XX sequence of the invention.
XX
XX Sequence 24 BP; 10 A; 2 C; 0 G; 12 T; 0 other;
XX
XX Query Match 1.2%; Score 14.6; DB 1; Length 24;
XX Best Local Similarity 81.0%; Pred. No. 2.6e+02;
XX Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
XX
XX QY 1139 TAAATTATTATTATTACAT 1159
XX ||||| ||||| ||||| ||
XX 4 TAAATATATAATTATTACAT 24
XX
XX RESULT 128
XX AAAT74329/c
XX ID AAAT74329 standard; DNA; 16 BP.
XX
XX AC AAAT74329;
XX
XX 29-NOV-2000 (first entry)
XX
XX Loblolly pine SSR repeat of locus RIPPT67.
XX
XX Loblolly pine; Simple Sequence Repeat; SSR;
XX microsatellite DNA repeat; genetic marker; mapping; inheritance study;
XX population genetics study; plant breeding programme; ss.
XX
XX Pinus taeda.
XX
XX WO200042210-A2.
XX
XX 20-JUL-2000.
XX
XX 06-JAN-2000; 2000WO-US00325.
XX
XX 15-JAN-1999; 99US-0232884.
XX
XX 19-JAN-1999; 99US-0232785.
XX
XX (INTO ) INT PAPER CO.
XX
XX (ECHT/) ECHT C S.
XX
XX (NELS/) NELSON C D.
XX
XX (USDA ) US SEC OF AGRIC.
XX
XX ECHT CS, Nelson CD;
XX
XX WPI; 2000-482836/42.
XX
XX Polynucleotide having simple sequence repeat useful as markers in
XX plants for genetic characterization e.g. genetic mapping study, an
XX inheritance study of a commercially important trait in a plant breeding
XX program -
XX

```


PR 30-JAN-2001; 2001WO-US00668.
PR 30-JAN-2001; 2001WO-US00669.
PR 23-MAY-2001; 2001US-0864761.
PR 09-OCT-2001; 2001US-0327898.
XX (AEOM-) AEOMICA INC.
XX Zhan J;
XX WPI; 2002-676582/73.
XX Novel isolated human testis expressed Patched like protein (HTPL),
PT useful for identifying agonist and antagonist and specific binding
PT partners, and for treating subjects having defects in HTPL -
XX Example 2; Page 282; 718pp; English.
XX The present invention relates to human testis expressed Patched like
CC protein (HTPL), see ABV78759 to ABV78762 and AB98519 to AB98520. HTPL
CC has two isoforms, with a few single base pair differences between the
CC two. One of the single base pair changes introduces a premature stop
CC codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL
CC shares an overall structure organisation with the Patched protein. The
CC shared structural features strongly imply that HTPL plays a role similar
CC to that of Patched, and is a potential tumour suppressor. HTPL is
CC important in regulating male germ cell development, and the HTPL gene was
CC mapped to human chromosome 10p12.1. HTPL and its coding sequence are
CC useful for diagnosing a disorder caused by mutation in HTPL, and in
CC therapy and manufacture of a medicament for treatment or prevention of
CC such disorder associated with decreased expression or activity of human
CC HTPL. Such disorders include disorders of testis, or adrenal, adult and
CC foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,
CC skeletal muscle or colon function. HTPL proteins and nucleic acids are
CC clinically useful diagnostic markers and potential therapeutic agents for
CC male infertility and cancer. The present oligonucleotide was used in an
CC example from the invention.
XX Sequence 17 BP; 3 A; 1 C; 1 G; 12 T; 0 other;
SQ Query Match 1.2%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 675 ATACAAATAGCAAAAT 691
Db 17 ATATAAATAGCAAAAT 2
RESULT 134
ABV80427/c
ID ABV80427 standard; DNA; 17 BP.
XX AC ABV80427;
XX DT 03-JAN-2003 (first entry)
XX DE Human HTPL scanning oligonucleotide SEQ ID 1673.
XX Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;
KW human testis expressed Patched like protein; testis; adrenal; liver;
KW male germ cell development; bone marrow; brain; kidney; lung; placenta;
KW prostate; skeletal muscle; colon; male infertility; cancer; ss.
XX Homo sapiens.
XX EP1229046-A2.
XX PN 07-AUG-2002.
XX PD 28-JAN-2002; 2002EP-0001167.
XX PF 30-JAN-2001; 2001WO-US00663.
XX PR 30-JAN-2001; 2001WO-US00664.

PR 30-JAN-2001; 2001WO-US00665.
PR 30-JAN-2001; 2001WO-US00667.
PR 30-JAN-2001; 2001WO-US00668.
PR 30-JAN-2001; 2001WO-US00669.
PR 23-MAY-2001; 2001US-0864761.
PR 09-OCT-2001; 2001US-0327898.
XX (AEOM-) AEOMICA INC.
XX Zhan J;
XX WPI; 2002-676582/73.
XX Novel isolated human testis expressed Patched like protein (HTPL),
PT useful for identifying agonist and antagonist and specific binding
PT partners, and for treating subjects having defects in HTPL -
XX Example 2; Page 283; 718pp; English.
XX The present invention relates to human testis expressed Patched like
CC protein (HTPL), see ABV78759 to ABV78762 and AB98519 to AB98520. HTPL
CC has two isoforms, with a few single base pair differences between the
CC two. One of the single base pair changes introduces a premature stop
CC codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL
CC shares an overall structure organisation with the Patched protein. The
CC shared structural features strongly imply that HTPL plays a role similar
CC to that of Patched, and is a potential tumour suppressor. HTPL is
CC important in regulating male germ cell development, and the HTPL gene was
CC mapped to human chromosome 10p12.1. HTPL and its coding sequence are
CC useful for diagnosing a disorder caused by mutation in HTPL, and in
CC therapy and manufacture of a medicament for treatment or prevention of
CC such disorder associated with decreased expression or activity of human
CC HTPL. Such disorders include disorders of testis, or adrenal, adult and
CC foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,
CC skeletal muscle or colon function. HTPL proteins and nucleic acids are
CC clinically useful diagnostic markers and potential therapeutic agents for
CC male infertility and cancer. The present oligonucleotide was used in an
CC example from the invention.
XX Sequence 17 BP; 4 A; 1 C; 1 G; 11 T; 0 other;
SQ Query Match 1.2%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 675 TATACAAATAGCAAAA 690
Db 16 TATAAATAGCAAAA 1
RESULT 135
ABT37900/c
ID ABT37900 standard; DNA; 17 BP.
XX AC ABT37900;
XX DT 12-JUN-2003 (first entry)
XX DE Tumour suppression related human fukutin oligo SEQ ID No 3537.
XX Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; protein chip; gene therapy; tumour suppression;
KW human fukutin; ds.
XX Homo sapiens.
XX OS WO2003025175-A2.
XX PN 27-MAR-2003.
XX PD 17-SEP-2002; 2002WO-IB04208.
XX PF 17-SEP-2002; 2002WO-IB04208.
XX PR 17-SEP-2002; 2002WO-IB04208.